

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: November 26, 2003, 13:36:45 ; Search time 12.8077 Seconds

(without alignments)
833,462 Million cell updates/sec

Title: US-09-880-748-327_COPY_139_249

Perfect score: 583
Sequence: 1 AFSSSLTQDPDAVSAVALGQTV.....RDSGSHHWFGGTELTVLG 111

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283308 seqs, 96168682 residues

number of hits satisfying chosen parameters: 283308

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :
1: pir1.*
2: pir2.*
3: pir3.*
4: pir4.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	551	94.5	109	2	S19663 Ig lambda chain V
2	545	93.5	108	2	S38498 Ig lambda chain -
3	545	93.5	108	2	S47184 Ig lambda chain -
4	539	92.5	127	2	S70444 Ig lambda chain pr
5	534.5	91.7	110	2	S36272 Ig lambda chain V
6	528	90.6	109	2	S38496 Ig lambda chain -
7	513	88.0	233	2	S25748 Ig lambda chain -
8	510	87.5	108	1	L3HUSH Ig lambda chain V-
9	505.5	86.7	110	2	S19672 Ig lambda chain V
10	500.5	85.8	146	2	S02083 Ig lambda chain V-
11	497	85.2	96	2	S36060 Ig lambda chain -
12	497	85.2	115	2	S13726 Ig lambda chain V
13	489	83.9	233	2	S25741 Ig lambda chain -
14	430.5	73.8	106	2	S38495 Ig lambda chain -
15	408	70.0	105	2	S49533 anti-sm antibody V
16	407	69.8	119	2	S30526 Ig lambda chain V
17	402	69.0	190	2	S25740 Ig lambda chain -
18	385.5	66.1	120	2	S30525 Ig lambda chain -
19	385	66.0	107	2	PC4283 anti-SS-A/Ro 60K p
20	381	65.4	226	2	S25745 Ig lambda chain -
21	376	64.5	231	2	S25738 Ig lambda chain -
22	375.5	64.4	231	2	S70431 Ig lambda chain -
23	374	64.2	120	2	S30527 Ig lambda chain V
24	372	63.8	151	2	S25739 Ig lambda chain -
25	371	63.6	231	1	S25751 Ig lambda chain -
26	367	63.0	107	1	L4HURL Ig lambda chain V-
27	366	62.8	231	2	S25753 Ig lambda chain -
28	364	62.4	109	2	S68171 Ig lambda chain V
29	362	62.1	111	2	S36274 Ig lambda chain V

30	362	62.1	233	2	S25747 Ig lambda chain -
31	358	61.4	108	1	L5HURL Ig lambda chain V-
32	357	61.2	106	1	L4HURL Ig lambda chain V-
33	355	60.9	132	2	S09713 Ig lambda chain V-
34	351.5	60.3	112	2	S51148 antibody light cha
35	351.5	60.3	232	2	S25756 Ig lambda chain -
36	350	60.0	106	1	L4HURL Ig lambda chain V-
37	348	59.7	106	1	L4HURL Ig lambda chain V-
38	346.5	59.4	236	2	S25746 Ig lambda chain V
39	346	59.3	105	2	S44124 Ig lambda chain V
40	344	59.0	110	2	S57442 Ig lambda chain V-
41	344	59.0	130	1	L4HURL Ig lambda chain pr
42	342.5	58.7	112	2	S31515 Ig lambda chain V
43	342	58.7	95	2	S36065 Ig lambda chain V-
44	342	58.7	111	1	L2HURL Ig lambda chain V-
45	342	58.7	114	2	S16440 Ig lambda chain -

ALIGNMENTS

RESULT 1

S19663 Ig lambda chain V region (clone alpha-BSA3) - human

C:Species: Homo sapiens (man)

C>Date: 22-Jan-1993 #sequence_revision 22-Jan-1993 #text_change 20-Jun-2000

C:Accession: S19663

R:Marks: J.D.: Hoogenboom, H.R.: Bonmert, T.P.: McCafferty, J.: Griffiths, A.D.: Winter, J. Mol. Biol. 222, 581-597, 1991

A>Title: By-passing immunization. Human antibodies from V-gene libraries displayed on ph

A:Reference number: S19663; MUID:92085276; PMID:1748994

A:Accession: S19663

A:Molecule type: mRNA

A:Residues: 1-109 <MAR>

A:Cross-references: EMBL:X61640; NID:929492; PIDN:CAA3821.1; PID:91340166

C:Superfamily: Immunoglobulin V region; Immunoglobulin homology

C:Keywords: heterotrimer; immunoglobulin

F:15-89/Domain: immunoglobulin homology <IMM>

Query Match	94.5%	Score 551	DB 2	Length 109
Best Local Similarity	96.3%	Pred. No. 2.7e-40		
Matches 105; Conservative 3; Mismatches 1; Indels 0; Gaps 0;				
Qy	3	SSSLTQDPDAVSAVALGQTVRITTCGDSLSRYASWYQKPGQAPLVITGKNNRPSGIPDR	62	
Db	1	SSSLTQDPDAVSAVALGQTVRITTCGDSLSRYASWYQKPGQAPLVITGKNNRPSGIPDR	60	
Qy	63	FSGSSGNTASLTITGAQAEDEADYCCSRDSSGNHWFGGTELTVLG	111	
Db	61	FSGSSGNTASLTITGAQAEDEADYCCSRDSSGNHWFGGTELTVLG	109	

RESULT 2

S38498 Ig lambda chain - human (fragment)

C:Species: Homo sapiens (man)

C>Date: 06-Jan-1995 #sequence_revision 06-Jan-1995 #text_change 21-Jan-2000

C:Accession: S38498

R:Marks: J.D.: Owehand, W.H.: Bye, J.M.: Finnen, R.: Gorick, B.D.: Voak, D.: Thorpe, S

A:Description: Human antibody fragments specific for human blood group antigens from a p

A:Reference number: S38488

A:Accession: S38498

A>Status: preliminary

A:Molecule type: DNA

A:Residues: 1-108 <MAR>

A:Cross-references: EMBL:Z23035; NID:9414043; PIDN:CAA80570.1; PID:9414044

C:Superfamily: immunoglobulin V region; immunoglobulin homology

C:Keywords: heterotrimer; immunoglobulin

F:14-88/Domain: immunoglobulin homology <IMM>

Query Match 93.5%; Score 545; DB 2; Length 108;
Best Local Similarity 95.4%; Pred. No. 8.8e-40;

Matches	103;	Conservative	3;	Mismatches	2;	Indels	0;	Gaps	0;																	
Oy	4	SELTODP	PAVS	VALG	GTG	VTTC	CGD	SLR	SVYS	WMY	OKO	KGA	PVL	VI	YG	KNN	PS	GI	PDR	63						
Db	1	SELTOD	PAVS	VALG	GT	VT	IT	CG	D	SLR	SV	YS	WM	Y	OKO	KGA	PVL	VI	YG	KNN	PS	GI	PDR	60		
Oy	64	SGSSSG	NA	SL	IT	TA	QA	DE	AD	Y	CS	R	DS	SG	NN	W	V	GG	G	T	EL	V	L	G	111	
Db	61	SGSSSG	NA	SL	IT	TA	QA	DE	AD	Y	CS	R	DS	T	SG	NN	W	V	GG	G	T	EL	V	L	G	108

RESULT 3
S47184
IG lambda chain - human
C:Species: Homo sapiens (man)
C:Date: 06-Jan-1995 #sequence_revision 06-Jan-1995 #text_change 21-Jan-2000
C:Accession: S47184
R:McIntosh, R.S.; Tandon, N.; Metcalfe, R.A.; Weetman, A.P.
Submitted to the EMBL Data library, June 1994
Description: Cloning and analysis of IGM anti-thyroglobulin autoantibodies from patient
Reference number: S47181
A:Accession: S47184
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-108 <MCI>
A:Cross-references: EMBL:X79783; NID:G506426; PIDD:CAA56179.1, PIDD:G506427
C:Superfamily: immunoglobulin V region, immunoglobulin homology
C:Keywords: heterodimer; immunoglobulin
F:15-89/Domain: immunoglobulin homology <IM>

Query Match	93.5%	Score 545;	DB 2;	Length 108;
Best Local Similarity	96.3%	Pred. No. 8.8e-40;		
Matches 104;	Conservative 3;	Mismatches 1;	Indels 0;	Gaps 0;

QY	3	SSELTODPAVSAAGQIVRTVTCQGGSLSSYASVWYQKRPQAPVVIYIGKNNRPSGIDPR	62
Db	1	SSELTODPAVSAAGQIVRTVTCQGGSLSSYASVWYQKRPQAPVVIYIGKNNRPSGIDPR	60
QY	63	FSGSSSGNTASLTITGAQAEDEADYCCSSRDSGNNWTFGGGTETLVL	110
Db	61	FSGSSSGNTASLTITGAQAEDEADYCCNSRDSGNNWTFGGGTETLVL	108

```

RESULT 4
S70444
Ig lambda chain precursor V region - human (fragment)
C:Species: Homo sapiens (man)
Date: 24-Jul-1998 #sequence_revision 24-Jul-1998 #text_change 21-Jan-2000
Accession: S70444; S70426
R:Listier, A.M.; Fumoux, F.; Fougereau, M.; Tonnelle, C.
Mol. Immunol. 29, 1363-1373, 1992
A:Title: 1M kappa/lambda EBV human B cell clone: an early step of differentiation of fe
A:Reference number: S70442; MUID:93024508; PMID:1383695
A:Accession: S70444
A:Status: not compared with conceptual translation
A:Molecule type: mRNA
A:Residues: 1-127 <CUI>
A:Experimental source: clone E29.1
R:Tonnelle, C.
submitted to the EMBL Data Library, May 1990
A:Reference number: S70426
A:Accession: S70426
A:Molecule type: mRNA
A:Residues: 1-90 <TON>
A:Cross-references: EMBL:X53070
A:Experimental source: cell line E29.1, clone VL 29-1
C:Superfamily: Immunoglobulin V region; immunoglobulin homology
C:Keywords: heterodimer; immunoglobulin
F:1-20/Domain: signal sequence #status predicted <SIG>
F:21-127/Product: Ig lambda chain V region (fragment) #status predicted <MAT>
F:34-106/Domain: immunoglobulin homology <IMV>

```

[illegible]

```

RESULT 5
S36272
Ig lambda chain V region (clone alpha-THY-29) - human (fragment)
C:Species: Homo sapiens (man)
C:Date: 03-Feb-1994 #sequence_revision 03-Feb-1994 #text_change 21-Jan-2000
A:Accession: S36272
R:Gift:Ritchie, A.D.; Malmqvist, M.; Marks, J.D.; Bye, J.M.; Embleton, M.U.; McCafferty, J
EMBO J. 12, 725-734, 1993
A>Title: Human anti-self antibodies with high specificity from phage display libraries.
A:Reference number: S36256; MUID:91178448; PMID:7679990
A:Accession: S36272
A:Status: preliminary; nucleic acid sequence not shown
A:Molecule type: mRNA
A:Residues: 1-110 <GR>
A:Cross-references: EMBL:Z18833; NID:933419; PIDD:CAA79285.1; PID:g939912
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-89/Domain: immunoglobulin homology <IM>

```

[illegible]

RESULT 6
S38496
ig lambda chain - human (fragment)
C|Species: Homo sapiens (man)
C|Date: 06-Jan-1995 #sequence_revision 06-Jan-1995 #text_change 21-Jan-2000
C|Accession: S38496
R|Marks, J.D.; Ouwehand, W.H.; Bye, J.M.; Finnern, R.; Gorick, B.D.; Vaak, D.; Thorpe, S.
submitted to the EMBL Data Library, June 1993
A|Description: Human antibody fragments specific for human blood group antigens from a p
A|Reference number: S38488
A|Accession: S38496
A|Status: preliminary
A|Molecule type: DNA
A|Residues: 1-109 <MAR>
A|Cross-references: EMBL:223031, NID:g414039, PIDN:CAAB0566.1, PID:g414040
C|Superfamily: Immunoglobulin V region, Immunoglobulin homology
C|Keywords: heterodetramer, Immunoglobulin
F|15-89/Domain: immunoglobulin homology <IMM>

	Query Match	90.6%;	Score 528;	DB 2;	Length 109;	
	Best Local Similarity	90.8%;	Pred. No. 2.5e-38;			
	Matches	99;	Mismatches	3;	Indels	0; Gaps 0;
Oy	3	SSELTODPAVSVALGOTVRVTCQGDSSRSYASWYQKPGCAPVLVIYGNKNRRPSGIPIR	62			
Dd	1	SSETLTPAVSVALGOTVRITTCQGDSSLSKYASWYQKPGCAPVLVMYGKNRRPSGIPIR	60			
Oy	63	FSGSSSGNTASLTITGAODEADLYCYSSSRDSSGNHWVFGGTILTYLG	111			

Db 61 FSGSSGNTASLTITGAQAEDEADYCTSRDTSNGHVLFGGGLTLVLG 109

RESULT 7

525748
Ig lambda chain - human
C/Species: Homo sapiens (man)
C/Date: 22-Nov-1993 #sequence_revision 26-May-1995 #text_change 21-Jan-2000
C/Accession: S25748
R/Combriato, G.; Kloebeck, H.G.
Eur. J. Immunol. 21, 1513-1522, 1991
A/Title: V(Lambda) and V(Lambda)-C(Lambda) gene segments of the human immunoglobulin lambda
A/Reference number: S16439; MUID:91257162; PMID:1904362
A/Accession: S25748
A/Status: preliminary; translation not shown
A/Molecule type: mRNA
A/Residues: 1-233 <COM>
A/Cross-references: EMBL:X57813; NID:G33725; PIDN:CAA0950.1; PID:G33726
C/Superfamily: immunoglobulin V region; immunoglobulin homology
C/Keywords: heterotetramer; immunoglobulin
F:14-88/Domain: immunoglobulin homology <IMM>

Query Match 88.0%; Score 513; DB 2; Length 233;
Best Local Similarity 88.1%; Pred. No. 1e-36;
Matches 96; Conservative 8; Mismatches 5; Indels 0; Gaps 0;

Qy 3 SSELTPAVSVALGQTVRTCCGDSLSRSYASWYQKPGQAPLVITYGKNNRPSGIPDR 62
|||||
Db 20 SSELTPAVSVALGQTVRTCCGDSLSRSYASWYQKPGQAPLVITYGKNNRPSGIPDR 79

Qy 63 FSGSSGNTASLTITGAQAEDEADYCCSRDSSGNHWFVGGGTETVLV 111
|||||
Db 80 FSGSSGNTASLTITGAQAEDEADYCCSRDSSGNHWFVGGGTETVLV 128

RESULT 8

L3HUSH
Ig lambda chain V-III region (SH) - human
C/Species: Homo sapiens (man)
C/Date: 24-Apr-1984 #sequence_revision 24-Apr-1984 #text_change 02-Sep-1997
C/Accession: A01980
R/Tittman, K.; Wikler, M.; Shinoda, T.; Putnam, F.W.
J. Biol. Chem. 245, 2171-2176, 1970
A/Title: The amino acid sequence of a lambda type Bence-Jones protein. III. The complete
A/Reference number: A92057; MUID:70166723; PMID:4909564
A/Accession: A01980
A/Molecule type: protein
A/Residues: 1-108 <TIT>
F:14-88/Domain: the sequence of the C region is also given

C/Keywords: heterotetramer; immunoglobulin
F:14-88/Domain: immunoglobulin homology <IMM>
F:21-86/Disulfide bonds: #status experimental

Query Match 87.5%; Score 510; DB 1; Length 108;
Best Local Similarity 88.9%; Pred. No. 8.4e-37;
Matches 96; Conservative 8; Mismatches 4; Indels 0; Gaps 0;

Qy 4 SSELTPAVSVALGQTVRTCCGDSLSRSYASWYQKPGQAPLVITYGKNNRPSGIPDR 63
|||||
Db 1 SSELTPAVSVALGQTVRTCCGDSLSRSYASWYQKPGQAPLVITYGKNNRPSGIPDR 60

Qy 64 SSGSSGNTASLTITGAQAEDEADYCCSRDSSGNHWFVGGGTETVLV 111
|||||
Db 61 SSGSSGNTASLTITGAQAEDEADYCCSRDSSGNHWFVGGGTETVLV 108

RESULT 9

519672
Ig lambda chain V region (clone alpha-TEL14) - human
C/Species: Homo sapiens (man)
C/Date: 22-Jan-1993 #sequence_revision 22-Jan-1993 #text_change 20-Jun-2000
C/Accession: S19672
R/Marks, J.D.; Hoozenboom, H.R.; Bonner, T.P.; McCafferty, J.; Griffiths, A.D.; Winter, J. Mol. Biol. 222, 581-597, 1991
A/Title: By-passing immunization. Human antibodies from V-gene libraries displayed on phage
A/Reference number: S19663; MUID:92085276; PMID:1748994
A/Accession: S19672
A/Molecule type: mRNA
A/Residues: 1-110 <MAR>
A/Cross-references: EMBL:X61644; NID:G37856; PIDN:CAA43825.1; PID:G1335384
C/Superfamily: immunoglobulin V region; immunoglobulin homology
C/Keywords: heterotetramer; immunoglobulin
F:15-89/Domain: immunoglobulin homology <IMM>

Query Match 86.7%; Score 505.5; DB 2; Length 110;
Best Local Similarity 89.1%; Pred. No. 2.1e-36;
Matches 98; Conservative 6; Mismatches 5; Indels 1; Gaps 1;

Qy 3 SSELTPAVSVALGQTVRTCCGDSLSRSYASWYQKPGQAPLVITYGKNNRPSGIPDR 62
|||||
Db 1 SSELTPAVSVALGQTVRTCCGDSLSRSYASWYQKPGQAPLVITYGKNNRPSGIPDR 60

Qy 63 FSGSSGNTASLTITGAQAEDEADYCCSRDSSGNHWFVGGGTETVLV 111
|||||
Db 61 FSGSSGNTASLTITGAQAEDEADYCCSRDSSGNHWFVGGGTETVLV 110

RESULT 10

S02083
Ig lambda chain V-IV region - human (tentative sequence) (fragments)
N/Alternate names: amyloid-fibril protein GIL
C/Species: Homo sapiens (man)
C/Date: 01-Dec-1989 #sequence_revision 01-Dec-1989 #text_change 31-Mar-2000
C/Accession: S02083
R/Fyfe, E.M.; Sletten, K.; Hubby, G.; Cornwell III, G.G.
Biochem. J. 256, 973-980, 1988
A/Title: The primary structure of the variable region of an immunoglobulin IV light-chain
A/Reference number: S02083; MUID:89134210; PMID:3146981
A/Accession: S02083
A/Molecule type: protein
A/Residues: 1-70;71-72;73-75;76-131;132-146 <FYK>
C/Superfamily: immunoglobulin V region; immunoglobulin homology
C/Keywords: heterotetramer; immunoglobulin
F:14-88/Domain: immunoglobulin homology <IMM>

Query Match 85.8%; Score 500.5; DB 2; Length 146;
Best Local Similarity 88.0%; Pred. No. 7.3e-36;
Matches 95; Conservative 10; Mismatches 2; Indels 1; Gaps 1;

Qy 4 SSELTPAVSVALGQTVRTCCGDSLSRSYASWYQKPGQAPLVITYGKNNRPSGIPDR 63
|||||
Db 1 SSELTPAVSVALGQTVRTCCGDSLSRSYASWYQKPGQAPLVITYGKNNRPSGIPDR 60

Qy 64 SSGSSGNTASLTITGAQAEDEADYCCSRDSSGNHWFVGGGTETVLV 110
|||||
Db 61 SSGSSGNTASLTITGAQAEDEADYCCSRDSSGNHWFVGGGTETVLV 108

RESULT 11

S36060
Ig lambda chain - human (fragment)
C/Species: Homo sapiens (man)
C/Date: 22-Nov-1993 #sequence_revision 01-Dec-1995 #text_change 21-Jan-2000
C/Accession: S36060
R/Williams, S.C.
submitted to the EMBL Data Library, April 1993
A/Reference number: S36046
A/Accession: S36060
A/Status: preliminary

A:Molecule type: DNA
A:Residues: 1-96 <MWL>
A:Cross-references: EMBL:Z22202; NID:G312325; PIDN:CAA80211.1; PID:G312326
C:Superfamily: Immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-89/Domain: immunoglobulin homology <IMM>

Query Match 85.2%; Score 497; DB 2; Length 96;
Best Local Similarity 97.9%; Pred. No. 9,6e-36;
Matches 94; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SSETLDPAVSVALGQTVRTTCGGDSLRSYASWYQKPGQAPVLVIYKNNRPSGIPDR 62
Db 1 SSETLDPAVSVALGQTVRTTCGGDSLRSYASWYQKPGQAPVLVIYKNNRPSGIPDR 60

Qy 63 FSGSSSGNTASLTITGAQAEDEADYCCSRDSSGNH 98
Db 61 FSGSSSGNTASLTITGAQAEDEADYCCSRDSSGNH 96

IT 12

Ig lambda chain V region - human
C:Species: Homo sapiens (man)
C:Date: 25-Feb-1994 #sequence_revision 10-Nov-1995 #text_change 21-Jan-2000
C:Accession: S13726
R:Frippat, J.P.; Chuchana, P.; Bernard, F.; Buluwela, L.; Lefranc, G.; Lefranc, M.P.
Nucleic Acids Res. 18, 7134, 1990
A:Title: First genomic sequence of a human Ig variable lambda gene belonging to subgroup
A:Reference number: S13726; MUID:91088295; PMID:2124677
A:Accession: S13726
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-115 <FRI>
A:Cross-references: EMBL:X56178; NID:G33404; PIDN:CAA39639.1; PID:G33405
C:Genetics:
A:introns: 16/1
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:13-108/Domain: immunoglobulin homology <IMM>

Query Match 85.2%; Score 497; DB 2; Length 115;
Best Local Similarity 97.9%; Pred. No. 1.1e-35;
Matches 94; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SSETLDPAVSVALGQTVRTTCGGDSLRSYASWYQKPGQAPVLVIYKNNRPSGIPDR 62
Db 20 SSETLDPAVSVALGQTVRTTCGGDSLRSYASWYQKPGQAPVLVIYKNNRPSGIPDR 79

Qy 63 FSGSSSGNTASLTITGAQAEDEADYCCSRDSSGNH 98
Db 80 FSGSSSGNTASLTITGAQAEDEADYCCSRDSSGNH 115

RESULT 13
S25741
Ig lambda chain - human
C:Species: Homo sapiens (man)
C:Date: 22-Nov-1993 #sequence_revision 26-May-1995 #text_change 21-Jan-2000
C:Accession: S25741
R:Combratio, G.; Klobbeck, H.G.
Eur. J. Immunol. 21, 1513-1522, 1991
A:Title: V(lambda) and J(lambda) gene segments of the human immunoglobulin lan
A:Reference number: S16439; MUID:91257162; PMID:1904362
A:Accession: S25741
A:Status: preliminary; translation not shown
A:Molecule type: mRNA
A:Residues: 1-233 <COM>
A:Cross-references: EMBL:X57805; NID:G33707; PIDN:CAA40943.1; PID:G33708
C:Superfamily: Immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:148-216/Domain: immunoglobulin homology <IMM>

Query Match 83.9%; Score 489; DB 2; Length 233;
Best Local Similarity 84.3%; Pred. No. 1.1e-34;
Matches 91; Conservative 10; Mismatches 7; Indels 0; Gaps 0;

Qy 3 SSETLDPAVSVALGQTVRTTCGGDSLRSYASWYQKPGQAPVLVIYKNNRPSGIPDR 62
Db 20 SSETLDPAVSVALGQTVRTTCGGDSLRSYASWYQKPGQAPVLVIYKNNRPSGIPDR 79

Qy 63 FSGSSSGNTASLTITGAQAEDEADYCCSRDSSGNHVFSGGTETVLV 110
Db 80 FSGSSSGNTASLTITGAQAEDEADYCCSRDSSGNHVFSGGTETVLV 127

RESULT 14

Ig lambda chain - human (fragment)
C:Species: Homo sapiens (man)
C:Date: 06-Jan-1995 #sequence_revision 06-Jan-1995 #text_change 21-Jan-2000
C:Accession: S38495
R:Maiz, J.D.; Ouwehand, W.H.; Bye, J.M.; Finnern, R.; Gorick, B.D.; Voak, D.; Thorpe, S
submitted to the EMBL Data Library, June 1993
A:Description: Human antibody fragments specific for human blood group antigens from a p
A:Reference number: S38498
A:Accession: S38495
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-106 <MAR>
A:Cross-references: EMBL:Z22029; NID:G414037; PIDN:CAA80564.1; PID:G414038
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-89/Domain: immunoglobulin homology <IMM>

Query Match 73.8%; Score 430.5; DB 2; Length 106;
Best Local Similarity 76.1%; Pred. No. 4.9e-30;
Matches 83; Conservative 13; Mismatches 10; Indels 3; Gaps 1;

Qy 3 SSETLDPAVSVALGQTVRTTCGGDSLRSYASWYQKPGQAPVLVIYKNNRPSGIPDR 62
Db 1 SSETLDPAVSVALGQTVRTTCGGDSLRSYASWYQKPGQAPVLVIYKNNRPSGIPDR 60

Qy 63 FSGSSSGNTASLTITGAQAEDEADYCCSRDSSGNHVFSGGTETVLV 111
Db 61 FSGSSSGNTASLTITGAQAEDEADYCCSRDSSGNHVFSGGTETVLV 106

RESULT 15

S49533
anti-Sm antibody VL chain (V lambda 3b/J lambda 2/3) - human
C:Species: Homo sapiens (man)
C:Date: 01-Feb-1995 #sequence_revision 12-May-1995 #text_change 21-Jan-2000
C:Accession: S49533
R:Mamoudi, M.; Edwards, J.; Cairns, E.; Bell, D.
submitted to the EMBL Data Library, October 1994
A:Description: Molecular characterization of natural human anti-Sm autoantibodies.
A:Reference number: S48797
A:Accession: S49533
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-105 <RNA>
A:Cross-references: EMBL:Z46346; NID:G560845; PIDN:CAA86465.1; PID:G1340169
C:Superfamily: immunoglobulin V region; immunoglobulin homology
F:111-85/Domain: immunoglobulin homology <IMM>

Query Match 70.0%; Score 408; DB 2; Length 105;
Best Local Similarity 73.3%; Pred. No. 4e-28;
Matches 77; Conservative 10; Mismatches 18; Indels 0; Gaps 0;

Qy 7 TDPASVVALGQTVRTTCGGDSLRSYASWYQKPGQAPVLVIYKNNRPSGIPDR 66
Db 1 TDPASVVALGQTVRTTCGGDSLRSYASWYQKPGQAPVLVIYKNNRPSGIPDR 60

Qy 67 SSGNTASLTITGAQAEDEADYCCSRDSSGNHVFSGGTETVLV 111
Db 67 SSGNTASLTITGAQAEDEADYCCSRDSSGNHVFSGGTETVLV 111

Db 61 SSGTITLITISGVQAEADADYICQASDSSGTYVFGGKTLTVLG 105

RESULT 16

S30526

Ig lambda chain V region - human

C/Species: Homo sapiens (man)

C/Date: 06-Jan-1995 #sequence_revision 06-Jan-1995 #text_change 21-Jan-2000

C/Accession: S30526

R/Mariette, X.

submitted to the EMBL Data Library, October 1992

A/Reference number: S30520

A/Accession: S30526

A/Status: preliminary

A/Molecule type: mRNA

A/Residues: 1-119 <MAR>

A/Cross-references: EMBL:Z18332

C/Superfamily: immunoglobulin V region; immunoglobulin homology

C/Keywords: heterotetramer; immunoglobulin

F:15-89/Domain: immunoglobulin homology <IMM>

Query Match 69.8%; Score 407; DB 2; Length 119;

Best Local Similarity 73.4%; Pred. No. 5.5e-28;

Matches 80; Conservative 9; Mismatches 18; Indels 2; Gaps 1;

Qy 3 SSELTPDAVSVALGQTVRTVTCGDSLSRYASWYQKPGQAPLVITYGKNNRPSGIPDR 62

Db 1 SYELTPPSVSVSPQGTARITCSGDALPKQYAVWYQKPGQAPLVITYKDSRPSGIPER 60

Qy 63 FSGSSSGNTASLTITGAQAEADADYICSSRDSSGNHWVFGGKTLTVLG 111

Db 61 FSGSSSGTITLITISGVQAEADADYICQASDSSGTYVFGGKTLTVLG 107

RESULT 17

S25740

Ig lambda chain - human (fragment)

C/Species: Homo sapiens (man)

C/Date: 22-Nov-1993 #sequence_revision 26-May-1995 #text_change 21-Jan-2000

C/Accession: S25740

R/Combratio, G.; Klobbeck, H.G.

Eur. J. Immunol. 21, 1513-1522, 1991

A/Title: V(lambda) and J(lambda)-C(lambda) gene segments of the human immunoglobulin lam

A/Reference number: S16439; MUID:91257162; PMID:1904362

A/Accession: S25740

A/Status: preliminary; translation not shown

A/Molecule type: mRNA

A/Residues: 1-190 <COM>

C/Cross-references: EMBL:X57804; NID:933705; PIDN:CAA40942.1; PID:933706

C/Superfamily: immunoglobulin V region; immunoglobulin homology

C/Keywords: heterotetramer; immunoglobulin

F:105-173/Domain: immunoglobulin homology <IMM>

Query Match 69.0%; Score 402; DB 2; Length 190;

Best Local Similarity 87.1%; Pred. No. 2.3e-27;

Matches 74; Conservative 8; Mismatches 3; Indels 0; Gaps 0;

Qy 27 DSLRYSVSWYQKPGQAPLVITYGKNNRPSGIPRFGSSSGNTASLTITGAQAEADAD 86

Db 1 DSLRYSVSWYQKPGQAPLVITYGKNNRPSGIPRFGSSSGNTASLTITGAQAEADAD 60

Qy 87 YYCSGRDSSGNHWVFGGKTLTVLG 111

Db 61 YYCNSRDSSGNHWVFGGKTLTVLG 85

Qy 87 YYCSGRDSSGNHWVFGGKTLTVLG 111

Db 61 YYCNSRDSSGNHWVFGGKTLTVLG 85

RESULT 18

S30525

Ig lambda chain V region - human

C/Species: Homo sapiens (man)

C/Date: 06-Jan-1995 #sequence_revision 06-Jan-1995 #text_change 21-Jan-2000

C/Accession: S30525

R/Mariette, X.

submitted to the EMBL Data Library, October 1992

A/Reference number: S30520

A/Accession: S30525

A/Status: preliminary

A/Molecule type: mRNA

A/Residues: 1-120 <MAR>

A/Cross-references: EMBL:Z18331

C/Superfamily: immunoglobulin V region; immunoglobulin homology

C/Keywords: heterotetramer; immunoglobulin

F:15-89/Domain: immunoglobulin homology <IMM>

Query Match 66.1%; Score 385.5; DB 2; Length 120;

Best Local Similarity 68.8%; Pred. No. 3.8e-26;

Matches 75; Conservative 14; Mismatches 19; Indels 1; Gaps 1;

Qy 3 SSELTPDAVSVALGQTVRTVTCGDSLSRYASWYQKPGQAPLVITYGKNNRPSGIPDR 62

Db 1 SYELTPPSVSVSPQGTARITCSGDALPKQYAVWYQKPGQAPLVITYKDSRPSGIPER 60

Qy 63 FSGSSSGNTASLTITGAQAEADADYICSSRDSSGNHWVFGGKTLTVLG 111

Db 61 FSGSSSGTITLITISGVQAEADADYICQASDSSGTYVFGGKTLTVLG 108

RESULT 19

PC4283

anti-Ss-A/Re 60K peptide light chain E-60 - human (fragment)

C/Species: Homo sapiens (man)

C/Date: 07-Jul-1997 #sequence_revision 29-Aug-1997 #text_change 16-Jul-1999

C/Accession: PC4283

R/Suzuki, H.; Takemura, H.; Suzuki, M.; Sekine, Y.; Kashiwagi, H.

Biochem. Biophys. Res. Commun. 232, 101-106, 1997

A/Title: Molecular cloning of anti-Ss-A/Re 60-kDa peptide fab fragments from infiltratin

A/Reference number: PC4279; MUID:97236289; PMID:9125110

A/Accession: PC4283

A/Molecule type: protein

A/Residues: 1-107 <SD2>

C/Comment: This antibody is commonly found in systemic autoimmune diseases such as Sjog

C/Superfamily: immunoglobulin V region; immunoglobulin homology

F:13-87/Domain: immunoglobulin homology <IMM>

Query Match 66.0%; Score 385; DB 2; Length 107;

Best Local Similarity 69.2%; Pred. No. 3.7e-26;

Matches 74; Conservative 10; Mismatches 23; Indels 0; Gaps 0;

Qy 5 ELTPDPAVSVALGQTVRTVTCGDSLSRYASWYQKPGQAPLVITYGKNNRPSGIPRFS 64

Db 1 ELTPDPAVSVALGQTVRTVTCGDSLSRYASWYQKPGQAPLVITYGKNNRPSGIPRFS 60

Qy 65 GSSSGNTASLTITGAQAEADADYICSSRDSSGNHWVFGGKTLTVLG 111

Db 61 GSSSGNTATLITISGVQAEADADYICQASDSSGTYVFGGKTLTVLG 107

Qy 65 GSSSGNTASLTITGAQAEADADYICSSRDSSGNHWVFGGKTLTVLG 111

Db 61 GSSSGNTATLITISGVQAEADADYICQASDSSGTYVFGGKTLTVLG 107

RESULT 20

S25745

Ig lambda chain - human (fragment)

C/Species: Homo sapiens (man)

C/Date: 22-Nov-1993 #sequence_revision 26-May-1995 #text_change 21-Jan-2000

C/Accession: S25745

R/Combratio, G.; Klobbeck, H.G.

Eur. J. Immunol. 21, 1513-1522, 1991

A/Title: V(lambda) and J(lambda)-C(lambda) gene segments of the human immunoglobulin lam

A/Reference number: S16439; MUID:91257162; PMID:1904362

A/Accession: S25745

A/Status: preliminary; translation not shown

A/Molecule type: mRNA

A/Residues: 1-226 <COM>

A/Cross-references: EMBL:X57810; NID:933717; PIDN:CAA40947.1; PID:933718

C/Superfamily: immunoglobulin V region; immunoglobulin homology

C/Keywords: heterotetramer; immunoglobulin

F:141-209/Domain: immunoglobulin homology <IMM>

C:Keywords: heterotetramer; immunoglobulin
F:15-91/Domain: immunoglobulin homology <IMM>

Query Match 62.1%; Score 362; DB 2; Length 111;
Best Local Similarity 65.5%; Pred. No. 3.5e-24;
Matches 72; Conservative 10; Mismatches 26; Indels 2; Gaps 1;

QY 4 SELTDDPAVVALGQTVRYTCQDGL--RSYASYQOKPGQAPVLVIYKKNRPSGIPDRFG 61
DB 2 SVLTQPPSVAGPQGRVITSCGSSNIGAGYDVHWYQOLPGAAPKLLIYGNMNRPSGVDP 61
QY 62 RFGSSSSNTASLITTTGAQAEDEADYCCSRDSSGNHWVFGGTELTIVLG 111
DB 62 RFGSGKSGTSALITTTGAQAEDEADYCCSYDSSLGSHVFGGTELTIVLG 111

RESULT 30

S25747
Ig lambda chain - human
C:Species: Homo sapiens (man)
C:Date: 22-Nov-1993 #sequence_revision 26-May-1995 #text_change 21-Jan-2000
C:Accession: S25747

R:Combiarto, G.; Klobbeck, H.G.
Eur. J. Immunol. 21, 1513-1522, 1991
A:Title: V(lambda) and J(lambda)-C(lambda) gene segments of the human immunoglobulin lam
A:Reference number: S16439; MUID:91257162; PMID:1904362
A:Accession: S25747
A:Status: preliminary; translation not shown
A:Molecule type: mRNA
A:Residues: 1-233 <COM>
A:Cross-references: EMBL:X57812; NID:933723; PID:CAA40949.1; PID:933724
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:148-216/Domain: immunoglobulin homology <IMM>

Query Match 62.1%; Score 362; DB 2; Length 233;
Best Local Similarity 65.1%; Pred. No. 7.3e-24;
Matches 69; Conservative 15; Mismatches 22; Indels 0; Gaps 0;

QY 6 LTQDPASVALGQTVRYTCQDGLRSYASYQOKPGQAPVLVIYKKNRPSGIPDRFG 65
DB 23 LTQPPSVAGPQGRVITSCGSSNIGAGYDVHWYQOLPGAAPKLLIYGNMNRPSGVDP 61
QY 66 SSSGNTASLITTTGAQAEDEADYCCSRDSSGNHWVFGGTELTIVLG 111
DB 83 SNSGTTATLITTSRVEAGDEADYCCVWDSSDHVFGGTELTIVLG 128

RESULT 31

IG lambda chain V-V region (Del) - human (tentative sequence)
C:Species: Homo sapiens (man)
C:Date: 24-Apr-1984 #sequence_revision 24-Apr-1984 #text_change 31-Mar-2000
C:Accession: A01985

R:Enlitz, M.
Eur. J. Biochem. 50, 49-69, 1974
A:Title: A new subgroup of human I-chains of the lambda-type. Primary structure of Bence
A:Reference number: A01985; MUID:75112179; PMID:4452363
A:Accession: A01985
A:Molecule type: protein
A:Residues: 1-108 <EUI>
A:Note: this is the first sequenced V region of lambda chain subgroup V
C:Comment: This is a Bence Jones protein.
C:Genetics:

A:Gene: GDB:IGLV@
A:Cross-references: GDB:119342; OMIM:147240
A:Map position: 22q11.2-22q11.2
C:Complex: An immunoglobulin heterotetramer subunit consists of two identical light (kap
hain disulfide bonds. In some cases, such as IgA and IgM, the subunits associate into la
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer
F:14-88/Domain: immunoglobulin homology <IMM>
F:21-86/Disulfide bonds: #status predicted

Query Match 61.4%; Score 358; DB 1; Length 108;
Best Local Similarity 64.2%; Pred. No. 7.5e-24;
Matches 68; Conservative 14; Mismatches 24; Indels 0; Gaps 0;

QY 6 LTQDPASVALGQTVRYTCQDGLRSYASYQOKPGQAPVLVIYKKNRPSGIPDRFG 65
DB 3 LSQPSVAVAGQGRVITSCGSSNIGAGYDVHWYQOLPGAAPKLLIYGNMNRPSGVDP 61
QY 66 SSSGNTASLITTTGAQAEDEADYCCSRDSSGNHWVFGGTELTIVLG 111
DB 63 SNSGTTATLITTSRVEAGDEADYCCVWDSSDHVFGGTELTIVLG 108

RESULT 32

L4HUBU
Ig lambda chain V-IV region (Bau) - human
C:Species: Homo sapiens (man)
C:Date: 24-Apr-1984 #sequence_revision 24-Apr-1984 #text_change 02-Sep-1997
C:Accession: A01981

R:Baczko, K.; Braun, D.; Hilschmann, N.
Hoppe-Seyler's Z. Physiol. Chem. 355, 131-154, 1974
A:Title: Pattern of antibody structure. The primary structure of a monoclonal immunoglob
A:Reference number: A01981; MUID:75059189; PMID:4435717
A:Accession: A01981
A:Molecule type: protein
A:Residues: 1-106 <BAC>
C:Comment: This is a Bence Jones protein.
C:Genetics:
A:Gene: GDB:IGLV@
A:Cross-references: GDB:119342; OMIM:147240
A:Map position: 22q11.2-22q11.2
C:Complex: An immunoglobulin heterotetramer subunit consists of two identical light (kap
hain disulfide bonds. In some cases, such as IgA and IgM, the subunits associate into la
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer
F:14-88/Domain: immunoglobulin homology <IMM>
F:21-86/Disulfide bonds: #status predicted

Query Match 61.2%; Score 357; DB 1; Length 106;
Best Local Similarity 65.1%; Pred. No. 8.9e-24;
Matches 69; Conservative 13; Mismatches 22; Indels 2; Gaps 1;

QY 6 LTQDPASVALGQTVRYTCQDGLRSYASYQOKPGQAPVLVIYKKNRPSGIPDRFG 65
DB 3 LTQPPSVAGPQGRVITSCGSSNIGAGYDVHWYQOLPGAAPKLLIYGNMNRPSGVDP 61
QY 66 SSSGNTASLITTTGAQAEDEADYCCSRDSSGNHWVFGGTELTIVLG 111
DB 63 SNSGTTATLITTSRVEAGDEADYCCVWDSSDHVFGGTELTIVLG 106

RESULT 33

S09713
Ig lambda chain V region - human
C:Species: Homo sapiens (man)
C:Date: 21-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 21-Jan-2000
C:Accession: S09713

R:Hughes-Jones, N.C.; Bye, J.M.; Beale, D.; Coadwell, J.
Biochem. J. 268, 135-140, 1990
A:Title: Nucleotide sequences and three-dimensional modelling of the VH and VL domains o
A:Reference number: S09710; MUID:90262535; PMID:2111699
A:Accession: S09713
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-132 <HUG>
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:14-110/Domain: immunoglobulin homology <IMM>

Query Match 60.9%; Score 355; DB 2; Length 132;
Best Local Similarity 66.4%; Pred. No. 1.6e-23;
Matches 73; Conservative 11; Mismatches 22; Indels 4; Gaps 2;

Qy 6 LTDPAPVAVAGQTVRVTCGDS--LRSYVASWYQKPGQAPVLYYKNNRPSGIPDRF 63
Db 23 LTDPAPVAVAGQTVRVTCGDS--LRSYVASWYQKPGQAPVLYYKNNRPSGIPDRF 82
Qy 64 GSSSGNTASLTITGAQAEDEADYCCSRDSSGNH--VWFGGTELTVLG 111
Db 83 GSSSGNTATLTISRVAAGDEADYCCQWMDSSSAHPGVFGGTELTVLG 132

RESULT 34

S51148
antibody light chain V region - human (fragment)
C/Species: Homo sapiens (man)
C/Date: 07-May-1995 #sequence_revision 01-Sep-1995 #text_change 21-Jan-2000
C/Accession: S51148
R/de Kruff, J.; Boel, E.; Logtenberg, T.
submitted to the EMBL Data Library, January 1995
A/Description: Selection and application of human SCFV antibody fragments from a semi-sy
A/Accession: S51148
A/Status: preliminary
A/Molecule type: mRNA
A/Residues: 1-112 <DEK>
A/Cross-references: EMBL:X83713
C/Superfamily: immunoglobulin V region; immunoglobulin homology
F:13-90/Domain: immunoglobulin homology <IMM>

Query Match 60.3%; Score 351.5; DB 2; Length 112;
Best Local Similarity 64.5%; Pred. No. 2.8e-23;
Matches 71; Conservative 9; Mismatches 27; Indels 3; Gaps 1;

Qy 5 ELTDPAPVAVAGQTVRVTCGDSLR--SYVASWYQKPGQAPVLYYKNNRPSGIPDRF 61
Db 1 ELTDPAPVAVAGQTVRVTCGDSLR--SYVASWYQKPGQAPVLYYKNNRPSGIPDRF 60
Qy 62 RFGSSSGNTASLTITGAQAEDEADYCCSRDSSGNHFWFGGTELTVLG 111
Db 61 RFGSSSGNTATLTISRVAAGDEADYCCQWMDSSSAHPGVFGGTELTVLG 110

RESULT 35

S25756
Ig lambda chain - human
C/Species: Homo sapiens (man)
C/Date: 22-Nov-1993 #sequence_revision 26-May-1995 #text_change 21-Jan-2000
C/Accession: S25756
R/Combario, G.; Klobeck, H.G.
J. Immunol. 21, 1513-1522, 1991
A/Title: V(lambdai) and J(lambdai) gene segments of the human immunoglobulin lam
A/Reference number: S16439; MUID:91257162; PMID:1904362
A/Accession: S25756
A/Status: preliminary; translation not shown
A/Molecule type: mRNA
A/Residues: 1-232 <COM>
A/Cross-references: EMBL:X57821; NID:G33741; PIDN:CAA0958.1; PID:G33742
C/Superfamily: immunoglobulin V region; immunoglobulin homology
C/Keywords: heterotetramer; immunoglobulin
F:147-215/Domain: immunoglobulin homology <IMM>

Query Match 60.3%; Score 351.5; DB 2; Length 232;
Best Local Similarity 65.1%; Pred. No. 5.7e-23;
Matches 69; Conservative 16; Mismatches 20; Indels 1; Gaps 1;

Qy 6 LTDPAPVAVAGQTVRVTCGDSLRSYVASWYQKPGQAPVLYYKNNRPSGIPDRF 65
Db 23 LTDPAPVAVAGQTVRVTCGDSLRSYVASWYQKPGQAPVLYYKNNRPSGIPDRF 82

Qy 66 SSSSGNTASLTITGAQAEDEADYCCSRDSSGNHFWFGGTELTVLG 111
Db 83 SSSSGNTATLTISRVAAGDEADYCCQWMDSSD-VWFGGTELTVLG 127

RESULT 36

L4HUX
Ig lambda chain V-IV region (MoI) - human
C/Species: Homo sapiens (man)
C/Date: 30-Sep-1987 #sequence_revision 30-Sep-1987 #text_change 02-Sep-1997
C/Accession: A26019
R/Holm, E.; Sletten, K.; Husby, G.
Biochem. J. 239, 545-551, 1986
A/Title: Structural studies of a carbohydrate-containing immunoglobulin-lambda-light-chain
A/Reference number: A26019; MUID:87156515; PMID:3103603
A/Accession: A26019

A/Molecule type: protein
A/Residues: 1-106 <HOL>
A/Note: Residues 29-30 and 56-58 were positioned by homology
C/Genetics:
A/Gene: GDB:IGLV@
A/Cross-references: GDB:119342; OMIM:147240
A/Map position: 22q11.2-22q11.2
C/Complex: An immunoglobulin heterotetramer subunit consists of two identical light (kappa)
chain disulfide bonds. In some cases, such as IgA and IgM, the subunits associate into la
C/Superfamily: immunoglobulin V region; immunoglobulin homology
C/Keywords: amyloid; glycoprotein; heterotetramer; immunoglobulin
F:14-88/Domain: immunoglobulin homology <IMM>
F:21-86/Disulfide bonds: #status predicted
F:90/Binding site: carbohydrate (asn) (covalent) #status predicted

Query Match 60.0%; Score 350; DB 1; Length 106;
Best Local Similarity 62.6%; Pred. No. 3.5e-23;
Matches 67; Conservative 17; Mismatches 21; Indels 2; Gaps 1;

Qy 5 ELTDPAPVAVAGQTVRVTCGDSLRSYVASWYQKPGQAPVLYYKNNRPSGIPDRF 64
Db 2 ELTDPAPVAVAGQTVRVTCGDSLRSYVASWYQKPGQAPVLYYKNNRPSGIPDRF 61
Qy 65 GSSSGNTASLTITGAQAEDEADYCCSRDSSGNHFWFGGTELTVLG 111
Db 62 GSSSGNTATLTISRVAAGDEADYCCQWMDSSD-VWFGGTELTVLG 106

RESULT 37

L4HUX
Ig lambda chain V-IV region (X) - human
C/Species: Homo sapiens (man)
C/Date: 24-Apr-1984 #sequence_revision 24-Apr-1984 #text_change 02-Sep-1997
C/Accession: A01982
R/Milstein, C.; Clegg, J.B.; Davis, J.M.
Biochem. J. 110, 631-652, 1968
A/Title: Immunoglobulin lambda-chains. The complete amino acid sequence of a Bence-Jones
A/Reference number: A90243; MUID:69088380; PMID:4883841
A/Accession: A01982
A/Molecule type: protein
A/Residues: 1-106 <MIL>
C/Comment: This is a Bence Jones protein.
C/Genetics:
A/Gene: GDB:IGLV@
A/Cross-references: GDB:119342; OMIM:147240
A/Map position: 22q11.2-22q11.2
C/Complex: An immunoglobulin heterotetramer subunit consists of two identical light (kappa)
chain disulfide bonds. In some cases, such as IgA and IgM, the subunits associate into la
C/Superfamily: immunoglobulin V region; immunoglobulin homology
C/Keywords: heterotetramer
F:14-88/Domain: immunoglobulin homology <IMM>
F:21-86/Disulfide bonds: #status predicted

Query Match 59.7%; Score 348; DB 1; Length 106;
Best Local Similarity 65.1%; Pred. No. 5.2e-23;
Matches 69; Conservative 11; Mismatches 24; Indels 2; Gaps 1;

Qy 5 ELTDPAPVAVAGQTVRVTCGDSLRSYVASWYQKPGQAPVLYYKNNRPSGIPDRF 64
Db 2 ELTDPAPVAVAGQTVRVTCGDSLRSYVASWYQKPGQAPVLYYKNNRPSGIPDRF 61
Qy 65 GSSSGNTASLTITGAQAEDEADYCCSRDSSGNHFWFGGTELTVL 110

Db 62 GSNSTNTATLTITSGTQAMDEADYICQAMDSMS--VFQGGTTLTVL 105

RESULT 38

S25746

Ig lambda chain - human

C/Species: Homo sapiens (man)

C/Date: 22-Nov-1995 #sequence_revision 26-May-1995 #text_change 21-Jan-2000

C/Accession: S25746

R/Combiarto: G.; Klobbeck, H.G.

Eur. J. Immunol. 21, 1513-1522, 1991

A/Title: V(lambda) and J(lambda)-C(lambda) Gene segments of the human immunoglobulin lambda

A/Reference number: S16439; MUID:91257162; PMID:1904362

A/Accession: S25746

A/Status: Preliminary; translation not shown

A/Molecule type: mRNA

A/Residues: 1-236 <COM>

A/Cross-references: EMBL:X57811; NID:933721; PIDN:CAA40948.1; PID:933722

C/Keywords: heterotetramer; immunoglobulin

F/15-219/Domain: immunoglobulin homology <IMM>

Query Match 59.4%; Score 346.5; DB 2; Length 236;
Best Local Similarity 61.3%; Pred. No. 1.5e-22;
Matches 68; Conservative 12; Mismatches 28; Indels 3; Gaps 1;

Db 21 SVLTQPPSVASGAPGQKIRISCSGTSSNIGAGHHVWYQOVPGTAPKLIYADNNRPSGVP 80

Qy 4 SELTQDPASVALGQTVRVTCQGDSLR--SYASWYQQRGQAPVLYIGKNNRPSGIP 60

Db 61 DRFGSSSGNTASLTITGAQAEADYICSSRDSGNNHWVGGGTETLVG 111

Qy 61 DRFGSSSGNTASLTITGAQAEADYICSSRDSGNNHWVGGGTETLVG 111

Db 81 DRISGSKGTSATLITGLQADEADYICGTFDSLSGWFVGATKLTVLG 131

RESULT 39

S44124

Ig lambda chain V region - human

C/Species: Homo sapiens (man)

C/Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 24-May-2001

C/Accession: S44124; S44109

R/Hawkins, R.E.; Zhu, D.; Owecka, M.; Winter, G.; Hamblin, T.J.; Stevenson, F.K.

submitted to the EMBL Data Library, March 1994

A/Description: Idiotypic vaccination against human B-cell lymphoma: rescue of variable

A/Reference number: S44105

A/Accession: S44124

A/Molecule type: DNA

A/Residues: 1-105 <HAW>

A/Cross-references: EMBL:Z31380

A/Accession: S44109

A/Molecule type: DNA

A/Residues: 1-105 <HAW>

A/Cross-references: EMBL:Z31381; NID:9472963; PIDN:CAA83256.1; PID:940521

C/Superfamily: immunoglobulin V region; immunoglobulin homology

C/Keywords: heterotetramer; immunoglobulin

F/15-89/Domain: immunoglobulin homology <IMM>

Query Match 59.3%; Score 346; DB 2; Length 105;
Best Local Similarity 64.2%; Pred. No. 7.6e-23;
Matches 70; Conservative 12; Mismatches 23; Indels 4; Gaps 2;

Qy 3 SSETQDPASVALGQTVRVTCQGDSLRSYASWYQQRGQAPVLYIGKNNRPSGIPDR 62

Db 1 SYLTQPPSVASVSPQATISCTSGDKGDXKVCWYQQRGQSPVLYIYQDTKRPSGIPER 60

Qy 63 FSGSSSGNTASLTITGAQAEADYICSSRDSGNNHWVGGGTETLVG 111

Db 61 FSGSSSGNTATLTITSGTQAMDEADYICQAMDSMT--TVFGGCTQ-AVLG 105

RESULT 40

S57442

Ig lambda chain V-J region - human (fragment)

C/Species: Homo sapiens (man)

C/Date: 10-Oct-1995 #sequence_revision 17-Nov-1995 #text_change 21-Jan-2000

C/Accession: S57442

R/Paterson, G.; Wilson, G.; Kennedy, P.G.E.; Willison, H.J.

submitted to the EMBL Data Library, June 1995

A/Description: Analysis of anti-GM1 ganglioside IgM antibodies cloned from motor neuropath

A/Reference number: S57408

A/Accession: S57442

A/Status: Preliminary

A/Molecule type: mRNA

A/Residues: 1-110 <PAT>

A/Cross-references: EMBL:X87892; NID:9871287; PIDN:CAA61143.1; PID:9871288

C/Superfamily: immunoglobulin V region; immunoglobulin homology

F/15-92/Domain: immunoglobulin homology <IMM>

Query Match 59.0%; Score 344; DB 2; Length 110;
Best Local Similarity 62.7%; Pred. No. 1.2e-22;
Matches 69; Conservative 17; Mismatches 20; Indels 4; Gaps 3;

Qy 4 SELTQDPASVALGQTVRVTCQGDS--LRSY-YASWYQQRGQAPVLYIGKNNRPSGIP 60

Db 2 SALTQPPASVSGSPQATISCTGTSTDIGAVNYSWYQQRGQAPKLIYVNNRPSGVS 61

Qy 61 DRFGSSSGNTASLTITGAQAEADYICSSRDSGNNHWVGGGTETLV 110

Db 62 TRFGSSSGNTASLTITGLQADEADYICGTFDSLSGWFVGATKLTVL 110

RESULT 41

L1HUBL

Ig lambda chain precursor V-I region (BL2) - human

C/Species: Homo sapiens (man)

C/Date: 30-Jun-1987 #sequence_revision 30-Jun-1987 #text_change 22-Jun-1999

C/Accession: A01966

R/Tsujimoto, Y.; Croce, C.M.

Nucleic Acids Res. 12, 9407-9414, 1984

A/Title: Molecular cloning of a human immunoglobulin lambda chain variable sequence.

A/Reference number: A01966; MUID:85062823; PMID:6095199

A/Accession: A01966

A/Molecule type: mRNA

A/Residues: 1-130 <TRSU>

A/Cross-references: GB:X01147; NID:933335; PIDN:CAA25598.1; PID:9758087

C/Genetic: GB

A/Genes: GDB:IGLV@

A/Cross-references: GDB:119342; OMIM:147240

A/Map position: 22q11.2-22q11.2

C/Complex: An immunoglobulin heterotetramer subunit consists of two identical light (Kap

hain disulfide bonds. In some cases, such as IgA and IgM, the subunits associate into la

C/Superfamily: immunoglobulin V region; immunoglobulin homology

C/Keywords: heterotetramer; immunoglobulin

F/120-130/Product: Ig lambda chain V-I region. (BL2) #status predicted <SIG>

F/20-115/Region: V segment

F/34-110/Domain: immunoglobulin homology <IMM>

F/116-130/Region: J segment

F/41-108/Disulfide bonds: #status predicted

Query Match 59.0%; Score 344; DB 1; Length 130;
Best Local Similarity 61.8%; Pred. No. 1.4e-22;
Matches 68; Conservative 13; Mismatches 27; Indels 2; Gaps 1;

Qy 4 SELTQDPASVALGQTVRVTCQGDS--LRSYASWYQQRGQAPVLYIGKNNRPSGIPD 61

Db 21 SVLTQPPSVASAPQATISCTSGSSNIGDNDYVSWYQQRGQAPKLIYDNNRPSGIPD 80

Qy 62 RFGSSSGNTASLTITGAQAEADYICSSRDSGNNHWVGGGTETLVG 111

Db 81 RFGSSSGNTATLTITGLQADEADYICGTFDSLSGWFVGATKLTVLG 130

RESULT 42

S31515

A:Residues: 1-129 <HMB>
A:Cross-references: EMBL:X54446; NID:G37923; PIDD:CA438313.1; PID:G930121
R:Haiderarachchi, N.; Goldfarb, I.S.; Ikematsu, H.; Burratero, S.E.; Wilder, R.L.; Nockings
Int. Immunol. 3, 865-875, 1991
A:Title: Complete sequence of the genes encoding the V(H) and V(L) regions of low- and h
patient.
A:Reference number: S23716; MUID:92031262; PMID:1718404
A:Accession: S23723
A:Molecule type: mRNA
A:Residues: 19-129 <HAW>
A:Cross-references: EMBL:X54446
A:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: immunoglobulin
F:1-18/Domain: signal sequence (fragment) #status predicted <SIG>
F:19-129/Product: Ig lambda chain (fragment) #status predicted <MAT>
F:33-109/Domain: immunoglobulin homology <IMM>

Query Match 58.1%; Score 339; DB 2; Length 129;
 Percent Identity 60.0%; Pred. No. 3.7e-22;
 Conserved Domains 66; Conservative 14; Mismatches 28; Indels 2; Gaps 1.

QY 4 SELQDDPVSVVALGGTVARTCCGDS--RASYASVYQOQKPGQAPLTVLYGKNNRPSGIPD 61
 DB 20 SVLRQPFASGTPGQGRVITISCGSSSNIGSNVYVYQDLPGRAPKLLIRYNNQRPSSVDP 79

QY 62 RFGSSSGSNTVSLTTGAQADDEADYYCSSRDSGNHHVFGGGLTLLVIG 111
 DB 80 RFGSGKSTASLAIISGRSEDEADYYCAAMDSDLSGNVFGGGLTLLVIG 129

Search completed: November 26, 2003, 13:41:42
Job time : 13.8077 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using SW model

Run on: November 26, 2003, 13:37:50 ; Search time 13.7564 Seconds
(without alignments)
341.405 Million cell updates/sec

Title: US-09-880-748-327_COPY_139_249

Perfect score: 583

Sequence: 1 AFSSELTQDPVAVSVALGQTV.....RDSGNHWVFGGTELTVLG 111

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 328717 seqs, 42310858 residues

1 number of hits satisfying chosen parameters: 328717

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	551	94.5	278	3	US-09-260-527-3
2	551	94.5	280	3	US-09-260-527-1
3	551	94.5	309	4	US-09-079-029-9
4	551	94.5	312	4	US-09-079-029-10
5	535.5	91.9	109	2	US-08-665-202-34
6	535.5	91.9	109	4	US-09-315-574-34
7	524	88.9	109	2	US-08-652-816A-16
8	489	83.9	97	2	US-08-665-202-35
9	489	83.9	97	4	US-09-315-574-35
10	484.5	83.1	104	4	US-08-793-450-2
11	484.5	83.1	238	4	US-08-793-450-6
12	478	82.0	104	3	US-09-240-274-49
13	468	80.3	106	3	US-09-240-274-48
14	466	79.9	106	3	US-09-240-274-50
15	464	79.6	103	2	US-08-273-146-71
16	461	79.1	106	4	US-09-240-274-47
17	436.5	73.9	108	4	US-09-025-769B-20
18	426.5	73.2	105	1	US-08-488-113B-157
19	426.5	73.2	105	1	US-08-477-484B-157
20	426.5	73.2	105	1	US-08-107-669D-21
21	426.5	73.2	105	1	US-08-472-788A-21
22	426.5	73.2	105	2	US-08-477-531B-21
23	426.5	73.2	105	2	US-08-646-360-157
24	426.5	73.2	105	2	US-08-082-842A-21
25	426.5	73.2	105	3	US-08-839-765-157
26	426.5	73.2	105	3	US-09-136-389-157
27	426.5	73.2	105	4	US-09-610-838-157

28	417	71.5	108	1	US-08-360-125-12	Sequence 12, Appl
29	417	71.5	108	2	US-08-450-578-12	Sequence 12, Appl
30	417	71.5	108	2	US-09-017-628-12	Sequence 12, Appl
31	417	71.5	108	2	US-09-014-880-12	Sequence 12, Appl
32	417	71.5	108	4	US-08-450-363-12	Sequence 12, Appl
33	407	69.8	109	3	US-09-157-370-5	Sequence 5, Appl
34	395	67.8	107	4	US-09-025-769B-34	Sequence 55, Appl
35	395	67.8	107	4	US-10-039-785-53	Sequence 53, Appl
36	392.5	67.3	249	4	US-08-478-039-91	Sequence 91, Appl
37	385	66.0	109	1	US-08-476-349A-91	Sequence 91, Appl
38	385	66.0	109	1	US-08-345-321-8	Sequence 8, Appl
39	381.5	65.4	143	2	US-08-259-372A-10	Sequence 10, Appl
40	379	65.0	108	1	US-08-468-671-10	Sequence 2, Appl
41	379	65.0	108	1	US-08-468-671-10	Sequence 2, Appl
42	379	65.0	234	4	US-09-526-098-2	Sequence 16, Appl
43	379	65.0	234	4	US-08-259-372A-16	Sequence 16, Appl
44	371	63.6	106	1	US-08-468-671-16	Sequence 16, Appl
45	371	63.6	106	1	US-08-468-671-16	Sequence 16, Appl

ALIGNMENTS

```
RESULT 1
US-09-260-527-3
; Sequence 3, Application US/09260527A
; Patent No. 6228599
; GENERAL INFORMATION:
; APPLICANT: Knox, J.P.
; APPLICANT: Mikkelsen, J.D.
; APPLICANT: Willats, W.G.
; TITLE OF INVENTION: ANTIBODY
; FILE REFERENCE: DYOUI9.001AUS
; CURRENT APPLICATION NUMBER: US/09/260,527A
; CURRENT FILING DATE: 1999-02-26
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 3
; LENGTH: 278
; TYPE: PRT
; ORGANISM: UNKNOWN
; FEATURE:
; OTHER INFORMATION: Anti-homogalacturonan specific antibodies selected
; OTHER INFORMATION: from a native phage display library known as the
; OTHER INFORMATION: Synthetic scFv Library (#1) from the Centre for
; OTHER INFORMATION: Protein Engineering, MRC Centre, Cambridge, UK
US-09-260-527-3
Query Match          94.5% Score 551; DB 3; Length 278;
Best Local Similarity 96.3% Pred. No. 6e-45; 1; Indels 0; Gaps 0;
Matches 105; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
QY      3 SSELTPDPAVAVSVALGQTVRTCCGDSLSRSYASWYQKFGQAPVLIYKNNRPSGIDPR 62
      |||
DB      153 SSELTPDPAVAVSVALGQTVRTCCGDSLSRSYASWYQKFGQAPVLIYKNNRPSGIDPR 212
      |||
QY      63 FSGSSSGNTASTITTCGAQAEDEADYCCSRSSSGNHWVFGGTELTVLG 111
      |||
DB      213 FSGSSSGNTASTITTCGAQAEDEADYCCSRSSSGNHWVFGGTELTVLG 261
      |||
RESULT 2
US-09-260-527-1
; Sequence 1, Application US/09260527A
; Patent No. 6228599
; GENERAL INFORMATION:
; APPLICANT: Knox, J.P.
; APPLICANT: Mikkelsen, J.D.
; APPLICANT: Willats, W.G.
; TITLE OF INVENTION: ANTIBODY
; FILE REFERENCE: DYOUI9.001AUS
; CURRENT APPLICATION NUMBER: US/09/260,527A
; CURRENT FILING DATE: 1999-02-26
```

NUMBER OF SEQ ID NOS: 7
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO: 1
LENGTH: 280
TYPE: PRT
ORGANISM: UNKNOWN
FEATURE:
OTHER INFORMATION: Anti-homogalacturonan specific antibodies from a
OTHER INFORMATION: phage display library known as the Synthetic scfv
OTHER INFORMATION: Library (#1) from the Centre for Protein
OTHER INFORMATION: Engineering, MRC Centre, Cambridge, UK.
US-09-260-527-1

Query Match 94.5%; Score 551; DB 3; Length 280;
Best Local Similarity 96.3%; Pred. No. 6,1e-45;
Matches 105; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 3 SSELTPDPAVSVALGQTVRTTCGDSLSRSYASWYQKPGQAPVLVIYKNNRPSGIPDR 62
155 SSELTPDPAVSVALGQTVRTTCGDSLSRSYASWYQKPGQAPVLVIYKNNRPSGIPDR 214
DB 215 FSGSSSGNTASLTITGAQAEDEADYCCNSRDSSGNHVVFGGTTKLTVLG 263

RESULT 3
US-09-079-029-9
Sequence 9, Application US/09079029
Patent No. 6342369

GENERAL INFORMATION:
APPLICANT: Adams, Camilla W.
APPLICANT: Ashkenazi, Avi J.
APPLICANT: Chuntcharapai, Anan
APPLICANT: Kim, Kyung J.
TITLE OF INVENTION: Apo-2 Receptor
NUMBER OF SEQUENCES: 14
CORRESPONDENCE ADDRESS:
ADDRESSER: Genentech, Inc.
STREET: 1 DNA Way
CITY: South San Francisco
STATE: California
COUNTRY: USA
ZIP: 94080
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Winpatin (Genentech)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/079,029
FILING DATE:
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Marschang, Diane L.
REGISTRATION NUMBER: 35,600
REFERENCE/DOCKET NUMBER: P1101R2
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650/225-5416
TELEFAX: 650/952-9881
INFORMATION FOR SEQ ID NO: 9:
SEQUENCE CHARACTERISTICS:
LENGTH: 309 amino acids
TYPE: Amino Acid
TOPOLOGY: Linear
US-09-079-029-9

Query Match 94.5%; Score 551; DB 4; Length 309;
Best Local Similarity 96.3%; Pred. No. 6,8e-45;
Matches 105; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 3 SSELTPDPAVSVALGQTVRTTCGDSLSRSYASWYQKPGQAPVLVIYKNNRPSGIPDR 62
155 SSELTPDPAVSVALGQTVRTTCGDSLSRSYASWYQKPGQAPVLVIYKNNRPSGIPDR 214

DB 175 SSELTPDPAVSVALGQTVRTTCGDSLSRSYASWYQKPGQAPVLVIYKNNRPSGIPDR 234

QY 63 FSGSSSGNTASLTITGAQAEDEADYCCNSRDSSGNHVVFGGTTKLTVLG 111
235 FSGSSSGNTASLTITGAQAEDEADYCCNSRDSSGNHVVFGGTTKLTVLG 283

RESULT 4
US-09-079-029-10
Sequence 10, Application US/09079029
Patent No. 6342369

GENERAL INFORMATION:
APPLICANT: Adams, Camilla W.
APPLICANT: Ashkenazi, Avi J.
APPLICANT: Chuntcharapai, Anan
APPLICANT: Kim, Kyung J.
TITLE OF INVENTION: Apo-2 Receptor
NUMBER OF SEQUENCES: 14
CORRESPONDENCE ADDRESS:
ADDRESSER: Genentech, Inc.
STREET: 1 DNA Way
CITY: South San Francisco
STATE: California
COUNTRY: USA
ZIP: 94080
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Winpatin (Genentech)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/079,029
FILING DATE:
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Marschang, Diane L.
REGISTRATION NUMBER: 35,600
REFERENCE/DOCKET NUMBER: P1101R2
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650/225-5416
TELEFAX: 650/952-9881
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 312 amino acids
TYPE: Amino Acid
TOPOLOGY: Linear
US-09-079-029-10

Query Match 94.5%; Score 551; DB 4; Length 312;
Best Local Similarity 96.3%; Pred. No. 6,9e-45;
Matches 105; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 3 SSELTPDPAVSVALGQTVRTTCGDSLSRSYASWYQKPGQAPVLVIYKNNRPSGIPDR 62
178 SSELTPDPAVSVALGQTVRTTCGDSLSRSYASWYQKPGQAPVLVIYKNNRPSGIPDR 237
DB 63 FSGSSSGNTASLTITGAQAEDEADYCCNSRDSSGNHVVFGGTTKLTVLG 111
238 FSGSSSGNTASLTITGAQAEDEADYCCNSRDSSGNHVVFGGTTKLTVLG 286

RESULT 5
US-08-665-202-34
Sequence 34, Application US/08665202
Patent No. 5977322

GENERAL INFORMATION:
APPLICANT: Marks, James D.
APPLICANT: Schier, Robert
TITLE OF INVENTION: No. 5977322e1 High Affinity Human Antibodies to
TITLE OF INVENTION: Tumor Antigens
NUMBER OF SEQUENCES: 141
CORRESPONDENCE ADDRESS:
ADDRESSER: Townsend and Townsend and Crew LLP

STREET: Two Embarcadero Center, Eighth Floor
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111-3834
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/665,202
FILING DATE: 13-JUN-1996
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/000,238
FILING DATE: 14-JUN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/000,250
FILING DATE: 15-JUN-1995
ATTORNEY/AGENT INFORMATION:
NAME: Hunter, Tom
REGISTRATION NUMBER: 38,498
REFERENCE/DOCKET NUMBER: 02307E-061410
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 576-0200
TELEFAX: (415) 576-0300
INFORMATION FOR SEQ ID NO: 34:
SEQUENCE CHARACTERISTICS:
LENGTH: 109 amino acids
TYPE: amino acid
STRANDEDNESS:
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-665-202-34

Query Match 91.9%; Score 535.5; DB 2; Length 109;
Best Local Similarity 93.6%; Pred. No. 6.2e-44;
Matches 102; Conservative 5; Mismatches 1; Indels 1; Gaps 1;

QY 4 SELTDDPAVSVALGQTVRTCCGDSLRSYASWYQOKPGQAPVLVIYGNRNPSCGIPDRF 63
DB 1 SELTDDPAVSVALGQTVRTCCGDSLRSYASWYQOKPGQAPVLVIYGNRNPSCGIPDRF 60

QY 64 SSSSGNTASLTITGAQAEDEADYCCSRDSSGN-HWVFGGTELTVLG 111
DB 61 SSSSGNTASLTITGAQAEDEADYCCSRDSSGNPWVFGGTKVTVLG 109

US-09-315-574-34
Sequence 34, Application US/09315574
Patent No. 6512097
GENERAL INFORMATION:
APPLICANT: Marks, James D.
APPLICANT: Schier, Robert
TITLE OF INVENTION: No. 6512097el High Affinity Human Antibodies to
TITLE OF INVENTION: Tumor Antigens
NUMBER OF SEQUENCES: 141
CORRESPONDENCE ADDRESS:
ADDRESSER: Majestic, Parsons, Siebert & Hsue P.C.
STREET: Four Embarcadero Center, Suite 1100
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111-4106
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/315,574

FILING DATE: 20-MAY-99
CLASSIFICATION: 530
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/000,238
FILING DATE: 14-JUN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/000,250
FILING DATE: 15-JUN-1995
ATTORNEY/AGENT INFORMATION:
NAME: Hunter, Tom
REGISTRATION NUMBER: 38,498
REFERENCE/DOCKET NUMBER: 02307E-061411
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 576-0200
TELEFAX: (415) 576-0300
INFORMATION FOR SEQ ID NO: 34:
SEQUENCE CHARACTERISTICS:
LENGTH: 109 amino acids
TYPE: amino acid
STRANDEDNESS:
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-09-315-574-34

Query Match 91.9%; Score 535.5; DB 4; Length 109;
Best Local Similarity 93.6%; Pred. No. 6.2e-44;
Matches 102; Conservative 5; Mismatches 1; Indels 1; Gaps 1;

QY 4 SELTDDPAVSVALGQTVRTCCGDSLRSYASWYQOKPGQAPVLVIYGNRNPSCGIPDRF 63
DB 1 SELTDDPAVSVALGQTVRTCCGDSLRSYASWYQOKPGQAPVLVIYGNRNPSCGIPDRF 60

QY 64 SSSSGNTASLTITGAQAEDEADYCCSRDSSGN-HWVFGGTELTVLG 111
DB 61 SSSSGNTASLTITGAQAEDEADYCCSRDSSGNPWVFGGTKVTVLG 109

RESULT 7
US-08-652-816A-16
Sequence 16, Application US/08652816A
Patent No. 5872215
GENERAL INFORMATION:
APPLICANT: Osbourn, JK
APPLICANT: Allen, DJ
TITLE OF INVENTION: Specific binding members, materials and
TITLE OF INVENTION: methods.
NUMBER OF SEQUENCES: 53
CORRESPONDENCE ADDRESS:
ADDRESSER: Marshall, O'Toole, Gerstein, Murray & Borun
STREET: 6300 Sears Tower, 233 South Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: United States of America
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/652,816A
FILING DATE: 23-MAY-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9125579.4
FILING DATE: 02-DEC-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9125579.8
FILING DATE: 02-DEC-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9206318.9

FILING DATE: 24-MAR-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9206372.6
FILING DATE: 23-SEP-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9525004.9
FILING DATE: 07-DEC-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9610824.6
FILING DATE: 23-MAY-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/GB92/02240
FILING DATE: 02-DEC-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/244,597
FILING DATE: 01-JUN-1994
ATTORNEY/AGENT INFORMATION:
NAME: David W. Clough
REGISTRATION NUMBER: 36,107
REFERENCE/DOCKET NUMBER: 2811/33308
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312-474-6300
INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 109 amino acids
TYPE: amino acid
TOPOLOGY: linear
US-08-652-816A-16

Query Match 89.9%; Score 524; DB 2; Length 109;
Best Local Similarity 92.5%; Pred. No. 7.6e-43;
Matches 99; Conservative 4; Mismatches 4; Indels 0; Gaps 0;

QY 3 SSELTDPAVSVALGQTVAVTCQGDLSRSYASWYQKRGQAPVLYIGKNNRPSGIPDR 62
DB 1 SSELTDPAVSVALGQTVAVTCQGDLSRSYASWYQKRGQAPVLYIGKNNRPSGIPDR 60
QY 63 FSGSSSGNTASLTITGAQAEADYCCSRDSSGNHNVFGGKLETV 109
DB 61 FSGSSSGNTASLTITGAQAEADYCCSRDSSGNHNVFGGKLETV 107

RESULT 8

US-08-665-202-35
Sequence 35, Application US/08665202
Patent No. 5977322

GENERAL INFORMATION:

APPLICANT: Marks, James D.

TITLE OF INVENTION: No. 5977322el High Affinity Human Antibodies to

TITLE OF INVENTION: Tumor Antigens

NUMBER OF SEQUENCES: 141

CORRESPONDENCE ADDRESS:

ADDRESSEE: Townsend and Townsend and Crew LLP

STREET: Two Embarcadero Center, Eighth Floor

CITY: San Francisco

STATE: California

COUNTRY: USA

ZIP: 94111-3834

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/665,202

FILING DATE: 13-JUN-1996

CLASSIFICATION: 424

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 60/000,238

FILING DATE: 14-JUN-1995

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 60/000,250

FILING DATE: 15-JUN-1995
ATTORNEY/AGENT INFORMATION:
NAME: Hunter, Tom
REGISTRATION NUMBER: 38,498
REFERENCE/DOCKET NUMBER: 02307E-061410
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 576-0200
TELEFAX: (415) 576-0300
INFORMATION FOR SEQ ID NO: 35:
SEQUENCE CHARACTERISTICS:
LENGTH: 97 amino acids
TYPE: amino acid
STRANDEDNESS:
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-665-202-35

Query Match 83.9%; Score 489; DB 2; Length 97;
Best Local Similarity 95.9%; Pred. No. 1.4e-39;
Matches 93; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 4 SELTDPAVSVALGQTVAVTCQGDLSRSYASWYQKRGQAPVLYIGKNNRPSGIPDR 63
DB 1 SSELTDPAVSVALGQTVAVTCQGDLSRSYASWYQKRGQAPVLYIGKNNRPSGIPDR 60
QY 64 SGSSSGNTASLTITGAQAEADYCCSRDSSGNHNV 100
DB 61 SGSSSGNTASLTITGAQAEADYCCSRDSSGNHNV 97

RESULT 9

US-09-315-574-35
Sequence 35, Application US/09315574
Patent No. 6512097

GENERAL INFORMATION:

APPLICANT: Marks, James D.

TITLE OF INVENTION: No. 6512097el High Affinity Human Antibodies to

TITLE OF INVENTION: Tumor Antigens

NUMBER OF SEQUENCES: 141

CORRESPONDENCE ADDRESS:

ADDRESSEE: Majestic, Parsons, Siebert & Haue P. C.

STREET: Four Embarcadero Center, Suite 1100

CITY: San Francisco

STATE: California

COUNTRY: USA

ZIP: 94111-4106

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/315,574

FILING DATE: 20-MAY-99

CLASSIFICATION: 530

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 60/000,238

FILING DATE: 14-JUN-1995

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 60/000,250

FILING DATE: 15-JUN-1995

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/665,202

FILING DATE: 13-JUN-1996

ATTORNEY/AGENT INFORMATION:

NAME: Hunter, Tom

REGISTRATION NUMBER: 38,498

REFERENCE/DOCKET NUMBER: 02307E-061411

TELECOMMUNICATION INFORMATION:

TELEPHONE: (415) 576-0200

TELEFAX: (415) 576-0300

INFORMATION FOR SEQ ID NO: 35:

SEQUENCE CHARACTERISTICS:
LENGTH: 97 amino acids
TYPE: amino acid
STRANDEDNESS:
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-09-315-574-35

Query Match 83.9%; Score 489; DB 4; Length 97;
Best Local Similarity 95.9%; Pred. No. 1.4e-39;
Matches 93; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 4 ELTODPAVVALGQTVRTTCGDSLRSYASWYQKPGQAPVLVIYGNRPSSGIPDRF 63
DB 1 SLTODPAVVALGQTVRTTCGDSLRSYASWYQKPGQAPVLVIYGNRPSSGIPDRF 60

QY 64 GSSSGNTASLTITGAQAEDEADYCCSRDSSGNHVV 100
DB 61 GSSSGNTASLTITGAQAEDEADYCCSRDSSGNHVV 97

US-08-793-450-2
Sequence 2, Application US/08793450

PATENT No. 6312690
GENERAL INFORMATION:
APPLICANT: EDELMAN, LENA
APPLICANT: MARGARITTE, CHRISTEL
APPLICANT: KACZOREK, MICHEL
APPLICANT: CHABIRI, HASSAN
TITLE OF INVENTION: MONOCLONAL RECOMBINANT ANTI-RHESUS D
NUMBER OF SEQUENCES: 25
CORRESPONDENCE ADDRESS:
ADDRESS: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,
STREET: 1755 SOUTH JEFFERSON DAVIS HIGHWAY, SUITE 400
CITY: ARLINGTON
STATE: VA
COUNTRY: USA
ZIP: 22202

COMPUTER READABLE FORM:
MEDIUM TYPE: floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/793,450
FILING DATE: 03-MAR-1997
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: FR 94/10566
FILING DATE: 02-SEP-1994
ATTORNEY/AGENT INFORMATION:
NAME: OBLON, NORMAN F.
REGISTRATION NUMBER: 24,618
REFERENCE/DOCKET NUMBER: 660-118-0 PCT
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-413-3000
TELEFAX: 703-413-2220
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 104 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-793-450-2

Query Match 83.1%; Score 484.5; DB 4; Length 104;
Best Local Similarity 94.1%; Pred. No. 4.1e-39;
Matches 94; Conservative 5; Mismatches 3; Indels 5; Gaps 1;

QY 5 ELTODPAVVALGQTVRTTCGDSLRSYASWYQKPGQAPVLVIYGNRPSSGIPDRF 64

DB 3 ELTODPAVVALGQTVRTTCGDSLRSYASWYQKPGQAPVLVIYGNRPSSGIPDRF 62
QY 65 GSSSGNTASLTITGAQAEDEADYCCSRDSSGNHVVFGGTELTVLG 111
DB 63 GSSSGNTASLTITGAQAEDEADYCCNSGK-----VFGGTELTVLG 104

RESULT 11
US-08-793-450-6

Sequence 6, Application US/08793450
PATENT No. 6312690
GENERAL INFORMATION:
APPLICANT: EDELMAN, LENA
APPLICANT: MARGARITTE, CHRISTEL
APPLICANT: KACZOREK, MICHEL
APPLICANT: CHABIRI, HASSAN
TITLE OF INVENTION: MONOCLONAL RECOMBINANT ANTI-RHESUS D
NUMBER OF SEQUENCES: 25
CORRESPONDENCE ADDRESS:
ADDRESS: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,
STREET: 1755 SOUTH JEFFERSON DAVIS HIGHWAY, SUITE 400
CITY: ARLINGTON
STATE: VA
COUNTRY: USA
ZIP: 22202

COMPUTER READABLE FORM:
MEDIUM TYPE: floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/793,450
FILING DATE: 03-MAR-1997
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: FR 94/10566
FILING DATE: 02-SEP-1994
ATTORNEY/AGENT INFORMATION:
NAME: OBLON, NORMAN F.
REGISTRATION NUMBER: 24,618
REFERENCE/DOCKET NUMBER: 660-118-0 PCT
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-413-3000
TELEFAX: 703-413-2220
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 238 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-793-450-6

Query Match 83.1%; Score 484.5; DB 4; Length 238;
Best Local Similarity 87.9%; Pred. No. 1e-38;
Matches 94; Conservative 5; Mismatches 3; Indels 5; Gaps 1;

QY 5 ELTODPAVVALGQTVRTTCGDSLRSYASWYQKPGQAPVLVIYGNRPSSGIPDRF 64
DB 22 ELTODPAVVALGQTVRTTCGDSLRSYASWYQKPGQAPVLVIYGNRPSSGIPDRF 81
QY 65 GSSSGNTASLTITGAQAEDEADYCCSRDSSGNHVVFGGTELTVLG 111
DB 82 GSSSGNTASLTITGAQAEDEADYCCNSGK-----VFGGTELTVLG 123

RESULT 12
US-09-240-274-49
Sequence 49, Application US/09240274
PATENT No. 6255455
GENERAL INFORMATION:

APPLICANT: Siegel, Donald L.
TITLE OF INVENTION: Rh(D)-BINDING PROTEINS AND MAGNETICALLY ACTIVATED CELL
TITLE OF INVENTION: SORTING METHOD FOR PRODUCTION THEREOF
FILE REFERENCE: 09596-4202
CURRENT APPLICATION NUMBER: US/09/240,274
CURRENT FILING DATE: 1999-01-29
EARLIER APPLICATION NUMBER: 60/081,380
EARLIER FILING DATE: 1998-04-10
EARLIER APPLICATION NUMBER: 60/028,550
EARLIER FILING DATE: 1996-10-11
NUMBER OF SEQ ID NOS: 224
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 49
LENGTH: 104
TYPE: PRF
ORGANISM: Homo sapiens
FEATURE:
OTHER INFORMATION: anti-Rh(D) chain J04
US-09-240-274-49

Query Match 82.0%; Score 478; DB 3; Length 104;
Best Local Similarity 90.3%; Pred. No. 1.7e-38;
Matches 93; Conservative 3; Mismatches 5; Indels 2; Gaps 1;

QY 8 QDPVSVAGGTAVTCGGDSLRSYASWYQKFGQAPVLVIYGNRPSGIPDRFGSS 67
DB 4 QDPVSVAGGTAVTCGGDSLRSYASWYQKFGQAPVLVIYGNRPSGIPDRFGSS 63
QY 68 SGNATSLTTGAQAEDEADYCCSRDSSGNHWFVGGTETLTVL 110
DB 64 SGNATSLTTGAQAEDEADYCCSRDSSGNHWFVGGTETLTVL 104

RESULT 13
US-09-240-274-48

Sequence 48, Application US/09240274
Patent No. 6255455
GENERAL INFORMATION:
APPLICANT: Siegel, Donald L.
TITLE OF INVENTION: Rh(D)-BINDING PROTEINS AND MAGNETICALLY ACTIVATED CELL
TITLE OF INVENTION: SORTING METHOD FOR PRODUCTION THEREOF
FILE REFERENCE: 09596-4202
CURRENT APPLICATION NUMBER: US/09/240,274
CURRENT FILING DATE: 1999-01-29
EARLIER APPLICATION NUMBER: 60/081,380
EARLIER FILING DATE: 1998-04-10
EARLIER APPLICATION NUMBER: 60/028,550
EARLIER FILING DATE: 1996-10-11
NUMBER OF SEQ ID NOS: 224
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 48
LENGTH: 106
TYPE: PRF
ORGANISM: Homo sapiens
FEATURE:
OTHER INFORMATION: anti-Rh(D) chain J02
US-09-240-274-48

Query Match 80.3%; Score 468; DB 3; Length 106;
Best Local Similarity 85.4%; Pred. No. 1.5e-37;
Matches 88; Conservative 6; Mismatches 9; Indels 0; Gaps 0;

QY 8 QDPVSVAGGTAVTCGGDSLRSYASWYQKFGQAPVLVIYGNRPSGIPDRFGSS 67
DB 4 QDPVSVAGGTAVTCGGDSLRSYASWYQKFGQAPVLVIYGNRPSGIPDRFGSS 63
QY 68 SGNATSLTTGAQAEDEADYCCSRDSSGNHWFVGGTETLTVL 110
DB 64 SGNATSLTTGAQAEDEADYCCSRDSSGNHWFVGGTETLTVL 106

RESULT 14
US-09-240-274-50

Sequence 50, Application US/09240274
Patent No. 6255455
GENERAL INFORMATION:
APPLICANT: Siegel, Donald L.
TITLE OF INVENTION: Rh(D)-BINDING PROTEINS AND MAGNETICALLY ACTIVATED CELL
TITLE OF INVENTION: SORTING METHOD FOR PRODUCTION THEREOF
FILE REFERENCE: 09596-4202
CURRENT APPLICATION NUMBER: US/09/240,274
CURRENT FILING DATE: 1999-01-29
EARLIER APPLICATION NUMBER: 60/081,380
EARLIER FILING DATE: 1998-04-10
EARLIER APPLICATION NUMBER: 60/028,550
EARLIER FILING DATE: 1996-10-11
NUMBER OF SEQ ID NOS: 224
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 50
LENGTH: 106
TYPE: PRF
ORGANISM: Homo sapiens
FEATURE:
OTHER INFORMATION: anti-Rh(D) chain J05
US-09-240-274-50

Query Match 79.9%; Score 466; DB 3; Length 106;
Best Local Similarity 83.5%; Pred. No. 2.4e-37;
Matches 86; Conservative 9; Mismatches 8; Indels 0; Gaps 0;

QY 8 QDPVSVAGGTAVTCGGDSLRSYASWYQKFGQAPVLVIYGNRPSGIPDRFGSS 67
DB 4 QDPVSVAGGTAVTCGGDSLRSYASWYQKFGQAPVLVIYGNRPSGIPDRFGSS 63
QY 68 SGNATSLTTGAQAEDEADYCCSRDSSGNHWFVGGTETLTVL 110
DB 64 SGNATSLTTGAQAEDEADYCCSRDSSGNHWFVGGTETLTVL 106

RESULT 15
US-08-273-146-71

Sequence 71, Application US/08273146
Patent No. 5855885
GENERAL INFORMATION:
APPLICANT: Smith, Rodger
APPLICANT: McCafferty, John
APPLICANT: Chiswell, David
APPLICANT: Darsley, Michael J.
APPLICANT: Fitzgerald, Kevin
APPLICANT: Kanten, John H.
APPLICANT: Martin, Mark T.
APPLICANT: Tiltman, Richard C.
APPLICANT: Williams, Richard O.
TITLE OF INVENTION: The Isolation and Production of
TITLE OF INVENTION: Catalytic Antibodies using Phage Technology
NUMBER OF SEQUENCES: 71
CORRESPONDENCE ADDRESS:
ADDRESSER: IGEN, Inc.
STREET: 1530 East Jefferson St.
CITY: Rockville
STATE: MD
COUNTRY: USA
ZIP: 20852

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/273,146
FILING DATE: 14-JUL-1994
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Ryan, John W.
REGISTRATION NUMBER: 33,771
REFERENCE/DOCKET NUMBER: 09000

TELECOMMUNICATION INFORMATION:
TELEPHONE: 301-984-8000
TELEFAX: 301-230-0158
INFORMATION FOR SEQ ID NO: 71:
SEQUENCE CHARACTERISTICS:
LENGTH: 103 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-273-146-71

Query Match
Best Local Similarity 79.1%; Score 461; DB 2; Length 103;
Matches 89; Conservative 2; Mismatches 7; Indels 0; Gaps 0;

QY 14 VALGQVTRVTCGGDSLRSYASMYOQKPGQAPVLVIYGNKRRPSGIPDRFSSSGNTAS 73
DB 6 VALGQVTRVTCGGDSLRSYASMYOQKPGQAPVLVIYGNKRRPSGIPDRFSSSGNTAS 65
74 LITIGAQAEDADYYCCSRDSSGNHWFVGGGTETVLG 111
66 LITIGAQAEDADYYCLSRDSSGNHWFVGGGTETVLG 103

RESULT 16
US-09-240-274-47
Sequence 47, Application US/09240274
Patent No. 6255455
GENERAL INFORMATION:
APPLICANT: Siegel, Donald L.
TITLE OF INVENTION: RHD-BINDING PROTEINS AND MAGNETICALLY ACTIVATED CELL
FILE REFERENCE: 09596-4202
CURRENT APPLICATION NUMBER: US/09/240,274
CURRENT FILING DATE: 1999-01-29
EARLIER APPLICATION NUMBER: 60/081,380
EARLIER FILING DATE: 1998-04-10
EARLIER APPLICATION NUMBER: 60/028,550
EARLIER FILING DATE: 1996-10-11
NUMBER OF SEQ ID NOS: 224
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 47
LENGTH: 106
TYPE: PRT
ORGANISM: Homo sapiens
FEATURE:
OTHER INFORMATION: anti-Rh(D) chain J01
US-09-240-274-47

Query Match
Best Local Similarity 79.1%; Score 461; DB 3; Length 106;
Matches 87; Conservative 6; Mismatches 10; Indels 0; Gaps 0;

QY 8 QDPANVALGQVTRVTCGGDSLRSYASMYOQKPGQAPVLVIYGNKRRPSGIPDRFSSSS 67
DB 4 QDPANVALGQVTRVTCGGDSLRSYASMYOQKPGQAPVLVIYGNKRRPSGIPDRFSSSS 63
QY 68 SGNASLITITGAQAEDADYYCCSRDSSGNHWFVGGGTETVLG 110
DB 64 SGNALITITGAQAEDADYYCCSRDSSGNHWFVGGGTETVLG 106

RESULT 17
US-09-025-769B-20
Sequence 20, Application US/09025769B
Patent No. 630064
GENERAL INFORMATION:
APPLICANT: Knappik, Achim
APPLICANT: Pack, Peter
APPLICANT: Ilag, Vic
APPLICANT: Ge, Liming
APPLICANT: Moroney, Simon
APPLICANT: Plueckthun, Andreas

TITLE OF INVENTION: Protein/(poly)peptide libraries
NUMBER OF SEQUENCES: 373
CORRESPONDENCE ADDRESS:
ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
STREET: 1251 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: USA
ZIP: 10021

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/025,769B
FILING DATE: 18-FEB-1998
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: EP 95 11 3021.0
FILING DATE: 18-AUG-1995
ATTORNEY/AGENT INFORMATION:
NAME: James F. Haley, Jr., Esq.
REGISTRATION NUMBER: 27,794
REFERENCE/DOCKET NUMBER: MORPHO/5
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212)596-9000
TELEFAX: (212)596-9000
INFORMATION FOR SEQ ID NO: 20:
SEQUENCE CHARACTERISTICS:
LENGTH: 108 amino acids
TYPE: amino acid
STRANDEDNESS:
TOPOLOGY: linear
MOLECULE TYPE: protein
US-09-025-769B-20

Query Match
Best Local Similarity 74.9%; Score 436.5; DB 4; Length 108;
Matches 86; Conservative 7; Mismatches 13; Indels 1; Gaps 1;

QY 5 ELTQDPANVALGQVTRVTCGGDSLRSYASMYOQKPGQAPVLVIYGNKRRPSGIPDRFS 64
DB 2 ELTQDPANVALGQVTRVTCGGDSLRSYASMYOQKPGQAPVLVIYGNKRRPSGIPDRFS 61
QY 65 GSSSGNTASLITITGAQAEDADYYCCSRDSSGNHWFVGGGTETVLG 111
DB 62 GSSSGNTASLITITGAQAEDADYYCCSRDSSGNHWFVGGGTETVLG 107

RESULT 18
US-08-488-113B-157
Sequence 157, Application US/08488113B
Patent No. 5744580
GENERAL INFORMATION:
APPLICANT: Better, Marc D.
APPLICANT: Carrioli, Stephen F.
APPLICANT: Studnika, Gary M.
TITLE OF INVENTION: Immunotoxins Comprising Ribosome-Inactivating
NUMBER OF SEQUENCES: 169
CORRESPONDENCE ADDRESS:
ADDRESSEE: McAndrews, Held & Malloy, Ltd.
STREET: 500 West Madison Street, 34th floor
CITY: Chicago
STATE: Illinois
COUNTRY: USA
ZIP: 60661

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/488,113B
FILING DATE: 07-JUN-1995
CLASSIFICATION: 530
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/425,336
FILING DATE: 18-APR-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/064,691
FILING DATE: 12-MAY-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/988,430
FILING DATE: 09-DEC-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/901,707
FILING DATE: 19-JUN-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/787,567
FILING DATE: 04-NOV-1991
ATTORNEY/AGENT INFORMATION:
NAME: McNicholas, Janet M.
REGISTRATION NUMBER: 32,918
REFERENCE/DOCKET NUMBER: 11022US07/200-70.P3.C2A
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312/707-8889
TELEFAX: 312/707-9155
TELEX: 650 388-1248
INFORMATION FOR SEQ ID NO: 157:
SEQUENCE CHARACTERISTICS:
LENGTH: 105 amino acids
TYPE: amino acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-488-113B-157

Query Match 73.2%; Score 426.5; DB 1; Length 105;
Best Local Similarity 80.6%; Pred. No. 1.3e-33;
Matches 87; Conservative 8; Mismatches 10; Indels 3; Gaps 3;
QY 4 SEITDPAVSVALGQTVAVTCQDSLRYSYASWYQOKPGQAPLVITYKNNRPSGIPDRF 63
DB 1 SEITDPAVSVALGQTVAVTCQDSLRYSYASWYQOKPGQAPLVITYGR-NRPSGIPDRF 58
QY 64 SSSSSGNTASLTITGAQAEDEADYICSSRDSGNHWFVGGGTELTVLG 111
DB 59 SSSSSGHTASLTITGAQAEDEADYICNSRDSGK-VLFGGTELTVLG 105
ULT 19
US-08-477-484B-157
Sequence 157, Application US/08477484B
Patent No. 5756699
GENERAL INFORMATION:
APPLICANT: Better, Marc D.
APPLICANT: Carroli, Stephen F.
APPLICANT: Studnicka, Gary M.
TITLE OF INVENTION: Immunotoxins Comprising Ribosome-Inactivating
NUMBER OF SEQUENCES: 169
CORRESPONDENCE ADDRESS:
ADDRESSER: McAndrews, Held & Malloy, Ltd.
STREET: 500 West Madison Street, 34th Floor
CITY: Chicago
STATE: Illinois
COUNTRY: USA
ZIP: 60661
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/477,484B

FILING DATE: 07-JUN-1995
CLASSIFICATION: 530
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/425,336
FILING DATE: 18-APR-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/064,691
FILING DATE: 12-MAY-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/988,430
FILING DATE: 09-DEC-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/901,707
FILING DATE: 19-JUN-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/787,567
FILING DATE: 04-NOV-1991
ATTORNEY/AGENT INFORMATION:
NAME: McNicholas, Janet M.
REGISTRATION NUMBER: 32,918
REFERENCE/DOCKET NUMBER: 11022US07/200-70.P3.C2A
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312/707-8889
TELEFAX: 312/707-9155
TELEX: 650 388-1248
INFORMATION FOR SEQ ID NO: 157:
SEQUENCE CHARACTERISTICS:
LENGTH: 105 amino acids
TYPE: amino acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-477-484B-157

Query Match 73.2%; Score 426.5; DB 1; Length 105;
Best Local Similarity 80.6%; Pred. No. 1.3e-33;
Matches 87; Conservative 8; Mismatches 10; Indels 3; Gaps 3;
QY 4 SEITDPAVSVALGQTVAVTCQDSLRYSYASWYQOKPGQAPLVITYKNNRPSGIPDRF 63
DB 1 SEITDPAVSVALGQTVAVTCQDSLRYSYASWYQOKPGQAPLVITYGR-NRPSGIPDRF 58
QY 64 SSSSSGNTASLTITGAQAEDEADYICSSRDSGNHWFVGGGTELTVLG 111
DB 59 SSSSSGHTASLTITGAQAEDEADYICNSRDSGK-VLFGGTELTVLG 105
RESULT 20
US-08-107-669D-21
Sequence 21, Application US/08107669D
Patent No. 576886
GENERAL INFORMATION:
APPLICANT: Studnicka, Gary M.
TITLE OF INVENTION: Modified Antibody Variable Domains (as amended)
NUMBER OF SEQUENCES: 67
CORRESPONDENCE ADDRESS:
ADDRESSER: Sterne, Kessler, Goldstein and Fox P.L.L.C.
STREET: 1100 New York Ave., N.W., Suite 600
CITY: Washington
STATE: D.C.
COUNTRY: United States of America
ZIP: 20005-3934
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/107,669D
FILING DATE: 13-AUG-1993
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US92/10906

[illegible]

RESULT 23

US-08-646-360-157
Sequence 157, Application US/08646360
Patent No. 5837491
GENERAL INFORMATION:
APPLICANT: Betteer, Marc D.
APPLICANT: Carroll, Stephen F.
APPLICANT: Studilka, Gary M.
TITLE OF INVENTION: Immunotoxins Comprising Ribosome-Inactivating
TITLE OF INVENTION: Proteins
NUMBER OF SEQUENCES: 173
CORRESPONDENCE ADDRESSES:
ADDRESSEE: McAndrews, Held & Malloy, Ltd.
STREET: 500 West Madison Street, 34th floor
CITY: Chicago
STATE: Illinois
COUNTRY: USA
ZIP: 60661
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/646,360
FILING DATE: 13-MAY-1996
CLASSIFICATION: 530
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US94/05348
FILING DATE: 12-MAY-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/064,691
FILING DATE: 12-MAY-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/988,430
FILING DATE: 09-DEC-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/901,707
FILING DATE: 19-JUN-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/787,567
FILING DATE: 04-NOV-1991
ATTORNEY/AGENT INFORMATION:
NAME: McNicholas, Janet M.
REGISTRATION NUMBER: 32,918
REFERENCE/DOCKET NUMBER: 200-70.P4
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312/707-8889
TELEFAX: 312/707-9155
TELEX: 650 388-1248
INFORMATION FOR SEQ ID NO: 157:
SEQUENCE CHARACTERISTICS:
LENGTH: 105 amino acids
TYPE: amino acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-646-360-157

Query	4	SELTDPANSVALLGTVRVTCQGDLSRYSVYASVYQKQPGQAPVVLVIYKNNRPSGIPDRF	63
Query Match	73.2%	Score 426.5; DB 2; Length 105;	
Best Local Similarity	80.6%;	Pred. No. 1.3e-33;	
Matches	87; Conservative	8; Mismatches 10; Indels 3; Gaps 3	

Db 1 SELLPPPSVVAAGQR-RTTCGSDXLGXVDAXWYQQKPCQAPFLVIYGR-NRPSGIPIDRF 58

Qy 64 SGSSSGNTASLITTTGAQAEADYYCSSRDSGNHWVFGGTELVLG 111

Db 59 SGSSSGHTASLITTTGAQAEADYYCNSRDSGK-VLFGGTELVIVLG 105

RESULT 24

```

US-08-082-842A-21
: Sequence 21, Application US/08082842A
: Patent No. 5869619
: GENERAL INFORMATION:
: APPLICANT: Studnicka, Gary M.
: TITLE OF INVENTION: Modified Antibody Variable Domains
: NUMBER OF SEQUENCES: 89
: CORRESPONDENCE ADDRESS:
: ADDRESSEE: Sterne, Kessler, Goldstein and Fox P.L.L.C.
: STREET: 1100 New York Ave., N.W., Suite 600
: CITY: Washington
: STATE: D.C.
: COUNTRY: USA
: ZIP: 20005-3934
: COMPUTER READABLE FORM:
: MEDIUM TYPE: Floppy disk
: COMPUTER: IBM PC compatible
: OPERATING SYSTEM: PC-DOS/MS-DOS
: SOFTWARE: Patent Release #1.0, Version #1.25
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/082.842A
: FILING DATE: 23-JUN-1993
: CLASSIFICATION: 530
: PRIOR APPLICATION DATA:
: APPLICATION NUMBER: PCT/US92/10906
: FILING DATE: 14-DEC-1992
: PRIOR APPLICATION DATA:
: APPLICATION NUMBER: US 07/808,464
: FILING DATE: 13-DEC-1991
: ATTORNEY/AGENT INFORMATION:
: NAME: Cimbala, Michele A.
: REGISTRATION NUMBER: 33,851
: REFERENCE/DOCKET NUMBER: 0610.1000002
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: 202/371-2600
: TELEFAX: 202/371-2540
: TELEX:
: INFORMATION FOR SEQ ID NO: 21:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 105 amino acids
: TYPE: amino acid
: TOPOLOGY: linear
: MOLECULE TYPE: protein
: US-08-082-842A-21

Query Match 73.2%; Score 426.5; DB 2; Length 105;
Best Local Similarity 80.6%; Pred. No. 1.3e-33;
Matches 87; Conservative 8; Mismatches 10; Indels 3; Gaps 3

QY 4 SELLTDDPAVSVALGTVTCGGSDLSRKYASWYQKPGQA PVLTYIGKNNRPPSGIPDRF 63
||||| 1 SELLTDDPAVSVALGTVTCGGSDLSRKYASWYQKPGQA PVLTYIGKNNRPPSGIPDRF 63
Db 1 SELLTDDPAVSVALGTVTCGGSDLSRKYASWYQKPGQA PVLTYIGKNNRPPSGIPDRF 63
||||| 1 SELLTDDPAVSVALGTVTCGGSDLSRKYASWYQKPGQA PVLTYIGKNNRPPSGIPDRF 63
QY 64 SSSSSGHTASLTITGAQAEADADYYC SSRDSSGNHWVFGGTELTVLG 111
||||| 64 SSSSSGHTASLTITGAQAEADADYYC SSRDSSGNHWVFGGTELTVLG 111
Db 59 SSSSSGHTASLTITGAQAEADADYYC SSRDSSGNHWVFGGTELTVLG 105
||||| 59 SSSSSGHTASLTITGAQAEADADYYC SSRDSSGNHWVFGGTELTVLG 105

RESULT 25
US-08-839-765-157
: Sequence 157, Application US/08839765
: Patent No. 6146631
: GENERAL INFORMATION:
: APPLICANT: Better, Marc D.

```

APPLICANT: Carroll, Stephen F.
TITLE OF INVENTION: Immunotoxins Comprising Ribosome-Inactivating
NUMBER OF SEQUENCES: 169
CORRESPONDENCE ADDRESS:
ADDRESSEE: McAndrews, Held & Malloy, Ltd.
STREET: 500 West Madison Street, 34th floor
CITY: Chicago
STATE: Illinois
COUNTRY: USA
ZIP: 60661
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/939,765
FILING DATE: 15-APR-1997
CLASSIFICATION: 530
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/425,336
FILING DATE: 18-APR-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/064,691
FILING DATE: 12-MAY-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/988,430
FILING DATE: 09-DEC-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/901,707
FILING DATE: 19-JUN-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/787,567
FILING DATE: 04-NOV-1991
ATTORNEY/AGENT INFORMATION:
NAME: McNicholas, Janet M.
REGISTRATION NUMBER: 32,918
REFERENCE/DOCKET NUMBER: 11022US09/200-70.P3.C3
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312/707-8889
TELEFAX: 312/707-9155
TELEX: 650 388-1248
INFORMATION FOR SEQ ID NO: 157:
SEQUENCE CHARACTERISTICS:
LENGTH: 105 amino acids
TYPE: amino acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-839-765-157

Query Match 73.2%; Score 426.5; DB 3; Length 105;
Best Local Similarity 80.6%; Pred. No. 1.3e-33;
Matches 87; Conservative 8; Mismatches 10; Indels 3; Gaps 3;

QY 4 SELTODPAVSVALGQTVRVTCGDSLSRSYASWYQKPGQAPVLVIYGNRNPSPGIDPRF 63
DB 1 SELTQPPSVSAVPGQT-RITCSGDLGXYPDAXWYQKPGQAPVLVIYGR-NRPSGIDPRF 58

QY 64 SGSSSGNTASLTITGAQAEDADYVYCSSRDSGSGNHWFVGGTETLVLG 111
DB 59 SGSSSGHTASLTITGAQAEDADYVYCNRSRDSGK-VLFGGGRKLTVLG 105

RESULT 26
US-09-136-389-157
Sequence 157, Application US/09136389
Patent No. 6146850
GENERAL INFORMATION:
APPLICANT: Better, Marc D.
APPLICANT: Carroll, Stephen F.

APPLICANT: Studnika, Gary M.
TITLE OF INVENTION: Immunotoxins Comprising Ribosome-Inactivating
NUMBER OF SEQUENCES: 173
CORRESPONDENCE ADDRESS:
ADDRESSEE: McAndrews, Held & Malloy, Ltd.
STREET: 500 West Madison Street, 34th floor
CITY: Chicago
STATE: Illinois
COUNTRY: USA
ZIP: 60661
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/136,389
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/646,360
FILING DATE: 13-MAY-1996
APPLICATION NUMBER: PCT/US94/05348
FILING DATE: 12-MAY-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/064,691
FILING DATE: 12-MAY-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/988,430
FILING DATE: 09-DEC-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/901,707
FILING DATE: 19-JUN-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/787,567
FILING DATE: 04-NOV-1991
ATTORNEY/AGENT INFORMATION:
NAME: McNicholas, Janet M.
REGISTRATION NUMBER: 32,918
REFERENCE/DOCKET NUMBER: 200-70.P4
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312/707-8889
TELEFAX: 312/707-9155
TELEX: 650 388-1248
INFORMATION FOR SEQ ID NO: 157:
SEQUENCE CHARACTERISTICS:
LENGTH: 105 amino acids
TYPE: amino acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: protein
US-09-136-389-157

Query Match 73.2%; Score 426.5; DB 3; Length 105;
Best Local Similarity 80.6%; Pred. No. 1.3e-33;
Matches 87; Conservative 8; Mismatches 10; Indels 3; Gaps 3;

QY 4 SELTODPAVSVALGQTVRVTCGDSLSRSYASWYQKPGQAPVLVIYGNRNPSPGIDPRF 63
DB 1 SELTQPPSVSAVPGQT-RITCSGDLGXYPDAXWYQKPGQAPVLVIYGR-NRPSGIDPRF 58

QY 64 SGSSSGNTASLTITGAQAEDADYVYCSSRDSGSGNHWFVGGTETLVLG 111
DB 59 SGSSSGHTASLTITGAQAEDADYVYCNRSRDSGK-VLFGGGRKLTVLG 105

RESULT 27
US-09-610-838-157
Sequence 157, Application US/09610838
Patent No. 6376217
GENERAL INFORMATION:
APPLICANT: Better, Marc D.

APPLICANT: Carroll, Stephen F.
APPLICANT: Studinka, Gary M.
TITLE OF INVENTION: Immunotoxins Comprising Ribosome-Inactivating
TITLE OF INVENTION: Proteins
NUMBER OF SEQUENCES: 173
CORRESPONDENCE ADDRESS:
ADDRESSEE: McAndrews, Held & Malloy, Ltd.
STREET: 500 West Madison Street, 34th floor
CITY: Chicago
STATE: Illinois
COUNTRY: USA
ZIP: 60661
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/610,838
CLASSIFICATION:
FILING DATE: 06-JUL-2000
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/136,389
FILING DATE: 18-AUG-1998
APPLICATION NUMBER: 08/646,360
FILING DATE: 13-MAY-1996
APPLICATION NUMBER: PCT/US94/05348
FILING DATE: 12-MAY-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/064,691
FILING DATE: 12-MAY-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/988,430
FILING DATE: 09-DEC-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/901,707
FILING DATE: 19-JUN-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/787,567
FILING DATE: 04-NOV-1991
ATTORNEY/AGENT INFORMATION:
NAME: McMichols, Janet M.
REGISTRATION NUMBER: 32,918
REFERENCE/DOCKET NUMBER: 200-70-P4
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312/707-8889
TELEFAX: 312/707-9155
TELEX: 650 388-1248
INFORMATION FOR SEQ ID NO: 157:
SEQUENCE CHARACTERISTICS:
LENGTH: 105 amino acids
TYPE: amino acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: protein
US-09-610-838-157
Query Match 73.2%; Score 426.5; DB 4; Length 105;
Best Similarity 80.6%; Pred. No. 1.3e-33;
Matches 87; Conservative 8; Mismatches 10; Indels 3; Gaps 3;
QY 4 SELTODPAVSVALQIVRTVTCQSDLSRSYASWYQKPGQAPVLYVYKKNRPSGIPDRP 63
DB 1 SELTODPAVSVALQIVRTVTCQSDLSRSYASWYQKPGQAPVLYVYKKNRPSGIPDRP 58
QY 64 SSSSSGNTASLTITGAADPEADYICSSRSSGHHWVFGGCTELTVIG 111
DB 59 SSSSSGHTASLTITGAADPEADYICSSRSSGK-VLFGGCTELTVIG 105
RESULT 28
US-08-360-125-12
Sequence 12, Application US/08360125

Patent No. 5767246
GENERAL INFORMATION:
APPLICANT: Saiko HOSOKAWA
APPLICANT: Toshiaki TAGAWA
APPLICANT: Yoko HIRAKAWA
APPLICANT: No. 5767246hiko ITO
APPLICANT: Kazuhito NAGAIKE
TITLE OF INVENTION: Human Monoclonal Antibody
TITLE OF INVENTION: Specifically Binding to Surface Antigen of Cancer
NUMBER OF SEQUENCES: 42
CORRESPONDENCE ADDRESS:
ADDRESSEE: Menderoth, Lind & Ponack
STREET: 805 Fifteenth Street, N.W., #700
CITY: Washington
STATE: D.C.
COUNTRY: U.S.A.
ZIP: 20005
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 5.25 inch, 500 kb
COMPUTER: IBM Compatible
OPERATING SYSTEM: MS-DOS
SOFTWARE: WordPerfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/360,125
FILING DATE:
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/905,534
FILING DATE: June 29, 1992
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warren M. Cheek, Jr.
REGISTRATION NUMBER: 33,367
REFERENCE/DOCKET NUMBER:
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-371-8850
TELEFAX:
TELEX:
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 108 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: protein
HYPOTHETICAL:
ANTI-SENSE:
FRAGMENT TYPE:
ORIGINAL SOURCE:
ORGANISM:
STRAIN:
INDIVIDUAL ISOLATE:
DEVELOPMENTAL STAGE:
HAPLOTYPE:
TISSUE TYPE:
CELL TYPE: Hybridoma producing human antibody 1-3-1
CELL LINE:
ORGANELLE:
IMMEDIATE SOURCE:
LIBRARY:
CLONE:
POSITION IN GENOME:
CHROMOSOME/SEGMENT:
MAP POSITION:
UNITS:
FEATURE:
NAME/KEY:
LOCATION:
IDENTIFICATION METHOD:
OTHER INFORMATION:
PUBLICATION INFORMATION:

NUMBER OF SEQ ID NOS: 42
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 12
LENGTH: 108
TYPE: PRT
ORGANISM: Unknown
FEATURE:
OTHER INFORMATION: Hybridoma producing human antibody 1-3-1
US-09-017-628-12

Query Match 71.5%; Score 417; DB 2; Length 108;
Best Local Similarity 73.8%; Pred. No. 1,1e-32;
Matches 79; Conservative 10; Mismatches 18; Indels 0; Gaps 0;

QY 5 ELTOPPAVSVALGQTVRVTCQGSLSRSYASWYQKPGQAPVLYYKKNRPSGIPDRFS 64
DB 2 ELTOPPSVSVSPGQTVRITCSGDALPKQYAYWYQKPGQAPVLYYKDSERPSGIPERS 61
65 GSSSGNTASLTITGAQAEDEADYCCSRDSSGNHWFVGGTGLTVLG 111
62 GSSSGTTLTITISGVQAEDEADYCCSADSSGTVEVFGGTLTVLG 108

RESULT 31
US-09-014-880-12
Sequence 12, Application US/09014880
Patent No. 5990297
GENERAL INFORMATION:
APPLICANT: Saiko HOSOKAWA et al.
TITLE OF INVENTION: HUMAN MONOCLONAL ANTIBODY SPECIFICALLY
TITLE OF INVENTION: BINDING TO SURFACE ANTIGEN OF CANCER CELL MEMBRANE
NUMBER OF SEQUENCES: 42
CORRESPONDENCE ADDRESS:
ADDRESSEE: Wenderoth, Lind & Ponack, L.L.P.
STREET: 2033 K Street, N.W., #800
CITY: Washington
STATE: D.C.
COUNTRY: U.S.A.
ZIP: 20006

COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.5 inch, 1.44 mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: MS-DOS
SOFTWARE: WordPerfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/014,880
FILING DATE: January 28, 1998
CLASSIFICATION: 536

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/450,578
FILING DATE: May 25, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/360,125
FILING DATE: December 20, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/905,534
FILING DATE: June 29, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warren M. Cheek, Jr.
REGISTRATION NUMBER: 33,367
REFERENCE/DOCKET NUMBER:
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-721-8200
TELEFAX: 202-721-8250

TELEX:
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 108 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: protein
ORIGINAL SOURCE:

CELL TYPE: Hybridoma producing human antibody 1-3-1
US-09-014-880-12

Query Match 71.5%; Score 417; DB 2; Length 108;
Best Local Similarity 73.8%; Pred. No. 1,1e-32;
Matches 79; Conservative 10; Mismatches 18; Indels 0; Gaps 0;

QY 5 ELTOPPAVSVALGQTVRVTCQGSLSRSYASWYQKPGQAPVLYYKKNRPSGIPDRFS 64
DB 2 ELTOPPSVSVSPGQTVRITCSGDALPKQYAYWYQKPGQAPVLYYKDSERPSGIPERS 61
65 GSSSGNTASLTITGAQAEDEADYCCSRDSSGNHWFVGGTGLTVLG 111
62 GSSSGTTLTITISGVQAEDEADYCCSADSSGTVEVFGGTLTVLG 108

RESULT 32
US-08-450-363-12
Sequence 12, Application US/08450363
Patent No. 6436434

GENERAL INFORMATION:
APPLICANT: Saiko HOSOKAWA
APPLICANT: Toshiaki TAGAWA
APPLICANT: Yoko HIRAKAWA
APPLICANT: No. 6436434-Ihiko ITO
TITLE OF INVENTION: Human Monoclonal Antibody
TITLE OF INVENTION: Specifically Binding to Surface Antigen of Cancer
NUMBER OF SEQUENCES: 42
CORRESPONDENCE ADDRESS:
ADDRESSEE: Wenderoth, Lind & Ponack
STREET: 805 Fifteenth Street, N.W., #700
CITY: Washington
STATE: D.C.
COUNTRY: U.S.A.
ZIP: 20005

COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 5.25 inch, 500 kb
COMPUTER: IBM Compatible
OPERATING SYSTEM: MS-DOS
SOFTWARE: WordPerfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/450,363
FILING DATE: May 25, 1995
CLASSIFICATION: 530

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/360,125
FILING DATE: December 20, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/905,534
FILING DATE: June 29, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warren M. Cheek, Jr.
REGISTRATION NUMBER: 33,367
REFERENCE/DOCKET NUMBER:
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-371-8850
TELEFAX:

TELEX:
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 108 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: protein
HYPOTHETICAL:
ANTI-SENSE:
FRAGMENT TYPE:
ORIGINAL SOURCE:
ORGANISM:
STRAIN:

INDIVIDUAL ISOLATE:
DEVELOPMENTAL STAGE:
HAPLOTYPE:
TISSUE TYPE:
CELL TYPE: Hybridoma producing human antibody 1-3-1
CELL LINE:
ORGANELLAR:
IMMEDIATE SOURCE:
LIBRARY:
CLONE:
POSITION IN GENOME:
CHROMOSOME/SEGMENT:
MAP POSITION:
UNITS:
FEATURE:
NAME/KEY:
LOCATION:
IDENTIFICATION METHOD:
OTHER INFORMATION:
PUBLICATION INFORMATION:
AUTHORS:
TITLE:
JOURNAL:
VOLUME:
ISSUE:
PAGES:
DATE:
DOCUMENT NUMBER:
FILING DATE:
PUBLICATION DATE:
RELEVANT RESIDUES IN SEQ ID NO:
US-08-450-363-12

Query Match 71.5%; Score 417; DB 4; Length 108;
Best Local Similarity 73.8%; Pred. No. 1.1e-32;
Matches 79; Conservative 10; Mismatches 18; Indels 0; Gaps 0;

Qy 5 ELTODPAVSVALGQTVRVTCQDLSRSYASWYQKPGQAPLVLYIGKNNRPSGIPDRF 64
Db 2 ELTODPAVSVALGQTVRVTCQDLSRSYASWYQKPGQAPLVLYIGKNNRPSGIPDRF 61
Qy 65 GSSSGNTASLTITGAQAEDEADYCCSRDSSGNHWVFGGTELTVLG 111
Db 62 GSSSGNTASLTITGAQAEDEADYCCSRDSSGNHWVFGGTELTVLG 108

RESULT 33

US-09-157-370-5
Sequence 5, Application US/09157370A
Patent No. 6262238

GENERAL INFORMATION:
APPLICANT: STEIBE, Boris
TITLE OF INVENTION: PROCESS FOR MODIFYING THE STABILITY OF ANTIBODIES
FILE REFERENCE: P8341-8072
CURRENT APPLICATION NUMBER: US/09/157,370A
EARLIER FILING DATE: 1998-09-21
EARLIER APPLICATION NUMBER: 08/765,179
EARLIER FILING DATE: 1997-01-14
EARLIER APPLICATION NUMBER: PCT/EP95/02626
EARLIER FILING DATE: 1995-07-06
EARLIER APPLICATION NUMBER: DE/P44 25 115.7
EARLIER FILING DATE: 1994-07-15
NUMBER OF SEQ ID NOS: 10
SOFTWARE: Patent Ver. 2.1
SEQ ID NO 5
LENGTH: 109
TYPE: PRT
ORGANISM: Homo sapiens
US-09-157-370-5

Query Match 69.8%; Score 407; DB 3; Length 109;
Best Local Similarity 75.9%; Pred. No. 9.7e-32;

Matches 82; Conservative 6; Mismatches 18; Indels 2; Gaps 1;
Qy 4 SELTODPAVSVALGQTVRVTCQDLSRSYASWYQKPGQAPLVLYIGKNNRPSGIPDRF 63
Db 2 SELTODPAVSVALGQTVRVTCQDLSRSYASWYQKPGQAPLVLYIGKNNRPSGIPDRF 61
Qy 64 GSSSGNTASLTITGAQAEDEADYCCSRDSSGNHWVFGGTELTVLG 111
Db 62 GSSSGNTASLTITGAQAEDEADYCCSRDSSGNHWVFGGTELTVLG 107

RESULT 34

US-09-025-769B-34
Sequence 34, Application US/09025769B
Patent No. 630064

GENERAL INFORMATION:
APPLICANT: Knappik, Achim
APPLICANT: Pack, Peter
APPLICANT: Ilag, Vic
APPLICANT: Ge, Liming
APPLICANT: Moroney, Simon
APPLICANT: Plueckthun, Andreas
TITLE OF INVENTION: Protein/(Poly)peptide libraries
NUMBER OF SEQUENCES: 373
CORRESPONDENCE ADDRESS:
ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
STREET: 1251 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: USA
ZIP: 10021
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/025,769B
FILING DATE: 18-FEB-1998
PRIOR APPLICATION DATA:
APPLICATION NUMBER: EP 95 11'3021.0
FILING DATE: 18-AUG-1995
ATTORNEY/AGENT INFORMATION:
NAME: James F. Haley, Jr., Esq.
REGISTRATION NUMBER: 27,794
REFERENCE/DOCKET NUMBER: MORPHO/5
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212)596-9000
TELEFAX: (212)596-9090
INFORMATION FOR SEQ ID NO: 34:
SEQUENCE CHARACTERISTICS:
LENGTH: 107 amino acids
TYPE: amino acid
STRANDEDNESS:
TOPOLOGY: linear
MOLECULE TYPE: protein
US-09-025-769B-34

Query Match 67.8%; Score 395; DB 4; Length 107;
Best Local Similarity 69.0%; Pred. No. 1.3e-30;
Matches 78; Conservative 12; Mismatches 13; Indels 10; Gaps 2;

Qy 3 SSELTOPPAVSVALGQTVRVTCQDLSRSYASWYQKPGQAPLVLYIGKNNRPSGIPDR 62
Db 1 SYELTOPPAVSVALGQTVRVTCQDLSRSYASWYQKPGQAPLVLYIGKNNRPSGIPDR 60
Qy 63 FSSSGNTASLTITGAQAEDEADYCCSRDSSGNHWVFGGTELTVLG 111
Db 61 FSSSGNTASLTITGAQAEDEADYCCSRDSSGNHWVFGGTELTVLG 107

RESULT 35
US-09-025-769B-55

Sequence 55, Application US/090257698
Patent No. 6300064
GENERAL INFORMATION:
APPLICANT: Knappik, Achim
APPLICANT: Pack, Peter
APPLICANT: Ilag, Vic
APPLICANT: Ge, Liming
APPLICANT: Moroney, Simon
APPLICANT: Plueckhuhn, Andreas
TITLE OF INVENTION: Protein/(Poly)peptide libraries
NUMBER OF SEQUENCES: 373
CORRESPONDENCE ADDRESS:
ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
STREET: 1251 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: USA
ZIP: 10021
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/025,769B
FILING DATE: 18-FEB-1998
PRIOR APPLICATION DATA:
APPLICATION NUMBER: EP 95 11 3021.0
FILING DATE: 18-AUG-1995
ATTORNEY/AGENT INFORMATION:
NAME: James F. Haley, Jr., Esq.
REGISTRATION NUMBER: 27,794
REFERENCE/DOCKET NUMBER: MORPHO/5
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212)596-9000
TELEFAX: (212)596-9090
INFORMATION FOR SEQ. ID NO: 55:
SEQUENCE CHARACTERISTICS:
LENGTH: 107 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-09-025-769B-55

Query Match 67.8%; Score 395; DB 4; Length 107;
Best Local Similarity 69.0%; Pred. No. 1.3e-30;
Matches 78; Conservative 12; Mismatches 13; Indels 10; Gaps 2;

Db 3 SSELTDPAVSVALGQTVRVTTCGDSLSRYSVSWYQKPGQAPVLYIGKNNRPSGIPDR 62
1 SYELTPPSVSVAPGGTARISCSGDLGDKYASWYQKPGQAPVLYIDSDSPSGIPER 60

QY 63 FSGSSSGNTASLTITGAQAEDEADYVCCSRDSSGNHW---VFGGTELTVLG 111
DB 61 FSGSSSGNTATLTISGTADEADYVCC---QHTTPPVVGGGKTLVLG 107

RESULT 36
US-10-039-785-53
Sequence 53, Application US/10039785
Patent No. 6538938
GENERAL INFORMATION:
APPLICANT: Salcedo et al.
TITLE OF INVENTION: Antibodies that Immunospecifically Bind to TRAIL
FILE REFERENCE: P5550
CURRENT APPLICATION NUMBER: US/10/039,785
FILING DATE: 2002-05-07
PRIOR APPLICATION NUMBER: 60/369,860
PRIOR FILING DATE: 2002-04-05
PRIOR APPLICATION NUMBER: 60/341,237
PRIOR FILING DATE: 2001-12-20
PRIOR APPLICATION NUMBER: 60/331,310

PRIOR FILING DATE: 2001-11-14
PRIOR APPLICATION NUMBER: 60/331,044
PRIOR FILING DATE: 2001-11-07
PRIOR APPLICATION NUMBER: 60/327,364
PRIOR FILING DATE: 2001-10-09
PRIOR APPLICATION NUMBER: 60/323,807
PRIOR FILING DATE: 2001-09-21
PRIOR APPLICATION NUMBER: 60/309,176
PRIOR FILING DATE: 2001-08-02
PRIOR APPLICATION NUMBER: 60/294,981
PRIOR FILING DATE: 2001-06-04
PRIOR APPLICATION NUMBER: 60/293,473
PRIOR FILING DATE: 2001-05-25
NUMBER OF SEQ ID NOS: 66
SOFTWARE: Patentin Ver. 2.1
SEQ ID NO 53
LENGTH: 249
TYPE: PRT
ORGANISM: Artificial sequence
FEATURE:
OTHER INFORMATION: T1006F07 scfv
US-10-039-785-53

Query Match 67.3%; Score 392.5; DB 4; Length 249;
Best Local Similarity 69.4%; Pred. No. 5.8e-30;
Matches 75; Conservative 13; Mismatches 19; Indels 1; Gaps 1;

QY 4 SELTDPAVSVALGQTVRVTTCGDSLSRYSVSWYQKPGQAPVLYIGKNNRPSGIPDR 63
DB 143 SYELTPPSVSVAPGGTARITCSGDLGDKYASWYQKPGQAPVLYIDNRPSGIPER 202

QY 64 SSGSSSGNTASLTITGAQAEDEADYVCCSRDSSGNHWVGGTELTVLG 111
DB 203 SSGSSSGNTATLTISGTADEADYVCCSRDSSGNHWVGGGKTLVLG 249

RESULT 37
US-08-478-039-91
Sequence 91, Application US/08478039
Patent No. 5681722
GENERAL INFORMATION:
APPLICANT: Newman, Roland A.
APPLICANT: Hanna, Nabil W.
TITLE OF INVENTION: Recombinant Antibodies for Human Therapy
NUMBER OF SEQUENCES: 114
CORRESPONDENCE ADDRESS:
ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS
STREET: 699 Prince St.
CITY: Alexandria
STATE: VA
COUNTRY: USA
ZIP: 22313-1404
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/478,039
FILING DATE: 07-JUN-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/379,072
FILING DATE: 25-JAN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/912,292
FILING DATE: 10-JUL-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/856,281
FILING DATE: 23-MAR-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/735,064

```

1 FILING DATE: 25-JUL-1991
2 ATTORNEY/AGENT INFORMATION:
3 NAME: Teskin Esq., Robin L.
4 REGISTRATION NUMBER: 35,030
5 REFERENCE/DOCKET NUMBER: 012712-160
6 TELECOMMUNICATION INFORMATION:
7 TELEPHONE: 703-836-6620
8 TELEFAX: 703-836-2021
9 INFORMATION FOR SEQ ID NO: 91:
10 SEQUENCE CHARACTERISTICS:
11 LENGTH: 109 amino acids
12 TYPE: amino acid
13 STRANDEDNESS: not relevant
14 TOPOLOGY: not relevant
15 MOLECULE TYPE: peptide
16 ORIGINAL SOURCE:
17 ORGANISM: Homo sapiens
18 POSITION IN GENOME:
19 CHROMOSOME/SEGMENT: Lambda VIII consensus
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1
```

```

? NAME: Teskin Beq., Robin L.
? REGISTRATION NUMBER: 35,030
? REFERENCE/DOCKET NUMBER: 012712-161
? TELECOMMUNICATION INFORMATION:
? TELEPHONE: 703-836-6620
? TELEFAX: 703-836-2021
? INFORMATION FOR SEQ ID NO: 91:
? SEQUENCE CHARACTERISTICS:
? LENGTH: 109 amino acids
? TYPE: amino acid
? STRANDEDNESS: not relevant
? TOPOLOGY: not relevant
? MOLECULE TYPE: peptide
? ORIGINAL SOURCE:
? ORGANISM: Homo sapiens
? POSITION IN GENOME:
? CHROMOSOME/SEGMENT: Lambda VIII consensus
? US-08-476-349A-91

```

RESULT 38
US-08-476-349A-91
Sequence 91, Application US/08476349A
Patent No. 5750105
GENERAL INFORMATION:
APPLICANT: Newman, Roland A.
APPLICANT: Hanna, Nabil
APPLICANT: Raab, Ronald W.
TITLE OF INVENTION: Recombinant Antibodies for Human Therapy
NUMBER OF SEQUENCES: 114
CORRESPONDENCE ADDRESSES:
ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS
STREET: 699 Prince St.
CITY: Alexandria
STATE: VA
COUNTRY: USA
ZIP: 22113-1404
COMPUTER READABLE FORM:
MEDIUM TYPE: floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/476,349A
FILING DATE: 07-JUN-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/379,072
FILING DATE: 25-JAN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/912,292
FILING DATE: 10-JUL-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/856,281
FILING DATE: 23-MAR-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/735,064
FILING DATE: 23-JUL-1991
ATTORNEY/AGENT INFORMATION:

```

;      TOPOLOGY: linear
;      MOLECULE TYPE: protein
US-08-345-321-8

```

Query Match	65.4%	Score 381.5	DB 2	length 143
Best Local Similarity	67.0%	Pred. No. 3.5e-29		
Matches	73	Conservative	14	Mismatches 21, Indels 1, Gaps 1

```
QY      3 SSELTPDPAVSALGGQTVRTCCGDSLRSYYASVYQCKPQAPVLVIYGNKRRPSGIPDR 62
      |||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db      20 SYELTPSPSVSVSGQTARITCGDALPQYVWVYQQRPGQAPVVLKYKTERPSGIPER 79
```

```

QY      63 FSGSSSGNTASLTITGAQAEDEADYYCSSRDSGNH-WVFGGTELTVL 110
      ||||| :||: ||||| ||||| :||: |||||: |||||
Db      80 FSGSSSGTIVLTITISGVAEDEADYYCQADNSGAYPLFFGGTETKLTVL 128

```

RESULT 40
US-08-259-372A-10
Sequence 10, Application US/08259372A

GENERAL INFORMATION: Lars G.
APPLICANT: Ostberg, Lars G.
TITLE OF INVENTION: PRODUCTION OF HUMAN MONOCLONAL
TITLE OF INVENTION: ANTIBODIES SPECIFIC FOR HEPATITIS B SURFACE ANTIGEN
NUMBER OF SEQUENCES: 16
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, Eighth Floor
CITY: San Francisco
STATE: CA
COUNTRY: USA

US-08-259-372A-10

Query Match	65.0%;	Score 379;	DB 1;	Length 108;
Best Local Similarity	67.3%;	Pred. No. 4.3e-29;		
Matches	72;	Conservative	15;	Mismatches 20;
			Indels	0;
			Gaps	0;

Oy

4 SELTDDPAVSVALGQIVRVTCQGDSLRSYYASNVYQQKPEQAFLVLYIGKNRRPSGI PDRF 63

Dd

2 SQTLPSPSVSAVPGQTARITCGSDNIGSKSVNNFYQQKPGAFLVVYD DNERPPSGISERF 61

```
QY 64 SSSSSGNTASLTITGAQAEDEADYYCSSRDSGNHWFGGGTELTVL 110
      |||:|||||: : ||||| |||: |||||: |||
Db 62 SSSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHVVFGGCTKLTVL 108
```

RESULT 41
US-08-468-671-10
: Sequence 10, Application US/08468671

```

? GENERAL INFORMATION:
? APPLICANT: Ostberg, Lars G.
? TITLE OF INVENTION: PRODUCTION OF HUMAN MONOCLONAL
? TITLE OF INVENTION: ANTIBODIES SPECIFIC FOR HEPATITIS B SURFACE ANTIGEN
? NUMBER OF SEQUENCES: 16
? CORRESPONDENCE ADDRESS:
? ADDRESSEE: Townsend and Townsend and Crew LLP
? STREET: Two Embarcadero Center, Eighth Floor
? CITY: San Francisco
? STATE: CA
? COUNTRY: USA

```


MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/478,039
FILING DATE: 07-JUN-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/379,072
FILING DATE: 25-JAN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/912,292
FILING DATE: 10-JUL-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/856,281
FILING DATE: 23-MAR-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/735,064
FILING DATE: 25-JUL-1991
ATTORNEY/AGENT INFORMATION:
NAME: Teskin Esq., Robin L.
REGISTRATION NUMBER: 35,030
REFERENCE/DOCKET NUMBER: 012712-160
TELEPHONE: 703-836-6620
TELEFAX: 703-836-6620
INFORMATION FOR SEQ ID NO: 110:
SEQUENCE CHARACTERISTICS:
LENGTH: 128 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-478-039-110

Query Match 63.3%; Score 369; DB 1; Length 128;
Best Local Similarity 64.9%; Pred. No. 4.7e-28;
Matches 72; Conservative 12; Mismatches 27; Indels 0; Gaps 0;

Qy 1 AFSSSLTQDPVAVSLGTVRTCCGDSLRSYASWYQKPGQAPVLYIGKNNRPSGIP 60
Db 18 AASTELSPRSVSVPQGTAGFTCGDVGKRSVQWYQKPPQAPVLYIADSERPSGIP 77

Qy 61 DRFGSSSGNTASLTITGAQAEADYVCSRSRSGNHWFGGTELTVLG 111
Db 78 ARFSGNSGNTATLTISGEVGEADYVCCQWVDSTADHWFGGTELTVLG 128

T 47
US-08-476-349A-110
Sequence 110, Application US/08476349A
Patent No. 5750105
GENERAL INFORMATION:
APPLICANT: Newman, Roland A.
APPLICANT: Hanna, Nabil
APPLICANT: Raab, Ronald W.
TITLE OF INVENTION: Recombinant Antibodies for Human Therapy
NUMBER OF SEQUENCES: 114
CORRESPONDENCE ADDRESS:
ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS
STREET: 699 Prince St.
CITY: Alexandria
STATE: VA
COUNTRY: USA
ZIP: 22313-1404
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/476,349A
FILING DATE: 07-JUN-1995

CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/379,072
FILING DATE: 25-JAN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/912,292
FILING DATE: 10-JUL-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/856,281
FILING DATE: 23-MAR-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/735,064
FILING DATE: 25-JUL-1991
ATTORNEY/AGENT INFORMATION:
NAME: Teskin Esq., Robin L.
REGISTRATION NUMBER: 35,030
REFERENCE/DOCKET NUMBER: 012712-161
TELEPHONE: 703-836-6620
TELEFAX: 703-836-6620
INFORMATION FOR SEQ ID NO: 110:
SEQUENCE CHARACTERISTICS:
LENGTH: 128 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-476-349A-110

Query Match 63.3%; Score 369; DB 1; Length 128;
Best Local Similarity 64.9%; Pred. No. 4.7e-28;
Matches 72; Conservative 12; Mismatches 27; Indels 0; Gaps 0;

Qy 1 AFSSSLTQDPVAVSLGTVRTCCGDSLRSYASWYQKPGQAPVLYIGKNNRPSGIP 60
Db 18 AASTELSPRSVSVPQGTAGFTCGDVGKRSVQWYQKPPQAPVLYIADSERPSGIP 77

Qy 61 DRFGSSSGNTASLTITGAQAEADYVCSRSRSGNHWFGGTELTVLG 111
Db 78 ARFSGNSGNTATLTISGEVGEADYVCCQWVDSTADHWFGGTELTVLG 128

RESULT 48
US-08-523-894-4
Sequence 4, Application US/08523894
Patent No. 6136310
GENERAL INFORMATION:
APPLICANT: Hanna, Nabil
APPLICANT: Newman, Roland A.
APPLICANT: Reff, Mitchell E.
TITLE OF INVENTION: Recombinant Anti-CD4 Antibodies for Human
NUMBER OF SEQUENCES: 59
CORRESPONDENCE ADDRESS:
ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS
STREET: 699 Prince Street
CITY: Alexandria
STATE: VA
COUNTRY: USA
ZIP: 22314-3187
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/523,894
FILING DATE: 06-SEP-1995
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: Teskin, Robin L.
REGISTRATION NUMBER: 35,030
REFERENCE/DOCKET NUMBER: 012712-165
TELECOMMUNICATION INFORMATION:

TELEPHONE: 703-836-6620
TELEFAX: 703-836-2021
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 128 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-523-894-4

Query Match 63.3%; Score 369; DB 3; Length 128;
Best Local Similarity 64.9%; Pred. No. 4, 7e-28;
Matches 72; Conservative 12; Mismatches 27; Indels 0; Gaps 0;

QY 1 AFSSSETLQDPAVSVALGQTVRTVTCGDSLSRSYYASWYQOKPGQAPVLYIGKNNRPSGIP 60
DB 18 AASYELSGPRSVSVSPGQVTCGAGTCGGDNVGRSVQWYQOKPGQAPVLYIGKNNRPSGIP 77
61 DRFGSSSGNTASLTITGAQAEDEADYCCSRDSSGNHWFPGGTELTVLG 111
78 ARFGSSSGNTATLTISGVEADGADYCCQWMDSTADHWVFGGTRTLVLG 128

RESULT 49
US-08-523-894-6
Sequence 6, Application US/08523894
Patent No. 6136310
GENERAL INFORMATION:
APPLICANT: Hanna, Nabil
APPLICANT: Newman, Roland A.
APPLICANT: Reft, Mitchell E.
TITLE OF INVENTION: Recombinant Anti-CD4 Antibodies for Human
NUMBER OF SEQUENCES: 59
CORRESPONDENCE ADDRESS:
ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS
STREET: 699 Prince Street
CITY: Alexandria
STATE: VA
COUNTRY: USA
ZIP: 22314-3187
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/523,894
FILING DATE: 06-SEP-1995
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: Teeklin, Robin L.
REGISTRATION NUMBER: 35,030
REFERENCE/DOCKET NUMBER: 012712-165
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-836-6620
TELEFAX: 703-836-2021
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 233 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-523-894-6

Query Match 63.3%; Score 369; DB 3; Length 233;
Best Local Similarity 64.9%; Pred. No. 9, 2e-28;
Matches 72; Conservative 12; Mismatches 27; Indels 0; Gaps 0;

QY 1 AFSSSETLQDPAVSVALGQTVRTVTCGDSLSRSYYASWYQOKPGQAPVLYIGKNNRPSGIP 60
DB 18 AASYELSGPRSVSVSPGQVTCGAGTCGGDNVGRSVQWYQOKPGQAPVLYIGKNNRPSGIP 77

QY 61 DRFGSSSGNTASLTITGAQAEDEADYCCSRDSSGNHWFPGGTELTVLG 111
DB 78 ARFGSSSGNTATLTISGVEADGADYCCQWMDSTADHWVFGGTRTLVLG 128

RESULT 50
US-10-039-785-42
Sequence 42, Application US/10039785
Patent No. 6538938
GENERAL INFORMATION:
APPLICANT: Salcedo et al.
TITLE OF INVENTION: Antibodies that Immunoselectively Bind to TRAIL
FILE REFERENCE: PFS50
CURRENT APPLICATION NUMBER: US/10/039,785
CURRENT FILING DATE: 2002-05-07
PRIOR APPLICATION NUMBER: 60/369,860
PRIOR FILING DATE: 2002-04-05
PRIOR APPLICATION NUMBER: 60/341,237
PRIOR FILING DATE: 2001-12-20
PRIOR APPLICATION NUMBER: 60/331,310
PRIOR FILING DATE: 2001-11-14
PRIOR APPLICATION NUMBER: 60/331,044
PRIOR FILING DATE: 2001-11-07
PRIOR APPLICATION NUMBER: 60/327,364
PRIOR FILING DATE: 2001-10-09
PRIOR APPLICATION NUMBER: 60/323,807
PRIOR FILING DATE: 2001-09-21
PRIOR APPLICATION NUMBER: 60/309,176
PRIOR FILING DATE: 2001-08-02
PRIOR APPLICATION NUMBER: 60/294,981
PRIOR FILING DATE: 2001-06-04
PRIOR APPLICATION NUMBER: 60/293,473
PRIOR FILING DATE: 2001-05-25
NUMBER OF SEQ ID NOS: 66
SOFTWARE: Patentin Ver. 2.1
SEQ ID NO 42
LENGTH: 245
TYPE: PRT
ORGANISM: Artificial sequence
FEATURE:
OTHER INFORMATION: T101A04 scFv
US-10-039-785-42

Query Match 63.0%; Score 367; DB 4; Length 245;
Best Local Similarity 65.8%; Pred. No. 1, 5e-27;
Matches 73; Conservative 13; Mismatches 21; Indels 4; Gaps 3;

QY 4 SELTQDPAVSVALGQTVRTVTCG--DSLRSY-VASWYQOKPGQAPVLYIGKNNRPSGIP 60
DB 136 SVLTQPFPSASGSPGQSVTISCTGTTSDVGYNYSWYQOKPGQAPVLYIGKNNRPSGIP 195
QY 61 DRFGSSSGNTASLTITGAQAEDEADYCCSRDSSGNHWFPGGTELTVLG 111
DB 136 DRFGSSSGNTASLTIVSGLQAEDEADYCCSSYASG--NNWVYGGGKTLVLG 245

Search completed: November 26, 2003, 13:42:24
Job time: 14.7564 secs


```
Db 2 OSGAEVKKPGSSVSKVSCASGCTFSSYALISWVRQAPGQLEWGGIIPILIGIANYAQKQ 61
Qy 66 GRAVATDESGTASMLSLRSRSDTAVYVCARSDLLPPIHALSWGGMVTYSS 123
Db 62 GRVITADKSTIATYVMELSLRSDTAVYVCASSN--WGPYWFIDLMGGTIVTSS 116

RESULT 2
O96QSO PRELIMINARY; PRT; 159 AA.
AC O96QSO;
DT 01-DEC-2001 (TREMBlrel. 19, Created)
DT 01-DEC-2001 (TREMBlrel. 19, Last sequence update)
DT 01-MAR-2003 (TREMBlrel. 23, Last annotation update)
DE Putative matrix cell adhesion molecule-3.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
OX NCBI_TaxId=9606;
RN [1]
RS SEQUENCE FROM N.A.
RT Nilson M.D.;
RT "Homo sapiens putative microfibrillar protein with Ig-like domain 3
RT mRNA (Matrix Cell Adhesion Molecule-3, Mat-CAM 3).";
RL Submitted (JUN-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AY039025; AAK82649.1; -
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF00047; Ig; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
SQ SEQUENCE 159 AA; 17497 MW; 5D29537EB81FAF02 CRC64;

Query Match 63.9%; Score 409.5; DB 4; Length 159;
Best Local Similarity 62.3%; Pred. No. 1.2e-35;
Matches 81; Conservative 17; Mismatches 25; Indels 7; Gaps 1;

Qy 1 QVQLVQSGAEVKKPGSSVRVSCKASGCTFNNNAIMWVRQAPGQLEWGGIIPMFGTAKY 60
Db 20 QVQLVQSGAEVKKPGSSVRVSCKASGCTFNNNAIMWVRQAPGQLEWGGIIPMFGTAKY 79

Qy 61 SQNFGRAVATDESGTASMLSLRSRSDTAVYVCARSDLLPPIHALSPW 113
Db 80 SQKQGRITMTDRDSTSTVWMDLSLRSDTAVYVCAREMELITGGANVSKGFYYGMDVW 139

Qy 114 GRGTMVTYSS 123
Db 140 GQGITVTYSS 149

RESULT 3
O9UL92 PRELIMINARY; PRT; 124 AA.
ID O9UL92;
AC O9UL92;
DT 01-MAY-2000 (TREMBlrel. 13, Created)
DT 01-MAY-2000 (TREMBlrel. 13, Last sequence update)
DT 01-MAR-2003 (TREMBlrel. 23, Last annotation update)
DE Myosin-reactive immunoglobulin heavy chain variable region
DE (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
OX NCBI_TaxId=9606;
RN [1]
RS SEQUENCE FROM N.A.
RT Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berney S.M.,
RT "Myosin-reactive autoantibodies in rheumatic carditis and normal
RT fetus.";
RL Clin. Immunol. Immunopathol. 87:184-192(1998).
DR EMBL; AF035022; AAD56258.1; -
```

```
DR HSSP; P01772; 2FB4.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF00047; Ig; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
FT NON_TER 1
FT NON_TER 124
SQ SEQUENCE 124 AA; 13580 MW; 1BAACBD96ACD2A2 CRC64;

Query Match 61.1%; Score 391.5; DB 4; Length 124;
Best Local Similarity 65.1%; Pred. No. 7.4e-34;
Matches 82; Conservative 14; Mismatches 25; Indels 5; Gaps 2;

Qy 1 QVQLVQSGAEVKKPGSSVRVSCKASGCTFNNNAIMWVRQAPGQLEWGGIIPMFGTAKY 60
Db 1 EVQLVSGAEVKKPGSSVRVSCKASGCTFSSYMHVVRQAPGQLEWGGIIPSGGSTY 60

Qy 61 SQNFGRAVATDESGTASMLSLRSRSDTAVYVCARSDLLPPIHALSP--WGRGT 117
Db 61 AQKFGRTVMTDRDSTSTVYVMELSLRSDTAVYVCARG--LYVVPAFASRDYWGQGT 118

Qy 118 MVTYSS 123
Db 119 LVTYSS 124

RESULT 4
O96DKO PRELIMINARY; PRT; 496 AA.
ID O96DKO;
AC O96DKO;
DT 01-DEC-2001 (TREMBlrel. 19, Created)
DT 01-DEC-2001 (TREMBlrel. 19, Last sequence update)
DT 01-MAR-2003 (TREMBlrel. 23, Last annotation update)
DE Hypothetical protein FLJ25298.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
OX NCBI_TaxId=9606;
RN [1]
RS SEQUENCE FROM N.A.
RC TISSUE=Gastric mucosa;
RA Ishibashi T., Kanehori K., Yosida M., Watanabe S., Ishida S., Ono Y.,
RA Hoshura T., Hirooka S., Murakawa K., Takiguchi S., Kusano J.,
RA Watanabe M., Fujimori K., Tanai H., Ishida M., Yamashita H., Chiba Y.,
RA Suzuki Y., Hata H., Nakagawa K., Mizuno S., Morinaga M., Kawamura M.,
RA Sugiyama T., Irie R., Otsuki T., Sato H., Nishikawa T., Sugiyama A.,
RA Kawakami B., Nagai K., Isogai T., Sugano S.;
RT "NEDO human cDNA sequencing project.";
RL Submitted (OCT-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AK058027; BAB71633.1; -
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF00047; Ig; 4.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; 1.
KW Hypothetical protein.
SQ SEQUENCE 496 AA; 53532 MW; C72BE1E247C86FED CRC64;

Query Match 60.1%; Score 385.5; DB 4; Length 496;
Best Local Similarity 61.9%; Pred. No. 1.8e-32;
Matches 78; Conservative 13; Mismatches 30; Indels 5; Gaps 2;

Qy 1 QVQLVQSGAEVKKPGSSVRVSCKASGCTFNNNAIMWVRQAPGQLEWGGIIPMFGTAKY 60
Db 20 QVQLVQSGAEVKKPGSSVRVSCKASAMVFRSYAFTWVRQAPGQGLQWGGIIPMFGAPNY 79

Qy 61 SQNFGRAVATDESGTASMLSLRSRSDTAVYVCARSDLLPPIHALSPMGRGT 117
Db 80 AQNFQDRVTISADSTTIVYVMELSLRSDTAVYVCARG--LTYVSGSYVYLDHMGQGT 137
```


Db 61 AOKVQGRVMTTRDTTISTFAYWELSLRSDPTAVYYCARSGGGRILAAAGAFDIWGQTM 120
QY 119 VTWSS 123
Db 121 VTWSS 125

RESULT 8
Q9GYZ2 PRELIMINARY; PRT; 119 AA.
AC Q9GYZ2;
DT 01-MAR-2001 (TRENBLrel. 16, Created)
DT 01-MAR-2001 (TRENBLrel. 16, Last sequence update)
DT 01-MAR-2003 (TRENBLrel. 23, Last annotation update)
DE Monoclonal anti-idiotypic antibody NP30 heavy chain variable region (Fragment).
OS Schistosoma japonicum (Blood fluke).
OC Eukaryota; Metazoa; Platyhelminthes; Trematoda; Digenea; Strigeidida;
OC Schistosomatidae; Schistosomatidae; Schistosoma.
OX NCBI_TaxID=6182;
F [1]
F SEQUENCE FROM N.A.
RA Song X.T., Fang Z.Q., Guan X.H.;
RT "Amplification, cloning and sequence analysis of the heavy chain variable region gene of monoclonal anti-idiotypic antibody NP30 of Schistosoma japonicum";
RL Submitted (JUN-2000) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF282622; AAG01452.1; -.
DR HSSP; P01772; 2FB4.
DR InterPro; IPR007110; IG-1like.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_v.
DR Pfam; PF00047; IG_1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
FT NON_TER 1
FT NON_TER 119
SQ SEQUENCE 119 AA; 13567 MW; BA893873FD5FA6AB CRC64;

Query Match 56.3%; Score 374; DB 5; Length 119;
Best Local Similarity 61.8%; Pred. No. 5, 1e-32;
Matches 76; Conservative 13; Mismatches 30; Indels 4; Gaps 1;

QY 1 QVQLQSGAEVKKPGSSVRVSCKASGSGTFNNAINWVROAPGGGLEMMGIIIPMGRTAKY 60
Db 1 QVQLVESAEVKKPGSSVRVSCKASGSGTFNMMVWVQAGHGLEMMGIIIPMGRTAKY 60

QY 61 SQNFGQVAITADESTGTASMSLSLRSEDPTAVYYCARSDLLFPFHALLSPWGRGTMT 120
Db 61 NQKFPDRTVMTTDSFSFAYWDLNLSRSDSAVYYCARYD---DHYCLDYMGGTTVT 116

QY 121 VSS 123
Db 117 VSS 119

RESULT 9
Q8WY24 PRELIMINARY; PRT; 497 AA.
AC Q8WY24;
DT 01-MAR-2002 (TRENBLrel. 20, Created)
DT 01-MAR-2002 (TRENBLrel. 20, Last sequence update)
DT 01-MAR-2003 (TRENBLrel. 23, Last annotation update)
DE SNC66 protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
OX NCBI_TaxID=9606;
F [1]
F SEQUENCE FROM N.A.
RA Zheng S., Shao X., Cao J., Geng L., Fang Y., Dong Q.;
RT "Identification and characterization of SNC66, a Ig-like gene which is down-regulated in colorectal cancer";

RL Submitted (JUN-2000) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF283666; AAL6987.1; -.
DR InterPro; IPR007110; IG-1like.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_v.
DR Pfam; PF00047; IG; 4.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; 1.
SQ SEQUENCE 497 AA; 53665 MW; F24D08DFA5663E5 CRC64;

Query Match 56.9%; Score 365; DB 4; Length 497;
Best Local Similarity 59.2%; Pred. No. 2, 7e-30;
Matches 74; Conservative 16; Mismatches 33; Indels 2; Gaps 1;

QY 1 QVQLQSGAEVKKPGSSVRVSCKASGSGTFNNAINWVROAPGGGLEMMGIIIPMGRTAKY 60
Db 20 QEQLEQSGAEVTPKPGASVKVSCASGTFAYVDINWVROAPGGGLEMMGMMNPQTGNTFR 79

QY 61 SQNFGQVAITADESTGTASMSLSLRSEDPTAVYYCARSDLLFPFHALLSPWGRGTMT 118
Db 80 AOKVQGRVMTTRDTTISTFAYWELSLRSDPTAVYYCARSGGGRILAAAGAFDIWGQTM 129

QY 119 VTWSS 123
Db 140 VTWSS 144

RESULT 10
Q9DBL4 PRELIMINARY; PRT; 473 AA.
AC Q9DBL4;
DT 01-JUN-2001 (TRENBLrel. 17, Created)
DT 01-JUN-2001 (TRENBLrel. 17, Last sequence update)
DT 01-MAR-2003 (TRENBLrel. 23, Last annotation update)
DE 181060C009Rik protein.
GN IGH-1 OR 181060C009Rik.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
F [1]
F SEQUENCE FROM N.A.
RA STRAIN=C57BL/6J; TISSUE=Pancreas;
RC MEDLINE=21085660; PubMed=11217851;
RA Kawai J., Shinagawa A., Shibata K., Yoshino M., Itoh M., Ishii Y.,
RA Atakawa T., Hara A., Fukunishi Y., Konno H., Adachi J., Fukuda S.,
RA Aizawa K., Izawa M., Nishi K., Kiyosawa H., Kondo S., Yamataka I.,
RA Saito T., Okazaki Y., Gojobori T., Bono H., Kasukawa T., Saito R.,
RA Kadota K., Matsuda H.A., Ashburner M., Batalov S., Casavant T.,
RA Fleischmann W., Gaasterland T., Gissi C., King B., Kochiwa H.,
RA Kuehl P., Lewis S., Matsuo Y., Nikaido I., Pesole G., Quackenbush J.,
RA Schirml L.M., Staudt F., Suzuki R., Tomita M., Wagner L., Wagner T.,
RA Sakai K., Okido T., Futuno M., Aono H., Baldarelli R., Barsh G.,
RA Blake J., Boffelli D., Bojunga N., Carninci P., de Bonaldo M.F.,
RA Brownstein M.J., Bult C., Fletcher C., Fujita M., Gariboldi M.,
RA Gustincich S., Hill D., Hofmann M., Hume D.A., Kamiya M., Lee N.H.,
RA Lyons P., Marchionni L., Mashima J., Mazzarelli J., Mombauts P.,
RA Nordone P., Ring B., Ringwald M., Rodriguez I., Sakamoto N.,
RA Saeki H., Sato K., Schoenbach C., Seta T., Shibata Y., Storch K.-F.,
RA Suzuki H., Toyo-oka K., Wang K.H., Wetz C., Whitaker C., Wilming L.,
RA Wynshaw-Boris A., Yoshida K., Hasegawa Y., Kawaji H., Kohsaki S.,
RA Hayashizaki Y.,
RT "Functional annotation of a full-length mouse cDNA collection";
RL Nature 409:685-690(2001).
DR EMBL; AK007918; BAB25349.1; -.
DR HSSP; P01842; 7PAB.
DR MGD; MGI:96443; IGH-1.
DR InterPro; IPR007110; IG-1like.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_v.
DR Pfam; PF00047; IG; 4.
DR SMART; SM00406; IGV; 1.

DR PROSITE; PS50835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; 1.
SQ SEQUENCE 473 AA; 51699 MW; 9DEDS7A514475FBB CRC64;

Query Match 56.8%; Score 364; DB 11; Length 473;
Best Local Similarity 56.9%; Pred. No. 3.3e-30;
Matches 70; Conservative 25; Mismatches 24; Indels 4; Gaps 1;

QY 1 QVQLQSGAEVKKPGSSVRVSCKASGCTFNNNAINWVROAPGQLEWGGIIPMGFTAKY 60
DB 20 QVQLQSGAEVKKPGSSVRVSCKASGCTFNNNAINWVROAPGQLEWGGIIPMGFTAKY 79
QY 61 SQNFGKVAITADESTGASMEISLRSEDTAVYYCARSDLLFPFHALLSPMGRTMT 120
DB 80 NEKFKKATLTADKSSSTAVYQSLTSEDSAVYFCARSG---YDYDMFAVWGQTLVT 135

QY 121 VSS 123
DB 136 VSA 138

RESULT 11

Q9BRV0 PRELIMINARY; PRT; 500 AA.

AC Q9BRV0; 01-JUN-2001 (TREMBlrel. 17, Created)
DT 01-JUN-2001 (TREMBlrel. 17, Last sequence update)
DT 01-MAR-2003 (TREMBlrel. 23, Last annotation update)
DE Hypothetical protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
OX NCBI_TaxId=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Prostate;
RA Strauberg R.;
RL Submitted (APR-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC005951; AA05951.1; -
DR HSSP; P01789; IMCP
DR InterPro; IPR007110; IG_1like.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_V.
DR Pfam; PF00047; IG; 4.
DR SMART; SM00406; IG; 1.
DR PROSITE; PS50835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; 1.
DR Hypothetical protein.
SQ SEQUENCE 500 AA; 54154 MW; 0A9BFA3F2A3CC6D9 CRC64;

Query Match 56.2%; Score 360.5; DB 4; Length 500;
Best Local Similarity 56.5%; Pred. No. 8.2e-30;
Matches 74; Conservative 14; Mismatches 32; Indels 11; Gaps 2;

QY 1 QVQLQSGAEVKKPGSSVRVSCKASGCTFNNNAINWVROAPGQLEWGGIIPMGFTAKY 60
DB 20 QVQLQSGAEVKKPGSSVRVSCKASGCTFNNNAINWVROAPGQLEWGGIIPMGFTAKY 79
QY 61 SQNFGKVAITADESTGASMEISLRSEDTAVYYCARSDLLFPFHALLSP 112
DB 80 AKKFGKATLTADKSSSTAVYQSLTSEDSAVYFCARSG---YDYDMFAVWGQTLVT 136
QY 113 WGRGTMTVSS 123
DB 137 WGRGTMTVSS 147

RESULT 12

Q92409 PRELIMINARY; PRT; 145 AA.

AC Q92409; 01-DEC-2001 (TREMBlrel. 19, Created)
DT 01-DEC-2001 (TREMBlrel. 19, Last sequence update)

DT 01-MAR-2003 (TREMBlrel. 23, Last annotation update)
DE VH186.2-D-J-C mu protein (Fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Muridae; Murinae; Mus.
OX NCBI_TaxId=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6;
RA Kozono Y., Kozono H., Azuma T.;
RT "Direct Estimation of Relative Affinity by Flow Cytometry Reveals
RT Affinity Maturation of B Cell Antigen Receptors in Response to (4-
RT Hydroxy-3-Nitrophenyl)Acetyl (NP)."
RL Submitted (AUG-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AB067791; BAB63276.1; -
DR InterPro; IPR007110; IG_1like.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_V.
DR Pfam; PF00047; IG; 1.
DR SMART; SM00406; IG; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
FT NON_TER 1
FT NON_TER 145
SQ SEQUENCE 145 AA; 16001 MW; 0F409EB09FA333D2 CRC64;

Query Match 55.8%; Score 357.5; DB 11; Length 145;
Best Local Similarity 56.1%; Pred. No. 3.7e-30;
Matches 69; Conservative 24; Mismatches 27; Indels 3; Gaps 1;

QY 1 QVQLQSGAEVKKPGSSVRVSCKASGCTFNNNAINWVROAPGQLEWGGIIPMGFTAKY 60
DB 1 QVQLQSGAEVKKPGSSVRVSCKASGCTFNNNAINWVROAPGQLEWGGIIPMGFTAKY 60
QY 61 SQNFGKVAITADESTGASMEISLRSEDTAVYYCARSDLLFPFHALLSPMGRTMT 120
DB 61 NEKFKKATLTADKSSSTAVYQSLTSEDSAVYFCARSG---YDYDMFAVWGQTLVT 117
QY 121 VSS 123
DB 118 VSS 120

RESULT 13

Q9Y298 PRELIMINARY; PRT; 150 AA.

AC Q9Y298; 01-NOV-1999 (TREMBlrel. 12, Created)
DT 01-NOV-1999 (TREMBlrel. 12, Last sequence update)
DT 01-MAR-2003 (TREMBlrel. 23, Last annotation update)
DE IGG VH protein precursor (Fragment).
GN IGG VH.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
OX NCBI_TaxId=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC MEDLINE=98322155; PubMed=9657749;
RA Jacquemin M.G., Vander Elst L.P.L.;
RT "Mechanism and kinetics of factor VIII inactivation: study with an
RT IGG4 monoclonal antibody derived from a hemophilia A patient with
RT inhibitor."
RT Inhibitor."
RL Blood 92:496-506 (1998).
DR EMBL; AJ224083; CAA11829.1; -
DR HSSP; P01772; 2FB4.
DR InterPro; IPR007110; IG_1like.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_V.
DR Pfam; PF00047; IG; 1.
DR SMART; SM00406; IG; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
KW SIGNAL.
FT SIGNAL 1 19 POTENTIAL.

FT NON TER 150 150
SQ SEQUENCE 150 AA; 16031 MW; 563D164AB2802D5 CRC64;
Query Match 55.5%; Score 356; DB 4; Length 150;
Best Local Similarity 60.2%; Pred. No. 5.6e-30;
Matches 74; Conservative 13; Mismatches 30; Indels 6; Gaps 1;
QY 1 QVQLQSGAEVKKPGSSVRVSCKASGCTFNNNAIMVROAPGQGLEWMGIIIMFGTAKY 60
DB 20 QVQLVQSGAEVKKPGASVKVSCKVGYTLTELPHVWVGOAIPGKGLIEWGSEFDPSSGSIT 79
QY 61 SONFGRAVITADESTGTASMEISLRSEPTAVYICARSRDLLEPHHALSPWGRGTMT 120
DB 80 AREPQSVYTMADTSTDAIMELSSLSDDPAVYCA-----VPDDPAFDIMGQGTMT 133
QY 121 VSS 123
DB 134 VSS 136
FT 14
QY 1 QVQLQSGAEVKKPGSSVRVSCKASGCTFNNNAIMVROAPGQGLEWMGIIIMFGTAKY 60
AC Q99LC4 PRELIMINARY; PRT; 463 AA.
DT 01-JUN-2001 (TReMBLrel. 17, Created)
DT 01-JUN-2001 (TReMBLrel. 17, Last sequence update)
DT 01-MAR-2003 (TReMBLrel. 23, Last annotation update)
DE Similar to RIKEN CDNA 181006009 gene.
GN IGH-4.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
CX NCBI_TaxId=10090;
RN [1]
RP SEQUENCE FROM N.A.
RA Strausberg R.;
RL Submitted (FEB-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC003435; AAH03435.1; -
DR HSSD; P01842; 7FAB.
DR MGD; MGI:96446; Igh-4.
DR InterPro; IPR007110; Igh-1like.
DR InterPro; IPR003006; Igh_MHC.
DR InterPro; IPR003596; Igh_v.
DR Pfam; PF00047; Igh_4.
DR SMART; SM00406; Igv_1.
DR PROSITE; PS50835; Igh_LIKE; 4.
DR PROSITE; PS00290; Igh_MHC; 1.
SQ SEQUENCE 463 AA; 51007 MW; EAA674C6B8C30783 CRC64;
Best Match 55.5%; Score 355.5; DB 11; Length 463;
Best Local Similarity 55.3%; Pred. No. 2.5e-29;
Matches 68; Conservative 22; Mismatches 30; Indels 3; Gaps 1;
QY 1 QVQLQSGAEVKKPGSSVRVSCKASGCTFNNNAIMVROAPGQGLEWMGIIIMFGTAKY 60
DB 20 QVQLVQSGAEVKKPGASVKVSCKVGYTLTELPHVWVGOAIPGKGLIEWGSEFDPSSGSIT 79
QY 61 SONFGRAVITADESTGTASMEISLRSEPTAVYICARSRDLLEPHHALSPWGRGTMT 120
DB 80 SEKFKGKATLTITDKSSSTAYMHLSSLSBDSAVYICARSS--YYSYDLFAVWQGTTLVT 136
QY 121 VSS 123
DB 137 VSS 139
RESULT 15
QY 08VCX7 PRELIMINARY; PRT; 613 AA.
AC Q8VCX7
DT 01-MAR-2002 (TReMBLrel. 20, Created)
DT 01-MAR-2002 (TReMBLrel. 20, Last sequence update)
DT 01-MAR-2003 (TReMBLrel. 23, Last annotation update)

DE Hypoetical 67.9 kDa protein.
GN IGH-6.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
CX NCBI_TaxId=10090;
RN [1]
RP SEQUENCE FROM N.A.
RA Strausberg R.;
RL Submitted (DEC-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC018315; AAH18315.1; -
DR MGD; MGI:96448; Igh-6.
DR InterPro; IPR007110; Igh-1like.
DR InterPro; IPR003006; Igh_MHC.
DR InterPro; IPR003596; Igh_v.
DR Pfam; PF00047; Igh_5.
DR SMART; SM00406; Igv_1.
DR PROSITE; PS50835; Igh_LIKE; 5.
DR PROSITE; PS00290; Igh_MHC; 3.
KW Hypothetical protein.
SQ SEQUENCE 613 AA; 67855 MW; 41A9384DD4C22862 CRC64;
Query Match 55.5%; Score 355.5; DB 11; Length 613;
Best Local Similarity 56.9%; Pred. No. 3.6e-29;
Matches 70; Conservative 18; Mismatches 30; Indels 5; Gaps 1;
QY 1 QVQLQSGAEVKKPGSSVRVSCKASGCTFNNNAIMVROAPGQGLEWMGIIIMFGTAKY 60
DB 20 QVQLVQSGAEVKKPGASVKVSCKATGYTSSVYIEWKORPGHGLIGILPGSSSTNY 79
QY 61 SONFGRAVITADESTGTASMEISLRSEPTAVYICARSRDLLEPHHALSPWGRGTMT 120
DB 80 NEKFKGKATFTADTSSNTAYMQLSLTSBDSAVYICARLRGRYF-----DVWAGATTVT 134
QY 121 VSS 123
DB 135 VSS 137
RESULT 16
QY 092406 PRELIMINARY; PRT; 145 AA.
AC Q92406
DT 01-DEC-2001 (TReMBLrel. 19, Created)
DT 01-DEC-2001 (TReMBLrel. 19, Last sequence update)
DT 01-MAR-2003 (TReMBLrel. 23, Last annotation update)
DE VH186.2-D-J-C mu protein (Fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
CX NCBI_TaxId=10090;
RN [1]
RP SEQUENCE FROM N.A.
RA STRAIN=C57BL/6;
RC Kozono Y., Kozono H., Azuma T.;
RT Affinity Estimation of Relative Affinity by Flow Cytometry Reveals
RT Direct Estimation of B Cell Antigen Receptors in Response to (4-
RT RT Hydroxy-3-Nitrophenyl)Acetyl (NP)."
RL Submitted (AUG-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AB067794; BAB63279.1; -
DR InterPro; IPR007110; Igh-1like.
DR InterPro; IPR003006; Igh_MHC.
DR InterPro; IPR003596; Igh_v.
DR Pfam; PF00047; Igh_1.
DR SMART; SM00406; Igv_1.
DR PROSITE; PS50835; Igh_LIKE; 1.
FT NON TER 1
FT NON TER 1
SQ SEQUENCE 145 AA; 16011 MW; 9BC0846D40DF97BA CRC64;
Query Match 55.1%; Score 353.5; DB 11; Length 145;
Best Local Similarity 56.1%; Pred. No. 9.8e-30;


```
Db 1 QVQLQSGAEIVKPGASVVKSCASGTYFTISYTWIKQKPGQGLEWIGDINPFGSTNY 60
QY 61 SQNFGRAVITADESTGTASMEISLRSEDTAVYCARSDLLPPHALSPWGRGTWY 120
Db 61 NEKFKSKATLVDPKPSSTAVYMQLSLTSSEDAVYYCAIPDSNHLTFDY-----WGGTTLT 115
QY 121 VSS 123
Db 116 VSS 118

RESULT 20
ID Q921C4 PRELIMINARY; PRT; 118 AA.
AC Q921C4;
DT 01-MAY-1999 (Tremblrel. 10, Created)
DT 01-MAY-1999 (Tremblrel. 10, Last sequence update)
DT 01-MAR-2003 (Tremblrel. 23, Last annotation update)
DE Anti-porcine VCAM rmb 3F4 heavy chain variable region (Fragment).
OC Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=Balb/c;
RA Mueller J.P., Giannoni M.A., Hartman S.L., Elliott E.A., Squinto S.P.,
RA Macis L.M., Evans M.J.;
RT "Humanized porcine VCAM-specific monoclonal antibodies with chimeric
RT IgG2/g4 constant regions block human leukocyte binding to porcine
RT endothelial cells."
RL Submitted (NOV-1996) to the EMBL/GenBank/DBJ databases.
DR EMBL; U78801; AAD00293.1; -.
DR HSSP; P01810; 2FBJ.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_V.
DR Pfam; PF00047; Ig; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
FT NON_TER 1
FT NON_TER 118
SQ SEQUENCE 118 AA; 13036 MW; 90ECC559D31EC4FC CRC64;

Query Match 53.7%; Score 344.5; DB 11; Length 118;
Best Local Similarity 53.3%; Pred. No. 6.9e-29;
Matches 68; Conservative 21; Mismatches 29; Indels 5; Gaps 1;

Db 1 QVQLQSGAEIVKPGASVVKSCASGTYFTISYTWIKQKPGQGLEWIGDINPFGSTNY 60
QY 61 SQNFGRAVITADESTGTASMEISLRSEDTAVYCARSDLLPPHALSPWGRGTWY 120
Db 61 TQKFGKATLVDPKSSSTAVYMQLSLTSSEDAVYYCARRTVGGYDY-----WGGTTLT 115
QY 121 VSS 123
Db 116 VSS 118

RESULT 21
ID Q924P7 PRELIMINARY; PRT; 145 AA.
AC Q924P7;
DT 01-DEC-2001 (Tremblrel. 19, Created)
DT 01-DEC-2001 (Tremblrel. 19, Last sequence update)
DT 01-MAR-2003 (Tremblrel. 23, Last annotation update)
DE VH16.2-D-J-C mu protein (Fragment).
OC Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
```

```
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6;
RA Kozono Y., Kozono H., Azuma T.;
RT "Direct Estimation of Relative Affinity by Flow Cytometry Reveals
RT Affinity Maturation of B Cell Antigen Receptors in Response to (4-
RT Hydroxy-3-Nitrophenyl)Acetyl (NP)";
RL Submitted (AUG-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AB069918; BAB63934.1; -.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_V.
DR Pfam; PF00047; Ig; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
FT NON_TER 1
FT NON_TER 145
SQ SEQUENCE 145 AA; 15988 MW; FB73958704796C9A CRC64;

Query Match 53.7%; Score 344.5; DB 11; Length 145;
Best Local Similarity 56.1%; Pred. No. 8.9e-29;
Matches 69; Conservative 23; Mismatches 28; Indels 3; Gaps 2;

QY 1 QVQLQSGAEIVKPGASVVKSCASGTYFTISYTWIKQKPGQGLEWIGDINPFGSTNY 60
Db 1 QVQLQSGAEIVKPGASVVKSCASGTYFTISYTWIKQKPGQGLEWIGDINPFGSTNY 60
QY 61 SQNFGRAVITADESTGTASMEISLRSEDTAVYCARSDLLPPHALSPWGRGTWY 120
Db 61 NEKFKSKATLVDPKPSSTAVYMQLSLTSSEDAVYYCAR-KDGSF--YAMDYWGQGTSTV 117
QY 121 VSS 123
Db 118 VSS 120

RESULT 22
ID Q9QX9 PRELIMINARY; PRT; 117 AA.
AC Q9QX9;
DT 01-MAY-2000 (Tremblrel. 13, Created)
DT 01-MAY-2000 (Tremblrel. 13, Last sequence update)
DT 01-MAR-2003 (Tremblrel. 23, Last annotation update)
DE Immunoglobulin heavy chain V-D-J region (Fragment).
OC Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RA Clemens A., Rademakers A., Specht C., Koelsch E.;
RL Submitted (DEC-1997) to the EMBL/GenBank/DBJ databases.
DR EMBL; AJ225174; CAB65237.1; -.
DR HSSP; P01810; 2FBJ.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_V.
DR Pfam; PF00047; Ig; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
FT NON_TER 1
FT NON_TER 117
SQ SEQUENCE 117 AA; 13000 MW; CDD22AF84D499724 CRC64;

Query Match 53.7%; Score 344; DB 11; Length 117;
Best Local Similarity 53.7%; Pred. No. 7.7e-29;
Matches 66; Conservative 24; Mismatches 27; Indels 6; Gaps 1;

QY 1 QVQLQSGAEIVKPGASVVKSCASGTYFTISYTWIKQKPGQGLEWIGDINPFGSTNY 60
Db 1 EVQLQSGAEIVKPGASVVKSCASGTYFTIDYWKVKQSHGKSLWIGDINPFGSTNY 60
```


Qy	61	SONFGGRVAITADESTGTSMELSSLRSEDTAYVYCARSRDLLFPFHALLSPMGRTMYT	120
		: :	
		: :	
		: :	
Db	61	NQKFGKRLTLTVDKSSSTAYMQLNSLTSEDSAYVYCARDR-----YYANDYMGQGISVT	114
		: :	
		: :	
Qy	121	VSS	123
		: : :	
Db	115	VSS	117

Db 61 SQRKDKATLTVDDSSRTAVYQMLSLTSEDSAVYYCAADYTYTYTYDECCAFYWGQGLT 120
Qy 121 VSS 123
Db 121 VSA 123

RESULT 26

Q924Q1 PRELIMINARY; PRT; 142 AA.
AC Q924Q1; 01-DEC-2001 (TREMBlrel. 19, Created)
DT 01-DEC-2001 (TREMBlrel. 19, Last sequence update)
DE 01-MAR-2003 (TREMBlrel. 23, Last annotation update)
DE V23-D-J-C mu protein (Fragment).
GN V23-D-J-C MU.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
NCBI_TaxId=10090;
[1]
SEQUENCE FROM N.A.
RA STRAIN=C57BL/6;
RC Kozono Y., Kozono H., Azuma T.;
RT "Direct Estimation of Relative Affinity by Flow Cytometry Reveals
Affinity Maturation of B Cell Antigen Receptors in Response to (4-
Hydroxy-3-Nitrophenyl)Acetyl (NP).";
RL Submitted (Aug-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AB065913; BAB63929.1; -.
DR InterPro; IPR007110; IG_1like.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_V.
DR Pfam; PF00047; IG_1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
FT NON_TER 1
FT NON_TER 142
SQ SEQUENCE 142 AA; 15622 MW; 24A265CE4EA4318B CRC64;

Query Match 53.4%; Score 342; DB 11; Length 142;
Best Local Similarity 54.5%; Pred. No. 1.6e-28;
Matches 67; Conservative 20; Mismatches 30; Indels 6; Gaps 1;

Qy 1 QVQLQSGAEVKKPKSSVRVSCKASGTFNNAINWVROAPGQGLEWGGIIPMFRTAKY 60
Db 1 QVQLQPGALVLRGASVSKSCASGYTFTSYMMHWVKRPGKLEWIGRIDPRSGGTX 60
61 SQNFGRAVITADESTGTASMELSLRSEDTAVYYCARSDLLFPFHALLSPWGRTWVT 120
61 NEKFKSKATLTVDDSSRTAVYQMLSLTSEDSAVYYCAADYTYTYTYDECCAFYWGQGLT 114

Qy 121 VSS 123
Db 115 VSS 117

RESULT 27

Q924Q5 PRELIMINARY; PRT; 143 AA.
AC Q924Q5; 01-DEC-2001 (TREMBlrel. 19, Created)
DT 01-DEC-2001 (TREMBlrel. 19, Last sequence update)
DE 01-MAR-2003 (TREMBlrel. 23, Last annotation update)
DE VHI86.2-D-J-C mu protein (Fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
NCBI_TaxId=10090;
[1]
SEQUENCE FROM N.A.
RA STRAIN=C57BL/6;
RC Kozono Y., Kozono H., Azuma T.;

RT "Direct Estimation of Relative Affinity by Flow Cytometry Reveals
RT Affinity Maturation of B Cell Antigen Receptors in Response to (4-
Hydroxy-3-Nitrophenyl)Acetyl (NP).";
RL Submitted (Aug-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AB067795; BAB63280.1; -.
DR InterPro; IPR007110; IG_1like.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_V.
DR Pfam; PF00047; IG_1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
FT NON_TER 1
FT NON_TER 143
SQ SEQUENCE 143 AA; 15908 MW; 55A2372870F0D568 CRC64;

Query Match 53.3%; Score 341.5; DB 11; Length 143;
Best Local Similarity 55.3%; Pred. No. 1.8e-28;
Matches 68; Conservative 19; Mismatches 31; Indels 5; Gaps 1;

Qy 1 QVQLQSGAEVKKPKSSVRVSCKASGTFNNAINWVROAPGQGLEWGGIIPMFRTAKY 60
Db 1 QVQLQPGALVLRGASVSKSCASGYTFTSYMMHWVKRPGKLEWIGRIDPRSGGTX 60
61 SQNFGRAVITADESTGTASMELSLRSEDTAVYYCARSDLLFPFHALLSPWGRTWVT 120
61 NEKFKSKATLTVDDSSRTAVYQMLSLTSEDSAVYYCAADYTYTYTYDECCAFYWGQGLT 115

Qy 121 VSS 123
Db 116 VSS 118

RESULT 28

Q924R1 PRELIMINARY; PRT; 145 AA.
AC Q924R1; 01-DEC-2001 (TREMBlrel. 19, Created)
DT 01-DEC-2001 (TREMBlrel. 19, Last sequence update)
DE 01-MAR-2003 (TREMBlrel. 23, Last annotation update)
DE VHI86.2-D-J-C mu protein (Fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
NCBI_TaxId=10090;
[1]
SEQUENCE FROM N.A.
RA STRAIN=C57BL/6;
RC Kozono Y., Kozono H., Azuma T.;
RT "Direct Estimation of Relative Affinity by Flow Cytometry Reveals
Affinity Maturation of B Cell Antigen Receptors in Response to (4-
Hydroxy-3-Nitrophenyl)Acetyl (NP).";
RL Submitted (Aug-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AB067789; BAB63274.1; -.
DR InterPro; IPR007110; IG_1like.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_V.
DR Pfam; PF00047; IG_1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
FT NON_TER 1
FT NON_TER 145
SQ SEQUENCE 145 AA; 15979 MW; 0162D0A26C746C04 CRC64;

Query Match 53.1%; Score 340.5; DB 11; Length 145;
Best Local Similarity 56.1%; Pred. No. 2.4e-28;
Matches 69; Conservative 22; Mismatches 29; Indels 3; Gaps 2;

Qy 1 QVQLQSGAEVKKPKSSVRVSCKASGTFNNAINWVROAPGQGLEWGGIIPMFRTAKY 60
Db 1 QVQLQPGALVLRGASVSKSCASGYTFTSYMMHWVKRPGKLEWIGRIDPRSGGTX 60
61 SQNFGRAVITADESTGTASMELSLRSEDTAVYYCARSDLLFPFHALLSPWGRTWVT 120
61 NEKFKSKATLTVDDSSRTAVYQMLSLTSEDSAVYYCAADYTYTYTYDECCAFYWGQGLT 115

Db 61 NEFKSKATLTVKPSSTAYMQLSLTSEDSAVYYCAR-YDGSF--YANDYWGQGTSTVT 117
QY 121 VSS 123
Db 118 VSS 120

RESULT 29
Q924R8 PRELIMINARY; PRT; 146 AA.
ID 0924R8
AC 0924R8
DT 01-DEC-2001 (TEMBLrel. 19, Created)
DT 01-DEC-2001 (TEMBLrel. 19, Last sequence update)
DT 01-MAR-2003 (TEMBLrel. 23, Last annotation update)
DE V1186.2-D-J-C mu protein (Fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
NCBI_TaxID=10090;
FX [1]
RC STRAIN=C57BL/6;
RA Kozono Y., Kozono H., Azuma T.;
RT "Direct Estimation of Relative Affinity by Flow Cytometry Reveals
RT Affinity Maturation of B Cell Antigen Receptors in Response to (4-
RT Hydroxy-3-Nitrophenyl)Acetyl (NP)."
RL Submitted (AUG-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL: AB067781; BAB63266.1; -
DR InterPro: IPR007110; Ig-like.
DR InterPro: IPR003006; Ig_MHC.
DR InterPro: IPR003596; Ig_v.
DR Pfam: PF00047; Ig; 1.
DR SMART: SM00406; IGV; 1.
DR PROSITE: PSS0835; IG_LIKE; 1.
FT NON_TER 1 146
SQ SEQUENCE 146 AA; 16216 MW; 92460F1DF1B7538 CRC64;

Query Match 53.0%; Score 340; DB 11; Length 146;
Best Local Similarity 54.0%; Pred. No. 2,7e-28;
Matches 68; Conservative 22; Mismatches 28; Indels 8; Gaps 2;

QY 1 QVQLQSGAEVKKPGSSVRVSCKASGCTFNNNAINVVRQAPGGCLEMGGIIMFGTAKY 60
Db 1 QVQLQPGAEIVKPGASVSKLSCASGYFTSYMMHWVKQPGRLGRLMIGRIDPNSGGTKY 60

QY 61 SQNFGRAVITADESTGTASMEISLSRSEDTAYVYCARSDLLFPFHHLSPKGRGTMVT 117
Db 61 NEFKSKATLTVKPSSTAYMQLSLTSEDSAVYYCARSYGSSLYYFDY-----WGQGT 115

QY 118 MVTVSS 123
Db 116 TLTVSS 121

RESULT 30
Q924R7 PRELIMINARY; PRT; 143 AA.
ID 0924R7
AC 0924R7
DT 01-DEC-2001 (TEMBLrel. 19, Created)
DT 01-DEC-2001 (TEMBLrel. 19, Last sequence update)
DT 01-MAR-2003 (TEMBLrel. 23, Last annotation update)
DE V1186.2-D-J-C mu protein (Fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
NCBI_TaxID=10090;
FX [1]
RC STRAIN=C57BL/6;
RA Kozono Y., Kozono H., Azuma T.;
RT "Direct Estimation of Relative Affinity by Flow Cytometry Reveals
RT Affinity Maturation of B Cell Antigen Receptors in Response to (4-

RT Hydroxy-3-Nitrophenyl)Acetyl (NP)."
RL Submitted (AUG-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL: AB067782; BAB63267.1; -
DR InterPro: IPR007110; Ig-like.
DR InterPro: IPR003006; Ig_MHC.
DR InterPro: IPR003596; Ig_v.
DR Pfam: PF00047; Ig; 1.
DR SMART: SM00406; IGV; 1.
DR PROSITE: PSS0835; IG_LIKE; 1.
FT NON_TER 1 143
SQ SEQUENCE 143 AA; 15648 MW; 51894D22EA9FDD47 CRC64;

Query Match 52.8%; Score 338.5; DB 11; Length 143;
Best Local Similarity 53.7%; Pred. No. 3.8e-28;
Matches 66; Conservative 22; Mismatches 30; Indels 5; Gaps 1;

QY 1 QVQLQSGAEVKKPGSSVRVSCKASGCTFNNNAINVVRQAPGGCLEMGGIIMFGTAKY 60
Db 1 QVQLQPGAEIVKPGASVSKLSCASGYFTSYMMHWVKQPGRLGRLMIGRIDPNSGGTKY 60

QY 61 SQNFGRAVITADESTGTASMEISLSRSEDTAYVYCARSDLLFPFHHLSPKGRGTMVT 120
Db 61 NEFKSKATLTVKPSSTAYMQLSLTSEDSAVYYCARSDLLFPFHHLSPKGRGTMVT 120

QY 121 VSS 123
Db 116 VSS 118

RESULT 31
Q924R2 PRELIMINARY; PRT; 140 AA.
ID 0924R2
AC 0924R2
DT 01-DEC-2001 (TEMBLrel. 19, Created)
DT 01-DEC-2001 (TEMBLrel. 19, Last sequence update)
DT 01-MAR-2003 (TEMBLrel. 23, Last annotation update)
DE V1186.2-D-J-C mu protein (Fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
NCBI_TaxID=10090;
FX [1]
RC STRAIN=C57BL/6;
RA Kozono Y., Kozono H., Azuma T.;
RT "Direct Estimation of Relative Affinity by Flow Cytometry Reveals
RT Affinity Maturation of B Cell Antigen Receptors in Response to (4-
RT Hydroxy-3-Nitrophenyl)Acetyl (NP)."
RL Submitted (AUG-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL: AB067788; BAB63273.1; -
DR InterPro: IPR007110; Ig-like.
DR InterPro: IPR003006; Ig_MHC.
DR InterPro: IPR003596; Ig_v.
DR Pfam: PF00047; Ig; 1.
DR SMART: SM00406; IGV; 1.
DR PROSITE: PSS0835; IG_LIKE; 1.
FT NON_TER 1 140
SQ SEQUENCE 140 AA; 15361 MW; 60739B790FC6AF24 CRC64;

Query Match 52.7%; Score 338; DB 11; Length 140;
Best Local Similarity 54.5%; Pred. No. 4.2e-28;
Matches 67; Conservative 21; Mismatches 27; Indels 8; Gaps 1;

QY 1 QVQLQSGAEVKKPGSSVRVSCKASGCTFNNNAINVVRQAPGGCLEMGGIIMFGTAKY 60
Db 1 QVQLQPGAEIVKPGASVSKLSCASGYFTSYMMHWVKQPGRLGRLMIGRIDPNSGGTKY 60

QY 61 SQNFGRAVITADESTGTASMEISLSRSEDTAYVYCARSDLLFPFHHLSPKGRGTMVT 120
Db 61 NEFKSKATLTVKPSSTAYMQLSLTSEDSAVYYCARL-----YAGDWYGQGTSTVT 112

QY 121 VSS 123
Db 113 VSS 115

RESULT 32

Q8VDC9 PRELIMINARY; PRT; 168 AA.

DT 01-MAR-2002 (TREMBlrel. 20, Created)
DT 01-MAR-2002 (TREMBlrel. 20, Last sequence update)
DT 01-MAR-2003 (TREMBlrel. 23, Last annotation update)
DE Anti-MOG 212 variable gamma 2a (fragment).

GN 1GG2A.

OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OC NCBI_TaxID=10090;

RN [1] SEQUENCE FROM N.A.

RP STRAIN=BALB/c;

RL Submitted (OCT-2001) to the EMBL/GenBank/DBJ databases.

RN [2] SEQUENCE FROM N.A.

RP STRAIN=BALB/c;

RT "Targeting T cells to the CNS."

RL Submitted (JAN-2002) to the EMBL/GenBank/DBJ databases.

DR EMBL; AJ416332; CAC94867.1; -.

DR InterPro; IPR007110; IG-like.

DR InterPro; IPR003006; IG_MHC.

DR InterPro; IPR003596; IG_v.

DR Pfam; PF00047; IG_1.

DR SMART; SM00406; IG; 1.

DR PROSITE; PS00835; IG LIKE; 1.

DR NON TER 168

FT SEQUENCE 168 AA; 18293 MW; 1B3719FCC0E72723 CRC64;

Query Match 52.7%; Score 338; DB 11; Length 168;

Best Local Similarity 53.7%; Pred. No. 5.2e-28;

Matches 66; Conservative 20; Mismatches 33; Indels 4; Gaps 1;

QY 1 QVOLOQSGAEVKKPGSSVRVSCKASGTFNNNAIINWVROAPQGLGEMWGIIPMGRTAKY 60

Db 20 QVOLOQSGAEVKKPGSSVRVSCKASGTFNNNAIINWVROAPQGLGEMWGIIPMGRTAKY 79

QY 61 SQNFGARVAITADESTGASMEISLSRSEDPTAVYVCARSDDLFPFHALLSPMGRTMTV 120

Db 80 NEKFKGATLTADKSSNTAYMHLSSLTSSENSAVYFCARSK-----LGGFAYWGQGLT 135

QY 121 VSS 123

Db 136 VSS 138

RESULT 33

Q99L25 PRELIMINARY; PRT; 473 AA.

AC Q99L25; 01-JUN-2001 (TREMBlrel. 17, Created)

DT 01-JUN-2001 (TREMBlrel. 17, Last sequence update)

DE Similar to RIKEN CDNA 181060009 gene.

OS Mus musculus (Mouse).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

OC NCBI_TaxID=10090;

RN [1] SEQUENCE FROM N.A.

RP Strausberg R.;

RL Submitted (FEB-2001) to the EMBL/GenBank/DBJ databases.

EMBL; BC003888; AAH03888.1; -.

QY 121 VSS 123

Db 134 VSS 136

RESULT 34

Q8K024 PRELIMINARY; PRT; 480 AA.

AC Q8K024; 01-OCT-2002 (TREMBlrel. 22, Created)

DT 01-OCT-2002 (TREMBlrel. 22, Last sequence update)

DE Similar to expressed sequence A1893585.

OS Mus musculus (Mouse).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

OC NCBI_TaxID=10090;

RN [1] SEQUENCE FROM N.A.

RP Strausberg R.;

RL Submitted (FEB-2001) to the EMBL/GenBank/DBJ databases.

EMBL; BC003888; AAH03888.1; -.

QY 121 VSS 123

Db 134 VSS 136

DR HSP: P01842; 7FAB.

DR InterPro; IPR007110; IG-like.

DR InterPro; IPR003006; IG_MHC.

DR InterPro; IPR003596; IG_v.

DR Pfam; PF00047; IG; 3.

DR SMART; SM00406; IG; 1.

DR PROSITE; PS00835; IG LIKE; 4.

DR PROSITE; PS00290; IG_MHC; 1.

DR SEQUENCE 473 AA; 52449 MW; BE9889B7986DA155 CRC64;

QY 1 QVOLOQSGAEVKKPGSSVRVSCKASGTFNNNAIINWVROAPQGLGEMWGIIPMGRTAKY 60

Db 20 QVOLOQSGAEVKKPGSSVRVSCKASGTFNNNAIINWVROAPQGLGEMWGIIPMGRTAKY 79

QY 61 SQNFGARVAITADESTGASMEISLSRSEDPTAVYVCARSDDLFPFHALLSPMGRTMTV 119

Db 80 NEKFKGATLTADKSSNTAYMHLSSLTSSENSAVYFCARSK-----LGGFAYWGQGLT 139

QY 120 TVSS 123

Db 140 TVSS 143

Query Match

Best Local Similarity 51.6%; Pred. No. 2.1e-27;

Matches 64; Conservative 27; Mismatches 32; Indels 1; Gaps 1;

QY 1 QVOLOQSGAEVKKPGSSVRVSCKASGTFNNNAIINWVROAPQGLGEMWGIIPMGRTAKY 60

Db 20 QVOLOQSGAEVKKPGSSVRVSCKASGTFNNNAIINWVROAPQGLGEMWGIIPMGRTAKY 79

QY 61 SQNFGARVAITADESTGASMEISLSRSEDPTAVYVCARSDDLFPFHALLSPMGRTMTV 119

Db 80 NEKFKGATLTADKSSNTAYMHLSSLTSSENSAVYFCARSK-----LGGFAYWGQGLT 139

QY 120 TVSS 123

Db 140 TVSS 143

Query Match

Best Local Similarity 52.8%; Pred. No. 2.5e-27;

Matches 65; Conservative 27; Mismatches 25; Indels 6; Gaps 1;

QY 1 QVOLOQSGAEVKKPGSSVRVSCKASGTFNNNAIINWVROAPQGLGEMWGIIPMGRTAKY 60

Db 20 QVOLOQSGAEVKKPGSSVRVSCKASGTFNNNAIINWVROAPQGLGEMWGIIPMGRTAKY 79

QY 61 SQNFGARVAITADESTGASMEISLSRSEDPTAVYVCARSDDLFPFHALLSPMGRTMTV 120

Db 80 NEKFKGATLTADKSSNTAYMHLSSLTSSENSAVYFCARSK-----LGGFAYWGQGLT 133

QY 121 VSS 123

Db 134 VSS 136

RESULT 35
Q924P8 PRELIMINARY; PRT; 140 AA.

ID Q924P8
AC Q924P8; 01-DEC-2001 (TREMBLrel. 19, Created)
DT 01-DEC-2001 (TREMBLrel. 19, Last sequence update)
DE 01-MAR-2003 (TREMBLrel. 23, Last annotation update)
DE V23-D-J-C mu protein (Fragment).
GN V23-D-J-C MU.
OS Mus musculus (mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
NCBI_TaxId=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6;
RA Kozono Y., Kozono H., Azuma T.;
F "Direct Estimation of Relative Affinity by Flow Cytometry Reveals Affinity Maturation of B Cell Antigen Receptors in Response to (4-Hydroxy-3-Nitrophenyl)Acetyl (NP)." ;
RL Submitted (Aug-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AB069917; BAB63933.1; -
DR InterPro; IPR007110; Ig_Like.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_V.
DR Pfam; PR00047; Ig_1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PSS0835; IG_LIKE; 1.
FT NON TER 1
FT NON TER 140
SQ SEQUENCE 140 AA; 15392 MW; 904C80C82548C936 CRC64;

Query Match 52.4%; Score 336; DB 11; Length 140;
Best Local Similarity 52.8%; Pred. No. 6.8e-28;
Matches 65; Conservative 21; Mismatches 29; Indels 8; Gaps 1;

QY 1 QVQLQSGAEVKKRQGSFVRSCAKASGTFNNNAINWVROAPGQGLEWGGIIPMFGRATKY 60
DB 1 QVQLQSGAEVKKRQGSFVRSCAKASGTFNNNAINWVROAPGQGLEWGGIIPMFGRATKY 60

QY 61 SQNFGKVAITADESTGTASMEISLRSEDTAVYYCARSDLLFPFHALLSPWGRGTMT 120
DB 61 NEKFKSRATLTVDKPSSTACTQSLTSEDSAVYYCARND-----FDYMGQGITLT 112

QY 121 VSS 123
113 VSS 115

RESULT 36
Q924Q8 PRELIMINARY; PRT; 146 AA.

ID Q924Q8
AC Q924Q8; 01-DEC-2001 (TREMBLrel. 19, Created)
DT 01-DEC-2001 (TREMBLrel. 19, Last sequence update)
DE 01-MAR-2003 (TREMBLrel. 23, Last annotation update)
DE V186.2-D-J-C mu protein (Fragment).
OS Mus musculus (mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
NCBI_TaxId=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6;
RA Kozono Y., Kozono H., Azuma T.;
F "Direct Estimation of Relative Affinity by Flow Cytometry Reveals Affinity Maturation of B Cell Antigen Receptors in Response to (4-Hydroxy-3-Nitrophenyl)Acetyl (NP)." ;
RL Submitted (Aug-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AB067792; BAB63277.1; -
DR InterPro; IPR007110; Ig_Like.

DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_V.
DR Pfam; PR00047; IGV; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PSS0835; IG_LIKE; 1.
FT NON TER 1
FT NON TER 146
SQ SEQUENCE 146 AA; 16023 MW; 4B04959991D49159 CRC64;

Query Match 52.4%; Score 336; DB 11; Length 146;
Best Local Similarity 53.2%; Pred. No. 7.2e-28;
Matches 67; Conservative 23; Mismatches 28; Indels 8; Gaps 2;

QY 1 QVQLQSGAEVKKRQGSFVRSCAKASGTFNNNAINWVROAPGQGLEWGGIIPMFGRATKY 60
DB 1 QVQLQSGAEVKKRQGSFVRSCAKASGTFNNNAINWVROAPGQGLEWGGIIPMFGRATKY 60

QY 61 SQNFGKVAITADESTGTASMEISLRSEDTAVYYCARSDLLFPFHALLSPWGRGTMT 117
DB 61 NEKFKSRATLTVDKPSSTACTQSLTSEDSAVYYCARND-----FTTVVAPFDYMGQGIT 115

QY 118 MVTVSS 123
116 TLTVSS 121

RESULT 37
Q924R5 PRELIMINARY; PRT; 139 AA.

ID Q924R5
AC Q924R5; 01-DEC-2001 (TREMBLrel. 19, Created)
DT 01-DEC-2001 (TREMBLrel. 19, Last sequence update)
DE 01-MAR-2003 (TREMBLrel. 23, Last annotation update)
DE V186.2-D-J-C mu protein (Fragment).
OS Mus musculus (mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
NCBI_TaxId=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6;
RA Kozono Y., Kozono H., Azuma T.;
F "Direct Estimation of Relative Affinity by Flow Cytometry Reveals Affinity Maturation of B Cell Antigen Receptors in Response to (4-Hydroxy-3-Nitrophenyl)Acetyl (NP)." ;
RL Submitted (Aug-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AB067784; BAB63269.1; -
DR InterPro; IPR007110; Ig_Like.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_V.
DR Pfam; PR00047; Ig_1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PSS0835; IG_LIKE; 1.
FT NON TER 1
FT NON TER 139
SQ SEQUENCE 139 AA; 15221 MW; 8491E2F85614736A CRC64;

Query Match 52.3%; Score 335.5; DB 11; Length 139;
Best Local Similarity 55.3%; Pred. No. 7.6e-28;
Matches 68; Conservative 22; Mismatches 24; Indels 9; Gaps 2;

QY 1 QVQLQSGAEVKKRQGSFVRSCAKASGTFNNNAINWVROAPGQGLEWGGIIPMFGRATKY 60
DB 1 QVQLQSGAEVKKRQGSFVRSCAKASGTFNNNAINWVROAPGQGLEWGGIIPMFGRATKY 60

QY 61 SQNFGKVAITADESTGTASMEISLRSEDTAVYYCARSDLLFPFHALLSPWGRGTMT 120
DB 61 NEKFKSRATLTVDKPSSTACTQSLTSEDSAVYYCARND-----LTVVAPFDYMGQGIT 111

QY 121 VSS 123
112 VSA 114

```
RESULT 38
091WT1 PRELIMINARY; PRT; 143 AA.
AC 091WT1;
DT 01-DEC-2001 (TRENBLREL. 19, Created)
DT 01-DEC-2001 (TRENBLREL. 19, Last sequence update)
DE 01-MAR-2003 (TRENBLREL. 23, Last annotation update)
DE VHA16.2-D-J-C mu protein (V304-D-J-C mu protein) (Fragment).
GN V304-D-J-C MU
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6;
RA Kozono Y., Kozono H., Azuma T.;
RT "Direct Estimation of Relative Affinity by Flow Cytometry Reveals
RT Affinity Maturation of B Cell Antigen Receptors in Response to (4-
RT Hydroxy-3-Nitrophenyl)Acetyl (NP)";
RN Submitted (AUG-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AB069912; BAB63928.1; -
DR EMBL; AB069914; BAB63930.1; -
DR InterPro; IPR007110; IG_1-like.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_V.
DR Pfam; PF00047; IG_1.
DR SMART; SM00406; IG_1.
DR PROSITE; PS50835; IG_LIKE; 1.
FT NON_TER 1
FT NON_TER 143
SQ SEQUENCE 143 AA; 15775 MW; 91BC6012B44EFEBF CRC64;

Query Match
Best Local Similarity 52.3%; Score 335.5; DB 11; Length 143;
Matches 68; Conservative 18; Mismatches 32; Indels 5; Gaps 1;

QY 1 QVQLQSGAEVKKPGSSVRVSCKASGCTFNNNAIMNWVROAPGQGLEWMGIIIPMGFTAKY 60
DB 1 QVQLQPGALVLPKPSVYKLSCKASGYTFSTYIMHWVQKRGQGLEWIGVDPDSSTNY 60
QY 61 SQNFGRAVITADESTGTSAMELSLSRSEDYAVYVCARSDDLFPFHALLSPMGRTMYT 120
DB 61 NQKFKGKATLTVDKSSSTAYVQLSLTSEDSAVYVCAPTVDWYF-----DVGRTGTITV 115
QY 121 VSS 123
DB 116 VSS 118

RESULT 39
091WT1 PRELIMINARY; PRT; 481 AA.
AC 091WT1;
DT 01-DEC-2001 (TRENBLREL. 19, Created)
DT 01-DEC-2001 (TRENBLREL. 19, Last sequence update)
DE 01-MAR-2003 (TRENBLREL. 23, Last annotation update)
DE Hypothetical 52.1 kDa protein.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Colon;
RA Strauberg R.;
RT Submitted (SEP-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC013490; AAH13490.1; -
DR InterPro; IPR007110; IG_1-like.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_V.
DR Pfam; PF00047; IG_1.
SQ SEQUENCE 481 AA; 52105 MW; 97DF68D159463F65 CRC64;

Query Match
Best Local Similarity 52.8%; Score 334.5; DB 11; Length 141;
Matches 65; Conservative 23; Mismatches 28; Indels 7; Gaps 1;

QY 1 QVQLQSGAEVKKPGSSVRVSCKASGCTFNNNAIMNWVROAPGQGLEWMGIIIPMGFTAKY 60
DB 1 QVQLQPGALVLPKPSVYKLSCKASGYTFSTYIMHWVQKRGQGLEWIGVDPDSSTNY 60
QY 61 SQNFGRAVITADESTGTSAMELSLSRSEDYAVYVCARSDDLFPFHALLSPMGRTMYT 120
DB 61 NEKFKGKATLTVDKSSSTAYVQLSLTSEDSAVYVCARD-----DVGRTWGQGTTLT 113
QY 121 VSS 123
DB 114 VSS 116

RESULT 41
0924R3
```

```
DR SMART; SM00406; IG_1.
DR PROSITE; PS50835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; 2.
DR Hypothetical protein.
SQ SEQUENCE 481 AA; 52105 MW; 97DF68D159463F65 CRC64;

Query Match
Best Local Similarity 52.3%; Score 335; DB 11; Length 481;
Matches 67; Conservative 19; Mismatches 31; Indels 6; Gaps 1;

QY 1 QVQLQSGAEVKKPGSSVRVSCKASGCTFNNNAIMNWVROAPGQGLEWMGIIIPMGFTAKY 60
DB 20 QVQLQSGPVLVLPKPSVYKLSCKASGYTFSTYIMHWVQKRGQGLEWIGVDPDSSTNY 79
QY 61 SQNFGRAVITADESTGTSAMELSLSRSEDYAVYVCARSDDLFPFHALLSPMGRTMYT 120
DB 80 NEKFKGKATLTVDKSSSTAYVQLSLTSEDSAVYVCTRGG-----WADVYWGQGTTLT 133
QY 121 VSS 123
DB 134 VSS 136

RESULT 40
0924Q4 PRELIMINARY; PRT; 141 AA.
AC 0924Q4;
DT 01-DEC-2001 (TRENBLREL. 19, Created)
DT 01-DEC-2001 (TRENBLREL. 19, Last sequence update)
DE 01-MAR-2003 (TRENBLREL. 23, Last annotation update)
DE VHA16.2-D-J-C mu protein (Fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6;
RA Kozono Y., Kozono H., Azuma T.;
RT "Direct Estimation of Relative Affinity by Flow Cytometry Reveals
RT Affinity Maturation of B Cell Antigen Receptors in Response to (4-
RT Hydroxy-3-Nitrophenyl)Acetyl (NP)";
RN Submitted (AUG-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AB067796; BAB63281.1; -
DR InterPro; IPR007110; IG_1-like.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_V.
DR Pfam; PF00047; IG_1.
DR SMART; SM00406; IG_1.
DR PROSITE; PS50835; IG_LIKE; 1.
FT NON_TER 1
FT NON_TER 141
SQ SEQUENCE 141 AA; 15561 MW; DDD80482D6B76A0 CRC64;

Query Match
Best Local Similarity 52.8%; Score 334.5; DB 11; Length 141;
Matches 65; Conservative 23; Mismatches 28; Indels 7; Gaps 1;

QY 1 QVQLQSGAEVKKPGSSVRVSCKASGCTFNNNAIMNWVROAPGQGLEWMGIIIPMGFTAKY 60
DB 1 QVQLQPGALVLPKPSVYKLSCKASGYTFSTYIMHWVQKRGQGLEWIGVDPDSSTNY 60
QY 61 SQNFGRAVITADESTGTSAMELSLSRSEDYAVYVCARSDDLFPFHALLSPMGRTMYT 120
DB 61 NEKFKGKATLTVDKSSSTAYVQLSLTSEDSAVYVCARD-----DVGRTWGQGTTLT 113
QY 121 VSS 123
DB 114 VSS 116

RESULT 41
0924R3
```

ID Q924R3 PRELIMINARY; PRT; 145 AA.
 AC Q924R3
 DT 01-DEC-2001 (TREMBlrel. 19, Created)
 DT 01-DEC-2001 (TREMBlrel. 19, Last sequence update)
 DT 01-MAR-2003 (TREMBlrel. 23, Last annotation update)
 DE VAI86.2-D-J-C mu protein (Fragment).
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 NCBI_TaxID=10090;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=C57BL/6;
 RA Kozono Y., Kozono H., Azuma T.;
 RT "Direct Estimation of Relative Affinity by Flow Cytometry Reveals
 Affinity Maturation of B Cell Antigen Receptors in Response to (4-
 RT Hydroxy-3-Nitrophenyl)acetyl (NP)."
 RL Submitted (AUG-2001) to the EMBL/Genbank/DBJ databases.
 DR EMBL; AB067787; BAB63272.1;
 DR InterPro; IPR007110; Ig_Like.
 DR InterPro; IPR003006; Ig_MHC.
 DR InterPro; IPR003596; Ig_V.
 DR Pfam; PF00047; Ig_1.
 DR SMART; SM00406; IGV; 1.
 DR PROSITE; PSS0835; IG_LIKE; 1.
 FT NON TER 1
 FT NON TER 1
 SQ SEQUENCE 145 AA; 15996 MW; 35B1A36E4280BA81 CRC64;

Query Match 52.2%; Score 334.5; DB 11; Length 145;
 Best Local Similarity 54.5%; Pred. No. 1e-27;
 Matches 67; Conservative 20; Mismatches 33; Indels 3; Gaps 1;
 QY 1 OVQLQSGAEVKKRGSVRVSCKASGTFNNNNINWROAPGGLMMGGIIPMFGRAXY 60
 DB 1 OVQLQSGAEVKKRGSVRVSCKASGTFNNNNINWROAPGGLMMGGIIPMFGRAXY 60
 QY 61 SGNFGRVAITADESTGTASMEISLRSEDTAVYVCARSDDLFPFHALLSPMGRTMT 120
 DB 61 NEKSKATLTVDKSSTAYVQNSLTSSEDSAVYYCARG---LYDGMWYFVWGTGTTVT 117
 QY 121 VSS 123
 DB 118 VSS 120

RESULT 42
 AC Q921A6 PRELIMINARY; PRT; 241 AA.
 DT 01-DEC-2001 (TREMBlrel. 19, Created)
 DT 01-DEC-2001 (TREMBlrel. 19, Last sequence update)
 DT 01-MAR-2003 (TREMBlrel. 23, Last annotation update)
 DE Anti-CEA 79 single chain Fv fragment (Fragment).
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 NCBI_TaxID=10090;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC MEDLINE=98170165; PubMed=9509426;
 RA Chung J.H., Choi S.J., Kim H.J., Kim I.J., Choi I.H., Lee S.D.,
 RA Yi K.S., Suh P.G., Ryu S.H., Chung H.K.;
 RT "Cloning and characterization of cDNAs encoding VH and VL of a
 monoclinal anti-CEA antibody (CEA 79) cross-reactive with NCA-95 and
 RT generation of a single-chain Fv molecule (scfv)."
 RL EMBL; U88067; AAB48044.1;
 DR InterPro; IPR007110; Ig_Like.
 DR InterPro; IPR003006; Ig_MHC.
 DR InterPro; IPR003596; Ig_V.
 DR Pfam; PF00047; Ig_2.
 DR SMART; SM00406; IGV; 2.

DR PROSITE; PSS0835; IG_LIKE; 2.
 FT NON TER 1
 FT NON TER 241
 SQ SEQUENCE 241 AA; 26086 MW; 0276887248B9C771 CRC64;
 Query Match 52.2%; Score 334.5; DB 11; Length 241;
 Best Local Similarity 52.0%; Pred. No. 1.9e-27;
 Matches 64; Conservative 26; Mismatches 28; Indels 5; Gaps 2;
 QY 1 OVQLQSGAEVKKRGSVRVSCKASGTFNNNNINWROAPGGLMMGGIIPMFGRAXY 60
 DB 1 OVQLQSGAEVKKRGSVRVSCKASGTFNNNNINWROAPGGLMMGGIIPMFGRAXY 60
 QY 61 SGNFGRVAITADESTGTASMEISLRSEDTAVYVCARSDDLFPFHALLSPMGRTMT 120
 DB 61 ADFPKGFALSLRISATATLQINLNKEDTATFYFCAR-KDLRY----FDYMGQGTTLT 115
 QY 121 VSS 123
 DB 116 VSS 118

RESULT 43
 ID Q9QXFO PRELIMINARY; PRT; 117 AA.
 AC Q9QXFO
 DT 01-MAY-2000 (TREMBlrel. 13, Created)
 DT 01-MAY-2000 (TREMBlrel. 13, Last sequence update)
 DT 01-MAR-2003 (TREMBlrel. 23, Last annotation update)
 DE Immunoglobulin heavy chain V-D-J region (Fragment).
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 NCBI_TaxID=10090;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Clemens A., Rademakers A., Specht C., Koelsch E.;
 RL EMBL; AJ225171; CAB65236.1;
 DR HSP; P01789; IMCP.
 DR InterPro; IPR007110; Ig_Like.
 DR InterPro; IPR003006; Ig_MHC.
 DR InterPro; IPR003596; Ig_V.
 DR Pfam; PF00047; Ig_1.
 DR SMART; SM00406; IGV; 1.
 DR PROSITE; PSS0835; IG_LIKE; 1.
 FT NON TER 1
 FT NON TER 1
 SQ SEQUENCE 117 AA; 13060 MW; D816AD0858A47E4C CRC64;

Query Match 52.1%; Score 334; DB 11; Length 117;
 Best Local Similarity 52.0%; Pred. No. 8.9e-28;
 Matches 64; Conservative 24; Mismatches 29; Indels 6; Gaps 1;
 QY 1 OVQLQSGAEVKKRGSVRVSCKASGTFNNNNINWROAPGGLMMGGIIPMFGRAXY 60
 DB 1 EVQLQSGPELVKPGASVKSCASGYTFDYIMKWKVQSHGSLKIGIDINPNNGTSTY 60
 QY 61 SGNFGRVAITADESTGTASMEISLRSEDTAVYVCARSDDLFPFHALLSPMGRTMT 120
 DB 61 NQFKGKATLTVDKSSTAYVQNSLTSSEDSAVYYCARDMD-----YYFDYMGQGTTLT 114
 QY 121 VSS 123
 DB 115 VSS 117

RESULT 44
 ID Q920B8 PRELIMINARY; PRT; 120 AA.
 AC Q920B8
 DT 01-DEC-2001 (TREMBlrel. 19, Created)
 DT 01-DEC-2001 (TREMBlrel. 19, Last sequence update)

DT 01-MAR-2003 (Tremblrel. 23, last annotation update)
DE Pterin-mimicking anti-idiotope heavy chain variable region
DE (Fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RA Atkin J.D., Jape A., Jennings I.G., Horaitis O., Cotton R.G.H.,
RT "Definition of the idiotope of Pterin-Mimicking Antibodies Expressed
in Mammalian Cells."
RL Submitted (SEP-2000) to the EMBL/Genbank/DBJ databases.
DR EMBL; AF307936; AAL09420.1; -
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_V.
DR Pfam; PF00047; IG_1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PSS0835; IG_LIKE; 1.
DR NON_TER 1
SQ SEQUENCE 120 AA; 13204 MW; DC4834ABIDE56F3C CRC64;
Query Match 52.1%; Score 334; DB 11; Length 120;
Best Local Similarity 50.4%; Pred. No. 9.2e-28;
Matches 64; Conservative 25; Mismatches 26; Indels 12; Gaps 2;
QY 1 QVQLQSGAEVKKPSQSVRVSCASGCTFPNNAINWVROAPQGLEMMGGIIPMGRTAKY 60
DB 1 EVQLQSGDELKPKASVVKISCKASGYSPTGYNNMVAQSNKSLIEMIGNDIPYGGTSTY 60
QY 61 SQNFGRAVITADESTGASMEISLRSEDTAVVYCARSDLLLPFHALS-----WGR 115
DB 61 NQKFGKATLTVDKSSSTAVYQKLSTSEDSAVYYCA-----VYIGNSPAMFAVYQG 113
QY 116 GEMTVVS 122
DB 114 GLTVVS 120

RESULT 45
Q91VA2 PRELIMINARY; PRT; 143 AA.
ID Q91VA2
AC Q91VA2
DT 01-DEC-2001 (Tremblrel. 19, Created)
DT 01-DEC-2001 (Tremblrel. 19, last sequence update)
DT 01-MAR-2003 (Tremblrel. 23, last annotation update)
DE Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RA STRAIN=C57BL/6;
RC Kozono Y., Kozono H., Azuma T.,
RT "Direct Estimation of Relative Affinity by Flow Cytometry Reveals
Affinity Maturation of B Cell Antigen Receptors in Response to (4-
Hydroxy-3-Nitrophenyl)Acetyl (NP)."
RL Submitted (AUG-2001) to the EMBL/Genbank/DBJ databases.
DR EMBL; AB067786; BAB63271.1; -
DR EMBL; AB069911; BAB63927.1; -
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_V.
DR Pfam; PF00047; IG_1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PSS0835; IG_LIKE; 1.
DR NON_TER 1
SQ SEQUENCE 143 AA; 15617 MW; 51952152F6F3AD47 CRC64;

Query Match 52.0%; Score 333.5; DB 11; Length 143;
Best Local Similarity 52.8%; Pred. No. 1.3e-27;
Matches 65; Conservative 22; Mismatches 31; Indels 5; Gaps 1;
QY 1 QVQLQSGAEVKKPSQSVRVSCASGCTFPNNAINWVROAPQGLEMMGGIIPMGRTAKY 60
DB 1 QVQLQSGAEVKKPSQSVRVSCASGCTFPNNAINWVROAPQGLEMMGGIIPMGRTAKY 60
QY 61 SQNFGRAVITADESTGASMEISLRSEDTAVVYCARSDLLLPFHALS-----WGR 115
DB 61 NQKFGKATLTVDKSSSTAVYQKLSTSEDSAVYYCA-----VYIGNSPAMFAVYQG 113
QY 121 VSS 123
DB 116 VSS 118

RESULT 46
Q924Q7 PRELIMINARY; PRT; 145 AA.
ID Q924Q7
AC Q924Q7
DT 01-DEC-2001 (Tremblrel. 19, Created)
DT 01-DEC-2001 (Tremblrel. 19, last sequence update)
DT 01-MAR-2003 (Tremblrel. 23, last annotation update)
DE VHL86.2-D-J-C mu protein (Fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RA STRAIN=C57BL/6;
RC Kozono Y., Kozono H., Azuma T.,
RT "Direct Estimation of Relative Affinity by Flow Cytometry Reveals
Affinity Maturation of B Cell Antigen Receptors in Response to (4-
Hydroxy-3-Nitrophenyl)Acetyl (NP)."
RL Submitted (AUG-2001) to the EMBL/Genbank/DBJ databases.
DR EMBL; AB067793; BAB63278.1; -
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_V.
DR Pfam; PF00047; IG_1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PSS0835; IG_LIKE; 1.
DR NON_TER 1
SQ SEQUENCE 145 AA; 16141 MW; 55A59A7908B2CD6A CRC64;
Query Match 51.9%; Score 332.5; DB 11; Length 145;
Best Local Similarity 52.4%; Pred. No. 1.7e-27;
Matches 66; Conservative 24; Mismatches 27; Indels 9; Gaps 2;
QY 1 QVQLQSGAEVKKPSQSVRVSCASGCTFPNNAINWVROAPQGLEMMGGIIPMGRTAKY 60
DB 1 QVQLQSGAEVKKPSQSVRVSCASGCTFPNNAINWVROAPQGLEMMGGIIPMGRTAKY 60
QY 61 SQNFGRAVITADESTGASMEISLRSEDTAVVYCARSDLLLPFHALS-----WGR 117
DB 61 NEKFGKATLTVDKSSSTAVYQKLSTSEDSAVYYCA-----VYIGNSPAMFAVYQG 114
QY 118 MVTSS 123
DB 115 TLTVSS 120

RESULT 47
Q924R6 PRELIMINARY; PRT; 137 AA.
ID Q924R6
AC Q924R6
DT 01-DEC-2001 (Tremblrel. 19, Created)
DT 01-DEC-2001 (Tremblrel. 19, last sequence update)
DT 01-MAR-2003 (Tremblrel. 23, last annotation update)
DE VHL86.2-D-J-C mu protein (Fragment).

OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6;
RA Kozono Y., Kozono H., Azuma T.;
RT "Direct Estimation of Relative Affinity by Flow Cytometry Reveals
Affinity Maturation of B Cell Antigen Receptors in Response to (4-
Hydroxy-3-Nitrophenyl)Acetyl (NP).";
RL Submitted (AUG-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AB067783; BAB63268.1; -.
DR InterPro; IPR007110; IG_1like.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_v.
DR Pfam; PF00047; IG_1.
DR SMART; SM00406; IGV_1.
DR PROSITE; PSS0835; IG_LIKE; 1.
DR NON_TER 1
SQ SEQUENCE 137 AA; 15171 MW; 5C3BD966DC6A124 CRC64;
Query Match 51.7%; Score 331.5; DB 11; Length 137;
Best Local Similarity 52.8%; Pred. No. 2e-27;
Matches 65; Conservative 21; Mismatches 26; Indels 11; Gaps 1;
QY 1 QVQLQSGAEVKKRPGSSVRVSCAKSGTFFNNAINVWROAPGGGLEMGIIIPFGTAKY 60
DB 1 QVQLQSGAEVKKRPGSSVRVSCAKSGTFFNNAINVWROAPGGGLEMGIIIPFGTAKY 60
QY 61 SQNFGKVAITADESTGTASMEISLRSEDTAVYYCARSDLLFPFHALLSPMGRTMT 120
DB 61 NEKFKSKATITVDTSSNTAYLQSLTSEDSAVYYCAR-----WDYMGQGITLT 109
QY 121 VSS 123
DB 110 VSS 112
RESULT 48
Q924P9 PRELIMINARY; PRT; 143 AA.
ID Q924P9
AC Q924P9
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT 01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DR V03-D-J-C mu protein (Fragment).
DR V03-D-J-C mu.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6;
RA Kozono Y., Kozono H., Azuma T.;
RT "Direct Estimation of Relative Affinity by Flow Cytometry Reveals
Affinity Maturation of B Cell Antigen Receptors in Response to (4-
Hydroxy-3-Nitrophenyl)Acetyl (NP).";
RL Submitted (AUG-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AB069916; BAB63932.1; -.
DR InterPro; IPR007110; IG_1like.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_v.
DR Pfam; PF00047; IG_1.
DR SMART; SM00406; IGV_1.
DR PROSITE; PSS0835; IG_LIKE; 1.
DR NON_TER 1
SQ SEQUENCE 143 AA; 15704 MW; 43CDB6C72D521346 CRC64;
Query Match 51.6%; Score 330.5; DB 11; Length 143;

Best Local Similarity 54.0%; Pred. No. 2.7e-27;
Matches 68; Conservative 18; Mismatches 29; Indels 11; Gaps 2;
QY 1 QVQLQSGAEVKKRPGSSVRVSCAKSGTFFNNAINVWROAPGGGLEMGIIIPFGTAKY 60
DB 1 QVQLQSGAEVKKRPGSSVRVSCAKSGTFFNNAINVWROAPGGGLEMGIIIPFGTAKY 60
QY 61 SQNFGKVAITADESTGTASMEISLRSEDTAVYYCARSDLLFPFHALLSPMGRTMT 117
DB 61 NEKFKSKATITVDTSSNTAYLQSLTSEDSAVYYCAR-----SHYGGSSDYMGQGT 112
QY 118 MVTVSS 123
DB 113 TLTVSS 118
RESULT 49
Q99L31 PRELIMINARY; PRT; 468 AA.
ID Q99L31
AC Q99L31
DT 01-JUN-2001 (TrEMBLrel. 17, Created)
DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
DT 01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DE Similar to RIKEN CDNA 181060009 gene.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RA Strausberg R.;
RL Submitted (FEB-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC003878; AAH03878.1; -.
DR HSSP; P01842; 7FAB.
DR InterPro; IPR007110; IG_1like.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_v.
DR Pfam; PF00047; IG_3.
DR SMART; SM00406; IGV_1.
DR PROSITE; PSS0835; IG_LIKE; 4.
DR PROSITE; PSS0290; IG_MHC; 1.
SQ SEQUENCE 468 AA; 51661 MW; 96352328B3332ADB CRC64;
Query Match 51.5%; Score 330; DB 11; Length 468;
Best Local Similarity 53.7%; Pred. No. 1.3e-26;
Matches 66; Conservative 23; Mismatches 30; Indels 4; Gaps 2;
QY 1 QVQLQSGAEVKKRPGSSVRVSCAKSGTFFNNAINVWROAPGGGLEMGIIIPFGTAKY 60
DB 20 EVQLQSGAEVKKRPGSSVRVSCAKSGTFFNNAINVWROAPGGGLEMGIIIPFGTAKY 79
QY 61 SQNFGKVAITADESTGTASMEISLRSEDTAVYYCARSDLLFPFHALLSPMGRTMT 120
DB 80 APRFKGKATITVDTSSNTAYLQSLTSEDSAVYYCARN---LLYGGY-YDYMGQGITLT 135
QY 121 VSS 123
DB 136 VSS 138
RESULT 50
Q925S3 PRELIMINARY; PRT; 147 AA.
ID Q925S3
AC Q925S3
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT 01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DE NKP3.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]

RP SEQUENCE FROM N.A.
 RC STRAIN=BALB/c;
 RX PubMed=11819679;
 RA Cui D., Zeng G., Yan X., Wang F., Tian F., Ren D., Zhao T., Li X.,
 RA Su C.;
 RT "Mechanism of exogenous nucleic acids and their precursors improving
 RT the repair of intestinal epithelium after irradiation in mice.";
 RL World J. Gastroenterol. 6:709-717(2000).
 RN [2]
 RP SEQUENCE FROM N.A.
 RC STRAIN=BALB/c;
 RA Cui D., Zeng G., Yan X., Li X., Su C.;
 RT "Cloning of mouse genes related to repairing of intestinal epithelium
 RT of the irradiated mice by treatment with the intestinal RNA of mice of
 RT the same strain.";
 RL Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med. 19:71-80(2001).
 DR EMBL; AF240166; AAK43731.1; -
 DR InterPro; IPR007110; IG-like.
 DR InterPro; IPR003006; IG_MHC.
 DR InterPro; IPR003596; IG_V.
 DR Pfam; PF00047; Ig; 1.
 DR SMART; SM00406; IgV; 1.
 DR PROSITE; PS50835; IG LIKE; 1.
 SQ SEQUENCE 147 AA; 16274 MW; 800594A12B97191F CRC64;

Query March 51.3%; Score 329; DB 11; Length 147;
 Best Local Similarity 52.8%; Pred. No. 4e-27;
 Matches 65; Conservative 21; Mismatches 33; Indels 4; Gaps 1;

OY 1 QVQLQQSGAEVKKPKSSVSVKSCAKSGTFFNNNAIMVRAQAPQGLIEMWGIIIPMFGTAKY 60
 DB 3 QVKLHSGSPVVKKGASVKLSCKASGYIFTSYDIDWRQTPQGLIEMIGWIFPGSGSTY 62
 OY 61 SQNFGQVVAITADSTGTASWELSSLRSEDTAVTYCARSDLLFPFHALLSPWGRGTMT 120
 DB 63 NEKFKGRATLSVDKSSSTAVMELTSLTSEDSAVVFCARGD----YRRYFDLMGQGTVT 118
 OY 121 VSS 123
 DB 119 VSS 121

Search completed: November 26, 2003, 13:41:01
 Job time : 33.0641 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: November 26, 2003, 13:30:14 ; Search time 10.5128 Seconds
(without alignments)
550.212 Million cell updates/sec

Title: US-09-880-748-327_COPY_1_123
Perfect score: 641
Sequence: 1 QVQLQSGAEVKKRPGSSVRY.....LFPFHALSPWGRGTMTVSS 123

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 127863 seqs, 47026705 residues
number of hits satisfying chosen parameters: 127863

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : SwissProt_41.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	421	65.7	117	1	HV1A_HUMAN
2	370	57.7	117	1	HV1B_HUMAN
3	362.5	56.6	147	1	HV1C_HUMAN
4	345	53.8	117	1	HV1G_HUMAN
5	341	53.2	120	1	HV03_MOUSE
6	336	52.4	138	1	HV48_MOUSE
7	336	52.4	140	1	HV02_MOUSE
8	335.5	52.3	114	1	HV00_MOUSE
9	334	52.1	125	1	HV1F_HUMAN
10	332.5	51.9	119	1	HV07_MOUSE
11	331	51.6	117	1	HV13_MOUSE
12	330.5	51.6	137	1	HV11_MOUSE
13	329.5	51.4	118	1	HV51_MOUSE
14	329	51.3	117	1	HV12_MOUSE
15	329	51.3	121	1	HV01_MOUSE
16	324	50.5	117	1	HV52_MOUSE
17	313.5	48.9	124	1	HV1D_HUMAN
18	311.5	48.6	120	1	HV1H_HUMAN
19	310.5	48.4	120	1	HV50_MOUSE
20	310	48.4	117	1	HV05_MOUSE
21	309.5	48.3	124	1	HV1E_HUMAN
22	309	48.2	119	1	HV31_HUMAN
23	307	47.9	117	1	HV06_MOUSE
24	304.5	47.5	122	1	HV3G_HUMAN
25	304	47.4	117	1	HV04_MOUSE
26	304	47.4	117	1	HV09_MOUSE
27	299	46.6	117	1	HV49_MOUSE
28	297.5	46.4	114	1	HV3B_HUMAN
29	297	46.3	117	1	HV14_MOUSE
30	297	46.3	121	1	HV3J_HUMAN
31	296	46.2	117	1	HV10_MOUSE
32	295	46.0	136	1	HV15_MOUSE
33	286.5	44.7	136	1	HV16_MOUSE

34	285	44.5	115	1	HV3D_HUMAN	P01765 homo sapien
35	284	44.3	117	1	HV42_MOUSE	P01812 mus musculu
36	277.5	43.3	122	1	HV3H_HUMAN	P01769 homo sapien
37	275.5	43.0	119	1	HV40_MOUSE	P01810 mus musculu
38	275	42.9	115	1	HV3E_HUMAN	P01767 homo sapien
39	272	42.4	117	1	HV02_CANFA	P01785 canis fami1
40	271.5	42.4	119	1	HV37_MOUSE	P01807 mus musculu
41	268.5	41.9	119	1	HV38_MOUSE	P01808 mus musculu
42	266.5	41.6	119	1	HV3H_HUMAN	P01777 homo sapien
43	266.5	41.6	122	1	HV3A_HUMAN	P01762 homo sapien
44	265	41.3	117	1	HV3C_HUMAN	P01764 homo sapien
45	264.5	41.3	116	1	HV3I_HUMAN	P01781 homo sapien

ALIGNMENTS

RESULT 1	ID	HV1A_HUMAN	STANDARD;	PRT;	117 AA.
AC	P01742;	21-JUL-1986 (Rel. 01, Created)			
DT	21-JUL-1986 (Rel. 01, Last sequence update)				
DT	15-SEP-2003 (Rel. 42, Last annotation update)				
DE	Ig heavy chain V-I region EU.				
OS	Homo sapiens (Human)				
OC	Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;				
OC	Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.				
OX	NCBI_TaxID=9606;				
RN	[1]				
RP	DISULFIDE BOND.				
RP	SEQUENCE.				
RX	MEDLINE=71064024; PubMed=5489771;				
RA	Cunningham B.A., Rutishauser U., Gall W.E., Gottlieb P.D.,				
RA	Waxdal M.J., Edelman G.M.,				
RT	"The covalent structure of a human gamma G-immunoglobulin. VII. Amino				
RT	acid sequence of heavy-chain cyanogen bromide fragments H1-H4."				
RT	Biochemistry 9:3188-3196(1970).				
RN	[2]				
RP	DISULFIDE BOND.				
RX	MEDLINE=71064027; PubMed=4923144;				
RA	Gall W.E., Edelman G.M.,				
RT	"The covalent structure of a human gamma G-immunoglobulin. X.				
RT	Intrachain disulfide bonds."				
RL	Biochemistry 9:3188-3196(1970).				
CC	-I- MISCELLANEOUS: THE SEQUENCE OF THE GAMMA-1 C REGION OF THIS				
CC	MYELOMA PROTEIN HAS ALSO BEEN DETERMINED.				
CC	-I- SIMILARITY: Contains 1 immunoglobulin-like domain.				
CC	PIR; A90563; GIHUEU.				
DR	HSSP; P01772; 2F84.				
DR	GO: GO:0005576; C:extracellular; NAS.				
DR	GO: GO:0003823; F:antigen binding activity; NAS.				
DR	GO: GO:0006955; P:immune response; NAS.				
DR	InterPro; IPR007110; Ig-like.				
DR	InterPro; IPR003006; Ig_MHC.				
DR	InterPro; IPR003596; Ig_v.				
DR	Pfam; PF00047; Ig; 1.				
DR	SMART; SMD0406; Ig; 1.				
DR	PROSITE; PSS0835; IG_LIKE; 1.				
KW	Immunoglobulin V region; Pyrrolidone carboxylic acid.				
FT	DOMAIN 1 112				
FT	MOD RES 1 1				
FT	DISULFID 22 96				
FT	NON TER 117 117				
SQ	SEQUENCE 117 AA; 12472 MW; 99D60ADAEED52818 CRC64;				
OY	Query Match 65.7%; Score 421; DB 1; Length 117;				
OY	Best local Similarity 71.0%; Pred. No. 3.9e-37;				
OY	Matches 88; Conservative 8; Mismatches 20; Indels 8; Gaps 2;				
DB	1 QVQLQSGAEVKKRPGSSVRYSCAKSGTFFRNNAIINWYRQAPGGLGEMGGIIPMFGRAXY 60				
DB	1 QVQLVDSGAEVKKRPGSSVRYSCAKSGTFFRSALIIWYRQAPGGLGEMGGIIVMFGRPNY 60				

```

QY 61 SQNFGKVAITADESTGTASMELSLRSEDTAVYYCARSDLLFPNHLSPMG-RGTMV 119
DB 61 AQRFGKVAITADESTGTASMELSLRSEDTAVYYCARSDLLFPNHLSPMG-RGTMV 113
QY 120 TVSS 123
DB 114 TVSS 117

RESULT 2
HVLB HUMAN STANDARD; PRT; 117 AA.
ID HVLB HUMAN
AC 21-JUN-1986 (Rel. 01, Created)
DT 21-JUN-1986 (Rel. 01, Last sequence update)
DE 15-SEP-2003 (Rel. 42, Last annotation update)
OS Homo sapiens (Human)
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
NCBI_TaxID=9606;
CC NCBI_TaxID=9606;
PP SEQUENCE FROM N.A.
RX MEDLINE=83144028; PubMed=6298778;
RA Rechavi G., Ram D., Glazer L., Zakut R., Givol D.;
RT "Evolutionary aspects of immunoglobulin heavy chain variable region
RL (VH) gene subgroups";
RL Proc. Natl. Acad. Sci. U.S.A. 80:855-859(1983).
CC -1- SIMILARITY: Contains 1 immunoglobulin-like domain.
CC CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation -
the European Bioinformatics Institute. There are no restrictions on its
use by non-profit institutions as long as its content is in no way
modified and this statement is not removed. Usage by and for commercial
entities requires a license agreement (See http://www.isb-sib.ch/announce/
or send an email to license@sib-sib.ch).
CC CC
DR EMBL; J00240; AAA52988.1; -.
DR PIR; A02024; HVH0HG.
DR HSSP; P01772; 2FB4.
DR GO; GO:0005576; C:extracellular; NAS.
DR GO; GO:0003823; F:antigen binding activity; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003006; IG-MHC.
DR InterPro; IPR003596; IG_V.
DR Pfam; PF00047; Ig; 1.
DR SMART; SM00406; IgV; 1.
DR PROSITE; PS50835; IG LIKE; 1.
DR Immunoglobulin V region; Signal.
FT SIGNAL 1 19
FT CHAIN 20 117 IG HEAVY CHAIN V-I REGION HG3.
FT DOMAIN 20 >117 IG-LIKE.
FT NON_TER 117 117
SQ SEQUENCE 117 AA; 12946 MW; 203F92FC6C0DFE7 CRC64;

Query Match 57.7%; Score 370; DB 1; Length 117;
Best Local Similarity 74.5%; Pred. No. 8.2e-32;
Matches 73; Conservative 8; Mismatches 17; Indels 0; Gaps 0;

QY 1 QVQLQSGAEVKKPGSSVRVSCKASGCTFNNAINMWQAQPGGLEMMGIIIMFGTAKY 60
DB 20 QVQLVQSGAEVKKPGASVKVSCKASGCTFNNYSYHWQAQPGGLEMMGIINPSGGSISY 79

QY 61 SQNFGKVAITADESTGTASMELSLRSEDTAVYYCAR 98
DB 80 AQRFGKVAITADESTGTASMELSLRSEDTAVYYCAR 117

RESULT 3
HVLG HUMAN STANDARD; PRT; 147 AA.
ID HVLG HUMAN

```

```

AC P01744;
DT 21-JUN-1986 (Rel. 01, Created)
DT 15-OCT-2001 (Rel. 40, Last sequence update)
DT 15-SEP-2003 (Rel. 42, Last annotation update)
DE Ig heavy chain V-I region ND precursor (Fragments)
OS Homo sapiens (Human)
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
NCBI_TaxID=9606;
CC NCBI_TaxID=9606;
PP SEQUENCE FROM N.A.
RX MEDLINE=83065234; PubMed=6815656;
RA Kenten J.H., Molgaard H.V., Houghton M., Derbyshire R.B., Viney J.,
RA Bell L.O., Gould H.J.;
RT "Cloning and sequence determination of the gene for the human
RT immunoglobulin epsilon chain expressed in a myeloma cell line.";
RL Proc. Natl. Acad. Sci. U.S.A. 79:6661-6665(1982).
RN [2]
RP SEQUENCE OF 20-147.
RA Bemmich H.H., Johanson S.G.O., von Bahr-Lindstrom H.;
RL (in) Bach M.K. (eds.);
RL Immediate hypersensitivity: modern concepts and developments, pp.1-36,
RL Marcel Dekker, New York (1978).
CC -1- MISCELLANEOUS: THIS EPSILON CHAIN WAS ISOLATED FROM A MYELOMA
CC PROTEIN.
CC CC
CC -1- SIMILARITY: Contains 1 immunoglobulin-like domain.
DR HSSP; P01789; 1MCP.
DR GO; GO:0005576; C:extracellular; NAS.
DR GO; GO:0003823; F:antigen binding activity; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003006; IG-MHC.
DR InterPro; IPR003596; IG_V.
DR Pfam; PF00047; Ig; 1.
DR SMART; SM00406; IgV; 1.
DR PROSITE; PS50835; IG LIKE; 1.
DR Immunoglobulin V region; Signal; Pyrolydine carboxylic acid.
FT SIGNAL 1 19
FT CHAIN 20 147 IG HEAVY CHAIN V-I REGION ND.
FT DOMAIN 20 131 IG-LIKE.
FT MOD_RES 20 20 PYROLYDINE CARBOXYLIC ACID.
FT DISULFID 41 115
FT CONFLICT 21 21 T -> V (IN REF. 2).
FT CONFLICT 53 54 IH -> HI (IN REF. 2).
FT CONFLICT 67 68 VG -> GV (IN REF. 2).
FT CONFLICT 125 125 MISSING (IN REF. 2).
FT NON_TER 147 147
SQ SEQUENCE 147 AA; 16491 MW; 948F9F72A5366C20 CRC64;

Query Match 56.6%; Score 362.5; DB 1; Length 147;
Best Local Similarity 58.6%; Pred. No. 6.5e-31;
Matches 75; Conservative 17; Mismatches 31; Indels 5; Gaps 2;

QY 1 QVQLQSGAEVKKPGSSVRVSCKASGCTFNNAINMWQAQPGGLEMMGIIIMFGTAKY 60
DB 20 QVQLVQSGAEVKKPGASVKVSCKASGCTFIDSYHWQAQPGGLEMMGIINPSGGSISY 79

QY 61 SQNFGKVAITADESTGTASMELSLRSEDTAVYYCARSDLLFPNHLSPMG-RGTMV 115
DB 80 AQRFGKVAITADESTGTASMELSLRSEDTAVYYCARSDLLFPNHLSPMG-RGTMV 139

QY 116 GTWTVSS 123
DB 140 GTWTVSS 147

RESULT 4
HVLG HUMAN STANDARD; PRT; 117 AA.
ID HVLG HUMAN
AC P23083;
DT 01-NOV-1991 (Rel. 20, Created)
DT 01-NOV-1991 (Rel. 20, Last sequence update)
DT 15-SEP-2003 (Rel. 42, Last annotation update)

```

DE Ig heavy chain V-I region V35 precursor.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 CC Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.
 NCBI_TaxID=9606;
 RN [1]
 RP MEDLINE=88296408; PubMed=2841108;
 RA Matsuda F., Lee K.H., Nakai S., Sato T., Kodaira M., Zong S.Q.,
 RT "Dispersed localization of D segments in the human immunoglobulin
 heavy-chain locus."
 RL EMO J. 7:1047-1051(1988).
 CC -1- SIMILARITY: Contains 1 immunoglobulin-like domain.
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 between the Swiss Institute of Bioinformatics and the EMBL Outstation -
 the European Bioinformatics Institute. There are no restrictions on its
 use by non-profit institutions as long as its content is in no way
 modified and this statement is not removed. Usage by and for commercial
 entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 or send an email to license@isb-sib.ch).
 CC
 CC
 DR EMBL; X07448; -; NOT_ANNOTATED_CDS.
 DR PIR; S00476; HVMU35.
 DR HSSP; P01772; 2FB4.
 DR GO; GO:0005576; C:extracellular; NAS.
 DR GO; GO:0003823; F:antigen binding activity; NAS.
 DR GO; GO:0006955; P:immune response; NAS.
 DR InterPro; IPR007110; Ig-like.
 DR InterPro; IPR003596; Ig_MHC.
 DR Pfam; PF00047; Ig; 1.
 DR SMART; SM00406; IGV; 1.
 DR PROSITE; PSS50835; IG-LIKE; 1.
 KW Immunoglobulin V region; Signal.
 FT SIGNAL 1 19
 FT CHAIN 20 117 IG HEAVY CHAIN V-I REGION V35.
 FT DOMAIN 20 >117 IG-LIKE.
 FT NON_TER 117 117
 SQ SEQUENCE 117 AA; 13009 MW; BE61CE63F8CE97ED CRC64;
 Query Match 53.8%; Score 345; DB 1; Length 117;
 Best Local Similarity 70.4%; Pred. No. 3.4e-29;
 Matches 69; Conservative 6; Mismatches 23; Indels 0; Gaps 0;
 QY 1 QVQLQSGAEVKKRQSSVSRVSCKASGTFNNAINWVROAPGQGLEWMGIIIPMFITAKY 60
 20 QVQLVDSGAEVKKRQSSVSRVSCKASGYTFGTGYMHMWRQAPGQGLEWMGRINPNSGTTY 79
 DB 61 SONFGRAVITADSTGTASMETLSLRSEDTAVYYCAR 98
 80 AOKFGKRVSTTRDTSTSTAYMELSLRSDDTVYYCAR 117
 RESULT 5
 ID HV03 MOUSE STANDARD; PRT; 120 AA.
 AC P01747;
 DT 21-JUL-1986 (Rel. 01, Created)
 DT 21-JUL-1986 (Rel. 01, Last sequence update)
 DT 15-SEP-2003 (Rel. 42, Last annotation update)
 DE Ig heavy chain V region 36-65.
 OS Mus musculus (Mouse)
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 CC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 NCBI_TaxID=10090;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=83131846; PubMed=6186498;
 RA Stekevitz M., Geffter M.L., Brodeur P., Riblet R.,
 RA Marshak-Rothstein A.;
 RT "The genetic basis of antibody production: the dominant anti-arsenate

RT idotype response of the strain A mouse."
 RL Eur. J. Immunol. 12:1023-1032(1982).
 CC -1- MISCELLANEOUS: FROM ANALYSIS OF THE SIZES OF SEVERAL OTHER
 CC DIFFERENTIATED GENES THAT HYBRIDIZE TO THIS ONE, THE AUTHORS
 CC CONCLUDE THAT ALL OF THESE V REGIONS HAVE REARRANGED TO THE SAME J
 CC SEGMENT, JH2.
 CC -1- SIMILARITY: Contains 1 immunoglobulin-like domain.
 CC HSSP; P01789; IMCP.
 DR InterPro; IPR007110; Ig-like.
 DR InterPro; IPR003596; Ig_MHC.
 DR Pfam; PF00047; Ig; 1.
 DR SMART; SM00406; IGV; 1.
 DR PROSITE; PSS50835; IG-LIKE; 1.
 KW Immunoglobulin V region; Hybridoma.
 FT DOMAIN 1 111 IG-LIKE.
 FT NON_TER 120 120
 SQ SEQUENCE 120 AA; 13307 MW; FF04E4A167B654AF CRC64;
 Query Match 53.2%; Score 341; DB 1; Length 120;
 Best Local Similarity 55.7%; Pred. No. 9e-29;
 Matches 68; Conservative 21; Mismatches 31; Indels 2; Gaps 1;
 QY 2 VQLQSGAEVKKRQSSVSRVSCKASGTFNNAINWVROAPGQGLEWMGIIIPMFITAKY 61
 1 VQLQSGAEVLRAGSSVYKMSCKASGYFTSYGINWVRQPGQGLEWIGYINPGNGYTKYN 60
 QY 62 QNFGRAVITADSTGTASMETLSLRSEDTAVYYCARLLLPFHIALSPMGKGTWTV 121
 61 EKFGKTTLTVDKSSSTAYMQLSLTSEDSAVFYCAR--VYGGSYFDYWGQGTTLTV 118
 DB 122 SS 123
 119 SS 120
 RESULT 6
 ID HV48 MOUSE STANDARD; PRT; 138 AA.
 AC P03980;
 DT 23-OCT-1986 (Rel. 02, Created)
 DT 23-OCT-1986 (Rel. 02, Last sequence update)
 DT 15-JUL-1999 (Rel. 38, Last annotation update)
 DE Ig heavy chain V region T8PC 1017 precursor.
 OS Mus musculus (Mouse)
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 CC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 NCBI_TaxID=10090;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=84248078; PubMed=6429663;
 RA Gilliam A.C., Shen A., Richards J.E., Blattner F.R., Mushinski J.F.,
 RA Tucker P.W.;
 RT "Illegitimate recombination generates a class switch from C mu to C
 RT delta in an Igd-secreting plasmacytoma."
 RL Proc. Natl. Acad. Sci. U.S.A. 81:4164-4168(1984).
 DR PIR; A02033; HVMST7.
 DR HSSP; P01810; 2FBJ.
 DR InterPro; IPR007110; Ig-like.
 DR InterPro; IPR003596; Ig_MHC.
 DR Pfam; PF00047; Ig; 1.
 DR SMART; SM00406; IGV; 1.
 DR PROSITE; PSS50835; IG-LIKE; 1.
 KW Immunoglobulin V region; Signal.
 FT SIGNAL 1 20
 FT CHAIN 21 138 IG HEAVY CHAIN V REGION T8PC 1017.
 FT DOMAIN 21 49 FRAMEWORK-1.
 FT DOMAIN 50 54 COMPLEMENTARITY-DETERMINING-1.
 FT DOMAIN 55 68 FRAMEWORK-2.
 FT DOMAIN 69 85 COMPLEMENTARITY-DETERMINING-2.
 FT DOMAIN 86 117 FRAMEWORK-3.
 FT DOMAIN 118 127 COMPLEMENTARITY-DETERMINING-3.

```

FT DOMAIN 128 138 FRAMEWORK-4.
FT DISULFID 41 115 BY SIMILARITY.
FT NON TER 138 138
SQ SEQUENCE 138 AA; 15576 MW; 748157E4C6907B8E CRC64;

Query Match 52.4%; Score 336; DB 1; Length 138;
Best Local Similarity 53.2%; Pred. No. 3.5e-28;
Matches 67; Conservative 22; Mismatches 27; Indels 10; Gaps 2;

QY 1 QVQLQSGAEVKKPGSSVRVSCKASGCTFNNAINWVROAPGGLEWGGIIIPMGFTAKY 60
DB 20 QVQLQSGAEVKKPGSSVRVSCKASGCTFNNAINWVROAPGGLEWGGIIIPMGFTAKY 79
QY 61 SQNFGRAVITADESTGTASMEISLSRSEDPTAVYCARSDLLFPFHALLSPMGKRG 117
DB 80 NEKFKRKTLLTVDKSSSTAYVQSLTFPEEFAYVYCARSDGYDMFVY-----WGQGT 132
QY 118 MVTYSS 123
DB 133 LVTESA 138

RESULT 7
HVO2_MOUSE STANDARD; PRT; 140 AA.
AC P01746;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 15-SEP-2003 (Rel. 42, Last annotation update)
DE Ig heavy chain V region 9367 precursor.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_Taxid=10090;
RN 11
RP SEQUENCE FROM N.A.
RC STRAIN=A/J;
RX MEDLINE=82152818; PubMed=6801765;
RA Sims J., Rabbits T.H., Estess P., Slaughter C., Tucker P.W.,
RA Capra J.D.;
RT "Somatic mutation in genes for the variable portion of the
RT immunoglobulin heavy chain.";
RL Science 216:309-311(1982)
CC -1- SIMILARITY: Contains 1 immunoglobulin-like domain.
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial/
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@sib-sib.ch).
CC -----
CC EMBL; J00493; AAA38128.1; -
CC PIR; A94264; HVM5G7.
CC HSSP; P01810; 2FB4.
DR InterPro; IPR007110; IG_1like.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_V.
DR Pfam; PF00047; Ig; 1.
DR SMART; SM00406; IgV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
KW Immunoglobulin V region; HydrIdoma; Signal.
FT SIGNAL 1 19
FT CHAIN 20 140 IG HEAVY CHAIN V REGION 9367.
FT DOMAIN 20 139 IG-LIKE.
FT NON TER 140 140
SQ SEQUENCE 140 AA; 15514 MW; 25A4CBBE31DA5CE8 CRC64;

Query Match 52.4%; Score 336; DB 1; Length 140;
Best Local Similarity 53.1%; Pred. No. 3.6e-28;
Matches 68; Conservative 21; Mismatches 27; Indels 12; Gaps 2;

```

```

QY 1 QVQLQSGAEVKKPGSSVRVSCKASGCTFNNAINWVROAPGGLEWGGIIIPMGFTAKY 60
DB 20 EVQLQSGAEVKKPGSSVRVSCKASGCTFNNAINWVROAPGGLEWGGIIIPMGFTAKY 79
QY 61 SQNFGRAVITADESTGTASMEISLSRSEDPTAVYCARSDLLFPFHALLSPMGKRG 115
DB 80 NEKFKRKTLLTVDKSSSTAYVQSLTFPEEFAYVYCARSDGYDMFVY-----WGQGT 132
QY 116 GIMTVSS 123
DB 133 GTPLTVSS 140

RESULT 8
HVO2_MOUSE STANDARD; PRT; 114 AA.
AC P01741;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 15-SEP-2003 (Rel. 42, Last annotation update)
DE Ig heavy chain V region (Anti-arsenate antibody).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_Taxid=10090;
RN 11
RP SEQUENCE.
RC STRAIN=A/J;
RX MEDLINE=79195438; PubMed=109536;
RA Capra J.D., Nisencoff A.;
RT "Structural studies on induced antibodies with defined idiotypic
RT specificities. VII. The complete amino acid sequence of the heavy
RT chain variable region of anti-p-azophenylarsenate antibodies from A/J
RT mice bearing a cross-reactive idotype.";
RL J. Immunol. 123:279-284(1979).
CC -1- MISCELLANEOUS: ANTIBODY ISOLATED FROM TEN MICE WAS EXCLUSIVELY OF
CC THE IG1 SUBCLASS. THERE WAS NO HETEROGENEITY IN THE HEAVY CHAIN V
CC REGION SEQUENCE.
CC -1- SIMILARITY: Contains 1 immunoglobulin-like domain.
CC PIR; A02022; GIMSA.
CC HSSP; P01772; 2FB4.
DR InterPro; IPR007110; IG_1like.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_V.
DR Pfam; PF00047; Ig; 1.
DR SMART; SM00406; IgV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
KW Immunoglobulin V region.
FT DOMAIN 1 106 IG-LIKE.
FT NON TER 114 114
SQ SEQUENCE 114 AA; 12555 MW; 99DD8F0B6A69F4BE CRC64;

Query Match 52.3%; Score 335.5; DB 1; Length 114;
Best Local Similarity 59.7%; Pred. No. 3.2e-28;
Matches 71; Conservative 14; Mismatches 29; Indels 5; Gaps 1;

QY 1 QVQLQSGAEVKKPGSSVRVSCKASGCTFNNAINWVROAPGGLEWGGIIIPMGFTAKY 60
DB 1 EVQLQSGAEVKKPGSSVRVSCKASGCTFNNAINWVROAPGGLEWGGIIIPMGFTAKY 60
QY 61 SQNFGRAVITADESTGTASMEISLSRSEDPTAVYCARSDLLFPFHALLSPMGKRG 119
DB 61 AQKFGRAVITADESTGTASMEISLSRSEDPTAVYCARSDLLFPFHALLSPMGKRG 114

RESULT 9
HVL1F_HUMAN STANDARD; PRT; 125 AA.
AC P06326;
DT 01-JAN-1988 (Rel. 06, Created)
DT 01-JAN-1988 (Rel. 06, Last sequence update)
DT 15-JUL-1999 (Rel. 38, Last annotation update)
DE Ig heavy chain V-I region Mot.

```

OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 RN NCB1_TaxID=9606;
 RP SEQUENCE
 RX MEDLINE=66203277; Pubmed=3084950;
 RA Kojima M., Koide T., Odani S., Ono T.;
 RT "Amino acid sequence of the variable region of heavy chain in
 immunoglobulin (Mc) having unusual papain cleavage sites.";
 RL Mol. Immunol. 23:169-174(1986).
 DR PIR: A02025; HYHUMO.
 DR HSSP: P01772; 2PB4.
 DR GO: GO:0005576; C:extracellular; NAS.
 DR GO: GO:0003823; F:antigen binding activity; NAS.
 DR GO: GO:0006955; P:immune response; NAS.
 DR InterPro: IPR007110; IG-like.
 DR InterPro: IPR003065; IG_MHC.
 DR InterPro: IPR003596; IG_V.
 DR Pfam: PF00047; IG; 1.
 DR SMART: SM00406; IG; 1.
 DR PROSITE: PS50835; IG LIKE; 1.
 KW Immunoglobulin V region.
 FT DOMAIN 1 98 V SEGMENT.
 FT GO: GO:0005576; C:extracellular; NAS.
 FT DOMAIN 99 107 D SEGMENT.
 FT DOMAIN 108 125 J SEGMENT.
 FT DISULFID 22 96 BY SIMILARITY.
 FT NON_TER 125 125
 SQ SEQUENCE 125 AA; 13579 MW; F4C4285D6DF0C8EA CRC64;
 Query Match 52.4%; Score 334; DB 1; Length 125;
 Best Local Similarity 52.7%; Pred. No. 5.1e-28;
 Matches 69; Conservative 13; Mismatches 35; Indels 14; Gaps 2;
 QY 1 QVLOQSGAEVKKRPGSSVRVSCASGTFNNNAINWYRQAPGQLEMGIIIPMGFTAKY 60
 DB 1 QVLOVSGAEVKKRPGSSVRVSCASGTFNNNAINWYRQAPGQLEMGIIIPMGFTAKY 60
 QY 61 SQNPGKRVATTAESTGTASMEISLRSEDTAVYYCARSDLLFPNHL-----ALSP 112
 DB 61 GPRSQARFTYTRSSSTTYVMELTALISADTAIYCARG-----AHYSOTDSSGSLGP 114
 QY 113 WGRGTWTVSS 123
 DB 115 WQGTLLTVSS 125
 QY 118 MVTVSS 123
 DB 134 TLTVSS 139
 QY 134 TLTVSS 139
 DB 134 TLTVSS 139
 RESULT 10
 HV07_MOUSE
 ID HV07_MOUSE STANDARD; PRT; 139 AA.
 AC P01751; P01752;
 DT 21-JUL-1986 (Rel. 01, Last sequence update)
 DT 21-JUL-1986 (Rel. 01, Last sequence update)
 DT 15-SEP-2003 (Rel. 42, Last annotation update)
 DE 1g heavy chain V region B1-8/186-2 precursor.
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 RN NCB1_TaxID=10090;
 RP SEQUENCE FROM N.A.
 RX STRAIN=C57BL/6;
 MEDLINE=81234548; Pubmed=6788376;
 RA Botthell A.L.M., Paskind M., Rech M., Imanishi-Kari T., Rajewsky K.,
 Baltimore D.;
 RT "Heavy chain variable region contribution to the NpB family of
 antibodies: somatic mutation evident in a gamma 2a variable region";
 RL Cell 24:625-637(1981).
 CC -1- MISCELLANEOUS: THE B1-8 MU CHAIN mRNA WAS CLONED FROM A HYBRIDOMA
 MAKING ANTIBODIES TO THE HAPTEN (4-HYDROXY-3-NITROPHENYL)ACETYL
 (NPB ANTIBODIES).
 CC THIS SWISS-PROT entry is copyright. It is produced through a collaboration

CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL: J00529; AAA38170.1; -.
 DR PIR: A90809; MHMS18.
 DR PDB: 1A6U; 27-MAY-98.
 DR PDB: 1A6W; 15-JUL-98.
 DR InterPro: IPR007110; IG-like.
 DR InterPro: IPR003065; IG_MHC.
 DR InterPro: IPR003596; IG_V.
 DR Pfam: PF00047; IG; 1.
 DR SMART: SM00406; IG; 1.
 DR PROSITE: PS50835; IG LIKE; 1.
 KW Immunoglobulin V region; Signal; 3D-structure.
 FT SIGNAL 1 19
 FT CHAIN 20 139 IG HEAVY CHAIN V REGION B1-8/186-2.
 FT DOMAIN 20 49 FRAMEWORK-1.
 FT DOMAIN 50 54 COMPLEMENTARITY-DETERMINING-1.
 FT DOMAIN 55 68 FRAMEWORK-2.
 FT DOMAIN 69 85 COMPLEMENTARITY-DETERMINING-2.
 FT DOMAIN 86 117 FRAMEWORK-3.
 FT DOMAIN 118 124 D SEGMENT.
 FT DOMAIN 125 139 JH2 SEGMENT.
 FT DISULFID 41 115 BY SIMILARITY.
 FT NON_TER 139 139
 SQ SEQUENCE 139 AA; 15419 MW; 1B57DD4FD0C9FA65 CRC64;
 Query Match 51.9%; Score 332.5; DB 1; Length 139;
 Best Local Similarity 52.4%; Pred. No. 8.3e-28;
 Matches 66; Conservative 24; Mismatches 27; Indels 9; Gaps 2;
 QY 1 QVLOQSGAEVKKRPGSSVRVSCASGTFNNNAINWYRQAPGQLEMGIIIPMGFTAKY 60
 DB 20 QVLOQSGAEVKKRPGSSVRVSCASGTFNNNAINWYRQAPGQLEMGIIIPMGFTAKY 79
 QY 61 SQNPGKRVATTAESTGTASMEISLRSEDTAVYYCARSDLLFPNHL-----PMSRGT 117
 DB 61 NEKFSKATLTVDKPSSTAYMQLSLTSEDSAVYCAR-----YDYSSSYFDYWGQT 133
 QY 118 MVTVSS 123
 DB 134 TLTVSS 139
 QY 134 TLTVSS 139
 DB 134 TLTVSS 139
 RESULT 11
 HV13_MOUSE
 ID HV13_MOUSE STANDARD; PRT; 117 AA.
 AC P01757;
 DT 21-JUL-1986 (Rel. 01, Created)
 DT 21-JUL-1986 (Rel. 01, Last sequence update)
 DT 15-SEP-2003 (Rel. 42, Last annotation update)
 DE 1g heavy chain V region J558.
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 RN NCB1_TaxID=10090;
 RP SEQUENCE.
 RX MEDLINE=80078170; Pubmed=6765983;
 RA Schilling J., Clevinger B., Davie J.M., Hood L.;
 RT "Amino acid sequence of homogeneous antibodies to dextran and DNA
 rearrangements in heavy chain V-region gene segments";
 RL Nature 283:35-40(1980).
 CC -1- MISCELLANEOUS: THE SEQUENCES OF 10 HYBRIDOMA PROTEINS THAT ALSO
 BIND DEXTRAN DIFFER FROM THAT SHOWN AT 1-7 POSITIONS, MANY OF
 WHICH OCCUR IN THE D AND J SEGMENTS.
 CC -1- SIMILARITY: THIS PROTEIN BINDS DEXTRAN.
 CC PIR: A26242; MHMSJ5.

DR HSSP; P01789; IMCP.
 DR InterPro; IPR007110; IG-like.
 DR InterPro; IPR003006; IG_MHC.
 DR InterPro; IPR003596; IG_V.
 DR Pfam; PF00047; IG_1.
 DR SMART; SM00406; IGV_1.
 DR PROSITE; PS50835; IG-LIKE; 1.
 DR Immunoglobulin V region.
 KW DOMAIN 116
 FT DISULFID 22 96
 FT NON TER 117 117
 SQ SEQUENCE 117 AA; 13024 MW; 292E2AF4BE447E41 CRC64;
 Query Match 51.6%; Score 331; DB 1; Length 117;
 Best Local Similarity 52.8%; Pred. No. 9.7e-26;
 Matches 65; Conservative 21; Mismatches 31; Indels 6; Gaps 1;
 QY 1 QVQLQSGAEVKKRQSSVRSCKASGGTFNNNAINWVROAPGQLEWNGGIIIPMFCTAKY 60
 DB 1 EVQLQSGPELVKRGASVKMSCKASGYTFDYNNKWKQSHGKSLIEWIGDINPNNGGTSY 60
 QY 61 SQNFGRAVITADESTGTASMELSLSRSEDYAVYCARSRDLLEFPFHALLSPMGRTMT 120
 DB 61 NQKRGKATLTVDKSSSTAVYQMLSLTSEDSAVYVCARD-----WYEPVWAGATTVT 114
 QY 121 VSS 123
 DB 115 VSS 117
 RESULT 12
 HV11 MOUSE STANDARD; PRT; 137 AA.
 ID HV11 MOUSE
 AC P01755;
 DT 21-JUL-1986 (Rel. 01, Created)
 DT 21-JUL-1986 (Rel. 01, Last sequence update)
 DT 15-JUL-1999 (Rel. 38, Last annotation update)
 DE Ig heavy chain V region S43 precursor.
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 OC NCBI_TaxID=10090;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=81234548; PubMed=6788376;
 RA Baltimore A.L.M., Paekind M., Reith M., Imanishi-Kari T., Rajewsky K.,
 RA Baltimore D.;
 RT "Heavy chain variable region contribution to the NPB family of
 RT antibodies: somatic mutation evident in a gamma 2a variable region.";
 RT Cell 24:625-637(1981).
 CC -I- MISCELLANEOUS: THE GAMMA-2A CHAIN MRNA WAS CLONED FROM A HYBRIDOMA
 CC MAKING ANTIBODIES TO THE HAPTEN (4-HYDROXY-3-NITROPHENYL)ACETYL
 CC (NPB ANTIBODIES).
 CC
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@sib.ch).
 CC
 CC EMBL; J00539; AAA8172.1; -
 DR FIR; A02038; GZMS43.
 DR HSSP; P01810; 2FBU.
 DR InterPro; IPR007110; IG-like.
 DR InterPro; IPR003006; IG_MHC.
 DR InterPro; IPR003596; IG_V.
 DR Pfam; PF00047; IG_1.
 DR SMART; SM00406; IGV_1.
 DR PROSITE; PS50835; IG-LIKE; 1.
 DR Immunoglobulin V region; Signal.
 KW SIGNAL 1 19

FT CHAIN 20 137 IG HEAVY CHAIN V REGION S43.
 FT DOMAIN 20 49 FRAMEWORK-1.
 FT DOMAIN 50 54 COMPLEMENTARITY-DETERMINING-1.
 FT DOMAIN 55 68 FRAMEWORK-2.
 FT DOMAIN 69 85 COMPLEMENTARITY-DETERMINING-2.
 FT DOMAIN 86 117 FRAMEWORK-3.
 FT DOMAIN 118 122 D SEGMENT.
 FT DOMAIN 123 137 JH2 SEGMENT.
 FT DISULFID 41 115 BY SIMILARITY.
 FT NON TER 137 137
 SQ SEQUENCE 137 AA; 15200 MW; ADD58B1BF44B8EC9 CRC64;
 Query Match 51.6%; Score 330.5; DB 1; Length 137;
 Best Local Similarity 53.7%; Pred. No. 1.3e-27;
 Matches 66; Conservative 21; Mismatches 31; Indels 5; Gaps 1;
 QY 1 QVQLQSGAEVKKRQSSVRSCKASGGTFNNNAINWVROAPGQLEWNGGIIIPMFCTAKY 60
 DB 20 QVQLQSGAEVKKRQSSVRSCKASGGTFNNNAINWVROAPGQLEWNGGIIIPMFCTAKY 79
 QY 61 SQNFGRAVITADESTGTASMELSLSRSEDYAVYCARSRDLLEFPFHALLSPMGRTMT 120
 DB 80 NEHFRKATLTIDKPSSTAVYQMLSLTSEDSAVYVCARYLGRYFDY-----WGQGITLT 134
 QY 121 VSS 123
 DB 135 VSS 137
 RESULT 13
 HV11 MOUSE STANDARD; PRT; 118 AA.
 ID HV11 MOUSE
 AC P06330;
 DT 01-JAN-1988 (Rel. 06, Created)
 DT 01-JAN-1988 (Rel. 06, Last sequence update)
 DT 15-JUL-1999 (Rel. 38, Last annotation update)
 DE Ig heavy chain V region AC38 205.12.
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 OC NCBI_TaxID=10090;
 RN [1]
 RP SEQUENCE.
 RX MEDLINE=84182519; PubMed=6201362;
 RA Dildrop R., Bovens J., Siekevitz M., Beyreuther K., Rajewsky K.;
 RT "A V region determinant (idiotope) expressed at high frequency in B
 RT lymphocytes is encoded by a large set of antibody structural genes.";
 RL EMBO J. 3:517-523(1984).
 DR PIR; A02040; MEMS38.
 DR HSSP; P01789; IMCP.
 DR InterPro; IPR007110; IG-like.
 DR InterPro; IPR003006; IG_MHC.
 DR InterPro; IPR003596; IG_V.
 DR Pfam; PF00047; IG_1.
 DR SMART; SM00406; IGV_1.
 DR PROSITE; PS50835; IG-LIKE; 1.
 KW Immunoglobulin V region.
 FT DOMAIN 98 98 V SEGMENT.
 FT DOMAIN 99 104 D SEGMENT.
 FT DOMAIN 105 118 J SEGMENT.
 FT DISULFID 22 96 BY SIMILARITY.
 FT NON TER 118 118
 SQ SEQUENCE 118 AA; 12934 MW; 94F7BEE4C762A018 CRC64;
 Query Match 51.4%; Score 329.5; DB 1; Length 118;
 Best Local Similarity 52.0%; Pred. No. 1.4e-27;
 Matches 64; Conservative 20; Mismatches 34; Indels 5; Gaps 1;
 QY 1 QVQLQSGAEVKKRQSSVRSCKASGGTFNNNAINWVROAPGQLEWNGGIIIPMFCTAKY 60
 DB 1 EVQLQSGPELVKRGASVKMSCKASGYTFDYNNKWKQSHGKSLIEWIGDINPNNGGTSY 60
 QY 61 SQNFGRAVITADESTGTASMELSLSRSEDYAVYCARSRDLLEFPFHALLSPMGRTMT 120


```

Db      61 NQFKKATLTIVDKSSATYMEIKRLSTSDSAIVYICARG-----YGIPIFDVWGKGTITVT 115
QY      121 VSS 123
        |||
Db      116 VSS 118

```

CC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
CC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murine; Mus.
OX	NCBI_TaxID=10090;
CC	[1]
RP	SEQUENCE FROM N.A.
RX	MEDLINE=81053741; PubMed=6253904;
RA	Zakut R., Cohen J., Givol D.;
RT	"Cloning and sequence of the cDNA corresponding to the variable
RL	region of immunoglobulin heavy chain MC11.";
RL	Nucleic Acids Res. 8:3591-3601 (1980).
LN	[2]
RP	REVISIONS.
RA	Zakut R., Cohen J., Givol D.;
RL	Nucleic Acids Res. 8:4839-4840 (1980).
CC	-1- MISCELANEOUS: THIS SEQUENCE WAS TRANSLATED FROM AN MRNA ISOLATED
CC	FROM A MELOMA THAT SECRETES IgG2B.
CC	-1- SIMILARITY: Contains 1 immunoglobulin-like domain.
CC	PIR: A93708; GVMS11.
DR	HSSP: P01810; 2PBJ.
DR	InterPro: IPR007110; Ig-like.
DR	InterPro: IPR003006; Ig_MHC.
DR	InterPro: IPR003596; Ig_v.
DR	Pfam: PF00047; Ig; 1.
DR	SMART: SMO0406; Igv; 1.
DR	PROSITE: PSS0835; IG-LIKE; 1.
DR	Immunoglobulin V region.
KW	DOMAIN 1 112
FT	NON TER 121 121
FT	IG-LIKE.
SO	SEQUENCE 121 AA; 13135 MW; 227AEF3E5C6ED0BF CRC64;

RESULT 15	RT	unrearranged VH gene segments. ";
HV01 MOUSE	RL	Cell 40:271-281 (1985).
ID HV01 MOUSE	CC	-----
AC P01745	CC	This SWISS-PROT entry is copyright. It is produced through a collaboration
DT 21-JUN-1986 (Rel. 01, Created)	CC	between the Swiss Institute of Bioinformatics and the EMBL outstation -
DT 21-JUN-1986 (Rel. 01, Last sequence update)	CC	the European Bioinformatics Institute. There are no restrictions on its
DT 15-SEP-2003 (Rel. 42, Last annotation update)	CC	use by non-profit institutions as long as its content is in no way
DE IG heavy chain V region MPC 11.	CC	modified and this statement is not removed. Usage by and for commercial
OS Mus musculus (Mouse).	CC	entities requires a license agreement (see http://www.isb-sib.ch/announce/)

or send an email to license@isb-sib.cn).

```

CC  or send an email to license@isb-sib.cn).
CC  -----
DR  EMBL; M13787; AAA349.1; -.
DR  PIR; A02029; HVMSA1.
DR  HSSP; P01810; 2FB4.
DR  InterPro; IPR007110; IG-like.
DR  InterPro; IPR003006; IG_MHC.
DR  InterPro; IPR003596; IG_V.
DR  Pfam; PF00047; Ig; 1.
DR  SMART; SM00406; Ig; 1.
DR  PROSITE; PS50835; IG LIKE; 1.
KM  Immunoglobulin V region; Signal.
FT  SIGNAL 1 19
FT  CHAIN 20 117 IG HEAVY CHAIN V REGION VH58 A1/A4.
FT  DOMAIN 20 49 FRAMEWORK-1.
FT  DOMAIN 50 54 COMPLEMENTARITY-DETERMINING-1.
FT  DOMAIN 55 68 FRAMEWORK-2.
FT  DOMAIN 69 85 COMPLEMENTARITY-DETERMINING-2.
FT  DOMAIN 86 117 FRAMEWORK-3.
FT  DISULFID 41 115 BY SIMILARITY.
FT  NON TER 117 117
SEQUENCE 117 AA; 12971 MW; 8B0BC138856DFC9D CRC64;

Query March 50.5%; Score 324; DB 1; Length 117;
Best Local Similarity 61.2%; Pred. No. 5.2e-27;
Matches 60; Conservative 19; Mismatches 19; Indels 0; Gaps 0;

Qy 1 QVQLQSGAEVKKPKSSSVKSCASGTFNNNAIINWVROAPQGLGEMWGIIIPMGTAKY 60
Db 20 QVQLQSGPELVKPKSSSVKSCASGYFTSDINMWVQRPQGLGEMWIGWIPGDSGTKY 79
Qy 61 SQNFGRAVITADESTGTASMEISLRSEDTAVYYCAR 98
Db 80 NEKFKGKATLTADKSSSTAYVQLSSLTSENSAVYFCAR 117

RESULT 17
HVID HUMAN STANDARD; PRT; 124 AA.
AC P01760;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 15-SEP-2003 (Rel. 42, Last annotation update)
DE Ig heavy chain V-I region MOL.
OS Homo sapiens (Human)
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RS SEQUENCE.
FM MEDLINE=82046599; PubMed=7028111;
RA Andrews D.W., Capra J.D.;
RT "Amino acid sequence of the variable regions of heavy chains from two
RT idiotypically cross-reactive human IgM anti-gamma-globulins of the wa
RT group."
RL Biochemistry 20:5822-5830(1981).
CC -1- MISCELLANEOUS: THIS CHAIN WAS ISOLATED FROM AN IGM WITH ANTI-GAMMA
CC GLOBULIN ACTIVITY.
CC -1- SIMILARITY: Contains 1 immunoglobulin-like domain.
CC PIR; A02043; M1H0ML.
DR HSSP; P01772; 2FB4.
DR GO; GO:0005576; C:extracellular; NAS.
DR GO; GO:0003823; F:antigen binding activity; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_V.
DR Pfam; PF00047; Ig; 1.
DR SMART; SM00406; Ig; 1.
DR PROSITE; PS50835; IG LIKE; 1.
KM Immunoglobulin V region; Pyroglutamate carboxylic acid.
FT DOMAIN 1 112
FT MOD_RES 1 112 PYROGLUTAMATE CARBOXYLIC ACID.

```

```

FT  NON TER 124 124
SQ  SEQUENCE 124 AA; 13684 MW; CB98F365D004EC8B CRC64;

Query Match 48.9%; Score 313.5; DB 1; Length 124;
Best Local Similarity 56.2%; Pred. No. 7e-26;
Matches 72; Conservative 11; Mismatches 34; Indels 11; Gaps 2;

Qy 1 QVQLQSGAEVKKPKSSSVKSCASGTFNNNAIINWVROAPQGLGEMWGIIIPMGTAKY 60
Db 1 QVQLQSGAEVKKPKSSSVKSCASGYFTSDINMWVQRPQGLGEMWIGWIPGDSGTKY 79
Qy 61 SQNFGRAVITADESTGTASMEISLRSEDTAVYYCAR-----SRDLLFPHHALSPMGK 115
Db 61 NPGSVRVSVLSLKPSSVNOAHMELSLFSEDTAVYYCARFVGFTSDIY---YMQQ 114
Qy 116 GINVTYSS 123
Db 115 GILVTYSS 122

RESULT 18
HVID HUMAN STANDARD; PRT; 120 AA.
AC P80421;
DT 01-NOV-1995 (Rel. 32, Created)
DT 01-NOV-1995 (Rel. 32, Last sequence update)
DT 15-SEP-2003 (Rel. 42, Last annotation update)
DE Ig heavy chain V-I region DOT.
OS Homo sapiens (Human)
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RS SEQUENCE.
FM MEDLINE=95255298; PubMed=7737190;
RA Scoppini M., Bellotti V., Negri A., Merlini G., Garver F., Ferri G.;
RT "Characterization of the two unique human anti-flavon monoclinal
RT immunoglobulins."
RL Eur. J. Biochem. 228:886-893(1995).
CC -1- SIMILARITY: Contains 1 immunoglobulin-like domain.
CC HSSP; P01772; 2FB4.
DR GO; GO:0005576; C:extracellular; NAS.
DR GO; GO:0003823; F:antigen binding activity; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_V.
DR Pfam; PF00047; Ig; 1.
DR SMART; SM00406; Ig; 1.
DR PROSITE; PS50835; IG LIKE; 1.
KM Immunoglobulin V region.
FT DOMAIN 1 111
FT DISULFID 22 95 BY SIMILARITY.
FT NON TER 120 120
SEQUENCE 120 AA; 13272 MW; F1307FD253A782F1 CRC64;

Query Match 48.6%; Score 311.5; DB 1; Length 120;
Best Local Similarity 54.5%; Pred. No. 1.1e-25;
Matches 67; Conservative 17; Mismatches 34; Indels 5; Gaps 3;

Qy 2 VQLQSGAEVKKPKSSSVKSCASGTFNNNAIINWVROAPQGLGEMWGIIIPMGTAKY 61
Db 2 VQLQSGAEVKKPKSSSVKSCASGYFTSDINMWVQRPQGLGEMWIGWIPGDSGTKY 79
Qy 62 QNFGRAVITADESTGTASMEISLRSEDTAVYYCAR-SRDLLEFPHHALSPMGK 120
Db 61 EKFDRLVMSDYSANTVSPQLRLKSDDTGRIFCARVSD--FSQYGDVWQGGITVI 117
Qy 121 VSS 123
Db 118 VSS 120

```

```

RESULT 19
HV50_MOUSE STANDARD; PRT; 120 AA.
AC P06329;
DT 01-JAN-1988 (Rel. 06, Created)
DT 01-JAN-1988 (Rel. 06, Last sequence update)
DT 15-JUL-1999 (Rel. 38, Last annotation update)
DE 15 heavy chain V region AC38 15.3.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.
NCBI_TaxID=10090;
RN [1]
RP MEDLINE=4182519; Pubmed=6201362;
RX Dildrop R., Boyens J., Stekevitz M., Beyreuther K., Rajewsky K.;
RT "A V region determinant (idiotope) expressed at high frequency in B
RT lymphocytes is encoded by a large set of antibody structural genes.";
EMBO J. 3:517-523(1984).
PIR; A02037; MHMS15.
DR HSP; P01810; 2PBJ.
DR InterPro: IPR007110; Ig-like.
DR InterPro: IPR003006; Ig_MHC.
DR InterPro: IPR003596; Ig_V.
DR Pfam; PF00047; Ig; 1.
DR SMART; SM00406; IgV; 1.
DR PROSITE; PS50835; IG LIKE; 1.
KW Immunoglobulin V region.
FT DOMAIN 1 98 V SEGMENT.
FT DOMAIN 99 105 D SEGMENT.
FT DOMAIN 106 120 J SEGMENT.
FT DISULFID 22 96 BY SIMILARITY.
FT NON TER 120 120
SQ SEQUENCE 120 AA; 13311 MM; 914453P426F09814 CRC64;

Query Match 48.4%; Score 310.5; DB 1; Length 120;
Best Local Similarity 50.0%; Pred. No. 1.4e-25;
Matches 63; Conservative 18; Mismatches 36; Indels 9; Gaps 2;

QY 1 QVQLQSGAEVKKPGSSVRVSCKASGTFPNNAINWVROAPGGGLEMMGCIIPMFGRATKY 60
DB 1 QVQLQPGTELVPRGASVNIKCSKASGYTFSTYMMHWKORPGGLEWIGINPENGSTNY 60
QY 61 SQNFGKVAITADESTGTASMEISLSRSEPTAVYYCAR---SRDLLEFPFHSLSPMGRT 117
DB 61 NEKFKKATITVDKSSSATYMQSLSTPSEDSAVYYCARMDYEGD-----RYPDVGSTGT 114

118 MVTVSS 123
115 TVTVSS 120

RESULT 20
HV05_MOUSE STANDARD; PRT; 117 AA.
AC P01749;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE 1g heavy chain V region 3 precursors.
GN IGH-VJ558.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RX STRAIN=C57BL/6;
RX MEDLINE=81234548; Pubmed=6788376;
RA Bothwell A.L.M., Peakind M., Reith M., Imanishi-Kari T., Rajewsky K.,
RA Baltimore D.;
RT "Heavy chain variable region contribution to the NPb family of
RT antibodies: somatic mutation evident in a gamma 2a variable region.";

```

```

RL Cell 24:625-637(1981).
CC -1- MISCELLANEOUS: THIS GERMLINE GENE BELONGS TO A SET OF CLOSELY
CC RELATED GENES THAT COULD ENCODE V REGIONS OF NPb ANTIBODIES.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL Outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.ebi.ch/announce/
CC or send an email to license@ebi-sib.ch).
CC
DR EMBL; J00536; AAA38605.1; -.
DR PIR; A02031; HVMS3.
DR HSP; P01810; 2PBJ.
DR MGD; MGI:96486; Igh-VJ558.
DR InterPro: IPR007110; Ig-like.
DR InterPro: IPR003006; Ig_MHC.
DR InterPro: IPR003596; Ig_V.
DR Pfam; PF00047; Ig; 1.
DR SMART; SM00406; IgV; 1.
DR PROSITE; PS50835; IG LIKE; 1.
KW Immunoglobulin V region; Signal.
FT SIGNAL 1 19
FT CHAIN 20 117 IG HEAVY CHAIN V REGION 3.
FT DOMAIN 20 49 FRAMEWORK-1.
FT DOMAIN 50 54 COMPLEMENTARITY-DETERMINING-1.
FT DOMAIN 55 68 FRAMEWORK-2.
FT DOMAIN 69 85 FRAMEWORK-3.
FT DOMAIN 86 117 COMPLEMENTARITY-DETERMINING-2.
FT DISULFID 41 115 BY SIMILARITY.
FT NON TER 117 117
SQ SEQUENCE 117 AA; 13016 MM; 427C861C53975EDC CRC64;

Query Match 48.4%; Score 310; DB 1; Length 117;
Best Local Similarity 59.2%; Pred. No. 1.5e-25;
Matches 58; Conservative 17; Mismatches 23; Indels 0; Gaps 0;

QY 1 QVQLQSGAEVKKPGSSVRVSCKASGTFPNNAINWVROAPGGGLEMMGCIIPMFGRATKY 60
DB 20 QVQLQGAELVPRGSSVKLSKASGYTFSTYMMHWKORPGGLEWIGINYPDSSETHY 79
QY 61 SQNFGKVAITADESTGTASMEISLSRSEPTAVYYCAR 98
DB 80 NQKFKKATITVDKSSSATYMQSLSTPSEDSAVYYCAR 117

RESULT 21
HV1E_HUMAN STANDARD; PRT; 124 AA.
AC P01761;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 15-SEP-2003 (Rel. 42, Last annotation update)
DE 1g heavy chain V-I region SIE.
OS Homo sapiens (Human)
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
NCBI_TaxID=9606;
RN [1]
RP SEQUENCE.
RX MEDLINE=82046599; Pubmed=7028111;
RA Andrews D.W., Capra J.D.;
RT "Amino acid sequence of the variable regions of heavy chains from two
RT idiotypically cross-reactive human IgM anti-gamma-globulins of the Wa
RT group.";
RL Biochemistry 20:5822-5830(1981).
CC -1- MISCELLANEOUS: THIS CHAIN WAS ISOLATED FROM AN IGM WITH ANTI-GAMMA
CC GLOBULIN ACTIVITY.
CC
DR PIR; A02044; MAHUS1.
DR HSP; P01825; 7FAB.
DR GO; GO:0005576; C:extracellular; NAS.

```

DR GO: GO:0003823; F:antigen binding activity; NAS.
DR GO: GO:0006955; P:immune response; NAS.
DR InterPro: IPR007110; Ig-like.
DR InterPro: IPR003006; Ig_MHC.
DR InterPro: IPR003596; Ig_v.
DR Pfam: PF00047; Ig; 1.
DR SMART: SM00406; IGV; 1.
DR PROSITE: PS50835; IG LIKE; 1.
KM Immunoglobulin V region; Pyroliidone carboxylic acid.
FT DOMAIN 1 112
FT MOD RES 1 124
FT NON TER 124
SQ SEQUENCE 124 AA; 13732 MW; 62CED4573BDE59F CRC64;
Query Match 48.3%; Score 309.5; DB 1; Length 124;
Best Local Similarity 53.4%; Pred. No. 1.8e-25;
Matches 70; Conservative 15; Mismatches 29; Indels 17; Gaps 4;
QY 1 QVQLQSGAEYKRRGSSVRSCKASGTFENNAIINWVROAPGQLEWVGIIIPMGTAKY 60
D 1 QVQLVQSGAEYKRRGSSVRSCKASGTFENNAIINWVROAPGQLEWVGIIIPMGTAKY 54
D 61 SQNFG-----RVAITADESTGTASMEISLRSEDTAIVYCAR--SRDLLLPFHALLSP 112
D 55 TDPEQGVYIKWERYTVSLKPSFNQAYVELVNLFNEDGAVVYCARLWKQGVVNP---FDY 111
QY 113 WGRGTMTVSS 123
D 112 WGGVLTVTSS 122
Db
RESULT 22
HV31 HUMAN
ID HV31 HUMAN STANDARD; PRT; 119 AA.
AC P01770;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 15-SEP-2003 (Rel. 42, Last annotation update)
DE Ig heavy chain V-II region NIE.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
ON NCBI_Taxid=9606;
RX MEDLINE=77070269; PubMed=826475;
RA Ponsingl H., Hilschmann N.;
RT "The rule of antibody structure. The primary structure of a monoclonal IgG1 immunoglobulin (myeloma protein Nie). III. The chymotryptic peptides of the H-chain, alignment of the tryptic peptides and discussion of the complete structure";
RL Hoppe-Seyler's Z. Physiol. Chem. 357:1571-1604(1976).
RN [2]
RP DISULFIDE BOND.
RX MEDLINE=77070267; PubMed=1002129;
RA Dreker L., Schwarz J., Reichel W., Hilschmann N.;
RT "Rule of antibody structure. The primary structure of a monoclonal IgG1 immunoglobulin (myeloma protein Nie). I: Purification and characterization of the protein, the L- and H-chains, the cytosogen bromide cleavage products, and the disulfide bridges";
RT Hoppe-Seyler's Z. Physiol. Chem. 357:1515-1540(1976).
CC -1- MISCELLANEOUS: THIS CHAIN WAS ISOLATED FROM AN IG1 MYELOMA PROTEIN.
CC -1- SIMILARITY: Contains 1 immunoglobulin-like domain.
DR PIR: A9168; GIHUNI.
DR HSSP: P01772; 2FB4.
DR GO: GO:0005576; C:extracellular; NAS.
DR GO: GO:0003823; F:antigen binding activity; NAS.
DR GO: GO:0006955; P:immune response; NAS.
DR InterPro: IPR007110; Ig-like.
DR InterPro: IPR003006; Ig_MHC.
DR InterPro: IPR003596; Ig_v.
DR Pfam: PF00047; Ig; 1.

DR SMART: SM00406; IGV; 1.
DR PROSITE: PS50835; IG LIKE; 1.
KM Immunoglobulin V region; Pyroliidone carboxylic acid.
FT DOMAIN 1 112
FT MOD RES 1 124
FT DISULFID 22 96
FT NON TER 119 119
SQ SEQUENCE 119 AA; 13242 MW; C96935A6E55E165B CRC64;
Query Match 48.2%; Score 309; DB 1; Length 119;
Best Local Similarity 52.4%; Pred. No. 2e-25;
Matches 65; Conservative 20; Mismatches 33; Indels 6; Gaps 3;
QY 1 QVQLQSGAEYKRRGSSVRSCKASGTFENNAIINWVROAPGQLEWVGIIIPMGTAKY 59
D 1 QVQLVQSGGVVQPGSLRLSCASGFTSRITTHWVROAPGKGLENV-AVMSYGBBK 59
D 60 YADSVNGRFTSRNDSKNTLYLNMNSLRPEDTAIVYCARIRDTAMFFAH---WGQCTLV 115
QY 120 TVSS 123
D 116 TVSS 119
Db
RESULT 23
HV06 MOUSE
ID HV06 MOUSE STANDARD; PRT; 117 AA.
AC P01750;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 15-JUL-1999 (Rel. 38, Last annotation update)
DE Ig heavy chain V region 102 precursor.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
ON NCBI_Taxid=10090;
RX [1]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6;
RX MEDLINE=61234548; PubMed=6788376;
RA Botchwell A.L.M., Paskind M., Rech M., Imanishi-Kari T., Rajewsky K., Baltimore D.;
RT "Heavy chain variable region contribution to the Npb family of antibodies: somatic mutation evident in a gamma 2a variable region";
RL Cell 24:625-637(1981).
CC -1- MISCELLANEOUS: THIS GERM LINE GENE BELONGS TO A SET OF CLOSELY RELATED GENES THAT COULD ENCODE V REGIONS OF NP8 ANTIBODIES.
DR PIR: A02032; HWS02.
DR HSSP: P01810; 2FBJ.
DR InterPro: IPR007110; Ig-like.
DR InterPro: IPR003006; Ig_MHC.
DR InterPro: IPR003596; Ig_v.
DR Pfam: PF00047; Ig; 1.
DR SMART: SM00406; IGV; 1.
DR PROSITE: PS50835; IG LIKE; 1.
KM Immunoglobulin V region; Signal.
FT SIGNAL 1 19
FT CHAIN 20 117
FT DOMAIN 20 49
FT DOMAIN 50 54
FT DOMAIN 55 68
FT DOMAIN 69 85
FT DOMAIN 86 117
FT DISULFID 41 115
FT NON TER 117 117
SQ SEQUENCE 117 AA; 12867 MW; 740A65DD851FCA8C CRC64;
Query Match 47.9%; Score 307; DB 1; Length 117;
Best Local Similarity 60.4%; Pred. No. 3.1e-25;
Matches 58; Conservative 16; Mismatches 22; Indels 0; Gaps 0;

```

QY 2 VOLQSGAEVKKPGSSVRSVSCASGCTFNNNAINWYRQAPGQGLEWGGIIMFGTAKYS 61
DB 21 VOLQSGAEVKKPGASVYSCKASGCTFTSYMMHWKQPGQGLEWIGRIHPDSPTNNY 80
QY 62 QNFQGRVAITADESTGTAAMELSLSRSEDPAVYYCA 97
DB 81 QNFQGRVAITLVDSKSSSTAYVYQLSLTSEDSAVYYCA 116

RESULT 24
HV9G_HUMAN STANDARD; PRT; 122 AA.
ID HV9G_HUMAN
AC P01768;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 15-SEP-2003 (Rel. 42, Last annotation update)
DE Ig heavy chain V-II region CAM.
OS Homo sapiens (human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
NCBI_TaxId=9606;
RN [1]
RP SEQUENCE.
RX MEDLINE=81013859; PubMed=6774332;
RA Lehman D.W., Putnam F.W.;
RT "Amino acid sequence of the variable region of a human mu chain:
RT location of a possible JH segment."
RL Proc. Natl. Acad. Sci. U.S.A. 77:3239-3243(1980).
CC -1- MISCELLANEOUS: THIS MU CHAIN WAS ISOLATED FROM THE PLASMA OF A
CC -1- PATIENT WITH MACROGLOBULINEMIA.
CC -1- SIMILARITY: Contains 1 immunoglobulin-like domain.
DR HSSP; P01772; 2FB4.
DR GO; GO:0005576; C:extracellular; NAS.
DR GO; GO:0003823; F:antigen binding activity; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_V.
DR Pfam; PF00047; Ig_1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
KW Immunoglobulin V region; Pyroglutamate carboxylic acid.
FT DOMAIN 1 112 IG-LIKE.
FT MOD_RES 1 1 PYROGLUTAMATE CARBOXYLIC ACID.
FT NON_TER 122 122
SQ SEQUENCE 122 AA; 13668 MW; A42D0F17D252F1C2 CRC64;

Query Match 47.5%; Score 304.5; DB 1; Length 122;
Best Local Similarity 50.8%; Pred. No. 6e-25;
Matches 63; Conservative 26; Mismatches 32; Indels 3; Gaps 3;

```

```

OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
NCBI_TaxId=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6;
RX MEDLINE=81234548; PubMed=6788376;
RA Botwell A.L.M., Paskind M., Reith M., Imanishi-Kari T., Rajewsky K.,
RA Baltimore D.;
RT "Heavy chain variable region contribution to the NPb family of
RT antibodies: somatic mutation evident in a gamma 2a variable region.";
RL Cell 24:625-637(1981).
CC -1- MISCELLANEOUS: THIS GERMLINE GENE BELONGS TO A SET OF CLOSELY
CC RELATED GENES THAT COULD ENCODE V REGIONS OF NPb ANTIBODIES.
DR PIR; A02030; HWS23.
DR HSSP; P01810; 2FB4.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_V.
DR Pfam; PF00047; Ig_1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
KW Immunoglobulin V region; Signal.
FT SIGNAL 1 19
FT CHAIN 20 117 IG HEAVY CHAIN V REGION 23.
FT DOMAIN 20 49 FRAMEWORK-1.
FT DOMAIN 50 54 FRAMEWORK-2.
FT DOMAIN 55 68 FRAMEWORK-2.
FT DOMAIN 69 85 COMPLEMENTARITY-DETERMINING-2.
FT DOMAIN 86 117 FRAMEWORK-3.
FT DISULFID 41 115 BY SIMILARITY.
FT NON_TER 117 117
SQ SEQUENCE 117 AA; 12772 MW; C530F829C906F69B CRC64;

Query Match 47.4%; Score 304; DB 1; Length 117;
Best Local Similarity 58.2%; Pred. No. 6.4e-25;
Matches 57; Conservative 18; Mismatches 23; Indels 0; Gaps 0;

```

```

DR InterPro: IPR007110; IG-like.
DR InterPro: IPR003006; IG_MHC.
DR InterPro: IPR003596; IG_V.
DR Pfam: PF00047; Ig; 1.
DR SMART: SM00406; IgV; 1.
DR PROSITE: PS50835; IG LIKE; 1.
DR Immunoglobulin V region; Signal.
FT SIGNAL 1 19
FT CHAIN 20 117
FT DOMAIN 20 49
FT DOMAIN 50 54
FT DOMAIN 55 68
FT DOMAIN 69 85
FT DOMAIN 86 117
FT DISULFID 41 115
FT NON TER 117 117
SQ SEQUENCE 117 AA; 12890 MW; 16191A086CB17F5A CRC64;

Query Match
Best Local Similarity 47.4%; Score 304; DB 1; Length 117;
Matches 57; Conservative 18; Mismatches 23; Indels 0; Gaps 0;

1 QVQLQSGAEVKKPGSSVRVSCKASGCTFNNAIMVWRQAPGGLGEMWGIIIPMGFTAKY 60
20 QVQLQSGAEVKKPGSSVRVSCKASGCTFNNAIMVWRQAPGGLGEMWGIIIPMGFTAKY 79
Db 80 NEFKSKATLTVDKSSSTAYWQLSLTSEDSAVYYCAR 117

RESULT 27
HV49 MOUSE STANDARD; PRT; 117 AA.
AC P06328;
DT 01-JAN-1988 (Rel. 06, Created).
DT 01-JAN-1988 (Rel. 06, Last sequence update).
DT 15-JUL-1999 (Rel. 38, Last annotation update).
DE Ig heavy chain V region VH558 B4 precursor.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OC NCBI_TaxID=10090;
RN [1]
RP MEDLINE=8509340; PubMed=2578321;
RA Yancopoulos G.D., Alt F.W.,
RT "Developmentally controlled and tissue-specific expression of
RT rearranged VH gene segments.";
Cell 40:271-281(1985).

CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.ebi.ac.uk/announcements
CC or send an email to license@ebi.ac.uk).
DR EMBL: M13788; AAA38506.1; --
DR PIR: A02035; MHMSB4.
DR HSSP: P01810; 2PBJ.
DR InterPro: IPR007110; IG-like.
DR InterPro: IPR003006; IG_MHC.
DR InterPro: IPR003596; IG_V.
DR Pfam: PF00047; Ig; 1.
DR SMART: SM00406; IgV; 1.
DR PROSITE: PS50835; IG LIKE; 1.
DR Immunoglobulin V region; Signal.
FT SIGNAL 1 19
FT CHAIN 20 117
FT DOMAIN 20 49
FT DOMAIN 50 54
SQ SEQUENCE 117 AA; 12890 MW; 16191A086CB17F5A CRC64;

```

```

FT DOMAIN 55 68
FT DOMAIN 69 85
FT DOMAIN 86 117
FT DISULFID 41 115
FT NON TER 117 117
SQ SEQUENCE 117 AA; 12834 MW; B0862FAC67ABD345 CRC64;

Query Match
Best Local Similarity 46.6%; Score 299; DB 1; Length 117;
Matches 55; Conservative 19; Mismatches 23; Indels 0; Gaps 0;

2 VOLQLOSGAEVKKPGSSVRVSCKASGCTFNNAIMVWRQAPGGLGEMWGIIIPMGFTAKY 61
21 VOLQLOSGAEVKKPGSSVRVSCKASGCTFNNAIMVWRQAPGGLGEMWGIIIPMGFTAKY 80
Db 81 EFKSKATLTVDKSSSTAYWQLSLTSEDSAVYYCAR 117

RESULT 28
HV3B HUMAN STANDARD; PRT; 114 AA.
AC P01763;
DT 21-JUL-1986 (Rel. 01, Created).
DT 21-JUL-1986 (Rel. 01, Last sequence update).
DT 15-SEP-2003 (Rel. 42, Last annotation update).
DE Ig heavy chain V-II region WEA.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
OC NCBI_TaxID=9606;
RN [1]
RP MEDLINE=63273707; PubMed=6410398;
RA Goni F., Frangione B.;
RT "Amino acid sequence of the Fv region of a human monoclonal IgM
RT (protein WEA) with antibody activity against 3,4-pyruvylated
RT galactose in Klebsiella polysaccharides K30 and K33.";
RL Proc. Natl. Acad. Sci. U.S.A. 80:4837-4841(1983).
CC -1- MISCELLANEOUS: THIS CHAIN WAS OBTAINED FROM A MONOCLONAL ANTIBODY
CC AGAINST 3,4-PYRUVYLATED GALACTOSE AND ISOLATED FROM A PATIENT WITH
CC WALDENSTROM'S MACROGLOBULINEMIA.
CC -1- SIMILARITY: Contains 1 immunoglobulin-like domain.
DR PIR: A02046; M3HWE.
DR HSSP: P01772; 2PB4.
DR GO: GO:0005576; C:extracellular; NAS.
DR GO: GO:0003823; P:antigen binding activity; NAS.
DR GO: GO:0006955; P:immune response; NAS.
DR InterPro: IPR007110; IG-like.
DR InterPro: IPR003006; IG_MHC.
DR InterPro: IPR003596; IG_V.
DR Pfam: PF00047; Ig; 1.
DR SMART: SM00406; IgV; 1.
DR PROSITE: PS50835; IG LIKE; 1.
DR Immunoglobulin V region; Pyroglutamate carboxylic acid.
FT DOMAIN 1 112
FT MOD RES 1 112
FT MOD RES 1 114
FT NON TER 114 114
SQ SEQUENCE 114 AA; 12256 MW; D88294FB418A07B7 CRC64;

Query Match
Best Local Similarity 46.4%; Score 297.5; DB 1; Length 114;
Matches 61; Conservative 21; Mismatches 32; Indels 9; Gaps 1;

1 QVQLQSGAEVKKPGSSVRVSCKASGCTFNNAIMVWRQAPGGLGEMWGIIIPMGFTAKY 60
20 QVQLQSGAEVKKPGSSVRVSCKASGCTFNNAIMVWRQAPGGLGEMWGIIIPMGFTAKY 79
Db 80 NEFKSKATLTVDKSSSTAYWQLSLTSEDSAVYYCAR 117

```

OY 121 VSS 123
 DB 112 VSS 114

RESULT 29

HV14 MOUSE STANDARD; PRT; 117 AA.

AC P01758;
 DT 21-JUL-1986 (Rel. 01, Created)
 RT 21-JUL-1986 (Rel. 01, Last sequence update)
 DE 15-SEP-2003 (Rel. 42, Last annotation update)
 GN IGH-VJ558.
 OS Mus musculus (Mouse).
 CC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 CC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 NCBI_TaxID=10090;

SEQUENCE FROM N.A.

RA MEDLINE=81245215; PubMed=6789211;
 GIv01.D.; Zakut R., Effron K., Rechavi G., Ram D., Cohen J.B.;
 RT "Diversity of germ-line immunoglobulin VH genes."
 RL Nature 292:426-430 (1981).

CC -1 SIMILARITY: Contains 1 immunoglobulin-like domain.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 between the Swiss Institute of Bioinformatics and the EMBL outstation -
 the European Bioinformatics Institute. There are no restrictions on its
 use. By non-profit institutions as long as its content is in no way
 modified and this statement is not removed. Usage by and for commercial
 entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 or send an email to license@isb-sib.ch).

EMBL; J00488; AA3851.1; -

DR PIR; A02041; HVMS8A.

DR HSSP; P01810; 2FB4.

DR MGD; MGI:96486; IGH-VJ558.

DR InterPro; IPR007110; IG-like.

DR InterPro; IPR003006; IG_MHC.

DR InterPro; IPR003596; IG_V.

DR Pfam; PF00047; Ig_1.

DR SMART; SM00406; IGV; 1.

DR PROSITE; PS50835; IG LIKE; 1.

DR Immunoglobulin V region; Signal.

FT SIGNAL 1 19 IG HEAVY CHAIN V REGION 108A.

FT CHAIN 20 117 IG HEAVY CHAIN V REGION 108A.

FT DOMAIN 20 >117 IG-LIKE.

FT NON_TER 117 117 IG-LIKE.

SO SEQUENCE 117 AA; 12972 MW; 428CB44DF25D1BC2 CRC64;

Query Match 46.3%; Score 297; DB 1; Length 117;

Best Local Similarity 57.1%; Pred. No. 3.5e-24;

Matches 56; Conservative 18; Mismatches 24; Indels 0; Gaps 0;

OY 1 QVQLQSGAEVKKPSSVSVCASGCTFNNAIMVWQAPQGLEWMGIIIPMGTKAY 60

DB 20 EVQLQSGPELVKPKASVKISCKGTYFTDYNMHWQSHCKSLDWIIGIYIPYNGGTGY 79

OY 61 SQNFGRAVITADSTGTASWELSLRSEDTAVYYCAR 98

DB 80 NQFKSKATLTVDNSSLAVYMWELSLTSEDSAVYYCAR 117

DB 80 NQFKSKATLTVDNSSLAVYMWELSLTSEDSAVYYCAR 117

RESULT 30

HV3J HUMAN STANDARD; PRT; 121 AA.

AC P01771;
 DT 21-JUL-1986 (Rel. 01, Created)

RT 21-JUL-1986 (Rel. 01, Last sequence update)

DE 15-SEP-2003 (Rel. 42, Last annotation update)

GN Ig heavy chain V-III region HIL.

OS Homo sapiens (Human).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
 NCBI_TaxID=9606;
 RN [1]
 RP SEQUENCE.
 RX MEDLINE=79124695; PubMed=420800;
 RA Chin Y.-Y.H., Lopez de Castro J.A., Poljak R.J.;
 RT "Amino acid sequence of the VH region of human myeloma
 RT cryoimmunoglobulin IGG H1.";
 RL Biochemistry 18:553-560 (1979).
 CC -1 MISCELLANEOUS: THIS CHAIN WAS ISOLATED FROM AN IGG1 MYELOMA
 CC PROTEIN.
 CC -1 SIMILARITY: Contains 1 immunoglobulin-like domain.
 DR PIR; A02054; GIHUL.
 DR HSSP; P01772; 2FB4.
 DR GO; GO:0005576; C:extracellular; NAS.
 DR GO; GO:0003823; F:antigen binding activity; NAS.
 DR GO; GO:0006955; P:immune response; NAS.
 DR InterPro; IPR007110; IG-like.
 DR InterPro; IPR003006; IG_MHC.
 DR InterPro; IPR003596; IG_V.
 DR Pfam; PF00047; Ig_1.
 DR SMART; SM00406; IGV; 1.
 DR PROSITE; PS50835; IG LIKE; 1.
 KW Immunoglobulin V region; Pyroliadone carboxylic acid.
 FT DOMAIN 1 112 IG-LIKE.
 FT MOD_RES 1 112 PYROLIDONE CARBOXYLIC ACID.
 FT NON_TER 121 121

SO SEQUENCE 121 AA; 13566 MW; 480FC53610EF5DAB CRC64;

Query Match 46.3%; Score 297; DB 1; Length 121;

Best Local Similarity 49.6%; Pred. No. 3.6e-24;

Matches 61; Conservative 21; Mismatches 39; Indels 2; Gaps 1;

OY 1 QVQLQSGAEVKKPSSVSVCASGCTFNNAIMVWQAPQGLEWMGIIIPMGTKAY 60

DB 1 QVQLVAGGAVQVQGRSLRLSCIASGFTFSNYGMHWQAPQGLEWAVAVIYNGSRITY 60

OY 61 SQNFGRAVITADSTGTASWELSLRSEDTAVYYCARSDLLFPFHIALSPMGRTVYT 120

DB 61 GDSVAGRTFTSRDMSKRLTYMKNLSLRTEDTAVYYCARDPIL--TAFSPDYWGQGLVLT 118

OY 121 VSS 123

DB 119 VSS 121

DB 119 VSS 121

RESULT 31

HV10 MOUSE STANDARD; PRT; 117 AA.

AC P01754; P11270;

DT 21-JUL-1986 (Rel. 01, Created)

RT 01-JUL-1989 (Rel. 11, Last sequence update)

DE 28-FEB-2003 (Rel. 41, Last annotation update)

GN Ig heavy chain V region 145 precursor.

OS Mus musculus (Mouse).

CC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

CC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

NCBI_TaxID=10090;

RP SEQUENCE FROM N.A.

RC STRAIN=C57BL/6;

RA MEDLINE=81234548; PubMed=6788376;

RT Bothelell A.L.M., Paekind M., Reth M., Imanishi-Kari T., Rajewsky K.,

Baltimore D.;

"Heavy chain variable region contribution to the NpB family of

antibodies: somatic mutation evident in a gamma 2a variable region.";

Cell 24:625-637 (1991).

CC -1 MISCELLANEOUS: THIS GERM LINE GENE BELONGS TO A SET OF CLOSELY

RELATED GENES THAT COULD ENCODE V REGIONS OF NPB ANTIBODIES.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration

CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).

CC -----
 CC EMBL J00533; AAA38602.1; -
 CC PIR; G90809; HWS45.
 CC HSSP; P01810; 2FBJ.
 CC MCD; MGI:96486; Igh-VJ558.
 CC InterPro; IPR007110; Ig-like.
 CC InterPro; IPR003006; Ig_MHC.
 CC InterPro; IPR003596; Ig_V.
 CC Pfam; PF00047; Ig; 1.
 CC SMART; SM00406; IGV; 1.
 CC PROSITE; PS50835; IG LIKE; 1.
 CC Immunoglobulin V region; Signal.
 CC KW
 CC FT SIGNAL 1 19
 CC FT CHAIN 20 117 IG HEAVY CHAIN V REGION 145.
 CC FT DOMAIN 20 49 FRAMEWORK-1.
 CC FT DOMAIN 50 54 COMPLEMENTARITY-DETERMINING-1.
 CC FT DOMAIN 55 68 FRAMEWORK-2.
 CC FT DOMAIN 69 85 COMPLEMENTARITY-DETERMINING-2.
 CC FT DOMAIN 86 117 FRAMEWORK-3.
 CC FT NON TER 117 117
 CC SQ SEQUENCE 117 AA; 12921 MW; D37DE8A3F543E996 CRC64;

Query Match 46.2%; Score 296; DB 1; Length 117;
 Best Local Similarity 57.1%; Pred. No. 4.4e-24;
 Matches 56; Conservative 19; Mismatches 23; Indels 0; Gaps 0;

Qy 1 QVOLOQSGAEVYKRRGSSVRVSCKASGCTFNNNAIMVWROAPGCGLEMMGIIIPMGCTAKY 60
 ID HV16 MOUSE STANDARD; PRT; 136 AA.
 AC P01759;
 DT 21-JUL-1986 (Rel. 01, Created)
 DT 21-JUL-1986 (Rel. 01, Last sequence update)
 DT 15-SEP-2003 (Rel. 42, Last annotation update)
 DT Ig heavy chain V region BCL1 precursor.
 DE Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.
 OC NCB1_TaxID=10090;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=8222262; PubMed=6806821;
 RA Knapp M.R., Liu C.-P., Newell N., Ward R.B., Tucker P.W., Strober S.,
 RA Blattner F.R.;
 RT "Simultaneous expression of immunoglobulin mu and delta heavy chains
 RT by a cloned B-cell lymphoma: a single copy of the VH gene is shared
 RT by two adjacent CH genes";
 RL Proc. Natl. Acad. Sci. U.S.A. 79:2996-3000(1982).
 CC -1- SIMILARITY: Contains 1 immunoglobulin-like domain.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).

CC -----
 CC EMBL J00494; AAA38130.1; -

DR PIR; A02042; HWSB1.
 DR HSSP; P01772; 2FBJ.
 DR InterPro; IPR007110; Ig-like.
 DR InterPro; IPR003006; Ig_MHC.
 DR InterPro; IPR003596; Ig_V.
 DR Pfam; PF00047; Ig; 1.
 DR SMART; SM00406; IGV; 1.
 DR PROSITE; PS50835; IG LIKE; 1.
 DR Immunoglobulin V region; Signal.
 DR KW
 DR FT SIGNAL 1 19
 DR FT CHAIN 20 136 IG HEAVY CHAIN V REGION BCL1.
 DR FT DOMAIN 20 135 IG-LIKE.
 DR FT NON TER 136 136
 DR SQ SEQUENCE 136 AA; 15078 MW; 6827CFBC6DB3F35E CRC64;

Query Match 46.0%; Score 295; DB 1; Length 136;
 Best Local Similarity 48.0%; Pred. No. 6.7e-24;
 Matches 59; Conservative 22; Mismatches 36; Indels 6; Gaps 1;

Qy 1 QVOLOQSGAEVYKRRGSSVRVSCKASGCTFNNNAIMVWROAPGCGLEMMGIIIPMGCTAKY 60
 ID HV16 MOUSE STANDARD; PRT; 136 AA.
 AC P01783;
 DT 21-JUL-1986 (Rel. 01, Created)
 DT 21-JUL-1986 (Rel. 01, Last sequence update)
 DT 15-SEP-2003 (Rel. 42, Last annotation update)
 DT Ig heavy chain V region WOPC 21 precursor (Fragment).
 DE Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 OC NCB1_TaxID=10090;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=81234548; PubMed=6788376;
 RA Bothwell A.L.M., Paekind M., Reth M., Imanishi-Kari T., Rajewsky K.,
 RA Baltimore D.;
 RT "Heavy chain variable region contribution to the NpB family of
 RT antibodies: somatic mutation evident in a gamma 2a variable region";
 RL Cell 24:625-637(1981).
 RN [2]
 RP SEQUENCE OF 17-136.
 RX MEDLINE=77100368; PubMed=401950;
 RA Adetubio K., Milstein C., Secher D.S.;
 RT "Molecular analysis of spontaneous somatic mutants";
 RL Nature 265:299-304(1977).
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).

CC -----
 CC EMBL J00522; AAD15290.1; -
 CC PIR; E90809; GIMS21.
 CC PDB; 1IGC; 03-JUN-95.
 CC InterPro; IPR007110; Ig-like.
 CC InterPro; IPR003006; Ig_MHC.
 CC InterPro; IPR003596; Ig_V.

DR PFam; PF00047; Ig; 1.
DR SMART; SMO0406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 1.
KW Immunoglobulin V region; Signal; 3D-structure.
FT NON TER 1
FT SIGNAL 1
FT CHAIN 16 IG HEAVY CHAIN V REGION MOPC 21.
FT DOMAIN 117 D SEGMENT.
FT DOMAIN 120 136 JH4 SEGMENT.
FT DISULFID 38 112
FT CONFLICT 75 78 HYAD -> DYAH (IN REF. 2).
FT CONFLICT 89 90 DN -> ND (IN REF. 2).
FT CONFLICT 115 115 W -> H (IN REF. 2).
FT CONFLICT 120 120 Y -> W (IN REF. 2).
FT NON TER 136
SQ SEQUENCE 136 AA; 15071 MW; 2276A98DBDF016 CRC64;

Query Match 44.7%; Score 286.5; DB 1; Length 136;
Best Local Similarity 46.7%; Pred. No. 5.2e-23;
Matches 57; Conservative 25; Mismatches 37; Indels 3; Gaps 1;

QY 2 VOLQSGAEVKKPGSSVRVSCKASGCTFNNAINMTVRQAPGQLEWMGCIIPMEGTAKYS 61
DB 18 VOLVESGGGLVQPGGSRKLSCAASGFTFSFGMRWVRQAPKGLKEMWVAYISSGSTLHYA 77
QY 62 QNFGRAVITADSTGTASMELSLRSEDTAVYYCARSRDLLLFPFHALLSPMGRTWTV 121
DB 78 DTVAGRFTISRDNPRNTIFLQMTSLRSEDTAMTCARNGN---YVYAMDVWGQSTSTV 134
QY 122 SS 123
DB 135 SS 136

RESULT 34
HV42 HUMAN STANDARD; PRT; 115 AA.
ID HV42_HUMAN
AC P01765;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 15-SEP-2003 (Rel. 42, Last annotation update)
DE Ig heavy chain V-III region TIL.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
CC SEQUENCE.
RE MEDLINE=78005528; PubMed=409716;
RA Wang A.-C., Wang I.Y., Fudenberg H.H.;
RT "Immunoglobulin structure and genetics. Identity between variable
RT regions of a mu and a gamma2 chain.";
RL J. Biol. Chem. 252:7192-7199 (1977).
CC -1- MISCELLANEOUS: THE SEQUENCES OF THE V REGIONS OF THE HEAVY CHAINS
CC OF IGM AND IGG2 ISOLATED FROM A SINGLE PATIENT WITH BICLONAL
CC GAMOPATHY ARE IDENTICAL. THEIR LIGHT CHAINS ARE APPARENTLY ALSO
CC IDENTICAL.
CC -1- SIMILARITY: Contains 1 immunoglobulin-like domain.
DR PIR; A02048; H3HUTL.
DR HSSP; P01772; 2F84.
DR GO; GO:0005576; C:extracellular; NAS.
DR GO; GO:0003823; F:antigen binding activity; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; Ig_LMC.
DR InterPro; IPR003006; Ig_LMC.
DR InterPro; IPR003596; Ig_V.
DR Pfam; PF00047; Ig; 1.
DR SMART; SMO0406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 1.
KW Immunoglobulin V region.
FT DOMAIN 1 108 IG-LIKE.
FT NON TER 115
SQ SEQUENCE 115 AA; 12356 MW; 4DC67D179F62326 CRC64;

Query Match 44.5%; Score 285; DB 1; Length 115;
Best Local Similarity 45.5%; Pred. No. 6.1e-23;
Matches 56; Conservative 27; Mismatches 32; Indels 8; Gaps 2;

QY 1 QVOLQSGAEVKKPGSSVRVSCKASGCTFNNAINMTVRQAPGQLEWMGCIIPMEGTAKY 60
DB 1 EVQLLESGGGLVQPGGSRKLSCAASGFTFSFGMRWVRQAPKGLZMWGALZGLSVS2SY 60
QY 61 QNFGRAVITADSTGTASMELSLRSEDTAVYYCARSRDLLLFPFHALLSPMGRTWTV 120
DB 61 ABSVGRFTISRDKSKT---MNSLRADETAVYYCAKGVSAVYFBI---WG2GLVLT 112
QY 121 VSS 123
DB 113 VSS 115

RESULT 35
HV42 MOUSE STANDARD; PRT; 117 AA.
ID HV42_MOUSE
AC P01812;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 15-SEP-2003 (Rel. 42, Last annotation update)
DE Ig heavy chain V region MOPC 173.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
CC SEQUENCE OF 1-104.
RE MEDLINE=72105531; PubMed=5062012;
RA Bourgois A., Fougereau M., de Preval C.;
RT "Sequence of amino acids of the NH 2 -terminal region of a
RT mouse-clonal immunoglobulin heavy chain.";
RL Eur. J. Biochem. 24:446-455 (1972).
RN [2]
CC SEQUENCE OF 105-117.
RE MEDLINE=76091933; PubMed=812695;
RA Rocca-Serra J., Milili M., Fougereau M.;
RT "Determination of the primary structure of a mouse IgG2a
RT immunoglobulin. Amino-acid sequence of the H4 cyanogen-bromide
RT fragment.";
RL Eur. J. Biochem. 59:511-523 (1975).
RN [3]
CC SEQUENCE OF 96-117 FROM N.A.
RE MEDLINE=81223769; PubMed=6787590;
RA Gough N.M., Bernard O.;
RT "Sequences of the joining region genes for immunoglobulin heavy
RT chains and their role in generation of antibody diversity.";
RL Proc. Natl. Acad. Sci. U.S.A. 78:509-513 (1981).
RN [4]
CC DISULFIDE BOND.
RA Bourgois A., Fougereau M.;
RT "Partial amino acid sequence of the variable region of a mouse
RT gammaG2a immunoglobulin heavy chain. Evidence for the existence of a
RT third sub-group of variability for the heavy chain pool.";
RL FEBS Lett. 8:265-268 (1970).
CC -1- MISCELLANEOUS: THIS GAMMA-2A CHAIN WAS ISOLATED FROM A MYELOMA
CC PROTEIN.
CC -1- SIMILARITY: Contains 1 immunoglobulin-like domain.
DR PIR; A91190; G2MS73.
DR HSSP; P01810; 2F8J.
DR InterPro; IPR007110; Ig-Like.
DR InterPro; IPR003006; Ig_LMC.
DR InterPro; IPR003596; Ig_V.
DR Pfam; PF00047; Ig; 1.
DR SMART; SMO0406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 1.
KW Immunoglobulin V region.
FT DOMAIN 1 116 IG-LIKE.
FT DISULFID 22 96

FT CONFLICT 105 105 N -> D (IN REF. 2).
FT NON TER 117 117
SQ SEQUENCE 117 AA; 13051 MW; 156DCCC259380F19 CRC64;

Query Match 44.3%; Score 284; DB 1; Length 117;
Best Local Similarity 43.9%; Pred. No. 7.9e-23;
Matches 54; Conservative 31; Mismatches 32; Indels 6; Gaps 1;

QY 1 QVOLOQSGAEVKKPSSSVRSVCASGTFNNNAIMVWVQAQAGLEMMGGIIPMGCTAKY 60
DB 1 EVKLESQGLVQPGSLKLSGASGFPFSRYMWSVQAQPGKLEWIGELIDPNSGTINY 60
QY 61 SONFGQVAITADESTGTASMELSLRSEDTAVVYCARSDLLLPFHALLSPWGRGTWVT 120
DB 61 TPLSKDKFTISRNDAKNTLYLQMSKYRSEDTALYYCARS-----PYAMNWWGCTSVT 114

QY 121 VSS 123
DB 115 VSS 117

LT 36

HV3H HUMAN STANDARD; PRT; 122 AA.
AC P01769;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 15-SEP-2003 (Rel. 42, Last annotation update)
OS Ig heavy chain V-II region GA.
DE Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
OX NCBI_TaxId=9606;

RP SEQUENCE.
RX MEDLINE=74175307; PubMed=4208843;
RA Florent G., Lehman D., Putnam F.W.;
RT "The switch point in mu heavy chains of human IgM immunoglobulins."
RL Biochemistry 13:2482-2498(1974).
CC -1- MISCELLANEOUS: THIS CHAIN WAS ISOLATED FROM A WALDENSTROM'S
MACROGLOBULIN.
CC -1- SIMILARITY: Contains 1 immunoglobulin-like domain.

DR PIR; A02052; M3HUGA.
DR HSSP; P01772; 2F84.
DR GO; GO:0005576; C:extracellular; NAS.
DR GO; GO:0003823; F:antigen binding activity; NAS.
DR GO; GO:0006955; P:immune response; NAS.

DR InterPro; IPR007110; Ig_LIKE.
DR InterPro; IPR003006; Ig_MHC.
DR Pfam; PF00047; Ig_1.

DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
KW Immunoglobulin V region; Pyroliidone carboxylic acid.
FT DOMAIN 1 112
FT MOD RES 1 112 PYROLIIDONE CARBOXYLIC ACID.

FT NON TER 122 122
SQ SEQUENCE 122 AA; 13166 MW; 74E5B6959E84100A CRC64;

Query Match 43.3%; Score 277.5; DB 1; Length 122;
Best Local Similarity 45.5%; Pred. No. 4e-22;
Matches 56; Conservative 26; Mismatches 40; Indels 1; Gaps 1;

QY 1 QVOLOQSGAEVKKPSSSVRSVCASGTFNNNAIMVWVQAQAGLEMMGGIIPMGCTAKY 60
DB 1 QVZLVZVSGGAVZPGRSLRSLSCAASGFSPTYAMHWRAQPGKGLZMLVISYBGBZY 60

QY 61 SONFGQVAITADESTGTASMELSLRSEDTAVVYCARSDLLLPFHALLSPWGRGTWVT 120
DB 61 ASVSKRFTLSRBSKBTWLENNSLAENTAYYYCARS-GIALSGVAGTDVWGZTIVT 119
QY 121 VSS 123

DB 120 ISS 122

RESULT 37

ID HV40 MOUSE STANDARD; PRT; 119 AA.
AC P01810;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Ig heavy chain V region J539.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxId=10090;

RP PRELIMINARY SEQUENCE.
RX MEDLINE=79223895; PubMed=111245;
RA Rao D.N., Rudikoff S., Kruttsch H., Potter M.;
RT "Structural evidence for independent joining region gene in
immunoglobulin heavy chains from anti-galactan myeloma proteins and
its potential role in generating diversity in
complementarity-determining regions."
RL Proc. Natl. Acad. Sci. U.S.A. 76:2890-2894(1979).
RN [2]

RP X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS).
RX MEDLINE=88217852; PubMed=3449853;
RA Suh S.W., Bhat T.N., Navia M.A., Cohen G.H., Rao D.N., Rudikoff S.,
RA Davies D.R.;
RT "The galactan-binding immunoglobulin Fab J539: an X-ray diffraction
study at 2.6-A resolution."
RL Proteins 1:74-80(1986).
CC -1- MISCELLANEOUS: THIS CHAIN WAS ISOLATED FROM A MYELOMA PROTEIN THAT
BINDS GALACTAN.

DR PIR; A02080; AVM55.
DR PDB; 2FBU; 15-OCT-90.
DR InterPro; IPR007110; Ig_LIKE.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_V.
DR Pfam; PF00047; Ig_1.

DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
KW Immunoglobulin V region; 3d-structure.

FT NON TER 119 119
FT STRAND 3 7
FT TUR 10 12
FT TUR 14 15
FT STRAND 18 25
FT HELIX 29 31
FT STRAND 34 39
FT TUR 41 42
FT STRAND 45 51
FT TUR 53 54
FT TUR 58 60
FT TUR 62 67
FT STRAND 68 72
FT STRAND 78 83
FT STRAND 88 90
FT HELIX 92 100
FT TUR 101 103
FT TUR 104 108
FT STRAND 112 116

SQ SEQUENCE 119 AA; 13240 MW; 57B4P1DB675C1F1 CRC64;

Query Match 43.0%; Score 275.5; DB 1; Length 119;
Best Local Similarity 43.9%; Pred. No. 6.2e-22;
Matches 54; Conservative 31; Mismatches 33; Indels 5; Gaps 2;

QY 1 QVOLOQSGAEVKKPSSSVRSVCASGTFNNNAIMVWVQAQAGLEMMGGIIPMGCTAKY 60
DB 1 EVKLESQGLVQPGSLKLSGASGFPFSRYMWSVQAQPGKLEWIGELIDPNSGTINY 60
QY 61 SONFGQVAITADESTGTASMELSLRSEDTAVVYCARSDLLLPFHALLSPWGRGTWVT 120

DR InterPro: IPR007110; IG-like.
DR InterPro: IPR003006; IG_MHC.
DR InterPro: IPR003596; IG_V.
DR Pfam: PF00047; Ig_1.
DR SMART: SM00406; IGV; 1.
DR PROSITE: PS00835; IG_LIKE; 1.
KW Immunoglobulin V region.
FT DOMAIN 1 117
FT NON_TER 119 119 IG-LIKE.
SQ SEQUENCE 119 AA; 13246 MW; BC34FC8F31CD41B3 CRC64;

Query Match 42.4%; Score 271.5; DB 1; Length 119;
Best Local Similarity 43.1%; Pred. No. 1.6e-21;
Matches 53; Conservative 29; Mismatches 36; Indels 5; Gaps 1;

QY 1 QVQLQSGAEVKKPGSSVRVSCKASGTFNNAIHWYRQAPQGLEWMGIIIPMFETAKY 60
DB 1 EVKLLESGGGLVQPGSLKLSCAASGFDPSRYMGMVWQAPGKLEWIGELINPDSSTINY 60
QY 61 SONFGRAVITADESTGTASMEISLSRSEDYAVYYCARSDLLPFPHALSPWGRGTMT 120
DB 61 TPSLKDKFTIISRDNAKNTLVYQMISKVSRSEDTALYYCAR----LHYGYAAVWGAGTIVT 115

QY 121 VSS 123
DB 116 VSA 118

RESULT 41

HV38_MOUSE
ID HV38_MOUSE STANDARD; PRT; 119 AA.
AC P01808;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 15-SEP-2003 (Rel. 42, Last annotation update)
DE Ig heavy chain V region T601.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxId=10090;
RN [1]
RP SEQUENCE.
RX MEDLINE=79223895; PubMed=111245;
RA Rao D.N., Rudnikoff S., Kruttsch H., Potter M.;
RT "Structural evidence for independent joining region gene in
immunoglobulin heavy chains from anti-galactan myeloma proteins and
its potential role in generating diversity in
complementarity-determining regions";
RT Proc. Natl. Acad. Sci. U.S.A. 76:2890-2894(1979).
CC -1- MISCELLANEOUS: THIS CHAIN WAS ISOLATED FROM AN IGA MYELOMA PROTEIN
THAT BINDS GALACTAN.

CC -1- SIMILARITY: Contains 1 immunoglobulin-like domain.
DR PIR: A02078; AVMS76.
DR HSSP: P01810; 2FB4.
DR InterPro: IPR007110; IG-like.
DR InterPro: IPR003006; IG_MHC.
DR InterPro: IPR003596; IG_V.
DR Pfam: PF00047; Ig_1.
DR SMART: SM00406; IGV; 1.
DR PROSITE: PS00835; IG_LIKE; 1.
KW Immunoglobulin V region.
FT DOMAIN 1 112
FT NON_TER 119 119 IG-LIKE.
SQ SEQUENCE 119 AA; 13169 MW; BC38C84BEEA00E8 CRC64;

Query Match 41.9%; Score 268.5; DB 1; Length 119;
Best Local Similarity 43.9%; Pred. No. 3.4e-21;
Matches 54; Conservative 25; Mismatches 39; Indels 5; Gaps 1;

QY 1 QVQLQSGAEVKKPGSSVRVSCKASGTFNNAIHWYRQAPQGLEWMGIIIPMFETAKY 60
DB 1 EVKLLESGGGLVQPGSLKLSCAASGFDPSRYMGMVWQAPGKLEWIGELINPDSSTINY 60

QY 61 SONFGRAVITADESTGTASMEISLSRSEDYAVYYCARSDLLPFPHALSPWGRGTMT 120
DB 61 TPSLKDKFTIISRDNAKNTLVYQMISKVSRSEDTALYYCAR----LGYGYPDWAGAGTIVT 115
QY 121 VSS 123
DB 116 VSS 118

RESULT 42

HV3P_HUMAN
ID HV3P_HUMAN STANDARD; PRT; 119 AA.
AC P01777;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 15-SEP-2003 (Rel. 42, Last annotation update)
DE Ig heavy chain V-III region TE1.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
OX NCBI_TaxId=9606;
RN [1]
RP SEQUENCE.
RX MEDLINE=74142702; PubMed=4522793;
RA Capra J.D., Kehoe J.M.;
RT "Variable region sequences of five human immunoglobulin heavy chains
of the VH3 subgroup: definitive identification of four heavy chain
hypervariable regions";
RT Proc. Natl. Acad. Sci. U.S.A. 71:845-848(1974).
CC -1- MISCELLANEOUS: THIS CHAIN WAS ISOLATED FROM AN IGG1 MYELOMA
PROTEIN.

CC -1- SIMILARITY: Contains 1 immunoglobulin-like domain.
DR PIR: A02060; G1HTE.
DR HSSP: P01772; 2FB4.
DR GO: GO:000576; C:extracellular; NAS.
DR GO: GO:0003823; F:antigen binding activity; NAS.
DR GO: GO:0006955; P:immune response; NAS.
DR InterPro: IPR007110; IG-like.
DR InterPro: IPR003006; IG_MHC.
DR InterPro: IPR003596; IG_V.
DR Pfam: PF00047; Ig_1.
DR SMART: SM00406; IGV; 1.
DR PROSITE: PS00835; IG_LIKE; 1.
KW Immunoglobulin V region.

FT DOMAIN 1 107
FT NON_TER 119 119 IG-LIKE.
SQ SEQUENCE 119 AA; 12802 MW; 7E24DC85C7290A9 CRC64;

Query Match 41.6%; Score 266.5; DB 1; Length 119;
Best Local Similarity 43.9%; Pred. No. 5.4e-21;
Matches 54; Conservative 25; Mismatches 37; Indels 7; Gaps 2;

QY 1 QVQLQSGAEVKKPGSSVRVSCKASGTFNNAIHWYRQAPQGLEWMGIIIPMFETAKY 60
DB 1 EVKLLESGGGLVQPGSLKLSCAASGFTFSYAVYWQAPGKLEWGMVEGSSLTTHY 60
QY 61 SONFGRAVITADESTGTASMEISLSRSEDYAVYYCAR---SRDLLPFPHALSPWGRGT 117
DB 61 AVSVOGRTIISRDNAKNTLVYQMISKVSRSEDTALYYCARVTPPAASLTFS---AVWGQT 116

QY 118 MVT 120
DB 117 LVT 119

RESULT 43

HV3A_HUMAN
ID HV3A_HUMAN STANDARD; PRT; 122 AA.
AC P01762;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 15-SEP-2003 (Rel. 42, Last annotation update)
DE Ig heavy chain V-III region TRO.

```

OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE (MWELMA PROTEIN TRO).
RX MEDLINE=76023781; PubMed=809331;
RA Kircziz H., Altevogt P., Ruban E., Kortt A., Starosck K.,
RA Hilschmann N.;
RT "The primary structure of a monoclonal IGA-immunoglobulin (IGA Tro.),
RT II. The amino acid sequence of the H-chain, alpha-type, subgroup III;
RL Hoppe-Seyler's Z. Physiol. Chem. 356:1337-1342(1975).
CC -1- MISCELLANEOUS: THE SEQUENCE OF THE C REGION IS ALSO GIVEN.
CC -1- SIMILARITY: Contains 1 immunoglobulin-like domain.
DR PIR; A02045; A1HUTR.
DR HSSP; P01772; 2PB4.
DR GO; GO:0005576; C:extracellular; NAS.
DR GO; GO:0003823; F:antigen binding activity; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_V.
DR Pfam; PF00447; Ig_1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG-LIKE; 1.
KW Immunoglobulin V region; Pyroliidone carboxylic acid.
FT DOMAIN 1 108 IG-LIKE.
FT MOD_RES 1 1 PYRROLIDONE CARBOXYLIC ACID.
FT NON_TER 122 122
SQ SEQUENCE 122 AA; 13472 MW; 2E21A11DA04D80F9 CRC64;

Query Match 41.6%; Score 266.5; DB 1; Length 122;
Best Local Similarity 41.5%; Pred. No. 5.6e-21;
Matches 51; Conservative 29; Mismatches 42; Indels 1; Gaps 1;

OY 1 QVQLQSGAEVKKPGSSVRVSCKASGTFNNNAIMVWVQAPQGLEWMGIIIMFGTAKY 60
DB 1 QVQLVQSGGGLVPGGSLRLSCVASGFSFRDPMWIRNRTFGKGLZMWVSIGSGSSTLYY 60

OY 61 SQNFGKAVATADSTGTASMSLSLRSEDTAVYVCARSDLLFPHIALSPWGRGTMYT 120
DB 61 ADVSKGRFTISRDNKSLYLZMBSLRTZBTAVYCAATB-FBWSTPSLBYWZGLVLT 119

OY 121 VSS 123
DB 120 VSS 122

RESULT 44
HV3C HUMAN STANDARD; PRT; 117 AA.
AC P01764;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 15-SEP-2003 (Rel. 42, Last annotation update)
DE Ig heavy chain V-III region VH26 precursor.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=81101090; PubMed=6450418;
RA Matthyssens G., Rabbits T.H.;
RT "Structure and multiplicity of genes for the human immunoglobulin
RT heavy chain variable region.";
RL Proc. Natl. Acad. Sci. U.S.A. 77:6561-6565(1980).
CC -1- SIMILARITY: Contains 1 immunoglobulin-like domain.
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its

```

```

CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; J00236; AAAS3516.1; -
DR EMBL; M35415; AAAS8735.1; -
DR PIR; A02047; H3H026.
DR PDB; 1H0U; 23-DEC-99.
DR Genew; HGNC:5545; IGHV@.
DR GO; GO:0005576; C:extracellular; NAS.
DR GO; GO:0003823; F:antigen binding activity; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_V.
DR Pfam; PF00447; Ig_1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG-LIKE; 1.
KW Immunoglobulin V region; Signal; 3D-structure.
FT SIGNAL 1 19
FT CHAIN 20 117 IG HEAVY CHAIN V-III REGION VH26.
FT DOMAIN 20 >117 IG-LIKE.
FT NON_TER 117 117
SQ SEQUENCE 117 AA; 12582 MW; E826733F1A3CB0F1 CRC64;

Query Match 41.3%; Score 265; DB 1; Length 117;
Best Local Similarity 50.0%; Pred. No. 7.6e-21;
Matches 49; Conservative 22; Mismatches 27; Indels 0; Gaps 0;

OY 1 QVQLQSGAEVKKPGSSVRVSCKASGTFNNNAIMVWVQAPQGLEWMGIIIMFGTAKY 60
DB 20 EVQLLEGSGGLVQGGSLRLSCASGTFPSYAMSWVQAPGKLEWVSALISGSGSSTYY 79

OY 61 SQNFGKAVATADSTGTASMSLSLRSEDTAVYVCAR 98
DB 80 GDSVKGRTISRDNKSLYLQNMNSLRAPEDTAVYCAK 117

RESULT 45
HV3T HUMAN STANDARD; PRT; 116 AA.
AC P01781;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 15-SEP-2003 (Rel. 42, Last annotation update)
DE Ig heavy chain V-III region GAL.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE.
RX MEDLINE=75059123; PubMed=4803843;
RA Watanabe S., Barnikol H.U., Horn J., Berttram J., Hilschmann N.;
RT "The primary structure of a monoclonal IGM-immunoglobulin
RT (macroglobulin Gal.), II: the amino acid sequence of the H-chain (mu-
RT type), subgroup H III. Architecture of the complete IGM-molecule.";
RL Hoppe-Seyler's Z. Physiol. Chem. 354:1505-1509(1973).
RN [2]
RP REVISION TO 28-33.
RA Hilschmann N.;
RT Submitted (JUN-1975) to the PIR data bank.
CC -1- MISCELLANEOUS: THIS MU CHAIN WAS ISOLATED FROM A WALDENSTROM'S
CC MACROGLOBULIN.
CC -1- SIMILARITY: Contains 1 immunoglobulin-like domain.
DR PIR; A02064; M3HUGL.
DR HSSP; P01772; 2PB4.
DR GO; GO:0005576; C:extracellular; NAS.
DR GO; GO:0003823; F:antigen binding activity; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003006; IG_MHC.

```


DT 15-SEP-2003 (Rel. 42, Last annotation update)
 DE Ig heavy chain V region IR2 precursor.
 OS Rattus norvegicus (Rat).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
 OX NCBI_TaxID=10116;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=83064537; PubMed=6292865;
 RA Hellman L., Petersson U., Engstrem A., Karlsson T., Bennich H.;
 RT "Structure and evolution of the heavy chain from rat immunoglobulin
 E."
 RL Nucleic Acids Res. 10:6041-6049 (1982).
 CC -I- MISCELLANEOUS: THE MRNA WAS ISOLATED FROM AN IGE-SECRETING
 IMMUNOCYTOMA THAT ARISES SPONTANEOUSLY IN LOU/C/MSL RATS.
 CC -I- SIMILARITY: Contains 1 immunoglobulin-like domain.
 DR PIR; A02075; EVRTR2.
 DR HSSP; P01789; IMCP.
 DR InterPro; IPR007110; IG-like.
 DR InterPro; IPR03006; IG_MHC.
 DR InterPro; IPR003596; IG_V.
 DR Pfam; PF00047; Ig; 1.
 DR SMART; SM00406; IGV; 1.
 DR PROSITE; PS50835; IG LIKE; 1.
 KW Immunoglobulin V region; Signal.
 FT SIGNAL 1 19
 FT CHAIN 20 142 IG HEAVY CHAIN V REGION IR2.
 FT DOMAIN 20 133 IG-LIKE.
 FT NON_TER 142 142
 SQ SEQUENCE 142 AA; 16024 MW; DE29E6CFE745DF3B CRC64;

Query Match 40.4%; Score 259; DB 1; Length 142;
 Best Local Similarity 39.2%; Pred. No. 4e-20; Mismatches 33; Indels 14; Gaps 3;
 Matches 51; Conservative 32;

QY	1	QVQLQOQSGAEVKKPQSSVSVSCASGTFPNNNAIMVRRQAPGQGLEWMGGLTPMG--TA	58
DB	20	EYKLESGGGGLVQPGMSVYLTSCATSGFTPSDYMEMEVRQAPGKGLMVAEIRNKANNYYA	79
QY	59	KYSQNFQGRVAITADESTASMELSLRSEPTAVYYCAR-----SRDLLLPFHALLSPW	113
DB	80	YYGKSLKGRFTLSRDDSRSIVYLQMNINIRSEDTGIYCSRGYGYSENWFFY-----W	132
QY	114	GRGIVTVSS	123
DB	133	GQGIVTVSS	142

Search completed: November 26, 2003, 13:39:47
 Time: 11.5128 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compen Ltd.

OM protein - protein search, using sw model

Run on: November 26, 2003, 13:36:45 ; Search time 14.1923 Seconds
(without alignments)
833.462 Million cell updates/sec

Title: US-09-880-748-327_COPY_1_123

Perfect score: 641

Sequence: 1 QVQLQSGAEVKKPGSSVRV.....LPPHSLSPMGRTMTVSS 123

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 283308 seqs, 96168682 residues

al number of hits satisfying chosen parameters: 283308

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :
1: pir1:*
2: pir2:*
3: pir3:*
4: pir4:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	482.5	75.3	116	2 PH0959	Ig heavy chain V r
2	481	75.0	135	2 PH0953	Ig heavy chain V r
3	480	74.9	119	2 PH0961	Ig heavy chain V r
4	478.5	74.6	122	2 PH0958	Ig heavy chain V r
5	478	74.6	125	2 PH0957	Ig heavy chain V r
6	476.5	74.3	132	2 S46394	Ig heavy chain V-1
7	476	74.3	129	2 A33548	Ig heavy chain V-1
8	475	74.1	127	2 PH0955	Ig heavy chain V r
9	474.5	74.0	120	2 PH0962	Ig heavy chain V r
10	474.5	74.0	132	2 PH0954	Ig heavy chain V r
11	472.5	73.7	128	2 PH0952	Ig heavy chain V r
12	472	73.6	133	2 C33548	Ig heavy chain V-1
13	472	73.6	627	2 S14683	Ig mu chain precu
14	471.5	73.6	126	2 B33548	Ig heavy chain V-1
15	471.5	73.6	136	2 PH0960	Ig heavy chain V r
16	465	72.5	122	2 B49590	Ig heavy chain V r
17	445.5	69.5	116	2 S36261	Ig heavy chain V r
18	440	68.6	98	2 S26915	Ig heavy chain V r
19	440	68.6	113	2 PH1663	Ig heavy chain V r
20	440	68.6	116	2 S31698	Ig heavy chain V r
21	440	68.6	123	2 S44108	Ig heavy chain V-1
22	436.5	68.1	135	2 B32274	Ig heavy chain V-1
23	436	68.0	98	2 S24680	Ig heavy chain V-1
24	434.5	67.8	108	2 PH1664	Ig heavy chain V r
25	431.5	67.3	119	2 S44106	Ig heavy chain V-1
26	421	65.7	117	1 GH100	Ig heavy chain V-1
27	415	64.7	98	2 A30523	Ig heavy chain V-1
28	414	64.6	121	2 A49590	Ig heavy chain V r
29	412	64.3	98	2 S46463	Ig heavy chain V-1

30	410	64.0	109	2 PH1671	Ig heavy chain V r
31	410	64.0	122	2 C49590	Ig heavy chain V r
32	407	63.5	116	2 S31667	Ig heavy chain V r
33	404	63.0	97	2 PH0870	Ig heavy chain V r
34	402.5	62.8	118	2 S36265	Ig heavy chain V r
35	401.5	62.6	124	2 S19665	Ig heavy chain V r
36	400.5	62.5	136	2 S31600	Ig heavy chain V r
37	397	61.9	142	2 A32483	Ig heavy chain V r
38	396	61.8	129	2 S36260	Ig heavy chain V r
39	394.5	61.5	119	2 P49590	Ig heavy chain V r
40	392.5	61.2	135	2 S49530	Ig heavy chain V r
41	387	60.4	123	2 D33548	Ig heavy chain V-1
42	382	59.6	121	2 S20783	Ig heavy chain V r
43	382	59.6	127	2 S34014	Ig heavy chain V r
44	380	59.3	148	2 S29257	Ig heavy chain V r
45	374.5	58.4	114	2 PH1667	Ig heavy chain V r

ALIGNMENTS

RESULT 1

Ig heavy chain V region (G6+T-L26) - human (fragment)
C:Species: Homo sapiens (man)
C:Date: 17-Apr-1993 #sequence_revision 17-Apr-1993 #text_change 16-Aug-1996
C:Accession: PH0959
R:Martin, T.; Duffly, S.F.; Carson, D.A.; Kipps, T.J.
J. Exp. Med. 175, 983-991, 1992

A:Title: Evidence for somatic selection of natural autoantibodies.

A:Reference number: PH0952; MUID:92202880; PMID:1552291

A:Accession: PH0959

A>Status: nucleic acid sequence not shown

A:Molecule type: DNA

A:Residues: 1-116 <MAR>

C:Superfamily: immunoglobulin V region; immunoglobulin homology

C:Keywords: heterotetramer; immunoglobulin

F:1-30/Region: framework 1

F:15-98/Domain: immunoglobulin homology <IMM>

F:31-35/Region: complementarity-determining 1

F:36-50/Region: framework 2

F:51-67/Region: complementarity-determining 2

F:68-98/Region: framework 3

F:99-104/Region: complementarity-determining 3

Query Match 75.3%; Score 482.5; DB 2; Length 116;

Best Local Similarity 77.2%; Pred. No. 2e-37;

Matches 95; Conservative 9; Mismatches 12; Indels 7; Gaps 1;

QY 1 OVQLQSGAEVKKPGSSVRVSCKASGTFNNNAIMVVRQAPQGLGEMNGIIPMGFTAKY 60

DB 1 OVQLQSGAEVKKPGSSVRVSCKASGTFSSAISVWQAPQGLGEMNGIIPMGFTAKY 60

QY 61 SQNFGRAVITADESTGASMSLSLRSEDTAVVYCARSDLLPFPHSLSPMGRTMTV 120

DB 61 AQKFGRTITRDESTGASMSLSLRSEDTAVVYCARSDLLPFPHSLSPMGRTMTV 113

QY 121 VSS 123

DB 114 VSS 116

RESULT 2

PH0953

Ig heavy chain V region (G6+ CIL-SIC) - human (fragment)

C:Species: Homo sapiens (man)

C:Date: 17-Apr-1993 #sequence_revision 17-Apr-1993 #text_change 16-Aug-1996

C:Accession: PH0953

R:Martin, T.; Duffly, S.F.; Carson, D.A.; Kipps, T.J.

J. Exp. Med. 175, 983-991, 1992

A:Title: Evidence for somatic selection of natural autoantibodies.

A:Reference number: PH0952; MUID:92202880; PMID:1552291

A:Accession: PH0953

A:Status: nucleic acid sequence not shown

A:Molecule type: DNA

A:Residues: 1-135 <MAR>

C:Superfamily: immunoglobulin V region; immunoglobulin homology

C:Keywords: heterotetramer; immunoglobulin

F:1-30/Region: framework 1

F:15-98/Domain: immunoglobulin homology <IMM>

F:31-35/Region: complementarity-determining 1

F:36-50/Region: framework 2

F:51-67/Region: complementarity-determining 2

F:68-98/Region: framework 3

F:99-123/Region: complementarity-determining 3

Query Match 75.0%; Score 481; DB 2; Length 135;

Best Local Similarity 74.8%; Pred. No. 3.2e-37;

Matches 101; Conservative 6; Mismatches 16; Indels 12; Gaps 2;

QY 1 QVOLOQSGAEVKKPGSSVRVSCKASGCTFNNNAIMWVQAPOGLEMGGIIPMGTAKY 60

1 QVOLVQSGAEVKKPGSSVRVSCKASGCTFSSVAISWVQAPOGLEMGGIIPGTANY 60

61 SONFGRAVITADESTGTASMLSLRSEDYAVVYCAR-----SRDLL--FPHH 108

61 AOKFGRTVITADESTGTASMLSLRSEDYAVVYCARNGYCGDCYSRWELLRFDSFD 120

Db 61 AOKFGRTVITADESTGTASMLSLRSEDYAVVYCARNGYCGDCYSRWELLRFDSFD 120

QY 109 ALSPMGRTMTVSS 123

121 AFDWPGRTMTVSS 135

Db 121 AFDWPGRTMTVSS 135

QY 109 ALSPMGRTMTVSS 123

121 AFDWPGRTMTVSS 135

Db 121 AFDWPGRTMTVSS 135

QY 109 ALSPMGRTMTVSS 123

121 AFDWPGRTMTVSS 135

Db 121 AFDWPGRTMTVSS 135

QY 109 ALSPMGRTMTVSS 123

121 AFDWPGRTMTVSS 135

Db 121 AFDWPGRTMTVSS 135

QY 109 ALSPMGRTMTVSS 123

121 AFDWPGRTMTVSS 135

Db 121 AFDWPGRTMTVSS 135

QY 109 ALSPMGRTMTVSS 123

121 AFDWPGRTMTVSS 135

Db 121 AFDWPGRTMTVSS 135

QY 109 ALSPMGRTMTVSS 123

121 AFDWPGRTMTVSS 135

Db 121 AFDWPGRTMTVSS 135

QY 109 ALSPMGRTMTVSS 123

121 AFDWPGRTMTVSS 135

Db 121 AFDWPGRTMTVSS 135

QY 109 ALSPMGRTMTVSS 123

121 AFDWPGRTMTVSS 135

Db 121 AFDWPGRTMTVSS 135

QY 109 ALSPMGRTMTVSS 123

121 AFDWPGRTMTVSS 135

Db 121 AFDWPGRTMTVSS 135

QY 109 ALSPMGRTMTVSS 123

121 AFDWPGRTMTVSS 135

Db 121 AFDWPGRTMTVSS 135

QY 109 ALSPMGRTMTVSS 123

121 AFDWPGRTMTVSS 135

Db 121 AFDWPGRTMTVSS 135

QY 109 ALSPMGRTMTVSS 123

121 AFDWPGRTMTVSS 135

Db 121 AFDWPGRTMTVSS 135

QY 109 ALSPMGRTMTVSS 123

121 AFDWPGRTMTVSS 135

Db 121 AFDWPGRTMTVSS 135

QY 109 ALSPMGRTMTVSS 123

121 AFDWPGRTMTVSS 135

Db 121 AFDWPGRTMTVSS 135

QY 109 ALSPMGRTMTVSS 123

121 AFDWPGRTMTVSS 135

Db 121 AFDWPGRTMTVSS 135

QY 109 ALSPMGRTMTVSS 123

121 AFDWPGRTMTVSS 135

Db 121 AFDWPGRTMTVSS 135

QY 109 ALSPMGRTMTVSS 123

121 AFDWPGRTMTVSS 135

Db 121 AFDWPGRTMTVSS 135

QY 109 ALSPMGRTMTVSS 123

121 AFDWPGRTMTVSS 135

Db 121 AFDWPGRTMTVSS 135

QY 109 ALSPMGRTMTVSS 123

121 AFDWPGRTMTVSS 135

Ig heavy chain V region (G6+ CLL-HUR) - human (fragment)

C:Species: Homo sapiens (man)

C:Date: 17-Apr-1993 #sequence_revision 17-Apr-1993 #text_change 16-Aug-1996

C:Accession: PH0958

R:Martin, T.; Duffly, S.F.; Carson, D.A.; Kipps, T.J.

J. Exp. Med. 175, 983-991, 1992

A:Title: Evidence for somatic selection of natural autoantibodies.

A:Reference number: PH0952; MUID:92202880; PMID:1552291

A:Accession: PH0958

A:Status: nucleic acid sequence not shown

A:Molecule type: DNA

A:Residues: 1-122 <MAR>

C:Superfamily: immunoglobulin V region; immunoglobulin homology

C:Keywords: heterotetramer; immunoglobulin

F:1-30/Region: framework 1

F:15-98/Domain: immunoglobulin homology <IMM>

F:31-35/Region: complementarity-determining 1

F:36-50/Region: framework 2

F:51-67/Region: complementarity-determining 2

F:68-98/Region: framework 3

F:99-110/Region: complementarity-determining 3

Query Match 74.6%; Score 478.5; DB 2; Length 122;

Best Local Similarity 70.0%; Pred. No. 4.9e-37;

Matches 96; Conservative 9; Mismatches 17; Indels 1; Gaps 1;

QY 1 QVOLOQSGAEVKKPGSSVRVSCKASGCTFNNNAIMWVQAPOGLEMGGIIPMGTAKY 60

1 QVOLVQSGAEVKKPGSSVRVSCKASGCTFSSVAISWVQAPOGLEMGGIIPGTANY 60

61 SONFGRAVITADESTGTASMLSLRSEDYAVVYCARSDLLFPHHLSPMRGTTWT 120

61 AOKFGRTVITADESTGTASMLSLRSEDYAVVYCARVPLPFA-VGMDVWGCTTWT 119

Db 61 AOKFGRTVITADESTGTASMLSLRSEDYAVVYCARVPLPFA-VGMDVWGCTTWT 119

QY 121 VSS 123

120 VSS 122

Db 120 VSS 122

QY 121 VSS 123

120 VSS 122

Db 120 VSS 122

QY 121 VSS 123

120 VSS 122

Db 120 VSS 122

QY 121 VSS 123

120 VSS 122

Db 120 VSS 122

QY 121 VSS 123

120 VSS 122

Db 120 VSS 122

QY 121 VSS 123

120 VSS 122

Db 120 VSS 122

QY 121 VSS 123

120 VSS 122

Db 120 VSS 122

QY 121 VSS 123

120 VSS 122

Db 120 VSS 122

QY 121 VSS 123

120 VSS 122

Db 120 VSS 122

QY 121 VSS 123

120 VSS 122

Db 120 VSS 122

QY 121 VSS 123

120 VSS 122

Db 120 VSS 122

QY 121 VSS 123

120 VSS 122

Db 120 VSS 122

QY 121 VSS 123

120 VSS 122

Db 120 VSS 122

QY 121 VSS 123

120 VSS 122

Db 120 VSS 122

QY 121 VSS 123

120 VSS 122

Db 120 VSS 122

QY 121 VSS 123

120 VSS 122

Db 120 VSS 122

QY 121 VSS 123

120 VSS 122

A:Residues: 1-120 <MAR>
 C:Superfamily: immunoglobulin V region; immunoglobulin homology
 C:Keywords: heterotetramer; immunoglobulin
 F:1-30/Region: framework 1
 F:15-98/Domain: immunoglobulin homology <IMM>
 F:31-35/Region: complementarity-determining 1
 F:36-50/Region: framework 2
 F:51-67/Region: complementarity-determining 2
 F:68-98/Region: framework 3
 F:99-108/Region: complementarity-determining 3

Query Match
 Best Local Similarity 74.0%; Score 474.5; DB 2; Length 120;
 Matches 96; Conservative 9; Mismatches 15; Indels 3; Gaps 2;

QY 1 QVQLQSGAEVKKPKSSVSVSCASGCTFNNNAIMWVROAPQGLMMGGIIPMEGTAKY 60
 DB 1 QVQLVDSAEVKKPKSSVSVSCASGCTFSSVAISMVROAPQGLMMGGIIPFGTANY 60

QY 61 SQNFGRAVITADESTGTASMLSLRSEDITAVYVCARSDLLP-----LFP-----HHALS 111
 DB 61 AAKFGQRTVITADESTGTASMLSLRSEDITAVYVCARPHASIDDPWDSGYIPNYYYGMD 120

QY 112 PMGRGTMTVSS 123
 DB 121 VWGGGTITVSS 132

RESULT 10

PH0954
 Ig heavy chain V region (G6+ CLL-HEN) - human (fragment)
 C:Species: Homo sapiens (man)
 C:Date: 17-Apr-1993 #sequence_revision 17-Apr-1993 #text_change 16-Aug-1996
 C:Accession: PH0954
 R:Martin, T.; Duffy, S.F.; Carson, D.A.; Kipps, T.J.
 J. Exp. Med. 175, 983-991, 1992
 A:Title: Evidence for somatic selection of natural autoantibodies.
 A:Reference number: PH0952; MUID:92202880; PMID:1552291
 A:Accession: PH0954
 A:Status: nucleic acid sequence not shown
 A:Molecule type: DNA
 A:Residues: 1-132 <MAR>
 C:Superfamily: immunoglobulin V region; immunoglobulin homology
 C:Keywords: heterotetramer; immunoglobulin
 F:1-30/Region: framework 1
 F:15-98/Domain: immunoglobulin homology <IMM>
 F:31-35/Region: complementarity-determining 1
 F:36-50/Region: framework 2
 F:51-67/Region: complementarity-determining 2
 F:68-98/Region: framework 3
 F:99-120/Region: complementarity-determining 3

Query Match
 Best Local Similarity 74.0%; Score 474.5; DB 2; Length 132;
 Matches 95; Conservative 12; Mismatches 16; Indels 9; Gaps 2;

QY 1 QVQLQSGAEVKKPKSSVSVSCASGCTFNNNAIMWVROAPQGLMMGGIIPMEGTAKY 60
 DB 1 QVQLVDSAEVKKPKSSVSVSCASGCTFSSVAISMVROAPQGLMMGGIIPFGTANY 60

QY 61 SQNFGRAVITADESTGTASMLSLRSEDITAVYVCARSDLLP-----LFP-----HHALS 111
 DB 61 AAKFGQRTVITADESTGTASMLSLRSEDITAVYVCARPHASIDDPWDSGYIPNYYYGMD 120

QY 112 PMGRGTMTVSS 123
 DB 121 VWGGGTITVSS 132

RESULT 11

PH0952
 Ig heavy chain V region (G6+ CLL-SMI) - human (fragment)
 C:Species: Homo sapiens (man)

C:Date: 17-Apr-1993 #sequence_revision 17-Apr-1993 #text_change 16-Aug-1996
 C:Accession: PH0952
 R:Martin, T.; Duffy, S.F.; Carson, D.A.; Kipps, T.J.
 J. Exp. Med. 175, 983-991, 1992
 A:Title: Evidence for somatic selection of natural autoantibodies.
 A:Reference number: PH0952; MUID:92202880; PMID:1552291
 A:Accession: PH0952
 A:Status: nucleic acid sequence not shown
 A:Molecule type: DNA
 A:Residues: 1-128 <MAR>
 C:Superfamily: immunoglobulin V region; immunoglobulin homology
 C:Keywords: heterotetramer; immunoglobulin
 F:1-30/Region: framework 1
 F:15-98/Domain: immunoglobulin homology <IMM>
 F:31-35/Region: complementarity-determining 1
 F:36-50/Region: framework 2
 F:51-67/Region: complementarity-determining 2
 F:68-98/Region: framework 3
 F:99-116/Region: complementarity-determining 3

Query Match
 Best Local Similarity 73.7%; Score 472.5; DB 2; Length 128;
 Matches 97; Conservative 8; Mismatches 11; Indels 19; Gaps 2;

QY 1 QVQLQSGAEVKKPKSSVSVSCASGCTFNNNAIMWVROAPQGLMMGGIIPMEGTAKY 60
 DB 1 QVQLVDSAEVKKPKSSVSVSCASGCTFSSVAISMVROAPQGLMMGGIIPFGTANY 60

QY 61 SQNFGRAVITADESTGTASMLSLRSEDITAVYCA-----RSRDLLP 108
 DB 61 AAKFGQRTVITADESTGTASMLSLRSEDITAVYVCARGVNDYIWGSYRND----- 113

QY 109 ALSPWGRGTMTVSS 123
 DB 114 AFDIWDGRTVSS 128

RESULT 12

C33548
 Ig heavy chain V-1 region (783) - human
 C:Species: Homo sapiens (man)
 C:Date: 17-Jan-1990 #sequence_revision 17-Jan-1990 #text_change 16-Aug-1996
 C:Accession: C33548
 R:Kipps, T.J.; Tomhave, E.; Pratt, L.F.; Duffy, S.; Chen, P.P.; Carson, D.A.
 Proc. Natl. Acad. Sci. U.S.A. 86, 5913-5917, 1989
 A:Title: Developmentally restricted immunoglobulin heavy chain variable region gene expr
 A:Reference number: A33548; MUID:89345575; PMID:2503826
 A:Accession: C33548
 A:Status: preliminary; nucleic acid sequence not shown; not compared with conceptual tra
 A:Molecule type: DNA
 A:Residues: 1-133 <KIP>
 A:Experimental source: the sequence was determined from the differentiated gene
 C:Superfamily: immunoglobulin V region; immunoglobulin homology
 C:Keywords: heterotetramer; immunoglobulin
 F:15-98/Domain: immunoglobulin homology <IMM>

Query Match
 Best Local Similarity 73.6%; Score 472; DB 2; Length 133;
 Matches 95; Conservative 13; Mismatches 13; Indels 14; Gaps 2;

QY 1 QVQLQSGAEVKKPKSSVSVSCASGCTFNNNAIMWVROAPQGLMMGGIIPMEGTAKY 60
 DB 1 QVQLVDSAEVKKPKSSVSVSCASGCTFSSVAISMVROAPQGLMMGGIIPFGTANY 60

QY 61 SQNFGRAVITADESTGTASMLSLRSEDITAVYVCARSDLLP-----LFP-----HH 108
 DB 61 AAKFGQRTVITADESTGTASMLSLRSEDITAVYVCARTG--ILGYSYSGWYPSNDYXX 118

QY 109 ALSPWGRGTMTVSS 123
 DB 119 GMDIWDGRTVSS 133

RESULT 13

SI4683
Ig mu chain precursor, membrane-bound (clone 201) - human
C:Species: Homo sapiens (man)
C:Date: 31-Dec-1991 #sequence_revision 31-Dec-1991 #text_change 23-Jul-1999
C:Accession: SI4683; S08047
R:Friedlander, R.M.; Nusse, M.C.; Leder, P.
Nucleic Acids Res. 18, 4278, 1990
A:Title: Complete nucleotide sequence of the membrane form of the human Igm heavy chain.
A:Reference number: SI4683; MUID:90332450; PMID:2115996
A:Accession: SI4683
A:Molecule type: mRNA
A:Residues: 1-627 <FRI>
A:Cross-references: EMBL:X17115; NID:G33450; PID:CAA34971.1; PID:G33451
C:Superfamily: immunoglobulin C region; immunoglobulin homology
C:Keywords: immunoglobulin; membrane protein
F:1-15/Domain: signal sequence #status predicted <SIG>
F:16-627/Product: Ig mu chain #status predicted <MAT>
F:34-117/Domain: immunoglobulin homology <IMM>

Query Match 73.6%; Score 472; DB 2; Length 627;
Best Local Similarity 70.4%; Pred. No. 1,1e-35;
Matches 95; Conservative 13; Mismatches 13; Indels 14; Gaps 2;

Qy 1 QVQLVQSGAEVKKPKSSVRVSCAKSGGTENNAINWVROAPGQGLEWMGIIPIFGTAKY 60
Db 20 QVQLVQSGAEVKKPKSSVRVSCAKSGGTENNAINWVROAPGQGLEWMGIIPIFGTANY 79

Qy 61 SQNQGKVAITADSTGTASMEISLRSEDTAVYYCARSDLLFPH-----HH 108
Db 80 AQRQGRVTITADSTGTASMEISLRSEDTAVYYCAKGTG--ILGPSSGMYPNSDYVY 137

Qy 109 ALSPMGKGTWTVSS 123
Db 138 GMDVWGQGTITVTVSS 152

RESULT 14

B33548

Ig heavy chain V-1 region (AND) - human
C:Species: Homo sapiens (man)
C:Date: 17-Jan-1990 #sequence_revision 17-Jan-1990 #text_change 16-Aug-1996
C:Accession: B33548
R:Kippes, T.J.; Tomhave, E.; Pratt, L.F.; Duffy, S.; Chen, P.F.; Carson, D.A.
Proc. Natl. Acad. Sci. U.S.A. 86, 5913-5917, 1989
A:Title: Developmentally restricted immunoglobulin heavy chain variable region gene expression.
A:Reference number: A33548; MUID:89345575; PMID:2503826
A:Accession: B33548
A:Status: preliminary; nucleic acid sequence not shown; not compared with conceptual translation
A:Molecule type: DNA
A:Residues: 1-126 <KIP>
A:Experimental source: the sequence was determined from the differentiated gene
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-98/Domain: immunoglobulin homology <IMM>

Query Match 73.6%; Score 471.5; DB 2; Length 126;
Best Local Similarity 75.4%; Pred. No. 2.2e-36;
Matches 95; Conservative 9; Mismatches 19; Indels 3; Gaps 1;

Qy 1 QVQLVQSGAEVKKPKSSVRVSCAKSGGTENNAINWVROAPGQGLEWMGIIPIFGTAKY 60
Db 1 QVQLVQSGAEVKKPKSSVRVSCAKSGGTENNAINWVROAPGQGLEWMGIIPIFGTANY 60

Qy 61 SQNQGKVAITADSTGTASMEISLRSEDTAVYYCARSDLLFPH--HALSPMGKGT 117
Db 61 AQRQGRVTITADSTGTASMEISLRSEDTAVYYCARVSIQVVOHYYYYYYMDVWGIGT 120

Qy 118 MVTVSS 123
Db 121 TVTVSS 126

RESULT 15

PH0960

Ig heavy chain V region (G6+T-L30) - human (fragment)
C:Species: Homo sapiens (man)
C:Date: 17-Apr-1993 #sequence_revision 17-Apr-1993 #text_change 16-Aug-1996
C:Accession: PH0960
R:Martin, T.; Duffy, S.F.; Carson, D.A.; Kippes, T.J.
J. Exp. Med. 175, 983-991, 1992
A:Title: Evidence for somatic selection of natural autoantibodies.
A:Reference number: PH0960; MUID:92202880; PMID:1552291
A:Accession: PH0960
A:Status: nucleic acid sequence not shown
A:Molecule type: DNA
A:Residues: 1-136 <MAR>
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:1-30/Region: framework 1
F:15-98/Domain: immunoglobulin homology <IMM>
F:31-35/Region: complementarity-determining 1
F:36-50/Region: framework 2
F:51-67/Region: complementarity-determining 2
F:68-98/Region: framework 3
F:99-124/Region: complementarity-determining 3

Query Match 73.6%; Score 471.5; DB 2; Length 136;
Best Local Similarity 69.1%; Pred. No. 2.4e-36;
Matches 94; Conservative 12; Mismatches 17; Indels 13; Gaps 1;

Qy 1 QVQLVQSGAEVKKPKSSVRVSCAKSGGTENNAINWVROAPGQGLEWMGIIPIFGTAKY 60
Db 1 QVQLVQSGAEVKKPKSSVRVSCAKSGGTENNAINWVROAPGQGLEWMGIIPIFGTANY 60

Qy 61 SQNQGKVAITADSTGTASMEISLRSEDTAVYYCARSDLLFPH-----LFPH 107
Db 61 AQRQGRVTITADSTGTASMEISLRSEDTAVYYCARGRVSVSTLYDSSGYDPDSG 120

Qy 108 HALSPMGKGTWTVSS 123
Db 121 YGMDVWGQGTITVTVSS 136

RESULT 16

B49590

Ig heavy chain V region (ACHSVL; clone 18) - human (fragment)
C:Species: Homo sapiens (man)
C:Date: 06-Oct-1994 #sequence_revision 18-Nov-1994 #text_change 23-May-1997
C:Accession: B49590
R:Burton, R.; Williamson, R.A.; Sanna, P.P.; Bloom, F.E.; Burton, D.R.
Proc. Natl. Acad. Sci. U.S.A. 91, 355-359, 1994
A:Title: Recombinant human Fab to glycoprotein D neutralizes infectivity and prevents cell
A:Reference number: A49590; MUID:94105168; PMID:8278393
A:Accession: B49590
A:Status: preliminary; not compared with conceptual translation
A:Molecule type: nucleic acid
A:Residues: 1-122 <BUR>
A:Experimental source: bone marrow lymphocytes
A:Note: sequence extracted from NCBI backbone (NCBI:141851)
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:12-95/Domain: immunoglobulin homology <IMM>

Query Match 72.5%; Score 465; DB 2; Length 122;
Best Local Similarity 73.0%; Pred. No. 8.5e-36;
Matches 89; Conservative 15; Mismatches 16; Indels 2; Gaps 1;

Qy 4 LQSGAEVKKPKSSVRVSCAKSGGTENNAINWVROAPGQGLEWMGIIPIFGTAKY 63
Db 1 LQSGAEVKKPKSSVRVSCAKSGGTENNAINWVROAPGQGLEWMGIIPIFGTAKY 60

Qy 64 PQGRVAITADSTGTASMEISLRSEDTAVYYCARSDLLFPHALSPMGKGTWTV 121
Db 61 PQGRVAITADSTGTASMEISLRSEDTAVYYCARSDLLFPHALSPMGKGTWTV 120

Qy 122 SS 123
Db 121 AS 122

RESULT 17

S36261
Ig heavy chain V region (clone alpha-TNF-E7) - human (fragment)
C/Species: Homo sapiens (man)
C/Date: 03-Feb-1994 #sequence_revision 03-Feb-1994 #text_change 23-Jul-1999
C/Accession: S36261
R/Griffiths, A.D.; Malmqvist, M.; Marke, J.D.; Bye, J.M.; Embleton, M.J.; McCafferty, J.
EMBO J. 12, 725-734, 1993
A/Title: Human anti-self antibodies with high specificity from phage display libraries.
A/Reference number: S36256; PMID:93178448; PMID:7679990
A/Accession: S36261
A/Status: preliminary; nucleic acid sequence not shown
A/Molecule type: mRNA
A/Residues: 1-116 <GRI>
A/Cross-references: EMBL:Z18841; NID:933119; PIDN:CAA79293.1; PID:9939899
A/Superfamily: immunoglobulin V region; immunoglobulin homology
A/Keywords: heterotetramer; immunoglobulin
F:15-98/Domain: immunoglobulin homology <IMM>

Query Match 69.5%; Score 445.5; DB 2; Length 116;
Best Local Similarity 73.9%; Pred. No. 4.9e-34;
Matches 88; Conservative 12; Mismatches 12; Indels 7; Gaps 2;

Qy 1 QVQLQSGAEVKKPSSSVKSCASGCTFNNNAIHWVROAPQGQLEMMGGIIPMFRTAKY 60
Db 1 QVQLQSGAEVKKPSSSVKSCASGCTFSSVAISWVRAPQGQLEMMGGIIPIFGTANY 60

Qy 61 SQNFGRAVITADESTGASMSLSLRSEDTAVYYCA-----RSRLDLPFHIALSPKGR 115
Db 61 AAKFGQRTVITADESTGASMSLSLRSEDTAVYYCARGLRGYD-----YYYYMDVWGK 116

RESULT 18

S26915
Ig heavy chain V region (DP-10) - human (fragment)
C/Species: Homo sapiens (man)
C/Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999
C/Accession: S26915
R/Tomlinson, I.M.; Walter, G.; Marks, J.D.; Llewellyn, M.B.; Winter, G.
J. Mol. Biol. 227, 776-798, 1992
A/Title: The repertoire of human germline V(H) sequences reveals about fifty groups of V
A/Reference number: S26885; PMID:93021117; PMID:1404388
A/Accession: S26915
A/Status: preliminary
A/Molecule type: DNA
A/Residues: 1-98 <TCM>
A/Cross-references: EMBL:Z12312; NID:933849; PIDN:CAA78182.1; PID:932850
C/Superfamily: immunoglobulin V region; immunoglobulin homology
C/Keywords: heterotetramer; immunoglobulin
F:15-98/Domain: immunoglobulin homology <IMM>

Query Match 68.6%; Score 440; DB 2; Length 98;
Best Local Similarity 86.7%; Pred. No. 1.3e-33;
Matches 85; Conservative 6; Mismatches 7; Indels 0; Gaps 0;

Qy 1 QVQLQSGAEVKKPSSSVKSCASGCTFNNNAIHWVROAPQGQLEMMGGIIPMFRTAKY 60
Db 1 QVQLVSGAEVKKPSSSVKSCASGCTFSSVAISWVRAPQGQLEMMGGIIPIFTANY 60

Qy 61 SQNFGRAVITADESTGASMSLSLRSEDTAVYYCAR 98
Db 61 AAKFGQRTVITADESTGASMSLSLRSEDTAVYYCAR 98

RESULT 19

PH1663
Ig heavy chain V region (clone 5B7) - human (fragment)
C/Species: Homo sapiens (man)

C/Date: 24-Feb-1994 #sequence_revision 24-Feb-1994 #text_change 16-Aug-1996
C/Accession: PH1663
R/Hillson, J.L.; Karr, N.S.; Opliger, I.R.; Mamik, M.; Sasso, E.H.
J. Exp. Med. 178, 331-336, 1993

A/Title: The structural basis of germline-encoded VH3 immunoglobulin binding to staphylo
A/Reference number: PH1642; PMID:93301610; PMID:8315388
A/Accession: PH1663
A/Molecule type: mRNA
A/Residues: 1-113 <RTL>
A/Experimental source: B cell
C/Superfamily: immunoglobulin V region; immunoglobulin homology
A/Keywords: heterotetramer; immunoglobulin
F:7-90/Domain: immunoglobulin homology <IMM>

Query Match 68.6%; Score 440; DB 2; Length 113;
Best Local Similarity 73.2%; Pred. No. 1.5e-33;
Matches 90; Conservative 5; Mismatches 10; Indels 18; Gaps 2;

Qy 9 AEVKKPSSSVKSCASGCTFNNNAIHWVROAPQGQLEMMGGIIPMFRTAKYSQNFQGRV 68
Db 1 AEVKKPSSSVKSCASGCTFTGVAISWVRAPQGQLEMMGGIIPIFTANYAKFGGRV 60

Qy 69 AITADESTGASMSLSLRSEDTAVYYCAR-----DLLFPFHIALSPKGRIMVT 120
Db 61 TITADESTGASMSLSLRSEDTAVYYCARLRWGSQGYRDL-----WGRGLVT 110

Qy 121 VSS 123
Db 111 VSS 113

RESULT 20

S31698
Ig heavy chain precursor V region - human
C/Species: Homo sapiens (man)
C/Date: 03-Mar-1994 #sequence_revision 03-May-1996 #text_change 23-Jul-1999
C/Accession: S31698
R/Cuisinier, A.M.; Gauthier, L.; Boublil, L.; Fougereau, M.; Tonnelie, C.
submitted to the EMBL Data Library, June 1992
A/Description: Mechanisms that generate human immunoglobulin diversity operate from the
A/Reference number: S31585
A/Accession: S31698
A/Status: preliminary
A/Molecule type: mRNA
A/Residues: 1-116 <CU>
A/Cross-references: EMBL:Z14214; NID:937797; PIDN:CAA78583.1; PID:937798
C/Superfamily: immunoglobulin V region; immunoglobulin homology
C/Keywords: heterotetramer; immunoglobulin
F:33-116/Domain: immunoglobulin homology <IMM>
F:40-114/Disulfide bonds: #status predicted

Query Match 68.6%; Score 440; DB 2; Length 116;
Best Local Similarity 86.7%; Pred. No. 1.6e-33;
Matches 85; Conservative 6; Mismatches 7; Indels 0; Gaps 0;

Qy 1 QVQLQSGAEVKKPSSSVKSCASGCTFNNNAIHWVROAPQGQLEMMGGIIPMFRTAKY 60
Db 19 QVQLVSGAEVKKPSSSVKSCASGCTFSSVAISWVRAPQGQLEMMGGIIPIFTANY 78

Qy 61 SQNFGRAVITADESTGASMSLSLRSEDTAVYYCAR 98
Db 79 AAKFGQRTVITADESTGASMSLSLRSEDTAVYYCAR 116

RESULT 21

S44108
Ig heavy chain V-D-J region - human
C/Species: Homo sapiens (man)
C/Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 24-May-2001
C/Accession: S44108
R/Hawkins, R.E.; Zhu, D.; Ovecka, M.; Winter, G.; Hamblin, T.J.; Stevenson, F.K.
submitted to the EMBL Data Library, March 1994
A/Description: Idiotypic vaccination against human B-cell lymphoma: rescue of variable r

A:Reference number: S44105
A:Accession: S44108
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-123 <HAW>
A:Cross-references: EMBL:Z31397, NID:9472962, PIDN:CAA83272.1, PID:9940520
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-98/Domain: immunoglobulin homology <IMM>

Query Match 68.6%; Score 440; DB 2; Length 123;
Best Local Similarity 86.7%; Pred. No. 1.7e-33;
Matches 85; Conservative 6; Mismatches 7; Indels 0; Gaps 0;

Qy 1 QVQLQSGAEVKKPSSVSVCCKASGCTFNNAINMVRQAPQGGLMMGGIIPMFCTAKY 60
Db 1 QVQLVQSGAEVKKPSSVSVCCKASGCTFSSYALISWVQAPOGGLMMGGIIPFGTANY 60

61 SQNFGRAVITADESTGTASMEISLRSEDTAVYCAR 98
61 AQKFGRTVITADESTGTAYMELSLRSEDTAVYCAR 98

RESULT 22

B32274
Ig heavy chain precursor V-I region (EVI-15) - human (fragment)

C:Species: Homo sapiens (man)
C:Date: 31-Dec-1989 #sequence_revision 31-Dec-1989 #text_change 18-Oct-1996
C:Accession: B32274
R:Newkirk, M.M.; Gram, H.; Heinrich, G.F.; Oestberg, L.; Capra, J.D.; Masserman, R.L.
J. Clin. Invest. 81, 1511-1518, 1988
A:Title: Complete protein sequences of the variable regions of the cloned heavy and light
actors of the Wa idiotype family.
A:Reference number: A82767; MUID:88213701; PMID:2452836
A:Accession: B32274
A:Residues: 1-135 <NEW>
A:Molecule type: DNA
A:Cross-references: GB:M20003
A:Note: this sequence was determined from the differentiated gene
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:4-135/Product: Ig heavy chain V-I region EVI-15 #status predicted <HVI>
F:18-101/Domain: immunoglobulin homology <IMM>

Query Match 68.1%; Score 436.5; DB 2; Length 135;
Best Local Similarity 67.4%; Pred. No. 3.9e-33;
Matches 89; Conservative 11; Mismatches 23; Indels 9; Gaps 2;

Qy 1 QVQLQSGAEVKKPSSVSVCCKASGCTFNNAINMVRQAPQGGLMMGGIIPMFCTAKY 60
Db 4 QVQLVQSGAEVKKPSSVSVCCKASGCTFSSYALISWVQAPOGGLMMGGIIPFGTANY 63

Qy 61 SQNFGRAVITADESTGTASMEISLRSEDTAVYCARSDI-----LLEPHH---ALS 111
Db 64 AQKFGRTVITADESTGTAYMELSLRSEDTAVYCARSDIENIEVPLDPNYVDGMD 123

Qy 112 PMGRGTMTVSS 123
Db 124 VMGGTITVSS 135

RESULT 23

S24680
Ig heavy chain V-I region - human

C:Species: Homo sapiens (man)
C:Date: 20-Feb-1995 #sequence_revision 20-Feb-1995 #text_change 23-Jul-1999
C:Accession: S24680
R:van Es, J.H.
submitted to the EMBL Data Library, July 1992
A:Reference number: S24679
A:Accession: S24680
A:Status: preliminary
A:Molecule type: DNA

A:Residues: 1-98 <VAN>
A:Cross-references: EMBL:X67905, NID:933128, PIDN:CAA49103.1, PID:933129
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-98/Domain: immunoglobulin homology <IMM>

Query Match 68.0%; Score 436; DB 2; Length 98;
Best Local Similarity 85.7%; Pred. No. 3.1e-33;
Matches 84; Conservative 6; Mismatches 8; Indels 0; Gaps 0;

Qy 1 QVQLQSGAEVKKPSSVSVCCKASGCTFNNAINMVRQAPQGGLMMGGIIPMFCTAKY 60
Db 1 QVQLVQSGAEVKKPSSVSVCCKASGCTFSSYALISWVQAPOGGLMMGGIIPFGTANY 60

Qy 61 SQNFGRAVITADESTGTASMEISLRSEDTAVYCAR 98
Db 61 AQKFGRTVITADESTGTAYMELSLRSEDTAVYCAR 98

RESULT 24

PH1664
Ig heavy chain V region (clone 6A3) - human (fragment)

C:Species: Homo sapiens (man)
C:Date: 24-Feb-1994 #sequence_revision 24-Feb-1994 #text_change 16-Aug-1996
C:Accession: PH1664
R:Hillson, J.L.; Kair, N.S.; Opplinger, I.R.; Mannik, M.; Sasso, E.H.
J. Exp. Med. 178, 331-336, 1993
A:Title: The structural basis of germ-line encoded VH3 immunoglobulin binding to staphylo
A:Reference number: PH1642; MUID:93301610; PMID:8315388
A:Accession: PH1664
A:Molecule type: mRNA
A:Residues: 1-108 <HIL>
A:Experimental source: B cell
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:7-90/Domain: immunoglobulin homology <IMM>

Query Match 67.8%; Score 434.5; DB 2; Length 108;
Best Local Similarity 75.7%; Pred. No. 4.7e-33;
Matches 87; Conservative 6; Mismatches 15; Indels 7; Gaps 1;

Qy 9 AEVKKPSSVSVCCKASGCTFNNAINMVRQAPQGGLMMGGIIPMFCTAKYSONFGRV 68
Db 1 AEVKKPSSVSVCCKASGCTFGVAILSWVQAPOGGLMMGGIIPFGTANYAQKFGRV 60

Qy 69 AITADESTGTASMEISLRSEDTAVYCARSDILLPFHALLSPWGRGTMTVSS 123
Db 61 TITADESTGTAYMELSLRSEDTAVYCARLGT-----GLDVGQGTITVSS 108

RESULT 25

S44106
Ig heavy chain V-D-J region - human

C:Species: Homo sapiens (man)
C:Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 24-May-2001
C:Accession: S44106
R:Hawkins, R.E.; Zhu, D.; Orecka, M.; Winter, G.; Hamblin, T.J.; Stevenson, F.K.
submitted to the EMBL Data Library, March 1994
A:Description: Idiotype vaccination against human B-cell lymphoma: rescue of variable r
A:Reference number: S44105
A:Accession: S44106
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-119 <HAW>
A:Cross-references: EMBL:Z31392, NID:9472960, PIDN:CAA83267.1, PID:9940518
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:13-96/Domain: immunoglobulin homology <IMM>

Query Match 67.3%; Score 431.5; DB 2; Length 119;
Best Local Similarity 78.0%; Pred. No. 9.8e-33;
Matches 85; Conservative 8; Mismatches 9; Indels 7; Gaps 1;

C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-98/Domain: immunoglobulin homology <IMM>

Query Match 64.3%; Score 412; DB 2; Length 98;
Best Local Similarity 81.6%; Pred. No. 4.9e-31;
Matches 80; Conservative 7; Mismatches 11; Indels 0; Gaps 0;

Qy 1 QVQLQSGAEVKKPKSSVRVSCKASGCTFNNNAIMNWROAPGQGLEWMGIIIPMGTA
Db 1 QVQLVQSGAEVKKPKSSVRVSCKASGCTFSSYTTISWVROAPGQGLEWMGRIIPILG
60

Qy 61 SQNFQGRVAITADESTGTAEMLSLSRSEDPTAVYYCAR 98
Db 61 AQRFGRVITADKSTSTAVYMWELSLRSEDPTAVYYCAR 98

RESULT 30

PH1671

heavy chain V region (clone 3C9) - human (fragment)

Species: Homo sapiens (man)

C:Date: 24-Feb-1994 #sequence_revision 24-Feb-1994 #text_change 16-Aug-1996

C:Accession: PH1671

R: Hillson, J. L.; Katz, N. S.; Opliger, I. R.; Mannik, M.; Sasso, E. H.

J. Exp. Med. 178, 331-336, 1993

A:Title: The structural basis of germline-encoded VH3 immunoglobulin binding to staphylo

A:Reference number: PH1642; MUID:93301610; PMID:8315388

A:Accession: PH1671

A:Molecule type: mRNA

A:Residues: 1-109 <HIL>

A:Experimental source: B cell

C:Superfamily: immunoglobulin V region; immunoglobulin homology

C:Keywords: heterotetramer; immunoglobulin

F:7-90/Domain: immunoglobulin homology <IMM>

Query Match 64.0%; Score 410; DB 2; Length 109;
Best Local Similarity 70.6%; Pred. No. 8.4e-31;
Matches 84; Conservative 9; Mismatches 12; Indels 14; Gaps 2;

Qy 9 AEVKKPSSVRVSCKASGCTFNNNAIMNWROAPGQGLEWMGIIIPMGTAQYSONFGCRV 68
Db 1 AEVKKPSSVRVSCKASGCTFSSYATISWVROAPGQGLEWMGRIIPILGIANVAAKFGCRV 60

Qy 69 AITADESTGTAEMLSLSRSEDPTAVYYCA---RSRDLLEPHHALSPMGRTAVTVSS 123
Db 61 TITDKSTSTAVYMWELSLRSEDPTAVYYCAWIMWGSQD-----WGGLTVTVSS 109

RESULT 31

C49590

Ig heavy chain V region (ACHSV1, clone 13) - human (fragment)

C:Species: Homo sapiens (man)

C:Date: 06-Oct-1994 #sequence_revision 18-Nov-1994 #text_change 23-May-1997

C:Accession: C49590

R: Burdick, R.; Williamson, R. A.; Sanna, P. P.; Bloom, F. E.; Burton, D. R.

Proc. Natl. Acad. Sci. U.S.A. 91, 355-359, 1994

A:Title: Recombinant human Fab to glycoprotein D neutralizes infectivity and prevents ce

A:Reference number: A49580; MUID:94105168; PMID:8278393

A:Accession: C49590

A:Status: preliminary; not compared with conceptual translation

A:Molecule type: nucleic acid

A:Residues: 1-122 <BUR>

A:Experimental source: bone marrow lymphocytes

C:Superfamily: immunoglobulin V region; immunoglobulin homology

C:Keywords: heterotetramer; immunoglobulin

F:12-95/Domain: immunoglobulin homology <IMM>

Query Match 64.0%; Score 410; DB 2; Length 122;
Best Local Similarity 65.6%; Pred. No. 9.4e-31;
Matches 80; Conservative 16; Mismatches 24; Indels 2; Gaps 1;

Qy 4 LOQSGAEVKKPKSSVRVSCKASGCTFNNNAIMNWROAPGQGLEWMGIIIPMGTAQYSON 63

Db 1 LEQSGAEVKKPKSSVRVSCKASGCTFSSYATISWVROAPGQGLEWMGIIIPMGTAQK 60

Qy 64 FQGRVAITADESTGTAEMLSLSRSEDPTAVYYCARSDLL--LPHHALSPMGRTAVTV 121
Db 61 FQDLRTTADVTSTAVYMWELSLRSEDPTAVYYCARVAMLEPTVAGGLDVGQGTIVTV 120

Qy 122 SS 123
Db 121 AS 122

RESULT 32

S31667

Ig heavy chain V region - human

C:Species: Homo sapiens (man)

C:Date: 03-Mar-1994 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999

C:Accession: S31667

R: Cuisinier, A. M.; Gauthier, L.; Boubli, L.; Fougereau, M.; Tonnelie, C.

submitted to the EMBL Data Library, June 1992

A:Description: Mechanisms that generate human immunoglobulin diversity operate from the

A:Reference number: S31585

A:Accession: S31667

A:Status: preliminary

A:Molecule type: mRNA

A:Residues: 1-116 <CU1>

A:Cross-references: EMBL:Z14215; NID:937799; PIDN:CA478584.1; PID:937800

C:Superfamily: immunoglobulin V region; immunoglobulin homology

C:Keywords: heterotetramer; immunoglobulin

F:33-116/Domain: immunoglobulin homology <IMM>

Query Match 63.5%; Score 407; DB 2; Length 116;
Best Local Similarity 81.6%; Pred. No. 1.7e-30;
Matches 80; Conservative 6; Mismatches 12; Indels 0; Gaps 0;

Qy 1 QVQLQSGAEVKKPKSSVRVSCKASGCTFNNNAIMNWROAPGQGLEWMGIIIPMGTAQY 60
Db 19 QVQLVQSGAEVKKPKSSVRVSCKASGCTFSSYATISWVROAPGQGLEWMGRIIPILGIANV 78

Qy 61 SQNFQGRVAITADESTGTAEMLSLSRSEDPTAVYYCAR 98
Db 79 AQRFGRVITADKSTSTAVYMWELSLRSEDPTAVYYCAR 116

RESULT 33

PH0870

Ig heavy chain V region (anti-DNA, III-2R) - human (fragment)

C:Species: Homo sapiens (man)

C:Date: 09-Oct-1992 #sequence_revision 09-Oct-1992 #text_change 16-Aug-1996

C:Accession: PH0870

R: Manheimer-Lory, A.; Katz, J. B.; Pillinger, M.; Ghosein, C.; Smith, A.; Diamond, B.

J. Exp. Med. 174, 1639-1652, 1991

A:Title: Molecular characteristics of antibodies bearing an anti-DNA-associated idiotype

A:Reference number: PH0862; MUID:92078875; PMID:1660528

A:Accession: PH0870

A:Molecule type: DNA

A:Residues: 1-97 <MAN>

C:Comment: This antibody is produced by Epstein-Barr virus-transformed B cell that bears

C:Superfamily: immunoglobulin V region; immunoglobulin homology

C:Keywords: heterotetramer; immunoglobulin

F:14-97/Domain: immunoglobulin homology <IMM>

F:30-34/Region: complementarity-determining 1

F:46-65/Region: complementarity-determining 2

Query Match 63.0%; Score 404; DB 2; Length 97;
Best Local Similarity 80.4%; Pred. No. 2.6e-30;
Matches 78; Conservative 8; Mismatches 11; Indels 0; Gaps 0;

Qy 2 VOLQSGAEVKKPKSSVRVSCKASGCTFNNNAIMNWROAPGQGLEWMGIIIPMGTAQY 61
Db 1 VOLQSGAEVKKPKSSVRVSCKASGCTFSSYATISWVROAPGQGLEWMGRIIPILGIANV 60

Qy 62 QNFQGRVAITADESTGTAEMLSLSRSEDPTAVYYCAR 98

Db 61 QKFGQRTTITADKSTISTAYMELSLRSDDTAVYICAR 97

RESULT 34

S36265
Ig heavy chain V region (clone alpha-MUCL-1) - human (fragment)

C:Species: Homo sapiens (man)
C:Date: 03-Feb-1994 #sequence_revision 03-Feb-1994 #text_change 23-Jul-1999
C:Accession: S36265
R:Griffiths, A.D.; Malmqvist, M.; Marks, J.D.; Bye, J.M.; Embleton, M.J.; McCafferty, J.
EMBO J. 12, 725-734, 1993
A:Title: Human anti-self antibodies with high specificity from phage display libraries.
A:Reference number: S36256; PMID:93178448; PMID:679990
A:Accession: S36265
A:Status: preliminary; nucleic acid sequence not shown
A:Molecule type: mRNA
A:Residues: 1-118 <GRI>
A:Cross-references: EMBL:Z18846; NID:G33121; PIDN:CAA79298.1; PID:G939900
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin

5-98/Domain: immunoglobulin homology <IMM>

Query Match 62.8%; Score 402.5; DB 2; Length 118;
Best Local Similarity 68.3%; Pred. No. 4.4e-30;
Matches 84; Conservative 7; Mismatches 27; Indels 5; Gaps 1;

QY 1 QVQLQSGAEVKKPKSSVRVSCKASGCTFNNAIINWROAPQGLWMGIIIPMFCTAKY 60
Db 1 QVQLVQSGAEVKKPKASVSKASGYFTFTGYMHVROAPQGLWMGWINPNSGNTNY 60

QY 61 SQNPGRAVITADESTGASMETSLRSEDTAVYICARSDLLFPHALSPMGRTAVT 120
Db 61 AOKFGQRTTITADKSTISTAYMELSLRSDDTAVYICAR-----PLSGYLDYWGQGLVLT 115

QY 121 VSS 123
Db 116 VSS 118

RESULT 35

S19665
Ig heavy chain V region (alpha-phox15) - human (fragment)

C:Species: Homo sapiens (man)
C:Date: 28-Oct-1994 #sequence_revision 28-Oct-1994 #text_change 20-Jun-2000
C:Accession: S19665; S24442
R:Marks, J.D.; Hoogenboom, H.R.; Bonnett, T.P.; McCafferty, J.; Griffiths, A.D.; Winter, J. Mol. Biol. 222, 581-597, 1991
A:Title: By-passing immunization. Human antibodies from V-gene libraries displayed on phage.
A:Reference number: S19663; PMID:92085276; PMID:1748994
A:Accession: S19665
A:Molecule type: mRNA
A:Residues: 1-124 <MAR>
A:Cross-references: EMBL:X61647
R:Jones, P.T.
submitted to the EMBL Data Library, October 1991

A:Reference number: S24442

A:Accession: S24442
A:Molecule type: mRNA
A:Residues: 1-40, 'GISGMDGSAITWVQSIIDK', 61-118, 'T', 120-124 <JON>
A:Cross-references: EMBL:X61647; NID:G37667; PIDN:CAA43888.1; PID:G1335368
A:Note: the difference for residues 41-60 results from misplacement of 10 bases in the C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-98/Domain: immunoglobulin homology <IMM>

Query Match 62.6%; Score 401.5; DB 2; Length 124;
Best Local Similarity 63.6%; Pred. No. 5.8e-30;
Matches 82; Conservative 11; Mismatches 25; Indels 11; Gaps 2;

QY 1 QVQLQSGAEVKKPKSSVRVSCKASGCTFNNAIINWROAPQGLWMGIIIPMFCTAKY 60
Db 1 QVQLVQSGAEVKKPKASVSKASGYFTFTSYISWROAPQGLWMGISAINGNTYX 60

QY 61 SQNPGRAVITADESTGASMETSLRSEDTAVYICARSDLLFP-----HHALSPMG 114
Db 61 AOKFGQRTTITADKSTISTAYMELSLRSDDTAVYICAR-----LLPKRTATLHYIDVWG 115

QY 115 RGTWTVSS 123
Db 116 KGLTVTVSS 124

RESULT 36

S31600
Ig heavy chain V region - human (fragment)

C:Species: Homo sapiens (man)
C:Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999
C:Accession: S31600
R:Cushtier, A.M.; Gauchier, L.; Boubli, L.; Fougereau, M.; Tonnelie, C.
submitted to the EMBL Data Library, June 1992
A:Description: Mechanisms that generate human immunoglobulin diversity operate from the
A:Reference number: S31585
A:Accession: S31600
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-136 <COI>
A:Cross-references: EMBL:Z14165; NID:G30994; PIDN:CAA78534.1; PID:G30995
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin

F:34-117/Domain: immunoglobulin homology <IMM>

Query Match 62.5%; Score 400.5; DB 2; Length 136;
Best Local Similarity 67.5%; Pred. No. 7.9e-30;
Matches 83; Conservative 9; Mismatches 24; Indels 7; Gaps 1;

QY 1 QVQLQSGAEVKKPKSSVRVSCKASGCTFNNAIINWROAPQGLWMGIIIPMFCTAKY 60
Db 20 QVQLVQSGAEVKKPKASVSKASGYFTFTSYDINWROATGQGLWMGWINPNSGNTGY 79

QY 61 SQNPGRAVITADESTGASMETSLRSEDTAVYICARSDLLFPHALSPMGRTAVT 120
Db 61 AOKFGQRTTITADKSTISTAYMELSLRSDDTAVYICARMRD-----APDIMGQGLVLT 132

QY 121 VSS 123
Db 133 VSS 135

RESULT 37

A32483
Ig heavy chain V region - human (fragment)

C:Species: Homo sapiens (man)
C:Date: 12-Oct-1989 #sequence_revision 12-Oct-1989 #text_change 16-Aug-1996
C:Accession: A32483
R:Watrick, J.W.; Danielson, L.; Brenner, C.A.; Abrahamson, M.; Fry, K.E.; Borrebaeck, C.
Biochem. Biophys. Res. Commun. 160, 1250-1256, 1989
A:Title: Rapid cloning of rearranged immunoglobulin genes from human hybridoma cells usi
A:Reference number: A32483; PMID:89273586; PMID:2499327
A:Accession: A32483
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-142 <LAR>
A:Cross-references: GB:M26463
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:25-108/Domain: immunoglobulin homology <IMM>

Query Match 61.9%; Score 397; DB 2; Length 142;

Best Local Similarity 63.6%; Pred. No. 1.7e-29;
Matches 82; Conservative 13; Mismatches 26; Indels 8; Gaps 2;

QY 1 QVQLQSGAEVKKPKSSVRVSCKASGCTFNNAIINWROAPQGLWMGIIIPMFCTAKY 60
Db 11 QVQLVQSGAEVKKPKASVSKASGYFTFTYMHVROAPQGLWMGIIIPNSGNTNY 70

Qy 61 SQNFQGRVAITADESTGTASMEISLSRSEDTAIVVYCAR-SRDLLFPFHALLSPMG 114
Db 71 AAKFGRTVMTDRISTSTVYMWELSLRSEDTAIVVYCARAKLATITFGLIIT-CMDYWG 128
Qy 115 RGTMTVSS 123
Db 129 QGTLTVSS 137

RESULT 38

S36260
Ig heavy chain V region (clone alpha-CEA4-8A) - human (fragment)
C/Species: Homo sapiens (man)
C/Date: 03-Feb-1994 #sequence_revision 03-Feb-1994 #text_change 23-Jul-1999
C/Accession: S36260
R:Griffiths, A.D.; Malmqvist, M.; Marks, J.D.; Bye, J.M.; Embleton, M.J.; McCafferty, J.
EMBO J. 12, 725-734, 1993
A>Title: Human anti-self antibodies with high specificity from phage display libraries.
A/Reference number: S36256; MUID:93178448; PMID:7679990
A/Accession: S36260
A>Status: preliminary; nucleic acid sequence not shown
A/Molecule type: mRNA
A/Residues: 1-129 <GRI>
A/Cross-references: EMBL:Z18851; NID:G33124; PIDN:CAA79303.1; PID:G939903
C/Superfamily: immunoglobulin V region; immunoglobulin homology
C/Keywords: heterotetramer; immunoglobulin
F:15-98/Domain: immunoglobulin homology <IM>

Query Match 61.8%; Score 396; DB 2; Length 129;
Best Local Similarity 62.8%; Pred. No. 1.9e-29;
Matches 81; Conservative 12; Mismatches 30; Indels 6; Gaps 1;

Qy 1 QVQLQSGAEVKKPKSSVRVSCKASGTFNNNAIMVWROAPGQGLEWMGIIIPMGRTAKY 60
Db 1 QVQLQSGAEVKKPKSSVRVSCKASGTFSTIGISWROAPGQGLEWMGIIIPMGRTAKY 60
Qy 61 SQNFQGRVAITADESTGTASMEISLSRSEDTAIVVYCAR-SRDLLFPFHALLSPMG 114
Db 61 AAKFGRTVMTDRISTSTVYMWELSLRSDDTAIVVYCARDSFGYCSSTSPYIYYMDYWG 120
Qy 115 RGTMTVSS 123
Db 121 KGTIVTVSS 129

RESULT 39

F49590
Ig heavy chain V region (ACHSV2, clone 11) - human (fragment)
C/Species: Homo sapiens (man)
C/Date: 06-Oct-1994 #sequence_revision 18-Nov-1994 #text_change 23-May-1997
C/Accession: F49590
R:Buttlin, R.; Williamson, R.A.; Sanna, P.P.; Bloom, F.E.; Burton, D.R.
Proc. Natl. Acad. Sci. U.S.A. 91, 355-359, 1994
A>Title: Recombinant human Fab to glycoprotein D neutralizes infectivity and prevents cell
A/Reference number: A49590; MUID:94105168; PMID:8278393
A/Accession: F49590
A>Status: preliminary; not compared with conceptual translation
A/Molecule type: nucleic acid
A/Residues: 1-119 <BDR>
A/Experimental source: bone marrow lymphocytes
A/Note: sequence extracted from NCBI backbone (NCBI:141855)
C/Superfamily: immunoglobulin V region; immunoglobulin homology
C/Keywords: heterotetramer; immunoglobulin
F:12-95/Domain: immunoglobulin homology <IM>

Query Match 61.5%; Score 394.5; DB 2; Length 119;
Best Local Similarity 64.5%; Pred. No. 2.4e-29;
Matches 78; Conservative 16; Mismatches 24; Indels 3; Gaps 2;

Qy 4 QVQLQSGAEVKKPKSSVRVSCKASGTFNNNAIMVWROAPGQGLEWMGIIIPMGRTAKY 63
Db 1 LEESGAEMKKPKSSVRVSCKASGTFNNNAIMVWROAPGQGLEWMGIIIPMGRTAKY 60

Qy 64 FQGRVAITADESTGTASMEISLSRSEDTAIVVYCAR-SRDLLFPFHALLSPMGRTMTVS 122
Db 61 FQGRVITADESTGTAVYMWELSLRSDTAIVVYCARHGDSDSGPFPDL-WGQGLVTVS 118
Qy 123 S 123
Db 119 S 119

RESULT 40

S49530
anti-Sm antibody VH chain (VH1/DK1 or DM1/JH4b) - human
C/Species: Homo sapiens (man)
C/Date: 01-Feb-1995 #sequence_revision 12-May-1995 #text_change 23-Jul-1999
C/Accession: S49530
R:Mamoudi, M.; Edwards, J.; Cairns, E.; Bell, D.
Submitted to the EMBL Data Library, October 1994
A>Description: Molecular characterization of natural human anti-Sm autoantibodies.
A/Reference number: S48797
A/Accession: S49530
A>Status: preliminary
A/Molecule type: mRNA
A/Residues: 1-135 <MAH>
A/Cross-references: EMBL:Z46348; NID:G560839; PIDN:CAA66467.1; PID:G560840
C/Superfamily: immunoglobulin V region; immunoglobulin homology
F:34-117/Domain: immunoglobulin homology <IM>

Query Match 61.2%; Score 392.5; DB 2; Length 135;
Best Local Similarity 65.0%; Pred. No. 4.2e-29;
Matches 80; Conservative 11; Mismatches 25; Indels 7; Gaps 1;

Qy 1 QVQLQSGAEVKKPKSSVRVSCKASGTFNNNAIMVWROAPGQGLEWMGIIIPMGRTAKY 60
Db 20 QVQLQSGAEVKKPKSSVRVSCKASGTFSTIGISWROAPGQGLEWMGIIIPMGRTAKY 79
Qy 61 SQNFQGRVAITADESTGTASMEISLSRSEDTAIVVYCAR-SRDLLFPFHALLSPMGRTMTV 120
Db 80 AAKFGRTVMTDRISTSTVYMWELSLRSDDTAIVVYCARART-GYVYWGQGLTVT 132
Qy 121 VSS 123
Db 133 VSS 135

RESULT 41

D33548
Ig heavy chain V-1 region (WIL2) - human
C/Species: Homo sapiens (man)
C/Date: 17-Jan-1990 #sequence_revision 17-Jan-1990 #text_change 16-Aug-1996
C/Accession: D33548
R:Kippes, T.J.; Tomhave, E.; Pratic, L.F.; Duffy, S.; Chen, P.P.; Carson, D.A.
Proc. Natl. Acad. Sci. U.S.A. 86, 5913-5917, 1989
A>Title: Developmentally restricted immunoglobulin heavy chain variable region gene expr
A/Reference number: A33548; MUID:89345575; PMID:2503826
A/Accession: D33548
A>Status: preliminary; nucleic acid sequence not shown; not compared with conceptual tra
A/Molecule type: mRNA
A/Residues: 1-123 <KIP>
C/Superfamily: immunoglobulin V region; immunoglobulin homology
C/Keywords: heterotetramer; immunoglobulin
F:15-98/Domain: immunoglobulin homology <IM>

Query Match 60.4%; Score 387; DB 2; Length 123;
Best Local Similarity 63.4%; Pred. No. 1.2e-28;
Matches 78; Conservative 14; Mismatches 31; Indels 0; Gaps 0;

Qy 1 QVQLQSGAEVKKPKSSVRVSCKASGTFNNNAIMVWROAPGQGLEWMGIIIPMGRTAKY 60
Db 1 QVQLQSGAEVKKPKSSVRVSCASGYTFTHVHWVWROAPGQGLEWMGIIIPMGRTAKY 60
Qy 61 SQNFQGRVAITADESTGTASMEISLSRSEDTAIVVYCARSDLLFPFHALLSPMGRTMTV 120
Db 61 AAKFGRTVITDRISTSTVYMWELSLRSDDTAIVVYCARASYCYDCYFFDYWGQGLTVT 120

QY 121 VSS 123
Db 121 VSS 123

RESULT 42

S20783
Ig heavy chain V region - human
C/Species: Homo sapiens (man)
C/Date: 20-Feb-1995 #sequence_revision 20-Feb-1995 #text_change 21-Jan-2000
C/Accession: S20783
R/Mortari, F.; Wang, J.; Schroeder, H.W.
Submitted to the EMBL Data Library, April 1992
A/Description: Analysis of human cord blood Ig heavy chain IGA and IGG repertoire.
A/Reference number: S20764
A/Accession: S20783
A/Status: preliminary
A/Molecule type: DNA
A/Residues: 1-121 <MOR>
A/References: EMBL:Z11957; NID:G33899; PIDN:CAA78014.1; PID:G33900
C/Superfamily: immunoglobulin V region; immunoglobulin homology
C/Keywords: heterotetramer; immunoglobulin
F:15-98/Domain: immunoglobulin homology <IMM>

Query Match 59.6%; Score 382; DB 2; Length 121;
Best Local Similarity 62.6%; Pred. No. 3.5e-28;
Matches 77; Conservative 13; Mismatches 31; Indels 2; Gaps 1;

QY 1 QVQLQSGAEVKKPSSSVRVSCASGCTFNNAINWVROAPGQLEWGGIIPMFGTAKY 60
Db 1 QVQLVQSGAEVKKPGASVTVSCASGYFTSYEMHWVROAPGQLEWGMINPHGSGTTF 60
QY 61 SONFGKVAITADESTGTASMEISLRSEDTAVYVCARSDLLFPFHALLSPWGRGTWVT 120
Db 61 AQLKQGRATMTDSTSTVYMDLSGLRSEDTALYVCARSD--TSPASTIDYWGQTLVT 118
QY 121 VSS 123
Db 119 VSS 121

RESULT 43

S34014
Ig heavy chain V region - human
C/Species: Homo sapiens (man)
C/Date: 02-Dec-1993 #sequence_revision 10-Nov-1995 #text_change 16-Aug-1996
C/Accession: S34014; S30535
A/Title: J. Tsaplis, A.; Brouet, J.C.
J. Immunol. 23, 846-851, 1993
A/Title: Nucleotide sequence analysis of the variable domains of four human monoclonal
A/Reference number: S34001; MUID:93209281; PMID:7681398
A/Accession: S34014
A/Status: preliminary
A/Molecule type: mRNA
A/Residues: 1-127 <MAR>
A/Cross-references: EMBL:Z18321
C/Superfamily: immunoglobulin V region; immunoglobulin homology
C/Keywords: heterotetramer; immunoglobulin
F:15-98/Domain: immunoglobulin homology <IMM>

Query Match 59.6%; Score 382; DB 2; Length 127;
Best Local Similarity 61.4%; Pred. No. 3.6e-28;
Matches 78; Conservative 17; Mismatches 28; Indels 4; Gaps 1;

QY 1 QVQLQSGAEVKKPSSSVRVSCASGCTFNNAINWVROAPGQLEWGGIIPMFGTAKY 60
Db 1 QVQLVQSGAEVKKPGASVTVSCASGYFTSYDINNVRQATGQLEWGMNPNSSGNTCY 60
QY 61 SONFGKVAITADESTGTASMEISLRSEDTAVYVCARSDU---LFPFHALLSPWGRG 116
Db 61 AQLKQGRATMTDSTSTVYMDLSGLRSEDTALYVCARALSTIGVAVIRGYTALDVWGQ 120

QY 117 TWTVSS 123
Db 121 TTVSVSS 127

RESULT 44

S29257
Ig heavy chain V region precursor - human (fragment)
C/Species: Homo sapiens (man)
C/Date: 22-Nov-1993 #sequence_revision 13-Mar-1997 #text_change 21-Jan-2000
C/Accession: S29257
R/Chouhan, L.; van Spronsen, A.; Breyer, J.; Guglielmi, P.; Strosberg, A.D.
Eur. J. Biochem. 207, 1115-1121, 1992
A/Title: Molecular characterization of a human anti-Rh(D) antibody with a D(H) segment e.
A/Reference number: S29257; MUID:92362614; PMID:1499555
A/Accession: S29257
A/Status: preliminary
A/Molecule type: DNA
A/Residues: 1-148 <CHO>
A/Cross-references: GB:S42403; NID:G253699; PIDN:AA822940.1; PID:G253700
C/Superfamily: immunoglobulin V region; immunoglobulin homology
F:34-111/Domain: immunoglobulin homology <IMM>

Query Match 59.3%; Score 380; DB 2; Length 148;
Best Local Similarity 63.6%; Pred. No. 6.5e-28;
Matches 82; Conservative 8; Mismatches 33; Indels 6; Gaps 1;

QY 1 QVQLQSGAEVKKPSSSVRVSCASGCTFNNAINWVROAPGQLEWGGIIPMFGTAKY 60
Db 20 QVQLVQSGAEVKKPGASVTVSCASGYFTFAMVYALHWVROAPGQLEWGMISVADGKTKY 79
QY 61 SONFGKVAITADESTGTASMEISLRSEDTAVYVCARSDLLFPFHALLSPWGRGTWVT 114
Db 80 SQKQDQVITITRDTSATTAIVAEVGRSEDTAVYVCARSPINWVGVLTTPWPDSSWG 139
QY 115 RGTWTVSS 123
Db 140 QGTLIVSS 148

RESULT 45

PH1667
Ig heavy chain V region (clone 2H7) - human (fragment)
C/Species: Homo sapiens (man)
C/Date: 24-Feb-1994 #sequence_revision 24-Feb-1994 #text_change 16-Aug-1996
C/Accession: PH1667
R/Hillson, J.L.; Karr, N.S.; Oppliger, I.R.; Mannik, M.; Sasso, E.H.
J. Exp. Med. 178, 331-336, 1993
A/Title: The structural basis of germ-line-encoded VH3 immunoglobulin binding to staphylo.
A/Reference number: PH1642; MUID:93301610; PMID:8315388
A/Accession: PH1667
A/Molecule type: mRNA
A/Residues: 1-114 <HIL>
A/Experimental source: B cell
C/Superfamily: immunoglobulin V region; immunoglobulin homology
C/Keywords: heterotetramer; immunoglobulin
F:7-90/Domain: immunoglobulin homology <IMM>

Query Match 58.4%; Score 374.5; DB 2; Length 114;
Best Local Similarity 67.8%; Pred. No. 1.6e-27;
Matches 78; Conservative 9; Mismatches 27; Indels 1; Gaps 1;

QY 9 AEVKKPSSSVRVSCASGCTFNNAINWVROAPGQLEWGGIIPMFGTAKYSONFGKRV 68
Db 1 AEVKKPSSSVRVSCASGYFTSYAMHWVROAPGQLEWGMINAGNNTKXAKFGQGRV 60
QY 69 AITADESTGTASMEISLRSEDTAVYVCARSDLLFPFHALLSPWGRGTWTVSS 123
Db 61 TITRDTASITAYMELSLRSEDTAVYVCARAYD-FWSGYAFDIDWGQGTWTVSS 114

RESULT 46

S46393

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: November 26, 2003, 13:41:10 ; Search time 26.2821 Seconds

(without alignments)
863.195 Million cell updates/sec

Title: US-09-880-748-327_COPY_1_123

Perfect score: 641

Sequence: 1 QVQLQSGAEVKKPKGSSVRV.....LPPHSLSPMGRTMTVSS 123

Scoring table:
BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 673684 seqs, 184443283 residues
number of hits satisfying chosen parameters: 673684

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%
Listing first 45 summaries

Database :

Published Applications_AA:*

- 1: /cgn2_6/ptodata/2/pubppaa/US07_PUBCOMB.pep:*
- 2: /cgn2_6/ptodata/2/pubppaa/PCT_NEW_PUB.pep:*
- 3: /cgn2_6/ptodata/2/pubppaa/US06_NEW_PUB.pep:*
- 4: /cgn2_6/ptodata/2/pubppaa/US06_PUBCOMB.pep:*
- 5: /cgn2_6/ptodata/2/pubppaa/US07_NEW_PUB.pep:*
- 6: /cgn2_6/ptodata/2/pubppaa/PCTUS_PUBCOMB.pep:*
- 7: /cgn2_6/ptodata/2/pubppaa/US08_NEW_PUB.pep:*
- 8: /cgn2_6/ptodata/2/pubppaa/US08_PUBCOMB.pep:*
- 9: /cgn2_6/ptodata/2/pubppaa/US09_PUBCOMB.pep:*
- 10: /cgn2_6/ptodata/2/pubppaa/US09_PUBCOMB.pep:*
- 11: /cgn2_6/ptodata/2/pubppaa/US09_PUB.pep:*
- 12: /cgn2_6/ptodata/2/pubppaa/US10_PUBCOMB.pep:*
- 13: /cgn2_6/ptodata/2/pubppaa/US10_PUBCOMB.pep:*
- 14: /cgn2_6/ptodata/2/pubppaa/US10C_PUBCOMB.pep:*
- 15: /cgn2_6/ptodata/2/pubppaa/US10C_PUBCOMB.pep:*
- 16: /cgn2_6/ptodata/2/pubppaa/US10_NEW_PUB.pep:*
- 17: /cgn2_6/ptodata/2/pubppaa/US00_NEW_PUB.pep:*
- 18: /cgn2_6/ptodata/2/pubppaa/US60_PUBCOMB.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	641	100.0	249	11	US-09-880-748-327
2	626	97.7	249	11	US-09-880-748-785
3	622	97.0	249	11	US-09-880-748-527
4	622	97.0	249	11	US-09-880-748-684
5	622	97.0	249	11	US-09-880-748-804
6	621	96.9	249	11	US-09-880-748-660
7	620	96.7	249	11	US-09-880-748-344
8	620	96.7	249	11	US-09-880-748-363
9	620	96.7	249	11	US-09-880-748-664
10	619	96.6	249	11	US-09-880-748-590
11	619	96.6	249	11	US-09-880-748-821
12	618	96.4	249	11	US-09-880-748-324
13	618	96.4	249	11	US-09-880-748-325
14	618	96.4	249	11	US-09-880-748-596
15	618	96.4	249	11	US-09-880-748-701

16	617	96.3	249	11	US-09-880-748-366	Sequence 366, App
17	617	96.3	249	11	US-09-880-748-404	Sequence 404, App
18	617	96.3	249	11	US-09-880-748-486	Sequence 486, App
19	617	96.3	249	11	US-09-880-748-723	Sequence 723, App
20	617	96.3	249	11	US-09-880-748-747	Sequence 743, App
21	616	96.1	249	11	US-09-880-748-375	Sequence 375, App
22	616	96.1	249	11	US-09-880-748-399	Sequence 399, App
23	616	96.1	249	11	US-09-880-748-696	Sequence 696, App
24	616	96.1	249	11	US-09-880-748-698	Sequence 698, App
25	616	96.1	249	11	US-09-880-748-709	Sequence 709, App
26	616	96.1	249	11	US-09-880-748-713	Sequence 713, App
27	616	96.1	249	11	US-09-880-748-729	Sequence 729, App
28	615	95.9	249	11	US-09-880-748-415	Sequence 415, App
29	615	95.9	249	11	US-09-880-748-428	Sequence 428, App
30	615	95.9	249	11	US-09-880-748-644	Sequence 644, App
31	615	95.9	249	11	US-09-880-748-655	Sequence 655, App
32	615	95.9	249	11	US-09-880-748-722	Sequence 722, App
33	615	95.9	249	11	US-09-880-748-748	Sequence 748, App
34	615	95.9	249	11	US-09-880-748-765	Sequence 765, App
35	615	95.9	249	11	US-09-880-748-786	Sequence 786, App
36	615	95.9	249	11	US-09-880-748-789	Sequence 789, App
37	615	95.9	249	11	US-09-880-748-794	Sequence 794, App
38	614	95.8	249	11	US-09-880-748-322	Sequence 322, App
39	614	95.8	249	11	US-09-880-748-329	Sequence 329, App
40	614	95.8	249	11	US-09-880-748-433	Sequence 433, App
41	614	95.8	249	11	US-09-880-748-461	Sequence 461, App
42	614	95.8	249	11	US-09-880-748-574	Sequence 574, App
43	614	95.8	249	11	US-09-880-748-652	Sequence 652, App
44	614	95.8	249	11	US-09-880-748-717	Sequence 717, App
45	614	95.8	249	11	US-09-880-748-744	Sequence 744, App

ALIGNMENTS

RESULT 1
US-09-880-748-327
Sequence 327, Application US/09880748
Publication No. US2003005937A1
GENERAL INFORMATION:
APPLICANT: Ruben et al.
TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
FILE REFERENCE: P5523
CURRENT APPLICATION NUMBER: US/09/880,748
CURRENT FILING DATE: 2001-06-15
PRIOR APPLICATION NUMBER: 60/212,210
PRIOR FILING DATE: 2000-06-15
PRIOR APPLICATION NUMBER: 60/240,816
PRIOR FILING DATE: 2000-10-17
PRIOR APPLICATION NUMBER: 60/276,248
PRIOR FILING DATE: 2001-03-16
PRIOR APPLICATION NUMBER: 60/277,379
PRIOR FILING DATE: 2001-03-21
PRIOR APPLICATION NUMBER: 60/293,499
PRIOR FILING DATE: 2001-05-25
NUMBER OF SEQ ID NOS: 3239
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 327
LENGTH: 249
TYPE: PRT
ORGANISM: Homo sapiens
US-09-880-748-327
Query Match 100.0%; Score 641, DB 11; Length 249;
Best Local Similarity 100.0%; Pred. No. 3e-54;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 QVQLQSGAEVKKPKGSSVRVSCAKSGTFFNNAINMWRAPGGLGEMWGIIIPMGFTAKY 60
DB 1 QVQLQSGAEVKKPKGSSVRVSCAKSGTFFNNAINMWRAPGGLGEMWGIIIPMGFTAKY 60
OY 61 SGNFQGVAVITADESTGTAASLSSLESDTAVYVCARSDLLFPHHSLSPMGRTMTV 120

Db 61 SONFGQVAITADESTGTASMSLSLRSEDTAVVYCARSDLLLPFHHLSPWGRGTMT 120

QY 121 VSS 123

Db 121 VSS 123

RESULT 2

US-09-880-748-785

; Sequence 785, Application US/09880748

; Publication No. US20030059937A1

; GENERAL INFORMATION:

; APPLICANT: Ruben et al.

; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys

; FILE REFERENCE: PF523

; CURRENT APPLICATION NUMBER: US/09/880,748

; CURRENT FILING DATE: 2001-06-15

; PRIOR APPLICATION NUMBER: 60/212,210

; PRIOR FILING DATE: 2000-06-15

; PRIOR APPLICATION NUMBER: 60/240,816

; PRIOR FILING DATE: 2000-10-17

; PRIOR APPLICATION NUMBER: 60/276,248

; PRIOR FILING DATE: 2001-03-16

; PRIOR APPLICATION NUMBER: 60/277,379

; PRIOR FILING DATE: 2001-03-21

; PRIOR APPLICATION NUMBER: 60/293,499

; PRIOR FILING DATE: 2001-05-25

; NUMBER OF SEQ ID NOS: 3239

; SOFTWARE: PatentIn Ver. 2.0

; SEQ ID NO 785

; LENGTH: 249

; TYPE: PRT

; ORGANISM: Homo sapiens

US-09-880-748-785

Query Match 97.7%; Score 626; DB 11; Length 249;

Best Local Similarity 97.6%; Pred. No. 8.4e-53;

Matches 120; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 QVQLQSGAEVKKPSSSVRVSCAKSGGTENNAINWVROAPGQGLEWMGGIIPMGITAKY 60

Db 1 QVQLQSGAEVKKPSSSVRVSCAKSGGTENNAINWVROAPGQGLEWMGGIIPMGITAKY 60

QY 61 SONFGQVAITADESTGTASMSLSLRSEDTAVVYCARSDLLLPFHHLSPWGRGTMT 120

Db 61 SONFGQVAITADESTGTASMSLSLRSEDTAVVYCARSDLLLPFHHLSPWGRGTMT 120

QY 121 VSS 123

Db 121 VSS 123

QY 121 VSS 123

Db 121 VSS 123

QY 121 VSS 123

Db 121 VSS 123

QY 121 VSS 123

Db 121 VSS 123

QY 121 VSS 123

Db 121 VSS 123

QY 121 VSS 123

Db 121 VSS 123

QY 121 VSS 123

Db 121 VSS 123

QY 121 VSS 123

Db 121 VSS 123

QY 121 VSS 123

Db 121 VSS 123

QY 121 VSS 123

Db 121 VSS 123

QY 121 VSS 123

Db 121 VSS 123

QY 121 VSS 123

Db 121 VSS 123

QY 121 VSS 123

Db 121 VSS 123

QY 121 VSS 123

Db 121 VSS 123

QY 121 VSS 123

Db 121 VSS 123

QY 121 VSS 123

Db 121 VSS 123

QY 121 VSS 123

SOFTWARE: PatentIn Ver. 2.0

; SEQ ID NO 527

; LENGTH: 249

; TYPE: PRT

; ORGANISM: Homo sapiens

US-09-880-748-527

Query Match 97.0%; Score 622; DB 11; Length 249;

Best Local Similarity 97.6%; Pred. No. 2.1e-52;

Matches 120; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 QVQLQSGAEVKKPSSSVRVSCAKSGGTENNAINWVROAPGQGLEWMGGIIPMGITAKY 60

Db 1 QVQLQSGAEVKKPSSSVRVSCAKSGGTENNAINWVROAPGQGLEWMGGIIPMGITAKY 60

QY 61 SONFGQVAITADESTGTASMSLSLRSEDTAVVYCARSDLLLPFHHLSPWGRGTMT 120

Db 61 SONFGQVAITADESTGTASMSLSLRSEDTAVVYCARSDLLLPFHHLSPWGRGTMT 120

QY 121 VSS 123

Db 121 VSS 123

QY 121 VSS 123

Db 121 VSS 123

QY 121 VSS 123

Db 121 VSS 123

QY 121 VSS 123

Db 121 VSS 123

QY 121 VSS 123

Db 121 VSS 123

QY 121 VSS 123

Db 121 VSS 123

QY 121 VSS 123

Db 121 VSS 123

QY 121 VSS 123

Db 121 VSS 123

QY 121 VSS 123

Db 121 VSS 123

QY 121 VSS 123

Db 121 VSS 123

QY 121 VSS 123

Db 121 VSS 123

QY 121 VSS 123

Db 121 VSS 123

QY 121 VSS 123

Db 121 VSS 123

QY 121 VSS 123

Db 121 VSS 123

QY 121 VSS 123

Db 121 VSS 123

QY 121 VSS 123

Db 121 VSS 123

QY 121 VSS 123

Db 121 VSS 123

QY 121 VSS 123

Db 121 VSS 123

QY 121 VSS 123

Db 121 VSS 123

QY 121 VSS 123

Db 121 VSS 123

QY 121 VSS 123

Db 121 VSS 123

QY 121 VSS 123

Db 121 VSS 123

QY 121 VSS 123

Db 121 VSS 123

QY 121 VSS 123

Db 121 VSS 123

QY 121 VSS 123

Db 121 VSS 123

QY 121 VSS 123

Db 121 VSS 123

QY 121 VSS 123

Db 121 VSS 123

QY 121 VSS 123

Db 121 VSS 123

QY 121 VSS 123

Db 121 VSS 123

QY 121 VSS 123


```
GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 804
; LENGTH: 249
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-804
```

```
Query Match          97.0%; Score 622; DB 11; Length 249;
Best Local Similarity 97.6%; Pred. No. 2.1e-52;
Matches 120; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY 1 QVQLQSGAEVKKPKSSVRVSCKASGTFNNNAIINWVROAPGQGLEWMGIIIPMGTKAY 60
Db 1 QVQLQSGAEVKKPKSSVRVSCKASGTFNNNAIINWVROAPGQGLEWMGIIIPMGTKAY 60
QY 61 SQNFGRAVITADESTGTASMEISSLRSEDTAVVYICARSDLLFPFHALLSPMGRTMVT 120
Db 61 SQNFGRAVITADESTGTASMEISSLRSEDTAVVYICARSDLLFPFHALLSPMGRTMVT 120
QY 121 VSS 123
Db 121 VSS 123
```

```
RESULT 6
US-09-880-748-660
; Sequence 660, Application US/09880748
; Publication No. US2003005937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 660
; LENGTH: 249
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-660
```

```
Query Match          96.9%; Score 621; DB 11; Length 249;
Best Local Similarity 97.6%; Pred. No. 2.6e-52;
Matches 120; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY 1 QVQLQSGAEVKKPKSSVRVSCKASGTFNNNAIINWVROAPGQGLEWMGIIIPMGTKAY 60
Db 1 QVQLQSGAEVKKPKSSVRVSCKASGTFNNNAIINWVROAPGQGLEWMGIIIPMGTKAY 60
QY 61 SQNFGRAVITADESTGTASMEISSLRSEDTAVVYICARSDLLFPFHALLSPMGRTMVT 120
Db 61 SQNFGRAVITADESTGTASMEISSLRSEDTAVVYICARSDLLFPFHALLSPMGRTMVT 120
QY 121 VSS 123
Db 121 VSS 123
```

```
RESULT 7
US-09-880-748-344
; Sequence 344, Application US/09880748
; Publication No. US2003005937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 344
; LENGTH: 249
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-344
```

```
Query Match          96.7%; Score 620; DB 11; Length 249;
Best Local Similarity 97.6%; Pred. No. 3.2e-52;
Matches 120; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY 1 QVQLQSGAEVKKPKSSVRVSCKASGTFNNNAIINWVROAPGQGLEWMGIIIPMGTKAY 60
Db 1 QVQLQSGAEVKKPKSSVRVSCKASGTFNNNAIINWVROAPGQGLEWMGIIIPMGTKAY 60
QY 61 SQNFGRAVITADESTGTASMEISSLRSEDTAVVYICARSDLLFPFHALLSPMGRTMVT 120
Db 61 SQNFGRAVITADESTGTASMEISSLRSEDTAVVYICARSDLLFPFHALLSPMGRTMVT 120
QY 121 VSS 123
Db 121 VSS 123
```

```
RESULT 8
US-09-880-748-363
; Sequence 363, Application US/09880748
; Publication No. US2003005937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
```

PRIOR FILING DATE: 2001-03-16
PRIOR APPLICATION NUMBER: 60/277,379
PRIOR FILING DATE: 2001-03-21
PRIOR APPLICATION NUMBER: 60/293,499
PRIOR FILING DATE: 2001-05-25
NUMBER OF SEQ ID NOS: 3239
SOFTWARE: Patent In Ver. 2.0
SEQ ID NO: 363
LENGTH: 249
TYPE: PRT
ORGANISM: Homo sapiens
US-09-880-748-363

Query Match 96.7%; Score 620; DB 11; Length 249;
Best Local Similarity 97.6%; Pred. No. 3, 2e-52;

Matches 120; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 QVQLQSGAEVKKPGSSVSVSCASGTFNNNAIMVWRAPOGLEGWGIIIMFGTAKY 60
DB 1 QVQLQSGAEVKKPGSSVSVSCASGTFNNNAIMVWRAPOGLEGWGIIIMFGTAKY 60
61 SONFGRAVITADESTGTASMEISLSRSEDVAVYICARSDLLFPFHALLSPWGRGTWVT 120
DB 61 SONFGRAVITADESTGTASMEISLSRSEDVAVYICARSDLLFPFHALLSPWGRGTWVT 120
QY 121 VSS 123
DB 121 VSS 123

RESULT 9

US-09-880-748-664
Sequence 664, Application US/09880748
Publication No. US20030059937A1

GENERAL INFORMATION:
APPLICANT: Ruben et al.
TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys

FILE REFERENCE: PF523

CURRENT APPLICATION NUMBER: US/09/880,748

PRIOR FILING DATE: 2001-06-15

PRIOR APPLICATION NUMBER: 60/212,210

PRIOR FILING DATE: 2000-06-15

PRIOR APPLICATION NUMBER: 60/240,816

PRIOR FILING DATE: 2000-10-17

PRIOR APPLICATION NUMBER: 60/276,248

PRIOR FILING DATE: 2001-03-16

PRIOR APPLICATION NUMBER: 60/277,379

PRIOR FILING DATE: 2001-03-21

PRIOR APPLICATION NUMBER: 60/293,499

PRIOR FILING DATE: 2001-05-25

NUMBER OF SEQ ID NOS: 3239

SOFTWARE: Patent In Ver. 2.0

SEQ ID NO: 664

LENGTH: 249

TYPE: PRT

ORGANISM: Homo sapiens

US-09-880-748-664

Query Match 96.7%; Score 620; DB 11; Length 249;
Best Local Similarity 97.6%; Pred. No. 3, 2e-52;
Matches 120; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 QVQLQSGAEVKKPGSSVSVSCASGTFNNNAIMVWRAPOGLEGWGIIIMFGTAKY 60
DB 1 QVQLQSGAEVKKPGSSVSVSCASGTFNNNAIMVWRAPOGLEGWGIIIMFGTAKY 60
61 SONFGRAVITADESTGTASMEISLSRSEDVAVYICARSDLLFPFHALLSPWGRGTWVT 120
DB 61 SONFGRAVITADESTGTASMEISLSRSEDVAVYICARSDLLFPFHALLSPWGRGTWVT 120
QY 121 VSS 123
DB 121 VSS 123

RESULT 10

US-09-880-748-590
Sequence 590, Application US/09880748
Publication No. US20030059937A1

GENERAL INFORMATION:

APPLICANT: Ruben et al.

TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys

FILE REFERENCE: PF523

CURRENT APPLICATION NUMBER: US/09/880,748

PRIOR FILING DATE: 2001-06-15

PRIOR APPLICATION NUMBER: 60/212,210

PRIOR FILING DATE: 2000-06-15

PRIOR APPLICATION NUMBER: 60/240,816

PRIOR FILING DATE: 2000-10-17

PRIOR APPLICATION NUMBER: 60/276,248

PRIOR FILING DATE: 2001-03-16

PRIOR APPLICATION NUMBER: 60/277,379

PRIOR FILING DATE: 2001-03-21

PRIOR APPLICATION NUMBER: 60/293,499

PRIOR FILING DATE: 2001-05-25

NUMBER OF SEQ ID NOS: 3239

SOFTWARE: Patent In Ver. 2.0

SEQ ID NO: 590

LENGTH: 249

TYPE: PRT

ORGANISM: Homo sapiens

US-09-880-748-590

Query Match 96.6%; Score 619; DB 11; Length 249;
Best Local Similarity 97.6%; Pred. No. 4e-52;
Matches 120; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 QVQLQSGAEVKKPGSSVSVSCASGTFNNNAIMVWRAPOGLEGWGIIIMFGTAKY 60
DB 1 QVQLQSGAEVKKPGSSVSVSCASGTFNNNAIMVWRAPOGLEGWGIIIMFGTAKY 60
61 SONFGRAVITADESTGTASMEISLSRSEDVAVYICARSDLLFPFHALLSPWGRGTWVT 120
DB 61 SONFGRAVITADESTGTASMEISLSRSEDVAVYICARSDLLFPFHALLSPWGRGTWVT 120
QY 121 VSS 123
DB 121 VSS 123

RESULT 11

US-09-880-748-821
Sequence 821, Application US/09880748
Publication No. US20030059937A1

GENERAL INFORMATION:

APPLICANT: Ruben et al.

TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys

FILE REFERENCE: PF523

CURRENT APPLICATION NUMBER: US/09/880,748

PRIOR FILING DATE: 2001-06-15

PRIOR APPLICATION NUMBER: 60/212,210

PRIOR FILING DATE: 2000-06-15

PRIOR APPLICATION NUMBER: 60/240,816

PRIOR FILING DATE: 2000-10-17

PRIOR APPLICATION NUMBER: 60/276,248

PRIOR FILING DATE: 2001-03-16

PRIOR APPLICATION NUMBER: 60/277,379

PRIOR FILING DATE: 2001-03-21

PRIOR APPLICATION NUMBER: 60/293,499

PRIOR FILING DATE: 2001-05-25

NUMBER OF SEQ ID NOS: 3239

SOFTWARE: Patent In Ver. 2.0

SEQ ID NO: 821

LENGTH: 249

TYPE: PRT

ORGANISM: Homo sapiens

US-09-880-748-821

Query Match	96.6%;	Score 619;	DB 11;	Length 249;
Best Local Similarity	97.6%;	Pred. NO. 4e-52;		
Matches 120; Conservative	0;	Mismatches 3;	Indels 0;	Gaps 0;

QY	1	QVQLOQSGAEVKKPKGSVAVSCKASGATFNNAIIMVWQAQGGLEMMGGIIIPMFGRAXY	60
Db	1	QVQLOQSGAEVKKPKGSVAVSCKASGATFNNAIIMVWQAQGGLEMMGGIIIPMFGRAXY	60
QY	61	SNQFQRRVAITADESGTSMELSLRSDPAVYVCASRDLLEPPHIALSPMGKGMVT	120
Db	61	SNQFQRRVAITADESGTSMELSLRSDPAVYVCASRDLLEPPHIALSPMGKGMVT	120

Qy	121	VSS	123
Db	121	VSS	123

Page 12
-880-748-324
Sequence 324, Application US/09880748
Publication No. US20030059937A1

;; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blyss
;; FILE REFERENCE: PF523
;; CURRENT APPLICATION NUMBER: US/09/880,748
;;

1
 2
 3
 4
 5
 6
 7
 8
 9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
 100
 101
 102
 103
 104
 105
 106
 107
 108
 109
 110
 111
 112
 113
 114
 115
 116
 117
 118
 119
 120
 121
 122
 123
 124
 125
 126
 127
 128
 129
 130
 131
 132
 133
 134
 135
 136
 137
 138
 139
 140
 141
 142
 143
 144
 145
 146
 147
 148
 149
 150
 151
 152
 153
 154
 155
 156
 157
 158
 159
 160
 161
 162
 163
 164
 165
 166
 167
 168
 169
 170
 171
 172
 173
 174
 175
 176
 177
 178
 179
 180
 181
 182
 183
 184
 185
 186
 187
 188
 189
 190
 191
 192
 193
 194
 195
 196
 197
 198
 199
 200
 201
 202
 203
 204
 205
 206
 207
 208
 209
 210
 211
 212
 213
 214
 215
 216
 217
 218
 219
 220
 221
 222
 223
 224
 225
 226
 227
 228
 229
 230
 231
 232
 233
 234
 235
 236
 237
 238
 239
 240
 241
 242
 243
 244
 245
 246
 247
 248
 249
 250
 251
 252
 253
 254
 255
 256
 257
 258
 259
 260
 261
 262
 263
 264
 265
 266
 267
 268
 269
 270
 271
 272
 273
 274
 275
 276
 277
 278
 279
 280
 281
 282
 283
 284
 285
 286
 287
 288
 289
 290
 291
 292
 293
 294
 295
 296
 297
 298
 299
 300
 301
 302
 303
 304
 305
 306
 307
 308
 309
 310
 311
 312
 313
 314
 315
 316
 317
 318
 319
 320
 321
 322
 323
 324
 325
 326
 327
 328
 329
 330
 331
 332
 333
 334
 335
 336
 337
 338
 339
 340
 341
 342
 343
 344
 345
 346
 347
 348
 349
 350
 351
 352
 353
 354
 355
 356
 357
 358
 359
 360
 361
 362
 363
 364
 365
 366
 367
 368
 369
 370
 371
 372
 373
 374
 375
 376
 377
 378
 379
 380
 381
 382
 383
 384
 385
 386
 387
 388
 389
 390
 391
 392
 393
 394
 395
 396
 397
 398
 399
 400
 401
 402
 403
 404
 405
 406
 407
 408
 409
 410
 411
 412
 413
 414
 415
 416
 417
 418
 419
 420
 421
 422
 423
 424
 425
 426
 427
 428
 429
 430
 431
 432
 433
 434
 435
 436
 437
 438
 439
 440
 441
 442
 443
 444
 445
 446
 447
 448
 449
 450
 451
 452
 453
 454
 455
 456
 457
 458
 459
 460
 461
 462
 463
 464
 465
 466
 467
 468
 469
 470
 471
 472
 473
 474
 475
 476
 477
 478
 479
 480
 481
 482
 483
 484
 485
 486
 487
 488
 489
 490
 491
 492
 493
 494
 495
 496
 497
 498
 499
 500
 501
 502
 503
 504
 505
 506
 507
 508
 509
 510
 511
 512
 513
 514
 515
 516
 517
 518
 519
 520
 521
 522
 523
 524
 525

ORGANISM: Homo sapiens
US-09-880-748-324

96.4%;	Score 618;	DB 11;	Length 249;
96.7%;	Pred. No. 5e-52;		
0;	Mismatches 4;	Indels 0;	Gaps 0;

Qy	Dy	Qy	Dy
3 QVQLOOSGAEVKKPKGSSVAVSCSKAGGTFNNNAIIMTWQAQGGGLEMMGGIIPMEGRAXY 60	1 QVQLOOSGAEVKKPKGSSVAVSCSKAGGTFNNNAIIMTWQAQGGGLEMMGGIIPMEGRAXY 60	61 SQNFORVAITADESGTASMLSLSLSEDTAVVYICASSRDLILPPIHIALSPMGRCMTT 120	61 SQNFORVAITADESGTASMLSLSLSEDTAVVYICASSRDLILPPIHGLDVMGRGMYT 120

QY	121	VSS	123
Db	121	VSS	123

RESULT 13
US-09-880-748-325
; Sequence 325, Application US/09880748
; Publication No. US20030059937A1

```

: APPLICANT: Ruben et al.
: TITLE OF INVENTION: Antibodies that Immunospecifically Bind BlyS
: FILE REFERENCE: PF523
: CURRENT APPLICATION NUMBER: US/09/880,748

```

```

CURRENT FILING DATE: 2001-06-15
PRIORITY APPLICATION NUMBER: 60/212,210
PRIORITY FILING DATE: 2000-06-15
PRIORITY APPLICATION NUMBER: 60/249,816
PRIORITY FILING DATE: 2000-10-17
PRIORITY APPLICATION NUMBER: 60/276,248
PRIORITY FILING DATE: 2001-03-16
PRIORITY APPLICATION NUMBER: 60/277,379
PRIORITY FILING DATE: 2001-03-21
PRIORITY APPLICATION NUMBER: 60/293,499
PRIORITY FILING DATE: 2001-05-25
NUMBER OF SEQ ID NOS: 3239
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 325
LENGTH: 249
TYPE: PRT
ORGANISM: Homo sapiens
US-09-880-748-325

```

Query Match	96.4%	Score 618;	DB 11;	Length 249;
Best Local Similarity	96.7%	Pred. No. 5e-52;		
Matches 119; Conservative	1;	Mismatches 3;	Indels 0;	Gaps 0;

Qy	Dy	Qy	Dy
1 QVQLQSGAEVKKPGSSRVASCASGGTFNNNAINMWRQAPGQLEMMGIIIPMGTRAKY 60	1 QVQLQSGAEVKKPGSSRVASCASGGTFNNNAINMWRQAPGQLEMMGIIIPMGTRAKY 60	61 SQNFQRAVITLDESGTASMTLSLRBPAAVYCAARSRLILFPHHSLSPMGGRGMVT 120	61 SQNFQRAVITLDESGTASMTLSLRBPAAVYCAARSRLILFPHHSLSPMGGRGMVT 120

QY	121	VSS	123
Db	121	VSS	123

RESULT 14
US-09-880-748-596
; Sequence: 596, Application US/09880748
; Publication No. US20030059937A1

```

; TITLE OF INVENTION: Antidodies that Immunospecifically Bind Blys
;
; FILE REFERENCE: PF523
;
; CURRENT APPLICATION NUMBER: US/09/880,748

```

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
84

ORGANISM: Homo sapiens
US-09-880-748-596

Query Match	96.4%;	Score 618;	DB 11;	Length 249;
Best Local Similarity	96.7%;	Pred. No. 5e-52;		
Matches 119; Conservative	1;	Mismatches 3;	Indels 0;	Gaps 0;

[illegible]

Db 61 SONFGRAVATDESTSTASMSLSLRSEDTAVVYCARSRDLLPFPHPAPWGRGTWVT 120

QY 121 VSS 123

Db 121 VSS 123

RESULT 15

US-09-880-748-701

; Sequence 701, Application US/09880748

; Publication No. US20030059937A1

; GENERAL INFORMATION:

; APPLICANT: Ruben et al.

; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys

; FILE REFERENCE: PF523

; CURRENT APPLICATION NUMBER: US/09/880,748

; CURRENT FILING DATE: 2001-06-15

; PRIOR APPLICATION NUMBER: 60/212,210

; PRIOR FILING DATE: 2000-06-15

; PRIOR APPLICATION NUMBER: 60/240,816

; PRIOR FILING DATE: 2000-10-17

; PRIOR APPLICATION NUMBER: 60/276,248

; PRIOR FILING DATE: 2001-03-16

; PRIOR APPLICATION NUMBER: 60/277,379

; PRIOR FILING DATE: 2001-03-21

; PRIOR APPLICATION NUMBER: 60/293,499

; PRIOR FILING DATE: 2001-05-25

; NUMBER OF SEQ ID NOS: 3239

; SOFTWARE: Patent In Ver. 2.0

; SEQ ID NO 701

; LENGTH: 249

; TYPE: PRT

; ORGANISM: Homo sapiens

; US-09-880-748-701

Query Match 96.4%; Score 618; DB 11; Length 249;

Best Local Similarity 96.7%; Pred. No. 56-52;

Matches 119; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 QVQLQSGAEVKKPGSSVRVSCKASGCTFNNNAIMWVROAPQGLEWMGIIIPMGITAKY 60

Db 1 QVQLQSGAEVKKPGSSVRVSCKASGCTFNNNAIMWVROAPQGLEWMGIIIPMGITAKY 60

QY 61 SONFGRAVATDESTSTASMSLSLRSEDTAVVYCARSRDLLPFPHPAPWGRGTWVT 120

Db 61 SONFGRAVATDESTSTASMSLSLRSEDTAVVYCARSRDLLPFPHPAPWGRGTWVT 120

QY 121 VSS 123

Db 121 VSS 123

US-09-880-748-366

; Sequence 366, Application US/09880748

; Publication No. US20030059937A1

; GENERAL INFORMATION:

; APPLICANT: Ruben et al.

; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys

; FILE REFERENCE: PF523

; CURRENT APPLICATION NUMBER: US/09/880,748

; CURRENT FILING DATE: 2001-06-15

; PRIOR APPLICATION NUMBER: 60/212,210

; PRIOR FILING DATE: 2000-06-15

; PRIOR APPLICATION NUMBER: 60/240,816

; PRIOR FILING DATE: 2000-10-17

; PRIOR APPLICATION NUMBER: 60/276,248

; PRIOR FILING DATE: 2001-03-16

; PRIOR APPLICATION NUMBER: 60/277,379

; PRIOR FILING DATE: 2001-03-21

; PRIOR APPLICATION NUMBER: 60/293,499

; PRIOR FILING DATE: 2001-05-25

; RESULT 16

US-09-880-748-404

; Sequence 404, Application US/09880748

; Publication No. US20030059937A1

; GENERAL INFORMATION:

; APPLICANT: Ruben et al.

; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys

; FILE REFERENCE: PF523

; NUMBER OF SEQ ID NOS: 3239

; SOFTWARE: Patent In Ver. 2.0

; SEQ ID NO 366

; LENGTH: 249

; TYPE: PRT

; ORGANISM: Homo sapiens

US-09-880-748-366

Query Match 96.3%; Score 617; DB 11; Length 249;

Best Local Similarity 96.7%; Pred. No. 63e-52;

Matches 119; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 1 QVQLQSGAEVKKPGSSVRVSCKASGCTFNNNAIMWVROAPQGLEWMGIIIPMGITAKY 60

Db 1 QVQLQSGAEVKKPGSSVRVSCKASGCTFNNNAIMWVROAPQGLEWMGIIIPMGITAKY 60

QY 61 SONFGRAVATDESTSTASMSLSLRSEDTAVVYCARSRDLLPFPHPAPWGRGTWVT 120

Db 61 SONFGRAVATDESTSTASMSLSLRSEDTAVVYCARSRDLLPFPHPAPWGRGTWVT 120

QY 121 VSS 123

Db 121 VSS 123

US-09-880-748-404

; Sequence 404, Application US/09880748

; Publication No. US20030059937A1

; GENERAL INFORMATION:

; APPLICANT: Ruben et al.

; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys

; FILE REFERENCE: PF523

; CURRENT APPLICATION NUMBER: US/09/880,748

; CURRENT FILING DATE: 2001-06-15

; PRIOR APPLICATION NUMBER: 60/212,210

; PRIOR FILING DATE: 2000-06-15

; PRIOR APPLICATION NUMBER: 60/240,816

; PRIOR FILING DATE: 2000-10-17

; PRIOR APPLICATION NUMBER: 60/276,248

; PRIOR FILING DATE: 2001-03-16

; PRIOR APPLICATION NUMBER: 60/277,379

; PRIOR FILING DATE: 2001-03-21

; PRIOR APPLICATION NUMBER: 60/293,499

; PRIOR FILING DATE: 2001-05-25

; NUMBER OF SEQ ID NOS: 3239

; SOFTWARE: Patent In Ver. 2.0

; SEQ ID NO 404

; LENGTH: 249

; TYPE: PRT

; ORGANISM: Homo sapiens

; US-09-880-748-404

Query Match 96.3%; Score 617; DB 11; Length 249;

Best Local Similarity 96.7%; Pred. No. 63e-52;

Matches 119; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 1 QVQLQSGAEVKKPGSSVRVSCKASGCTFNNNAIMWVROAPQGLEWMGIIIPMGITAKY 60

Db 1 QVQLQSGAEVKKPGSSVRVSCKASGCTFNNNAIMWVROAPQGLEWMGIIIPMGITAKY 60

QY 61 SONFGRAVATDESTSTASMSLSLRSEDTAVVYCARSRDLLPFPHPAPWGRGTWVT 120

Db 61 SONFGRAVATDESTSTASMSLSLRSEDTAVVYCARSRDLLPFPHPAPWGRGTWVT 120

QY 121 VSS 123

Db 121 VSS 123

US-09-880-748-486

; Sequence 486, Application US/09880748

; Publication No. US20030059937A1

; GENERAL INFORMATION:

; APPLICANT: Ruben et al.

; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys

; FILE REFERENCE: PF523

; CURRENT APPLICATION NUMBER: US/09/880,748

; CURRENT FILING DATE: 2001-06-15

; PRIOR APPLICATION NUMBER: 60/212,210

; PRIOR FILING DATE: 2000-06-15

; PRIOR APPLICATION NUMBER: 60/240,816

; PRIOR FILING DATE: 2000-10-17

; PRIOR APPLICATION NUMBER: 60/276,248

; PRIOR FILING DATE: 2001-03-16

; PRIOR APPLICATION NUMBER: 60/277,379

; PRIOR FILING DATE: 2001-03-21

; PRIOR APPLICATION NUMBER: 60/293,499

; PRIOR FILING DATE: 2001-05-25

; RESULT 18

Publication No. US20030059937A1
GENERAL INFORMATION:
APPLICANT: Ruben et al.
TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
FILE REFERENCE: PF523
CURRENT APPLICATION NUMBER: US/09/880,748
PRIOR FILING DATE: 2001-06-15
PRIOR APPLICATION NUMBER: 60/212,210
PRIOR FILING DATE: 2000-06-15
PRIOR APPLICATION NUMBER: 60/240,816
PRIOR FILING DATE: 2000-10-17
PRIOR APPLICATION NUMBER: 60/276,248
PRIOR FILING DATE: 2001-03-16
PRIOR APPLICATION NUMBER: 60/277,379
PRIOR FILING DATE: 2001-03-21
PRIOR APPLICATION NUMBER: 60/293,499
PRIOR FILING DATE: 2001-05-25
NUMBER OF SEQ ID NOS: 3239
SOFTWARE: Patent In Ver. 2.0
SEQ ID NO 486
LENGTH: 249
TYPE: PRT
ORGANISM: Homo sapiens
US-09-880-748-486

Query Match
Best Local Similarity 96.3%; Score 617; DB 11; Length 249;
Matches 119; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 1 QVQLQSGAEVYKPKGSSVRVSCKASGTFNNNAIMVWVQAPQGLWMGGIIPMGFTAKY 60
DB 1 QVQLQSGAEVYKPKGSSVRVSCKASGTFNNNAIMVWVQAPQGLWMGGIIPMGFTAKY 60
QY 61 SONFGRAVITADESTGASMSLSLRSEDTAVYYCARSRLLPFPHALSPWGRGTWVT 120
DB 61 SONFGRAVITADESTGASMSLSLRSEDTAVYYCARSRLLPFPHALSPWGRGTWVT 120
QY 121 VSS 123
DB 121 VSS 123

RESULT 19
US-09-880-748-723
Sequence 723, Application US/09880748
Publication No. US20030059937A1
GENERAL INFORMATION:
APPLICANT: Ruben et al.
TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
FILE REFERENCE: PF523
CURRENT APPLICATION NUMBER: US/09/880,748
PRIOR FILING DATE: 2001-06-15
PRIOR APPLICATION NUMBER: 60/212,210
PRIOR FILING DATE: 2000-06-15
PRIOR APPLICATION NUMBER: 60/240,816
PRIOR FILING DATE: 2000-10-17
PRIOR APPLICATION NUMBER: 60/276,248
PRIOR FILING DATE: 2001-03-16
PRIOR APPLICATION NUMBER: 60/277,379
PRIOR FILING DATE: 2001-03-21
PRIOR APPLICATION NUMBER: 60/293,499
PRIOR FILING DATE: 2001-05-25
NUMBER OF SEQ ID NOS: 3239
SOFTWARE: Patent In Ver. 2.0
SEQ ID NO 723
LENGTH: 249
TYPE: PRT
ORGANISM: Homo sapiens
US-09-880-748-723

Query Match
Best Local Similarity 96.3%; Score 617; DB 11; Length 249;
Matches 119; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 1 QVQLQSGAEVYKPKGSSVRVSCKASGTFNNNAIMVWVQAPQGLWMGGIIPMGFTAKY 60
DB 1 QVQLQSGAEVYKPKGSSVRVSCKASGTFNNNAIMVWVQAPQGLWMGGIIPMGFTAKY 60
QY 61 SONFGRAVITADESTGASMSLSLRSEDTAVYYCARSRLLPFPHALSPWGRGTWVT 120
DB 61 SONFGRAVITADESTGASMSLSLRSEDTAVYYCARSRLLPFPHALSPWGRGTWVT 120
QY 121 VSS 123
DB 121 VSS 123

RESULT 20
US-09-880-748-743
Sequence 743, Application US/09880748
Publication No. US20030059937A1
GENERAL INFORMATION:
APPLICANT: Ruben et al.
TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
FILE REFERENCE: PF523
CURRENT APPLICATION NUMBER: US/09/880,748
PRIOR FILING DATE: 2001-06-15
PRIOR APPLICATION NUMBER: 60/212,210
PRIOR FILING DATE: 2000-06-15
PRIOR APPLICATION NUMBER: 60/240,816
PRIOR FILING DATE: 2000-10-17
PRIOR APPLICATION NUMBER: 60/276,248
PRIOR FILING DATE: 2001-03-16
PRIOR APPLICATION NUMBER: 60/277,379
PRIOR FILING DATE: 2001-03-21
PRIOR APPLICATION NUMBER: 60/293,499
PRIOR FILING DATE: 2001-05-25
NUMBER OF SEQ ID NOS: 3239
SOFTWARE: Patent In Ver. 2.0
SEQ ID NO 743
LENGTH: 249
TYPE: PRT
ORGANISM: Homo sapiens
US-09-880-748-743

Query Match
Best Local Similarity 96.3%; Score 617; DB 11; Length 249;
Matches 119; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 1 QVQLQSGAEVYKPKGSSVRVSCKASGTFNNNAIMVWVQAPQGLWMGGIIPMGFTAKY 60
DB 1 QVQLQSGAEVYKPKGSSVRVSCKASGTFNNNAIMVWVQAPQGLWMGGIIPMGFTAKY 60
QY 61 SONFGRAVITADESTGASMSLSLRSEDTAVYYCARSRLLPFPHALSPWGRGTWVT 120
DB 61 SONFGRAVITADESTGASMSLSLRSEDTAVYYCARSRLLPFPHALSPWGRGTWVT 120
QY 121 VSS 123
DB 121 VSS 123

RESULT 21
US-09-880-748-375
Sequence 375, Application US/09880748
Publication No. US20030059937A1
GENERAL INFORMATION:
APPLICANT: Ruben et al.
TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
FILE REFERENCE: PF523
CURRENT APPLICATION NUMBER: US/09/880,748
PRIOR FILING DATE: 2001-06-15
PRIOR APPLICATION NUMBER: 60/212,210
PRIOR FILING DATE: 2000-06-15
PRIOR APPLICATION NUMBER: 60/240,816
PRIOR FILING DATE: 2000-10-17

PRIOR APPLICATION NUMBER: 60/276,248
PRIOR FILING DATE: 2001-03-16
PRIOR APPLICATION NUMBER: 60/277,379
PRIOR FILING DATE: 2001-03-21
PRIOR APPLICATION NUMBER: 60/293,499
PRIOR FILING DATE: 2001-05-25
NUMBER OF SEQ ID NOS: 3239
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 375
LENGTH: 249
TYPE: PRT
ORGANISM: Homo sapiens
US-09-880-748-375

Query Match 96.1%; Score 616; DB 11; Length 249;
Best Local Similarity 96.7%; Pred. No. 7,8e-52;
Matches 119; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 1 QVQLQSGAEVKKPKSSVAVSCASGCTFNNAIMVWRQAPQGLEWMGIIIMFGTAKY 60
1 QVQLQSGAEVKKPKSSVAVSCASGCTFNNAIMVWRQAPQGLEWMGIIIMFGTAKY 60
DB 61 SONFGRAVITADESTGTASMEISLRSEDYAVYICARSDLLLPFHALLSPWGRGTWVT 120
61 SONFGRAVITADESTGTASMEISLRSEDYAVYICARSDLLLPFHALLSPWGRGTWVT 120
QY 121 VSS 123
121 VSS 123
DB 121 VSS 123
121 VSS 123

RESULT 22
US-09-880-748-399
Sequence 399, Application US/09880748
Publication No. US20030059937A1

GENERAL INFORMATION:
APPLICANT: Ruben et al.
TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
FILE REFERENCE: PF523
CURRENT APPLICATION NUMBER: US/09/880,748
PRIOR FILING DATE: 2001-06-15
PRIOR APPLICATION NUMBER: 60/212,210
PRIOR FILING DATE: 2000-06-15
PRIOR APPLICATION NUMBER: 60/240,816
PRIOR FILING DATE: 2000-10-17
PRIOR APPLICATION NUMBER: 60/276,248
PRIOR FILING DATE: 2001-03-16
PRIOR APPLICATION NUMBER: 60/277,379
PRIOR FILING DATE: 2001-03-21
PRIOR APPLICATION NUMBER: 60/293,499
NUMBER OF SEQ ID NOS: 3239
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 399
LENGTH: 249
TYPE: PRT
ORGANISM: Homo sapiens
US-09-880-748-399

Query Match 96.1%; Score 616; DB 11; Length 249;
Best Local Similarity 96.7%; Pred. No. 7,8e-52;
Matches 119; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 QVQLQSGAEVKKPKSSVAVSCASGCTFNNAIMVWRQAPQGLEWMGIIIMFGTAKY 60
1 QVQLQSGAEVKKPKSSVAVSCASGCTFNNAIMVWRQAPQGLEWMGIIIMFGTAKY 60
DB 61 SONFGRAVITADESTGTASMEISLRSEDYAVYICARSDLLLPFHALLSPWGRGTWVT 120
61 SONFGRAVITADESTGTASMEISLRSEDYAVYICARSDLLLPFHALLSPWGRGTWVT 120
QY 121 VSS 123
121 VSS 123
DB 121 VSS 123
121 VSS 123

DB 121 VSS 123

RESULT 23
US-09-880-748-696
Sequence 696, Application US/09880748
Publication No. US20030059937A1

GENERAL INFORMATION:
APPLICANT: Ruben et al.
TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
FILE REFERENCE: PF523
CURRENT APPLICATION NUMBER: US/09/880,748
PRIOR FILING DATE: 2001-06-15
PRIOR APPLICATION NUMBER: 60/212,210
PRIOR FILING DATE: 2000-06-15
PRIOR APPLICATION NUMBER: 60/240,816
PRIOR FILING DATE: 2000-10-17
PRIOR APPLICATION NUMBER: 60/276,248
PRIOR FILING DATE: 2001-03-16
PRIOR APPLICATION NUMBER: 60/277,379
PRIOR FILING DATE: 2001-03-21
PRIOR APPLICATION NUMBER: 60/293,499
NUMBER OF SEQ ID NOS: 3239
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 696
LENGTH: 249
TYPE: PRT
ORGANISM: Homo sapiens
US-09-880-748-696

Query Match 96.1%; Score 616; DB 11; Length 249;
Best Local Similarity 96.7%; Pred. No. 7,8e-52;
Matches 119; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 QVQLQSGAEVKKPKSSVAVSCASGCTFNNAIMVWRQAPQGLEWMGIIIMFGTAKY 60
1 QVQLQSGAEVKKPKSSVAVSCASGCTFNNAIMVWRQAPQGLEWMGIIIMFGTAKY 60
DB 61 SONFGRAVITADESTGTASMEISLRSEDYAVYICARSDLLLPFHALLSPWGRGTWVT 120
61 SONFGRAVITADESTGTASMEISLRSEDYAVYICARSDLLLPFHALLSPWGRGTWVT 120
QY 121 VSS 123
121 VSS 123
DB 121 VSS 123
121 VSS 123

RESULT 24
US-09-880-748-698
Sequence 698, Application US/09880748
Publication No. US20030059937A1

GENERAL INFORMATION:
APPLICANT: Ruben et al.
TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
FILE REFERENCE: PF523
CURRENT APPLICATION NUMBER: US/09/880,748
PRIOR FILING DATE: 2001-06-15
PRIOR APPLICATION NUMBER: 60/212,210
PRIOR FILING DATE: 2000-06-15
PRIOR APPLICATION NUMBER: 60/240,816
PRIOR FILING DATE: 2000-10-17
PRIOR APPLICATION NUMBER: 60/276,248
PRIOR FILING DATE: 2001-03-16
PRIOR APPLICATION NUMBER: 60/277,379
PRIOR FILING DATE: 2001-03-21
PRIOR APPLICATION NUMBER: 60/293,499
NUMBER OF SEQ ID NOS: 3239
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 698
LENGTH: 249
TYPE: PRT

```
; ORGANISM: Homo sapiens
US-09-880-748-698

Query Match          96.1%; Score 616; DB 11; Length 249;
Best Local Similarity 95.9%; Pred. No. 7.8e-52;
Matches 118; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 1 QVOLOQSGAEVKKPGSSVRVSCKASGCTFNNNAIIMWVQAPOGQLEWNGIIPMGFTAKY 60
DB 1 QVOLOQSGAEVKKPGSSVRVSCKASGCTFNNNAIIMWVQAPOGQLEWNGIIPMGFTAKY 60
QY 61 SONFGRAVATADSTGTASMSLSLRSEDTAVVYCARSDLLLPFHSLPFWGRTWVT 120
DB 61 SONFGRAVATADSTGTASMSLSLRSEDTAVVYCARSDLLLPFHSLPFWGRTWVT 120
QY 121 VSS 123
DB 121 VSS 123

; ORGANISM: Homo sapiens
US-09-880-748-709

Query Match          96.1%; Score 616; DB 11; Length 249;
Best Local Similarity 95.9%; Pred. No. 7.8e-52;
Matches 118; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 1 QVOLOQSGAEVKKPGSSVRVSCKASGCTFNNNAIIMWVQAPOGQLEWNGIIPMGFTAKY 60
DB 1 QVOLOQSGAEVKKPGSSVRVSCKASGCTFNNNAIIMWVQAPOGQLEWNGIIPMGFTAKY 60
QY 61 SONFGRAVATADSTGTASMSLSLRSEDTAVVYCARSDLLLPFHSLPFWGRTWVT 120
DB 61 SONFGRAVATADSTGTASMSLSLRSEDTAVVYCARSDLLLPFHSLPFWGRTWVT 120
QY 121 VSS 123
DB 121 VSS 123

; ORGANISM: Homo sapiens
US-09-880-748-713

Query Match          96.1%; Score 616; DB 11; Length 249;
Best Local Similarity 95.9%; Pred. No. 7.8e-52;
Matches 118; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

; SEQUENCE: 709, Application US/09880748
; Publication No. US20030059937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PFS23
; CURRENT APPLICATION NUMBER: US/09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 709
; LENGTH: 249
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-709
```

```
; ORGANISM: Homo sapiens
US-09-880-748-713

Query Match          96.1%; Score 616; DB 11; Length 249;
Best Local Similarity 95.9%; Pred. No. 7.8e-52;
Matches 118; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

; SEQUENCE: 729, Application US/09880748
; Publication No. US20030059937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PFS23
; CURRENT APPLICATION NUMBER: US/09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 729
; LENGTH: 249
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-729

Query Match          96.1%; Score 616; DB 11; Length 249;
Best Local Similarity 95.9%; Pred. No. 7.8e-52;
Matches 118; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

; SEQUENCE: 729, Application US/09880748
; Publication No. US20030059937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PFS23
; CURRENT APPLICATION NUMBER: US/09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 729
; LENGTH: 249
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-729
```

QY 61 SONFGRAVATADSTGTASMEISLRSEDTAVYYCARSDLLFPFHSLSPWGRGTWVT 120
Db 61 SONFGRAVATADSTGTASMEISLRSEDTAVYYCARSDLLFPFHSLPFTWGRGTWVT 120

QY 121 VSS 123
Db 121 VSS 123

RESULT 28
US-09-880-748-415
Sequence 415, Application US/09880748
Publication No. US20030059937A1
GENERAL INFORMATION:
APPLICANT: Ruben et al.
TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
FILE REFERENCE: PF523
CURRENT APPLICATION NUMBER: US/09/880,748
PRIORITY FILING DATE: 2001-06-15
PRIORITY FILING DATE: 2000-06-15
PRIORITY FILING DATE: 2000-06-15
PRIORITY FILING DATE: 2000-10-17
PRIORITY FILING DATE: 2001-03-16
PRIORITY FILING DATE: 2001-03-16
PRIORITY FILING DATE: 2001-03-21
PRIORITY FILING DATE: 2001-05-25
NUMBER OF SEQ ID NOS: 3239
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 415
LENGTH: 249
TYPE: PRT
ORGANISM: Homo sapiens
US-09-880-748-415

Query Match 95.9%; Score 615; DB 11; Length 249;
Best Local Similarity 96.7%; Pred. No. 9.8e-52;
Matches 119; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 1 QVQLQSGAEVYKPKGSSVRSVSCASGCTFNNAIINWVROAPQGLIEMWGIIIPMGITAKY 60
Db 1 QVQLQSGAEVYKPKGSSVRSVSCASGCTFNNAIINWVROAPQGLIEMWGIIIPMGITAKY 60
QY 61 SONFGRAVATADSTGTASMEISLRSEDTAVYYCARSDLLFPFHSLSPWGRGTWVT 120
Db 61 SONFGRAVATADSTGTASMEISLRSEDTAVYYCARSDLLFPFHSLPFTWGRGTWVT 120

QY 121 VSS 123
Db 121 VSS 123

RESULT 29
US-09-880-748-428
Sequence 428, Application US/09880748
Publication No. US20030059937A1
GENERAL INFORMATION:
APPLICANT: Ruben et al.
TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
FILE REFERENCE: PF523
CURRENT APPLICATION NUMBER: US/09/880,748
PRIORITY FILING DATE: 2001-06-15
PRIORITY FILING DATE: 2000-06-15
PRIORITY FILING DATE: 2000-06-15
PRIORITY FILING DATE: 2000-10-17
PRIORITY FILING DATE: 2001-03-16
PRIORITY FILING DATE: 2001-03-16
PRIORITY FILING DATE: 2001-03-21
PRIORITY FILING DATE: 2001-05-25
NUMBER OF SEQ ID NOS: 3239
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 415
LENGTH: 249
TYPE: PRT
ORGANISM: Homo sapiens
US-09-880-748-415

PRIORITY FILING DATE: 2001-05-25
NUMBER OF SEQ ID NOS: 3239
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 428
LENGTH: 249
TYPE: PRT
ORGANISM: Homo sapiens
US-09-880-748-428

Query Match 95.9%; Score 615; DB 11; Length 249;
Best Local Similarity 96.7%; Pred. No. 9.8e-52;
Matches 118; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 1 QVQLQSGAEVYKPKGSSVRSVSCASGCTFNNAIINWVROAPQGLIEMWGIIIPMGITAKY 60
Db 1 QVQLQSGAEVYKPKGSSVRSVSCASGCTFNNAIINWVROAPQGLIEMWGIIIPMGITAKY 60
QY 61 SONFGRAVATADSTGTASMEISLRSEDTAVYYCARSDLLFPFHSLSPWGRGTWVT 120
Db 61 SONFGRAVATADSTGTASMEISLRSEDTAVYYCARSDLLFPFHSLPFTWGRGTWVT 120

QY 121 VSS 123
Db 121 VSS 123

RESULT 30
US-09-880-748-644
Sequence 644, Application US/09880748
Publication No. US20030059937A1
GENERAL INFORMATION:
APPLICANT: Ruben et al.
TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
FILE REFERENCE: PF523
CURRENT APPLICATION NUMBER: US/09/880,748
PRIORITY FILING DATE: 2001-06-15
PRIORITY FILING DATE: 2000-06-15
PRIORITY FILING DATE: 2000-06-15
PRIORITY FILING DATE: 2000-10-17
PRIORITY FILING DATE: 2001-03-16
PRIORITY FILING DATE: 2001-03-16
PRIORITY FILING DATE: 2001-03-21
PRIORITY FILING DATE: 2001-05-25
NUMBER OF SEQ ID NOS: 3239
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 644
LENGTH: 249
TYPE: PRT
ORGANISM: Homo sapiens
US-09-880-748-644

Query Match 95.9%; Score 615; DB 11; Length 249;
Best Local Similarity 96.7%; Pred. No. 9.8e-52;
Matches 119; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 QVQLQSGAEVYKPKGSSVRSVSCASGCTFNNAIINWVROAPQGLIEMWGIIIPMGITAKY 60
Db 1 QVQLQSGAEVYKPKGSSVRSVSCASGCTFNNAIINWVROAPQGLIEMWGIIIPMGITAKY 60
QY 61 SONFGRAVATADSTGTASMEISLRSEDTAVYYCARSDLLFPFHSLSPWGRGTWVT 120
Db 61 SONFGRAVATADSTGTASMEISLRSEDTAVYYCARSDLLFPFHSLPFTWGRGTWVT 120
QY 121 VSS 123
Db 121 VSS 123

RESULT 31
US-09-880-748-655


```
; Sequence 655, Application US/09880748
; Publication No. US2003005937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; ID NO 655
; LENGTH: 249
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-655

Query Match          95.9%; Score 615; DB 11; Length 249;
Best Local Similarity 96.7%; Pred. No. 9.8e-52;
Matches 119; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 QVQLQSGAEVKKPKSSVRVSCKASGTFNNNAINWVROAPQGILEMNGIIPMGFTAKY 60
Db 1 QVQLQSGAEVKKPKSSVRVSCKASGTFNNNAINWVROAPQGILEMNGIIPMGFTAKY 60

QY 61 SQNFQGRAVITADESTGTASMSLSLRSEDTAVYYCARSDLLFPFHSLSPWGRGTWVT 120
Db 61 SQNFQGRAVITADESTGTASMSLSLRSEDTAVYYCARSDLLFPFHSLPFWGRGTWVT 120

QY 121 VSS 123
Db 121 VSS 123

RESULT 32
US-09-880-748-722
; Sequence 722, Application US/09880748
; Publication No. US2003005937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 722
; LENGTH: 249
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-722

Query Match          95.9%; Score 615; DB 11; Length 249;
Best Local Similarity 95.9%; Pred. No. 9.8e-52;
Matches 119; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
```

```
Matches 118; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 1 QVQLQSGAEVKKPKSSVRVSCKASGTFNNNAINWVROAPQGILEMNGIIPMGFTAKY 60
Db 1 QVQLQSGAEVKKPKSSVRVSCKASGTFNNNAINWVROAPQGILEMNGIIPMGFTAKY 60

QY 61 SQNFQGRAVITADESTGTASMSLSLRSEDTAVYYCARSDLLFPFHSLSPWGRGTWVT 120
Db 61 SQNFQGRAVITADESTGTASMSLSLRSEDTAVYYCARSDLLFPFHSLPFWGRGTWVT 120

QY 121 VSS 123
Db 121 VSS 123

RESULT 33
US-09-880-748-748
; Sequence 748, Application US/09880748
; Publication No. US2003005937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 748
; LENGTH: 249
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-748

Query Match          95.9%; Score 615; DB 11; Length 249;
Best Local Similarity 96.7%; Pred. No. 9.8e-52;
Matches 119; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 1 QVQLQSGAEVKKPKSSVRVSCKASGTFNNNAINWVROAPQGILEMNGIIPMGFTAKY 60
Db 1 QVQLQSGAEVKKPKSSVRVSCKASGTFNNNAINWVROAPQGILEMNGIIPMGFTAKY 60

QY 61 SQNFQGRAVITADESTGTASMSLSLRSEDTAVYYCARSDLLFPFHSLSPWGRGTWVT 120
Db 61 SQNFQGRAVITADESTGTASMSLSLRSEDTAVYYCARSDLLFPFHSLPFWGRGTWVT 120

QY 121 VSS 123
Db 121 VSS 123

RESULT 34
US-09-880-748-765
; Sequence 765, Application US/09880748
; Publication No. US2003005937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
```

;; PRIOR FILING DATE: 2000-10-17
;; PRIOR APPLICATION NUMBER: 60/276,248
;; PRIOR FILING DATE: 2001-03-16
;; PRIOR APPLICATION NUMBER: 60/277,379
;; PRIOR FILING DATE: 2001-03-21
;; PRIOR APPLICATION NUMBER: 60/293,499
;; PRIOR FILING DATE: 2001-05-25
;; NUMBER OF SEQ ID NOS: 3239
;; SOFTWARE: Patent In Ver. 2.0
;; SEQ ID NO: 765
;; LENGTH: 249
;; TYPE: PRT
;; ORGANISM: Homo sapiens
US-09-880-748-765

Query Match 95.9%; Score 615; DB 11; Length 249;
Best Local Similarity 96.7%; Pred. No. 9,8e-52;
Matches 119; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

1 QVQLQSGAEVKKPSSSVRVSCKASGTFNNNAIMWVRQAPGQGLEWMGIIIMFGTAKY 60
1 QVQLQSGAEVKKPSSSVRVSCKASGTFNNNAIMWVRQAPGQGLEWMGIIIMFGTAKY 60
61 SONFGRAVITADESTGTASMEISLRSEDYAVVYCARSRDLLFPFHALLSPWGRGTWVT 120
61 SONFGRAVITADESTGTASMEISLRSEDYAVVYCARSRDLLFPFHALLSPWGRGTWVT 120
121 VSS 123
121 VSS 123
Db 121 VSS 123

RESULT 35
US-09-880-748-786

;; Sequence 786, Application US/09880748
;; Publication No. US20030059937A1
;; GENERAL INFORMATION:
;; APPLICANT: Ruben et al.
;; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
;; FILE REFERENCE: PFS23
;; CURRENT APPLICATION NUMBER: US/09/880,748
;; CURRENT FILING DATE: 2001-06-15
;; PRIOR APPLICATION NUMBER: 60/212,210
;; PRIOR FILING DATE: 2000-06-15
;; PRIOR APPLICATION NUMBER: 60/240,816
;; PRIOR FILING DATE: 2000-10-17
;; PRIOR APPLICATION NUMBER: 60/276,248
;; PRIOR FILING DATE: 2001-03-16
;; PRIOR APPLICATION NUMBER: 60/277,379
;; PRIOR FILING DATE: 2001-03-21
;; PRIOR APPLICATION NUMBER: 60/293,499
;; PRIOR FILING DATE: 2001-05-25
;; NUMBER OF SEQ ID NOS: 3239
;; SOFTWARE: Patent In Ver. 2.0
;; SEQ ID NO: 786
;; LENGTH: 249
;; TYPE: PRT
;; ORGANISM: Homo sapiens
US-09-880-748-786

Query Match 95.9%; Score 615; DB 11; Length 249;
Best Local Similarity 95.9%; Pred. No. 9,8e-52;
Matches 118; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

1 QVQLQSGAEVKKPSSSVRVSCKASGTFNNNAIMWVRQAPGQGLEWMGIIIMFGTAKY 60
1 QVQLQSGAEVKKPSSSVRVSCKASGTFNNNAIMWVRQAPGQGLEWMGIIIMFGTAKY 60
61 SONFGRAVITADESTGTASMEISLRSEDYAVVYCARSRDLLFPFHALLSPWGRGTWVT 120
61 SONFGRAVITADESTGTASMEISLRSEDYAVVYCARSRDLLFPFHALLSPWGRGTWVT 120
121 VSS 123
121 VSS 123
Db 61 SONFGRAVITADESTGTASMEISLRSEDYAVVYCARSRDLLFPFHALLSPWGRGTWVT 120
121 VSS 123

Db 121 VSS 123

RESULT 36
US-09-880-748-789
;; Sequence 789, Application US/09880748
;; Publication No. US20030059937A1
;; GENERAL INFORMATION:
;; APPLICANT: Ruben et al.
;; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
;; FILE REFERENCE: PFS23
;; CURRENT APPLICATION NUMBER: US/09/880,748
;; CURRENT FILING DATE: 2001-06-15
;; PRIOR APPLICATION NUMBER: 60/212,210
;; PRIOR FILING DATE: 2000-06-15
;; PRIOR APPLICATION NUMBER: 60/240,816
;; PRIOR FILING DATE: 2000-10-17
;; PRIOR APPLICATION NUMBER: 60/276,248
;; PRIOR FILING DATE: 2001-03-16
;; PRIOR APPLICATION NUMBER: 60/277,379
;; PRIOR FILING DATE: 2001-03-21
;; PRIOR APPLICATION NUMBER: 60/293,499
;; PRIOR FILING DATE: 2001-05-25
;; NUMBER OF SEQ ID NOS: 3239
;; SOFTWARE: Patent In Ver. 2.0
;; SEQ ID NO: 789
;; LENGTH: 249
;; TYPE: PRT
;; ORGANISM: Homo sapiens
US-09-880-748-789

Query Match 95.9%; Score 615; DB 11; Length 249;
Best Local Similarity 96.7%; Pred. No. 9,8e-52;
Matches 119; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

1 QVQLQSGAEVKKPSSSVRVSCKASGTFNNNAIMWVRQAPGQGLEWMGIIIMFGTAKY 60
1 QVQLQSGAEVKKPSSSVRVSCKASGTFNNNAIMWVRQAPGQGLEWMGIIIMFGTAKY 60
61 SONFGRAVITADESTGTASMEISLRSEDYAVVYCARSRDLLFPFHALLSPWGRGTWVT 120
61 SONFGRAVITADESTGTASMEISLRSEDYAVVYCARSRDLLFPFHALLSPWGRGTWVT 120
121 VSS 123
121 VSS 123
Db 121 VSS 123

RESULT 37
US-09-880-748-794
;; Sequence 794, Application US/09880748
;; Publication No. US20030059937A1
;; GENERAL INFORMATION:
;; APPLICANT: Ruben et al.
;; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
;; FILE REFERENCE: PFS23
;; CURRENT APPLICATION NUMBER: US/09/880,748
;; CURRENT FILING DATE: 2001-06-15
;; PRIOR APPLICATION NUMBER: 60/212,210
;; PRIOR FILING DATE: 2000-06-15
;; PRIOR APPLICATION NUMBER: 60/240,816
;; PRIOR FILING DATE: 2000-10-17
;; PRIOR APPLICATION NUMBER: 60/276,248
;; PRIOR FILING DATE: 2001-03-16
;; PRIOR APPLICATION NUMBER: 60/277,379
;; PRIOR FILING DATE: 2001-03-21
;; PRIOR APPLICATION NUMBER: 60/293,499
;; PRIOR FILING DATE: 2001-05-25
;; NUMBER OF SEQ ID NOS: 3239
;; SOFTWARE: Patent In Ver. 2.0
;; SEQ ID NO: 794
;; LENGTH: 249

RESULT 4

US-09-880-748-717
; Sequence 717, Application US/09880748
; Publication No. US20030059937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; CURRENT FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 717
; LENGTH: 249
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-717

Query Match 95.8%; Score 614; DB 11; Length 249;
Best Local Similarity 96.7%; Pred. No. 1.2e-51;

Matches 119; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1 QVOLOQSGAEYKPPSSVRSVSCKASGTFNNNAIMWVROAPQGLEMGGIIPMGTAKY 60
Db 1 QVOLOQSGAEYKPPSSVRSVSCKASGTFNNNAIMWVROAPQGLEMGGIIPMGTAKY 60
Qy 61 SQNFGRAVITADESTGTSAMELSLRSEDTAVVYCARSDLLFPFHLSFPMGRTVYT 120
Db 61 SQNFGRAVITADESTGTSAMELSLRSEDTAVVYCARSDLLFPFHLSFPMGRTVYT 120
Qy 121 VSS 123
Db 121 VSS 123

RESULT 45

US-09-880-748-744

; Sequence 744, Application US/09880748
; Publication No. US20030059937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; CURRENT FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 744
; LENGTH: 249
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-744

Query Match

95.8%; Score 614; DB 11; Length 249;

Best Local Similarity 95.9%; Pred. No. 1.2e-51;
Matches 118; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

Qy 1 QVOLOQSGAEYKPPSSVRSVSCKASGTFNNNAIMWVROAPQGLEMGGIIPMGTAKY 60
Db 1 QVOLOQSGAEYKPPSSVRSVSCKASGTFNNNAIMWVROAPQGLEMGGIIPMGTAKY 60
Qy 61 SQNFGRAVITADESTGTSAMELSLRSEDTAVVYCARSDLLFPFHLSFPMGRTVYT 120
Db 61 SQNFGRAVITADESTGTSAMELSLRSEDTAVVYCARSDLLFPFHLSFPMGRTVYT 120
Qy 121 VSS 123
Db 121 VSS 123

RESULT 46

US-09-880-748-752

; Sequence 752, Application US/09880748
; Publication No. US20030059937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; CURRENT FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 752
; LENGTH: 249
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-752

Query Match 95.8%; Score 614; DB 11; Length 249;
Best Local Similarity 95.9%; Pred. No. 1.2e-51;

Matches 118; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

Qy 1 QVOLOQSGAEYKPPSSVRSVSCKASGTFNNNAIMWVROAPQGLEMGGIIPMGTAKY 60
Db 1 QVOLOQSGAEYKPPSSVRSVSCKASGTFNNNAIMWVROAPQGLEMGGIIPMGTAKY 60
Qy 61 SQNFGRAVITADESTGTSAMELSLRSEDTAVVYCARSDLLFPFHLSFPMGRTVYT 120
Db 61 SQNFGRAVITADESTGTSAMELSLRSEDTAVVYCARSDLLFPFHLSFPMGRTVYT 120
Qy 121 VSS 123
Db 121 VSS 123

RESULT 47

US-09-880-748-766

; Sequence 766, Application US/09880748
; Publication No. US20030059937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; CURRENT FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15

Query Match

95.8%; Score 614; DB 11; Length 249;

PRIOR APPLICATION NUMBER: 60/240,816
PRIOR FILING DATE: 2000-10-17
PRIOR APPLICATION NUMBER: 60/276,248
PRIOR FILING DATE: 2001-03-16
PRIOR APPLICATION NUMBER: 60/277,379
PRIOR FILING DATE: 2001-03-21
PRIOR APPLICATION NUMBER: 60/293,499
PRIOR FILING DATE: 2001-05-25
NUMBER OF SEQ ID NOS: 3239
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO: 766
LENGTH: 249
TYPE: PRT
ORGANISM: Homo sapiens
US-09-880-748-766

Query Match 95.8%; Score 614; DB 11; Length 249;
Best Local Similarity 96.7%; Pred. No. 1.2e-51;
Matches 119; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

1 QVLOQSGAEVKKPGSSVRVSCKASGCTFNNNAIMWVROAPQGLEWVGIIIPMGTA
1 QVLOQSGAEVKKPGSSVRVSCKASGCTFNNNAIMWVROAPQGLEWVGIIIPMGTA
60
1 SONFGQVAITADESTGTASMEISLRSEDTAVVYCARSDLLFPFHLSFPMGRTMT
61 SONFGQVAITADESTGTASMEISLRSEDTAVVYCARSDLLFPFHLSFPMGRTMT
120
121 VSS 123
121 VSS 123
Db

RESULT 48
US-09-880-748-767

Sequence 767, Application US/09880748
Publication No. US20030059937A1
GENERAL INFORMATION:
APPLICANT: Ruben et al.
TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
FILE REFERENCE: PF523
CURRENT APPLICATION NUMBER: US/09/880,748
CURRENT FILING DATE: 2001-06-15
PRIOR FILING DATE: 2001-06-15
PRIOR APPLICATION NUMBER: 60/212,210
PRIOR FILING DATE: 2000-06-15
PRIOR APPLICATION NUMBER: 60/240,816
PRIOR FILING DATE: 2000-10-17
PRIOR APPLICATION NUMBER: 60/276,248
PRIOR FILING DATE: 2001-03-16
PRIOR APPLICATION NUMBER: 60/277,379
PRIOR FILING DATE: 2001-03-21
PRIOR APPLICATION NUMBER: 60/293,499
PRIOR FILING DATE: 2001-05-25
NUMBER OF SEQ ID NOS: 3239
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO: 767
LENGTH: 249
TYPE: PRT
ORGANISM: Homo sapiens
US-09-880-748-767

Query Match 95.8%; Score 614; DB 11; Length 249;
Best Local Similarity 96.7%; Pred. No. 1.2e-51;
Matches 119; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

1 QVLOQSGAEVKKPGSSVRVSCKASGCTFNNNAIMWVROAPQGLEWVGIIIPMGTA
1 QVLOQSGAEVKKPGSSVRVSCKASGCTFNNNAIMWVROAPQGLEWVGIIIPMGTA
60
1 SONFGQVAITADESTGTASMEISLRSEDTAVVYCARSDLLFPFHLSFPMGRTMT
61 SONFGQVAITADESTGTASMEISLRSEDTAVVYCARSDLLFPFHLSFPMGRTMT
120
61 SONFGQVAITADESTGTASMEISLRSEDTAVVYCARSDLLFPFHLSFPMGRTMT
120

QY 121 VSS 123
Db 121 VSS 123

RESULT 49
US-09-880-748-792

Sequence 792, Application US/09880748
Publication No. US20030059937A1
GENERAL INFORMATION:
APPLICANT: Ruben et al.
TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
FILE REFERENCE: PF523
CURRENT APPLICATION NUMBER: US/09/880,748
CURRENT FILING DATE: 2001-06-15
PRIOR APPLICATION NUMBER: 60/212,210
PRIOR FILING DATE: 2000-06-15
PRIOR APPLICATION NUMBER: 60/240,816
PRIOR FILING DATE: 2000-10-17
PRIOR APPLICATION NUMBER: 60/276,248
PRIOR FILING DATE: 2001-03-16
PRIOR APPLICATION NUMBER: 60/277,379
PRIOR FILING DATE: 2001-03-21
PRIOR APPLICATION NUMBER: 60/293,499
PRIOR FILING DATE: 2001-05-25
NUMBER OF SEQ ID NOS: 3239
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO: 792
LENGTH: 249
TYPE: PRT
ORGANISM: Homo sapiens
US-09-880-748-792

Query Match 95.8%; Score 614; DB 11; Length 249;
Best Local Similarity 95.9%; Pred. No. 1.2e-51;
Matches 118; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

1 QVLOQSGAEVKKPGSSVRVSCKASGCTFNNNAIMWVROAPQGLEWVGIIIPMGTA
1 QVLOQSGAEVKKPGSSVRVSCKASGCTFNNNAIMWVROAPQGLEWVGIIIPMGTA
60
1 SONFGQVAITADESTGTASMEISLRSEDTAVVYCARSDLLFPFHLSFPMGRTMT
61 SONFGQVAITADESTGTASMEISLRSEDTAVVYCARSDLLFPFHLSFPMGRTMT
120
121 VSS 123
121 VSS 123
Db

RESULT 50
US-09-880-748-797

Sequence 797, Application US/09880748
Publication No. US20030059937A1
GENERAL INFORMATION:
APPLICANT: Ruben et al.
TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
FILE REFERENCE: PF523
CURRENT APPLICATION NUMBER: US/09/880,748
CURRENT FILING DATE: 2001-06-15
PRIOR APPLICATION NUMBER: 60/212,210
PRIOR FILING DATE: 2000-06-15
PRIOR APPLICATION NUMBER: 60/240,816
PRIOR FILING DATE: 2000-10-17
PRIOR APPLICATION NUMBER: 60/276,248
PRIOR FILING DATE: 2001-03-16
PRIOR APPLICATION NUMBER: 60/277,379
PRIOR FILING DATE: 2001-03-21
PRIOR APPLICATION NUMBER: 60/293,499
PRIOR FILING DATE: 2001-05-25
NUMBER OF SEQ ID NOS: 3239
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO: 797

Query Match 95.8%; Score 614; DB 11; Length 249;
Best Local Similarity 95.9%; Pred. No. 1.2e-51;
Matches 118; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

1 QVLOQSGAEVKKPGSSVRVSCKASGCTFNNNAIMWVROAPQGLEWVGIIIPMGTA
1 QVLOQSGAEVKKPGSSVRVSCKASGCTFNNNAIMWVROAPQGLEWVGIIIPMGTA
60
1 SONFGQVAITADESTGTASMEISLRSEDTAVVYCARSDLLFPFHLSFPMGRTMT
61 SONFGQVAITADESTGTASMEISLRSEDTAVVYCARSDLLFPFHLSFPMGRTMT
120
61 SONFGQVAITADESTGTASMEISLRSEDTAVVYCARSDLLFPFHLSFPMGRTMT
120

; LENGTH: 249
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-797

Query Match 95.8%; Score 614; DB 11; Length 249;
Best Local Similarity 95.9%; Pred. No. 1.2e-51;
Matches 118; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

```
QY 1 QVQLQSGAEYVKRPGSSVRSCKASGGTFNNNAINMVRQAPQGLQWVGIIIMFGTAKY 60
   |||
Db 1 QVQLQSGAEYVKRPGSSVRSCKASGGTFNNNAINMVRQAPQGLQWVGIIIMFGTAKY 60
   |||
QY 61 SQNFQGRVAITADESTGTASMEISLSRSEDTAVYYCARSDLLFPFHALSPMGRGTMT 120
   |||
Db 61 SQNFQGRVAITADESTGTASMEISLSRSEDTAVYYCARSDLLFPFHSPDLMGRTMT 120
   |||
QY 121 VSS 123
   |||
   121 VSS 123
```

Search completed: November 26, 2003, 13:49:51
Job time : 27.2821 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: November 26, 2003, 13:37:50 ; Search time 15.2436 Seconds
(without alignments)
341.405 Million cell updates/sec

Title: US-09-880-748-327_COPY_1_123

Perfect score: 641
Sequence: 1 OVQLQSGAEVKKPGSSVRV.....LFPFHSLPWCGRMTVSS 123

Scoring table: BIOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 328717 seqs, 42310858 residues

number of hits satisfying chosen parameters: 328717

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 45 summaries

Database :

1: Issued Patents AA: *
2: /cgn2_6/ptodata/1/1aa/5A_COMB.pep: *
3: /cgn2_6/ptodata/1/1aa/5B_COMB.pep: *
4: /cgn2_6/ptodata/1/1aa/6A_COMB.pep: *
5: /cgn2_6/ptodata/1/1aa/PTUS_COMB.pep: *
6: /cgn2_6/ptodata/1/1aa/backfile1.pep: *

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	479	74.7	123	US-08-652-816A-8	Sequence 8, Appli
2	478	74.6	123	US-08-652-816A-1	Sequence 1, Appli
3	476	74.3	123	US-08-652-816A-9	Sequence 9, Appli
4	475.5	74.2	120	US-09-025-769B-35	Sequence 35, Appli
5	475.5	74.2	120	US-09-025-769B-57	Sequence 57, Appli
6	473	73.8	119	US-09-025-769B-21	Sequence 21, Appli
7	471	73.5	123	US-08-652-816A-6	Sequence 6, Appli
8	468	73.0	123	US-08-378-939-10	Sequence 10, Appli
9	460	71.8	120	US-08-652-816A-7	Sequence 7, Appli
10	451	70.4	120	US-08-428-197-12	Sequence 12, Appli
11	451	70.4	120	PCT-US93-10555-12	Sequence 12, Appli
12	443	69.1	119	US-08-983-607-50	Sequence 50, Appli
13	440	68.6	121	US-08-232-081B-41	Sequence 41, Appli
14	439.5	68.6	147	US-08-217-918-4	Sequence 4, Appli
15	438	68.3	120	US-08-428-197-13	Sequence 13, Appli
16	438	68.3	120	PCT-US93-10555-13	Sequence 13, Appli
17	422.5	65.9	128	US-08-635-109-3	Sequence 3, Appli
18	421	65.7	117	US-07-634-278-4	Sequence 4, Appli
19	421	65.7	117	US-07-634-278-15	Sequence 15, Appli
20	421	65.7	117	US-07-634-278-72	Sequence 72, Appli
21	421	65.7	117	US-07-634-278-104	Sequence 104, App
22	421	65.7	117	US-08-477-728-4	Sequence 4, Appli
23	421	65.7	117	US-08-477-728-15	Sequence 15, Appli
24	421	65.7	117	US-08-477-728-72	Sequence 72, Appli
25	421	65.7	117	US-08-477-728-104	Sequence 104, App
26	421	65.7	117	US-08-474-040-4	Sequence 4, Appli
27	421	65.7	117	US-08-474-040-15	Sequence 15, Appli

28	421	65.7	117	1	US-08-474-040-72	Sequence 72, Appli
29	421	65.7	117	1	US-08-474-040-104	Sequence 104, App
30	421	65.7	117	1	US-08-487-200-4	Sequence 4, Appli
31	421	65.7	117	1	US-08-487-200-15	Sequence 15, Appli
32	421	65.7	117	1	US-08-487-200-72	Sequence 72, Appli
33	421	65.7	117	1	US-08-487-200-104	Sequence 104, App
34	421	65.7	117	1	US-08-488-113B-166	Sequence 166, App
35	421	65.7	117	1	US-08-477-484B-166	Sequence 166, App
36	421	65.7	117	1	US-08-107-669D-52	Sequence 52, Appli
37	421	65.7	117	1	US-08-472-788A-52	Sequence 52, Appli
38	421	65.7	117	2	US-08-477-531B-52	Sequence 52, Appli
39	421	65.7	117	2	US-08-646-360-166	Sequence 166, App
40	421	65.7	117	2	US-08-082-842A-52	Sequence 52, Appli
41	421	65.7	117	3	US-08-839-765-166	Sequence 166, App
42	421	65.7	117	3	US-09-136-389-166	Sequence 166, App
43	421	65.7	117	3	US-08-484-537-4	Sequence 4, Appli
44	421	65.7	117	3	US-08-484-537-15	Sequence 15, Appli
45	421	65.7	117	3	US-08-484-537-72	Sequence 72, Appli

ALIGNMENTS

RESULT 1
US-08-652-816A-8
Sequence 8, Application US/06652816A
Patent No. 5872215
GENERAL INFORMATION:
APPLICANT: Osbourn, JK
APPLICANT: Allen, DJ
TITLE OF INVENTION: Specific binding members, materials and
TITLE OF INVENTION: methods.
NUMBER OF SEQUENCES: 53
CORRESPONDENCE ADDRESSES:
ADDRESS: Marshall, O'Toole, Gerstein, Murray & Borun
STREET: 6300 Sears Tower, 233 South Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: United States of America
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/652,816A
FILING DATE: 23-MAY-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9125579.4
FILING DATE: 02-DEC-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9125579.8
FILING DATE: 02-DEC-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9206318.9
FILING DATE: 24-MAR-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9206372.6
FILING DATE: 23-SEP-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9525004.9
FILING DATE: 07-DEC-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9610824.6
FILING DATE: 23-MAY-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/GB92/02240
FILING DATE: 02-DEC-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/244,597
FILING DATE: 01-JUN-1994
ATTORNEY/AGENT INFORMATION:

NAME: David W. Clough
REGISTRATION NUMBER: 36,107
REFERENCE/DOCKET NUMBER: 28111/33308
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312-474-6300
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 123 amino acids
TYPE: amino acid.
TOPOLOGY: linear
US-08-652-816A-8

Query Match 74.7%; Score 479; DB 2; Length 123;
Best Local Similarity 75.6%; Pred. No. 3.5e-43;
Matches 93; Conservative 10; Mismatches 20; Indels 0; Gaps 0;

QY 1 QVQLQSGAEVYKPPSSVRSVSCASGTFNNNAINWVROAPGQGLEWVGIIIPMGRTAKY 60
DB 1 QVQLVQSGAEVYKPPSSVRSVSCASGTFNSPIWMLRQAPGQGLEWVGIIIPSGTANY 60
61 SQNFQGRAVITADESTGTASMELSLRSEDTAVYYCAHSRDLLFPFHALLSPWGRGTWY 120
DB 61 AQKFGRLITTADESTGTASMELSLRSEDTAVYYCAHNNHNYELYYMDVWGQGTWY 120
QY 121 VSS 123
DB 121 VSS 123

RESULT 2
US-08-652-816A-1
Sequence 1, Application US/08652816A
Patent No. 5872215

GENERAL INFORMATION:

APPLICANT: Oebourn, JK
APPLICANT: Allen, DJ
APPLICANT: McCafferty, JG
TITLE OF INVENTION: Specific binding members, materials and
TITLE OF INVENTION: methods.
NUMBER OF SEQUENCES: 53
CORRESPONDENCE ADDRESS:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
STREET: 6300 Sears Tower, 233 South Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: United States of America

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25 (EPO)

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/652, 816A
FILING DATE: 23-MAY-1996

PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9125579.4
FILING DATE: 02-DEC-1991

PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9125579.8
FILING DATE: 02-DEC-1991

PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9206318.9
FILING DATE: 24-MAR-1992

PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9206372.6
FILING DATE: 23-SEP-1992

PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9525004.9
FILING DATE: 07-DEC-1995

PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9610824.6
FILING DATE: 23-MAY-1996

PRIOR APPLICATION DATA:

APPLICATION NUMBER: PCT/GB92/02240
FILING DATE: 02-DEC-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/244,597
FILING DATE: 01-JUN-1994
ATTORNEY/AGENT INFORMATION:
NAME: David W. Clough
REGISTRATION NUMBER: 36,107
REFERENCE/DOCKET NUMBER: 28111/33308
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312-474-6300
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 123 amino acids
TYPE: amino acid
TOPOLOGY: linear
US-08-652-816A-1

Query Match 74.6%; Score 478; DB 2; Length 123;
Best Local Similarity 76.6%; Pred. No. 4.5e-43;
Matches 95; Conservative 12; Mismatches 15; Indels 2; Gaps 2;

QY 1 QVQLQSGAEVYKPPSSVRSVSCASGTFNNNAINWVROAPGQGLEWVGIIIPMGRTAKY 60
DB 1 QVQLVQSGAEVYKPPSSVRSVSCASGTFNSPIWMLRQAPGQGLEWVGIIIPSGTANY 60
61 SQNFQGRAVITADESTGTASMELSLRSEDTAVYYCAHSRDLLFPFHALLSPWGRGTWY 119
QY 61 AQKFGRLITTADESTGTASMELSLRSEDTAVYYCAHNNHNYELYYMDVWGQGTWY 119
DB 61 AQKFGRLITTADESTGTASMELSLRSEDTAVYYCAHNNHNYELYYMDVWGQGTWY 119
QY 120 TVSS 123
DB 120 TVSS 123

RESULT 3
US-08-652-816A-9
Sequence 9, Application US/08652816A
Patent No. 5872215

GENERAL INFORMATION:

APPLICANT: Oebourn, JK
APPLICANT: Allen, DJ
APPLICANT: McCafferty, JG
TITLE OF INVENTION: Specific binding members, materials and
TITLE OF INVENTION: methods.
NUMBER OF SEQUENCES: 53
CORRESPONDENCE ADDRESS:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
STREET: 6300 Sears Tower, 233 South Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: United States of America

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25 (EPO)

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/652, 816A
FILING DATE: 23-MAY-1996

PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9125579.4
FILING DATE: 02-DEC-1991

PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9125579.8
FILING DATE: 02-DEC-1991

PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9206318.9
FILING DATE: 24-MAR-1992

PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9206372.6
FILING DATE: 23-SEP-1992

PRIOR APPLICATION DATA:

```

? APPLICATION NUMBER: GB 9525004.9
? FILING DATE: 07-DEC-1995
? PRIOR APPLICATION DATA:
? APPLICATION NUMBER: GB 9610824.6
? FILING DATE: 23-MAY-1996
? PRIOR APPLICATION DATA:
? APPLICATION NUMBER: PCT/GB92/02240
? FILING DATE: 02-DEC-1992
? PRIOR APPLICATION DATA:
? APPLICATION NUMBER: US 08/244,597
? FILING DATE: 01-JUN-1994
? ATTORNEY/AGENT INFORMATION:
? NAME: David W. Clough
? REGISTRATION NUMBER: 36,107
? REFERENCE/DOCKET NUMBER: 2811/33308
? TELECOMMUNICATION INFORMATION:
? TELEPHONE: 312-474-6300
? INFORMATION FOR SEQ ID NO: 9:
? SEQUENCE CHARACTERISTICS:
? LENGTH: 123 amino acids
? TYPE: amino acid
? TOPOLOGY: linear
?
US-08-652-816A-9

```

```

: NAME: James F. Haley, Jr., Esq.
:
: REGISTRATION NUMBER: 27,794
: REFERENCE/DOCKET NUMBER: MORPHO/5
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: (212)596-9000
: TELEFAX: (212)596-9090
: INFORMATION FOR SEQ ID NO: 35:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 120 amino acids
: TYPE: amino acid
: STRANDEDNESS:
: TOPOLOGY: linear
: MOLECULE TYPE: protein
:
US-09-025-769B-35

```

TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-09-025-769B-57

Query Match 74.2%; Score 475.5; DB 4; Length 120;
Best Local Similarity 77.4%; Pred. No. 8e-43; Indels 5; Gaps 2;
Matches 96; Conservative 10; Mismatches 13

QY 1 QVQLQSGAEVKKPGSSVRYSCKASGCTFNNAINVWROAPQGLPMWGIIIPMGTA
Db 1 QVQLVQSGAEVKKPGSSVRYSCKASGCTFSSYALISWVROAPQGLPMWGIIIPMGTA
60

QY 61 SQNFGKVAITADESTGTASMEISLRSEDTAVYYCAR-SRDLLFPNHALSPMGRTM
Db 61 AQKFGKVAITADESTGTASMEISLRSEDTAVYYCARWGD---GFYANDYWGQGLT
116

QY 120 TVSS 123
Db 117 TVSS 120

RESULT 6
US-09-025-769B-21

Sequence 21, Application US/09025769B

Patent No. 6300064

GENERAL INFORMATION:

APPLICANT: Knappik, Achim

APPLICANT: Pack, Peter

APPLICANT: Ilag, Vic

APPLICANT: Ge, Liming

APPLICANT: Moroney, Simon

APPLICANT: Pluckethum, Andreas

TITLE OF INVENTION: Protein/(Poly)peptide libraries

NUMBER OF SEQUENCES: 373

CORRESPONDENCE ADDRESS:

ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave

STREET: 1251 Avenue of the Americas

CITY: New York

STATE: New York

COUNTRY: USA

ZIP: 10021

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patent Release #1.0, Version #1.30 (EPO)

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/025,769B

FILING DATE: 18-FEB-1998

PRIOR APPLICATION DATA:

APPLICATION NUMBER: EP 95 11 3021.0

FILING DATE: 18-AUG-1995

ATTORNEY/AGENT INFORMATION:

NAME: James F. Haley, Jr., Esq.

REGISTRATION NUMBER: 27,794

REFERENCE/DOCKET NUMBER: MORPHO/5

TELECOMMUNICATION INFORMATION:

TELEPHONE: (212)596-9000

TELEFAX: (212)596-9090

INFORMATION FOR SEQ ID NO: 21:

SEQUENCE CHARACTERISTICS:

LENGTH: 119 amino acids

TYPE: amino acid

STRANDEDNESS:

TOPOLOGY: linear

MOLECULE TYPE: protein

US-09-025-769B-21

Query Match 73.8%; Score 473; DB 4; Length 119;

Best Local Similarity 76.0%; Pred. No. 1.4e-42;

Matches 95; Conservative 10; Mismatches 12; Indels 8; Gaps 2;

QY 1 QVQLQSGAEVKKPGSSVRYSCKASGCTFNNAINVWROAPQGLPMWGIIIPMGTA
Db 1 QVQLVQSGAEVKKPGSSVRYSCKASGCTFSSYALISWVROAPQGLPMWGIIIPMGTA
60

QY 61 SQNFGKVAITADESTGTASMEISLRSEDTAVYYCAR-SRDLLFPNHALSPMGRTM
Db 61 AQKFGKVAITADESTGTASMEISLRSEDTAVYYCARA-----DGYCSGFDYWGQGLT
114

QY 119 TVSS 123
Db 115 TVSS 119

RESULT 7
US-08-652-816A-6
Sequence 6, Application US/08652816A

Patent No. 5872215

GENERAL INFORMATION:

APPLICANT: Osbourn, JK

APPLICANT: Allen, DJ

APPLICANT: McCafferty, JG

TITLE OF INVENTION: Specific binding members, materials and

NUMBER OF SEQUENCES: 53

CORRESPONDENCE ADDRESS:

ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun

STREET: 6300 Sears Tower, 233 South Wacker Drive

CITY: Chicago

STATE: Illinois

COUNTRY: United States of America

ZIP: 60606

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patent Release #1.0, Version #1.25 (EPO)

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/652,816A

FILING DATE: 23-MAY-1996

PRIOR APPLICATION DATA:

APPLICATION NUMBER: GB 9125579.4

FILING DATE: 02-DEC-1991

PRIOR APPLICATION DATA:

APPLICATION NUMBER: GB 9125579.8

FILING DATE: 02-DEC-1991

PRIOR APPLICATION DATA:

APPLICATION NUMBER: GB 9206318.9

FILING DATE: 24-MAR-1992

PRIOR APPLICATION DATA:

APPLICATION NUMBER: GB 9206372.6

FILING DATE: 23-SEP-1992

PRIOR APPLICATION DATA:

APPLICATION NUMBER: GB 9525004.9

FILING DATE: 07-DEC-1995

PRIOR APPLICATION DATA:

APPLICATION NUMBER: GB 9610824.6

FILING DATE: 23-MAY-1996

PRIOR APPLICATION DATA:

APPLICATION NUMBER: PCT/GB92/02240

FILING DATE: 02-DEC-1992

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/244,597

FILING DATE: 01-JUN-1994

ATTORNEY/AGENT INFORMATION:

NAME: David W. Clough

REGISTRATION NUMBER: 36,107

REFERENCE/DOCKET NUMBER: 28111/33308

TELECOMMUNICATION INFORMATION:

TELEPHONE: 312-474-6300

INFORMATION FOR SEQ ID NO: 6:

SEQUENCE CHARACTERISTICS:

LENGTH: 123 amino acids

TYPE: amino acid

TOPOLOGY: linear

US-08-652-816A-6

Query Match 73.5%; Score 471; DB 2; Length 123;
Best Local Similarity 74.8%; Pred. No. 2.4e-42;
Matches 92; Conservative 10; Mismatches 21; Indels 0; Gaps 0;

Qy 1 QVQLQSGAEVKKPKSSVSVSCASGCTFNNNAIMWVQAQPGGLEMMGGIIPMGTAKY 60
Db 1 QVQLVQSGAEVKKPKSSVSVSCASGCTFNSPIWMLQAQPGGLEMMGGIIPSGTANY 60
Qy 61 SQNFGRAVITADESTGTASWELSLRSEDPTAVVYCAASRDLLFPFHALLSPWGRGTWVT 120
Db 61 AQRFGRLITADESTGTASWELSLRSEDPTAVVYCAACSHNYELYYVMDVWGQGTWVT 120
Qy 121 VSS 123
Db 121 VSS 123

US-08-378-939-10

Sequence 10, Application US/08378939
Patent No. 5876361

GENERAL INFORMATION:
APPLICANT: CROME, JAMES SCOTT
APPLICANT: LEWIS, ALAN PETER
TITLE OF INVENTION: PRODUCTION OF ANTIBODIES
NUMBER OF SEQUENCES: 46
CORRESPONDENCE ADDRESS:
ADDRESSEE: ROTHWELL, FIGG, ERNST & KURZ
STREET: 555 THIRTEENTH ST. N.W.
CITY: WASHINGTON
STATE: D. C.
COUNTRY: U.S.
ZIP: 20004
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/378,939
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/952640
FILING DATE: 01-DEC-1992
ATTORNEY/AGENT INFORMATION:
NAME: ERNST, BARBARA G
REGISTRATION NUMBER: 30,377
REFERENCE/DOCKET NUMBER: 1808-118
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 783-6040
TELEFAX: (202) 783-6031
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 476 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-378-939-10

Query Match 73.0%; Score 468; DB 2; Length 476;
Best Local Similarity 74.0%; Pred. No. 2.5e-41;
Matches 94; Conservative 9; Mismatches 20; Indels 4; Gaps 1;
Qy 1 QVQLQSGAEVKKPKSSVSVSCASGCTFNNNAIMWVQAQPGGLEMMGGIIPMGTAKY 60
Db 20 QMVGQSAEYKPKSSVSVSCASGCTFNSVIAISWVQAQPGGLEMMGGIIPMGTAKY 79
Qy 61 SQNFGRAVITADESTGTASWELSLRSEDPTAVVYCAASRDLLFPFHALLSPWGRG 116
Db 80 SQNFGRAVITADESTGTASWELSLRSEDPTAVVYCATDRYRQANFDRARVGMFPMGQG 139

Qy 117 TMVTSS 123
Db 140 TLVTSS 146

RESULT 9

US-08-652-816A-7
Sequence 7, Application US/08652816A
Patent No. 5872215

GENERAL INFORMATION:
APPLICANT: Osbourn, JK
APPLICANT: Allen, DJ
APPLICANT: McCafferty, JG
TITLE OF INVENTION: Specific binding members, materials and
TITLE OF INVENTION: methods.
NUMBER OF SEQUENCES: 53
CORRESPONDENCE ADDRESS:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
STREET: 6300 Sears Tower, 233 South Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: United States of America
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25 (ERO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/652,816A
FILING DATE: 23-MAY-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9125579.4
FILING DATE: 02-DEC-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9125579.8
FILING DATE: 02-DEC-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9206318.9
FILING DATE: 24-MAR-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9206372.6
FILING DATE: 23-SEP-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9525004.9
FILING DATE: 07-DEC-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9610824.6
FILING DATE: 23-MAY-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/GB92/02240
FILING DATE: 02-DEC-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/244,597
FILING DATE: 01-JUN-1994
ATTORNEY/AGENT INFORMATION:
NAME: David W. Clough
REGISTRATION NUMBER: 36,107
REFERENCE/DOCKET NUMBER: 28111/33308
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312-474-6300
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 123 amino acids
TYPE: amino acid
TOPOLOGY: linear
US-08-652-816A-7

Query Match 71.8%; Score 460; DB 2; Length 123;
Best Local Similarity 74.0%; Pred. No. 3.5e-41;
Matches 91; Conservative 11; Mismatches 21; Indels 0; Gaps 0;
Qy 1 QVQLQSGAEVKKPKSSVSVSCASGCTFNNNAIMWVQAQPGGLEMMGGIIPMGTAKY 60

Db 1 QVOVQSGAEVKKPSSSVKSCASGTFSSPINWLRQAPQGLEMMGIIIPFSTGTANY 60
QY 61 SONFGRAVTAIDESTGTASMEISLRSEDTAVYYCARSDLLFPFHALLSPWGRGTANY 120
Db 61 AKQFGRLTTIDESTGTASMEISLRSEDTAVYYCAGANSCNNSYYVMVRRGGTMT 120
QY 121 VSS 123
Db 121 VSS 123

RESULT 10
US-08-428-197-12
Sequence 12, Application US/08428197
Patent No. 5891438

GENERAL INFORMATION:
APPLICANT: SILVERMAN, GREGG J.
TITLE OF INVENTION: METHOD FOR STIMULATING PRODUCTION OF
TITLE OF INVENTION: VARIABLE REGION GENE FAMILY RESTRICTED ANTIBODIES THROUGH
TITLE OF INVENTION: VACCINATION WITH A B-CELL SUPERANTIGEN AND CONJUGATES
TITLE OF INVENTION: THEREOF
NUMBER OF SEQUENCES: 51
CORRESPONDENCE ADDRESS:
ADDRESSEE: Spensley Horn Jubas & Lubitz.
STREET: 1880 Century Park East - Suite 500
CITY: Los Angeles
STATE: California
COUNTRY: USA
ZIP: 90067

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/428,197

FILING DATE:

CLASSIFICATION:
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: PCT/US93/10555
FILING DATE: 29-OCT-1993

ATTORNEY/AGENT INFORMATION:

NAME: Howells, Stacy L.

REGISTRATION NUMBER: 34,842

REFERENCE/DOCKET NUMBER: FD-2630

TELECOMMUNICATION INFORMATION:

TELEPHONE: (619) 455-5100

TELEFAX: (619) 455-5110

INFORMATION FOR SEQ ID NO: 12:

SEQUENCE CHARACTERISTICS:

LENGTH: 120 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: peptide

IMMEDIATE SOURCE:

CLONE: BOR

FEATURE:

NAME/KEY: Peptide

LOCATION: 1..120

US-08-428-197-12

Query Match

Best Local Similarity 70.4%; Score 451; DB 2; Length 120;

Matches 89; Conservative 15; Mismatches 13; Indels 8; Gaps 2;

QY 2 VOLQSGAEVKKPSSSVKSCASGTFNNNAIINWVQAPQGLEMMGIIIPMGFTAKYS 61
Db 1 VOLVQSGAEVKKPSSSVKTCASGDTFSSSAISWVQAPQGLEMMGIIIPFGTPNYA 60
QY 62 QNFQGRAVTAIDESTGTASMEISLRSEDTAVYYCARSDLLFPFHALLSP---WGRGTM 118
Db 62 QNFQGRAVTAIDESTGTASMEISLRSEDTAVYYCARSDLLFPFHALLSP---WGRGTM 118

Db 61 QNFQGRAVTAIDESTGTASMEISLRSEDTALYYCAREGRM-----AINPFDYWGQCTL 115
QY 119 VTWSS 123
Db 116 VTWSS 120

RESULT 11
PCT-US93-10555-12
Sequence 12, Application PC/TUS9310555

GENERAL INFORMATION:
APPLICANT: SILVERMAN, GREGG J.
TITLE OF INVENTION: METHOD FOR STIMULATING PRODUCTION OF
TITLE OF INVENTION: VARIABLE REGION GENE FAMILY RESTRICTED ANTIBODIES THROUGH
TITLE OF INVENTION: VACCINATION WITH A B-CELL SUPERANTIGEN AND CONJUGATES
TITLE OF INVENTION: THEREOF
NUMBER OF SEQUENCES: 51
CORRESPONDENCE ADDRESS:
ADDRESSEE: Spensley Horn Jubas & Lubitz
STREET: 1880 Century Park East - Suite 500
CITY: Los Angeles
STATE: California
COUNTRY: USA
ZIP: 90067

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US93/10555
FILING DATE: 29-OCT-1993

CLASSIFICATION:

ATTORNEY/AGENT INFORMATION:

NAME: Howells, Stacy L.

REGISTRATION NUMBER: 34,842

REFERENCE/DOCKET NUMBER: FD-2630

TELECOMMUNICATION INFORMATION:

TELEPHONE: (619) 455-5100

TELEFAX: (619) 455-5110

INFORMATION FOR SEQ ID NO: 12:

SEQUENCE CHARACTERISTICS:

LENGTH: 120 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: peptide

IMMEDIATE SOURCE:

CLONE: BOR

FEATURE:

NAME/KEY: Peptide

LOCATION: 1..120

PCT-US93-10555-12

Query Match

Best Local Similarity 70.4%; Score 451; DB 5; Length 120;

Matches 89; Conservative 15; Mismatches 13; Indels 8; Gaps 2;

QY 2 VOLQSGAEVKKPSSSVKSCASGTFNNNAIINWVQAPQGLEMMGIIIPMGFTAKYS 61
Db 1 VOLVQSGAEVKKPSSSVKTCASGDTFSSSAISWVQAPQGLEMMGIIIPFGTPNYA 60
QY 62 QNFQGRAVTAIDESTGTASMEISLRSEDTAVYYCARSDLLFPFHALLSP---WGRGTM 118
Db 62 QNFQGRAVTAIDESTGTASMEISLRSEDTALYYCAREGRM-----AINPFDYWGQCTL 115

QY 119 VTWSS 123
Db 116 VTWSS 120

RESULT 12
US-08-983-607-50

* Sequence 50, Application US/08983607
Patent No. 6140470
GENERAL INFORMATION:
APPLICANT: Alan Garten
TITLE OF INVENTION: Human Anti-Tumor Monoclonal Anti-
TITLE OP INVENTION: bottles
NUMBER OF SEQUENCES: 51
CORRESPONDENCE ADDRESS:
ADDRESSEE: Department of Molecular Biophysics
and Biochemistry, Yale University
STREET: 266 Whitney Avenue
CITY: New Haven
STATE: Connecticut
COUNTRY: United States of America
ZIP: 06520-8114
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" 1.44 Mb diskette
COMPUTER: IBM PC
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Processing
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/983, 607
FILING DATE: April 27, 1998
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/IB96/01032
FILING DATE: June 28, 1996
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Mary M. Krinsky
REGISTRATION NUMBER: 32423
REFERENCE/DOCKET NUMBER: OCR-679
TELECOMMUNICATION INFORMATION:
TELEPHONE: 203-773-9544
TELEFAX: 203-773-1183
INFORMATION FOR SEQ ID NO: 50:
SEQUENCE CHARACTERISTICS:
LENGTH: 119 residues
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE:
DESCRIPTION: polypeptide
ORIGINAL SOURCE:
ORGANISM: Homo sapiens (melanoma patient
ORGANISM: immunized with autologous tumor cells)
INDIVIDUAL ISOLATE: peripheral blood lympho-
INDIVIDUAL ISOLATE: cytes
IMMEDIATE SOURCE:
LIBRARY: VH antibodies obtained from FUSES
LIBRARY: fusion phage construct
CLONE: 2-71
FEATURE:
NAME/KEY: heavy chain

IS-08-983-607-50

	Query March	69.1%; Score 443; DB 3;	Length 119;
	Best Local Similarity	75.0%; Pred. No. 2.1e-39;	
	Matches	87; Conservative	10; Mismatches 15; Indels 4; Gaps 1;
OY	8 GAETKKPSSSVRVCCKASGTFENNAIIVBQAPQGLEMGGITPMFGTAKYSNPFGR	67	
	: : : :		
Dd	8 GLEVKKPSRSKVSCSKASGGTFSSAISWVQAPQGLEMMGGIIPITGTANYAQKFGR	67	
OY	68 VAITADESTGASMELSLRSEDPFAVVYCARSRDLLPPHHALSPMGRTWTYSS	123	
	: : : :		
Dd	68 VTITADKSTAYIMELSLRSEDPAVVIYCAARGC---RYDAFDIMVGGLVTYSS	119	

RESULT 13
US-08-232-081B-41
Sequence 41, Application US/08232081B

```

1 Patent No. 5986152
2 GENERAL INFORMATION:
3 APPLICANT: NAKAFANI, TOMOYUKI
4 APPLICANT: GOMI, HIDEYUKI
5 APPLICANT: WIDENES, JOHN
6 APPLICANT: NOGUCHI, HIROSHI
7 TITLE OF INVENTION: HUMANIZED B-B10
8 NUMBER OF SEQUENCES: 42
9 CORRESPONDENCE ADDRESS:
10 ADDRESSEE: BIRCH, STEWART, KOLASCH AND BIRCH
11 STREET: PO BOX 747
12 CITY: FALLS CHURCH
13 STATE: VA
14 COUNTRY: USA
15 ZIP: 22040-0747
16 COMPUTER READABLE FORM:
17 MEDIUM TYPE: Floppy disk
18 COMPUTER: IBM PC compatible
19 OPERATING SYSTEM: PC-DOS/MS-DOS
20 SOFTWARE: Patent'n Release #1.0, Version #1.30
21 CURRENT APPLICATION DATA:
22 APPLICATION NUMBER: US/08/232,081B
23 FILING DATE:
24 CLASSIFICATION: 424
25 ATTORNEY/AGENT INFORMATION:
26 NAME: SVENSSON, LEONARD R
27 REGISTRATION NUMBER: 30,330
28 REFERENCE/DOCKET NUMBER: 20-3484
29 TELECOMMUNICATION INFORMATION:
30 TELEPHONE: (703) 205-8000
31 TELEFAX: (703) 205-8050
32 INFORMATION FOR SEQ ID NO: 41:
33 SEQUENCE CHARACTERISTICS:
34 LENGTH: 121 amino acids
35 TYPE: amino acid
36 STRANDEDNESS: not relevant
37 TOPOLOGY: linear
38 MOLECULE TYPE: peptide
39
40 US-08-232-081B-41

```

```

Query Match          68.6%; Score 440; DB 2; Length 121;
Best Local Similarity 67.9%; Pred. No. 4,38-39;
Matches 89; Conservative 11; Mismatches 13; Indels 18; Gaps 2.

QY      1 QVQLQSGAEVKKPGSSSVRVSCAKSGGTENNNAINWVROAPQGLGEMWGIIIPMFSTAKY 60
          |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db      1 EHLVQSGAEVKKPGSSSVRVSCAKSGGTFSSTYAIASWROAPQGLGEMWGIIIPFGQANY 60
          |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY      61 SGNFGVATITADSTGTASMETLSLSEPTAVVYCA-----RSNDLLFLPHHALSP 112
          :|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db      61 AQKQGVATITADSTGTATNATWELSLSDDTAMVYCAKEGYDYGRPDF----- 110
          |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY      113 WGRGTWTVSS 123
          ||:|||||:|||||
Db      111 WQGTTLVTVSS 121
          |||:|||||:|||||

RESULT 14
US-08-217-918-4
: Sequence 4, Application US/08217918
: Patent No. 5506132
: GENERAL INFORMATION:
: APPLICANT: LAKE, PHILIP
: APPLICANT: OSTBERG, LARS
: TITLE OF INVENTION: HUMAN ANTIBODIES AGAINST
: TITLE OF INVENTION: VARICELLA-ZOSTER VIRUS
: NUMBER OF SEQUENCES: 4
: CORRESPONDENCE ADDRESS:
: ADDRESSEE: Townsend and Townsend Khourie and Crew
: STREET: 379 Townson Avenue
: CITY: Palo Alto
: STATE: California
: COUNTRY: US

```

ZIP: 94301
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/217,918
FILING DATE: 24-MAR-1994
CLASSIFICATION: 530
ATTORNEY/AGENT INFORMATION:
NAME: Smith, William M
REGISTRATION NUMBER: 30,223
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 326-2400
TELEFAX: (415) 326-2422
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 147 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-217-918-4

Query Match 68.6% Score 439.5; DB 1; Length 147;
Best Local Similarity 68.7%; Pred No. 6,2e-39;
Matches 90; Conservative 13; Mismatches 17; Indels 11; Gaps 2;

QY 1 QVLOQSGAEVKKPSSSVKSCASGTFNNNAIMVROAPQGLEMMGGIIPMEGTAKY 60
DB 20 QVLOVSGAEVKKPSSSVKSCASGTFNNNAIMVROAPQGLEMMGGIIPMEGTAKY 79
QY 61 SQNFGRAVITDESTGTASMLSLRSEDITAVYICASRDLLFPFHALLSPW 112
DB 80 AQKFGGRVITASADASTAYMELSLRSDITAMYYCAARD--ITAPGAAPFLNFGMDV 136
QY 113 WGRGTMTVYSS 123
DB 137 WGGITTVYSS 147

RESULT 15
US-08-428-197-13
Sequence 13, Application US/08428197
Patent No. 5691438
GENERAL INFORMATION:
APPLICANT: SILVERMAN, GREGG J.
TITLE OF INVENTION: METHOD FOR STIMULATING PRODUCTION OF
TITLE OF INVENTION: VARIABLE REGION GENE FAMILY RESTRICTED ANTIBODIES THROUGH
TITLE OF INVENTION: VACCINATION WITH A B-CELL SUPERNATIGEN AND CONJUGATES
TITLE OF INVENTION: THEREOF
NUMBER OF SEQUENCES: 51
CORRESPONDENCE ADDRESS:
ADDRESSEE: Spensley Horn Jubas & Lubitz
STREET: 1880 Century Park East - Suite 500
CITY: Los Angeles
STATE: California
COUNTRY: USA
ZIP: 90067
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/428,197
FILING DATE: 29-OCT-1993
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US93/10555
FILING DATE: 29-OCT-1993
ATTORNEY/AGENT INFORMATION:
NAME: Howells, Stacy L.

REGISTRATION NUMBER: 34,842
REFERENCE/DOCKET NUMBER: FD-2630
TELECOMMUNICATION INFORMATION:
TELEPHONE: (619) 455-5100
TELEFAX: (619) 455-5110
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 120 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
IMMEDIATE SOURCE:
CLONE: KAS
FEATURE:
NAME/KEY: Peptide
LOCATION: 1..120
US-08-428-197-13

Query Match 68.3% Score 438; DB 2; Length 120;
Best Local Similarity 68.5%; Pred. No. 7e-39;
Matches 89; Conservative 10; Mismatches 13; Indels 18; Gaps 2;

QY 2 VLOQSGAEVKKPSSSVKSCASGTFNNNAIMVROAPQGLEMMGGIIPMEGTAKYS 61
DB 1 VHLVSGAEVKKPSSSVKSCASGTFNNNAIMVROAPQGLEMMGGIIPMEGTAKYS 60
QY 62 QNFGRAVITDESTGTASMLSLRSEDITAVYICASRDLLFPFHALLSPW 113
DB 61 QKFGGRVITDESTGTASMLSLRSEDITAMYYCAARD--ITAPGAAPFLNFGMDV 110
QY 114 WGRGTMTVYSS 123
DB 111 WGGITTVYSS 120

RESULT 16
PCT-US93-10555-13
Sequence 13, Application PC/TUS9310555
GENERAL INFORMATION:
APPLICANT: SILVERMAN, GREGG J.
TITLE OF INVENTION: METHOD FOR STIMULATING PRODUCTION OF
TITLE OF INVENTION: VARIABLE REGION GENE FAMILY RESTRICTED ANTIBODIES THROUGH
TITLE OF INVENTION: VACCINATION WITH A B-CELL SUPERNATIGEN AND CONJUGATES
TITLE OF INVENTION: THEREOF
NUMBER OF SEQUENCES: 51
CORRESPONDENCE ADDRESS:
ADDRESSEE: Spensley Horn Jubas & Lubitz
STREET: 1880 Century Park East - Suite 500
CITY: Los Angeles
STATE: California
COUNTRY: USA
ZIP: 90067
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US93/10555
FILING DATE: 29-OCT-1993
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Howells, Stacy L.
REGISTRATION NUMBER: 34,842
REFERENCE/DOCKET NUMBER: FD-2630
TELECOMMUNICATION INFORMATION:
TELEPHONE: (619) 455-5100
TELEFAX: (619) 455-5110
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 120 amino acids
TYPE: amino acid

STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
IMMEDIATE SOURCE:
CLONE: KAS
FEATURE:
NAME/KEY: Peptide
LOCATION: 1..120
PCT-US93-10555-13

Query Match 68.3%; Score 438; DB 5; Length 120;
Best Local Similarity 68.5%; Pred. No. 7e-39;
Matches 89; Conservative 10; Mismatches 13; Indels 18; Gaps 2;

Qy 2 VOLQSGAEVKKPGSSVRVSCASGCTFNNNAIMNWRAPGQGLEMMGGIIPMGFTAKS 61
Db 1 VHLVSGAEVKKPGSSVRVSCASGCTFSSVYAIISWVROAPGQGLEMMGGIIPGQANYA 60
Qy 62 QNFGQVAITADESTGTASMEISSLRSBDTAVYYCA-----RSRDLLFPNHALSPW 113
61 QKFGQVITADESTGTAVMEISSLRSDDTAVYYCAKEGYPGPFDP-----W 110
Qy 114 GRGTVTVSS 123
Db 111 GQGLTVTVSS 120

RESULT 17

US-08-635-109-3
Sequence 3, Application US/08635109
Patent No. 6538114
GENERAL INFORMATION:
APPLICANT: Persson, Mats A. A.
TITLE OF INVENTION: HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR
TITLE OF INVENTION: HEPATITIS C VIRUS (HCV) E2 ANTIGEN
NUMBER OF SEQUENCES: 23
CORRESPONDENCE ADDRESS:
ADDRESSEE: REED & ROBINS
STREET: 285 Hamilton Avenue, Suite 200
CITY: Palo Alto
STATE: California
COUNTRY: USA
ZIP: 94301
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/635,109
FILING DATE: 19-APR-1996
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: McCracken, Thomas P
REGISTRATION NUMBER: 38,548
REFERENCE/DOCKET NUMBER: 2300-6146
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 327-3400
TELEFAX: (415) 327-3331
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 128 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-635-109-3

Query Match 65.9%; Score 422.5; DB 4; Length 128;
Best Local Similarity 66.7%; Pred. No. 3.2e-37;
Matches 86; Conservative 14; Mismatches 22; Indels 7; Gaps 3;

Qy 1 QVQ-LQSGAEVKKPGSSVRVSCASGCTFNNNAIMNWRAPGQGLEMMGGIIPMGFTAK 59
Db 1 EVQLLEGGAEVKKPGSSVRVSCASGCTFGGVYISWVROAPGQGLEMMGGISIFGTSN 60
Qy 60 YSQNFGQVAITADESTGTASMEISSLRSBDTAVYYCAKRSDDL-----LFPNHALSPW 114
Db 61 SAQKFGQVSIITADESTAVMEISSLRSBDTAVYYCAKDPDFRCGNGCYPGF-FQQWG 119
Qy 115 RGTMTVTVSS 123
Db 120 QGTLTVTVSS 128

RESULT 18

US-07-634-278-4
Sequence 4, Application US/07634278
Patent No. 5530101
GENERAL INFORMATION:
APPLICANT: QUEEN, Cary L.
APPLICANT: CO, Man Sung
APPLICANT: SCHNEIDER, William P.
APPLICANT: LANDOLFI, Nicholas F.
APPLICANT: COELINGH, Kathleen L.
APPLICANT: SELICK, Harold E.
TITLE OF INVENTION: IMPROVED HUMANIZED IMMUNOGLOBULINS
NUMBER OF SEQUENCES: 113
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend Kourie and Crew
STREET: 379 Lytton Avenue
CITY: Palo Alto
STATE: California
COUNTRY: US
ZIP: 94301
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/634,278
FILING DATE: 19-DEC-1990
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/590,274
FILING DATE: 28-SEP-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/310,252
FILING DATE: 13-FEB-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/290,975
FILING DATE: 28-DEC-1988
ATTORNEY/AGENT INFORMATION:
NAME: Smith, William M
REGISTRATION NUMBER: 30,223
REFERENCE/DOCKET NUMBER: 11823-002600
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 326-2400
TELEFAX: (415) 326-2422
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 117 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: unknown
MOLECULE TYPE: protein
HYPOTHEICAL: NO
FEATURE:
NAME/KEY: Protein
LOCATION: 1..117
OTHER INFORMATION: /note= "Variable region of the human
OTHER INFORMATION: Eu antibody heavy chain."
US-07-634-278-4

Query Match 65.7%; Score 421; DB 1; Length 117;
Best Local Similarity 71.0%; Pred. No. 4.2e-37;
Matches 88; Conservative 8; Mismatches 20; Indels 8; Gaps 2;

QY 1 QVQLQSGAEVKKPKSSVRVSCKASGTFENNAINWVROAPQGLGEMWGIIIPMGFTAKY 60
Db 1 QVQLVQSGAEVKKPKSSVRVSCKASGTFERSALITWVROAPQGLGEMWGIIIPMGFPNY 60
QY 61 SQNFGRAVITADESTGTASMELSLSRSEDPAVYVCARSRLLLFPHHALSPWG-RGTMV 119
Db 61 AQKFGQRTITADESTNTAYMELSLRSRSDTAFFCAAG-----YGIYSPEEYNGGLV 113
QY 120 TVSS 123
Db 114 TVSS 117

RESULT 19

US-07-634-278-15
Sequence 15, Application US/07634278
Patent No. 5530101

GENERAL INFORMATION:

APPLICANT: QUEEN, Cary L.
APPLICANT: CO, Man Sung
APPLICANT: SCHNEIDER, William P.
APPLICANT: LANDOLFI, Nicholas F.
APPLICANT: COELINGH, Kathleen L.
APPLICANT: SELICK, Harold E.
TITLE OF INVENTION: IMPROVED HUMANIZED IMMUNOGLOBULINS
NUMBER OF SEQUENCES: 113
CORRESPONDENCE ADDRESS:
ADDRESSER: Townsend and Townsend Kourie and Crew
STREET: 379 Lytton Avenue
CITY: Palo Alto
STATE: California
COUNTRY: US
ZIP: 94301

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/634,278
FILING DATE: 19-DEC-1990
CLASSIFICATION: 424

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/590,274
FILING DATE: 28-SEP-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/310,252
FILING DATE: 13-FEB-1989

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/290,975
FILING DATE: 28-DEC-1988
ATTORNEY/AGENT INFORMATION:

NAME: Smith, William M.

REGISTRATION NUMBER: 30,223

REFERENCE/DOCKET NUMBER: 11823-002600

TELECOMMUNICATION INFORMATION:

TELEPHONE: (415) 326-2400

TELEFAX: (415) 326-2422

INFORMATION FOR SEQ ID NO: 15:

SEQUENCE CHARACTERISTICS:

LENGTH: 117 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: unknown

MOLECULE TYPE: protein

HYPOTHETICAL: NO

FEATURE:

NAME/KEY: Protein

LOCATION: 1..117

OTHER INFORMATION: /note= "Eu heavy chain amino acid
OTHER INFORMATION: sequence."

US-07-634-278-15

Query Match 65.7%; Score 421; DB 1; Length 117;
Best Local Similarity 71.0%; Pred. No. 4.2e-37;
Matches 88; Conservative 8; Mismatches 20; Indels 8; Gaps 2;

QY 1 QVQLQSGAEVKKPKSSVRVSCKASGTFENNAINWVROAPQGLGEMWGIIIPMGFTAKY 60
Db 1 QVQLVQSGAEVKKPKSSVRVSCKASGTFERSALITWVROAPQGLGEMWGIIIPMGFPNY 60
QY 61 SQNFGRAVITADESTGTASMELSLSRSEDPAVYVCARSRLLLFPHHALSPWG-RGTMV 119
Db 61 AQKFGQRTITADESTNTAYMELSLRSRSDTAFFCAAG-----YGIYSPEEYNGGLV 113
QY 120 TVSS 123
Db 114 TVSS 117

RESULT 20

US-07-634-278-72
Sequence 72, Application US/07634278
Patent No. 5530101

GENERAL INFORMATION:

APPLICANT: QUEEN, Cary L.
APPLICANT: CO, Man Sung
APPLICANT: SCHNEIDER, William P.
APPLICANT: LANDOLFI, Nicholas F.
APPLICANT: COELINGH, Kathleen L.
APPLICANT: SELICK, Harold E.
TITLE OF INVENTION: IMPROVED HUMANIZED IMMUNOGLOBULINS
NUMBER OF SEQUENCES: 113
CORRESPONDENCE ADDRESS:
ADDRESSER: Townsend and Townsend Kourie and Crew
STREET: 379 Lytton Avenue
CITY: Palo Alto
STATE: California
COUNTRY: US
ZIP: 94301

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/634,278
FILING DATE: 19-DEC-1990
CLASSIFICATION: 424

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/590,274
FILING DATE: 28-SEP-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/310,252
FILING DATE: 13-FEB-1989

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/290,975
FILING DATE: 28-DEC-1988
ATTORNEY/AGENT INFORMATION:

NAME: Smith, William M.

REGISTRATION NUMBER: 30,223

REFERENCE/DOCKET NUMBER: 11823-002600

TELECOMMUNICATION INFORMATION:

TELEPHONE: (415) 326-2400

TELEFAX: (415) 326-2422

INFORMATION FOR SEQ ID NO: 72:

SEQUENCE CHARACTERISTICS:

LENGTH: 117 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: peptide

US-07-634-278-72

Query Match 65.7%; Score 421; DB 1; Length 117;

Best Local Similarity 71.0%; Pred. No. 4.2e-37;

Matches 88; Conservative 8; Mismatches 20; Indels 8; Gaps 2;

QY 1 QVQLQSGAEVKKPKSSVSRVSCKASGTFNNNAIMWVROAPQGLEMMGGIIPMFETAKY 60
1 QVQLVQSGAEVKKPKSSVSRVSCKASGTFNSAIITWRQAPQGLEMMGGIIPMFETAKY 60
DB 61 SONFGRAVITADESTGTASMLSLRSEDTAVYYCARSDLLFPFHALLSPWG-RGTMV 119
61 AOKFGRTVITADESTNTAYMELSLRSEDTAFYFCAGG-----YGIYSPPEEYNGGLV 113
QY 120 TVSS 123
114 TVSS 117

RESULT 21

Sequence 104, Application US/07634278

Patent No. 5530101

GENERAL INFORMATION:

APPLICANT: QUEEN, Cary L.

APPLICANT: CO, Man Sung

APPLICANT: SCHNEIDER, William P.

APPLICANT: LANDOLFI, Nicholas F.

APPLICANT: COELINGH, Kathleen L.

APPLICANT: SELICK, Harold E.

TITLE OF INVENTION: IMPROVED HUMANIZED IMMUNOGLOBULINS

NUMBER OF SEQUENCES: 113

CORRESPONDENCE ADDRESS:

ADDRESS: Townsend and Townsend Kourie and Crew

STREET: 379 Lytton Avenue

CITY: Palo Alto

STATE: California

COUNTRY: US

ZIP: 94301

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patent Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/07/634,278

FILING DATE: 19-DEC-1990

CLASSIFICATION: 424

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/590,274

FILING DATE: 28-SEP-1990

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/310,252

FILING DATE: 13-FEB-1989

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/290,975

FILING DATE: 28-DEC-1988

ATTORNEY/AGENT INFORMATION:

NAME: Smith, William M

REGISTRATION NUMBER: 30,223

REFERENCE/DOCKET NUMBER: 11823-002600

TELECOMMUNICATION INFORMATION:

TELEPHONE: (415) 326-2400

TELEFAX: (415) 326-2422

INFORMATION FOR SEQ ID NO. 104:

SEQUENCE CHARACTERISTICS:

LENGTH: 117 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: peptide

Query Match 65.7%; Score 421; DB 1; Length 117;

Best Local Similarity 71.0%; Pred. No. 4.2e-37;

Matches 88; Conservative 8; Mismatches 20; Indels 8; Gaps 2;

QY 1 QVQLQSGAEVKKPKSSVSRVSCKASGTFNNNAIMWVROAPQGLEMMGGIIPMFETAKY 60
1 QVQLVQSGAEVKKPKSSVSRVSCKASGTFNSAIITWRQAPQGLEMMGGIIPMFETAKY 60
DB 61 SONFGRAVITADESTGTASMLSLRSEDTAVYYCARSDLLFPFHALLSPWG-RGTMV 119
61 AOKFGRTVITADESTNTAYMELSLRSEDTAFYFCAGG-----YGIYSPPEEYNGGLV 113
QY 120 TVSS 123
114 TVSS 117

RESULT 22

Sequence 4, Application US/08477728

Patent No. 5585089

GENERAL INFORMATION:

APPLICANT: QUEEN, Cary L.

APPLICANT: SCHNEIDER, William P.

APPLICANT: SELICK, Harold E.

TITLE OF INVENTION: IMPROVED HUMANIZED IMMUNOGLOBULINS

NUMBER OF SEQUENCES: 113

CORRESPONDENCE ADDRESS:

ADDRESS: Townsend and Townsend and Crew LLP

STREET: Two Embarcadero Center, 8th floor

CITY: Palo Alto

STATE: California

COUNTRY: US

ZIP: 94111

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patent Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/477,728

FILING DATE: 07-JUN-1995

CLASSIFICATION: 424

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/634,278

FILING DATE: 19-DEC-1990

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/590,274

FILING DATE: 28-SEP-1990

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/310,252

FILING DATE: 13-FEB-1989

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/290,975

FILING DATE: 28-DEC-1988

ATTORNEY/AGENT INFORMATION:

NAME: Smith, William M

REGISTRATION NUMBER: 30,223

REFERENCE/DOCKET NUMBER: 11823-002600

TELECOMMUNICATION INFORMATION:

TELEPHONE: (415) 326-2400

TELEFAX: (415) 326-2422

INFORMATION FOR SEQ ID NO. 4:

SEQUENCE CHARACTERISTICS:

LENGTH: 117 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: unknown

MOLECULE TYPE: protein

HYPOTHETICAL: NO

FEATURE:

NAME/KEY: Protein

LOCATION: 1..117

OTHER INFORMATION: /note="Variable region of the human
OTHER INFORMATION: Eu antibody heavy chain."
US-08-477-728-4

Query Match 65.7%; Score 421; DB 1; Length 117;
Best Local Similarity 71.0%; Pred. No. 4.2e-37;
Matches 88; Conservative 8; Mismatches 20; Indels 8; Gaps 2;

QY 1 QVQLQSGAEVKKPGSSVRVSCKASGCTFNNNAIMVWROAPGQGLEWMGIIIMFGTAKY 60
DB 1 QVQLVQSGAEVKKPGSSVRVSCKASGCTFSSALIMVROAPGQGLEWMGIIIMFGPPNY 60
QY 61 SQNFGRAVITADESTGTASWELSLRSEDTAVYYCARSDLLFPFHALLSPWG-RGTMV 119
DB 61 AOKFGRAVITADESTNTAVWELSLRSEDTAFYFCAG-----YGIYSPSEYNGGLV 113

QY 120 TVSS 123
DB 114 TVSS 117

US-08-477-728-15
Sequence 15, Application US/08477728
Patent No. 5585089
GENERAL INFORMATION:
APPLICANT: QUEEN, Gary L.
APPLICANT: SCHNEIDER, William P.
APPLICANT: SELICK, Harold E.
TITLE OF INVENTION: IMPROVED HUMANIZED IMMUNOGLOBULINS
NUMBER OF SEQUENCES: 113
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, 8th Floor
CITY: Palo Alto
STATE: California
COUNTRY: US
ZIP: 94111
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/477,728
FILING DATE: 07-JUN-1995
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/634,278
FILING DATE: 19-DEC-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/590,274
FILING DATE: 28-SEP-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/310,252
FILING DATE: 13-FEB-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/290,975
FILING DATE: 28-DEC-1988
ATTORNEY/AGENT INFORMATION:
NAME: Smith, William M
REGISTRATION NUMBER: 30,223
REFERENCE/DOCKET NUMBER: 11823-002600
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 326-2400
TELEFAX: (415) 326-2422
INFORMATION FOR SEQ ID NO: 15:
SEQUENCE CHARACTERISTICS:
LENGTH: 117 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: unknown
MOLECULE TYPE: protein

HYPOTHETICAL: NO
FEATURE: Protein
NAME/KEY: 1..117
LOCATION: 1..117
OTHER INFORMATION: /note="Eu heavy chain amino acid
sequence."
US-08-477-728-15

Query Match 65.7%; Score 421; DB 1; Length 117;
Best Local Similarity 71.0%; Pred. No. 4.2e-37;
Matches 88; Conservative 8; Mismatches 20; Indels 8; Gaps 2;

QY 1 QVQLQSGAEVKKPGSSVRVSCKASGCTFNNNAIMVWROAPGQGLEWMGIIIMFGTAKY 60
DB 1 QVQLVQSGAEVKKPGSSVRVSCKASGCTFSSALIMVROAPGQGLEWMGIIIMFGPPNY 60
QY 61 SQNFGRAVITADESTGTASWELSLRSEDTAVYYCARSDLLFPFHALLSPWG-RGTMV 119
DB 61 AOKFGRAVITADESTNTAVWELSLRSEDTAFYFCAG-----YGIYSPSEYNGGLV 113

QY 120 TVSS 123
DB 114 TVSS 117

RESULT 24
US-08-477-728-72
Sequence 72, Application US/08477728
Patent No. 5585089
GENERAL INFORMATION:
APPLICANT: QUEEN, Gary L.
APPLICANT: SCHNEIDER, William P.
APPLICANT: SELICK, Harold E.
TITLE OF INVENTION: IMPROVED HUMANIZED IMMUNOGLOBULINS
NUMBER OF SEQUENCES: 113
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, 8th Floor
CITY: Palo Alto
STATE: California
COUNTRY: US
ZIP: 94111
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/477,728
FILING DATE: 07-JUN-1995
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/634,278
FILING DATE: 19-DEC-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/590,274
FILING DATE: 28-SEP-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/310,252
FILING DATE: 13-FEB-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/290,975
FILING DATE: 28-DEC-1988
ATTORNEY/AGENT INFORMATION:
NAME: Smith, William M
REGISTRATION NUMBER: 30,223
REFERENCE/DOCKET NUMBER: 11823-002600
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 326-2400
TELEFAX: (415) 326-2422
INFORMATION FOR SEQ ID NO: 72:
SEQUENCE CHARACTERISTICS:
LENGTH: 117 amino acids

TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-477-728-72

Query Match 65.7%; Score 421; DB 1; Length 117;
Best Local Similarity 71.0%; Pred. No. 4.2e-37;
Matches 88; Conservative 8; Mismatches 20; Indels 8; Gaps 2;

QY 1 QVQLQSGAEVKKPKSSVRVSGCKAGGTFNNNAIMWVQAPOGQLEMMGGIIPMGTKAY 60
DB 1 QVQLVQSGAEVKKPKSSVRVSGCKAGGTFNSALIMWQAPOGQLEMMGGIIPMGFPNNY 60
QY 61 SQNFGRAVITADESTGASMSLSLRSBDPAVYVCARSDDLPHHALSPWG-RGTWV 119
DB 61 AQKQGRVITADESTNTAVYVMSLSLRSBDPAFYFCAGG-----YGIYSPPEYNGGLV 113
QY 120 TVSS 123
DB 114 TVSS 117

RESULT 25
US-08-477-728-104
Sequence 104, Application US/08477728
Patent No. 5565089

GENERAL INFORMATION:

APPLICANT: QUEEN, Cary L.
APPLICANT: SCHNEIDER, William P.
APPLICANT: SELICK, Harold E.
TITLE OF INVENTION: IMPROVED HUMANIZED IMMUNOGLOBULINS
NUMBER OF SEQUENCES: 113
CORRESPONDENCE ADDRESS:

ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, 8th Floor
CITY: Palo Alto
STATE: California
COUNTRY: US
ZIP: 94111

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/477,728
FILING DATE: 07-JUN-1995
CLASSIFICATION: 424

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/634,278
FILING DATE: 19-DEC-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/590,274
FILING DATE: 28-SEP-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/310,252
FILING DATE: 13-FEB-1989
PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/290,975
FILING DATE: 28-DEC-1988
ATTORNEY/AGENT INFORMATION:

NAME: Smith, William M

REGISTRATION NUMBER: 30,223
REFERENCE/DOCKET NUMBER: 11823-002600

TELECOMMUNICATION INFORMATION:

TELEPHONE: (415) 326-2400

TELEFAX: (415) 326-2422

INFORMATION FOR SEQ ID NO: 104:

SEQUENCE CHARACTERISTICS:

LENGTH: 117 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-477-728-104

Query Match 65.7%; Score 421; DB 1; Length 117;
Best Local Similarity 71.0%; Pred. No. 4.2e-37;
Matches 88; Conservative 8; Mismatches 20; Indels 8; Gaps 2;

QY 1 QVQLQSGAEVKKPKSSVRVSGCKAGGTFNNNAIMWVQAPOGQLEMMGGIIPMGTKAY 60
DB 1 QVQLVQSGAEVKKPKSSVRVSGCKAGGTFNSALIMWQAPOGQLEMMGGIIPMGFPNNY 60
QY 61 SQNFGRAVITADESTGASMSLSLRSBDPAVYVCARSDDLPHHALSPWG-RGTWV 119
DB 61 AQKQGRVITADESTNTAVYVMSLSLRSBDPAFYFCAGG-----YGIYSPPEYNGGLV 113
QY 120 TVSS 123
DB 114 TVSS 117

RESULT 26
US-08-474-040-4
Sequence 4, Application US/08474040
Patent No. 5693761

GENERAL INFORMATION:

APPLICANT: QUEEN, Cary L.
APPLICANT: CO, Man Sung
APPLICANT: SCHNEIDER, William P.
APPLICANT: LANDOLFI, Nicholas F.
APPLICANT: COELINGH, Kathleen L.
APPLICANT: SELICK, Harold E.
TITLE OF INVENTION: IMPROVED HUMANIZED IMMUNOGLOBULINS
NUMBER OF SEQUENCES: 113
CORRESPONDENCE ADDRESS:

ADDRESSEE: Townsend and Townsend Kourie and Crew
STREET: 379 Lytton Avenue
CITY: Palo Alto
STATE: California
COUNTRY: US
ZIP: 94301

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/474,040
FILING DATE: 07-JUN-1995
CLASSIFICATION: 536

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/634,278
FILING DATE: 19-DEC-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/590,274
FILING DATE: 28-SEP-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/310,252
FILING DATE: 13-FEB-1989
PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/290,975
FILING DATE: 28-DEC-1988
ATTORNEY/AGENT INFORMATION:

NAME: Smith, William M

REGISTRATION NUMBER: 30,223
REFERENCE/DOCKET NUMBER: 11823-002600

TELECOMMUNICATION INFORMATION:

TELEPHONE: (415) 326-2400

TELEFAX: (415) 326-2422

INFORMATION FOR SEQ ID NO: 4:

SEQUENCE CHARACTERISTICS:

LENGTH: 117 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: unknown
MOLECULE TYPE: Protein
HYPOTHEICAL: NO
FEATURE:
NAME/KEY: Protein
LOCATION: 1..117
OTHER INFORMATION: /note="Variable region of the human
OTHER INFORMATION: Eu antibody heavy chain."
US-08-474-040-4

Query Match
Best Local Similarity 71.0%; Pred. No. 4.2e-37;
Matches 88; Conservative 8; Mismatches 20; Indels 8; Gaps 2;

QY 1 QVQLQSGAEVKKPSSSVRVSKASGCTFNNNAIMWRQAPQGLIEMMGIIIPMGFTAKY 60
1 QVQLVQSGAEVKKPSSSVRVSKASGCTFNSAIITWVROAPQGLEMMGIIIPMGFPNNY 60
61 SQNFGRAVITADESTGTASMEISLRSEDTAVYYCARSRDLLPFPHALSPWG-RGTMV 119
61 AOKFGRAVITADESTGTASMEISLRSEDTAVYYCARSRDLLPFPHALSPWG-RGTMV 113

QY 120 TVSS 123
114 TVSS 117

Db 114 TVSS 117

RESULT 27
US-08-474-040-15
Sequence 15, Application US/08474040
Patent No. 5693761
GENERAL INFORMATION:
APPLICANT: QUEEN, Cary L.
APPLICANT: CO, Man Sung
APPLICANT: SCHNEIDER, William P.
APPLICANT: LANDOLFI, Nicholas P.
APPLICANT: COELINGH, Kathleen L.
APPLICANT: SELICK, Harold E.
TITLE OF INVENTION: IMPROVED HUMANIZED IMMUNOGLOBULINS
NUMBER OF SEQUENCES: 113
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend Kourie and Crew
STREET: 379 Lytton Avenue
CITY: Palo Alto
STATE: California
COUNTRY: US
ZIP: 94301
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/474,040
FILING DATE: 07-JUN-1995
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/634,278
FILING DATE: 19-DEC-1990
APPLICATION NUMBER: US 07/590,274
FILING DATE: 28-SEP-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/310,252
FILING DATE: 13-FEB-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/290,975
FILING DATE: 28-DEC-1988
ATTORNEY/AGENT INFORMATION:
NAME: Smith, William M
REGISTRATION NUMBER: 30,223
REFERENCE/DOCKET NUMBER: 11823-002600
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 326-2400

TELEFAX: (415) 326-2422
INFORMATION FOR SEQ ID NO: 15:
SEQUENCE CHARACTERISTICS:
LENGTH: 117 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: unknown
MOLECULE TYPE: protein
HYPOTHEICAL: NO
FEATURE:
NAME/KEY: Protein
LOCATION: 1..117
OTHER INFORMATION: /note="Eu heavy chain amino acid
OTHER INFORMATION: sequence."
US-08-474-040-15

Query Match
Best Local Similarity 71.0%; Pred. No. 4.2e-37;
Matches 88; Conservative 8; Mismatches 20; Indels 8; Gaps 2;

QY 1 QVQLQSGAEVKKPSSSVRVSKASGCTFNNNAIMWRQAPQGLIEMMGIIIPMGFTAKY 60
1 QVQLVQSGAEVKKPSSSVRVSKASGCTFNSAIITWVROAPQGLEMMGIIIPMGFPNNY 60
61 SQNFGRAVITADESTGTASMEISLRSEDTAVYYCARSRDLLPFPHALSPWG-RGTMV 119
61 AOKFGRAVITADESTGTASMEISLRSEDTAVYYCARSRDLLPFPHALSPWG-RGTMV 113

QY 120 TVSS 123
114 TVSS 117

Db 114 TVSS 117

RESULT 28
US-08-474-040-72
Sequence 72, Application US/08474040
Patent No. 5693761
GENERAL INFORMATION:
APPLICANT: QUEEN, Cary L.
APPLICANT: CO, Man Sung
APPLICANT: SCHNEIDER, William P.
APPLICANT: LANDOLFI, Nicholas P.
APPLICANT: COELINGH, Kathleen L.
APPLICANT: SELICK, Harold E.
TITLE OF INVENTION: IMPROVED HUMANIZED IMMUNOGLOBULINS
NUMBER OF SEQUENCES: 113
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend Kourie and Crew
STREET: 379 Lytton Avenue
CITY: Palo Alto
STATE: California
COUNTRY: US
ZIP: 94301
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/474,040
FILING DATE: 07-JUN-1995
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/634,278
FILING DATE: 19-DEC-1990
APPLICATION NUMBER: US 07/590,274
FILING DATE: 28-SEP-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/310,252
FILING DATE: 13-FEB-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/290,975
FILING DATE: 28-DEC-1988

ATTORNEY/AGENT INFORMATION:
NAME: Smith, William M
REGISTRATION NUMBER: 30,223
REFERENCE/DOCKET NUMBER: 11823-002600
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 326-2400
TELEFAX: (415) 326-2422
INFORMATION FOR SEQ ID NO: 72:
SEQUENCE CHARACTERISTICS:
LENGTH: 117 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-474-040-72

Query Match 65.7%; Score 421; DB 1; Length 117;
Best Local Similarity 71.0%; Pred. No. 4.2e-37;
Matches 88; Conservative 8; Mismatches 20; Indels 8; Gaps 2;

1 OVOLQOOSGAEVKKPGSSVRSVSCKASGCTNNNAIMVROAPQGLMMGGIIPMFGTAKY 60
1 QVQLVQSGAEVKKPGSSSVRSVSCKASGCTFRSAIIWROAPQGLMMGGIVPMFGPPNY 60
61 SQNFGRAVITADESTGTASMELSLRSEDYAVVYCARSDLLLPFHALLSPWG-RGTVV 119
61 AQPFGRTVITADESTNTAYMELSLRSEDYAFYFCAG-----YGIYSPDEYNGGLV 113
QY 120 TVSS 123
DB 114 TVSS 117

RESULT 29
US-08-474-040-104
Sequence 104, Application US/08474040
Patent No. 5693761

GENERAL INFORMATION:
APPLICANT: QUEEN, Cary L.
APPLICANT: CO, Man Sung
APPLICANT: SCHNEIDER, William P.
APPLICANT: LANDOLFI, Nicholas F.
APPLICANT: COELINGH, Kathleen L.
APPLICANT: SELICK, Harold E.
TITLE OF INVENTION: IMPROVED HUMANIZED IMMUNOGLOBULINS
NUMBER OF SEQUENCES: 113
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend Kourie and Crew
STREET: 379 Lytton Avenue
CITY: Palo Alto
STATE: California
COUNTRY: US

ZIP: 94301
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/474,040
FILING DATE: 07-JUN-1995

CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/634,278
FILING DATE: 19-DEC-1990
APPLICATION NUMBER: US 07/590,274
FILING DATE: 28-SEP-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/310,252
FILING DATE: 13-FEB-1989
APPLICATION NUMBER: US 07/290,975
FILING DATE: 28-DEC-1988

ATTORNEY/AGENT INFORMATION:
NAME: Smith, William M
REGISTRATION NUMBER: 30,223
REFERENCE/DOCKET NUMBER: 11823-002600
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 326-2400
TELEFAX: (415) 326-2422
INFORMATION FOR SEQ ID NO: 104:
SEQUENCE CHARACTERISTICS:
LENGTH: 117 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-474-040-104

Query Match 65.7%; Score 421; DB 1; Length 117;
Best Local Similarity 71.0%; Pred. No. 4.2e-37;
Matches 88; Conservative 8; Mismatches 20; Indels 8; Gaps 2;

1 OVOLQOOSGAEVKKPGSSVRSVSCKASGCTNNNAIMVROAPQGLMMGGIIPMFGTAKY 60
1 QVQLVQSGAEVKKPGSSSVRSVSCKASGCTFRSAIIWROAPQGLMMGGIVPMFGPPNY 60
61 SQNFGRAVITADESTGTASMELSLRSEDYAVVYCARSDLLLPFHALLSPWG-RGTVV 119
61 AQPFGRTVITADESTNTAYMELSLRSEDYAFYFCAG-----YGIYSPDEYNGGLV 113
QY 120 TVSS 123
DB 114 TVSS 117

RESULT 30
US-08-487-200-4
Sequence 4, Application US/08487200
Patent No. 5693762

GENERAL INFORMATION:
APPLICANT: QUEEN, Cary L.
APPLICANT: CO, Man Sung
APPLICANT: SCHNEIDER, William P.
APPLICANT: LANDOLFI, Nicholas F.
APPLICANT: COELINGH, Kathleen L.
APPLICANT: SELICK, Harold E.
TITLE OF INVENTION: IMPROVED HUMANIZED IMMUNOGLOBULINS
NUMBER OF SEQUENCES: 113
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend and Crew
STREET: 379 Lytton Avenue
CITY: Palo Alto
STATE: California
COUNTRY: US

ZIP: 94301
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/487,200
FILING DATE: 7-JUN-1995

CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/634,278
FILING DATE: 19-DEC-1990
APPLICATION NUMBER: US 07/590,274
FILING DATE: 28-SEP-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/310,252
FILING DATE: 13-FEB-1989
APPLICATION NUMBER: US 07/290,975

FILING DATE: 28-DEC-1988
ATTORNEY/AGENT INFORMATION:
NAME: Smith, William M.
REGISTRATION NUMBER: 30,223
REFERENCE/DOCKET NUMBER: 11823-002610
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 326-2400
TELEFAX: (415) 326-2422
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 117 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: unknown
MOLECULE TYPE: protein
HYPOTHETICAL: NO
FEATURE:
NAME/KEY: Protein
LOCATION: 1..117
OTHER INFORMATION: /note="Variable region of the human
8-487-200-4"
OTHER INFORMATION: Eu antibody heavy chain."
Query Match 65.7%; Score 421; DB 1; Length 117;
Best Local Similarity 71.0%; Pred. No. 4.2e-37;
Matches 88; Conservative 8; Mismatches 20; Indels 8; Gaps 2;
QY 1 QVQLQSGAEVKKPGSSSVRSCKASGCTFNNAIMWROAPQGLIEMWGIIIPMFGTAKY 60
DB 1 QVQLVQSGAEVKKPGSSSVRSCKASGCTFSRSALIMWROAPQGLIEMWGIIIPMFGPNNY 60
QY 61 SQNPGRAVITADSTGTASMLSLRSDTAIVYCAARSRLLLFPHHALSPWG-RGTMV 119
DB 61 AAKFGRAVITADSTNTAYMELSLRSEDTAIFYCAGG-----YGIYSPDEYNGLV 113
QY 120 TVSS 123
DB 114 TVSS 117
RESULT 31
US-08-487-200-15
Sequence 15, Application US/08487200
Patent No. 5693762
GENERAL INFORMATION:
APPLICANT: QUEEN, Cary L.
APPLICANT: CO, Man Sung
APPLICANT: SCHNEIDER, William P.
APPLICANT: LANDOLFI, Nicholas F.
APPLICANT: COELINGH, Kathleen L.
APPLICANT: SELICK, Harold E.
TITLE OF INVENTION: IMPROVED HUMANIZED IMMUNOGLOBULINS
NUMBER OF SEQUENCES: 113
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend and Crew
STREET: 379 Lytton Avenue
CITY: Palo Alto
STATE: California
COUNTRY: US
ZIP: 94301
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/487,200
FILING DATE: 7-JUN-1995
CLASSIFICATION: 424
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: US 07/634,278
FILING DATE: 19-DEC-1990
PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/590,274
FILING DATE: 28-SEP-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/310,252
FILING DATE: 13-FEB-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/290,975
FILING DATE: 28-DEC-1988
ATTORNEY/AGENT INFORMATION:
NAME: Smith, William M.
REGISTRATION NUMBER: 30,223
REFERENCE/DOCKET NUMBER: 11823-002610
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 326-2400
TELEFAX: (415) 326-2422
INFORMATION FOR SEQ ID NO: 15:
SEQUENCE CHARACTERISTICS:
LENGTH: 117 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: unknown
MOLECULE TYPE: protein
HYPOTHETICAL: NO
FEATURE:
NAME/KEY: Protein
LOCATION: 1..117
OTHER INFORMATION: /note="Eu heavy chain amino acid
US-08-487-200-15"
Query Match 65.7%; Score 421; DB 1; Length 117;
Best Local Similarity 71.0%; Pred. No. 4.2e-37;
Matches 88; Conservative 8; Mismatches 20; Indels 8; Gaps 2;
QY 1 QVQLQSGAEVKKPGSSSVRSCKASGCTFNNAIMWROAPQGLIEMWGIIIPMFGTAKY 60
DB 1 QVQLVQSGAEVKKPGSSSVRSCKASGCTFSRSALIMWROAPQGLIEMWGIIIPMFGPNNY 60
QY 61 SQNPGRAVITADSTGTASMLSLRSDTAIVYCAARSRLLLFPHHALSPWG-RGTMV 119
DB 61 AAKFGRAVITADSTNTAYMELSLRSEDTAIFYCAGG-----YGIYSPDEYNGLV 113
QY 120 TVSS 123
DB 114 TVSS 117
RESULT 32
US-08-487-200-72
Sequence 72, Application US/08487200
Patent No. 5693762
GENERAL INFORMATION:
APPLICANT: QUEEN, Cary L.
APPLICANT: CO, Man Sung
APPLICANT: SCHNEIDER, William P.
APPLICANT: LANDOLFI, Nicholas F.
APPLICANT: COELINGH, Kathleen L.
APPLICANT: SELICK, Harold E.
TITLE OF INVENTION: IMPROVED HUMANIZED IMMUNOGLOBULINS
NUMBER OF SEQUENCES: 113
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend and Crew
STREET: 379 Lytton Avenue
CITY: Palo Alto
STATE: California
COUNTRY: US
ZIP: 94301
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/487,200
FILING DATE: 7-JUN-1995
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/634,278
FILING DATE: 19-DEC-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/590,274
FILING DATE: 28-SEP-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/310,252
FILING DATE: 13-FEB-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/290,975
FILING DATE: 28-DEC-1988
ATTORNEY/AGENT INFORMATION:
NAME: Smith, William M
REGISTRATION NUMBER: 30,223
REFERENCE/DOCKET NUMBER: 11823-002610
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 326-2400
TELEFAX: (415) 326-2422
INFORMATION FOR SEQ ID NO: 72:
SEQUENCE CHARACTERISTICS:
LENGTH: 117 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-487-200-72

Query March 65.7%; Score 421; DB 1; Length 117;
Best Local Similarity 71.0%; Pred. No. 4.2e-37;
Matches 88; Conservative 8; Mismatches 20; Indels 8; Gaps 2;

QY 1 QVQLQSGAEVKKPKSSVRVSCKASGGTFNNNAINWVROAPGQGLEWMGGIIPMEGTAKY 60
DB 1 QVQLVQSGAEVKKPKSSVRVSCKASGGTFNRSALITWVROAPGQGLEWMGGIIPMEGPENY 60
QY 61 SQNFGRAVITADSTGTASWELSLRSEDTAVYYCARSRDLLFPFHALLSPWK-RGTMV 119
DB 61 AQRQGRVITADSTGTASWELSLRSEDTAVYYCARSRDLLFPFHALLSPWK-RGTMV 113
QY 120 TVSS 123
DB 114 TVSS 117

US-08-487-200-104
Sequence 104, Application US/08487200
Patent No. 5693762
GENERAL INFORMATION:
APPLICANT: QUEEN, Gary L.
APPLICANT: CO, Man Sung
APPLICANT: SCHNEIDER, William P.
APPLICANT: LANDOLFI, Nicholas F.
APPLICANT: COELINGH, Kathleen L.
APPLICANT: SELICK, Harold E.
TITLE OF INVENTION: IMPROVED HUMANIZED IMMUNOGLOBULINS
NUMBER OF SEQUENCES: 113
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend and Crew
STREET: 379 Lytton Avenue
CITY: Palo Alto
STATE: California
COUNTRY: US
ZIP: 94301
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/487,200
FILING DATE: 7-JUN-1995
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/634,278
FILING DATE: 19-DEC-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/590,274
FILING DATE: 28-SEP-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/310,252
FILING DATE: 13-FEB-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/290,975
FILING DATE: 28-DEC-1988
ATTORNEY/AGENT INFORMATION:
NAME: Smith, William M
REGISTRATION NUMBER: 30,223
REFERENCE/DOCKET NUMBER: 11823-002610
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 326-2400
TELEFAX: (415) 326-2422
INFORMATION FOR SEQ ID NO: 104:
SEQUENCE CHARACTERISTICS:
LENGTH: 117 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-487-200-104

Query March 65.7%; Score 421; DB 1; Length 117;
Best Local Similarity 71.0%; Pred. No. 4.2e-37;
Matches 88; Conservative 8; Mismatches 20; Indels 8; Gaps 2;

QY 1 QVQLQSGAEVKKPKSSVRVSCKASGGTFNNNAINWVROAPGQGLEWMGGIIPMEGTAKY 60
DB 1 QVQLVQSGAEVKKPKSSVRVSCKASGGTFNRSALITWVROAPGQGLEWMGGIIPMEGPENY 60
QY 61 SQNFGRAVITADSTGTASWELSLRSEDTAVYYCARSRDLLFPFHALLSPWK-RGTMV 119
DB 61 AQRQGRVITADSTGTASWELSLRSEDTAVYYCARSRDLLFPFHALLSPWK-RGTMV 113
QY 120 TVSS 123
DB 114 TVSS 117

US-08-488-113B-166
Sequence 166, Application US/08488113B
Patent No. 5744580
GENERAL INFORMATION:
APPLICANT: Better, Marc D.
APPLICANT: CARROLL, Stephen F.
APPLICANT: Studnika, Gary M.
TITLE OF INVENTION: Immunotoxins Comprising Ribosome-Inactivating
NUMBER OF SEQUENCES: 169
CORRESPONDENCE ADDRESS:
ADDRESSEE: McAndrews, Held & Malloy, Ltd.
STREET: 500 West Madison Street, 34th floor
CITY: Chicago
STATE: Illinois
COUNTRY: USA
ZIP: 60661
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/488,113B
FILING DATE: 07-JUN-1995
CLASSIFICATION: 530
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/425,336
FILING DATE: 18-APR-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/064,691
FILING DATE: 12-MAY-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/988,430
FILING DATE: 09-DEC-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/901,707
FILING DATE: 19-JUN-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/787,567
FILING DATE: 04-NOV-1991
ATTORNEY/AGENT INFORMATION:
NAME: McNicholas, Janet M.
REGISTRATION NUMBER: 32,918
REFERENCE/DOCKET NUMBER: 11022US07/200-70.P3.C2A
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312/707-9155
TELEFAX: 312/707-9155
TELEX: 650 388-1248
INFORMATION FOR SEQ ID NO: 166:
SEQUENCE CHARACTERISTICS:
LENGTH: 117 amino acids
TYPE: amino acid
STRANDEDNESS: not relevant
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-488-113B-166

Query Match 65.7%; Score 421; DB 1; Length 117;
Best Local Similarity 71.0%; Pred. No. 4,2e-37;

Matches 88; Conservative 8; Mismatches 20; Indels 8; Gaps 2;

QY 1 QVQLQSGAEVKKPKSSVRSVSCASGCTNNNAIINWROAPGQGLEWVGIIIPMGTRAKY 60
DB 1 QVQLVSGAEVKKPKSSVRSVSCASGCTFSRSALIWROAPGQGLEWVGIVPMFGPPNY 60
QY 61 SQNFGRAVITADESTGTASMEISLRSEDTAVYYCARSRDLFPFHALLSPWG-RGTMV 119
DB 61 AQLFGRAVITADESTGTASMEISLRSEDTAVYYCARSRDLFPFHALLSPWG-RGTMV 113
QY 120 TVSS 123
DB 114 TVSS 117

RESULT 35

US-08-477-484B-166

Sequence 166, Application US/08477484B

Patent No. 5756699

GENERAL INFORMATION:

APPLICANT: Better, Marc D.

APPLICANT: Carroll, Stephen F.

TITLE OF INVENTION: Immunotoxins Comprising Ribosome-Inactivating

NUMBER OF SEQUENCES: 169

CORRESPONDENCE ADDRESS:

ADDRESSEE: McAndrews, Held & Malloy, Ltd.

STREET: 500 West Madison Street, 34th floor

CITY: Chicago

STATE: Illinois

COUNTRY: USA

ZIP: 60661

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/477,484B
FILING DATE: 07-JUN-1995
CLASSIFICATION: 530
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/425,336
FILING DATE: 18-APR-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/064,691
FILING DATE: 12-MAY-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/988,430
FILING DATE: 09-DEC-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/901,707
FILING DATE: 19-JUN-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/787,567
FILING DATE: 04-NOV-1991
ATTORNEY/AGENT INFORMATION:
NAME: McNicholas, Janet M.
REGISTRATION NUMBER: 32,918
REFERENCE/DOCKET NUMBER: 11022US07/200-70.P3.C2A
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312/707-9155
TELEFAX: 312/707-9155
TELEX: 650 388-1248
INFORMATION FOR SEQ ID NO: 166:
SEQUENCE CHARACTERISTICS:
LENGTH: 117 amino acids
TYPE: amino acid
STRANDEDNESS: not relevant
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-477-484B-166

Query Match 65.7%; Score 421; DB 1; Length 117;
Best Local Similarity 71.0%; Pred. No. 4,2e-37;

Matches 88; Conservative 8; Mismatches 20; Indels 8; Gaps 2;

QY 1 QVQLQSGAEVKKPKSSVRSVSCASGCTNNNAIINWROAPGQGLEWVGIIIPMGTRAKY 60
DB 1 QVQLVSGAEVKKPKSSVRSVSCASGCTFSRSALIWROAPGQGLEWVGIVPMFGPPNY 60
QY 61 SQNFGRAVITADESTGTASMEISLRSEDTAVYYCARSRDLFPFHALLSPWG-RGTMV 119
DB 61 AQLFGRAVITADESTGTASMEISLRSEDTAVYYCARSRDLFPFHALLSPWG-RGTMV 113
QY 120 TVSS 123
DB 114 TVSS 117

RESULT 36

US-08-107-669D-52

Sequence 52, Application US/08107669D

Patent No. 5766886

GENERAL INFORMATION:

APPLICANT: Studnicka, Gary M.

TITLE OF INVENTION: Modified Antibody Variable Domains (as amended)

NUMBER OF SEQUENCES: 67

CORRESPONDENCE ADDRESS:

ADDRESSEE: Sterne, Kessler, Goldstein and Fox P.L.L.C.

STREET: 1100 New York Ave., N.W., Suite 600

CITY: Washington

STATE: D.C.

COUNTRY: United States of America

ZIP: 20005-3934

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/107, 669D
FILING DATE: 13-AUG-1993
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US92/10906
FILING DATE: 14-DEC-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/808,464
FILING DATE: 13-DEC-1991
ATTORNEY/AGENT INFORMATION:
NAME: Michele A. Cimbalà
REGISTRATION NUMBER: 33,851
REFERENCE/DOCKET NUMBER: 0610.1000001/MAC
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202/371-2540
TELEFAX: 202/371-2540
INFORMATION FOR SEQ ID NO: 52:
SEQUENCE CHARACTERISTICS:
LENGTH: 117 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-107-669D-52

Query March 65.7%; Score 421; DB 1; Length 117;
Best Local Similarity 71.0%; Pred. No. 4.2e-37;
Matches 88; Conservative 8; Mismatches 20; Indels 8; Gaps 2;

QY 1 QVQLQSGAEVKKPKSSVSVKSCKASGTFNNNAIMVWQAQPGQLEWNGIIPMEGTAKY 60
DB 1 QVQLVQSGAEVKKPKSSVSVKSCKASGTFNRSALITWVQAQPGQLEWNGIIPMGPPNY 60
QY 61 SQNFGRAVITADSTGTASWELSLRSEDYAVYYCARSDLLFPFHALLSPWG-RGTMY 119
DB 61 AOKFGRTVITADSTGTASWELSLRSEDYAVYYCARSDLLFPFHALLSPWG-RGTMY 113

QY 120 TVSS 123
DB 114 TVSS 117

RESULT 37
US-08-472-788A-52
Sequence 52, Application US/08472788A
Patent No. 5770196
GENERAL INFORMATION:
APPLICANT: Studnicka, Gary M.
TITLE OF INVENTION: Modified Antibody Variable Domains
NUMBER OF SEQUENCES: 89
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sterne, Kessler, Goldstein and Fox P.L.L.C.
STREET: 1100 New York Ave., N.W., Suite 600
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20005-3934
COMPUTER READABLE FORM:
MEDIUM TYPE: floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/472, 788A
FILING DATE: 07-JUN-1995
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/082, 842
FILING DATE: 23-JUN-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US92/10906

FILING DATE: 14-DEC-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/808,464
FILING DATE: 13-DEC-1991
ATTORNEY/AGENT INFORMATION:
NAME: Cimbalà, Michele A.
REGISTRATION NUMBER: 33,851
REFERENCE/DOCKET NUMBER: 0610.1000003
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202/371-2600
TELEFAX: 202/371-2540
TELEX:
INFORMATION FOR SEQ ID NO: 52:
SEQUENCE CHARACTERISTICS:
LENGTH: 117 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-472-788A-52

Query March 65.7%; Score 421; DB 1; Length 117;
Best Local Similarity 71.0%; Pred. No. 4.2e-37;
Matches 88; Conservative 8; Mismatches 20; Indels 8; Gaps 2;

QY 1 QVQLQSGAEVKKPKSSVSVKSCKASGTFNNNAIMVWQAQPGQLEWNGIIPMEGTAKY 60
DB 1 QVQLVQSGAEVKKPKSSVSVKSCKASGTFNRSALITWVQAQPGQLEWNGIIPMGPPNY 60
QY 61 SQNFGRAVITADSTGTASWELSLRSEDYAVYYCARSDLLFPFHALLSPWG-RGTMY 119
DB 61 AOKFGRTVITADSTGTASWELSLRSEDYAVYYCARSDLLFPFHALLSPWG-RGTMY 113

QY 120 TVSS 123
DB 114 TVSS 117

RESULT 38
US-08-477-531B-52
Sequence 52, Application US/08477531B
Patent No. 5821123
GENERAL INFORMATION:
APPLICANT: Studnicka, Gary M.
TITLE OF INVENTION: Modified Antibody Variable Domains (as amended)
NUMBER OF SEQUENCES: 67
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sterne, Kessler, Goldstein and Fox P.L.L.C.
STREET: 1100 New York Ave., N.W., Suite 600
CITY: Washington
STATE: D.C.
COUNTRY: United States of America
ZIP: 20005-3934
COMPUTER READABLE FORM:
MEDIUM TYPE: floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/477, 531B
FILING DATE: 07-JUN-1995
CLASSIFICATION: 436
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/107, 669
FILING DATE: 13-AUG-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US92/10906
FILING DATE: 14-DEC-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/808,464
FILING DATE: 13-DEC-1991
ATTORNEY/AGENT INFORMATION:
NAME: Michele A. Cimbalà
REGISTRATION NUMBER: 33,851

REFERENCE/DOCKET NUMBER: 0610.1000004/MAC
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202/371-2600
TELEFAX: 202/371-2540
INFORMATION FOR SEQ ID NO: 52:
SEQUENCE CHARACTERISTICS:
LENGTH: 117 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-477-531B-52

Query Match 65.7%; Score 421; DB 2; Length 117;
Best Local Similarity 71.0%; Pred. No. 4.2e-37;
Matches 88; Conservative 8; Mismatches 20; Indels 8; Gaps 2;

QY 1 QVQLQSGAEVKKPKSSVRVSCKASGCTFNNNAIMWVROAPGQLEMMGGIIPMEGTAKY 60
DB 1 QVQLVQSGAEVKKPKSSVRVSCKASGCTFNNNAIMWVROAPGQLEMMGGIIPMEGTAKY 60
61 SQNFGRAVITADESTGTASNELSLRSEDYAVYYCARSDLLFPFHALSPWG-RGTMV 119
61 AQKFGRAVITADESTGTASNELSLRSEDYAVYYCARSDLLFPFHALSPWG-RGTMV 113
QY 120 TVSS 123
DB 114 TVSS 117

RESULT 39
US-08-646-360-166
Sequence 166, Application US/08646360

PATENT No. 5837431
GENERAL INFORMATION:
APPLICANT: Better, Marc D.
APPLICANT: Carroll, Stephen F.
APPLICANT: Studnicka, Gary M.
TITLE OF INVENTION: Immunotoxins Comprising Ribosome-Inactivating
NUMBER OF SEQUENCES: 173
CORRESPONDENCE ADDRESSES:
ADDRESSEE: McAndrews, Held & Malloy, Ltd.
STREET: 500 West Madison Street, 34th floor
CITY: Chicago
STATE: Illinois
COUNTRY: USA
ZIP: 60661
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/646,360
FILING DATE: 13-MAY-1996
CLASSIFICATION: 530
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US94/05348
FILING DATE: 12-MAY-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/064,691
FILING DATE: 12-MAY-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/988,430
FILING DATE: 09-DEC-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/901,707
FILING DATE: 19-JUN-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/787,567
FILING DATE: 04-NOV-1991
ATTORNEY/AGENT INFORMATION:
NAME: McNicholas, Janet M.

REGISTRATION NUMBER: 32,918
REFERENCE/DOCKET NUMBER: 200-70.P4
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312/707-8889
TELEFAX: 312/707-9155
TELEX: 650 368-1248
INFORMATION FOR SEQ ID NO: 166:
SEQUENCE CHARACTERISTICS:
LENGTH: 117 amino acids
TYPE: amino acid
STRANDEDNESS: not relevant
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-646-360-166

Query Match 65.7%; Score 421; DB 2; Length 117;
Best Local Similarity 71.0%; Pred. No. 4.2e-37;
Matches 88; Conservative 8; Mismatches 20; Indels 8; Gaps 2;

QY 1 QVQLQSGAEVKKPKSSVRVSCKASGCTFNNNAIMWVROAPGQLEMMGGIIPMEGTAKY 60
DB 1 QVQLVQSGAEVKKPKSSVRVSCKASGCTFNNNAIMWVROAPGQLEMMGGIIPMEGTAKY 60
61 SQNFGRAVITADESTGTASNELSLRSEDYAVYYCARSDLLFPFHALSPWG-RGTMV 119
61 AQKFGRAVITADESTGTASNELSLRSEDYAVYYCARSDLLFPFHALSPWG-RGTMV 113
QY 120 TVSS 123
DB 114 TVSS 117

RESULT 40
US-08-082-842A-52
Sequence 52, Application US/08082842A

PATENT No. 5869619
GENERAL INFORMATION:
APPLICANT: Studnicka, Gary M.
TITLE OF INVENTION: Modified Antibody Variable Domains
NUMBER OF SEQUENCES: 89
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Sterne, Kessler, Goldstein and Fox P.L.L.C.
STREET: 1100 New York Ave., N.W., Suite 600
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20005-3934
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/082,842A
FILING DATE: 23-JUN-1993
CLASSIFICATION: 530
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US92/10906
FILING DATE: 14-DEC-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/808,464
FILING DATE: 13-DEC-1991
ATTORNEY/AGENT INFORMATION:
NAME: Cambala, Michele A.
REGISTRATION NUMBER: 33,851
REFERENCE/DOCKET NUMBER: 0610.1000002
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202/371-2600
TELEFAX: 202/371-2540
INFORMATION FOR SEQ ID NO: 52:
SEQUENCE CHARACTERISTICS:
LENGTH: 117 amino acids

TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-082-842A-52

Query Match 65.7% Score 421; DB 2; Length 117;
Best Local Similarity 71.0%; Pred. No. 4.2e-37;
Matches 88; Conservative 8; Mismatches 20; Indels 8; Gaps 2;

QY 1 OVQLQSGAEVKKPSSSVRSCKASGCTPNNNAIMVWQAPOGQLEMMGGIIPMGITAKY 60
DB 1 OVQLVQSGAEVKKPSSSVRSCKASGCTFSRSALIMVWQAPOGQLEMMGGIIPMGPPNY 60
QY 61 SONFGRAVITADESTGTASMSLSRSEDVAVYVCARSDDLFPFHALSFWG-RGTVV 119
DB 61 AOKFGRAVITADESTNTAVMELSLRSEDVAFYFCAGS-----YGIYSPEEYNGGLV 113
QY 120 TVSS 123
DB 114 TVSS 117

RESULT 41
US-08-839-765-166

Sequence 166, Application US/08839765

Patent No. 6146631

GENERAL INFORMATION:

APPLICANT: Better, Marc D.

APPLICANT: Carroll, Stephen F.

APPLICANT: Studnika, Gary M.

TITLE OF INVENTION: Immunotoxins Comprising Ribosome-Inactivating

NUMBER OF SEQUENCES: 169

CORRESPONDENCE ADDRESSES:

ADDRESSEE: McAndrews, Held & Malloy, Ltd.

STREET: 500 West Madison Street, 34th floor

CITY: Chicago

STATE: Illinois

COUNTRY: USA

ZIP: 60661

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/839,765

FILING DATE: 15-APR-1997

CLASSIFICATION: 530

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/425,336

FILING DATE: 18-APR-1995

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/064,691

FILING DATE: 12-MAY-1993

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/988,430

FILING DATE: 09-DEC-1992

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/901,707

FILING DATE: 19-JUN-1992

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/787,567

FILING DATE: 04-NOV-1991

ATTORNEY/AGENT INFORMATION:

NAME: McNicholas, Janet M.

REGISTRATION NUMBER: 32,918

TELECOMMUNICATION INFORMATION:

TELEPHONE: 312/707-9155

TELEFAX: 312/707-9155

TELEX: 650 386-1248

INFORMATION FOR SEQ ID NO: 166:

SEQUENCE CHARACTERISTICS:
LENGTH: 117 amino acids
TYPE: amino acid
STRANDEDNESS: not relevant
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-839-765-166

Query Match 65.7% Score 421; DB 3; Length 117;
Best Local Similarity 71.0%; Pred. No. 4.2e-37;
Matches 88; Conservative 8; Mismatches 20; Indels 8; Gaps 2;

QY 1 OVQLQSGAEVKKPSSSVRSCKASGCTPNNNAIMVWQAPOGQLEMMGGIIPMGITAKY 60
DB 1 OVQLVQSGAEVKKPSSSVRSCKASGCTFSRSALIMVWQAPOGQLEMMGGIIPMGPPNY 60
QY 61 SONFGRAVITADESTGTASMSLSRSEDVAVYVCARSDDLFPFHALSFWG-RGTVV 119
DB 61 AOKFGRAVITADESTNTAVMELSLRSEDVAFYFCAGS-----YGIYSPEEYNGGLV 113
QY 120 TVSS 123
DB 114 TVSS 117

RESULT 42
US-09-136-389-166

Sequence 166, Application US/09136389

Patent No. 6146850

GENERAL INFORMATION:

APPLICANT: Better, Marc D.

APPLICANT: Carroll, Stephen F.

APPLICANT: Studnika, Gary M.

TITLE OF INVENTION: Immunotoxins Comprising Ribosome-Inactivating

NUMBER OF SEQUENCES: 173

CORRESPONDENCE ADDRESSES:

ADDRESSEE: McAndrews, Held & Malloy, Ltd.

STREET: 500 West Madison Street, 34th floor

CITY: Chicago

STATE: Illinois

COUNTRY: USA

ZIP: 60661

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/136,389

FILING DATE:

CLASSIFICATION:

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/646,360

FILING DATE: 13-MAY-1996

APPLICATION NUMBER: PCT/US94/05348

FILING DATE: 12-MAY-1994

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/064,691

FILING DATE: 12-MAY-1993

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/988,430

FILING DATE: 09-DEC-1992

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/901,707

FILING DATE: 19-JUN-1992

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/787,567

FILING DATE: 04-NOV-1991

ATTORNEY/AGENT INFORMATION:

NAME: McNicholas, Janet M.

REGISTRATION NUMBER: 32,918

REFERENCE/DOCKET NUMBER: 200-70.P4

TELECOMMUNICATION INFORMATION:
TELEPHONE: 312/707-8889
TELEFAX: 312/707-9155
TELEX: 650 388-1248
INFORMATION FOR SEQ ID NO: 166:
SEQUENCE CHARACTERISTICS:
LENGTH: 117 amino acids
TYPE: amino acid
STRANDEDNESS: not relevant
TOPOLOGY: linear
MOLECULE TYPE: protein
US-09-136-389-166

Query Match 65.7%; Score 421; DB 3; Length 117;
Best Local Similarity 71.0%; Pred. No. 4.2e-37;
Matches 88; Conservative 8; Mismatches 20; Indels 8; Gaps 2;

Qy 1 QVQLQSGAEVYKPKSSVRSCKASGTFNNNAIHWYQAPQGLWMGIIIPMEGTAKY 60
Db 1 QVQLVQSGAEVYKPKSSVRSCKASGTFNRSALIIWYQAPQGLWMGIIIPMEGPENY 60
61 SONFGRAVITADESTGTASMELSLRSEDTAVYYCARSDLLFPFHALLSPWG-RGTMV 119
61 AOKFGRTVITADESTNTAYMELSLRSEDTAFYFCAGG-----YGIYSEEPYNGSLV 113
Qy 120 TVSS 123
Db 114 TVSS 117

RESULT 43
US-08-484-537-4
Sequence 4, Application US/08484537
Patent No. 6180370

GENERAL INFORMATION:
APPLICANT: QUEEN, Cary L.
APPLICANT: CO, Man Sung
APPLICANT: SCHNEIDER, William P.
APPLICANT: LANDOLFI, Nicholas F.
APPLICANT: COELINGH, Kathleen L.
APPLICANT: SELICK, Harold E.
TITLE OF INVENTION: IMPROVED HUMANIZED IMMUNOGLOBULINS
NUMBER OF SEQUENCES: 113
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend Kourie and Crew
STREET: 379 Lytton Avenue
CITY: Palo Alto
STATE: California
COUNTRY: US

ZIP: 94301
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/484,537
FILING DATE:

CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/07/634,278
FILING DATE: 19-DEC-1990
APPLICATION NUMBER: US 07/590,274
FILING DATE: 28-SEP-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/310,252
FILING DATE: 13-FEB-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/290,975
FILING DATE: 28-DEC-1988
ATTORNEY/AGENT INFORMATION:
NAME: Smith, William M
REGISTRATION NUMBER: 30,223

REFERENCE/DOCKET NUMBER: 11823-002600
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 326-2400
TELEFAX: (415) 326-2422
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 117 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: unknown
MOLECULE TYPE: protein
HYPOTHETICAL: NO
FEATURE:
NAME/KEY: Protein
LOCATION: 1..117
OTHER INFORMATION: /note= "Variable region of the human
OTHER INFORMATION: Eu antibody heavy chain."
US-08-484-537-4

Query Match 65.7%; Score 421; DB 3; Length 117;
Best Local Similarity 71.0%; Pred. No. 4.2e-37;
Matches 88; Conservative 8; Mismatches 20; Indels 8; Gaps 2;

Qy 1 QVQLQSGAEVYKPKSSVRSCKASGTFNNNAIHWYQAPQGLWMGIIIPMEGTAKY 60
Db 1 QVQLVQSGAEVYKPKSSVRSCKASGTFNRSALIIWYQAPQGLWMGIIIPMEGPENY 60
61 SONFGRAVITADESTGTASMELSLRSEDTAVYYCARSDLLFPFHALLSPWG-RGTMV 119
61 AOKFGRTVITADESTNTAYMELSLRSEDTAFYFCAGG-----YGIYSEEPYNGSLV 113
Qy 120 TVSS 123
Db 114 TVSS 117

RESULT 44
US-08-484-537-15
Sequence 15, Application US/08484537
Patent No. 6180370

GENERAL INFORMATION:
APPLICANT: QUEEN, Cary L.
APPLICANT: CO, Man Sung
APPLICANT: SCHNEIDER, William P.
APPLICANT: LANDOLFI, Nicholas F.
APPLICANT: COELINGH, Kathleen L.
APPLICANT: SELICK, Harold E.
TITLE OF INVENTION: IMPROVED HUMANIZED IMMUNOGLOBULINS
NUMBER OF SEQUENCES: 113
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend Kourie and Crew
STREET: 379 Lytton Avenue
CITY: Palo Alto
STATE: California
COUNTRY: US

ZIP: 94301
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/484,537
FILING DATE:

CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/07/634,278
FILING DATE: 19-DEC-1990
APPLICATION NUMBER: US 07/590,274
FILING DATE: 28-SEP-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/310,252
FILING DATE: 13-FEB-1989

PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/290,975
FILING DATE: 28-DEC-1988
ATTORNEY/AGENT INFORMATION:
NAME: Smith, William M
REGISTRATION NUMBER: 30,223
REFERENCE/DOCKET NUMBER: 11823-002600
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 326-2400
TELEFAX: (415) 326-2422
INFORMATION FOR SEQ ID NO: 15:
SEQUENCE CHARACTERISTICS:
LENGTH: 117 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: unknown
MOLECULE TYPE: protein
HYPOTHETICAL: NO
FEATURE:
NAME/KEY: Protein
LOCATION: 1..117
OTHER INFORMATION: /note="Eu heavy chain amino acid
OTHER INFORMATION: sequence."
US-08-484-537-15

Query Match 65.7%; Score 421; DB 3; Length 117;
Best Local Similarity 71.0%; Pred. No. 4.2e-37;
Matches 88; Conservative 8; Mismatches 20; Indels 8; Gaps 2;

QY 1 QVQLQSGAEVKKPGSSSVKSCASGSGTFNNAINWVROAPQGLIEMWGIIIPMFGTAKY 60
DB 1 QVQLVQSGAEVKKPGSSSVKSCASGSGTFSSAIIWVQAPQGLIEMWGIIIPMGPPNY 60

QY 61 SONQGRALTADESTGTAAMELSLSRESDTAIVYYCARSRLLLFPHALSPWG-RGTMV 119
DB 61 AOKQGRVLTADSTNTAYMELSLRSEDTAFYFCAGG-----YGIYSPPEEYNGLV 113

QY 120 TVSS 123
DB 114 TVSS 117

RESULT 45
US-08-484-537-72
Sequence 72, Application US/08484537
Patent No. 6180370
GENERAL INFORMATION:
APPLICANT: QUEEN, Cary L.
APPLICANT: CO, Man Sung
APPLICANT: SCHNEIDER, William P.
APPLICANT: LANDOLFI, Nicholas F.
APPLICANT: COELINGH, Kathleen L.
APPLICANT: SELICK, Harold E.
TITLE OF INVENTION: IMPROVED HUMANIZED IMMUNOGLOBULINS
NUMBER OF SEQUENCES: 113
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend Kourie and Crew
STREET: 379 Lytton Avenue
CITY: Palo Alto
STATE: California
COUNTRY: US
ZIP: 94301
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/484,537
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/07/634,278

FILING DATE: 19-DEC-1990
APPLICATION NUMBER: US 07/590,274
FILING DATE: 28-SEP-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/310,252
FILING DATE: 13-FEB-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/290,975
FILING DATE: 28-DEC-1988
ATTORNEY/AGENT INFORMATION:
NAME: Smith, William M
REGISTRATION NUMBER: 30,223
REFERENCE/DOCKET NUMBER: 11823-002600
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 326-2400
TELEFAX: (415) 326-2422
INFORMATION FOR SEQ ID NO: 72:
SEQUENCE CHARACTERISTICS:
LENGTH: 117 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-484-537-72

Query Match 65.7%; Score 421; DB 3; Length 117;
Best Local Similarity 71.0%; Pred. No. 4.2e-37;
Matches 88; Conservative 8; Mismatches 20; Indels 8; Gaps 2;

QY 1 QVQLQSGAEVKKPGSSSVKSCASGSGTFNNAINWVROAPQGLIEMWGIIIPMFGTAKY 60
DB 1 QVQLVQSGAEVKKPGSSSVKSCASGSGTFSSAIIWVQAPQGLIEMWGIIIPMGPPNY 60

QY 61 SONQGRALTADESTGTAAMELSLSRESDTAIVYYCARSRLLLFPHALSPWG-RGTMV 119
DB 61 AOKQGRVLTADSTNTAYMELSLRSEDTAFYFCAGG-----YGIYSPPEEYNGLV 113

QY 120 TVSS 123
DB 114 TVSS 117

RESULT 46
US-08-484-537-104
Sequence 104, Application US/08484537
Patent No. 6180370
GENERAL INFORMATION:
APPLICANT: QUEEN, Cary L.
APPLICANT: CO, Man Sung
APPLICANT: SCHNEIDER, William P.
APPLICANT: LANDOLFI, Nicholas F.
APPLICANT: COELINGH, Kathleen L.
APPLICANT: SELICK, Harold E.
TITLE OF INVENTION: IMPROVED HUMANIZED IMMUNOGLOBULINS
NUMBER OF SEQUENCES: 113
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend Kourie and Crew
STREET: 379 Lytton Avenue
CITY: Palo Alto
STATE: California
COUNTRY: US
ZIP: 94301
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/484,537
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/07/634,278

FILING DATE: 19-DEC-1990
APPLICATION NUMBER: US 07/590,274
FILING DATE: 28-SEP-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/310,252
FILING DATE: 13-FEB-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/290,975
FILING DATE: 28-DEC-1988
ATTORNEY/AGENT INFORMATION:
NAME: Smith, William M
REGISTRATION NUMBER: 30,223
REFERENCE/DOCKET NUMBER: 11823-002600
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 326-2400
TELEFAX: (415) 326-2422
INFORMATION FOR SEQ ID NO: 104:
SEQUENCE CHARACTERISTICS:
LENGTH: 117 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-484-537-104

Query Match 65.7%; Score 421; DB 3; Length 117;
Best Local Similarity 71.0%; Pred. No. 4.2e-37;
Matches 88; Conservative 8; Mismatches 20; Indels 8; Gaps 2;

QY 1 QVQLQSGAEVKKPKSSVSVKSCASGTFNNNAIMVWROAPGQGLEWMGIIIPMEGTAKY 60
DB 1 QVQLVQSGAEVKKPKSSVSVKSCASGTFNRSALIIWVRQAPGQGLEWMGIIIPMGPPNY 60
QY 61 SQNFGRAVITADESTGTSAMELSLRSEDTAVYYCARSDLLPFPHALSPWG-RGTMV 119
DB 61 AAKFGKRVITADESTNTAYVMELSLRSEDTAFYFCAGG-----YGIYSPEEYNGGLV 113
QY 120 TVSS 123
DB 114 TVSS 117

RESULT 47
US-09-450-520A-13
Sequence 13, Application US/09450520A
Patent No. 6329511
GENERAL INFORMATION:
APPLICANT: Vasquez, Maximiliano
APPLICANT: Landolfi, Nicholas F.
APPLICANT: Tsurushita, Naoya
APPLICANT: Queen, Cary L.
APPLICANT: Protein Design Labs, Inc.
TITLE OF INVENTION: Humanized Antibodies To Gamma-Interferon
FILE REFERENCE: 011823-008100US
CURRENT APPLICATION NUMBER: US/09/450,520A
CURRENT FILING DATE: 1999-11-29
PRIOR APPLICATION NUMBER: 60/110,523
PRIOR FILING DATE: 1998-12-01
NUMBER OF SEQ ID NOS: 13
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 13
LENGTH: 117
TYPE: PRT
ORGANISM: Homo sapiens
FEATURES:
OTHER INFORMATION: Variable region of the human Eu antibody heavy
US-09-450-520A-13

Query Match 65.7%; Score 421; DB 4; Length 117;
Best Local Similarity 71.0%; Pred. No. 4.2e-37;
Matches 88; Conservative 8; Mismatches 20; Indels 8; Gaps 2;

QY 1 QVQLQSGAEVKKPKSSVSVKSCASGTFNNNAIMVWROAPGQGLEWMGIIIPMEGTAKY 60
DB 1 QVQLVQSGAEVKKPKSSVSVKSCASGTFNRSALIIWVRQAPGQGLEWMGIIIPMGPPNY 60
QY 61 SQNFGRAVITADESTGTSAMELSLRSEDTAVYYCARSDLLPFPHALSPWG-RGTMV 119
DB 61 AAKFGKRVITADESTNTAYVMELSLRSEDTAFYFCAGG-----YGIYSPEEYNGGLV 113
QY 120 TVSS 123
DB 114 TVSS 117

RESULT 48
US-09-610-838-166
Sequence 166, Application US/09610838
Patent No. 6376217
GENERAL INFORMATION:
APPLICANT: Better, Marc D.
APPLICANT: Carroll, Stephen F.
APPLICANT: Studnicka, Gary M.
TITLE OF INVENTION: Immunotoxins Comprising Ribosome-Inactivating
NUMBER OF SEQUENCES: 173
CORRESPONDENCE ADDRESS:
ADDRESSEE: McAndrews, Held & Malloy, Ltd.
STREET: 500 West Madison Street, 34th floor
CITY: Chicago
STATE: Illinois
COUNTRY: USA
ZIP: 60661
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/610,838
FILING DATE: 06-JUL-2000
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/136,389
FILING DATE: 18-AUG-1998
APPLICATION NUMBER: 08/646,360
FILING DATE: 13-MAY-1996
APPLICATION NUMBER: PCT/US94/05348
FILING DATE: 12-MAY-1994
APPLICATION DATA:
APPLICATION NUMBER: US 08/064,691
FILING DATE: 12-MAY-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/988,430
FILING DATE: 09-DEC-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/901,707
FILING DATE: 19-JUN-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/787,567
FILING DATE: 04-NOV-1991
ATTORNEY/AGENT INFORMATION:
NAME: McNicholas, Janet M.
REGISTRATION NUMBER: 32,918
REFERENCE/DOCKET NUMBER: 200-70.P4
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312/707-9155
TELEFAX: 312/707-8889
TELEX: 650 388-1248
INFORMATION FOR SEQ ID NO: 166:
SEQUENCE CHARACTERISTICS:
LENGTH: 117 amino acids
TYPE: amino acid
STRANDEDNESS: No. 6376217 Relevant
TOPOLOGY: linear

MOLECULE TYPE: protein
US-09-610-838-166

Query Match 65.7%; Score 421; DB 4; Length 117;
Best Local Similarity 71.0%; Pred. No. 4,2e-37;
Matches 88; Conservative 8; Mismatches 20; Indels 8; Gaps 2;

QY 1 QVQLQSGAEVKKPQSSVRSVSCASGCTFNNAIMNWROAPQGLEWGGIIPMFETAKY 60
1 QVQLVQSGAEVKKPQSSVRSVSCASGCTFSRLIIVWRQAPQGLEWGGIIPMFETAKY 60

DB 61 SQNFGQVAITADESTGTASMEISLSRSEDYAVYCARSDLLLPFHALLSPWG-RGTWY 119
61 AOKFGQVITITADESTGTASMEISLSRSEDYAVYCARSDLLLPFHALLSPWG-RGTWY 113

QY 120 TVSS 123
DB 114 TVSS 117

LT 49
US-08-482-882-53

Sequence 53, Application US/08482882

Patent No. 5773218

GENERAL INFORMATION:

APPLICANT: Gallatin, W. Michael

APPLICANT: Vazeux, Rosemay

TITLE OF INVENTION: ICAM-Related Materials and Methods

NUMBER OF SEQUENCES: 116

CORRESPONDENCE ADDRESS:

ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun

STREET: 6300 Sears Tower, 233 S. Wacker Drive

CITY: Chicago

STATE: Illinois

COUNTRY: USA

ZIP: 60606

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/482,882

FILING DATE: 07-JUN-1995

CLASSIFICATION: 435

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/286,754

FILING DATE:

APPLICATION NUMBER: US 08/102,852

FILING DATE: 05-AUG-1993

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/009,266

FILING DATE: 22-JAN-1993

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/894,061

FILING DATE: 05-JUN-1992

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/889,724

FILING DATE: 26-MAY-1992

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/827,689

FILING DATE: 27-JAN-1992

ATTORNEY/AGENT INFORMATION:

NAME: No. 5773218and, Greta E.

REGISTRATION NUMBER: 35,302

REFERENCE/DOCKET NUMBER: 32178

TELECOMMUNICATION INFORMATION:

TELEPHONE: (312) 474-6300

TELEFAX: (312) 474-0448

TELEX: 25-3856

INFORMATION FOR SEQ ID NO: 53:

SEQUENCE CHARACTERISTICS:

LENGTH: 123 amino acids

TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-482-882-53

Query Match 65.4%; Score 419; DB 1; Length 123;
Best Local Similarity 70.7%; Pred. No. 7,2e-37;
Matches 87; Conservative 9; Mismatches 23; Indels 4; Gaps 2;

QY 1 QVQLQSGAEVKKPQSSVRSVSCASGCTFNNAIMNWROAPQGLEWGGIIPMFETAKY 60
5 QVQLVQSGAEVKKPQSSVRSVSCASGCTFSRLIIVWRQAPQGLEWGGIIPMFETAKY 64

DB 61 SQNFGQVAITADESTGTASMEISLSRSEDYAVYCARSDLLLPFHALLSPWG-RGTWY 120
65 NLKFGQVITITADESTGTASMEISLSRSEDYAVYCARSDLLLPFHALLSPWG-RGTWY 120

QY 121 VSS 123
DB 121 VSS 123

RESULT 50
US-08-483-389-53

Sequence 53, Application US/08483389

Patent No. 5811517

GENERAL INFORMATION:

APPLICANT: Gallatin, W. Michael

APPLICANT: Vazeux, Rosemay

TITLE OF INVENTION: ICAM-RELATED PROTEIN

NUMBER OF SEQUENCES: 118

CORRESPONDENCE ADDRESS:

ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun

STREET: 233 South Wacker Drive/6300 Sears tower

CITY: Chicago

STATE: Illinois

COUNTRY: United States of America

ZIP: 60606

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/483,389

FILING DATE: 07-JUN-1995

CLASSIFICATION: 530

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/102,852

FILING DATE: 05-AUG-1993

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/009,266

FILING DATE: 22-JAN-1993

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/894,061

FILING DATE: 05-JUN-1992

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/889,724

FILING DATE: 26-MAY-1992

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/827,689

FILING DATE: 27-JAN-1992

ATTORNEY/AGENT INFORMATION:

NAME: Suh, Young J.

REGISTRATION NUMBER: P-41,337

REFERENCE/DOCKET NUMBER: 27866/32760

TELECOMMUNICATION INFORMATION:

TELEPHONE: (312) 474-6300

TELEFAX: (312) 474-0448

TELEX: (312) 474-6600

INFORMATION FOR SEQ ID NO: 53:

SEQUENCE CHARACTERISTICS:

LENGTH: 123 amino acids

TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-483-389-53

Query Match 65.4%; Score 419; DB 2; Length 123;
Best Local Similarity 70.7%; Pred. No. 7.2e-37;
Matches 87; Conservative 9; Mismatches 23; Indels 4; Gaps 2;

QY	1	QVQLQQSGAEVKKPGSSVRVSCKASGGTFNNNAIINWVROAPGQGLEWMGGIIPMGITAKY	60
Db	5	QVQLVQSGAEVKKPGASVVSCKASGYTFDCTIIIMVRQAPGQGLEWMGKINPYFGITTY	64
QY	61	SONFGKRVATIDESTGTASMEISIRSEDTAVYYCARSRDILLFPNHALSPMGRTWYT	120
Db	65	NLKFGRVITIDTISTISTAYMELSSLRSEDTAVYCARKE--AYP-DANDYWGQGLVLT	120
QY	121	VSS 123	
Db	121	VSS 123	

Search completed: November 26, 2003, 13:42:23
Job time : 16.2436 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: November 26, 2003, 13:29:34 ; Search time 39.4231 Seconds
(without alignments)
495.227 Million cell updates/sec

Title: US-09-880-748-327_COPY_1_123
Perfect score: 641
Sequence: 1 QVQLQSGAEVKKPGSSVRV.....LPPHHAISPWGRTMTVSS 123

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1107863 seqs, 158726573 residues

number of hits satisfying chosen parameters: 1107863

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

A_Geneseq_19Jun03.*
1: /SIDSI/gcgdata/geneseq/geneseqp-emb1/AA1980.DAT.*
2: /SIDSI/gcgdata/geneseq/geneseqp-emb1/AA1981.DAT.*
3: /SIDSI/gcgdata/geneseq/geneseqp-emb1/AA1982.DAT.*
4: /SIDSI/gcgdata/geneseq/geneseqp-emb1/AA1983.DAT.*
5: /SIDSI/gcgdata/geneseq/geneseqp-emb1/AA1984.DAT.*
6: /SIDSI/gcgdata/geneseq/geneseqp-emb1/AA1985.DAT.*
7: /SIDSI/gcgdata/geneseq/geneseqp-emb1/AA1986.DAT.*
8: /SIDSI/gcgdata/geneseq/geneseqp-emb1/AA1987.DAT.*
9: /SIDSI/gcgdata/geneseq/geneseqp-emb1/AA1988.DAT.*
10: /SIDSI/gcgdata/geneseq/geneseqp-emb1/AA1989.DAT.*
11: /SIDSI/gcgdata/geneseq/geneseqp-emb1/AA1990.DAT.*
12: /SIDSI/gcgdata/geneseq/geneseqp-emb1/AA1991.DAT.*
13: /SIDSI/gcgdata/geneseq/geneseqp-emb1/AA1992.DAT.*
14: /SIDSI/gcgdata/geneseq/geneseqp-emb1/AA1993.DAT.*
15: /SIDSI/gcgdata/geneseq/geneseqp-emb1/AA1994.DAT.*
16: /SIDSI/gcgdata/geneseq/geneseqp-emb1/AA1995.DAT.*
17: /SIDSI/gcgdata/geneseq/geneseqp-emb1/AA1996.DAT.*
18: /SIDSI/gcgdata/geneseq/geneseqp-emb1/AA1997.DAT.*
19: /SIDSI/gcgdata/geneseq/geneseqp-emb1/AA1998.DAT.*
20: /SIDSI/gcgdata/geneseq/geneseqp-emb1/AA2000.DAT.*
21: /SIDSI/gcgdata/geneseq/geneseqp-emb1/AA2001.DAT.*
22: /SIDSI/gcgdata/geneseq/geneseqp-emb1/AA2002.DAT.*
23: /SIDSI/gcgdata/geneseq/geneseqp-emb1/AA2003.DAT.*
24: /SIDSI/gcgdata/geneseq/geneseqp-emb1/AA2003.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	641	100.0	249	23	ABP44316 Human Blys binding
2	626	97.7	249	23	ABP44774 Human Blys binding
3	622	97.0	249	23	ABP44516 Human Blys binding
4	622	97.0	249	23	ABP44673 Human Blys binding
5	622	96.9	249	23	ABP44793 Human Blys binding
6	621	96.9	249	23	ABP44649 Human Blys binding
7	620	96.7	249	23	ABP44333 Human Blys binding
8	620	96.7	249	23	ABP44352 Human Blys binding
9	620	96.7	249	23	ABP44653 Human Blys binding

10	619	96.6	249	23	ABP44579 Human Blys binding
11	619	96.6	249	23	ABP44810 Human Blys binding
12	618	96.4	249	23	ABP44313 Human Blys binding
13	618	96.4	249	23	ABP44314 Human Blys binding
14	618	96.4	249	23	ABP44585 Human Blys binding
15	618	96.4	249	23	ABP44690 Human Blys binding
16	617	96.3	249	23	ABP44355 Human Blys binding
17	617	96.3	249	23	ABP44393 Human Blys binding
18	617	96.3	249	23	ABP44475 Human Blys binding
19	617	96.3	249	23	ABP44732 Human Blys binding
20	617	96.3	249	23	ABP44732 Human Blys binding
21	616	96.1	249	23	ABP44364 Human Blys binding
22	616	96.1	249	23	ABP44388 Human Blys binding
23	616	96.1	249	23	ABP44685 Human Blys binding
24	616	96.1	249	23	ABP44687 Human Blys binding
25	616	96.1	249	23	ABP44698 Human Blys binding
26	616	96.1	249	23	ABP44702 Human Blys binding
27	616	96.1	249	23	ABP44718 Human Blys binding
28	615	95.9	249	23	ABP44404 Human Blys binding
29	615	95.9	249	23	ABP44417 Human Blys binding
30	615	95.9	249	23	ABP44633 Human Blys binding
31	615	95.9	249	23	ABP44644 Human Blys binding
32	615	95.9	249	23	ABP44711 Human Blys binding
33	615	95.9	249	23	ABP44737 Human Blys binding
34	615	95.9	249	23	ABP44754 Human Blys binding
35	615	95.9	249	23	ABP44775 Human Blys binding
36	615	95.9	249	23	ABP44778 Human Blys binding
37	615	95.9	249	23	ABP44783 Human Blys binding
38	614	95.8	249	23	ABP44311 Human Blys binding
39	614	95.8	249	23	ABP44318 Human Blys binding
40	614	95.8	249	23	ABP44422 Human Blys binding
41	614	95.8	249	23	ABP44450 Human Blys binding
42	614	95.8	249	23	ABP44563 Human Blys binding
43	614	95.8	249	23	ABP44705 Human Blys binding
44	614	95.8	249	23	ABP44735 Human Blys binding
45	614	95.8	249	23	ABP44741 Human Blys binding

ALIGNMENTS

RESULT 1
ABP44316
ID ABP44316 standard; Protein; 249 AA.
AC ABP44316;
XX
DT 19-AUG-2002 (first entry)
XX
DE Human Blys binding scfv SEQ ID 327.
XX
KW Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
KW tumour necrosis factor; B cell proliferation; B cell differentiation;
KW immunosuppressive; immunostimulant; immunomodulatory; antineutritic;
KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
KW systemic lupus erythematosus; rheumatoid arthritis; HIV; AIDS;
KW common variable immunodeficiency; acquired immunodeficiency syndrome.
XX
OS Homo sapiens.
XX
PN WO200202641-A1.
XX
PD 10-JAN-2002.
XX
PF 15-JUN-2001; 2001WO-US19110.
XX
PR 16-JUN-2000; 2000US-212210P.
XX
PR 17-OCT-2000; 2000US-240816P.
XX
PR 16-MAR-2001; 2001US-276248P.
XX
PR 21-MAR-2001; 2001US-277379P.
XX
PR 25-MAY-2001; 2001US-293499P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.

(CAME-) CAMBRIDGE ANTIBODY TECHNOLOGY.

XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
XX WPI; 2002-114799/15.

PT Antibodies against B Lymphocyte Stimulating polypeptides, useful for
PT the diagnosis and treatment of cancers and immune disorders -

PS Claim 1; Page 794-795; 3148pp; English.

CC This invention describes novel antibodies that immunospecifically bind to
CC B Lymphocyte Stimulator (Blys) polypeptides. Blys is a member of the
CC tumour necrosis factor (TNF) super family and induces B cell
CC proliferation and differentiation. The antibodies of the invention have
CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
CC antirheumatic and antiAIDS activity and can be used in vaccines to
CC inhibit the expression and activity of Blys. The antibodies bind to Blys
CC and so may be used to detect and quantitate the presence of Blys in
CC biological samples and may be used in this way to diagnose disease
CC associated with aberrant expression of Blys. They may also be
CC administered to treat diseases associated with aberrant Blys expression
CC and activity such as cancer, immune, and autoimmune disorders and
CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
CC the antibodies and fragments of the antibodies described in the method
CC of the invention.

SO Sequence 249 AA;

Query Match 100.0%; Score 641; DB 23; Length 249;
Best Local Similarity 100.0%; Pred. No. 1.9e-52;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLQSGAEVKKPGSSSVRSCKASGTFNNNAIMWVRQAPGQGLEWMGIIIMFGTAKY 60

DB 1 QVQLQSGAEVKKPGSSSVRSCKASGTFNNNAIMWVRQAPGQGLEWMGIIIMFGTAKY 60

QY 61 SQNFGRAVITADSTGTASMEISLSRSEDYAVYCARSDLLFPNHALSPWGRGTWVT 120
DB 61 SQNFGRAVITADSTGTASMEISLSRSEDYAVYCARSDLLFPNHALSPWGRGTWVT 120

QY 121 VSS 123
DB 121 VSS 123

ABP44774 standard; Protein; 249 AA.

ABP44774;

19-AUG-2002 (first entry)

Human Blys binding scFv SEQ ID 785.

Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
tumour necrosis factor; B cell proliferation; B cell differentiation;
immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
common variable immunodeficiency; acquired immunodeficiency syndrome.

Homo sapiens.

WO200202641-A1.

10-JAN-2002.

15-JUN-2001; 2001WO-US19110.

XX

PR 16-JUN-2000; 2000US-212210P.
PR 17-OCT-2000; 2000US-240816P.
PR 16-MAR-2001; 2001US-276248P.
PR 21-MAR-2001; 2001US-277379P.
PR 25-MAY-2001; 2001US-293499P.

PA (HUMA-) HUMAN GENOME SCI INC.
PA (CAME-) CAMBRIDGE ANTIBODY TECHNOLOGY.

XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
XX WPI; 2002-114799/15.

PT Antibodies against B Lymphocyte Stimulating polypeptides, useful for
PT the diagnosis and treatment of cancers and immune disorders -

PS Claim 1; Page 1338-1339; 3148pp; English.

CC This invention describes novel antibodies that immunospecifically bind to
CC B Lymphocyte Stimulator (Blys) polypeptides. Blys is a member of the
CC tumour necrosis factor (TNF) super family and induces B cell
CC proliferation and differentiation. The antibodies of the invention have
CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
CC antirheumatic and antiAIDS activity and can be used in vaccines to
CC inhibit the expression and activity of Blys. The antibodies bind to Blys
CC and so may be used to detect and quantitate the presence of Blys in
CC biological samples and may be used in this way to diagnose disease
CC associated with aberrant expression of Blys. They may also be
CC administered to treat diseases associated with aberrant Blys expression
CC and activity such as cancer, immune, and autoimmune disorders and
CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
CC the antibodies and fragments of the antibodies described in the method
CC of the invention.

SO Sequence 249 AA;

Query Match 97.7%; Score 626; DB 23; Length 249;
Best Local Similarity 97.6%; Pred. No. 5e-51;
Matches 120; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 QVQLQSGAEVKKPGSSSVRSCKASGTFNNNAIMWVRQAPGQGLEWMGIIIMFGTAKY 60

DB 1 QVQLQSGAEVKKPGSSSVRSCKASGTFNNNAIMWVRQAPGQGLEWMGIIIMFGTAKY 60

QY 61 SQNFGRAVITADSTGTASMEISLSRSEDYAVYCARSDLLFPNHALSPWGRGTWVT 120
DB 61 SQNFGRAVITADSTGTASMEISLSRSEDYAVYCARSDLLFPNHALSPWGRGTWVT 120

QY 121 VSS 123
DB 121 VSS 123

ABP44516 standard; Protein; 249 AA.

ABP44516;

19-AUG-2002 (first entry)

Human Blys binding scFv SEQ ID 527.

Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
tumour necrosis factor; B cell proliferation; B cell differentiation;
immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
common variable immunodeficiency; acquired immunodeficiency syndrome.

Homo sapiens.

OS

XX WO200202641-A1.
XX 10-JAN-2002.
XX 15-JUN-2001; 2001WO-US19110.
XX 16-JUN-2000; 2000US-212210P.
XX 17-OCT-2000; 2000US-240816P.
XX 16-MAR-2001; 2001US-276248P.
XX 21-MAR-2001; 2001US-277379P.
XX 25-MAY-2001; 2001US-293499P.
XX (HUMA-) HUMAN GENOME SCI INC.
XX (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
XX WPI; 2002-114799/15.
XX Antibodies against B Lymphocyte Stimulating polypeptides, useful for
XX the diagnosis and treatment of cancers and immune disorders -
XX Claim 1; Page 1031-1032; 3148pp; English.
XX This invention describes novel antibodies that immunospecifically bind to
XX B Lymphocyte Stimulator (BLyS) polypeptides. BLyS is a member of the
XX tumour necrosis factor (TNF) super family and induces B cell
XX proliferation and differentiation. The antibodies of the invention have
XX cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
XX antirheumatic and antiAIDS activity and can be used in vaccines to
XX inhibit the expression and activity of BLyS. The antibodies bind to BLyS
XX and so may be used to detect and quantitate the presence of BLyS in
XX biological samples and may be used in this way to diagnose disease
XX associated with aberrant expression of BLyS. They may also be
XX administered to treat diseases associated with aberrant BLyS expression
XX and activity such as cancer, immune, and autoimmune disorders and
XX diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
XX immunodeficiency (e.g. common variable immunodeficiency (CVID) and
XX acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
XX the antibodies and fragments of the antibodies described in the method
XX of the invention.
XX Sequence 249 AA;
XX
XX Query Match 97.0%; Score 622; DB 23; Length 249;
XX Best Local Similarity 97.6%; Pred. No. 1.2e-50;
XX Matches 120; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX 1 QVQLQSGAEVKKPGSSVRVSCKASGCTFNNNAIMWVRQAPGQGLEWMGIIIPMEGTAKY 60
XX 1 QVQLQSGAEVKKPGSSVRVSCKASGCTFNNNAIMWVRQAPGQGLEWMGIIIPMEGTAKY 60
XX Db 1 QVQLQSGAEVKKPGSSVRVSCKASGCTFNNNAIMWVRQAPGQGLEWMGIIIPMEGTAKY 60
XX 61 SQNFGRAVITADSTGTASMELSLSRSEDTAIVYCARSRDLLLFPFHALS PMWGRGTMVT 120
XX Db 61 SQNFGRAVITADSTGTASMELSLSRSEDTAIVYCARSRDLLLFPFHALS PMWGRGTMVT 120
XX Oy 121 VSS 123
XX 121 VSS 123
XX Db 121 VSS 123
XX
XX RESULT 4
XX ID ABP44673
XX ABP44673 standard; Protein; 249 AA.
XX AC ABP44673;
XX AC 19-AUG-2002 (first entry)
XX DT 19-AUG-2002 (first entry)
XX DE Human BLyS binding scFv SEQ ID 684.
XX KW BLyS; B Lymphocyte stimulator; TNF superfamily; human; cytostatic;

KW tumour necrosis factor; B cell proliferation; B cell differentiation;
KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
KW common variable immunodeficiency; acquired immunodeficiency syndrome.
XX Homo sapiens.
XX WO200202641-A1.
XX 10-JAN-2002.
XX 15-JUN-2001; 2001WO-US19110.
XX 16-JUN-2000; 2000US-212210P.
XX 17-OCT-2000; 2000US-240816P.
XX 16-MAR-2001; 2001US-276248P.
XX 21-MAR-2001; 2001US-277379P.
XX 25-MAY-2001; 2001US-293499P.
XX (HUMA-) HUMAN GENOME SCI INC.
XX (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
XX WPI; 2002-114799/15.
XX Antibodies against B Lymphocyte Stimulating polypeptides, useful for
XX the diagnosis and treatment of cancers and immune disorders -
XX Claim 1; Page 1218-1219; 3148pp; English.
XX This invention describes novel antibodies that immunospecifically bind to
XX B Lymphocyte Stimulator (BLyS) polypeptides. BLyS is a member of the
XX tumour necrosis factor (TNF) super family and induces B cell
XX proliferation and differentiation. The antibodies of the invention have
XX cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
XX antirheumatic and antiAIDS activity and can be used in vaccines to
XX inhibit the expression and activity of BLyS. The antibodies bind to BLyS
XX and so may be used to detect and quantitate the presence of BLyS in
XX biological samples and may be used in this way to diagnose disease
XX associated with aberrant expression of BLyS. They may also be
XX administered to treat diseases associated with aberrant BLyS expression
XX and activity such as cancer, immune, and autoimmune disorders and
XX diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
XX immunodeficiency (e.g. common variable immunodeficiency (CVID) and
XX acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
XX the antibodies and fragments of the antibodies described in the method
XX of the invention.
XX Sequence 249 AA;
XX
XX Query Match 97.0%; Score 622; DB 23; Length 249;
XX Best Local Similarity 97.6%; Pred. No. 1.2e-50;
XX Matches 120; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX 1 QVQLQSGAEVKKPGSSVRVSCKASGCTFNNNAIMWVRQAPGQGLEWMGIIIPMEGTAKY 60
XX 1 QVQLQSGAEVKKPGSSVRVSCKASGCTFNNNAIMWVRQAPGQGLEWMGIIIPMEGTAKY 60
XX Db 1 QVQLQSGAEVKKPGSSVRVSCKASGCTFNNNAIMWVRQAPGQGLEWMGIIIPMEGTAKY 60
XX 61 SQNFGRAVITADSTGTASMELSLSRSEDTAIVYCARSRDLLLFPFHALS PMWGRGTMVT 120
XX Db 61 SQNFGRAVITADSTGTASMELSLSRSEDTAIVYCARSRDLLLFPFHALS PMWGRGTMVT 120
XX Oy 121 VSS 123
XX 121 VSS 123
XX Db 121 VSS 123
XX
XX RESULT 5
XX ID ABP44793
XX ABP44793 standard; Protein; 249 AA.

AC ABP44793;
XX 19-AUG-2002 (first entry)
XX
DE Human Blys binding scfv SEQ ID 804.
XX
KM Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
KM tumour necrosis factor; B cell proliferation; B cell differentiation;
KM immunosuppressive; immunostimulant; immunomodulatory; antineumatic;
KM antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
KM systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
KM common variable immunodeficiency; acquired immunodeficiency syndrome.
XX
OS Homo sapiens.
XX
FN WO200202641-A1.
XX
PD 10-JAN-2002.
XX
XX 15-JUN-2001; 2001WO-US19110.
XX
PR 16-JUN-2000; 2000US-212210P.
PR 17-OCT-2000; 2000US-240816P.
PR 16-MAR-2001; 2001US-276248P.
PR 21-MAR-2001; 2001US-277379P.
PR 25-MAY-2001; 2001US-293499P.
XX
PA (HUMA-) HUMAN GENOME SCT INC.
PA (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX
XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
XX
XX WPI; 2002-114799/15.
XX
PT Antibodies against B lymphocyte Stimulating polypeptides, useful for
PT the diagnosis and treatment of cancers and immune disorders -
XX
PS Claim 1; Page 1360-1361; 3148pp; English.
XX
CC This invention describes novel antibodies that immunospecifically bind to
CC B lymphocyte Stimulator (Blys) polypeptides. Blys is a member of the
CC tumour necrosis factor (TNF) super family and induces B cell
CC proliferation and differentiation. The antibodies of the invention have
CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
CC antineumatic and antiAIDS activity and can be used in vaccines to
CC inhibit the expression and activity of Blys. The antibodies bind to Blys
CC and so may be used to detect and quantitate the presence of Blys in
CC biological samples and may be used in this way to diagnose disease
CC associated with aberrant expression of Blys. They may also be
CC administered to treat diseases associated with aberrant Blys expression
CC and activity such as cancer, immune, and autoimmune disorders and
CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
CC the antibodies and fragments of the antibodies described in the method
CC of the invention.
XX
SQ Sequence 249 AA;
Query Match 97.0%; Score 622; DB 23; Length 249;
Best Local Similarity 97.6%; Pred. No. 1.2e-50;
Matches 120; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

DB 121 VSS 123
RESULT 6
ID ABP44649 standard; Protein: 249 AA.
XX
XX ABP44649;
XX
XX 19-AUG-2002 (first entry)
XX
DE Human Blys binding scfv SEQ ID 660.
XX
KM Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
KM tumour necrosis factor; B cell proliferation; B cell differentiation;
KM immunosuppressive; immunostimulant; immunomodulatory; antineumatic;
KM antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
KM systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
KM common variable immunodeficiency; acquired immunodeficiency syndrome.
XX
OS Homo sapiens.
XX
FN WO200202641-A1.
XX
PD 10-JAN-2002.
XX
XX 15-JUN-2001; 2001WO-US19110.
XX
PR 16-JUN-2000; 2000US-212210P.
PR 17-OCT-2000; 2000US-240816P.
PR 16-MAR-2001; 2001US-276248P.
PR 21-MAR-2001; 2001US-277379P.
PR 25-MAY-2001; 2001US-293499P.
XX
PA (HUMA-) HUMAN GENOME SCT INC.
PA (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX
XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
XX
XX WPI; 2002-114799/15.
XX
PT Antibodies against B lymphocyte Stimulating polypeptides, useful for
PT the diagnosis and treatment of cancers and immune disorders -
XX
PS Claim 1; Page 1189-1190; 3148pp; English.
XX
CC This invention describes novel antibodies that immunospecifically bind to
CC B lymphocyte Stimulator (Blys) polypeptides. Blys is a member of the
CC tumour necrosis factor (TNF) super family and induces B cell
CC proliferation and differentiation. The antibodies of the invention have
CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
CC antineumatic and antiAIDS activity and can be used in vaccines to
CC inhibit the expression and activity of Blys. The antibodies bind to Blys
CC and so may be used to detect and quantitate the presence of Blys in
CC biological samples and may be used in this way to diagnose disease
CC associated with aberrant expression of Blys. They may also be
CC administered to treat diseases associated with aberrant Blys expression
CC and activity such as cancer, immune, and autoimmune disorders and
CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
CC the antibodies and fragments of the antibodies described in the method
CC of the invention.
XX
SQ Sequence 249 AA;
Query Match 96.9%; Score 621; DB 23; Length 249;
Best Local Similarity 97.6%; Pred. No. 1.5e-50;
Matches 120; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 61 SONFGQRAVITADESTGTASMELSLRSEDPTAVVYCARSRDLLLPPHIALSPWGRGTWVT 120
DB 61 SONFGQRAVITADESTGTASMELSLRSEDPTAVVYCARSRDLLLPPHIALSPWGRGTWVT 120
QY 121 VSS 123
DB 121 VSS 123

RESULT 7
ABP44333
ID ABP44333 standard; Protein; 249 AA.
XX AC ABP44333;
XX DT 19-AUG-2002 (first entry)
XX DE Human Blys binding scFv SEQ ID 344.

XX Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
XX tumour necrosis factor; B cell proliferation; B cell differentiation;
XX immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
XX antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
XX systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
XX common variable immunodeficiency; acquired immunodeficiency syndrome.

OS Homo sapiens.
XX WO200202641-A1.
XX PD 10-JAN-2002.
XX PF 15-JUN-2001; 2001WO-US19110.
XX PR 16-JUN-2000; 2000US-212210P.
XX PR 17-OCT-2000; 2000US-240816P.
XX PR 16-MAR-2001; 2001US-276248P.
XX PR 21-MAR-2001; 2001US-277379P.
XX PR 25-MAY-2001; 2001US-293499P.

PA (HUMA-) HUMAN GENOME SCI INC.
PA (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
PI Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
XX WPI; 2002-114799/15.

XX Antibodies against B lymphocyte Stimulating polypeptides, useful for
XX the diagnosis and treatment of cancers and immune disorders -
XX Claim 1; Page 814-815; 3148pp; English.

XX This invention describes novel antibodies that immunospecifically bind to
XX B lymphocyte Stimulator (Blys) polypeptides. Blys is a member of the
XX tumour necrosis factor (TNF) super family and induces B cell
XX proliferation and differentiation. The antibodies of the invention have
XX cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
XX antirheumatic and antiAIDS activity and can be used in vaccines to
XX inhibit the expression and activity of Blys. The antibodies bind to Blys
XX and so may be used to detect and quantitate the presence of Blys in
XX biological samples and may be used in this way to diagnose disease
XX associated with aberrant expression of Blys. They may also be
XX administered to treat diseases associated with aberrant Blys expression
XX and activity such as cancer, immune, and autoimmune disorders and
XX diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
XX immunodeficiency (e.g. common variable immunodeficiency (CVID) and
XX acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
XX the antibodies and fragments of the antibodies described in the method
XX of the invention.

XX Sequence 249 AA;
XX

Query Match 96.7%; Score 620; DB 23; Length 249;
Best Local Similarity 97.6%; Pred. No. 1.8e-50;
Matches 120; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 OVOLQSGAEYVKPPSSVRCSCASGGTFNNNAINWVQAPGQLEMMGGIIPMGTAKY 60
DB 1 OVOLQSGAEYVKPPSSVRCSCASGGTFNNNAINWVQAPGQLEMMGGIIPMGTAKY 60
QY 61 SONFGQRAVITADESTGTASMELSLRSEDPTAVVYCARSRDLLLPPHIALSPWGRGTWVT 120
DB 61 SONFGQRAVITADESTGTASMELSLRSEDPTAVVYCARSRDLLLPPHIALSPWGRGTWVT 120
QY 121 VSS 123
DB 121 VSS 123

RESULT 8
ABP44352
ID ABP44352 standard; Protein; 249 AA.
XX AC ABP44352;
XX DT 19-AUG-2002 (first entry)
XX DE Human Blys binding scFv SEQ ID 363.

XX Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
XX tumour necrosis factor; B cell proliferation; B cell differentiation;
XX immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
XX antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
XX systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
XX common variable immunodeficiency; acquired immunodeficiency syndrome.

OS Homo sapiens.
XX WO200202641-A1.
XX PD 10-JAN-2002.
XX PF 15-JUN-2001; 2001WO-US19110.
XX PR 16-JUN-2000; 2000US-212210P.
XX PR 17-OCT-2000; 2000US-240816P.
XX PR 16-MAR-2001; 2001US-276248P.
XX PR 21-MAR-2001; 2001US-277379P.
XX PR 25-MAY-2001; 2001US-293499P.

PA (HUMA-) HUMAN GENOME SCI INC.
PA (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
PI Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
XX WPI; 2002-114799/15.

XX Antibodies against B lymphocyte Stimulating polypeptides, useful for
XX the diagnosis and treatment of cancers and immune disorders -
XX Claim 1; Page 837-838; 3148pp; English.

XX This invention describes novel antibodies that immunospecifically bind to
XX B lymphocyte Stimulator (Blys) polypeptides. Blys is a member of the
XX tumour necrosis factor (TNF) super family and induces B cell
XX proliferation and differentiation. The antibodies of the invention have
XX cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
XX antirheumatic and antiAIDS activity and can be used in vaccines to
XX inhibit the expression and activity of Blys. The antibodies bind to Blys
XX and so may be used to detect and quantitate the presence of Blys in
XX biological samples and may be used in this way to diagnose disease
XX associated with aberrant expression of Blys. They may also be
XX administered to treat diseases associated with aberrant Blys expression
XX and activity such as cancer, immune, and autoimmune disorders and
XX diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,

CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
CC the antibodies and fragments of the antibodies described in the method
CC of the invention.

XX Sequence 249 AA;

Query Match 96.7%; Score 620; DB 23; Length 249;
Best Local Similarity 97.6%; Pred. No. 1.8e-50;
Matches 120; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 QVQLQSGAEVKKPKSSVRVSCKASGTFNNNAIMWVRQAPGQGLEWMGIIPEGTAKY 60
DB 1 QVQLQSGAEVKKPKSSVRVSCKASGTFNNNAIMWVRQAPGQGLEWMGIIPEGTAKY 60
QY 61 SQNFGRAVITADESTGTAEMSLSRSEDTAVYYCARSDLLFPFHALLSPWGRGTWVT 120
DB 61 SQNFGRAVITADESTGTAEMSLSRSEDTAVYYCARSDLLFPFHALLSPWGRGTWVT 120
QY 121 VSS 123
DB 121 VSS 123

RESULT 9

ABP44653
ID ABP44653 standard; Protein; 249 AA.

XX ABP44653;

DT 19-AUG-2002 (first entry)

DE Human Blys binding scFv SEQ ID 664.

XX Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
XX tumour necrosis factor; B cell proliferation; B cell differentiation;
XX immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
XX antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
XX systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
XX common variable immunodeficiency; acquired immunodeficiency syndrome.

OS Homo sapiens.

PN WO200202641-A1.

PD 10-JAN-2002.

XX 15-JUN-2001; 2001WO-US19110.

PR 16-JUN-2000; 2000US-212210P.

PR 17-OCT-2000; 2000US-240816P.

PR 16-MAR-2001; 2001US-276248P.

PR 21-MAR-2001; 2001US-277379P.

PR 25-MAY-2001; 2001US-293499P.

XX (HUMA-) HUMAN GENOME SCI INC.

PA (CAMP-) CAMBRIDGE ANTIBODY TECHNOLOGY.

PI Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;

DR WPI; 2002-114799/15.

XX Antibodies against B lymphocyte stimulating polypeptides, useful for

PT the diagnosis and treatment of cancers and immune disorders -

XX Claim 1; Page 1194-1195; 3148pp; English.

XX This invention describes novel antibodies that immunospecifically bind to

CC B lymphocyte stimulator (Blys) polypeptides. Blys is a member of the

CC tumour necrosis factor (TNF) super family and induces B cell

CC proliferation and differentiation. The antibodies of the invention have

CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,

CC antirheumatic and antiAIDS activity and can be used in vaccines to

CC inhibit the expression and activity of Blys. The antibodies bind to Blys
CC and so may be used to detect and quantitate the presence of Blys in
CC biological samples and may be used in this way to diagnose disease
CC associated with aberrant expression of Blys. They may also be
CC administered to treat diseases associated with aberrant Blys expression
CC and activity such as cancer, immune, and autoimmune disorders and
CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
CC the antibodies and fragments of the antibodies described in the method
CC of the invention.

XX Sequence 249 AA;

Query Match 96.7%; Score 620; DB 23; Length 249;
Best Local Similarity 97.6%; Pred. No. 1.8e-50;
Matches 120; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 QVQLQSGAEVKKPKSSVRVSCKASGTFNNNAIMWVRQAPGQGLEWMGIIPEGTAKY 60
DB 1 QVQLQSGAEVKKPKSSVRVSCKASGTFNNNAIMWVRQAPGQGLEWMGIIPEGTAKY 60
QY 61 SQNFGRAVITADESTGTAEMSLSRSEDTAVYYCARSDLLFPFHALLSPWGRGTWVT 120
DB 61 SQNFGRAVITADESTGTAEMSLSRSEDTAVYYCARSDLLFPFHALLSPWGRGTWVT 120
QY 121 VSS 123
DB 121 VSS 123

RESULT 10

ABP44579
ID ABP44579 standard; Protein; 249 AA.

XX ABP44579;

DT 19-AUG-2002. (first entry)

DE Human Blys binding scFv SEQ ID 590.

XX Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
XX tumour necrosis factor; B cell proliferation; B cell differentiation;
XX immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
XX antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
XX systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
XX common variable immunodeficiency; acquired immunodeficiency syndrome.

OS Homo sapiens.

PN WO200202641-A1.

PD 10-JAN-2002.

XX 15-JUN-2001; 2001WO-US19110.

PR 16-JUN-2000; 2000US-212210P.

PR 17-OCT-2000; 2000US-240816P.

PR 16-MAR-2001; 2001US-276248P.

PR 21-MAR-2001; 2001US-277379P.

PR 25-MAY-2001; 2001US-293499P.

XX (HUMA-) HUMAN GENOME SCI INC.

PA (CAMP-) CAMBRIDGE ANTIBODY TECHNOLOGY.

PI Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;

DR WPI; 2002-114799/15.

XX Antibodies against B lymphocyte stimulating polypeptides, useful for

PT the diagnosis and treatment of cancers and immune disorders -

XX Claim 1; Page 1106-1107; 3148pp; English.

XX This invention describes novel antibodies that immunospecifically bind to
CC B lymphocyte stimulator (Blys) polypeptides. Blys is a member of the
CC tumour necrosis factor (TNF) super family and induces B cell
CC proliferation and differentiation. The antibodies of the invention have
CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
CC antirheumatic and antiAIDS activity and can be used in vaccines to
CC inhibit the expression and activity of Blys. The antibodies bind to Blys
CC and so may be used to detect and quantitate the presence of Blys in
CC biological samples and may be used in this way to diagnose disease
CC associated with aberrant expression of Blys. They may also be
CC administered to treat diseases associated with aberrant Blys expression
CC and activity such as cancer, immune, and autoimmune disorders and
CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
CC acquired immunodeficiency syndrome (AIDS)). ABP4390-ABP47228 represent
CC the antibodies and fragments of the antibodies described in the method
CC of the invention.

XX Sequence 249 AA;

XX Query Match 96.6%; Score 619; DB 23; Length 249;

XX Best Local Similarity 97.6%; Pred. No. 2.3e-50; Mismatches 3; Indels 0; Gaps 0;

XX Matches 120; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1 QVQLQSGAEVKKKSSVRVSCKASGTFNNAINWVROAQGLWMGGIIPMFGRGAKY 60
Db 1 QVQLQSGAEVKKKSSVRVSCKASGTFNNAINWVROAQGLWMGGIIPMFGRGAKY 60
Qy 61 SQNFQGRVAITADESTGASWELSLRSEDTAVYYCARSDLLFPFHANLSPWGRGTWVT 120
Db 61 SQNFQGRVAITADESTGASWELSLRSEDTAVYYCARSDLLFPFHANLSPWGRGTWVT 120

Qy 121 VSS 123
Db 121 VSS 123

RESULT 11
ABP44810

ID ABP44810 standard; Protein: 249 AA.

AC ABP44810;
DT 19-AUG-2002 (first entry)
XX

DE Human Blys binding scFv SEQ ID 821.

XX Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
XX tumour necrosis factor; B cell proliferation; B cell differentiation;
XX immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
XX antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
XX systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
XX common variable immunodeficiency; acquired immunodeficiency syndrome.

OS Homo sapiens.

PN WO200202641-A1.

PD 10-JAN-2002.

PF 15-JUN-2001; 2001WO-US19110.

PR 16-JUN-2000; 2000US-212210P.

PR 17-OCT-2000; 2000US-240816P.

PR 16-MAR-2001; 2001US-276248P.

PR 21-MAR-2001; 2001US-277379P.

PR 25-MAY-2001; 2001US-293499P.

XX (HUMA-) HUMAN GENOME SCI INC.
XX (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;

XX WPI; 2002-114799/15.
DR Antibodies against B lymphocyte stimulating polypeptides; useful for
XX the diagnosis and treatment of cancers and immune disorders -
PT Claim 1; Page 1380-1381; 3148P; English.

XX This invention describes novel antibodies that immunospecifically bind to
CC B lymphocyte stimulator (Blys) polypeptides. Blys is a member of the
CC tumour necrosis factor (TNF) super family and induces B cell
CC proliferation and differentiation. The antibodies of the invention have
CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
CC antirheumatic and antiAIDS activity and can be used in vaccines to
CC inhibit the expression and activity of Blys. The antibodies bind to Blys
CC and so may be used to detect and quantitate the presence of Blys in
CC biological samples and may be used in this way to diagnose disease
CC associated with aberrant expression of Blys. They may also be
CC administered to treat diseases associated with aberrant Blys expression
CC and activity such as cancer, immune, and autoimmune disorders and
CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
CC acquired immunodeficiency syndrome (AIDS)). ABP4390-ABP47228 represent
CC the antibodies and fragments of the antibodies described in the method
CC of the invention.

XX Sequence 249 AA;

XX Query Match 96.6%; Score 619; DB 23; Length 249;

XX Best Local Similarity 97.6%; Pred. No. 2.3e-50; Mismatches 3; Indels 0; Gaps 0;

Qy 1 QVQLQSGAEVKKKSSVRVSCKASGTFNNAINWVROAQGLWMGGIIPMFGRGAKY 60
Db 1 QVQLQSGAEVKKKSSVRVSCKASGTFNNAINWVROAQGLWMGGIIPMFGRGAKY 60
Qy 61 SQNFQGRVAITADESTGASWELSLRSEDTAVYYCARSDLLFPFHANLSPWGRGTWVT 120
Db 61 SQNFQGRVAITADESTGASWELSLRSEDTAVYYCARSDLLFPFHANLSPWGRGTWVT 120

Qy 121 VSS 123
Db 121 VSS 123

RESULT 12
ABP44313

ID ABP44313 standard; Protein: 249 AA.

AC ABP44313;
DT 19-AUG-2002 (first entry)
XX

DE Human Blys binding scFv SEQ ID 324.

XX Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
XX tumour necrosis factor; B cell proliferation; B cell differentiation;
XX immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
XX antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
XX systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
XX common variable immunodeficiency; acquired immunodeficiency syndrome.

OS Homo sapiens.

PN WO200202641-A1.

PD 10-JAN-2002.

PF 15-JUN-2001; 2001WO-US19110.

PR 16-JUN-2000; 2000US-212210P.

PR 17-OCT-2000; 2000US-240816P.

PR 16-MAR-2001; 2001US-276248P.

KM systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
KM common variable immunodeficiency; acquired immunodeficiency syndrome.
XX
OS Homo sapiens.
XX
PN WO200202641-A1.
XX
PD 10-JAN-2002.
XX
PF 15-JUN-2001; 2001WO-US19110.
XX
PR 16-JUN-2000; 2000US-212210P.
PR 17-OCT-2000; 2000US-240816P.
PR 16-MAR-2001; 2001US-276248P.
PR 21-MAR-2001; 2001US-277379P.
PR 25-MAY-2001; 2001US-293499P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
PA (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX
DR Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
WPI, 2002-114799/15.
XX
PT Antibodies against B Lymphocyte Stimulating polypeptides, useful for
PT the diagnosis and treatment of cancers and immune disorders -
XX
PS Claim 1; Page 1113-1114; 3148pp; English.
XX
CC This invention describes novel antibodies that immunospecifically bind to
CC B Lymphocyte Stimulator (Blys) polypeptides. Blys is a member of the
CC tumour necrosis factor (TNF) super family and induces B cell
CC proliferation and differentiation. The antibodies of the invention have
CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
CC antirheumatic and antiAIDS activity and can be used in vaccines to
CC inhibit the expression and activity of Blys. The antibodies bind to Blys
CC and so may be used to detect and quantitate the presence of Blys in
CC biological samples and may be used in this way to diagnose disease
CC associated with aberrant expression of Blys. They may also be
CC administered to treat diseases associated with aberrant Blys expression
CC and activity such as cancer, immune, and autoimmune disorders and
CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
CC the antibodies and fragments of the antibodies described in the method
CC of the invention.
XX
SQ Sequence 249 AA;
SQ
Query Match 96.4%; Score 618; DB 23; Length 249;
Best Local Similarity 96.7%; Pred. No. 2.8e-50;
Matches 119; Conservative 1; Mismatches 3; Indels 0; Gaps 0;
QY 1 QVOLOQSGAEVYKKGSSVRSVCKASGTFNNNAINWVROAPQGLWMGIIIPMGFTAKY 60
DB 1 QVOLOQSGAEVYKKGSSVRSVCKASGTFNNNAINWVROAPQGLWMGIIIPMGFTAKY 60
QY 61 SONFOGRAVITADESTGASWELSLRSEDPTAVVYCARSDLLLPFHIALSPWGGTAVT 120
DB 61 SONFOGRAVITADESTGASWELSLRSEDPTAVVYCARSDLLLPFHIALSPWGGTAVT 120
QY 121 VSS 123
DB 121 VSS 123
RESULT 15
ABP44690 standard; Protein; 249 AA.
XX
AC ABP44690;
XX
DT 19-AUG-2002 (first entry)

XX
DE Human Blys binding scFv SEQ ID 701.
XX
XX Blys; B Lymphocyte stimulator; TNF superfamily; human; cytostatic;
KM tumour necrosis factor; B cell proliferation; B cell differentiation;
KM immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
KM antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
KM systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
KM common variable immunodeficiency; acquired immunodeficiency syndrome.
XX
OS Homo sapiens.
XX
PN WO200202641-A1.
XX
PD 10-JAN-2002.
XX
PF 15-JUN-2001; 2001WO-US19110.
XX
PR 16-JUN-2000; 2000US-212210P.
PR 17-OCT-2000; 2000US-240816P.
PR 16-MAR-2001; 2001US-276248P.
PR 21-MAR-2001; 2001US-277379P.
PR 25-MAY-2001; 2001US-293499P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
PA (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX
DR Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
WPI, 2002-114799/15.
XX
PT Antibodies against B Lymphocyte Stimulating polypeptides, useful for
PT the diagnosis and treatment of cancers and immune disorders -
XX
PS Claim 1; Page 1238-1239; 3148pp; English.
XX
CC This invention describes novel antibodies that immunospecifically bind to
CC B Lymphocyte Stimulator (Blys) polypeptides. Blys is a member of the
CC tumour necrosis factor (TNF) super family and induces B cell
CC proliferation and differentiation. The antibodies of the invention have
CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
CC antirheumatic and antiAIDS activity and can be used in vaccines to
CC inhibit the expression and activity of Blys. The antibodies bind to Blys
CC and so may be used to detect and quantitate the presence of Blys in
CC biological samples and may be used in this way to diagnose disease
CC associated with aberrant expression of Blys. They may also be
CC administered to treat diseases associated with aberrant Blys expression
CC and activity such as cancer, immune, and autoimmune disorders and
CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
CC the antibodies and fragments of the antibodies described in the method
CC of the invention.
XX
SQ Sequence 249 AA;
SQ
Query Match 96.4%; Score 618; DB 23; Length 249;
Best Local Similarity 96.7%; Pred. No. 2.8e-50;
Matches 119; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 1 QVOLOQSGAEVYKKGSSVRSVCKASGTFNNNAINWVROAPQGLWMGIIIPMGFTAKY 60
DB 1 QVOLOQSGAEVYKKGSSVRSVCKASGTFNNNAINWVROAPQGLWMGIIIPMGFTAKY 60
QY 61 SONFOGRAVITADESTGASWELSLRSEDPTAVVYCARSDLLLPFHIALSPWGGTAVT 120
DB 61 SONFOGRAVITADESTGASWELSLRSEDPTAVVYCARSDLLLPFHIALSPWGGTAVT 120
QY 121 VSS 123
DB 121 VSS 123

RESULT 16

ABP4355 ID ABP4355 standard; Protein; 249 AA.

XX AC ABP4355;

XX DT 19-AUG-2002 (first entry)

XX DE Human Blys binding scFv SEQ ID 366.

XX Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
XX tumor necrosis factor; B cell proliferation; B cell differentiation;
XX immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
XX antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
XX systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
XX common variable immunodeficiency; acquired immunodeficiency syndrome.

XX OS Homo sapiens.

XX WO200202641-A1.

XX PF 10-JAN-2002.

XX PF 15-JUN-2001; 2001WO-US19110.

XX PR 16-JUN-2000; 2000US-212210P.

XX PR 17-OCT-2000; 2000US-240816P.

XX PR 16-MAR-2001; 2001US-276248P.

XX PR 21-MAR-2001; 2001US-277379P.

XX PR 25-MAY-2001; 2001US-293499P.

XX PA (HUMA-) HUMAN GENOME SCI INC.

XX PA (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.

XX PI Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;

XX DR WPI; 2002-114799/15.

XX PT Antibodies against B lymphocyte stimulating polypeptides, useful for

XX PT the diagnosis and treatment of cancers and immune disorders -

XX PS Claim 1; Page 840-841; 3148pp; English.

XX This invention describes novel antibodies that immunospecifically bind to
XX B lymphocyte stimulator (Blys) polypeptides. Blys is a member of the
XX tumor necrosis factor (TNF) super family and induces B cell
XX proliferation and differentiation. The antibodies of the invention have
XX cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
XX antirheumatic and antiAIDS activity and can be used in vaccines to
XX inhibit the expression and activity of Blys. The antibodies bind to Blys
XX and so may be used to detect and quantitate the presence of Blys in
XX biological samples and may be used in this way to diagnose disease
XX associated with aberrant expression of Blys. They may also be
XX administered to treat diseases associated with aberrant Blys expression
XX and activity such as cancer, immune, and autoimmune disorders and
XX diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
XX immunodeficiency (e.g. common variable immunodeficiency (CVID) and
XX acquired immunodeficiency syndrome (AIDS)). ABP4390-ABP47228 represent
XX the antibodies and fragments of the antibodies described in the method
XX of the invention.

SQ Sequence 249 AA;

Query Match 96.3%; Score 617; DB 23; Length 249;

Best Local Similarity 96.7%; Pred. No. 3.5e-50;

Matches 119; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 1 QVLOOGSGAEVKKPGSSVRVSCKASGCTFNNAINNVRQAPGGLEMGGITPMFGTAXY 60

Db 1 QVLOOGSGAEVKKPGSSVRVSCKASGCTFNNAINNVRQAPGGLEMGGITPMFGTAXY 60

QY 61 SONFGRAVATIDESTGTASMEISLRSEDTAVYYCARSDLLLPFHALLSPWGRGTWVT 120

DB 61 SONFGRAVATIDESTGTASMEISLRSEDTAVYYCARSDLLLPFHALLSPWGRGTWVT 120

QY 121 VSS 123

DB 121 VSS 123

RESULT 17

ABP4393 ID ABP4393 standard; Protein; 249 AA.

XX AC ABP4393;

XX DT 19-AUG-2002 (first entry)

XX DE Human Blys binding scFv SEQ ID 404.

XX Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
XX tumor necrosis factor; B cell proliferation; B cell differentiation;
XX immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
XX antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
XX systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
XX common variable immunodeficiency; acquired immunodeficiency syndrome.

XX OS Homo sapiens.

XX WO200202641-A1.

XX PF 10-JAN-2002.

XX PF 15-JUN-2001; 2001WO-US19110.

XX PR 16-JUN-2000; 2000US-212210P.

XX PR 17-OCT-2000; 2000US-240816P.

XX PR 16-MAR-2001; 2001US-276248P.

XX PR 21-MAR-2001; 2001US-277379P.

XX PR 25-MAY-2001; 2001US-293499P.

XX PA (HUMA-) HUMAN GENOME SCI INC.

XX PA (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.

XX PI Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;

XX DR WPI; 2002-114799/15.

XX This invention describes novel antibodies that immunospecifically bind to
XX B lymphocyte stimulator (Blys) polypeptides. Blys is a member of the
XX tumor necrosis factor (TNF) super family and induces B cell
XX proliferation and differentiation. The antibodies of the invention have
XX cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
XX antirheumatic and antiAIDS activity and can be used in vaccines to
XX inhibit the expression and activity of Blys. The antibodies bind to Blys
XX and so may be used to detect and quantitate the presence of Blys in
XX biological samples and may be used in this way to diagnose disease
XX associated with aberrant expression of Blys. They may also be
XX administered to treat diseases associated with aberrant Blys expression
XX and activity such as cancer, immune, and autoimmune disorders and
XX diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
XX immunodeficiency (e.g. common variable immunodeficiency (CVID) and
XX acquired immunodeficiency syndrome (AIDS)). ABP4390-ABP47228 represent
XX the antibodies and fragments of the antibodies described in the method
XX of the invention.

SQ Sequence 249 AA;

Query Match 96.3%; Score 617; DB 23; Length 249;

Best Local Similarity 96.7%; Pred. No. 3.5e-50;

Matches 119; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY	1	QYQLOQOSGAEVKKPGSGSVAVSCASGCTFNNNAINNVPQAPGGLEMGIIIMPGTAKY	60
DB	1	QYQLOQOSGAEVKKPGSGSVAVSCASGCTFNNNAINNVPQAPGGLEMGIIIMPGTAKY	60
QY	61	SONFGQVAITADESTGTASMEILSRSEDTAVYYCARSRDLLLPPHIALSPMGRTMT	120
DB	61	SONFGQVAITADESTGTASMEILSRSEDTAVYYCARSRDLLLPPHIALSPMGRTMT	120
QY	121	VSS	123
DB	121	VSS	123
RESULT 18			
ABP44475			
ID	ABP44475	standard; Protein; 249 AA.	
AC	ABP44475;		
XX	19-AUG-2002	(first entry)	
DE	Human BlyS binding scFv SEQ ID 486.		
XX	BlyS; B lymphocyte stimulator; TNF superfamily; human; cytosolic;		
XX	tumour necrosis factor; B cell proliferation; B cell differentiation;		
XX	immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;		
XX	antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;		
XX	systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;		
XX	common variable immunodeficiency; acquired immunodeficiency syndrome.		
OS	Homo sapiens.		
XX	WO200202641-A1.		
PN	10-JAN-2002.		
PD	15-JUN-2001; 2001WO-US19110.		
PF	16-JUN-2000; 2000US-212210P.		
PR	17-OCT-2000; 2000US-240816P.		
PR	16-MAR-2001; 2001US-276248P.		
PR	21-MAR-2001; 2001US-277379P.		
PR	25-MAY-2001; 2001US-293499P.		
XX	(HUMA-) HUMAN GENOME SCI INC.		
PA	(CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.		
XX	Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;		
DR	WPI; 2002-114799/15.		
XX	Antibodies against B lymphocyte stimulating polypeptides, useful for		
PT	the diagnosis and treatment of cancers and immune disorders -		
XX	Claim 1; Page 983-984; 3148pp; English.		
PS	This invention describes novel antibodies that immunospecifically bind to		
CC	B lymphocyte stimulator (BlyS) polypeptides. BlyS is a member of the		
CC	tumour necrosis factor (TNF) super family and induces B cell		
CC	proliferation and differentiation. The antibodies of the invention have		
CC	cytostatic, immunosuppressive, immunostimulant, immunomodulatory,		
CC	antirheumatic and antiAIDS activity and can be used in vaccines to		
CC	inhibit the expression and activity of BlyS. The antibodies bind to BlyS		
CC	and so may be used to detect and quantitate the presence of BlyS in		
CC	biological samples and may be used in this way to diagnose disease		
CC	associated with aberrant expression of BlyS. They may also be		
CC	administered to treat diseases associated with aberrant BlyS expression		
CC	and activity such as cancer, immune, and autoimmune disorders and		
CC	diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,		
CC	immunodeficiency (e.g. common variable immunodeficiency (CVID)) and		
CC	acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent		
CC	the antibodies and fragments of the antibodies described in the method		

CC	XX	Sequence	249 AA:	96.3%;	Score 617;	DB 23;	Length 249;	
CC	XX	Query Match		96.3%;	Score 617;	DB 23;	Length 249;	
CC	XX	Best Local Similarity		96.7%;	Pred. No. 3.5e-50;			
CC	XX	Matches 119;	Conservative 1;		Indels 3;		Gaps 0	
CC	XX	QY	1	QVQLQSGAEVKKKQSSVRVSCKASGGFFNNNAIMWVQAPQGGEMMGII	PMFGTAKY	60		
CC	XX	DB	1	QVQLQSGAEVKKKQSSVRVSCKASGGFFNNNAIMWVQAPQGGEMMGII	PMFGTAKY	60		
CC	XX	QY	61	SONFGRAVITADESTGTASNELSLRSEDYAVVYCARSDLLLP	PPHALLSPWGRGTWVT	120		
CC	XX	DB	61	SONFGRAVITADESTGTASNELSLRSEDYAVVYCARSDLLLP	PPHALLSPWGRGTWVT	120		
CC	XX	QY	121	VSS	123			
CC	XX	DB	121	VSS	123			
CC	XX	RESULT 19						
CC	XX	ABP44712						
CC	XX	ID	ABP44712	standard;	Protein;	249 AA.		
CC	XX	AC	ABP44712;					
CC	XX	DT	19-AUG-2002	(first entry)				
CC	XX	DE	Human Blys binding scFv SEQ ID 723.					
CC	XX	KW	Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;					
CC	XX	KW	tumour necrosis factor; B cell proliferation; B cell differentiation;					
CC	XX	KW	immunoadhesive; immunostimulant; immunomodulatory; antirheumatic;					
CC	XX	KW	antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;					
CC	XX	KW	systemic lupus erythematosus; rheumatoid arthritis; CYID; AIDS;					
CC	XX	OS	Common variable immunodeficiency; acquired immunodeficiency syndrome.					
CC	XX	PN	Homo sapiens.					
CC	XX	PD	WO200202641-A1.					
CC	XX	PE	10-JAN-2002.					
CC	XX	PF	15-JUN-2001; 2001WO-US19110.					
CC	XX	PR	16-JUN-2000; 2000US-212210P.					
CC	XX	PR	17-OCT-2000; 2000US-240816P.					
CC	XX	PR	16-MAR-2001; 2001US-276248P.					
CC	XX	PR	21-MAR-2001; 2001US-277379P.					
CC	XX	PR	25-MAY-2001; 2001US-293499P.					
CC	XX	PA	(HUMA-) HUMAN GENOME SCI INC.					
CC	XX	PA	(CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.					
CC	XX	PI	Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;					
CC	XX	DR	WPI; 2002-114799/15.					
CC	XX	PT	Antibodies against B Lymphocyte Stimulating polypeptides, useful for					
CC	XX	PS	the diagnosis and treatment of cancers and immune disorders -					
CC	XX	XX	Claim 1; Page 1264-1265; 3148pp; English.					

CC associated with aberrant expression of BlyS. They may also be
CC administered to treat diseases associated with aberrant BlyS expression
CC and activity such as cancer, immune, and autoimmune disorders and
CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
CC immunodeficiency (e.g., common variable immunodeficiency (CVID) and
CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
CC the antibodies and fragments of the antibodies described in the method
CC of the invention.
XX
SQ Sequence 249 AA;
Query Match 96.3%; Score 617; DB 23; Length 249;
Best Local Similarity 96.7%; Pred. No. 3.5e-50;
Matches 119; Conservative 1; Mismatches 3; Indels 0; Gaps 0;
QY 1 QVQLQSGAEVKKPGSSVRVSCKASGCTFNNNAIMVWRQAPQGLEMGGIIPMGITAKY 60
DB 1 QVQLQSGAEVKKPGSSVRVSCKASGCTFNNNAIMVWRQAPQGLEMGGIIPMGITAKY 60
61 SONFGRAVITADESTGTASMEISLRSEDTAVYYCARSRDLLFPFHALLSPMGRTWVT 120
61 SONFGRAVITADESTGTASMEISLRSEDTAVYYCARSRDLLFPFHALLSPMGRTWVT 120
QY 121 VSS 123
DB 121 VSS 123
RESULT 20
ABP44732
ID ABP44732 standard; Protein; 249 AA.
XX
AC ABP44732;
XX
DT 19-AUG-2002 (first entry)
XX
DE Human BlyS binding scFv SEQ ID 743.
XX
KW BlyS; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
KW tumour necrosis factor; B cell proliferation; B cell differentiation;
KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
KW common variable immunodeficiency; acquired immunodeficiency syndrome.
OS Homo sapiens.
XX
XX WO200202641-A1.
XX
XX 10-JAN-2002.
XX
XX 15-JUN-2001; 2001WO-US19110.
XX
XX 16-JUN-2000; 2000US-212210P.
XX
XX 17-OCT-2000; 2000US-240816P.
XX
XX 16-MAR-2001; 2001US-276248P.
XX
XX 21-MAR-2001; 2001US-277379P.
XX
XX 25-MAY-2001; 2001US-293499P.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX
XX (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX
XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
XX
XX WPI; 2002-114799/15.
XX
XX Antibodies against B lymphocyte stimulating polypeptides, useful for
XX the diagnosis and treatment of cancers and immune disorders -
XX
XX Claim 1; Page 1288-1289; 3148pp; English.
XX
XX This invention describes novel antibodies that immunospecifically bind to
XX B lymphocyte stimulator (BlyS) polypeptides. BlyS is a member of the

CC tumour necrosis factor (TNF) super family and induces B cell
CC proliferation and differentiation. The antibodies of the invention have
CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
CC antirheumatic and antiAIDS activity and can be used in vaccines to
CC inhibit the expression and activity of BlyS. The antibodies bind to BlyS
CC and so may be used to detect and quantitate the presence of BlyS in
CC biological samples and may be used in this way to diagnose disease
CC associated with aberrant expression of BlyS. They may also be
CC administered to treat diseases associated with aberrant BlyS expression
CC and activity such as cancer, immune, and autoimmune disorders and
CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
CC the antibodies and fragments of the antibodies described in the method
CC of the invention.
XX
SQ Sequence 249 AA;
Query Match 96.3%; Score 617; DB 23; Length 249;
Best Local Similarity 96.7%; Pred. No. 3.5e-50;
Matches 119; Conservative 1; Mismatches 3; Indels 0; Gaps 0;
QY 1 QVQLQSGAEVKKPGSSVRVSCKASGCTFNNNAIMVWRQAPQGLEMGGIIPMGITAKY 60
DB 1 QVQLQSGAEVKKPGSSVRVSCKASGCTFNNNAIMVWRQAPQGLEMGGIIPMGITAKY 60
61 SONFGRAVITADESTGTASMEISLRSEDTAVYYCARSRDLLFPFHALLSPMGRTWVT 120
61 SONFGRAVITADESTGTASMEISLRSEDTAVYYCARSRDLLFPFHALLSPMGRTWVT 120
QY 121 VSS 123
DB 121 VSS 123
RESULT 21
ABP44364
ID ABP44364 standard; Protein; 249 AA.
XX
AC ABP44364;
XX
DT 19-AUG-2002 (first entry)
XX
DE Human BlyS binding scFv SEQ ID 375.
XX
KW BlyS; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
KW tumour necrosis factor; B cell proliferation; B cell differentiation;
KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
KW common variable immunodeficiency; acquired immunodeficiency syndrome.
OS Homo sapiens.
XX
XX WO200202641-A1.
XX
XX 10-JAN-2002.
XX
XX 15-JUN-2001; 2001WO-US19110.
XX
XX 16-JUN-2000; 2000US-212210P.
XX
XX 17-OCT-2000; 2000US-240816P.
XX
XX 16-MAR-2001; 2001US-276248P.
XX
XX 21-MAR-2001; 2001US-277379P.
XX
XX 25-MAY-2001; 2001US-293499P.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX
XX (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX
XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
XX
XX WPI; 2002-114799/15.
XX
XX

PT Antibodies against B Lymphocyte Stimulating polypeptides, useful for
PT the diagnosis and treatment of cancers and immune disorders -
XX
PS Claim 1; Page 851-852; 3148bp; English.
XX
CC This invention describes novel antibodies that immunospecifically bind to
CC B Lymphocyte Stimulator (Blys) polypeptides. Blys is a member of the
CC tumour necrosis factor (TNF) super family and induces B cell
CC proliferation and differentiation. The antibodies of the invention have
CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
CC antineumatic and antiAIDS activity and can be used in vaccines to
CC inhibit the expression and activity of Blys. The antibodies bind to Blys
CC and so may be used to detect and quantitate the presence of Blys in
CC biological samples and may be used in this way to diagnose disease
CC associated with aberrant expression of Blys. They may also be
CC administered to treat diseases associated with aberrant Blys expression
CC and activity such as cancer, immune, and autoimmune disorders and
CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
CC the antibodies and fragments of the antibodies described in the method
CC of the invention.
XX
SQ Sequence 249 AA;
XX
Query Match 96.1%; Score 616; DB 23; Length 249;
Best Local Similarity 96.7%; Pred. No. 4.4e-50;
Matches 119; Conservative 1; Mismatches 3; Indels 0; Gaps 0;
QY 1 QVQLQSGAEVKKPKSSVRVSCKASGTFNNNAINWVROAPQGLEWVGIIIMFGTAKY 60
DB 1 QVQLQSGAEVKKPKSSVRVSCKASGTFNNNAINWVROAPQGLEWVGIIIMFGTAKY 60
QY 61 SONFGRAVITADESTGASWELSLRSEDTAVVYCARSDLLFPHIALSPWGRGTWVT 120
DB 61 SONFGRAVITADESTGASWELSLRSEDTAVVYCARSDLLFPHIALSPWGRGTWVT 120
QY 121 VSS 123
DB 121 VSS 123
Db 121 VSS 123
RESULT 22
ABP44388
ID ABP44388 standard; Protein; 249 AA.
XX
AC ABP44388;
XX
YX 19-AUG-2002 (first entry)
XX
DE Human Blys binding scFv SEQ ID 399.
XX
XX Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
XX tumour necrosis factor; B cell proliferation; B cell differentiation;
XX immunosuppressive; immunostimulant; immunomodulatory; antineumatic;
XX antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
XX systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
XX common variable immunodeficiency; acquired immunodeficiency syndrome.
XX
XX Homo sapiens.
XX OS
XX PN WO200202641-A1.
XX PD 10-JAN-2002.
XX PF 15-JUN-2001; 2001WO-US19110.
XX
XX 16-JUN-2000; 2000US-212210P.
XX PR 17-OCT-2000; 2000US-240816P.
XX PR 16-MAR-2001; 2001US-276248P.
XX PR 21-MAR-2001; 2001US-277379P.
XX PR 25-MAY-2001; 2001US-293499P.
XX

PA (HUMA-) HUMAN GENOME SCI INC.
PA (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX
XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
XX WPI; 2002-114799/15.
XX
PS Claim 1; Page 879-880; 3148bp; English.
XX
XX This invention describes novel antibodies that immunospecifically bind to
XX B Lymphocyte Stimulator (Blys) polypeptides. Blys is a member of the
XX tumour necrosis factor (TNF) super family and induces B cell
XX proliferation and differentiation. The antibodies of the invention have
XX cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
XX antineumatic and antiAIDS activity and can be used in vaccines to
XX inhibit the expression and activity of Blys. The antibodies bind to Blys
XX and so may be used to detect and quantitate the presence of Blys in
XX biological samples and may be used in this way to diagnose disease
XX associated with aberrant expression of Blys. They may also be
XX administered to treat diseases associated with aberrant Blys expression
XX and activity such as cancer, immune, and autoimmune disorders and
XX diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
XX immunodeficiency (e.g. common variable immunodeficiency (CVID) and
XX acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
XX the antibodies and fragments of the antibodies described in the method
XX of the invention.
XX
SQ Sequence 249 AA;
XX
Query Match 96.1%; Score 616; DB 23; Length 249;
Best Local Similarity 96.7%; Pred. No. 4.4e-50;
Matches 119; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 1 QVQLQSGAEVKKPKSSVRVSCKASGTFNNNAINWVROAPQGLEWVGIIIMFGTAKY 60
DB 1 QVQLQSGAEVKKPKSSVRVSCKASGTFNNNAINWVROAPQGLEWVGIIIMFGTAKY 60
QY 61 SONFGRAVITADESTGASWELSLRSEDTAVVYCARSDLLFPHIALSPWGRGTWVT 120
DB 61 SONFGRAVITADESTGASWELSLRSEDTAVVYCARSDLLFPHIALSPWGRGTWVT 120
QY 121 VSS 123
DB 121 VSS 123
Db 121 VSS 123
RESULT 23
ABP44685
ID ABP44685 standard; Protein; 249 AA.
XX
AC ABP44685;
XX
DT 19-AUG-2002 (first entry)
XX
DE Human Blys binding scFv SEQ ID 696.
XX
XX Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
XX tumour necrosis factor; B cell proliferation; B cell differentiation;
XX immunosuppressive; immunostimulant; immunomodulatory; antineumatic;
XX antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
XX systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
XX common variable immunodeficiency; acquired immunodeficiency syndrome.
XX
XX Homo sapiens.
XX OS
XX PN WO200202641-A1.
XX PD 10-JAN-2002.
XX PF 15-JUN-2001; 2001WO-US19110.
XX

XX 16-JUN-2000; 2000US-212210P.
 PR 17-OCT-2000; 2000US-240816P.
 PR 16-MAR-2001; 2001US-276248P.
 PR 21-MAR-2001; 2001US-277379P.
 PR 25-MAY-2001; 2001US-293499P.
 XX
 PA (HUMA-) HUMAN GENOME SCI INC.
 PA (CAMP-) CAMBRIDGE ANTIBODY TECHNOLOGY.
 XX
 PI Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
 DR WPI; 2002-114799/15.
 XX
 PT Antibodies against B Lymphocyte Stimulating polypeptides, useful for
 PT the diagnosis and treatment of cancers and immune disorders -
 XX
 PS Claim 1; Page 1232-1233; 3148pp; English.
 XX
 CC This invention describes novel antibodies that immunospecifically bind to
 CC B Lymphocyte Stimulator (BLyS) polypeptides. BLyS is a member of the
 CC tumour necrosis factor (TNF) super family and induces B cell
 CC proliferation and differentiation. The antibodies of the invention have
 CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
 CC antineoplastic and antiAIDS activity and can be used in vaccines to
 CC inhibit the expression and activity of BLyS. The antibodies bind to BLyS
 CC and so may be used to detect and quantitate the presence of BLyS in
 CC biological samples and may be used in this way to diagnose disease
 CC associated with aberrant expression of BLyS. They may also be
 CC administered to treat diseases associated with aberrant BLyS expression
 CC and activity such as cancer, immune, and autoimmune disorders and
 CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
 CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
 CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
 CC the antibodies and fragments of the antibodies described in the method
 CC of the invention.
 XX
 SQ Sequence 249 AA;
 Query Match 96.1%; Score 616; DB 23; Length 249;
 Best Local Similarity 96.7%; Pred. No. 4.4e-50;
 Matches 119; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
 QY 1 OVULOQSGAEYKKGSSVRSCKASGCTFNNNAINWROAPQGLEWVGIIIPMFGRAXY 60
 DB 1 OVULOQSGAEYKKGSSVRSCKASGCTFNNNAINWROAPQGLEWVGIIIPMFGRAXY 60
 61 SQNFQGRVAITADESTGTASWELSLRSSEDTAVYYCARSDLLLPFHHSDSMGRGTMT 120
 61 SQNFQGRVAITADESTGTASWELSLRSSEDTAVYYCARSDLLLPFHHSDSMGRGTMT 120
 QY 121 VSS 123
 DB 121 VSS 123
 RESULT 24
 ABP44687 standard; Protein; 249 AA.
 AC ABP44687;
 XX
 DT 19-AUG-2002 (first entry)
 XX
 DE Human BLyS binding scFv SEQ ID 698.
 XX
 KW BLyS; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
 KW tumour necrosis factor; B cell proliferation; B cell differentiation;
 KW immunosuppressive; immunostimulant; immunomodulatory; antineoplastic;
 KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
 KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
 KW common variable immunodeficiency; acquired immunodeficiency syndrome.
 XX

OS Homo sapiens.
 XX
 XX WO200202641-A1.
 XX
 XX 10-JAN-2002;
 PD
 XX
 PF 15-JUN-2001; 2001WO-US19110.
 PR
 PR 16-JUN-2000; 2000US-212210P.
 PR 17-OCT-2000; 2000US-240816P.
 PR 16-MAR-2001; 2001US-276248P.
 PR 21-MAR-2001; 2001US-277379P.
 PR 25-MAY-2001; 2001US-293499P.
 XX
 PA (HUMA-) HUMAN GENOME SCI INC.
 PA (CAMP-) CAMBRIDGE ANTIBODY TECHNOLOGY.
 XX
 PI Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
 DR WPI; 2002-114799/15.
 XX
 PT Antibodies against B Lymphocyte Stimulating polypeptides, useful for
 PT the diagnosis and treatment of cancers and immune disorders -
 XX
 PS Claim 1; Page 1234-1235; 3148pp; English.
 XX
 CC This invention describes novel antibodies that immunospecifically bind to
 CC B Lymphocyte Stimulator (BLyS) polypeptides. BLyS is a member of the
 CC tumour necrosis factor (TNF) super family and induces B cell
 CC proliferation and differentiation. The antibodies of the invention have
 CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
 CC antineoplastic and antiAIDS activity and can be used in vaccines to
 CC inhibit the expression and activity of BLyS. The antibodies bind to BLyS
 CC and so may be used to detect and quantitate the presence of BLyS in
 CC biological samples and may be used in this way to diagnose disease
 CC associated with aberrant expression of BLyS. They may also be
 CC administered to treat diseases associated with aberrant BLyS expression
 CC and activity such as cancer, immune, and autoimmune disorders and
 CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
 CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
 CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
 CC the antibodies and fragments of the antibodies described in the method
 CC of the invention.
 XX
 SQ Sequence 249 AA;
 Query Match 96.1%; Score 616; DB 23; Length 249;
 Best Local Similarity 95.9%; Pred. No. 4.4e-50;
 Matches 118; Conservative 1; Mismatches 4; Indels 0; Gaps 0;
 QY 1 OVULOQSGAEYKKGSSVRSCKASGCTFNNNAINWROAPQGLEWVGIIIPMFGRAXY 60
 DB 1 OVULOQSGAEYKKGSSVRSCKASGCTFNNNAINWROAPQGLEWVGIIIPMFGRAXY 60
 61 SQNFQGRVAITADESTGTASWELSLRSSEDTAVYYCARSDLLLPFHHSDSMGRGTMT 120
 61 SQNFQGRVAITADESTGTASWELSLRSSEDTAVYYCARSDLLLPFHHSDSMGRGTMT 120
 QY 121 VSS 123
 DB 121 VSS 123
 RESULT 25
 ABP44698 standard; Protein; 249 AA.
 AC ABP44698;
 XX
 DT 19-AUG-2002 (first entry)
 XX
 DE Human BLyS binding scFv SEQ ID 709.
 XX

KW Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
KW tumour necrosis factor; B cell proliferation; B cell differentiation;
KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
KW common variable immunodeficiency; acquired immunodeficiency syndrome.
XX Homo sapiens.
XX OS
XX WO200202641-A1.
XX
XX 10-JAN-2002.
XX
XX 15-JUN-2001; 2001WO-US19110.
XX
XX 16-JUN-2000; 2000US-212210P.
XX 17-OCT-2000; 2000US-240816P.
XX 16-MAR-2001; 2001US-276248P.
XX 21-MAR-2001; 2001US-277379P.
XX 25-MAY-2001; 2001US-293499P.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX
XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
XX WPI; 2002-114799/15.
XX
XX Antibodies against B Lymphocyte Stimulating polypeptides, useful for
XX the diagnosis and treatment of cancers and immune disorders.
XX
XX Claim 1; Page 1247-1248; 3148pp; English.
XX
XX This invention describes novel antibodies that immunospecifically bind to
XX B Lymphocyte Stimulator (Blys) polypeptides. Blys is a member of the
XX tumour necrosis factor (TNF) super family and induces B cell
XX proliferation and differentiation. The antibodies of the invention have
XX cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
XX antirheumatic and antiAIDS activity and can be used in vaccines to
XX inhibit the expression and activity of Blys. The antibodies bind to Blys
XX and so may be used to detect and quantitate the presence of Blys in
XX biological samples and may be used in this way to diagnose disease
XX associated with aberrant expression of Blys. They may also be
XX administered to treat diseases associated with aberrant Blys expression
XX and activity such as cancer, immune, and autoimmune disorders and
XX diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis, and
XX immunodeficiency (e.g. common variable immunodeficiency (CVID) and
XX acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
XX the antibodies and fragments of the antibodies described in the method
XX of the invention.
XX
XX Sequence 249 AA;
SQ
Query Match 96.1%; Score 616; DB 23; Length 249;
Best Local Similarity 95.9%; Pred. No. 4.4e-50;
Matches 118; Conservative 1; Mismatches 4; Indels 0; Gaps 0;
QY 1 QVQLQSGAEVKKPPSSSVRVCCKASGCTFNNAIMWVROAPQGLEWMGIIIPMGFTAKY 60
DB 1 QVQLQSGAEVKKPPSSSVRVCCKASGCTFNNAIMWVROAPQGLEWMGIIIPMGFTAKY 60
QY 61 SONFGRAVITADESTGTASMEISLRSEDTAVVYCARSDLLPFPHALSPWGGTAVT 120
DB 61 SONFGRAVITADESTGTASMEISLRSEDTAVVYCARSDLLPFPHALSPWGGTAVT 120
QY 121 VSS 123
DB 121 VSS 123
RESULT 26
ABP44702
ID ABP44702 standard; Protein; 249 AA.

XX ABP44702;
AC 19-AUG-2002 (first entry)
XX
XX Human Blys binding scFv SEQ ID 713.
XX
XX Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
KW tumour necrosis factor; B cell proliferation; B cell differentiation;
KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
KW common variable immunodeficiency; acquired immunodeficiency syndrome.
XX Homo sapiens.
XX OS
XX WO200202641-A1.
XX
XX 10-JAN-2002.
XX
XX 15-JUN-2001; 2001WO-US19110.
XX
XX 16-JUN-2000; 2000US-212210P.
XX 17-OCT-2000; 2000US-240816P.
XX 16-MAR-2001; 2001US-276248P.
XX 21-MAR-2001; 2001US-277379P.
XX 25-MAY-2001; 2001US-293499P.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX
XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
XX WPI; 2002-114799/15.
XX
XX Antibodies against B Lymphocyte Stimulating polypeptides, useful for
XX the diagnosis and treatment of cancers and immune disorders -
XX
XX Claim 1; Page 1252-1253; 3148pp; English.
XX
XX This invention describes novel antibodies that immunospecifically bind to
XX B Lymphocyte Stimulator (Blys) polypeptides. Blys is a member of the
XX tumour necrosis factor (TNF) super family and induces B cell
XX proliferation and differentiation. The antibodies of the invention have
XX cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
XX antirheumatic and antiAIDS activity and can be used in vaccines to
XX inhibit the expression and activity of Blys. The antibodies bind to Blys
XX and so may be used to detect and quantitate the presence of Blys in
XX biological samples and may be used in this way to diagnose disease
XX associated with aberrant expression of Blys. They may also be
XX administered to treat diseases associated with aberrant Blys expression
XX and activity such as cancer, immune, and autoimmune disorders and
XX diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis, and
XX immunodeficiency (e.g. common variable immunodeficiency (CVID) and
XX acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
XX the antibodies and fragments of the antibodies described in the method
XX of the invention.
XX
XX Sequence 249 AA;
SQ
Query Match 96.1%; Score 616; DB 23; Length 249;
Best Local Similarity 96.7%; Pred. No. 4.4e-50;
Matches 119; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 1 QVQLQSGAEVKKPPSSSVRVCCKASGCTFNNAIMWVROAPQGLEWMGIIIPMGFTAKY 60
DB 1 QVQLQSGAEVKKPPSSSVRVCCKASGCTFNNAIMWVROAPQGLEWMGIIIPMGFTAKY 60
QY 61 SONFGRAVITADESTGTASMEISLRSEDTAVVYCARSDLLPFPHALSPWGGTAVT 120
DB 61 SONFGRAVITADESTGTASMEISLRSEDTAVVYCARSDLLPFPHALSPWGGTAVT 120
QY 121 VSS 123
DB 121 VSS 123

Query Match	Similarity	95.9%	Score 615	DB 23	Length 249
Best Local S1	Similarity 96.7%	Pred. No. 5.4e-50			
Matches 119	Conservative 1	Mismatches 3	Indels 0	Gaps 0	
Qy	1	QVQLQSGAEVKKPSSSVKSCAKSGGTNNNAIMNVRQAPGGGLEMMGGIIPMGSTAKY	60		
Db	1	QVQLQSGAEVKKPSSSVKSCAKSGGTNNNAIMNVRQAPGGGLEMMGGIIPMGSTAKY	60		
Qy	61	SONFGRAVITDESTGTSMELSSLRSDTAVYYCARSDLLFPFHALLSPWGRGTMTY	120		
Db	61	SONFGRAVITDESTGTSMELSSLRSDTAVYYCARSDLLFPFHALLSPWGRGTMTY	120		
Qy	121	VSS 123			
Db	121	VSS 123			
RESULT 29					
ABP44417					
ABP44417					
ABP44417					
19-AUG-2002					
(first entry)					
Human Blys binding ecFv SEQ ID 428.					
Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;					
tumour necrosis factor; B cell proliferation; B cell differentiation;					
immunopressive; immunostimulant; immunomodulatory; antirheumatic;					
antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;					
systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;					
common variable immunodeficiency; acquired immunodeficiency syndrome.					
Homo sapiens.					
WO200202641-A1.					
10-JAN-2002.					
15-JUN-2001; 2001WO-US19110.					
16-JUN-2000; 2000US-212210P.					
17-OCT-2000; 2000US-240816P.					
16-MAR-2001; 2001US-276248P.					
21-MAR-2001; 2001US-277379P.					
25-MAY-2001; 2001US-293499P.					
(HUMA-) HUMAN GENOME SCI INC.					
(CAMP-) CAMBRIDGE ANTIBODY TECHNOLOGY.					
Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;					
WPI; 2002-114799/15.					
Antibodies against B lymphocyte Stimulating polypeptides, useful for					
the diagnosis and treatment of cancers and immune disorders -					
Claim 1; Page 914-915; 3148pp; English.					
This invention describes novel antibodies that immunospecifically bind to					
B lymphocyte Stimulator (Blys) polypeptides. Blys is a member of the					
tumour necrosis factor (TNF) super family and induces B cell					
proliferation and differentiation. The antibodies of the invention have					
cytostatic, immunosuppressive, immunostimulant, immunomodulatory,					
antirheumatic and antiAIDS activity and can be used in vaccines to					
inhibit the expression and activity of Blys. The antibodies bind to Blys					
and so may be used to detect and quantitate the presence of Blys in					
biological samples and may be used in this way to diagnose disease					
associated with aberrant expression of Blys. They may also be					
administered to treat diseases associated with aberrant Blys expression					
and actively such as cancer, immune, and autoimmune disorders and					

	diseases e.g. systemic lupus erythematosus, rheumatoid arthritis,
CC	acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
CC	the antibodies and fragments of the antibodies described in the method
CC	of the invention.
XX	
SQ	Sequence 249 AA;
	Query Match 95.9%; Score 615; DB 23; Length 249;
	Best Local Similarity 95.9%; Pred. No. 5,4e-50;
	Matches 118; Conservative 2; Mismatches 3; Indels 0; Gaps 0
Oy	1 QVQLTSGAEVKRPGSSVAVSCSKASGCFPNNNATIMWVAQAQGILEMNGIIPMGRTAKY 60
Dd	1 QVQLTSGAEVKRPGSSVAVSCSKASGCFPNNNATIMWVAQAQGILEMNGIIPMGRTAKY 60
Oy	61 SQPFGRVAITADESTGTASMETLSLRSEDTAVVYCARSRLLLFPFHIALSPMGRTMT 120
Dd	61 SQPFGRVAITADESTGTASMETLSLRSEDTAVVYCARSRLLLFPFHILPMRGRTMT 120
Oy	121 VSS 123
Dd	121 VSS 123
RESULT 30	
ABP44633	ID ABP44633 standard; Protein; 249 AA.
XX	ABP44633;
XX	19-AUG-2002 (first entry)
DE	Human Bly's binding scFv SEQ ID 644.
XX	Blys: B lymphocyte stimulator; TNF superfamily; human; cytostatic;
KW	tumour necrosis factor; B cell proliferation; B cell differentiation;
KW	immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
KW	antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
KW	systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
XX	common variable immunodeficiency; acquired immunodeficiency syndrome.
OS	Homo sapiens.
XX	WO200202641-A1.
PD	10-JAN-2002.
XX	
PF	15-JUN-2001; 2001WO-US19110.
XX	
PR	16-JUN-2000; 2000US-212210P.
PR	17-OCT-2000; 2000US-240816P.
PR	16-MAR-2001; 2001US-376248P.
PR	21-MAR-2001; 2001US-277379P.
PR	25-MAY-2001; 2001US-293499P.
XX	(HUMA-) HUMAN GENOME SCI INC.
PA	(CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX	
PI	Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
DR	WPI; 2002-114799/15.
PS	
PT	Antibodies against B lymphocyte Stimulating polypeptides, useful for
PT	the diagnosis and treatment of cancers and immune disorders -
XX	Claim 1; Page 1170-1171; 3148bp; English.
CC	This invention describes novel antibodies that immunospecifically bind to
CC	B lymphocyte Stimulator (Blys) polypeptides. Blys is a member of the
CC	tumour necrosis factor (TNF) super family and induces B cell
CC	proliferation and differentiation. The antibodies of the invention have
CC	cytotoxic, immunosuppressive, immunostimulant, immunomodulatory,

CC antirheumatic and antiAIDS activity and can be used in vaccines to
CC inhibit the expression and activity of Blys. The antibodies bind to Blys
CC and so may be used to detect and quantitate the presence of Blys in
CC biological samples and may be used in this way to diagnose disease
CC associated with aberrant expression of Blys. They may also be
CC administered to treat diseases associated with aberrant Blys expression
CC and activity such as cancer, immune, and autoimmune disorders and
CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
CC the antibodies and fragments of the antibodies described in the method
CC of the invention.

CC Sequence 249 AA;

Query Match 95.9%; Score 615; DB 23; Length 249;
Best Local Similarity 96.7%; Pred. No. 5.4e-50;
Matches 119; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

1 OVQLQSGAEVKKPSSSVRSCKASGCTFNNNAIMWVQAQPGQLEMMGGIIPMGTAKY 60
1 OVQLQSGAEVKKPSSSVRSCKASGCTFNNNAIMWVQAQPGQLEMMGGIIPMGTAKY 60
61 SONFGRAVITADESTGTASMEISLRSEDTAVVYCARSDLLLPFHALSPWGRGTWVT 120
61 SONFGRAVITADESTGTASMEISLRSEDTAVVYCARSDLLLPFHALSPWGRGTWVT 120
121 VSS 123
121 VSS 123
121 VSS 123

RESULT 31

ABP44644
ID ABP44644 standard; Protein; 249 AA.

AC ABP44644;

DT 19-AUG-2002 (first entry)

DE Human Blys binding scFv SEQ ID 655.

KW Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
KW tumour necrosis factor; B cell proliferation; B cell differentiation;
KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
KW common variable immunodeficiency; acquired immunodeficiency syndrome.

Homio sapiens.

WO200202641-A1.

10-JAN-2002.

15-JUN-2001; 2001WO-US19110.

16-JUN-2000; 2000US-212210P.

17-OCT-2000; 2000US-240816P.

16-MAR-2001; 2001US-276248P.

21-MAR-2001; 2001US-277379P.

25-MAY-2001; 2001US-293499P.

PA (HUMA-) HUMAN GENOME SCI INC.

PA (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.

PI Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;

XX WPI; 2002-114799/15.

XX Antbodies against B Lymphocyte Stimulating polypeptides, useful for

XX the diagnosis and treatment of cancers and immune disorders -

PS Claim 1; Page 1183-1184; 3148pp; English.

CC This invention describes novel antibodies that immunospecifically bind to
CC B lymphocyte stimulator (Blys) polypeptides. Blys is a member of the
CC tumour necrosis factor (TNF) super family and induces B cell
CC proliferation and differentiation. The antibodies of the invention have
CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
CC antirheumatic and antiAIDS activity and can be used in vaccines to
CC inhibit the expression and activity of Blys. The antibodies bind to Blys
CC and so may be used to detect and quantitate the presence of Blys in
CC biological samples and may be used in this way to diagnose disease
CC associated with aberrant expression of Blys. They may also be
CC administered to treat diseases associated with aberrant Blys expression
CC and activity such as cancer, immune, and autoimmune disorders and
CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
CC the antibodies and fragments of the antibodies described in the method
CC of the invention.

CC Sequence 249 AA;

Query Match 95.9%; Score 615; DB 23; Length 249;
Best Local Similarity 96.7%; Pred. No. 5.4e-50;
Matches 119; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

1 OVQLQSGAEVKKPSSSVRSCKASGCTFNNNAIMWVQAQPGQLEMMGGIIPMGTAKY 60
1 OVQLQSGAEVKKPSSSVRSCKASGCTFNNNAIMWVQAQPGQLEMMGGIIPMGTAKY 60
61 SONFGRAVITADESTGTASMEISLRSEDTAVVYCARSDLLLPFHALSPWGRGTWVT 120
61 SONFGRAVITADESTGTASMEISLRSEDTAVVYCARSDLLLPFHALSPWGRGTWVT 120
121 VSS 123
121 VSS 123
121 VSS 123

RESULT 32

ABP44711
ID ABP44711 standard; Protein; 249 AA.

AC ABP44711;

DT 19-AUG-2002 (first entry)

DE Human Blys binding scFv SEQ ID 722.

KW Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
KW tumour necrosis factor; B cell proliferation; B cell differentiation;
KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
KW common variable immunodeficiency; acquired immunodeficiency syndrome.

Homio sapiens.

WO200202641-A1.

10-JAN-2002.

15-JUN-2001; 2001WO-US19110.

16-JUN-2000; 2000US-212210P.

17-OCT-2000; 2000US-240816P.

16-MAR-2001; 2001US-276248P.

21-MAR-2001; 2001US-277379P.

25-MAY-2001; 2001US-293499P.

PA (HUMA-) HUMAN GENOME SCI INC.

PA (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.

XX 10-JAN-2002.
 PD 15-JUN-2001; 2001WO-US19110.
 XX 16-JUN-2000; 2000US-212210P.
 PR 17-OCT-2000; 2000US-240816P.
 PR 16-MAR-2001; 2001US-276248P.
 PR 21-MAR-2001; 2001US-277379P.
 PR 25-MAY-2001; 2001US-293499P.
 PA (HUMA-) HUMAN GENOME SCI INC.
 PA (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
 XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
 PI WPI; 2002-114799/15.
 DR Antibodies against B lymphocyte stimulating polypeptides, useful for
 PT the diagnosis and treatment of cancers and immune disorders -
 XX Claim 1; Page 1314-1315; 3148pp; English.
 CC This invention describes novel antibodies that immunospecifically bind to
 CC B lymphocyte Stimulator (Blys) polypeptides. Blys is a member of the
 CC tumour necrosis factor (TNF) super family and induces B cell
 CC proliferation and differentiation. The antibodies of the invention have
 CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
 CC antineoplastic and antiAIDS activity and can be used in vaccines to
 CC inhibit the expression and activity of Blys. The antibodies bind to Blys
 CC and so may be used to detect and quantitate the presence of Blys in
 CC biological samples and may be used in this way to diagnose disease
 CC associated with aberrant expression of Blys. They may also be
 CC administered to treat diseases associated with aberrant Blys expression
 CC and activity such as cancer, immune, and autoimmune disorders and
 CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
 CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
 CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
 CC the antibodies and fragments of the antibodies described in the method
 CC of the invention.
 XX Sequence 249 AA;
 SQ
 Query Match 95.9%; Score 615; DB 23; Length 249;
 Best Local Similarity 96.7%; Pred. No. 5.4e-50;
 Matches 119; Conservative 1; Mismatches 3; Indels 0; Gaps 0;
 QY 1 OVOLQSGAEVKKPGSSVRSVSCASGTFNNNAINMWROAPGQLEWNGIIPMFGTAKY 60
 1 OVOLQSGAEVKKPGSSVRSVSCASGTFNNNAINMWROAPGQLEWNGIIPMFGTAKY 60
 QY 61 SONFOGRAVITADESTGTASMELSLSRSEDYAVYCARSRDLLPPHHALSPMGRTWVT 120
 61 SONFOGRAVITADESTGTASMELSLSRSEDYAVYCARSRDLLPPHHALSPMGRTWVT 120
 DB 61 SONFOGRAVITADESTGTASMELSLSRSEDYAVYCARSRDLLPPHHALSPMGRTWVT 120
 QY 121 VSS 123
 121 VSS 123
 DB 121 VSS 123
 RESULT 35
 ID ABP44775 standard; Protein; 249 AA.
 XX ABP44775;
 AC 19-AUG-2002 (first entry)
 DT Human Blys binding scFv SEQ ID 786.
 XX Blys; B lymphocyte stimulator; TNF superfamily; human; cytosolic;
 KW tumour necrosis factor; B cell proliferation; B cell differentiation;
 KW immunosuppressive; immunostimulant; immunomodulatory; antineoplastic;

KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
 KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
 KW common variable immunodeficiency; acquired immunodeficiency syndrome.
 XX Homo sapiens.
 OS WO200202641-A1.
 PN 10-JAN-2002.
 PD 15-JUN-2001; 2001WO-US19110.
 PF 16-JUN-2000; 2000US-212210P.
 PR 17-OCT-2000; 2000US-240816P.
 PR 16-MAR-2001; 2001US-276248P.
 PR 21-MAR-2001; 2001US-277379P.
 PR 25-MAY-2001; 2001US-293499P.
 PA (HUMA-) HUMAN GENOME SCI INC.
 PA (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
 XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
 PI WPI; 2002-114799/15.
 DR Antibodies against B lymphocyte stimulating polypeptides, useful for
 PT the diagnosis and treatment of cancers and immune disorders -
 XX Claim 1; Page 1339-1340; 3148pp; English.
 CC This invention describes novel antibodies that immunospecifically bind to
 CC B lymphocyte Stimulator (Blys) polypeptides. Blys is a member of the
 CC tumour necrosis factor (TNF) super family and induces B cell
 CC proliferation and differentiation. The antibodies of the invention have
 CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
 CC antineoplastic and antiAIDS activity and can be used in vaccines to
 CC inhibit the expression and activity of Blys. The antibodies bind to Blys
 CC and so may be used to detect and quantitate the presence of Blys in
 CC biological samples and may be used in this way to diagnose disease
 CC associated with aberrant expression of Blys. They may also be
 CC administered to treat diseases associated with aberrant Blys expression
 CC and activity such as cancer, immune, and autoimmune disorders and
 CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
 CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
 CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
 CC the antibodies and fragments of the antibodies described in the method
 CC of the invention.
 XX Sequence 249 AA;
 SQ
 Query Match 95.9%; Score 615; DB 23; Length 249;
 Best Local Similarity 95.9%; Pred. No. 5.4e-50;
 Matches 119; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
 QY 1 OVOLQSGAEVKKPGSSVRSVSCASGTFNNNAINMWROAPGQLEWNGIIPMFGTAKY 60
 1 OVOLQSGAEVKKPGSSVRSVSCASGTFNNNAINMWROAPGQLEWNGIIPMFGTAKY 60
 QY 61 SONFOGRAVITADESTGTASMELSLSRSEDYAVYCARSRDLLPPHHALSPMGRTWVT 120
 61 SONFOGRAVITADESTGTASMELSLSRSEDYAVYCARSRDLLPPHHALSPMGRTWVT 120
 DB 61 SONFOGRAVITADESTGTASMELSLSRSEDYAVYCARSRDLLPPHHALSPMGRTWVT 120
 QY 121 VSS 123
 121 VSS 123
 DB 121 VSS 123
 RESULT 36
 ID ABP44778 standard; Protein; 249 AA.
 XX ABP44778;
 AC 19-AUG-2002 (first entry)
 DT Human Blys binding scFv SEQ ID 786.
 XX Blys; B lymphocyte stimulator; TNF superfamily; human; cytosolic;
 KW tumour necrosis factor; B cell proliferation; B cell differentiation;
 KW immunosuppressive; immunostimulant; immunomodulatory; antineoplastic;

DT 19-AUG-2002 (first entry)
 XX Human Blys binding scFv SEQ ID 789.
 DE
 XX Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
 KW tumour necrosis factor; B cell proliferation; B cell differentiation;
 KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
 KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
 KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
 KW common variable immunodeficiency; acquired immunodeficiency syndrome.
 XX
 OS Homo sapiens.
 XX
 PN WO200202641-A1.
 XX
 PD 10-JAN-2002.
 XX
 PF 15-JUN-2001; 2001WO-US19110.
 XX
 PR 16-JUN-2000; 2000US-212210P.
 PR 17-OCT-2000; 2000US-240816P.
 PR 16-MAR-2001; 2001US-276248P.
 PR 21-MAR-2001; 2001US-277379P.
 PR 25-MAY-2001; 2001US-293499P.
 XX
 PA (HUMA-) HUMAN GENOME SCI INC.
 PA (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
 XX
 PI Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
 XX
 DR WPI; 2002-114799/15.
 XX
 PT Antibodies against B lymphocyte Stimulating polypeptides, useful for
 PT the diagnosis and treatment of cancers and immune disorders -
 XX
 PS Claim 1; Page 1342-1343; 3148pp; English.
 XX
 CC This invention describes novel antibodies that immunospecifically bind to
 CC B lymphocyte Stimulator (Blys) polypeptides. Blys is a member of the
 CC tumour necrosis factor (TNF) super family and induces B cell
 CC proliferation and differentiation. The antibodies of the invention have
 CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
 CC antirheumatic and antiAIDS activity and can be used in vaccines to
 CC inhibit the expression and activity of Blys. The antibodies bind to Blys
 CC and so may be used to detect and quantitate the presence of Blys in
 CC biological samples and may be used in this way to diagnose disease
 CC associated with aberrant expression of Blys. They may also be
 CC administered to treat diseases associated with aberrant Blys expression
 CC and activity such as cancer, immune, and autoimmune disorders and
 CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
 CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
 CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
 CC the antibodies and fragments of the antibodies described in the method
 CC of the invention.
 CC
 XX
 SO Sequence 249 AA;
 Query Match 95.9%; Score 615; DB 23; Length 249;
 Best Local Similarity 96.7%; Pred. No. 5.4e-50;
 Matches 119; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
 Oy 1 OVOLOQSGAEVYKPKSSVRVSCKASGTFNNNAINWVROAPOGGLMMWGIIIPMGTKAY 60
 Db 1 OVOLOQSGAEVYKPKSSVRVSCKASGTFNNNAINWVROAPOGGLMMWGIIIPMGTKAY 60
 Oy 61 SQNFGRAVAITADESTGTASWELSLRSEDPTAVVYCARSDLLLPFHHLSPWGRGTWVT 120
 Db 61 SQNFGRAVAITADESTGTASWELSLRSEDPTAVVYCARSDLLLPFHHLSPWGRGTWVT 120
 Oy 121 VSS 123
 Db 121 VSS 123

RESULT 37
 ID ABP44783
 XX ABP44783 standard; Protein; 249 AA.
 AC
 XX ABP44783;
 XX
 DT 19-AUG-2002 (first entry)
 XX
 DE Human Blys binding scFv SEQ ID 794.
 XX
 KW Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
 KW tumour necrosis factor; B cell proliferation; B cell differentiation;
 KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
 KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
 KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
 KW common variable immunodeficiency; acquired immunodeficiency syndrome.
 XX
 OS Homo sapiens.
 XX
 PN WO200202641-A1.
 XX
 PD 10-JAN-2002.
 XX
 PF 15-JUN-2001; 2001WO-US19110.
 XX
 PR 16-JUN-2000; 2000US-212210P.
 PR 17-OCT-2000; 2000US-240816P.
 PR 16-MAR-2001; 2001US-276248P.
 PR 21-MAR-2001; 2001US-277379P.
 PR 25-MAY-2001; 2001US-293499P.
 XX
 PA (HUMA-) HUMAN GENOME SCI INC.
 PA (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
 XX
 PI Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
 XX
 DR WPI; 2002-114799/15.
 XX
 PT Antibodies against B lymphocyte Stimulating polypeptides, useful for
 PT the diagnosis and treatment of cancers and immune disorders -
 XX
 PS Claim 1; Page 1348-1349; 3148pp; English.
 XX
 CC This invention describes novel antibodies that immunospecifically bind to
 CC B lymphocyte Stimulator (Blys) polypeptides. Blys is a member of the
 CC tumour necrosis factor (TNF) super family and induces B cell
 CC proliferation and differentiation. The antibodies of the invention have
 CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
 CC antirheumatic and antiAIDS activity and can be used in vaccines to
 CC inhibit the expression and activity of Blys. The antibodies bind to Blys
 CC and so may be used to detect and quantitate the presence of Blys in
 CC biological samples and may be used in this way to diagnose disease
 CC associated with aberrant expression of Blys. They may also be
 CC administered to treat diseases associated with aberrant Blys expression
 CC and activity such as cancer, immune, and autoimmune disorders and
 CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
 CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
 CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
 CC the antibodies and fragments of the antibodies described in the method
 CC of the invention.
 CC
 XX
 SO Sequence 249 AA;
 Query Match 95.9%; Score 615; DB 23; Length 249;
 Best Local Similarity 95.9%; Pred. No. 5.4e-50;
 Matches 118; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
 Oy 1 OVOLOQSGAEVYKPKSSVRVSCKASGTFNNNAINWVROAPOGGLMMWGIIIPMGTKAY 60
 Db 1 OVOLOQSGAEVYKPKSSVRVSCKASGTFNNNAINWVROAPOGGLMMWGIIIPMGTKAY 60
 Oy 61 SQNFGRAVAITADESTGTASWELSLRSEDPTAVVYCARSDLLLPFHHLSPWGRGTWVT 120

DB 61 SONFGRAVATTADESTSTASMELSLRSEDTAVVYCCARSDDLFPFHGSDAAGRGTMT 120
QY 121 VSS 123
DB 121 VSS 123

RESULT 38
ID ABP44311 standard; Protein; 249 AA.
XX ABP44311;
AC 19-AUG-2002 (first entry)
XX
DE Human Blys binding scFv SEQ ID 322.
XX
XX Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
KM tumour necrosis factor; B cell proliferation; B cell differentiation;
KM immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
KM antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
KM systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
KM common variable immunodeficiency; acquired immunodeficiency syndrome.

OS Homo sapiens.
XX
XX WO200202641-A1.
XX
XX 10-JAN-2002.
XX
XX 15-JUN-2001; 2001WO-US19110.
XX
XX 16-JUN-2000; 2000US-212210P.
XX 17-OCT-2000; 2000US-240816P.
XX 16-MAR-2001; 2001US-276248P.
XX 21-MAR-2001; 2001US-277379P.
XX 25-MAY-2001; 2001US-293499P.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX
XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
XX WPI; 2002-114799/15.
XX
XX Antibodies against B lymphocyte stimulating polypeptides, useful for
XX the diagnosis and treatment of cancers and immune disorders -
XX
XX Claim 1; Page 788-789; 314Bpp; English.

CC This invention describes novel antibodies that immunospecifically bind to
CC B lymphocyte stimulator (Blys) polypeptides. Blys is a member of the
CC tumour necrosis factor (TNF) super family and induces B cell
CC proliferation and differentiation. The antibodies of the invention have
CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
CC antirheumatic and antiAIDS activity and can be used in vaccines to
CC inhibit the expression and activity of Blys. The antibodies bind to Blys
CC and so may be used to detect and quantitate the presence of Blys in
CC biological samples and may be used in this way to diagnose disease
CC associated with aberrant expression of Blys. They may also be
CC administered to treat diseases associated with aberrant Blys expression
CC and actively such as cancer, immune, and autoimmune disorders and
CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
CC the antibodies and fragments of the antibodies described in the method
XX of the invention.

XX Sequence 249 AA;
SQ

Query Match 95.8%; Score 614; DB 23; Length 249;
Best Local Similarity 95.9%; Pred. No. 6.7e-50;

Matches 118; Conservative 1; Mismatches 4; Indels 0; Gaps 0;
QY 1 QVQLQDSGAEEVKPPSSVRSVSCASGTFNNNAIMWVQAPQGLIEMGGIIPMEGTAKY 60
DB 1 QVQLQDSGAEEVKPPSSVRSVSCASGTFNNNAIMWVQAPQGLIEMGGIIPMEGTAKY 60

QY 61 SONFGRAVATTADESTSTASMELSLRSEDTAVVYCCARSDDLFPFHALSWSGRTMT 120
DB 61 SONFGRAVATTADESTSTASMELSLRSEDTAVVYCCARSDDLFPFHHSFDLMGRGTMT 120

QY 121 VSS 123
DB 121 VSS 123

RESULT 39
ID ABP44318 standard; Protein; 249 AA.
XX ABP44318;
AC 19-AUG-2002 (first entry)
XX
DE Human Blys binding scFv SEQ ID 329.
XX
XX Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
KM tumour necrosis factor; B cell proliferation; B cell differentiation;
KM immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
KM antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
KM systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
KM common variable immunodeficiency; acquired immunodeficiency syndrome.

OS Homo sapiens.
XX
XX WO200202641-A1.
XX
XX 10-JAN-2002.
XX
XX 15-JUN-2001; 2001WO-US19110.
XX
XX 16-JUN-2000; 2000US-212210P.
XX 17-OCT-2000; 2000US-240816P.
XX 16-MAR-2001; 2001US-276248P.
XX 21-MAR-2001; 2001US-277379P.
XX 25-MAY-2001; 2001US-293499P.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX
XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
XX WPI; 2002-114799/15.
XX
XX Antibodies against B lymphocyte stimulating polypeptides, useful for
XX the diagnosis and treatment of cancers and immune disorders -
XX
XX Claim 1; Page 796-797; 314Bpp; English.

CC This invention describes novel antibodies that immunospecifically bind to
CC B lymphocyte stimulator (Blys) polypeptides. Blys is a member of the
CC tumour necrosis factor (TNF) super family and induces B cell
CC proliferation and differentiation. The antibodies of the invention have
CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
CC antirheumatic and antiAIDS activity and can be used in vaccines to
CC inhibit the expression and activity of Blys. The antibodies bind to Blys
CC and so may be used to detect and quantitate the presence of Blys in
CC biological samples and may be used in this way to diagnose disease
CC associated with aberrant expression of Blys. They may also be
CC administered to treat diseases associated with aberrant Blys expression
CC and actively such as cancer, immune, and autoimmune disorders and
CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent

CC the antibodies and fragments of the antibodies described in the method
CC of the invention.

XX Sequence 249 AA;

Query Match 95.8%; Score 614; DB 23; Length 249;

Best Local Similarity 95.9%; Pred. No. 6.7e-50;
Matches 118; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

1 QVQLQSGAEVYKRGSSVRVSCKASGTFNNNAINWVROAPGQGLEWMGGIIPMFGRATKY 60

1 QVQLQSGAEVYKRGSSVRVSCKASGTFNNNAINWVROAPGQGLEWMGGIIPMFGRATKY 60

61 SQNFGRAVITADESTGTASMEISLRSEDTAVYVCARSDLLFPFHALLSPMGRTMT 120

61 SQNFGRAVITADESTGTASMEISLRSEDTAVYVCARSDLLFPFHALLSPMGRTMT 120

121 VSS 123

121 VSS 123

RESULT 40

ABP44422

ID ABP44422 standard; Protein; 249 AA.

XX ABP44422;

XX 19-AUG-2002 (first entry)

XX Human Blys binding scfv SEQ ID 433.

XX Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;

XX tumour necrosis factor; B cell proliferation; B cell differentiation;

XX immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;

XX antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;

XX systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;

XX common variable immunodeficiency; acquired immunodeficiency syndrome.

XX Homo sapiens.

XX 16-JUN-2001; 2001WO-US19110.

XX 16-JUN-2000; 2000US-212210P.

XX 17-OCT-2000; 2000US-240816P.

XX 16-MAR-2001; 2001US-276248P.

XX 21-MAR-2001; 2001US-277379P.

XX 25-MAY-2001; 2001US-293499P.

XX (HUMA-) HUMAN GENOME SCI INC.

XX (CAMP-) CAMBRIDGE ANTIBODY TECHNOLOGY.

XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;

XX WPI; 2002-114799/15.

XX Antibodies against B lymphocyte stimulating polypeptides, useful for

XX the diagnosis and treatment of cancers and immune disorders -

XX Claim 1; Page 920-921; 3148pp; English.

XX This invention describes novel antibodies that immunospecifically bind to

XX B lymphocyte stimulator (Blys) polypeptides. Blys is a member of the

XX tumour necrosis factor (TNF) super family and induces B cell

XX proliferation and differentiation. The antibodies of the invention have

XX cyostatic, immunosuppressive, immunostimulant, immunomodulatory,

XX antirheumatic and antiAIDS activity and can be used in vaccines to

XX inhibit the expression and activity of Blys. The antibodies bind to Blys

XX and so may be used to detect and quantitate the presence of Blys in

CC biological samples and may be used in this way to diagnose disease

CC associated with aberrant expression of Blys. They may also be

CC administered to treat diseases associated with aberrant Blys expression

CC and activity such as cancer, immune, and autoimmune disorders and

CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,

CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and

CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent

CC the antibodies and fragments of the antibodies described in the method

CC of the invention.

XX Sequence 249 AA;

Query Match 95.8%; Score 614; DB 23; Length 249;

Best Local Similarity 96.7%; Pred. No. 6.7e-50;
Matches 119; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

1 QVQLQSGAEVYKRGSSVRVSCKASGTFNNNAINWVROAPGQGLEWMGGIIPMFGRATKY 60

1 QVQLQSGAEVYKRGSSVRVSCKASGTFNNNAINWVROAPGQGLEWMGGIIPMFGRATKY 60

61 SQNFGRAVITADESTGTASMEISLRSEDTAVYVCARSDLLFPFHALLSPMGRTMT 120

61 SQNFGRAVITADESTGTASMEISLRSEDTAVYVCARSDLLFPFHALLSPMGRTMT 120

121 VSS 123

121 VSS 123

RESULT 41

ABP44450

ID ABP44450 standard; Protein; 249 AA.

XX ABP44450;

XX 19-AUG-2002 (first entry)

XX Human Blys binding scfv SEQ ID 461.

XX Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;

XX tumour necrosis factor; B cell proliferation; B cell differentiation;

XX immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;

XX antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;

XX systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;

XX common variable immunodeficiency; acquired immunodeficiency syndrome.

XX Homo sapiens.

XX 16-JUN-2001; 2001WO-US19110.

XX 16-JUN-2000; 2000US-212210P.

XX 17-OCT-2000; 2000US-240816P.

XX 16-MAR-2001; 2001US-276248P.

XX 21-MAR-2001; 2001US-277379P.

XX 25-MAY-2001; 2001US-293499P.

XX (HUMA-) HUMAN GENOME SCI INC.

XX (CAMP-) CAMBRIDGE ANTIBODY TECHNOLOGY.

XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;

XX WPI; 2002-114799/15.

XX Antibodies against B lymphocyte stimulating polypeptides, useful for

XX the diagnosis and treatment of cancers and immune disorders -

XX Claim 1; Page 953-954; 3148pp; English.

XX This invention describes novel antibodies that immunospecifically bind to

CC B Lymphocyte Stimulator (Blys) polypeptides. Blys is a member of the
 CC tumour necrosis factor (TNF) super family and induces B cell
 CC proliferation and differentiation. The antibodies of the invention have
 CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
 CC antirheumatic and antiAIDS activity and can be used in vaccines to
 CC inhibit the expression and activity of Blys. The antibodies bind to Blys
 CC and so may be used to detect and quantitate the presence of Blys in
 CC biological samples and may be used in this way to diagnose disease
 CC associated with aberrant expression of Blys. They may also be
 CC administered to treat diseases associated with aberrant Blys expression
 CC and activity such as cancer, immune, and autoimmune disorders and
 CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
 CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
 CC acquired immunodeficiency syndrome (AIDS)). ABP4390-ABP47228 represent
 CC the antibodies and fragments of the antibodies described in the method
 CC of the invention.

SQ Sequence 249 AA;

Query Match 95.8%; Score 614; DB 23; Length 249;
 Best Local Similarity 95.9%; Pred. No. 6.7e-50;
 Matches 118; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 1 QVQLQSGAEVKKPKSSVRVSCAKSGGFENNAINWVRQAPGGLEWVGIIIPMGFTAKY 60
 Db 1 QVQLQSGAEVKKPKSSVRVSCAKSGGFENNAINWVRQAPGGLEWVGIIIPMGFTAKY 60

QY 61 SQNFGRAVITADESTGTASMETLSLRSEDTAVYYCARSRDLFPFHALLSPMGRTMT 120
 Db 61 SQNFGRAVITADESTGTASMETLSLRSEDTAVYYCARSRDLFPFHALLSPMGRTMT 120

QY 121 VSS 123
 Db 121 VSS 123

RESULT 42
 ABP44563
 ID ABP44563 standard; Protein; 249 AA.

AC ABP44563;
 DT 19-AUG-2002 (first entry)

DE Human Blys binding scFv SEQ ID 574.

KW Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
 KW tumour necrosis factor; B cell proliferation; B cell differentiation;
 KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
 KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
 KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
 KW common variable immunodeficiency; acquired immunodeficiency syndrome.

OS Homo sapiens.

PN WO200202641-A1.

PD 10-JAN-2002.

PF 15-JUN-2001; 2001WO-US19110.

PR 16-JUN-2000; 2000US-212210P.

PR 17-OCT-2000; 2000US-240816P.

PR 16-MAR-2001; 2001US-276248P.

PR 21-MAR-2001; 2001US-277379P.

PR 25-MAY-2001; 2001US-293499P.

PA (HUMA-) HUMAN GENOME SCI INC.

PA (CAMP-) CAMBRIDGE ANTI BODY TECHNOLOGY.

PI Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;

XX WPI; 2002-114799/15.

XX Antibodies against B Lymphocyte Stimulating polypeptides, useful for
 PT the diagnosis and treatment of cancers and immune disorders -
 XX Claim 1; Page 1087-1088; 3148pp; English.

CC This invention describes novel antibodies that immunospecifically bind to
 CC B Lymphocyte Stimulator (Blys) polypeptides. Blys is a member of the
 CC tumour necrosis factor (TNF) super family and induces B cell
 CC proliferation and differentiation. The antibodies of the invention have
 CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
 CC antirheumatic and antiAIDS activity and can be used in vaccines to
 CC inhibit the expression and activity of Blys. The antibodies bind to Blys
 CC and so may be used to detect and quantitate the presence of Blys in
 CC biological samples and may be used in this way to diagnose disease
 CC associated with aberrant expression of Blys. They may also be
 CC administered to treat diseases associated with aberrant Blys expression
 CC and activity such as cancer, immune, and autoimmune disorders and
 CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
 CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
 CC acquired immunodeficiency syndrome (AIDS)). ABP4390-ABP47228 represent
 CC the antibodies and fragments of the antibodies described in the method
 CC of the invention.

SQ Sequence 249 AA;

Query Match 95.8%; Score 614; DB 23; Length 249;
 Best Local Similarity 96.7%; Pred. No. 6.7e-50;
 Matches 119; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 QVQLQSGAEVKKPKSSVRVSCAKSGGFENNAINWVRQAPGGLEWVGIIIPMGFTAKY 60
 Db 1 QVQLQSGAEVKKPKSSVRVSCAKSGGFENNAINWVRQAPGGLEWVGIIIPMGFTAKY 60

QY 61 SQNFGRAVITADESTGTASMETLSLRSEDTAVYYCARSRDLFPFHALLSPMGRTMT 120
 Db 61 SQNFGRAVITADESTGTASMETLSLRSEDTAVYYCARSRDLFPFHALLSPMGRTMT 120

QY 121 VSS 123
 Db 121 VSS 123

RESULT 43
 ABP44706
 ID ABP44706 standard; Protein; 249 AA.

AC ABP44706;

DT 19-AUG-2002 (first entry)

DE Human Blys binding scFv SEQ ID 717.

KW Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
 KW tumour necrosis factor; B cell proliferation; B cell differentiation;
 KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
 KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
 KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
 KW common variable immunodeficiency; acquired immunodeficiency syndrome.

OS Homo sapiens.

PN WO200202641-A1.

PD 10-JAN-2002.

PF 15-JUN-2001; 2001WO-US19110.

PR 16-JUN-2000; 2000US-212210P.

PR 17-OCT-2000; 2000US-240816P.

PR 16-MAR-2001; 2001US-276248P.

PR 21-MAR-2001; 2001US-277379P.

PR 25-MAY-2001; 2001US-293499P.

XX (HUMA-) HUMAN GENOME SCI INC.
PA (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
XX WPI; 2002-114799/15.
XX
XX Antibodies against B lymphocyte Stimulating polypeptides, useful for
PT the diagnosis and treatment of cancers and immune disorders -
XX
XX Claim 1; Page 1257-1258; 3148pp; English.
XX
XX This invention describes novel antibodies that immunospecifically bind to
CC B lymphocyte Stimulator (Blys) polypeptides. Blys is a member of the
CC tumor necrosis factor (TNF) super family and induces B cell
CC proliferation and differentiation. The antibodies of the invention have
CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
CC antirheumatic and antiAIDS activity and can be used in vaccines to
CC inhibit the expression and activity of Blys. The antibodies bind to Blys
CC and so may be used to detect and quantitate the presence of Blys in
CC biological samples and may be used in this way to diagnose disease
CC associated with aberrant expression of Blys. They may also be
CC administered to treat diseases associated with aberrant Blys expression
CC and activity such as cancer, immune, and autoimmune disorders and
CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
CC the antibodies and fragments of the antibodies described in the method
CC of the invention.
XX
XX Sequence 249 AA:
SQ
Query Match 95.8%; Score 614; DB 23; Length 249;
Best Local Similarity 96.7%; Pred. No. 6.7e-50;
Matches 119; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
OY 1 OVLOOOSGAEVKKPSSSVRVSCKASGTFNNNAIMWVROAPQGLEMMGGIIPMEGTAKY 60
DB 1 OVLOOOSGAEVKKPSSSVRVSCKASGTFNNNAIMWVROAPQGLEMMGGIIPMEGTAKY 60
OY 61 SONFGRAVITADESTGTASMSLSLRSEDTAVVYCARSDLLLPFHNLSPWGRGTWT 120
DB 61 SONFGRAVITADESTGTASMSLSLRSEDTAVVYCARSDLLLPFHNLSPWGRGTWT 120
OY 121 VSS 123
DB 121 VSS 123
OY 121 VSS 123
DB 121 VSS 123
RESULT 44
ABP44733
ID ABP44733 standard; Protein; 249 AA.
XX
XX ABP44733;
AC
XX
XX 19-AUG-2002 (first entry)
DT
XX
XX Human Blys binding scFv SEQ ID 744.
DE
XX Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
XX tumor necrosis factor; B cell proliferation; B cell differentiation;
XX immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
XX antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
XX systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
XX common variable immunodeficiency; acquired immunodeficiency syndrome.
OS Homo sapiens.
XX
XX WO200202641-A1.
PN
XX
XX 10-JAN-2002.
PD
XX

PF 15-JUN-2001; 2001WO-US19110.
XX
XX 16-JUN-2000; 2000US-212210P.
PR 17-OCT-2000; 2000US-240816P.
PR 16-MAR-2001; 2001US-276248P.
PR 21-MAR-2001; 2001US-277379P.
PR 25-MAY-2001; 2001US-293499P.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
PA (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX
XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
XX WPI; 2002-114799/15.
XX
XX Antibodies against B lymphocyte Stimulating polypeptides, useful for
PT the diagnosis and treatment of cancers and immune disorders -
XX
XX Claim 1; Page 1289-1290; 3148pp; English.
XX
XX This invention describes novel antibodies that immunospecifically bind to
CC B lymphocyte Stimulator (Blys) polypeptides. Blys is a member of the
CC tumor necrosis factor (TNF) super family and induces B cell
CC proliferation and differentiation. The antibodies of the invention have
CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
CC antirheumatic and antiAIDS activity and can be used in vaccines to
CC inhibit the expression and activity of Blys. The antibodies bind to Blys
CC and so may be used to detect and quantitate the presence of Blys in
CC biological samples and may be used in this way to diagnose disease
CC associated with aberrant expression of Blys. They may also be
CC administered to treat diseases associated with aberrant Blys expression
CC and activity such as cancer, immune, and autoimmune disorders and
CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
CC the antibodies and fragments of the antibodies described in the method
CC of the invention.
XX
XX Sequence 249 AA:
SQ
Query Match 95.8%; Score 614; DB 23; Length 249;
Best Local Similarity 95.9%; Pred. No. 6.7e-50;
Matches 118; Conservative 1; Mismatches 4; Indels 0; Gaps 0;
OY 1 OVLOOOSGAEVKKPSSSVRVSCKASGTFNNNAIMWVROAPQGLEMMGGIIPMEGTAKY 60
DB 1 OVLOOOSGAEVKKPSSSVRVSCKASGTFNNNAIMWVROAPQGLEMMGGIIPMEGTAKY 60
OY 61 SONFGRAVITADESTGTASMSLSLRSEDTAVVYCARSDLLLPFHNLSPWGRGTWT 120
DB 61 SONFGRAVITADESTGTASMSLSLRSEDTAVVYCARSDLLLPFHNLSPWGRGTWT 120
OY 121 VSS 123
DB 121 VSS 123
OY 121 VSS 123
DB 121 VSS 123
RESULT 45
ABP44741
ID ABP44741 standard; Protein; 249 AA.
XX
XX ABP44741;
AC
XX
XX 19-AUG-2002 (first entry)
DT
XX
XX Human Blys binding scFv SEQ ID 752.
DE
XX Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
XX tumor necrosis factor; B cell proliferation; B cell differentiation;
XX immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
XX antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
XX systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
XX common variable immunodeficiency; acquired immunodeficiency syndrome.
KW

```
XX OS Homo sapiens.
XX PN WO200202641-A1.
XX PD 10-JAN-2002.
XX PF 15-JUN-2001; 2001WO-US19110.
XX PR 16-JUN-2000; 2000US-212210P.
XX PR 17-OCT-2000; 2000US-240816P.
XX PR 16-MAR-2001; 2001US-276248P.
XX PR 21-MAR-2001; 2001US-277379P.
XX PR 25-MAY-2001; 2001US-293499P.
XX PA (HUMA-) CAMBRIDGE ANTI-BODY TECHNOLOGY.
XX PA (CAME-) CAMBRIDGE ANTI-BODY TECHNOLOGY.
XX PI Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
XX PS WPI; 2002-114799/15.
XX PT Antibodies against B lymphocyte Stimulating polypeptides, useful for
XX PT the diagnosis and treatment of cancers and immune disorders -
XX PS Claim 1; Page 1298-1299; 3148pp; English.
XX CC This invention describes novel antibodies that immunospecifically bind to
XX CC B lymphocyte Stimulator (Blys) polypeptides. Blys is a member of the
XX CC tumor necrosis factor (TNF) super family and induces B cell
XX CC proliferation and differentiation. The antibodies of the invention have
XX CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
XX CC antirheumatic and antiAIDS activity and can be used in vaccines to
XX CC inhibit the expression and activity of Blys. The antibodies bind to Blys
XX CC and so may be used to detect and quantitate the presence of Blys in
XX CC biological samples and may be used in this way to diagnose disease
XX CC associated with aberrant expression of Blys. They may also be
XX CC administered to treat diseases associated with aberrant Blys expression
XX CC and activity such as cancer, immune, and autoimmune disorders and
XX CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
XX CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
XX CC acquired immunodeficiency syndrome (AIDS)). ABP4390-ABP47228 represent
XX CC the antibodies and fragments of the antibodies described in the method
XX CC of the invention.
XX SQ Sequence 249 AA;
XX
XX Query Match 95.8%; Score 614; DB 23; Length 249;
XX Best Local Similarity 95.8%; Pred. No. 6.7e-50;
XX Matches 118; Conservative 1; Mismatches 4; Indels 0; Gaps 0;
XX
XX QY 1 QVQLQSGAEVKKPPSSVRVSCKASGCTFNNAIMNWRQAPGGLPEWGGIIPEFGTAKY 60
XX DB 1 QVQLQSGAEVKKPPSSVRVSCKASGCTFNNAIMNWRQAPGGLPEWGGIIPEFGTAKY 60
XX QY 61 SONFGRAVITADESTGTASMELSLRSSEDTAVYYCARSRDLLPPHPLSPWGRTWT 120
XX DB 61 SONFGRAVITADESTGTASMELSLRSSEDTAVYYCARSRDLLPPHPLSPWGRTWT 120
XX QY 121 VSS 123
XX DB 121 VSS 123
XX
XX RESULT 46
XX ABP44755
XX ID ABP44755 standard; Protein; 249 AA.
XX AC ABP44755;
XX XX
XX DT 19-AUG-2002 (first entry)
XX XX
XX DE Human Blys binding gcfv seq ID 766.
```

```
XX OS Homo sapiens.
XX PN WO200202641-A1.
XX PD 10-JAN-2002.
XX PF 15-JUN-2001; 2001WO-US19110.
XX PR 16-JUN-2000; 2000US-212210P.
XX PR 17-OCT-2000; 2000US-240816P.
XX PR 16-MAR-2001; 2001US-276248P.
XX PR 21-MAR-2001; 2001US-277379P.
XX PR 25-MAY-2001; 2001US-293499P.
XX PA (HUMA-) HUMAN GENOME SCI INC.
XX PA (CAME-) CAMBRIDGE ANTI-BODY TECHNOLOGY.
XX PI Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
XX PS WPI; 2002-114799/15.
XX PT Antibodies against B lymphocyte Stimulating polypeptides, useful for
XX PT the diagnosis and treatment of cancers and immune disorders -
XX PS Claim 1; Page 1335-1336; 3148pp; English.
XX CC This invention describes novel antibodies that immunospecifically bind to
XX CC B lymphocyte Stimulator (Blys) polypeptides. Blys is a member of the
XX CC tumor necrosis factor (TNF) super family and induces B cell
XX CC proliferation and differentiation. The antibodies of the invention have
XX CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
XX CC antirheumatic and antiAIDS activity and can be used in vaccines to
XX CC inhibit the expression and activity of Blys. The antibodies bind to Blys
XX CC and so may be used to detect and quantitate the presence of Blys in
XX CC biological samples and may be used in this way to diagnose disease
XX CC associated with aberrant expression of Blys. They may also be
XX CC administered to treat diseases associated with aberrant Blys expression
XX CC and activity such as cancer, immune, and autoimmune disorders and
XX CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
XX CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
XX CC acquired immunodeficiency syndrome (AIDS)). ABP4390-ABP47228 represent
XX CC the antibodies and fragments of the antibodies described in the method
XX CC of the invention.
XX SQ Sequence 249 AA;
XX
XX Query Match 95.8%; Score 614; DB 23; Length 249;
XX Best Local Similarity 96.7%; Pred. No. 6.7e-50;
XX Matches 119; Conservative 1; Mismatches 3; Indels 0; Gaps 0;
XX
XX QY 1 QVQLQSGAEVKKPPSSVRVSCKASGCTFNNAIMNWRQAPGGLPEWGGIIPEFGTAKY 60
XX DB 1 QVQLQSGAEVKKPPSSVRVSCKASGCTFNNAIMNWRQAPGGLPEWGGIIPEFGTAKY 60
XX QY 61 SONFGRAVITADESTGTASMELSLRSSEDTAVYYCARSRDLLPPHPLSPWGRTWT 120
XX DB 61 SONFGRAVITADESTGTASMELSLRSSEDTAVYYCARSRDLLPPHPLSPWGRTWT 120
XX QY 121 VSS 123
XX DB 121 VSS 123
XX
XX RESULT 47
XX ABP44756
```

ID ABP4756 standard; Protein; 249 AA.
 XX
 AC ABP4756;
 XX
 DT 19-AUG-2002 (first entry)
 XX
 DE Human Blys binding scFv SEQ ID 767.
 XX
 KW Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
 KW tumour necrosis factor; B cell proliferation; B cell differentiation;
 KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
 KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
 KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
 KW common variable immunodeficiency; acquired immunodeficiency syndrome.
 XX
 OS Homo sapiens.
 XX
 PN WO200202641-A1.
 XX
 F1 10-JAN-2002.
 F2 15-JUN-2001; 2001WO-US19110.
 PR 16-JUN-2000; 2000US-212210P.
 PR 17-OCT-2000; 2000US-240816P.
 PR 16-MAR-2001; 2001US-276248P.
 PR 21-MAR-2001; 2001US-277379P.
 PR 25-MAY-2001; 2001US-293499P.
 PA (HUMA-) HUMAN GENOME SCT INC.
 PA (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
 PI Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
 DR WPI; 2002-114799/15.
 XX
 PT Antibodies against B lymphocyte stimulating polypeptides, useful for
 PT the diagnosis and treatment of cancers and immune disorders -
 XX
 PS Claim 1; Page 1316-1317; 3148pp; English.
 XX
 CC This invention describes novel antibodies that immunospecifically bind to
 CC B lymphocyte stimulator (Blys) polypeptides. Blys is a member of the
 CC tumour necrosis factor (TNF) super family and induces B cell
 CC proliferation and differentiation. The antibodies of the invention have
 CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
 CC antirheumatic and antiAIDS activity and can be used in vaccines to
 CC inhibit the expression and activity of Blys. The antibodies bind to Blys
 CC and so may be used to detect and quantitate the presence of Blys in
 CC biological samples and may be used in this way to diagnose disease
 CC associated with aberrant expression of Blys. They may also be
 CC administered to treat diseases associated with aberrant Blys expression
 CC and activity such as cancer, immune, and autoimmune disorders and
 CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
 CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
 CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
 CC the antibodies and fragments of the antibodies described in the method
 CC of the invention.
 XX
 SQ Sequence 249 AA;
 Query Match 95.8%; Score 614; DB 23; Length 249;
 Best Local Similarity 96.7%; Pred. No. 6.7e-50;
 Matches 119; Conservative 1; Mismatches 3; Indels 0; Gaps 0;
 QY 1 QVQLQSGAEVKKPKSSVRSCKASGTFNNNAIMWRAPQGLMMGGIIPMFGTAKY 60
 DB 1 QVQLQSGAEVKKPKSSVRSCKASGTFNNNAIMWRAPQGLMMGGIIPMFGTAKY 60
 QY 61 SONFGRAVITADESTGTASWELSLRSDTAIVYCARSDLLLPNHALSWGSGTWT 120
 DB 61 SONFGRAVITADESTGTASWELSLRSDTAIVYCARSDLLLPNHALSWGSGTWT 120

QY 121 VSS 123
 DB 121 VSS 123
 RESULT 48
 ID ABP4781
 AC ABP4781
 DT 19-AUG-2002 (first entry)
 DE Human Blys binding scFv SEQ ID 792.
 KW Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
 KW tumour necrosis factor; B cell proliferation; B cell differentiation;
 KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
 KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
 KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
 KW common variable immunodeficiency; acquired immunodeficiency syndrome.
 XX
 OS Homo sapiens.
 XX
 PN WO200202641-A1.
 XX
 F1 10-JAN-2002.
 F2 15-JUN-2001; 2001WO-US19110.
 PR 16-JUN-2000; 2000US-212210P.
 PR 17-OCT-2000; 2000US-240816P.
 PR 16-MAR-2001; 2001US-276248P.
 PR 21-MAR-2001; 2001US-277379P.
 PR 25-MAY-2001; 2001US-293499P.
 PA (HUMA-) HUMAN GENOME SCT INC.
 PA (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
 PI Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
 DR WPI; 2002-114799/15;
 XX
 PT Antibodies against B lymphocyte stimulating polypeptides, useful for
 PT the diagnosis and treatment of cancers and immune disorders -
 XX
 PS Claim 1; Page 1346-1347; 3148pp; English.
 XX
 CC This invention describes novel antibodies that immunospecifically bind to
 CC B lymphocyte stimulator (Blys) polypeptides. Blys is a member of the
 CC tumour necrosis factor (TNF) super family and induces B cell
 CC proliferation and differentiation. The antibodies of the invention have
 CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
 CC antirheumatic and antiAIDS activity and can be used in vaccines to
 CC inhibit the expression and activity of Blys. The antibodies bind to Blys
 CC and so may be used to detect and quantitate the presence of Blys in
 CC biological samples and may be used in this way to diagnose disease
 CC associated with aberrant expression of Blys. They may also be
 CC administered to treat diseases associated with aberrant Blys expression
 CC and activity such as cancer, immune, and autoimmune disorders and
 CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
 CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
 CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
 CC the antibodies and fragments of the antibodies described in the method
 CC of the invention.
 XX
 SQ Sequence 249 AA;
 Query Match 95.8%; Score 614; DB 23; Length 249;
 Best Local Similarity 95.9%; Pred. No. 6.7e-50;
 Matches 118; Conservative 1; Mismatches 4; Indels 0; Gaps 0;
 QY 1 QVQLQSGAEVKKPKSSVRSCKASGTFNNNAIMWRAPQGLMMGGIIPMFGTAKY 60

Db 1 QVQLQSGAEVKKGPSVRSVCKASGTFNNNAIMWVQAQPGGLEWGGIIIPMGTKAKY 60
 QY 61 SQNFGRAVITADESTGTASMEISLSRSEDPAVYVCARSDLLLPFHALLSPWGRGTWVT 120
 Db 61 SQNFGRAVITADESTGTASMEISLSRSEDPAVYVCARSDLLLPFHALLSPWGRGTWVT 120
 QY 121 VSS 123
 121 VSS 123
 Db 121 VSS 123

RESULT 49
 ID ABP44786 standard; Protein; 249 AA.
 AC ABP44786;
 DT 19-AUG-2002 (first entry)

Human Blys binding scFv SEQ ID 797.

Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
 tumour necrosis factor; B cell proliferation; B cell differentiation;
 immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
 antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
 systemic lupus erythematosus; rheumatoid arthritis; CID; AIDS;
 common variable immunodeficiency; acquired immunodeficiency syndrome.

Homo sapiens.
 MO200202641-A1.
 10-JAN-2002.
 15-JUN-2001; 2001WO-US19110.
 16-JUN-2000; 2000US-212210P.
 17-OCT-2000; 2000US-240816P.
 16-MAR-2001; 2001US-276248P.
 21-MAR-2001; 2001US-277379P.
 25-MAY-2001; 2001US-293499P.

(HUMA-) HUMAN GENOME SCI INC.
 (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.

Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
 WPI; 2002-114799/15.

Antibodies against B lymphocyte Stimulating polypeptides, useful for
 the diagnosis and treatment of cancers and immune disorders -

Claim 1; Page 1352-1353; 3148pp; English.

This invention describes novel antibodies that immunospecifically bind to
 B lymphocyte Stimulator (Blys) polypeptides. Blys is a member of the
 tumor necrosis factor (TNF) super family and induces B cell
 proliferation and differentiation. The antibodies of the invention have
 cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
 antirheumatic and antiAIDS activity and can be used in vaccines to
 inhibit the expression and activity of Blys. The antibodies bind to Blys
 and so may be used to detect and quantitate the presence of Blys in
 biological samples and may be used in this way to diagnose disease
 associated with aberrant expression of Blys. They may also be
 administered to treat diseases associated with aberrant Blys expression
 and activity such as cancer, immune, and autoimmune disorders and
 diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
 immunodeficiency (e.g. common variable immunodeficiency (CVID) and
 acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
 the antibodies and fragments of the antibodies described in the method
 of the invention.

SEQ Sequence 249 AA;
 Query Match 95.8%; Score 614; DB 23; Length 249;
 Best Local Similarity 95.9%; Pred. No. 6.7e-50;
 Matches 118; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 1 QVQLQSGAEVKKGPSVRSVCKASGTFNNNAIMWVQAQPGGLEWGGIIIPMGTKAKY 60
 Db 1 QVQLQSGAEVKKGPSVRSVCKASGTFNNNAIMWVQAQPGGLEWGGIIIPMGTKAKY 60
 QY 61 SQNFGRAVITADESTGTASMEISLSRSEDPAVYVCARSDLLLPFHALLSPWGRGTWVT 120
 Db 61 SQNFGRAVITADESTGTASMEISLSRSEDPAVYVCARSDLLLPFHALLSPWGRGTWVT 120
 QY 121 VSS 123
 121 VSS 123
 Db 121 VSS 123

RESULT 50
 ID ABP44788 standard; Protein; 249 AA.
 AC ABP44788;
 DT 19-AUG-2002 (first entry)

Human Blys binding scFv SEQ ID 799.

Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
 tumour necrosis factor; B cell proliferation; B cell differentiation;
 immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
 antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
 systemic lupus erythematosus; rheumatoid arthritis; CID; AIDS;
 common variable immunodeficiency; acquired immunodeficiency syndrome.

Homo sapiens.
 MO200202641-A1.
 10-JAN-2002.
 15-JUN-2001; 2001WO-US19110.
 16-JUN-2000; 2000US-212210P.
 17-OCT-2000; 2000US-240816P.
 16-MAR-2001; 2001US-276248P.
 21-MAR-2001; 2001US-277379P.
 25-MAY-2001; 2001US-293499P.

(HUMA-) HUMAN GENOME SCI INC.
 (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.

Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
 WPI; 2002-114799/15.

Antibodies against B lymphocyte Stimulating polypeptides, useful for
 the diagnosis and treatment of cancers and immune disorders -

Claim 1; Page 1354-1355; 3148pp; English.

This invention describes novel antibodies that immunospecifically bind to
 B lymphocyte Stimulator (Blys) polypeptides. Blys is a member of the
 tumor necrosis factor (TNF) super family and induces B cell
 proliferation and differentiation. The antibodies of the invention have
 cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
 antirheumatic and antiAIDS activity and can be used in vaccines to
 inhibit the expression and activity of Blys. The antibodies bind to Blys
 and so may be used to detect and quantitate the presence of Blys in
 biological samples and may be used in this way to diagnose disease
 associated with aberrant expression of Blys. They may also be
 administered to treat diseases associated with aberrant Blys expression

CC and actively such as cancer, immune, and autoimmune disorders and
CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
CC acquired immunodeficiency syndrome (AIDS)). ABP43390-ABP7228 represent
CC the antibodies and fragments of the antibodies described in the method
CC of the invention.

SQ **Sequence** **249 AA;**

Query Match	95.8%	Score 614	DB 23	length 249
Best Local Similarity	96.7%	Pred. No.	6, 7e-50	
Matches 119	Conservative	0	Mismatches 4	Indels 0
				Gaps 0

QY 1 QVQLDQSGAEVKKPGSSVRVSCASGGTFNNNAINWVROAPGQGLEWMGGII PMFGTAKY 600

db 1 QVQLDQSGAEVKKPGSSVRVSCASGGTFNNNAINWVROAPGQGLEWMGGII PMFGTAKY 600

61 SQNFGRAVATADESTASTAMELSSLRSEDRTAVYICARSRDLLFPQEPLESPWGRTMVT 120

QY	121	VSS	123
Db	121	VSS	123

Search completed: November 26, 2003, 13:39:14
Job time : 40.4231 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: November 26, 2003, 13:36:04 ; Search time 28.9359 Seconds
(without alignments)
989.907 Million cell updates/sec

Title: US-09-880-748-327_COPY_139_249

Perfect score: 583

Sequence: 1 AFSSSLQDPAPVAVSVALGQTV.....RDSGNNHVFQGGTETLVLG 111

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Number of hits satisfying chosen parameters: 830525

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

SPTREMBL_23:*
1: sp_archaea:*
2: sp_bacteria:*
3: sp_fungi:*
4: sp_human:*
5: sp_invertebrate:*
6: sp_mammal:*
7: sp_mhc:*
8: sp_organelle:*
9: sp_phage:*
10: sp_plant:*
11: sp_protent:*
12: sp_virus:*
13: sp_vertebrate:*
14: sp_unclassified:*
15: sp_virus:*
16: sp_bacteriap:*
17: sp_archaeap:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	539	92.5	107	4 Q9NSD6	Q9NSD6 homo sapien
2	438	75.1	233	4 Q8TBC9	Q8TBC9 homo sapien
3	427	73.0	233	4 Q8NSF4	Q8NSF4 homo sapien
4	367.5	63.0	107	4 Q9UL82	Q9UL82 homo sapien
5	367.5	63.0	234	4 Q8J355	Q8J355 homo sapien
6	346	59.3	237	4 Q8WUK4	Q8WUK4 homo sapien
7	340	58.3	237	4 Q8WUK6	Q8WUK6 homo sapien
8	335.5	57.5	236	4 Q8E6T1	Q8E6T1 homo sapien
9	323	55.4	116	4 Q96UD0	Q96UD0 homo sapien
10	322.5	55.3	112	4 Q96UD1	Q96UD1 homo sapien
11	319	54.7	110	4 Q8TE63	Q8TE63 homo sapien
12	316	54.2	112	4 Q96UD2	Q96UD2 homo sapien
13	311.5	53.4	236	4 Q8NEJ1	Q8NEJ1 homo sapien
14	301	51.6	233	4 Q8E169	Q8E169 homo sapien
15	297	50.9	101	4 Q81ZD8	Q81ZD8 homo sapien
16	278	47.7	108	4 Q96S80	Q96S80 homo sapien

17	270	46.3	113	11 Q8CGS1	Q8CGS1 mus musculu
18	270	46.3	235	11 Q99M11	Q99M11 mus musculu
19	268.5	46.1	129	11 Q8VDE2	Q8VDE2 mus musculu
20	248.5	42.6	108	4 Q9UL77	Q9UL77 homo sapien
21	248	42.5	109	11 Q9ET13	Q9ET13 mus musculu
22	247.5	42.5	240	4 Q8WUK3	Q8WUK3 homo sapien
23	246	42.2	134	11 Q8VDD0	Q8VDD0 mus musculu
24	245	42.0	107	4 Q9UL81	Q9UL81 homo sapien
25	244	41.9	109	4 Q9UL78	Q9UL78 homo sapien
26	243	41.7	107	4 Q8E6A9	Q8E6A9 homo sapien
27	237	40.7	114	11 Q8K1F1	Q8K1F1 mus musculu
28	235	40.3	112	11 Q8K1F2	Q8K1F2 mus musculu
29	233.5	40.1	109	11 Q920E6	Q920E6 mus musculu
30	233	40.0	109	4 Q9UL85	Q9UL85 homo sapien
31	232	39.8	112	11 Q8K1P3	Q8K1P3 mus musculu
32	230.5	39.5	234	4 Q8NEK1	Q8NEK1 homo sapien
33	230	39.5	239	4 Q8TCD0	Q8TCD0 homo sapien
34	229.5	39.4	108	4 Q9UL70	Q9UL70 homo sapien
35	229.5	39.4	298	11 Q9QYF0	Q9QYF0 mus musculu
36	229	39.3	101	11 Q9UL78	Q9UL78 mus musculu
37	228	39.1	109	4 Q9UL86	Q9UL86 homo sapien
38	228	39.1	112	11 Q8K1F0	Q8K1F0 mus musculu
39	226.5	38.9	111	11 Q920E9	Q920E9 mus musculu
40	226.5	38.9	234	11 Q8VCE0	Q8VCE0 mus musculu
41	226	38.8	106	5 Q9U410	Q9U410 schistosoma
42	225.5	38.7	109	6 Q9NOM5	Q9NOM5 oryctolagus
43	224.5	38.5	107	11 Q9ER29	Q9ER29 mus musculu
44	223	38.3	97	11 Q9UL76	Q9UL76 mus musculu
45	223	38.3	103	11 Q9UL80	Q9UL80 mus musculu

ALIGNMENTS

RESULT 1	ID	Q9NSD6	PRELIMINARY;	PRT;	107 AA.
AC	Q9NSD6	01-OCT-2000 (Tremblrel. 15, Created)			
DT	01-OCT-2000 (Tremblrel. 15, Last sequence update)				
DT	01-MAR-2003 (Tremblrel. 23, Last annotation update)				
DE	Hypothetical protein (Fragment)				
OS	Homo sapiens (Human)				
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;				
OC	Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.				
OX	NCBI_Taxid=9606;				
RN	(1)				
RP	SEQUENCE FROM N.A.				
RC	TISSUE=Lymphocytes;				
RA	Hohmann A;				
RT	"Autoimmunity ";				
RL	Submitted (JUL-1995) to the EMBL/GenBank/DBJ databases.				
DR	EMBL; L43092; AA69746.2; -				
DR	HSSP; P01709; 2MCG.				
DR	InterPro; IPR007110; IG_1like.				
DR	InterPro; IPR003006; IG_MHC.				
DR	InterPro; IPR003596; IG_V.				
DR	Pfam; PF00477; Ig_1.				
DR	SMART; SM00406; IGV_1.				
DR	PROSITE; PS50835; IG_LIKE; 1.				
FT	NON_TER	1			
FT	NON_TER	107			
SQ	SEQUENCE	107 AA; 11306 MW; A2B04B37187A5F00 CRC64;			
Query Match		92.5%; Score 539; DB 4; Length 107;			
Best Local Similarity		95.3%; Pred. No. 5e-47;			
Matches 102; Conservative		3; Mismatches 2; Indels 0; Gaps 0;			
Qy	5	ELTDDPVSVALGQTVVTCGDSLRYSYASWYQKQGOAPVLYTYGNNPSPGIPRFS 64			
Db	1	ELTDDPVSVALGQTVVTCGDSLRYSYASWYQKQGOAPVLYTYGNNPSPGIPRFS 60			
Qy	65	GSSSGNTASLTITGAQAEADYCCSSRDSSGNNHVFQGGTETLVLG 111			

Db 61 GSSSGNTASLTITGAQAEDEADYCYNSRDSGNHWFVGGGKLTIVLG 107

RESULT 2

08TBC9 PRELIMINARY; PRT; 233 AA.

AC 08TBC9; 01-JUN-2002 (Tremblrel. 21, Created)
DT 01-JUN-2002 (Tremblrel. 21, Last sequence update)
DE 01-MAR-2003 (Tremblrel. 23, Last annotation update)
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
OX NCBI_TaxID=9606;

RP SEQUENCE FROM N.A.

RA TISSUE=B-cell;

Submitted (FEB-2002) to the EMBL/GenBank/DBJ databases.

EMBL: BC022823; AAH22823.1; -

InterPro: IPR003596; IG_MHC.

InterPro: IPR003596; IG_V.

Pfam: PF00047; IG_2.

SMART; SM00406; IGV; 1.

PROSITE; PS00290; IG_MHC; 1.

Hypothetical protein

SEQUENCE 233 AA; 24867 MW; 367411BFD6F4DF92 CRC64;

Query Match

Best Local Similarity 75.1%; Score 438; DB 4; Length 233;

Matches 82; Conservative 9; Mismatches 18; Indels 0; Gaps 0;

QY 3 SSELTOPDAVSVALGOTVRVTCOGDSLRSYASWYQKPGQAPVLVIYGNRRPSGIPDR 62

Db 20 SYELTOPDSVSVSPGQTRITCSGDALPKQAYWYQKSGQPPVLVIYDTERPSGIPER 79

QY 63 FSGSSSGNTASLTITGAQAEDEADYCYNSRDSGNHWFVGGGKLTIVLG 111

Db 80 FSGSSSGTIVTLITISGAQVEDEADYCYNSRDSGNHWFVGGGKLTIVLG 128

QY 80 FSGSSSGTIVTLITISGAQVEDEADYCYNSRDSGNHWFVGGGKLTIVLG 128

RESULT 3

Q8N5F4 PRELIMINARY; PRT; 233 AA.

AC 08N5F4; 01-OCT-2002 (Tremblrel. 22, Created)

DT 01-OCT-2002 (Tremblrel. 22, Last sequence update)

DE 01-MAR-2003 (Tremblrel. 23, Last annotation update)

OS Homo sapiens (Human).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

OX NCBI_TaxID=9606;

RP SEQUENCE FROM N.A.

RA TISSUE=Brain, and Lung;

Submitted (JUN-2002) to the EMBL/GenBank/DBJ databases.

EMBL: BC032452; AAH32452.1; -

InterPro: IPR003599; IG.

InterPro: IPR003599; IG_1.

InterPro: IPR003599; IG_MHC.

InterPro: IPR003596; IG_V.

Pfam: PF00047; IG_2.

SMART; SM00406; IGV; 1.

PROSITE; PS00290; IG_MHC; 1.

Hypothetical protein

SEQUENCE 233 AA; 24961 MW; F092CFB6AA6E3A9A CRC64;

QY SEQUENCE FROM N.A.

Query Match 73.2%; Score 427; DB 4; Length 233;
Best Local Similarity 73.4%; Pred. No. 2.8e-35;
Matches 80; Conservative 9; Mismatches 20; Indels 0; Gaps 0;

QY 3 SSELTOPDAVSVALGOTVRVTCOGDSLRSYASWYQKPGQAPVLVIYGNRRPSGIPDR 62

Db 20 SYELTOPDSVSVSPGQTRITCSGDALPKQAYWYQKSGQPPVLVIYDTERPSGIPER 79

QY 63 FSGSSSGNTASLTITGAQAEDEADYCYNSRDSGNHWFVGGGKLTIVLG 111

Db 80 FSGSSSGTIVTLITISGAQVEDEADYCYNSRDSGNHWFVGGGKLTIVLG 128

QY 80 FSGSSSGTIVTLITISGAQVEDEADYCYNSRDSGNHWFVGGGKLTIVLG 128

RESULT 4

Q9ULB2 PRELIMINARY; PRT; 107 AA.

AC 09ULB2; 01-MAY-2000 (Tremblrel. 13, Created)

DT 01-MAY-2000 (Tremblrel. 13, Last sequence update)

DE 01-MAR-2003 (Tremblrel. 23, Last annotation update)

OS Myosin-reactive immunoglobulin light chain variable region

(fragment).

OC Homo sapiens (Human).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

OX NCBI_TaxID=9606;

RP SEQUENCE FROM N.A.

RA MEDLINE=96277139; PubMed=9614934;

Wu X., Liu B., Van der Merwe P.L., Kalle N.N., Berney S.M.,

Young D.C.;

"Myosin-reactive autoantibodies in rheumatic carditis and normal

fetus";

Clin. Immunol. Immunopathol. 87:184-192(1998).

EMBL: AF035032; AAD56268.1; -

DR HSP; P01703; 7FAB.

DR InterPro: IPR007110; IG_1like.

DR InterPro: IPR003006; IG_MHC.

DR InterPro: IPR003596; IG_V.

Pfam: PF00047; IG_1.

SMART; SM00406; IGV; 1.

PROSITE; PS50835; IG LIKE; 1.

FT NON_TER 1 107

FT NON_TER 1 107

SEQUENCE 107 AA; 11445 MW; 52F0CC1AB26821DC CRC64;

Query Match 63.0%; Score 367.5; DB 4; Length 107;

Best Local Similarity 67.0%; Pred. No. 1.1e-29;

Matches 73; Conservative 13; Mismatches 20; Indels 3; Gaps 2;

QY 3 SSELTOPDAVSVALGOTVRVTCOGDSLRSYASWYQKPGQAPVLVIYGNRRPSGIPDR 62

Db 1 SYELTOPDSVSVSPGQTRITCSGDALPKQAYWYQKSGQPPVLVIYDTERPSGIPER 60

QY 63 FSGSSSGNTASLTITGAQAEDEADYCYNSRDSGNHWFVGGGKLTIVLG 110

Db 61 FSGSSSGTIVTLITISGAQVEDEADYCYNSRDSGNHWFVGGGKLTIVLG 107

RESULT 5

Q8N355 PRELIMINARY; PRT; 234 AA.

AC 08N355; 01-OCT-2002 (Tremblrel. 22, Created)

DT 01-OCT-2002 (Tremblrel. 22, Last sequence update)

DE 01-MAR-2003 (Tremblrel. 23, Last annotation update)

OS Homo sapiens (Human).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

OX NCBI_TaxID=9606;

RP SEQUENCE FROM N.A.

RA TISSUE=Brain, and Lung;

Submitted (JUN-2002) to the EMBL/GenBank/DBJ databases.

EMBL: BC032452; AAH32452.1; -

InterPro: IPR003599; IG.

InterPro: IPR003599; IG_1.

InterPro: IPR003599; IG_MHC.

InterPro: IPR003596; IG_V.

Pfam: PF00047; IG_2.

RC TISSUE=Brain;
RA Strauberg R.;
RL Submitted (APR-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC028090; AAH28090.1; -
DR InterPro; IPR003599; Ig_1.
DR InterPro; IPR007110; Ig_1-like.
DR InterPro; IPR003597; Ig_c1.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF00047; Ig_2.
DR SMART; SM00409; Ig_2.
DR SMART; SM00407; IGC1; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 2.
DR PROSITE; PS00290; IG_MHC; 1.
KM Hypothetical protein.
SQ SEQUENCE 234 AA; 24792 MW; CC648CAEBA4A9D63 CRC64;

Query Match 63.0%; Score 367.5; DB 4; Length 234;
Best Local Similarity 67.3%; Pred. No. 2.9e-29;
Matches 72; Conservative 14; Mismatches 20; Indels 1; Gaps 1;

Oy 6 LTQDPASVALGQTVRVTCQDLSRYSYASWYQKPGQAPVLVIYGNKRRPSGIPDRPSG 65
Db 23 LTQPPSVSVAGPQRTVITISCTGSSNIGAGYDVHMYQQLPGTAPKLIYGNRRPSGVP 82
Oy 66 SSSGNTASLTITGAQAEDEADYCCSRDSSGNH-VFEGGTELTIVG 111
Db 83 SNSGNATLTITSRVDAGDEADYICQLWDSSDHPVFGGKTIVLG 129

RESULT 6
O8WTU6 PRELIMINARY; PRT; 237 AA.

AC O8WTU6; 01-MAR-2002 (TRENBLrel. 20, Created)
DT 01-MAR-2002 (TRENBLrel. 20, Last sequence update)
DT 01-MAR-2003 (TRENBLrel. 23, Last annotation update)
DE Hypothetical protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Euthera; Primates; Catarrhini; Homiidae; Homo.
NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Tonsil;
RA Strauberg R.;
RL Submitted (DEC-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC020233; AAH20233.1; -
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF00047; Ig_2.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00290; IG_MHC; 1.
KM Hypothetical protein.
SQ SEQUENCE 237 AA; 24897 MW; 73C7D70B8039D186 CRC64;

Query Match 59.3%; Score 346; DB 4; Length 237;
Best Local Similarity 64.3%; Pred. No. 4.4e-27;
Matches 72; Conservative 8; Mismatches 28; Indels 4; Gaps 2;
Oy 4 SELTQDPASVALGQTVRVTCQDLSR--SYASWYQKPGQAPVLVIYGNKRRPSGIP 60
Db 21 SVLQPPSVSVAGPQRTVITISCTGSSNIGAGYDVHMYQQLPGTAPKLIYGNRRPSGVP 80
Oy 61 DRFGSSSGNTASLTITGAQAEDEADYCCSRDSS-GNHVFGGTELTIVG 111
Db 81 DRFGSKSGTSASLTITGAQAEDEADYCCSYDSSLGFFVFGGTELTIVG 132

RESULT 7
O8WTU6 PRELIMINARY; PRT; 237 AA.

AC O8WTU6; 01-MAR-2002 (TRENBLrel. 20, Created)
DT 01-MAR-2002 (TRENBLrel. 20, Last sequence update)
DT 01-MAR-2003 (TRENBLrel. 23, Last annotation update)
DE Hypothetical protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Euthera; Primates; Catarrhini; Homiidae; Homo.
NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Tonsil;
RA Strauberg R.;
RL Submitted (JAN-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC022098; AAH22098.1; -
DR InterPro; IPR007110; Ig_1-like.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF00047; Ig_2.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 2.
DR PROSITE; PS00290; IG_MHC; 1.
KM Hypothetical protein.
SQ SEQUENCE 237 AA; 24884 MW; B6CF371E753968E8 CRC64;

Query Match 58.3%; Score 340; DB 4; Length 237;
Best Local Similarity 62.6%; Pred. No. 1.8e-26;
Matches 72; Conservative 9; Mismatches 24; Indels 10; Gaps 3;

Oy 4 SELTQDPASVALGQTVRVTCQDLSR--SYASWYQKPGQAPVLVIYGNKRRPSGIP 60
Db 21 SVLQPPSVSVAGPQRTVITISCTGSSNIGAGYDVHMYQQLPGTAPKLIYGNRRPSGVP 80
Oy 61 DRFGSSSGNTASLTITGAQAEDEADYCCSRD--SGNHVFGGTELTIVG 111
Db 81 DRFGSKSGTSASLTITGAQAEDEADYCCSYDSSLG--VFEGGTELTIVG 132

RESULT 8
O96E61 PRELIMINARY; PRT; 236 AA.

AC O96E61; 01-DEC-2001 (TRENBLrel. 19, Created)
DT 01-DEC-2001 (TRENBLrel. 19, Last sequence update)
DT 01-MAR-2003 (TRENBLrel. 23, Last annotation update)
DE Hypothetical protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Euthera; Primates; Catarrhini; Homiidae; Homo.
NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Brain;
RA Strauberg R.;
RL Submitted (AUG-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC012876; AAH12876.1; -
DR InterPro; IPR007110; Ig_1-like.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF00047; Ig_2.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 2.
DR PROSITE; PS00290; IG_MHC; 1.
KM Hypothetical protein.
SQ SEQUENCE 236 AA; 24712 MW; 7EC9FB3622FED957 CRC64;

Query Match 57.5%; Score 335.5; DB 4; Length 236;
Best Local Similarity 61.3%; Pred. No. 5.1e-26;
Matches 68; Conservative 10; Mismatches 30; Indels 3; Gaps 1;

Oy 4 SELTQDPASVALGQTVRVTCQDLSR--SYASWYQKPGQAPVLVIYGNKRRPSGIP 60
Db 21 SVLQPPSVSVAGPQRTVITISCTGSSNIGAGYDVHMYQQLPGTAPKLIYGNRRPSGVP 80

Db 1 SAAPGQKVTICSSSSNIGKNVSWYQVPGTAQLIHDTKRPSCIPDRFGSGSOST 60
 QY 71 TASLITGAQAEDEADYVCSSRDSSGNHWFVGGTETLVG 111
 61 SATLGITGLQGDDEADYCGTMDTSLSAVFGGKTLVLG 101

RESULT 16
 Q96SB0 PRELIMINARY; PRT; 108 AA.

AC 096SB0; PRELIMINARY; PRT; 108 AA.
 DT 01-DEC-2001 (TREMBLrel. 19, Created)
 DT 01-DEC-2001 (TREMBLrel. 19, Last sequence update)
 DT 01-MAR-2003 (TREMBLrel. 23, Last annotation update)
 DE Anti-streptococcal/anti-mysin immunoglobulin lambda light chain variable region (Fragment).
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
 NCBI_TaxId=9606;

SEQUENCE FROM N.A.
 MEDLINE=98375893; PubMed=9712075;
 RA Adderson E.E., Shikhan A.R., Ward K.B., Cunningham M.W.;
 RT "Molecular analysis of polyclonal monoclonal antibodies from rheumatic carditis: human anti-N-acetylglucosamine/anti-mysin antibody V region genes."
 RT J. Immunol. 161:2020-2031(1998).
 RL EMBL; U96394; AAB68783.1; -
 DR InterPro: IPR007110; IG-1ike.
 DR InterPro: IPR003006; IG_MHC.
 DR InterPro: IPR003596; IG_V.
 DR Pfam: PF00047; IG_1.
 DR SMART; SMO0406; IGV; 1.
 DR PROSITE; P50835; IG_LIKE; 1.
 DR NON TER 1
 FT SEQUENCE 108 AA; 11594 MW; F4B5DC478A043F48 CRC64;

Query Match 47.7%; Score 278; DB 4; Length 108;
 Best Local Similarity 54.3%; Pred. No. 1.3e-20;
 Matches 57; Conservative 12; Mismatches 32; Indels 4; Gaps 2;

QY 4 SELTDPASVALGQVTRVTCQDS--LRSYASWYQKPGQAPVLYIGKNNRPSGIP 61
 2 SVLTDPSSASGTPGQVTTISCGSSSSNIGKNVSWYQVPGTAQLIHDTKRPSCIPDRFGSGV 61
 QY 62 RFGSSSGNTASLTITGAQAEDEADYVCSSRDSS--SGNHWFVGGG 104
 62 RFGSGSGTSSASLISGLRSEDEADYCAAMDRLSGFMWYSAG 106

RESULT 17
 Q8CGS1 PRELIMINARY; PRT; 113 AA.

AC 08CGS1; PRELIMINARY; PRT; 113 AA.
 DT 01-MAR-2003 (TREMBLrel. 23, Created)
 DT 01-MAR-2003 (TREMBLrel. 23, Last sequence update)
 DT 01-MAR-2003 (TREMBLrel. 23, Last annotation update)
 DE Anti-deoxyribose scfv lambda light chain variable region (Fragment).
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 NCBI_TaxId=10090;
 RN 11
 RP SEQUENCE FROM N.A.
 RA SRAIN-BALB/C;
 RT Wang Z., Munshi K., Osawa F., Pestka J.J., Hart L.P.;
 RT "Molecular Cloning of a Functional Single-Chain Fv Antibody with Lambda Light Chain and its Application in Detection of the Mycotoxin Deoxyvalenol."
 RL Submitted (SEP-2002) to the EMBL/GenBank/DBJ databases.
 EMBL; AY151141; AAN75453.1; -

FT NON TER 1 1
 FT NON TER 113 113
 SQ SEQUENCE 113 AA; 12034 MW; 0C4E4C65597E22BE CRC64;

Query Match 46.3%; Score 270; DB 11; Length 113;
 Best Local Similarity 52.7%; Pred. No. 8.6e-20;
 Matches 58; Conservative 17; Mismatches 29; Indels 6; Gaps 3;

QY 6 LTQDPASVALGQVTRVTCQ---GDSLRYSYASWYQKPGQAPVLYIGKNNRPSGIPDR 62
 4 VTQESALITPGEIVTLTCRSSGTGAVTTRVYVWVDEKPHLFTALIGTNNRPPGVPAR 63
 QY 63 FSGSSSGNTASLTITGAQAEDEADYVCSSRDSSGNH--WVFGGTELTVLG 111
 64 FSGSLIDGKALITITGAQTEDEALFCAIYWYS--NHFWVGGGKTLVLG 111

RESULT 18
 Q99M11 PRELIMINARY; PRT; 235 AA.

AC 099M11; PRELIMINARY; PRT; 235 AA.
 DT 01-JUN-2001 (TREMBLrel. 17, Created)
 DT 01-JUN-2001 (TREMBLrel. 17, Last sequence update)
 DT 01-MAR-2003 (TREMBLrel. 23, Last annotation update)
 DE Hypothetical 25.4 kDa protein.
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 NCBI_TaxId=10090;

SEQUENCE FROM N.A.
 RA Strauberg R.;
 RL Submitted (JAN-2001) to the EMBL/GenBank/DBJ databases.
 DR EMBL; BC002129; AAB02129.1; -
 DR HSP; P01703; TEAB.
 DR InterPro: IPR003006; IG_MHC.
 DR InterPro: IPR003596; IG_V.
 DR Pfam: PF00047; IG_2.
 DR SMART; SMO0406; IGV; 1.
 DR PROSITE; P500290; IG_MHC; 1.
 DR Hypothetical protein.
 SQ SEQUENCE 235 AA; 25403 MW; 39807BFE6782A3FB CRC64;

Query Match 46.3%; Score 270; DB 11; Length 235;
 Best Local Similarity 54.9%; Pred. No. 2.1e-19;
 Matches 62; Conservative 14; Mismatches 23; Indels 14; Gaps 5;

QY 6 LTQDPASVALGQVTRVTCQ-----GDSLRYSYASWYQKPGQAPVLYIGKNNRPSGIP 59
 23 LTQPSVSTSLGSLTAKLPCKASTGNIGDS---YNNWYQVYGRSPFTMIYVGGDLRPSGV 78
 QY 60 PDRFSGS--SSGNTASLTITGAQAEDEADYVCSSRDSSGNHWFVGGGTELTVL 110
 79 SDRFSGSIDSSNSAFITITQVQADDEADYTCQY--SSGIR-VVGGGKTLVL 129

RESULT 19
 Q8VDE2 PRELIMINARY; PRT; 129 AA.

AC 08VDE2; PRELIMINARY; PRT; 129 AA.
 DT 01-MAR-2002 (TREMBLrel. 20, Created)
 DT 01-MAR-2002 (TREMBLrel. 20, Last sequence update)
 DT 01-MAR-2003 (TREMBLrel. 23, Last annotation update)
 DE Immunoglobulin lambda chain variable region (Fragment).
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 NCBI_TaxId=10090;
 RN 11
 RP SEQUENCE FROM N.A.
 RA Tissue= spleen;
 RC Blachere T.;

RL Submitted (NOV-2000) to the EMBL/GenBank/DBJ databases.
 RN (2)
 RP SEQUENCE FROM N.A.
 RC TISSUE=Spleen.
 RA Melle G.;
 RL Thesis (1995),
 RL Department of Ecole Supérieure de Technicien en Biologie Biochimie,
 RL Université Catholique de Lyon, Lyon, France.
 DR EMBL: AJ291694; CAC82790.1; -
 DR InterPro: IPR007110; IG-like.
 DR InterPro: IPR003006; IG-MHC.
 DR InterPro: IPR003596; IG_v.
 DR Pfam: PF00047; Ig; 1.
 DR SMART: SM00406; IGV; 1.
 DR PROSITE: PS50835; IG LIKE; 1.
 FT NON_TER 1
 FT NON_TER 129
 SQ SEQUENCE 129 AA; 13565 MW; C07F71003803ADBE CRC64;

Query Match 46.1%; Score 268.5; DB 11; Length 129;
 Best Local Similarity 53.2%; Pred. No. 1.4e-19;
 Matches 58; Conservative 16; Mismatches 30; Indels 5; Gaps 2;

QY 6 LTDPASVALGQTVRTQ--GDSLSRYASWYQKPGQAPVLVIYKNNRPSGIPDR 62
 DB 23 VTQSALTTSPGETVTLTCSRSTGAVTISNVAWVQEKPDYLFGLIGDTNNRPGVBAR 82
 QY 63 FSGSSSGTASLTITGAQAEADYCCSSRDSGNHWFGGTELTIVG 111
 DB 83 FSGSLIGDKALTTTGAQTEDEADYFCVLMWS--NHWFVGGTGLTVLG 129

RESULT 20

Q9UL77 PRELIMINARY; PRT; 108 AA.

AC Q9UL77;
 DT 01-MAY-2000 (TREMBLrel. 13, Created)
 DT 01-MAY-2000 (TREMBLrel. 13, Last sequence update)
 DT 01-MAR-2003 (TREMBLrel. 23, Last annotation update)
 DE Myosin-reactive immunoglobulin light chain variable region
 DE (Fragment).
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
 RX NCBI_TaxId=9606;
 RN (1)
 RP SEQUENCE FROM N.A.
 RL EMBL: AF035037; AAD56273.1; -
 RL MEDLINE=98277139; PubMed=9614934;
 RA Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berney S.M.,
 RA Young D.C.;
 RT "Myosin-reactive autoantibodies in rheumatic carditis and normal
 RT fetus";
 RL Clin. Immunol. Immunopathol. 87:184-192(1998).
 DR EMBL: AF035037; AAD56273.1; -
 DR HSSP: P01607; IREI.
 DR InterPro: IPR007110; IG-like.
 DR InterPro: IPR003006; IG-MHC.
 DR InterPro: IPR003596; IG_v.
 DR Pfam: PF00047; Ig; 1.
 DR SMART: SM00406; IGV; 1.
 DR PROSITE: PS50835; IG LIKE; 1.
 FT NON_TER 1
 FT NON_TER 108
 SQ SEQUENCE 108 AA; 11738 MW; C06681716C4D16F3 CRC64;

Query Match 42.6%; Score 248.5; DB 4; Length 108;
 Best Local Similarity 45.3%; Pred. No. 1.2e-17;
 Matches 48; Conservative 20; Mismatches 35; Indels 3; Gaps 2;

QY 5 ELTQDP-AVVALGQTVRTQCGDLSRYASWYQKPGQAPVLVIYKNNRPSGIPDR 63
 DB 3 QMTQSPSSLSASVGRVITTCRASQSISSLYNWYQKKGKAKNLLIYAASSLSQSGVPSRF 62

QY 64 SGSSSGTASLTITGAQAEADYCCSSRDSGNHWFGGTELTIV 109
 DB 63 SGSSSGTDFTLTISGLQPEDFATYYC--QGSYSTSWTGGSTKXBI 106

RESULT 21

Q9ET13 PRELIMINARY; PRT; 109 AA.

AC Q9ET13;
 DT 01-MAR-2001 (TREMBLrel. 16, Created)
 DT 01-MAR-2001 (TREMBLrel. 16, Last sequence update)
 DT 01-MAR-2003 (TREMBLrel. 23, Last annotation update)
 DE Immunoglobulin light chain variable region (Fragment).
 DE Mus musculus (Mouse).
 OS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 RX NCBI_TaxId=10090;
 RN (1)
 RP SEQUENCE FROM N.A.

RA STRAIN=BA1B/c;
 RA Song M.-Y., Kang H.-K., Kwag W.-J., Moon H.-J., Song T.-H., Ko I.-Y.;
 RT "Nucleotide sequences encoding the variable regions of monoclonal Ab,
 RT A9-11-5, directed against S antigen of Hepatitis B virus."
 RL Submitted (JUL-2000) to the EMBL/GenBank/DBJ databases.
 DR EMBL: AF287275; AAC03053.1; -
 DR HSSP: P01703; 7FAB.

DR InterPro: IPR007110; IG-like.
 DR InterPro: IPR003006; IG-MHC.
 DR InterPro: IPR003596; IG_v.
 DR Pfam: PF00047; Ig; 1.
 DR SMART: SM00406; IGV; 1.
 DR PROSITE: PS50835; IG LIKE; 1.
 FT NON_TER 1
 FT NON_TER 109
 SQ SEQUENCE 109 AA; 11554 MW; 4F91E9D351B1E158 CRC64;

Query Match 42.5%; Score 248; DB 11; Length 109;
 Best Local Similarity 48.6%; Pred. No. 1.4e-17;
 Matches 53; Conservative 20; Mismatches 30; Indels 6; Gaps 2;

QY 6 LTDPASVALGQTVRTQ--GDSLSRYASWYQKPGQAPVLVIYKNNRPSGIPDR 62
 DB 4 VTQSALTTSPGETVTLTCSRSTGAVTISNVAWVQEKPDYLFGLIGDTNNRPGVBAR 63
 QY 63 FSGSSSGTASLTITGAQAEADYCCSSRDSGNHWFGGTELTIVG 111
 DB 64 FSGSLIGDKALTTTGAQTEDEADYFCA--LWTNNWFGGTELTIVG 109

RESULT 22

Q8WUK3 PRELIMINARY; PRT; 240 AA.

AC Q8WUK3;
 DT 01-MAR-2002 (TREMBLrel. 20, Created)
 DT 01-MAR-2002 (TREMBLrel. 20, Last sequence update)
 DT 01-MAR-2003 (TREMBLrel. 23, Last annotation update)
 DE Hypothetical protein.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
 RX NCBI_TaxId=9606;
 RN (1)
 RP SEQUENCE FROM N.A.

RA STRAUBERG R.;
 RL Submitted (DEC-2001) to the EMBL/GenBank/DBJ databases.
 DR EMBL: BC020236; AAH20236.1; -
 DR InterPro: IPR007110; IG-like.
 DR InterPro: IPR003006; IG-MHC.
 DR InterPro: IPR003596; IG_v.
 DR Pfam: PF00047; Ig; 2.
 DR SMART: SM00406; IGV; 1.
 DR PROSITE: PS50835; IG LIKE; 2.

DR PROSITE; PS00290; IG_MHC; 1.
 KW Hypothetical protein.
 SQ SEQUENCE 240 AA; 25977 MW; 921E47DDCA7259F0 CRC64;

Query Match 42.5%; Score 247.5; DB 4; Length 240;
 Best Local Similarity 44.6%; Pred. No. 4.1e-17;
 Matches 50; Conservative 20; Mismatches 35; Indels 7; Gaps 3;

QY 6 LTQDPASVALGQTVVTCQ-GDSLRSYASWYQKPGAPVLVY---GKNNRPSGIP 60
 DB 23 LTQDPASVALGQTVVTCQ-GDSLRSYASWYQKPGAPVLVY---GKNNRPSGIP 82
 QY 61 DFFSGSSGNTASLTITGAQAEDEADYCSSRDSGNH--WFGGTELTVL 110
 DB 83 DFFSGSSGNTASLTITGAQAEDEADYCSSRDSGNH--WFGGTELTVL 134

RESULT 23

Q8VDDO PRELIMINARY; PRT; 134 AA.

Q8VDDO; 01-MAR-2002 (TRENBLrel. 20, Created)

DT 01-MAR-2002 (TRENBLrel. 20, Last sequence update)

DE 01-MAR-2003 (TRENBLrel. 23, Last annotation update)

GN ANTI-MOG 212 variable light chain (Fragment).

OS Mus musculus (Mouse).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

NCBI_TaxID=10090;

RP SEQUENCE FROM N.A.

RC STRAIN=BAIB/c;

RA Chernajovsky Y.;

RT Submitted (OCT-2001) to the EMBL/Genbank/DBJ databases.

DR EMBL; AJ16331; CAC94866.1; --

DR InterPro; IPR007110; I9-1like.

DR InterPro; IPR003006; IG_MHC.

DR Pfam; PF00047; Ig_V.

DR SMART; SM00406; IGV; 1.

DR PROSITE; PS50835; IG_LIKE; 1.

DR NON_TER 134

FT SEQUENCE 134 AA; 14525 MW; CDFE8E236ED20CF CRC64;

Query Match 42.2%; Score 246; DB 11; Length 134;
 Best Local Similarity 50.5%; Pred. No. 2.8e-17;
 Matches 53; Conservative 12; Mismatches 36; Indels 4; Gaps 3;

QY 6 LTQDPASVALGQTVVTCQ-GDSLRSYASWYQKPGAPVLVYKNNRPSGIPDFS 64
 DB 26 LTQDPASVALGQTVVTCQ-GDSLRSYASWYQKPGAPVLVYKNNRPSGIPDFS 84

QY 65 GSSSGNTASLTITGAQAEDEADYCSSRDSGNHWFVGGTELTVL 109
 DB 85 GSSSGNTASLTITGAQAEDEADYCSSRDSGNHWFVGGTELTVL 127

RESULT 24

Q9UL81 PRELIMINARY; PRT; 107 AA.

Q9UL81; 01-MAY-2000 (TRENBLrel. 13, Created)

DT 01-MAY-2000 (TRENBLrel. 13, Last sequence update)

DE 01-MAR-2003 (TRENBLrel. 23, Last annotation update)

DE Myosin-reactive immunoglobulin light chain variable region (Fragment).

OS Homo sapiens (Human).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

NCBI_TaxID=9606;

RP SEQUENCE FROM N.A.

RC MEDLINE=98277139; PubMed=9614934;

RT Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berney S.M.,

RA Young D.C.; "Myosin-reactive autoantibodies in rheumatic carditis and normal

RT fetus";

RL Clin. Immunol. Immunopathol. 87:184-192(1998).

DR EMBL; AF035033; AAD56269.1; --

DR HSP; P01607; IREI

DR InterPro; IPR007110; I9-1like.

DR InterPro; IPR003006; IG_MHC.

DR Pfam; PF00047; Ig_V.

DR SMART; SM00406; IGV; 1.

DR PROSITE; PS50835; IG_LIKE; 1.

DR NON_TER 107

FT SEQUENCE 107 AA; 11501 MW; 070549FDE0754748 CRC64;

Query Match 42.0%; Score 245; DB 4; Length 107;
 Best Local Similarity 46.2%; Pred. No. 2.7e-17;
 Matches 49; Conservative 20; Mismatches 33; Indels 4; Gaps 2;

QY 5 ELTQDPASVALGQTVVTCQ-GDSLRSYASWYQKPGAPVLVYKNNRPSGIPDF 63
 DB 3 QMTQSPSSLSASVGRVITCRASQISINLYNWYQKPGAPVLVYKNNRPSGIPDF 62

QY 64 SSSSGNTASLTITGAQAEDEADYCSSRDSGNHWFVGGTELTVL 109
 DB 63 SSSSGNTASLTITGAQAEDEADYCSSRDSGNHWFVGGTELTVL 105

RESULT 25

Q9UL78 PRELIMINARY; PRT; 109 AA.

Q9UL78; 01-MAY-2000 (TRENBLrel. 13, Created)

DT 01-MAY-2000 (TRENBLrel. 13, Last sequence update)

DE 01-MAR-2003 (TRENBLrel. 23, Last annotation update)

DE Myosin-reactive immunoglobulin light chain variable region (Fragment).

OS Homo sapiens (Human).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

NCBI_TaxID=9606;

RP SEQUENCE FROM N.A.

RC MEDLINE=98277139; PubMed=9614934;

RT Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berney S.M.,

RA Young D.C.; "Myosin-reactive autoantibodies in rheumatic carditis and normal

RT fetus";

RL Clin. Immunol. Immunopathol. 87:184-192(1998).


```

Qy 6 LTODP-AVSVALGQTVRTCO-GDLSRSYASWYQOKPGQAPVLVIYGNRRPSGIPDRF 63
    |||:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
Db 4 LTOSGTLISLPGERATISCRASQSVSSYLAWYQOKGAPRLIIVASSRATGIPDRF 63
    |||:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|

Qy 64 SGSSSGNTASLTITGAQAEADYCCSRDSSGNNHWFGGTELTIV 109
    |||:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
Db 64 SGSSGTDFTLTISLPEDECAVYCCQYQSS--LTFGGGTKVEI 107
    |||:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|

RESULT 26
Q96SA9 PRELIMINARY; PRT; 107 AA.
AC Q96SA9;
DT 01-DEC-2001 (TREMBlrel. 19, Created)
DT 01-DEC-2001 (TREMBlrel. 19, Last sequence update)
DT 01-MAR-2003 (TREMBlrel. 23, Last annotation update)
DE Anti-streptococcal/anti-mysin immunoglobulin kappa light chain
DE variable region (Fragment).
DE Homo sapiens (Human).
DE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
DE Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
CX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=98375893; Pubmed=9712075;
RA Adderson E.E., Shikman A.R., Ward K.E., Cunningham M.W.;
RT "Molecular analysis of polyclonal monoclonal antibodies from
RT rheumatic carditis: human anti-N-acetylglucosamine/anti-mysin
RT antibody V region genes."
RL J. Immunol. 161:2020-2031(1998).
DR EMBL; U96396; AAB68785.1; -.
DR InterPro; IPR007110; IG_1-like.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_V.
DR Pfam; PF00047; IG; 1.
DR SMART; SM00406; IG; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
DR NON_TER 1
FT NON_TER 1
SQ SEQUENCE 107 AA; 11520 MW; 4BB43B9C5B577F16 CRC64;

Query Match 41.7%; Score 243; DB 4; Length 107;
Best Local Similarity 45.3%; Pred. No. 4.3e-17;
Matches 48; Conservative 20; Mismatches 34; Indels 4; Gaps 2;

Qy 5 ELTODP-AVSVALGQTVRTCO-GDLSRSYASWYQOKPGQAPVLVIYGNRRPSGIPDRF 63
    |||:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
    3 QMTQSPFSLASVGRVITTCRASQSSISYLNWYQOKGAPKLIIVASSISQSVPSRF 62
    |||:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|

Qy 64 SGSSSGNTASLTITGAQAEADYCCSRDSSGNNHWFGGTELTIV 109
    |||:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
Db 63 SGSSGTDFTLTISLPEDECAVYCCQYQSS--LTFGGGTKVEI 105
    |||:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|

RESULT 27
Q8K1F1 PRELIMINARY; PRT; 114 AA.
AC Q8K1F1;
DT 01-OCT-2002 (TREMBlrel. 22, Created)
DT 01-OCT-2002 (TREMBlrel. 22, Last sequence update)
DT 01-MAR-2003 (TREMBlrel. 23, Last annotation update)
DE Anti-VIPase light chain variable region (Fragment).
DE Mus musculus (Mouse).
DE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
DE Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
CX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RX STRAIN=BALB/c; TISSUE=Hyperimmunized spleen;
RA Zhou Y.-X., Taguchi H., Planque S., Karle S., Nishiyama Y., Paul S.;
RT "Imine proteolytic antibodies: Failed D-VIPase response to the D-
RT entantomer of VIP and identification of L-VIPase VL domains."

```

```

RL Submitted (May-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF516284; AAM64202.1; -.
DR InterPro; IPR003599; IG_1.
DR InterPro; IPR007110; IG_1-like.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_V.
DR Pfam; PF00047; IG; 1.
DR SMART; SM00409; IG; 1.
DR SMART; SM00406; IG; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
DR NON_TER 1
FT NON_TER 1
SQ SEQUENCE 114 AA; 12162 MW; 8BD9833DBF3EEFD1 CRC64;

Query Match 40.7%; Score 237; DB 11; Length 114;
Best Local Similarity 49.1%; Pred. No. 1.9e-16;
Matches 52; Conservative 14; Mismatches 36; Indels 4; Gaps 3;

Qy 6 LTODPAV-SVALGQTVRTCO-GDLSRSYASWYQOKPGQAPVLVIYGNRRPSGIPDRF 63
    |||:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
Db 4 LTOSPALMSAPGKVTMTTCASSSVSSYLHWYQOKSGAPKLMIVTSLASGVPARF 63
    |||:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|

Qy 64 SGSSSGNTASLTITGAQAEADYCCSRDSSGNNHWFGGTELTIV 109
    |||:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
Db 64 SGSSGTSYSLTISMEADATYCCQYHSYPR--TFGGGTKLEI 107
    |||:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|

RESULT 28
Q8K1F2 PRELIMINARY; PRT; 112 AA.
AC Q8K1F2;
DT 01-OCT-2002 (TREMBlrel. 22, Created)
DT 01-OCT-2002 (TREMBlrel. 22, Last sequence update)
DT 01-MAR-2003 (TREMBlrel. 23, Last annotation update)
DE Anti-VIPase light chain variable region (Fragment).
DE Mus musculus (Mouse).
DE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
DE Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
CX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RX STRAIN=BALB/c; TISSUE=Hyperimmunized spleen;
RA Zhou Y.-X., Taguchi H., Planque S., Karle S., Nishiyama Y., Paul S.;
RT "Imine proteolytic antibodies: Failed D-VIPase response to the D-
RT entantomer of VIP and identification of L-VIPase VL domains."
RL Submitted (May-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF516283; AAM64201.1; -.
DR InterPro; IPR003599; IG_1.
DR InterPro; IPR007110; IG_1-like.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_V.
DR Pfam; PF00047; IG; 1.
DR SMART; SM00409; IG; 1.
DR SMART; SM00406; IG; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
DR NON_TER 1
FT NON_TER 1
SQ SEQUENCE 112 AA; 11953 MW; 4716B87FADB543ED CRC64;

Query Match 40.3%; Score 235; DB 11; Length 112;
Best Local Similarity 50.5%; Pred. No. 3e-16;
Matches 52; Conservative 12; Mismatches 35; Indels 4; Gaps 3;

Qy 6 LTODPAV-SVALGQTVRTCO-GDLSRSYASWYQOKPGQAPVLVIYGNRRPSGIPDRF 64
    |||:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
Db 4 LTOSPALMSAPGKVTMTTCASSSVS-YMFMFOOKGTSFKLIYTSNLASGVPARF 62
    |||:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|

Qy 65 GSSSGNTASLTITGAQAEADYCCSRDSSGNNHWFGGTELTIV 107
    |||:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
Db 63 SGSSGTSYSLTISMEADATYCCQYHSSYPLTFEAGTKL 103
    |||:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|

RESULT 29

```

Q920E6 PRELIMINARY: PRT; 109 AA.

AC Q920E6: 01-DEC-2001 (TREMBLrel. 19, Created)

DT 01-DEC-2001 (TREMBLrel. 19, Last sequence update)

DT 01-MAR-2003 (TREMBLrel. 23, Last annotation update)

DE Pterin-mimicking anti-idiotope kappa chain variable region (Fragment).

OS Mus musculus (Mouse)

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

OX NCBI_TaxId=10090;

RN [1]

RP SEQUENCE FROM N.A.

RA Atkin J.D., Iape A., Jennings I.G., Horaitis O., Cotton R.G.H.;

RT "Definition of the idiotope of Pterin-Mimicking Antibodies Expressed in Mammalian Cells."

RL Submitted (SEP-2000) to the EMBL/Genbank/DBJ databases.

DR EMBL; AF307938; AAL09422.1; -

DR InterPro: IPR007110; IG_1-like.

DR InterPro: IPR003006; IG_MHC.

DR InterPro: IPR003596; IG_V.

DR Pfam: PF00047; IG_1.

DR SMART; SM00406; IGv; 1.

DR PROSITE; PS50835; IG_LIKE; 1.

FT NON_TER 1

FT NON_TER 109

SQ SEQUENCE 109 AA; 11943 MW; DAD3F98E05DD1501 CRC64;

Query Match 40.1%; Score 233.5; DB 11; Length 109;

Best Local Similarity 43.4%; Pred. No. 4e-16;

Matches 46; Conservative 17; Mismatches 40; Indels 3; Gaps 2;

QY 5 ELTOPA-VSVALGQTVRTTCGDSLSRSYYASWYQKPEQAVLVLYGKNNRPSGIPDRF 63

DB 3 QTTQSPASISASVGEVITTCASGNINHYLAMYQCKQCKSPQLLYNAKTLADVPSRF 62

QY 64 GSSSGNTASLTITGAQAEDEADYYCSSRDSGNNHWVFGGTELV 109

DB 63 GSSSGTQVSLKINSIQPEDPSYCCQHWST--PWTFGGTKLEI 106

RESULT 30

Q9UL85 PRELIMINARY: PRT; 109 AA.

AC Q9UL85: 01-MAY-2000 (TREMBLrel. 13, Created)

DT 01-MAY-2000 (TREMBLrel. 13, Last sequence update)

DT 01-MAR-2003 (TREMBLrel. 23, Last annotation update)

DE Myosin-reactive immunoglobulin kappa chain variable region (Fragment).

OS Homo sapiens (Human)

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

OX NCBI_TaxId=9606;

RN [1]

RP SEQUENCE FROM N.A.

RA MEDLINE=98277139; PubMed=9614934;

RA Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berney S.M., Young D.C.;

RT "Myosin-reactive autoantibodies in rheumatic carditis and normal fetus."

RT Clin. Immunol. Immunopathol. 87:184-192 (1998).

RL EMBL; AF035029; AAD56265.1; -

DR HSRP; P80362; IWTU.

DR InterPro: IPR007110; IG_1-like.

DR InterPro: IPR003006; IG_MHC.

DR InterPro: IPR003596; IG_V.

DR Pfam: PF00047; IG_1.

DR SMART; SM00406; IGv; 1.

DR PROSITE; PS50835; IG_LIKE; 1.

FT NON_TER 1

FT NON_TER 109

SEQ SEQUENCE 109 AA; 11761 MW; FB1E43E7C7AFACC CRC64;

Query Match 40.0%; Score 233; DB 4; Length 109;

Best Local Similarity 46.3%; Pred. No. 4.5e-16;

Matches 50; Conservative 17; Mismatches 33; Indels 8; Gaps 3;

QY 6 LTOPA-VSVALGQTVRTTCGDSLSRSYYASWYQKPEQAVLVLYGKNNRPSGIPDRF 64

DB 4 MTQSPALISASVGEVITTCASGNINHYLAMYQCKQCKSPQLLYNAKTLADVPSRF 63

QY 65 GSSSGNTASLTITGAQAEDEADYYCSSRDSGNNHWVFGGTELV 109

DB 64 GSSGTEFTLTSSIQSEDFAIYHCQY---NSWPLTFGGTKVEI 107

RESULT 31

Q8K1F3 PRELIMINARY: PRT; 112 AA.

AC Q8K1F3: 01-OCT-2002 (TREMBLrel. 22, Created)

DT 01-OCT-2002 (TREMBLrel. 22, Last sequence update)

DT 01-MAR-2003 (TREMBLrel. 23, Last annotation update)

DE Anti-VIPase light chain variable region (Fragment).

OS Mus musculus (Mouse)

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

OX NCBI_TaxId=10090;

RN [1]

RP SEQUENCE FROM N.A.

RA STRAIN=BALB/c; TISSUE=Hyperimmunized spleen;

RA Zhou Y.-X., Taguchi H., Plaque S., Kari S., Nishiyama Y., Paul S.;

RT "Immune proteolytic antibodies: Failed D-VIPase response to the D-entantomer of VIP and identification of I-VIPase VL domains."

RT Submitted (MAY-2002) to the EMBL/Genbank/DBJ databases.

DR EMBL; AF516282; AAM64200.1; -

DR InterPro: IPR003599; IG_1.

DR InterPro: IPR007110; IG_1-like.

DR InterPro: IPR003006; IG_MHC.

DR InterPro: IPR003596; IG_V.

DR Pfam: PF00047; IG_1.

DR SMART; SM00409; IG; 1.

DR SMART; SM00406; IGv; 1.

DR PROSITE; PS50835; IG_LIKE; 1.

FT NON_TER 1

FT NON_TER 112

SQ SEQUENCE 112 AA; 12017 MW; 22DD75B5414CDB18 CRC64;

Query Match 39.8%; Score 232; DB 11; Length 112;

Best Local Similarity 48.6%; Pred. No. 5.9e-16;

Matches 51; Conservative 14; Mismatches 36; Indels 4; Gaps 3;

QY 6 LTOPA-VSVALGQTVRTTCGDSLSRSYYASWYQKPEQAVLVLYGKNNRPSGIPDRF 64

DB 4 LTQSPALISASVGEVITTCASGNINHYLAMYQCKQCKSPQLLYNAKTLADVPSRF 62

QY 65 GSSSGNTASLTITGAQAEDEADYYCSSRDSGNNHWVFGGTELV 109

DB 63 GSSGTSISLTSSMEADADATYYCCQYHS--YPTFGGTKLEI 105

RESULT 32

Q8NEK1 PRELIMINARY: PRT; 234 AA.

AC Q8NEK1: 01-OCT-2002 (TREMBLrel. 22, Created)

DT 01-OCT-2002 (TREMBLrel. 22, Last sequence update)

DT 01-MAR-2003 (TREMBLrel. 23, Last annotation update)

DE Hypothetical protein.

OS Homo sapiens (Human)

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

OX NCBI_TaxId=9606;

RN [1]

RP SEQUENCE FROM N.A.
 RC TISSUE=Lung;
 RA Strausberg R.;
 RL Submitted (JUN-2002) to the EMBL/Genbank/DBJ databases.
 DR EMBL: BC030813; AAH30813.1; -
 DR InterPro; IPR007110; Ig-like.
 DR InterPro; IPR003597; Ig_C1.
 DR InterPro; IPR003006; Ig_MHC.
 DR InterPro; IPR003596; Ig_V.
 DR Pfam: PF00047; Ig_2.
 DR SMART; SM00407; IGCL1.1.
 DR SMART; SM00406; IGV; 1.
 DR PROSITE; PS50835; IG_LIKE; 2.
 DR PROSITE; PS00290; IG_MHC; 1.
 DR Hypothetical protein.
 SQ SEQUENCE 234 AA; 25530 MW; 6316E8DEFD132F8 CRC64;

Query Match 39.5%; Score 230.5; DB 4; Length 234;
 Best Local Similarity 45.8%; Pred. No. 2.1e-15;
 Matches 49; Conservative 18; Mismatches 33; Indels 7; Gaps 3;

QY 6 LTQDPA-AVSALGQVRYVTCGDSLSRSYASWYQKPGQAPLVLYGKNNRSGIPDRS 64
 DB 24 MTQSPATLSVSPGERATLSCASQSVTSLNLAWYQQTPEGSPRLVYIGASSRASGVPARFS 83
 QY 65 GSSSGNTASLTITGAQAEDEADYCCSRDSSGNHW--VFGGTELTIV 109
 DB 84 GSGSGTEFTLTISLSQSEDFAYVYCCQY---NKNPHRTGGTKLDI 126

RESULT 33
 Q8TCD0 PRELIMINARY; PRT; 239 AA.
 Q8TCD0: 08TCD0:

DT 01-JUN-2002 (TREMBlrel. 21, Created)
 DT 01-JUN-2002 (TREMBlrel. 21, Last sequence update)
 DT 01-MAR-2003 (TREMBlrel. 23, Last annotation update)
 DE Hypothetical protein.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 CC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 CX NCBI_TaxID=9606;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Strausberg R.;
 RC TISSUE=Lung;
 RL Submitted (JUN-2002) to the EMBL/Genbank/DBJ databases.
 DR EMBL: BC022362; AAH22362.1; -
 DR InterPro; IPR007110; Ig-like.
 DR InterPro; IPR003006; Ig_MHC.
 DR InterPro; IPR003596; Ig_V.
 DR Pfam: PF00047; Ig_2.
 DR SMART; SM00406; IGV; 1.
 DR PROSITE; PS50835; IG_LIKE; 2.
 DR PROSITE; PS00290; IG_MHC; 1.
 DR Hypothetical protein.
 SQ SEQUENCE 239 AA; 26234 MW; FAGEDCA3B03871D CRC64;

Query Match 39.5%; Score 230; DB 4; Length 239;
 Best Local Similarity 42.9%; Pred. No. 2.4e-15;
 Matches 48; Conservative 18; Mismatches 34; Indels 12; Gaps 4;

QY 6 LTQDPA-AVSALGQVRYVTCGDSLSRSY-----YASWYQKPGQAPLVLYGKNNRSGI 59
 DB 24 MTQSPATLSVSPGERATLSCASQSVTSLNLAWYQQTPEGSPRLVYIGASSRASGVPARFS 83
 QY 60 PDRFSGSSGNTASLTITGAQAEDEADYCCSRDSSGNHW--VFGGTELTIV 109
 DB 84 PDRFSGSGSDPTLTKITRVEADGVYFC-----MGTHMPTSTFGTKLEI 131

RESULT 34
 Q9UL70

ID Q9UL70 PRELIMINARY; PRT; 108 AA.
 AC Q9UL70;
 DT 01-MAY-2000 (TREMBlrel. 13, Created)
 DT 01-MAY-2000 (TREMBlrel. 13, Last sequence update)
 DT 01-MAR-2003 (TREMBlrel. 23, Last annotation update)
 DE Myosin-reactive immunoglobulin light chain variable region
 DE (Fragment).
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 CC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 CX NCBI_TaxID=9606;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=98277139; PubMed=9614934;
 RA Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berner S.M.,
 RA Young D.C.;
 RT "Myosin-reactive autoantibodies in rheumatic carditis and normal
 RT fetus";
 RL Clin. Immunol. Immunopathol. 87:184-192(1998).
 DR EMBL: AF035044; AAD56280.1; -
 DR HSP; P01607; IREI.
 DR InterPro; IPR007110; Ig-like.
 DR InterPro; IPR003006; Ig_MHC.
 DR InterPro; IPR003596; Ig_V.
 DR Pfam: PF00047; Ig_1.
 DR SMART; SM00406; IGV; 1.
 DR PROSITE; PS50835; IG_LIKE; 1.
 FT NON_TER 1
 FT NON_TER 108
 SQ SEQUENCE 108 AA; 11633 MW; B7BEDC3E41FCCA37 CRC64;

Query Match 39.4%; Score 229.5; DB 4; Length 108;
 Best Local Similarity 43.4%; Pred. No. 1e-15;
 Matches 46; Conservative 19; Mismatches 36; Indels 3; Gaps 2;

QY 5 ELTQDP-AVSALGQVRYVTCGDSLSRSYASWYQKPGQAPLVLYGKNNRSGIPDRF 63
 DB 3 QMTQSPSLASVSGRVTITCRASQGISNYLAWYQKRGKVKSLIYASTLQSGVPSRF 62
 QY 64 GSSSGNTASLTITGAQAEDEADYCCSRDSSGNHWVFGGTELTIV 109
 DB 63 GSGSGTEFTLTISLSQSEDFAYVYCCQYNSAPR--TFPGTKLEI 106

RESULT 35
 Q9QYF0 PRELIMINARY; PRT; 298 AA.
 Q9QYF0: 09QYF0:

DT 01-MAY-2000 (TREMBlrel. 13, Created)
 DT 01-MAY-2000 (TREMBlrel. 13, Last sequence update)
 DT 01-MAR-2003 (TREMBlrel. 23, Last annotation update)
 DE CN 8 scfv.
 GN CN 8.
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 CC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 CX NCBI_TaxID=10090;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=Balb/c; TISSUE=Spleen;
 RX MEDLINE=20183931; PubMed=10706631;
 RA Shirohara N., Demura T., Fukuda H.;
 RT "Isolation of a cell polarity by using a phase display subtraction
 RT recognizing a cell polarity by using a phase display subtraction
 RT method.";
 RT Proc. Natl. Acad. Sci. U.S.A. 97:2585-2590(2000).
 DR EMBL: AB036341; BAA88633.1; -
 DR HSP; P01607; IREI.
 DR InterPro; IPR007110; Ig-like.
 DR InterPro; IPR003006; Ig_MHC.
 DR InterPro; IPR003596; Ig_V.
 DR Pfam: PF00047; Ig_2.
 DR SMART; SM00406; IGV; 2.

DR PROSITE; PS50835; IG_LIKE; 2.
SQ SEQUENCE 298 AA; 31867 MW; E0F96B8A17004317 CRC64;
Query Match 39.4%; Score 229.5; DB 11; Length 298;
Best Local Similarity 42.7%; Pred. No. 3,6e-15;
Matches 47; Conservative 15; Mismatches 37; Indels 11; Gaps 3;
QY 5 ELTQDPA-VSVALGQVAVTCGGDSLRSYASWYQKPGQAPVLVIYGNKRNPSGIPDRF 63
DB 175 ELTQSPASISAVGETVITTCASGNINHYLAWYQKQKSPQLVYNAKTADGVPSRF 234
QY 64 SSSSSGNTASLTITGQAQEDADYCCSRDSSGNHW---VFGGTELTIV 109
DB 235 SSSSGGTQYSLKINSLQPEDFSGYYCQ-----HFWTTTYTGCGTKLEI 278
RESULT 36
Q9UL78 PRELIMINARY; PRT; 101 AA.
AC Q9UL78; 01-OCT-2000 (TREMBLrel. 15, Created)
DI 01-OCT-2000 (TREMBLrel. 15, Last sequence update)
DE 01-MAR-2003 (TREMBLrel. 23, Last annotation update)
DE Anti-myosin immunoglobulin light chain variable region (Fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=A.CA;
RX MEDLINE=20448942; PubMed=10992488;
RA Malikel S., Liao U., Cunningham M.W., Diamond B.;
RT "T-cell-dependent antibody response to the dominant epitope of streptococcal polysaccharide, N-acetyl-glucosamine, is cross-reactive with cardiac myosin.";
RT Infect. Immun. 68:5803-5808 (2000).
DR EMBL; AF206028; AAF69326.1; -.
DR HSP; P01679; 2FBJ.
DR InterPro; IPR007110; IG_1like.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_V.
DR Pfam; PF00047; IG_1.
DR SMART; SM00406; IGV_1.
DR PROSITE; PS50835; IG_LIKE; 1.
FT NON_TER 1 101
FT NON_TER 101 101
FT SEQUENCE 101 AA; 10778 MW; 0A7F65E6A7E6F14D CRC64;
Query Match 39.3%; Score 229; DB 11; Length 101;
Best Local Similarity 50.0%; Pred. No. 1,1e-15;
Matches 47; Conservative 14; Mismatches 31; Indels 2; Gaps 2;
QY 17 GQTVAVTCQ-GDSLRSYASWYQKPGQAPVLVIYGNKRNPSGIPDRFSGNTAST 75
DB 8 GKXITTCASSISSNHYLAWYQKRGFSPKLLITRTSLAGVPIRFSGSSGTSYSLT 67
QY 76 ITGQAQEDADYCCSRDSSGNHWVFGGTELTIV 109
DB 68 IGTMEADVATYTC-QQSSSIDPRYFGGCKLEI 100
RESULT 37
Q9UL86 PRELIMINARY; PRT; 109 AA.
AC Q9UL86; 01-MAY-2000 (TREMBLrel. 13, Created)
DI 01-MAY-2000 (TREMBLrel. 13, Last sequence update)
DI 01-MAR-2003 (TREMBLrel. 23, Last annotation update)
DE Myosin-reactive immunoglobulin kappa chain variable region (Fragment).
OS Homo sapiens (Human).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=98277139; PubMed=9614934;
RA Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berney S.M.,
RA Young D.C.;
RT "Myosin-reactive autoantibodies in rheumatic carditis and normal fetus";
RT Clin. Immunol. Immunopathol. 87:184-192 (1998).
RL Clin. Immunol. Immunopathol. 87:184-192 (1998).
DR EMBL; AF035028; AAD56264.1; -.
DR HSP; P80362; 1WTU.
DR InterPro; IPR007110; IG_1like.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_V.
DR Pfam; PF00047; IG_1.
DR SMART; SM00406; IGV_1.
DR PROSITE; PS50835; IG_LIKE; 1.
FT NON_TER 1 109
FT NON_TER 109 109
FT SEQUENCE 109 AA; 11928 MW; 243325F72C7DAC83 CRC64;
Query Match 39.1%; Score 228; DB 4; Length 109;
Best Local Similarity 47.2%; Pred. No. 1,5e-15;
Matches 50; Conservative 19; Mismatches 33; Indels 4; Gaps 3;
QY 6 LTQDP-AVSVALGQVAVTCQ-GDSLRSYASWYQKPGQAPVLVIYGNKRNPSGIPDRF 63
DB 4 LTQSPGTLSPPEGRATLSCRASQSVSSSYLAWYQKPGQAPRLIYGTSSRATGIPDRF 63
QY 64 SSSSGNTASLTITGQAQEDADYCCSRDSSGNHWVFGGTELTIV 109
DB 64 SSSGSDPTFLITSLPEDEFAVYICQGYSS--LFTFGTKVDI 107
RESULT 38
Q9K1F0 PRELIMINARY; PRT; 112 AA.
AC Q9K1F0; 01-OCT-2002 (TREMBLrel. 22, Created)
DI 01-OCT-2002 (TREMBLrel. 22, Last sequence update)
DI 01-MAR-2003 (TREMBLrel. 23, Last annotation update)
DE Anti-VIPase light chain variable region (Fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=BALE/c; TISSUE=Hyperimmunized spleen;
RA Zhou Y.-X., Taguchi H., Planque S., Kari S., Nishiyama Y., Paul S.;
RT "Innate proteolytic antibodies: Failed D-VIPase response to the D-entactin of VIP and identification of L-VIPase VL domains.";
RT Submitted (May-2002) to the EMBL/Genbank/DBJ databases.
DR EMBL; AF516285; AAM64203.1; -.
DR InterPro; IPR003599; IG_1like.
DR InterPro; IPR007110; IG_1like.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_V.
DR Pfam; PF00047; IG_1.
DR SMART; SM00406; IGV_1.
DR SMART; SM00409; IG_1.
DR PROSITE; PS50835; IG_LIKE; 1.
FT NON_TER 1 112
FT NON_TER 112 112
FT SEQUENCE 112 AA; 11901 MW; F664463201AA239 CRC64;
Query Match 39.1%; Score 228; DB 11; Length 112;
Best Local Similarity 48.6%; Pred. No. 1,5e-15;
Matches 51; Conservative 13; Mismatches 37; Indels 4; Gaps 3;
QY 6 LTQDP-AV-SVALGQVAVTCQGDLSRSYASWYQKPGQAPVLVIYGNKRNPSGIPDRF 64

Db 4 LTQSPALMSASPEKVTITCSASSVS-YMHWYQCKSGTSPKRWIYDTSKLASGVPARFS 62
Qy 65 GSSSGNTASLTITGAQAEADYYCSDSSGNHWVFGGTELTV 109
Db 63 GSGSGNTSYLTITSTEGEDATYYC-QQWSNPPTFGGTELT 105

RESULT 39

Q920E9 PRELIMINARY; PRT; 111 AA.

AC Q920E9; 01-DEC-2001 (TREMBlrel. 19, Created)
DT 01-DEC-2001 (TREMBlrel. 19, Last sequence update)
DE 01-MAR-2003 (TREMBlrel. 23, Last annotation update)
DE Pterin-mimicking anti-idiotope kappa chain variable region
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.
NCBI_TaxID=10090;

RP SEQUENCE FROM N.A.
RA Atkin J.D., Jape A., Jennings I.G., Horatits O., Cotton R.G.H.;
RT "Definition of the Idiotope of Pterin-Mimicking Antibodies Expressed
in Mammalian Cells."
RL Submitted (SEP-2000) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF307935; AAL09419.1; -
DR InterPro; IPR007110; IG_1like.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_V.
DR Pfam; PF00047; IG_1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
FT NON_TER 1
FT 111
SQ SEQUENCE 111 AA; 12046 MW; 1E46988AA6856526 CRC64;

Query Match 38.9%; Score 226.5; DB 11; Length 111;
Best Local Similarity 47.3%; Pred. No. 2.1e-15;
Matches 52; Conservative 15; Mismatches 34; Indels 9; Gaps 5;

Qy 6 LTQDPA-VSVALGQTVRTVTCQD--SLRSY-YASWYQCKPGQAPVLVIYGNRPSSGIP 60
Db 4 LTQSPALMSASPEKVTITCSASSVS-YMHWYQCKSGTSPKRWIYDTSKLASGVPARFS 63
Qy 61 DRFGSSGNTASLTITGAQAEADYYCSDSSGNHWVFGGTELT 109
Db 64 ARFGSGSGTDTFLNIHVEEDATYYCOHSREL--YTFGGGTELT 110

RESULT 40

Q8VCP0 PRELIMINARY; PRT; 234 AA.

AC Q8VCP0; 01-MAR-2002 (TREMBlrel. 20, Created)
DT 01-MAR-2002 (TREMBlrel. 20, Last sequence update)
DE 01-MAR-2003 (TREMBlrel. 23, Last annotation update)
DE Hypothetical 25.7 kDa protein.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.
NCBI_TaxID=10090;

RP SEQUENCE FROM N.A.
RA Strausberg R.;
RT Submitted (DEC-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC019474; AAH19474.1; -
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_V.
DR Pfam; PF00047; IG_2.
DR SMART; SM00406; IGV; 1.

DR PROSITE; PS00290; IG_MHC; 1.
KW Hypothetical protein.
SQ SEQUENCE 234 AA; 25702 MW; 102551C50AC2FA9F CRC64;

Query Match 38.9%; Score 226.5; DB 11; Length 234;
Best Local Similarity 43.4%; Pred. No. 5.3e-15;
Matches 46; Conservative 17; Mismatches 40; Indels 3; Gaps 2;

Qy 5 LTQDPA-VSVALGQTVRTVTCQDLSRYSYASWYQCKPGQAPVLVIYGNRPSSGIP 63
Db 23 QLTQSPALMSASPEKVTITCSASSVS-YMHWYQCKSGTSPKRWIYDTSKLASGVPARFS 82
Qy 64 GSSSGNTASLTITGAQAEADYYCSDSSGNHWVFGGTELT 109
Db 83 GSGSGNTSYLTITSTEGEDATYYC-QQWSNPPTFGGTELT 105

RESULT 41

Q9U410 PRELIMINARY; PRT; 106 AA.

AC Q9U410; 01-MAY-2000 (TREMBlrel. 13, Created)
DT 01-MAY-2000 (TREMBlrel. 13, Last sequence update)
DE 01-MAR-2003 (TREMBlrel. 23, Last annotation update)
DE Monoclonal anti-idiotypic antibody NP30 immunoglobulin light chain
OS Schistosoma japonicum (Blood fluke).
OC Eukaryota; Metazoa; Platyhelminthes; Trematoda; Digenea; Strigeidida;
Schistosomatidae; Schistosomatidae; Schistosoma.
NCBI_TaxID=6182;

RP SEQUENCE FROM N.A.
RA Song X.T., Peng Z.O., Qiu Z.N., Li Y.Q., Huang H.L., Guan X.H.;
RT "Amplification, cloning and sequence analysis of the light chain
variable region gene of monoclonal anti-idiotypic antibody NP30 of
Schistosoma japonicum."
RL Submitted (NOV-1999) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF207620; AAF19434.1; -
DR HSP; P01679; 2FBF.

DR InterPro; IPR007110; IG_1like.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_V.
DR Pfam; PF00047; IG_1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.

FT NON_TER 1
FT 106
SQ SEQUENCE 106 AA; 11478 MW; F20F544426BAE63E CRC64;

Query Match 38.8%; Score 226; DB 5; Length 106;
Best Local Similarity 49.5%; Pred. No. 2.2e-15;
Matches 51; Conservative 13; Mismatches 35; Indels 4; Gaps 3;

Qy 6 LTQDPA-VSVALGQTVRTVTCQDLSRYSYASWYQCKPGQAPVLVIYGNRPSSGIP 64
Db 4 LTQSPALMSASPEKVTITCSASSVS-YMHWYQCKSGTSPKRWIYDTSKLASGVPARFS 62
Qy 65 GSSSGNTASLTITGAQAEADYYCSDSSGNHWVFGGTELT 107
Db 63 GSGSGNTSYLTITSTEGEDATYYC-QQWSNPPTFGGTELT 105

RESULT 42

Q9N0W5 PRELIMINARY; PRT; 109 AA.

AC Q9N0W5; 01-OCT-2000 (TREMBlrel. 15, Created)
DT 01-OCT-2000 (TREMBlrel. 15, Last sequence update)
DE 01-MAR-2003 (TREMBlrel. 23, Last annotation update)
DE Anti-human A33 light chain variable region (Fragment).
OS Oryctolagus cuniculus (Rabbit).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Lagomorpha; Leporidae; Oryctolagus.

NCBI_TaxID=9986;
[1]
SEQUENCE FROM N.A.
MEDLINE=20250927; PubMed=10788485;
RA Rader C., Ritter G., Nathan S., Elia M., Gout I., Junghuth A.A.,
Cohen L.S., Welt S., Old L.J., Barbas C.F. III;
"The rabbit antibody repertoire as a novel source for the generation
of therapeutic human antibodies";
RL J. Biol. Chem. 275:13668-13676(2000).
DR EMBL: AF245502; AAF68449.1; -.
DR HSSP: P80362; 1MTL.
DR InterPro: IPR007110; Ig-like.
DR InterPro: IPR003006; Ig_MHC.
DR InterPro: IPR003596; Ig_V.
DR Pfam: PF00047; Ig_1.
DR SMART: SM00406; IGV_1.
DR PROSITE: PS50835; IG-LIKE; 1.
FT NON_TER 1 109
FT NON_TER 109 109
SQ SEQUENCE 109 AA; 11323 MW; BD8B396EE75F94FB CRC64;
Query Match 38.7%; Score 225.5; DB 6; Length 109;
Best Local Similarity 44.8%; Pred. No. 2.6e-15;
Matches 47; Conservative 15; Mismatches 42; Indels 1; Gaps 1;
QY 6 LTQD-PAVSVALGQTVRTVTCQGDLSRSYASWYQKPGQAPVLYIGKNNRPSGIPDRFS 64
DB 4 LTQTPSPSLSPSVGETVRIRCLASDFLFGVSNWYQKPEKPTLLISGASDLETGVPRFS 63
QY 65 GSSSGNTASLTITGAQAEDEADYCCSSRDSSGNHWVFGGTELT 109
DB 64 GSGSGDYTLITIGVQAEADAATYICIGYSGSAGLTFAGTVEI 108
RESULT 43
Q9ERZ9 PRELIMINARY; PRT; 107 AA.
ID Q9ERZ9
AC Q9ERZ9; 01-MAR-2001 (TREMBlrel. 16, Created)
DT 01-MAR-2001 (TREMBlrel. 16, Last sequence update)
DT 01-MAR-2003 (TREMBlrel. 23, Last annotation update)
DE Anti human TNF-alpha light chain variable region (Fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
[1]
SEQUENCE FROM N.A.
RP Chen P., Deng J.B., Wang Z.L., Han H., Su C.Z.;
"Cloning and sequencing of the light chain fragment of variable region
genes of an anti-TNF-a monoclonal antibody";
RL J. Cell. Mol. Immunol. 12:21-26(1996).
[2]
SEQUENCE FROM N.A.
RP Chen P., Deng J.B., Wang Z.L., Han H., Su C.Z.;
"Construction and sequencing of the single-chain antibody gene of a
human TNF-alpha specific monoclonal antibody";
RL Ti 4 Chun 1 Ta Heuh Hsueh Pao 19:373-376(1998).
[3]
SEQUENCE FROM N.A.
RA Chen P., Deng J.B., Wang Z.L., Han H., Yao L.B., Su C.Z.;
Submitted (May-2000) to the EMBL/GenBank/DBJ databases.
DR EMBL: AF262753; AAG23804.1; -.
DR HSSP: P80362; 1MTL.
DR InterPro: IPR007110; Ig-like.
DR InterPro: IPR003006; Ig_MHC.
DR InterPro: IPR003596; Ig_V.
DR Pfam: PF00047; Ig_1.
DR SMART: SM00406; IGV_1.
DR PROSITE: PS50835; IG-LIKE; 1.
FT NON_TER 107
FT NON_TER 107 107
SQ SEQUENCE 107 AA; 11784 MW; 2B15EBA604A26C3 CRC64;

Query Match 38.5%; Score 224.5; DB 11; Length 107;
Best Local Similarity 40.4%; Pred. No. 3.2e-15;
Matches 44; Conservative 25; Mismatches 31; Indels 9; Gaps 3;
QY 6 LTQD-PAVSVALGQTVRTVTCQGDLSRSYASWYQKPGQAPVLYIGKNNRPSG 58
DB 1 MTQSPSSLSLMSGVQVYMVSCKSSQSVLSNQNKYLAHYQKPGQSPFLVFASTRSG 60
QY 59 IPDRFSSSGNTASLTITGAQAEDEADYCCSSRDSSGNHWVFGGTELT 107
DB 61 VPDRTMGSGSGTDFLTITSSVQTEDLADYFCQHQHRT--PFTFGSGTKL 107
RESULT 44
Q9JL76 PRELIMINARY; PRT; 97 AA.
ID Q9JL76
AC Q9JL76; 01-OCT-2000 (TREMBlrel. 15, Created)
DT 01-OCT-2000 (TREMBlrel. 15, Last sequence update)
DT 01-MAR-2003 (TREMBlrel. 23, Last annotation update)
DE Anti-myosin immunoglobulin light chain variable region
(Fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
[1]
SEQUENCE FROM N.A.
RP STRAIN=DBA/2;
RC MEDLINE=20446942; PubMed=10922488;
RA Markiel S., Liao L., Cunningham M.W., Diamond B.;
"T-cell-dependent antibody response to the dominant epitope of
streptococcal polysaccharide, N-acetyl-glucosamine, is cross-reactive
with cardiac myosin";
RL Infect. Immun. 68:5803-5808(2000).
DR EMBL: AF206030; AAF69328.1; -.
DR HSSP: P01679; 2FBJ.
DR InterPro: IPR007110; Ig-like.
DR InterPro: IPR003006; Ig_MHC.
DR InterPro: IPR003596; Ig_V.
DR Pfam: PF00047; Ig_1.
DR SMART: SM00406; IGV_1.
DR PROSITE: PS50835; IG-LIKE; 1.
FT NON_TER 97
FT NON_TER 97 97
SQ SEQUENCE 97 AA; 10542 MW; C9E1FBE1F49DA1C CRC64;
Query Match 38.3%; Score 223; DB 11; Length 97;
Best Local Similarity 49.0%; Pred. No. 4e-15;
Matches 48; Conservative 15; Mismatches 33; Indels 2; Gaps 2;
QY 12 VSVALGQTVRTVTCQGDLSRSYASWYQKPGQAPVLYIGKNNRPSGIPDRFSSSGNT 71
DB 1 LSASPGKVTWTCRASSVS-YMHWYQKPGSSPKPIVATSNLASGVPAFSSGSGT 59
QY 72 ASLTITGAQAEDEADYCCSSRDSSGNHWVFGGTELT 109
DB 60 YSLTISRVEADEADAATYIC-QQMSKMYTTFGGTKLEI 96
RESULT 45
Q9JL80 PRELIMINARY; PRT; 103 AA.
ID Q9JL80
AC Q9JL80; 01-OCT-2000 (TREMBlrel. 15, Created)
DT 01-OCT-2000 (TREMBlrel. 15, Last sequence update)
DT 01-MAR-2003 (TREMBlrel. 23, Last annotation update)
DE Anti-myosin immunoglobulin light chain variable region
(Fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;

RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=BALB/c;
 RX MEDLINE=20448942; PubMed=10992488;
 RA "T-Cell-dependent antibody response to the dominant epitope of streptococcal polysaccharide, N-acetyl-glucosamine, is cross-reactive with cardiac myosin.";
 RT Infect. Immun. 68:5803-5808(2000).
 RL EMBL; AF206026; AAF69324.1; -.
 DR HSSP; P80362; 1WTL.
 DR InterPro; IPR007110; IG_1like.
 DR InterPro; IPR003006; IG_MHC.
 DR InterPro; IPR003596; IG_V.
 DR Pfam; PF00047; IG_1.
 DR SMART; SM00406; IG; 1.
 DR PROSITE; PS50835; IG LIKE; 1.
 FT NON_TER 1
 FT NON_TER 103
 RN SEQUENCE 103 AA; 11224 MW; EC87D653DB3AAB21 CRC64;
 Query Match 38.3%; Score 223; DB 11; Length 103;
 Best Local Similarity 43.7%; Pred. No. 4,4e-15;
 Matches 45; Conservative 17; Mismatches 35; Indels 6; Gaps 2;
 QY 11 AVSVALGQTVRTCCGDSLRSYYA-----WTQKPGQAPVLYVYKNNRPSGIPDRFSGS 66
 DB 2 SLAVSLGGRATITSCASSESVETGSLMOWQKQKGPPLKIYASNVESGVPARFSGS 61
 QY 67 SSGNTASLTITGAQAEADYVYSSRDSSGNHWVFGGTELTIV 109
 DB 62 GSGTDFSLNHVVEDDIAMVFC--QQRKVPWTFGGTKLEI 102
 RESULT 46
 ID Q9UL83 PRELIMINARY; PRT; 108 AA.
 AC Q9UL83;
 DT 01-MAY-2000 (TrEMBLrel. 13, Created)
 DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
 DT 01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
 DE Myosin-reactive immunoglobulin light chain variable region (Fragment).
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 OX NCBI_TaxID=9606;
 OX [1]
 RP SEQUENCE FROM N.A.
 RA MEDLINE=98277139; PubMed=9614934;
 RA Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berney S.M., Young D.C.;
 RT "Myosin-reactive autoantibodies in rheumatic carditis and normal fetus";
 RL Clin. Immunol. Immunopathol. 87:184-192(1998).
 DR HSSP; P80362; 1WTL.
 DR InterPro; IPR007110; IG_1like.
 DR InterPro; IPR003006; IG_MHC.
 DR InterPro; IPR003596; IG_V.
 DR Pfam; PF00047; IG_1.
 DR SMART; SM00406; IG; 1.
 DR PROSITE; PS50835; IG LIKE; 1.
 FT NON_TER 1
 FT NON_TER 108
 RN SEQUENCE 108 AA; 11834 MW; 9F9C5A92EBA96EEA CRC64;
 Query Match 38.2%; Score 222.5; DB 4; Length 108;
 Best Local Similarity 45.8%; Pred. No. 5.2e-15;
 Matches 49; Conservative 17; Mismatches 34; Indels 7; Gaps 3;
 QY 6 LTQDPA-VSVALGQTVRTCCGDSLRSYYASWYQKPGQAPVLYVYKNNRPSGIPDRFS 64
 DB 14 VALGQTVRTCCGDSLRSYYASWYQKPGQAPVLYVYKNNRPSGIPDRFSGS 66
 DB 5 VSAGDRVYITCKASQSVSNVAVWYQKPGQAPVLYVYKNNRPSGIPDRFSGS 64
 QY 74 LTITGAQAEADYVYSSRDSSGNHWVFGGTELTIV 109
 DB 65 FTISTVQAEADYVYFCQDDYSSPR--TFGGTKLEI 98
 RESULT 48
 ID Q9UL80 PRELIMINARY; PRT; 114 AA.
 AC Q9UL80;
 DT 01-MAY-2000 (TrEMBLrel. 13, Created)
 DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
 DT 01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
 DE Myosin-reactive immunoglobulin light chain variable region (Fragment).
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 OX NCBI_TaxID=9606;
 OX [1]
 RP SEQUENCE FROM N.A.
 RA MEDLINE=98277139; PubMed=9614934;
 RA Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berney S.M., Young D.C.;
 RT "Myosin-reactive autoantibodies in rheumatic carditis and normal

DB 4 MTQSPATLVSPPGERATLSCRASQSVSSNLAWYQKPGQAPVLYVYKNNRPSGIPDRFS 63
 QY 65 SSGNTASLTITGAQAEADYVYSSRDSSGNHW--VFGGTELTIV 109
 DB 64 GSGTDFSLNHVVEDDIAMVFC--QQRKVPWTFGGTKLEI 102
 RESULT 47
 ID Q9UL74 PRELIMINARY; PRT; 99 AA.
 AC Q9UL74;
 DT 01-OCT-2000 (TrEMBLrel. 15, Created)
 DT 01-OCT-2000 (TrEMBLrel. 15, Last sequence update)
 DT 01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
 DE Anti-myosin immunoglobulin light chain variable region (Fragment).
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 OX NCBI_TaxID=10090;
 OX [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=BALB/c;
 RX MEDLINE=20448942; PubMed=10992488;
 RA Malkiel S., Liao L., Cunningham M.W., Diamond B.;
 RT "T-Cell-dependent antibody response to the dominant epitope of streptococcal polysaccharide, N-acetyl-glucosamine, is cross-reactive with cardiac myosin.";
 RT Infect. Immun. 68:5803-5808(2000).
 RL EMBL; AF206032; AAF69330.1; -.
 DR HSSP; P80362; 1WTL.
 DR InterPro; IPR007110; IG_1like.
 DR InterPro; IPR003006; IG_MHC.
 DR InterPro; IPR003596; IG_V.
 DR Pfam; PF00047; IG_1.
 DR SMART; SM00406; IG; 1.
 DR PROSITE; PS50835; IG LIKE; 1.
 FT NON_TER 1
 FT NON_TER 99
 RN SEQUENCE 99 AA; 10939 MW; 3B25D0E784533324 CRC64;
 Query Match 37.9%; Score 221; DB 11; Length 99;
 Best Local Similarity 46.9%; Pred. No. 6.6e-15;
 Matches 45; Conservative 15; Mismatches 34; Indels 2; Gaps 1;
 QY 14 VALGQTVRTCCGDSLRSYYASWYQKPGQAPVLYVYKNNRPSGIPDRFSGS 66
 DB 5 VSAGDRVYITCKASQSVSNVAVWYQKPGQAPVLYVYKNNRPSGIPDRFSGS 64
 QY 74 LTITGAQAEADYVYSSRDSSGNHWVFGGTELTIV 109
 DB 65 FTISTVQAEADYVYFCQDDYSSPR--TFGGTKLEI 98
 RESULT 48
 ID Q9UL80 PRELIMINARY; PRT; 114 AA.
 AC Q9UL80;
 DT 01-MAY-2000 (TrEMBLrel. 13, Created)
 DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
 DT 01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
 DE Myosin-reactive immunoglobulin light chain variable region (Fragment).
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 OX NCBI_TaxID=9606;
 OX [1]
 RP SEQUENCE FROM N.A.
 RA MEDLINE=98277139; PubMed=9614934;
 RA Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berney S.M., Young D.C.;
 RT "Myosin-reactive autoantibodies in rheumatic carditis and normal

```

RT fetus."
RL Clin. Immunol. Immunopathol. 87:184-192(1998).
DR EMBL; AF035034; AAD56270.1; -.
DR HSSP; P80362; 1MTL.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_V.
DR Pfam; PF00047; Ig; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG_LIKE; 1.
FT NON_TER 1
FT NON_TER 114
SQ SEQUENCE 114 AA; 12775 MW; 070E31E210D1CB01 CRC64;

Query Match
Best Local Similarity 37.7%; Score 219.5; DB 4; Length 114;
Matches 46; Conservative 19; Mismatches 35; Indels 13; Gaps 4;

QY 6 LTQDP-AVSVALGQTVRVTCQGDLSRSY-----YASWYQKRGQAPVLYIKNNRPSGDI 59
   |||  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :
   4 MTQSPSLSPVTLRQPASISCRSSQSPVSDGNTYINWFQGRDQSPRRILYKVSNRDSGV 63
QY |||  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :
   60 PRFSGSSSGNTASLTITGAQAEADYCCSRDSSGNH--WFGGTELTIV 109
   |||  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :
   64 PRFSGSGSGTFTLKISRVEADLVGYIC---WQTHMPWTIGQGTKEI 112

RESULT 49
Q99M37 PRELIMINARY; PRT; 238 AA.
ID 099M37
AC 099M37
DT 01-JUN-2001 (TrEMBLrel. 17, Created)
DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
DT 01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DE Hypothetical 26.3 kDa protein.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RA Strausberg R.;
RL Submitted (JAN-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC002035; AAH02035.1; -.
DR HSSP; P01679; 2FBU.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_V.
DR Pfam; PR00047; Ig; 2.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG_LIKE; 2.
DR PROSITE; PS00290; IG_MHC; 1.
KM Hypothetical protein.
SQ SEQUENCE 238 AA; 26344 MW; FB2B06A0B801330A CRC64;

Query Match
Best Local Similarity 37.6%; Score 219; DB 11; Length 238;
Matches 51; Conservative 20; Mismatches 34; Indels 14; Gaps 5;

QY 1 AFSSS--LTQDP-AVSVALGQTVRVTCQGD-----SLRSYASWYQKRGQAPVLYIKG 52
   |||  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :
   16 ASSSDVVMQTPTSLVSLGDQASISCRSSQSIHNSNGNTYLEWYLQKPGQSPKLLIYKV 75
QY 53 NNRPSCIPDRFSGSSSGNTASLTITGAQAEADYCCSRDSSGNH--WFGGTELTIV 109
   |||  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :
   76 SNRFSGVPDRFSGSGGTFTLKISRVEADLVGYIC---FQSHVPTFSGGTKEI 130

RESULT 50
Q9RIAS PRELIMINARY; PRT; 214 AA.
ID 09RIAS
AC 09RIAS
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
```

```

DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DE Kappa light chain of Mab7 (Fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RA Wilde K.G., Yu X., Ekramoddoullah A.K.M., Misra S.;
RT "Cloning of cDNAs encoding for anti-white pine blister rust monoclonal
RT antibody (Mab 7, its light and heavy chains) and construction of a
RT single chain antibody (scFv).";
RL Submitted (MAY-1999) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF152371; AAD04242.1; -.
DR HSSP; P01679; 2FBU.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_V.
DR Pfam; PF00047; Ig; 2.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG_LIKE; 2.
DR PROSITE; PS00290; IG_MHC; 1.
FT NON_TER 1
FT NON_TER 11
FT NON_TER 214
SQ SEQUENCE 214 AA; 23922 MW; 52BA205FDE995E2A CRC64;

Query Match
Best Local Similarity 37.5%; Score 218.5; DB 11; Length 214;
Matches 45; Conservative 18; Mismatches 40; Indels 3; Gaps 2;

QY 5 ELTQDP-AVSVALGQTVRVTCQGDLSRSYASWYQKRGQAPVLYIKNNRPSGIDPRF 63
   |||  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :
   3 QLTQSPSSMTASLSEERVTITKASQDINSYISWYQKRGKSPKLLYRARNLVGVSRF 62
QY 64 SGSSSGNTASLTITGAQAEADYCCSRDSSGNHWWFGGTELTIV 109
   |||  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :
   63 SGSSGQDYSLTISLSLEYEDWGIYICQYDF--PFTFGSGTKLEI 106
```

Search completed: November 26, 2003, 13:41:03
Job time : 30.9359 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: November 26, 2003, 13:30:14 ; Search time 9.48718 Seconds
(without alignments)
550.212 Million cell updates/sec

Title: US-09-880-748-327_COPY_139_249
Perfect score: 583
Sequence: 1 AFSSELTQDPVAVSVALGQTV.....RDSGNHWFGGTELTVLG 111

Scoring table: BIOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 127863 seqs, 47026705 residues

number of hits satisfying chosen parameters: 127863

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 45 summaries

Database : SwissProt_41.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	510	87.5	108	1	LV3A_HUMAN
2	367	63.0	107	1	LV4C_HUMAN
3	365	62.6	111	1	LV3B_HUMAN
4	358	61.4	108	1	LV5A_HUMAN
5	357	61.2	106	1	LV4E_HUMAN
6	350	60.0	106	1	LV4E_HUMAN
7	348	59.7	106	1	LV4B_HUMAN
8	344	59.0	130	1	LV1G_HUMAN
9	342	58.7	111	1	LV2F_HUMAN
10	333	57.1	106	1	LV4D_HUMAN
11	332	56.9	111	1	LV2C_HUMAN
12	328	56.3	111	1	LV2H_HUMAN
13	327	56.1	111	1	LV1D_HUMAN
14	326.5	56.0	112	1	LV2K_HUMAN
15	325	55.7	111	1	LV2G_HUMAN
16	323	55.4	111	1	LV6C_HUMAN
17	319	54.7	111	1	LV7A_HUMAN
18	318	54.5	109	1	LV1F_HUMAN
19	313	53.7	111	1	LV1C_HUMAN
20	311	53.3	111	1	LV2I_HUMAN
21	310	53.2	109	1	LV2E_HUMAN
22	309.5	53.1	112	1	LV6A_HUMAN
23	306.5	52.6	131	1	LV6E_HUMAN
24	306	52.5	111	1	LV2A_HUMAN
25	301.5	51.7	110	1	LV2J_HUMAN
26	300	51.5	109	1	LV1I_HUMAN
27	298	51.1	111	1	LV2B_HUMAN
28	297	50.9	111	1	LV6D_HUMAN
29	295	50.6	111	1	LV2D_HUMAN
30	293.5	50.3	112	1	LV6B_HUMAN
31	292.5	50.2	112	1	LV1B_HUMAN
32	292	50.1	113	1	LV1I_CHICK
33	291.5	50.0	112	1	LV1H_HUMAN

34	283	48.5	111	1	LV1A_HUMAN	P01699 homo sapien
35	282.5	48.5	129	1	LV1B_MOUSE	P01724 mus musculus
36	274.5	47.1	110	1	KV13_RABIT	P01694 oryctolagus
37	270.5	46.4	129	1	LV1D_MOUSE	P01726 mus musculus
38	270.5	46.4	129	1	LV1E_MOUSE	P01725 mus musculus
39	268.5	46.1	110	1	LV1C_MOUSE	P01725 mus musculus
40	263	45.1	111	1	LV2L_HUMAN	P80422 homo sapien
41	261	44.8	117	1	KV10_RABIT	P01691 oryctolagus
42	254	43.6	103	1	LV1E_HUMAN	P01703 homo sapien
43	251.5	43.1	136	1	KV5B_MOUSE	P01634 mus musculus
44	247.5	42.5	108	1	KV1M_HUMAN	P01605 homo sapien
45	244.5	41.9	110	1	KV01_RABIT	P01682 oryctolagus

ALIGNMENTS

RESULT 1	
LV3A_HUMAN	STANDARD; PRT; 108 AA.
ID LV3A_HUMAN	
AC P01714:	
DT 21-JUL-1986 (Rel. 01, Created)	
DT 21-JUL-1986 (Rel. 01, Last sequence update)	
DT 15-SEP-2003 (Rel. 42, Last annotation update)	
DE Ig lambda chain V-III region SH.	
OS Homo sapiens (Human).	
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;	
OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.	
OC NCBI_Taxid=9606;	
RN [1]	
RP MEDLINE=70166723; PubMed=4909564;	
RA Titani K., Wikler M., Shinoda T., Putnam F.W.;	
RT "The amino acid sequence of a lambda type Bence-Jones protein. 3. The complete amino acid sequence and the location of the disulfide bridges."	
RL J. Biol. Chem. 245:2171-2176(1970).	
CC -1- MISCELLANEOUS: THIS IS A BENCE-JONES PROTEIN.	
CC -1- SIMILARITY: Contains 1 immunoglobulin-like domain.	
DR PIR, A01980; L3HUSH.	
DR HSSP, P80748; ZLOT.	
DR GO; GO:0005576; C:extracellular; NAS.	
DR GO; GO:0003823; F:antigen binding activity; NAS.	
DR GO; GO:0006955; P:immune response; NAS.	
DR InterPro; IPR007110; Ig-like.	
DR InterPro; IPR003006; Ig_MHC.	
DR InterPro; IPR003596; Ig_V.	
DR SMART; SM00406; IGV; 1.	
DR PROSITE; PS50835; IG_LIKE; 1.	
KW Immunoglobulin V region; Bence-Jones protein.	
FT DOMAIN 1 97	
FT DISULFD 21 86	
FT NON_TER 108	
SQ SEQUENCE 108 AA; 11392 MW; E7E1229586411A56 CRC64;	
Query Match	87.5%; Score 510; DB 1; Length 108;
Best local Similarity	88.9%; Pred. No. 1.2e-44;
Matches 96; Conservative 8; Mismatches 4; Indels 0; Gaps 0;	
OY 4 SELTQDPVAVSVALGQTVVTCQGSLSRSYSWYQKRGQAPLVITYGKNNRPSGIPDRF 63	
DB 1 SELTQDPVAVSVALGQTVVTCQGSLSRSYDAWYQKRGQAPLVITYGKNNRPSGIPDRF 60	
OY 64 SGSSSGHTASLTITGAQAEADYDCSSRDSGNHWFGGTELTVLG 111	
DB 61 SGSSSGHTASLTITGAQAEADYDCNSRDSGKGVLFGGGTELTVLG 108	
RESULT 2	
LV4C_HUMAN	STANDARD; PRT; 107 AA.
ID LV4C_HUMAN	
AC P01717;	

DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last annotation update)
DT 15-SEP-2003 (Rel. 42, Last annotation update)
DE Ig lambda chain V-IV region H11.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE.
RX MEDLINE=78187276; PubMed=418804;
RA Lopez de Castro J.A., Chiu Y.-Y.H., Poljak R.J.;
RT "Amino acid sequence of the variable region of the light (lambda)
chain from human myeloma cryoglobulin IgG H11."
RL Biochemistry 17:1718-1723(1978).
CC -1- MISCELLANEOUS: THE SEQUENCE OF THE C REGION IS APPARENTLY
IDENTICAL WITH THAT OF HUMAN SH LAMBDA CHAIN EXCEPT IN HAVING
155-IDE (HIL NUMBERING) INSTEAD OF VAL.
CC -1- MISCELLANEOUS: THIS CHAIN WAS ISOLATED FROM A MYELOMA PROTEIN.
CC -1- SIMILARITY: Contains 1 immunoglobulin-like domain.
PIR: A01983; L4HHL.
DR HSSP; P80748; 2LOI.
DR GO; GO:0005576; C:extracellular; NAS.
DR GO; GO:0003823; F:antigen binding activity; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_V.
DR Pfam; PF00047; Ig; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 1.
KW Immunoglobulin V region.
FT DOMAIN 1 97 IG-LIKE.
FT NON_TER 107 107
SQ SEQUENCE 107 AA; 11517 MW; ASC8AFEE0CC590A CRC64;
Query Match 63.0%; Score 367; DB 1; Length 107;
Best Local Similarity 64.2%; Pred. No. 3e-30;
Matches 70; Conservative 16; Mismatches 21; Indels 2; Gaps 1;
QY 3 SSELTPDAVSVALGQTVRVTCQSDLSRSYASWYQKPGQAPVLIYGNRRPSGIPDR 62
DB 1 SYELTPDPSVSVSPQGTARITCSANALPQVAYWYQKGRAPVVIYDTQRPSPGIPDR 60
QY 63 FSGSSGNTASLTITGAQAEDEADYCCSSRDSSGNHWVFGGCTELTVL 111
DB 61 FSSSTSGTTLTISGVADEADYCCQMDNSAS--IFGSGTKLTVL 107
RESULT 3
LV3B_HUMAN STANDARD; PRT; 111 AA.
AC P80748;
DT 15-JUL-1999 (Rel. 38, Created)
DT 15-JUL-1999 (Rel. 38, Last sequence update)
DT 15-SEP-2003 (Rel. 42, Last annotation update)
DE Ig lambda chain V-III region LOI.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE, SUBUNIT, DISEASE, AND 3D-STRUCTURE MODELLING.
RC TISUE=urine;
RX MEDLINE=9441384; PubMed=10510403;
RA Jokiranta T.S., Solomon A., Pangburn M.K., Zipfel P.F., Meri S.;
RT "Nephritogenic lambda light chain dimer: a unique human
minutoantibody against complement factor H."
RL J. Immunol. 163:4590-4596(1999).
CC -1- FUNCTION: ACTIVATES THE ALTERNATIVE COMPLEMENT PATHWAY BY BINDING
TO THE SHORT CONSENSUS REPEAT DOMAIN 3 (SCR3) OF FACTOR H.
CC -1- SUBUNIT: Homodimer.
CC -1- DISEASE: THE BLOCKING OF FACTOR H BY LOI PROTEIN LEADS TO THE

CC DEVELOPMENTAL OF MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS (MPGN).
CC -1- SIMILARITY: Contains 1 immunoglobulin-like domain.
DR PDB; 2LOI; 28-DEC-99.
DR GO; GO:0005576; C:extracellular; NAS.
DR GO; GO:0003823; F:antigen binding activity; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_V.
DR Pfam; PF00047; Ig; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 1.
KW Immunoglobulin V region; 3D-structure.
FT DOMAIN 1 97
FT BINDING 15 15 SCR3.
FT BINDING 25 25 SCR3.
FT BINDING 29 29 SCR3.
FT BINDING 48 51 SCR3.
FT BINDING 94 94 SCR3.
FT DISULFID 21 86 BY SIMILARITY.
FT STRAND 4 4
FT STRAND 8 8
FT TURN 13 14
FT STRAND 16 22
FT STRAND 32 37
FT TURN 38 40
FT STRAND 41 46
FT TURN 49 50
FT STRAND 54 54
FT TURN 55 55
FT TURN 58 59
FT STRAND 60 61
FT STRAND 64 65
FT TURN 66 67
FT STRAND 68 74
FT TURN 78 79
FT STRAND 82 88
FT TURN 91 93
FT STRAND 97 98
FT STRAND 102 104
FT TURN 107 108
FT NON_TER 111 111
SQ SEQUENCE 111 AA; 11935 MW; 69498BFEDE82053 CRC64;
Query Match 62.6%; Score 365; DB 1; Length 111;
Best Local Similarity 67.6%; Pred. No. 4.9e-30;
Matches 71; Conservative 12; Mismatches 22; Indels 0; Gaps 0;
QY 6 LTODPAVSVALGQTVRVTCQSDLSRSYASWYQKPGQAPVLIYGNRRPSGIPDRFSG 65
DB 3 LTQPSVSVAPGFTARLTCGSDNDCSEVHWYQKPGQAPVLIYFDNRDRSPGIPDRFSG 62
QY 66 SSSGNTASLTITGAQAEDEADYCCSSRDSSGNHWVFGGCTELTVL 110
DB 63 SNSGNTATLTISRVAEGDEADYCCQMDNSSEHVVFGGCTELTVL 107
RESULT 4
LV5A_HUMAN STANDARD; PRT; 108 AA.
AC P01719;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 15-SEP-2003 (Rel. 42, Last annotation update)
DE Ig lambda chain V-V region DEL.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE.
RX MEDLINE=75112179; PubMed=4452363;
RA Eulitz M.;

"A new subgroup of human L-chains of the lambda-type. Primary structure of Bence-Jones protein DEL.";
 RT Eur. J. Biochem. 50:49-69(1974).
 CC -1- MISCELLANEOUS: THIS IS THE FIRST SEQUENCED V REGION OF LAMBDA CHAIN SUBGROUP V.
 CC -1- MISCELLANEOUS: THIS IS A BENGE-JONES PROTEIN.
 CC -1- SIMILARITY: Contains 1 immunoglobulin-like domain.
 DR PIR: A01985; L5HJUL.
 DR HSSP: P80748; 2LOI.
 DR GO: GO:0005576; C:extracellular; NAS.
 DR GO: GO:0003823; F:antigen binding activity; NAS.
 DR GO: GO:0006955; P:immune response; NAS.
 DR InterPro: IPR007110; IG-like.
 DR InterPro: IPR003006; IG_MHC.
 DR InterPro: IPR003596; IG_V.
 DR Pfam: PF00047; Ig; 1.
 DR SMART: SM00406; IGV; 1.
 DR PROSITE: PS50835; IG-LIKE; 1.
 KW Immunoglobulin V region; Bence-Jones protein.
 F DOMAIN 1 97 IG-LIKE.
 S NON TER 108 108
 SQ SEQUENCE 108 AA; 11342 MW; B8B8ED9C09C9B451 CRC64;
 Query Match 61.4%; Score 358; DB 1; Length 108;
 Best Local Similarity 64.2%; Pred. No. 2.4e-29;
 Matches 68; Conservative 14; Mismatches 24; Indels 0; Gaps 0;
 QY 6 LTQDPASVALGQTVRTVTCGDSLRSYASWYQKPGQAPLVLYGKNNRPSGIPDRFS 65
 DB 3 LTQPPSVSVSPGQVARTICGSDGKSGKSWYQKPGQAPLVLYHEDRDAGIPDRFS 62
 QY 66 SSSGNTASLTITGAQAEDEADYCCSRDSSGNHWFPGGTELTVLG 111
 DB 63 SNSGNTATLTISRVAGDEADYCEWBDRTAHVVFPGGTELTVLG 108
 RESULT 5
 LV4A HUMAN STANDARD; PRT; 106 AA.
 AC P01715;
 DT 21-JUL-1986 (Rel. 01, Created)
 DT 21-JUL-1986 (Rel. 01, Last sequence update)
 DT 15-SEP-2003 (Rel. 42, Last annotation update)
 DE IG lambda chain V-IV region Bau.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 NC NCBI_TaxID=9606;
 F [1]
 R SEQUENCE.
 RX MEDLINE=75059189; PubMed=4435717;
 RA Baczko K., Braun D., Hilschmann N.;
 RT "Pattern of antibody structure, the primary structure of monoclonal immunoglobulin L-chain of the lambda-type, subgroup IV (Bence-Jones protein Bau).";
 RT Hoppe-Seyler's Z. Physiol. Chem. 355:131-154(1974).
 CC -1- MISCELLANEOUS: THIS IS A BENGE-JONES PROTEIN.
 CC -1- SIMILARITY: Contains 1 immunoglobulin-like domain.
 DR PIR: A01981; L4HJBU.
 DR HSSP: P80748; 2LOI.
 DR GO: GO:0005576; C:extracellular; NAS.
 DR GO: GO:0003823; F:antigen binding activity; NAS.
 DR GO: GO:0006955; P:immune response; NAS.
 DR InterPro: IPR007110; IG-like.
 DR InterPro: IPR003006; IG_MHC.
 DR InterPro: IPR003596; IG_V.
 DR Pfam: PF00047; Ig; 1.
 DR SMART: SM00406; IGV; 1.
 DR PROSITE: PS50835; IG-LIKE; 1.
 KW Immunoglobulin V region; Bence-Jones protein.
 F DOMAIN 1 102 IG-LIKE.
 S NON TER 106 106
 SQ SEQUENCE 106 AA; 11305 MW; 4B6A6880EC46571 CRC64;

Query Match 61.2%; Score 357; DB 1; Length 106;
 Best Local Similarity 65.1%; Pred. No. 3e-29;
 Matches 69; Conservative 13; Mismatches 22; Indels 2; Gaps 1;
 QY 6 LTQDPASVALGQTVRTVTCGDSLRSYASWYQKPGQAPLVLYGKNNRPSGIPDRFS 65
 DB 3 LTQPPSVSVSPGQVARTICGSDGKSGKSWYQKPGQAPLVLYHDSKRPSPGIPDRFS 62
 QY 66 SSSGNTASLTITGAQAEDEADYCCSRDSSGNHWFPGGTELTVLG 111
 DB 63 SNSGNTATLTISRVAGDEADYCOAMDS--YTVIFPGGTELTVLG 106
 RESULT 6
 LV4E HUMAN STANDARD; PRT; 106 AA.
 AC P06889;
 DT 01-JAN-1988 (Rel. 06, Created)
 DT 01-JAN-1988 (Rel. 06, Last sequence update)
 DT 15-SEP-2003 (Rel. 42, Last annotation update)
 DE IG lambda chain V-IV region MOL.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 NC NCBI_TaxID=9606;
 F [1]
 R SEQUENCE.
 RX MEDLINE=87156515; PubMed=3103603;
 RA Holm E., Sletten K., Husby G.;
 RT "Structural studies of a carbohydrate-containing immunoglobulin-lambda-light-chain amyloid-fibril protein (AL) of variable subgroup III";
 RT Biochem. J. 239:545-551(1986).
 CC -1- MISCELLANEOUS: RESIDUES 29-30 AND 56-58 WERE POSITIONED BY HOMOMOLOGY.
 CC -1- SIMILARITY: Contains 1 immunoglobulin-like domain.
 DR PIR: A26019; L4HJUL.
 DR HSSP: P80748; 2LOI.
 DR GO: GO:0005576; C:extracellular; NAS.
 DR GO: GO:0003823; F:antigen binding activity; NAS.
 DR GO: GO:0006955; P:immune response; NAS.
 DR InterPro: IPR007110; IG-like.
 DR InterPro: IPR003006; IG_MHC.
 DR InterPro: IPR003596; IG_V.
 DR Pfam: PF00047; Ig; 1.
 DR SMART: SM00406; IGV; 1.
 DR PROSITE: PS50835; IG-LIKE; 1.
 KW Immunoglobulin V region; Amyloid; Glycoprotein.
 F DOMAIN 1 103 BY SIMILARITY.
 FT DISULFID 21 86
 FT CARBOHYD 90 90 N-LINKED (GLCNAC. . .) (PROBABLE).
 FT NON TER 106 106
 SQ SEQUENCE 106 AA; 11272 MW; D9B877D4797D2123 CRC64;
 Query Match 60.0%; Score 350; DB 1; Length 106;
 Best Local Similarity 62.6%; Pred. No. 1.5e-28;
 Matches 67; Conservative 17; Mismatches 21; Indels 2; Gaps 1;
 QY 5 ELTQDPASVALGQTVRTVTCGDSLRSYASWYQKPGQAPLVLYGKNNRPSGIPDRFS 64
 DB 2 ELTQPPSVSVSPGQVARTICGSDGKSGKSWYQKPGQAPLVLYHDSKRPSPGIPDRFS 61
 QY 65 SSSGNTASLTITGAQAEDEADYCCSRDSSGNHWFPGGTELTVLG 111
 DB 62 SNSGNTATLTISRVAGDEADYCOAMNDS--VLEFGGTELTVLG 106
 RESULT 7
 LV4B HUMAN STANDARD; PRT; 106 AA.
 AC P01716;
 DT 21-JUL-1986 (Rel. 01, Created)

DT 21-JUL-1986 (Rel. 01, Last sequence update)
 DT 15-SEP-2003 (Rel. 42, Last annotation update)
 DE Ig lambda chain V-IV region X.
 OS Homo sapiens (Human).
 CC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 CC Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
 CC NCBI_TaxId=9606;
 RN [1]
 RP SEQUENCE.
 RX MEDLINE=69088380; PubMed=4883841;
 RA Milstein C., Clegg J.B., Jarvis J.M.;
 RT "Immunoglobulin lambda-chains. The complete amino acid sequence of a
 Bence-Jones protein.";
 RL Biochem. J. 110:631-652(1966).
 CC -1- SIMILARITY: THIS IS A BENCE-JONES PROTEIN.
 CC -1- SIMILARITY: Contains 1 immunoglobulin-like domain.
 DR PIR: A01982; L4HUX.
 DR HSSP; P80748; 2L0I.
 DR GO; GO:0005576; C:extracellular; NAS.
 DR GO; GO:0003823; F:antigen binding activity; NAS.
 DR GO; GO:0006955; P:immune response; NAS.
 DR InterPro; IPR007110; IG-like.
 DR InterPro; IPR003006; IG_MHC.
 DR InterPro; IPR003596; IG_V.
 DR Pfam; PF00047; Ig_1.
 DR SMART; SM00406; IGV; 1.
 DR PROSITE; PS50835; IG-LIKE; 1.
 KW Immunoglobulin V region; Bence-Jones protein.
 FT DOMAIN
 FT NON TER 1 102 IG-LIKE.
 SQ SEQUENCE 106 AA; 11334 MW; 24D04344A812855 CRC64;

Query Match 59.7%; Score 348; DB 1; Length 106;
 Best Local Similarity 65.1%; Pred. No. 2.4e-28;
 Matches 69; Conservative 11; Mismatches 24; Indels 2; Gaps 1;

QY 5 ELTOPAPASVALGQTVRVTCQGS--LRSYASWYQKPGQAPLVITYGKNNRPSGIPDRFS 64
 DB 2 DLTOPPSVSPSGQASITCSGSDKGDVCMYQRPQSPVLVITYQDNQSSGIPDRFS 61
 QY 65 GSSSGNTASLTITGQAQAEADADYCSSRDSGNHWFPGGTELTVL 110
 DB 62 GNSGNTATLTITSGTQAMDEADYQCAWDSMS--VVFGGGTRTLTVL 105

RESULT 8

LVIG_HUMAN STANDARD; PRT; 130 AA.
 P06316;
 DT 01-JAN-1988 (Rel. 06, Created)
 DT 01-JAN-1988 (Rel. 06, Last sequence update)
 DT 15-JUL-1999 (Rel. 38, Last annotation update)
 DE Ig lambda chain V-I region BL2 precursor.
 OS Homo sapiens (Human).
 CC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 CC Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
 CC NCBI_TaxId=9606;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=85062823; PubMed=6095199;
 RA Tsujimoto Y., Croce C.M.;
 RT "Molecular cloning of a human immunoglobulin lambda chain variable
 sequence.";
 RL Nucleic Acids Res. 12:8407-8414(1984).
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).

DR EMBL; X01147; CAA25598.1; -
 DR PIR; A01966; L1HUBL.
 DR HSSP; P01703; 7FAB.
 DR GO; GO:0005576; C:extracellular; NAS.
 DR GO; GO:0003823; F:antigen binding activity; NAS.
 DR GO; GO:0006955; P:immune response; NAS.
 DR InterPro; IPR007110; IG-like.
 DR InterPro; IPR003006; IG_MHC.
 DR InterPro; IPR003596; IG_V.
 DR Pfam; PF00047; Ig_1.
 DR SMART; SM00406; IGV; 1.
 DR PROSITE; PS50835; IG-LIKE; 1.
 KW Immunoglobulin V region; Signal.
 FT SIGNAL 1 19
 FT CHAIN 20 130 IG LAMBDA CHAIN V-I REGION BL2.
 FT DOMAIN 20 115 V SEGMENT.
 FT DOMAIN 116 130 J SEGMENT.
 FT DISULFID 41 108 BY SIMILARITY.
 FT NON TER 130 130
 SQ SEQUENCE 130 AA; 13564 MW; FA44B817D3A55EBF CRC64;

Query Match 59.0%; Score 344; DB 1; Length 130;
 Best Local Similarity 61.8%; Pred. No. 7.7e-28;
 Matches 68; Conservative 13; Mismatches 27; Indels 2; Gaps 1;

QY 4 SELTOPAPASVALGQTVRVTCQGS--LRSYASWYQKPGQAPLVITYGKNNRPSGIPD 61
 DB 21 SVLQPPSVSPAPOKATITCSGSSNIGNYVHYQVPTGAPRLTLTDNNKRPSGIPD 80
 QY 62 RFGSSGNTASLTITGQAQAEADADYCSSRDSGNHWFPGGTELTVL 111
 DB 81 RFGSGSGTSATLTIGITGQTDADYCGTWNNSLSGWFPGGTRTLTVL 130

RESULT 9

LV2F_HUMAN STANDARD; PRT; 111 AA.
 P01709;
 DT 21-JUL-1986 (Rel. 01, Created)
 DT 21-JUL-1986 (Rel. 01, Last sequence update)
 DT 15-SEP-2003 (Rel. 42, Last annotation update)
 DE Ig lambda chain V-II region MGC.
 OS Homo sapiens (Human).
 CC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 CC Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
 CC NCBI_TaxId=9606;
 RN [1]
 RP SEQUENCE.
 RX MEDLINE=75013804; PubMed=4415202;
 RA Felt J.W., Deutech H.F.;
 RT "Primary structure of the MCG lambda chain.";
 RL Biochemistry 13:4102-4114(1974).
 RN [2]
 RP LAMBDA CHAIN GENES.
 RX MEDLINE=76093781; PubMed=812801;
 RA Felt J.W., Deutech H.F.;
 RT "A new lambda-chain gene.";
 RL Immunochimistry 12:643-652(1975).
 RN [3]
 RP X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS).
 RA Edmundson A.B., Ely K.R., Abola E.E., Schiffer M.,
 RA Panagiotopoulos N.;
 RT "Rotational alomerism and divergent evolution of domains in
 RT immunoglobulin light chains.";
 RL Biochemistry 14:3953-3961(1975).
 RN [4]
 RP X-RAY CRYSTALLOGRAPHY.
 RX MEDLINE=90133913; PubMed=2515285;
 RA Ely K.R., Herron J.N., Harker M., Edmundson A.B.;
 RT "Three-dimensional structure of a light chain dimer crystallized in
 RT water. Conformational flexibility of a molecule in two crystal
 RT forms.";
 RL J. Mol. Biol. 210:601-615(1989).

FT	DISULFID	22	90		BY SIMILARITY.
FT	NON TER	111	111		
SO	SEQUENCE	111 AA;	11650 MW;	94520309932623E8 CRC64;	
	Query Match		56.9%;	Score 332; DB 1; Length 111;	
	Best Local Similarity		61.6%;	Pred. No. 1e-26;	
	Matches	69;	Conservative	13; Mismatches	24; Indels
OY		4	SELTDDPAVSVALGQTVRVTTCGGDSL--RSYYASWYQQKPGQAPFLVLYIGNKRRPSGP	60	
			: : : : : : : : : : : : : : : :		
DB		2	SALTQPRPVSVCSPGOSVTISCGTSSDVGNCFHFWYQOHPKAKPLTIYGNNKRPBGVP	61	
OY		61	DRFSGSSSGNTASTLITTTGAQAEDEADYCCSRSDSGNHWFGGGETLVLG	111	
DB		62	YRFSGSKGNATSLTISGLQAEDADYCCS--YAGRTFWFGGGINTLVLG	111	
	RESULT 12				
	LVZH_HUMAN				
	LVZH_HUMAN	STANDARD;	PRT;	111 AA.	
	P01711;				
DB		21-JUL-1986	(Rel. 01, Created)		
DT		21-JUL-1986	(Rel. 01, Last sequence update)		
DT		15-SEP-2003	(Rel. 42, Last annotation update)		
DE		Ig lambda chain V-II region VII.			
DS		Homo sapiens (Human).			
OC		Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;			
OC		Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.			
OX		NCBI_Taxid=9606;			
RN		[1]			
RP		SEQUENCE.			
RX		MEDLINE=71215142; PubMed=5087637;			
RA		Postelngl H., Hilschmann N.;			
RT		"Structural rule of antibodies. Complete primary structure of a			
RT		monoclonal immunoglobulin L chain of the lambda type, subgroup II			
RL		(Bence Jones protein VII).";			
HL		Hope-Seyler's Z. Physiol. Chem. 352:859-877(1971).			
CC		-I- MICELLANEOUS: THIS IS A BENGE-JONES PROTEIN.			
CC		-I- SIMILARITY: Contains 1 immunoglobulin-like domain.			
DR		PIR; A01977; L2HUVL.			
DR		HSSP; P01709; 2MCG.			
DR		GO; GO:0005576; C:extracellular; NAS.			
DR		GO; GO:0003823; F:antigen binding activity; NAS.			
DR		GO; GO:0006955; P:immune response; NAS.			
DR		InterPro; IPR007110; IG-I like.			
DR		InterPro; IPR003006; IG_MHC.			
DR		InterPro; IPR003596; IG_V.			
PFam;		PF00047; Ig_1.			
SMART;		SM00406; IGV_1.			
KW		PROSITE; PS50835; IG_LIKE; 1.			
KW		Immunoglobulin V region; Bence-Jones protein.			
FT		DOMAIN	1	100	
FT		DISULFID	22	90	
FT		NON TER	111	111	
SO		SEQUENCE	111 AA;	11445 MW;	3913736B3EF367E0 CRC64;
	Query Match		56.3%;	Score 328; DB 1; Length 111;	
	Best Local Similarity		63.1%;	Pred. No. 2.6e-26;	
	Matches	70;	Conservative	12; Mismatches	25; Indels
OY		4	SELTDPAVSVALGQTVRVTTCGDS--LRSY-YASWYQQKPGQAPFLVLYIGNKRRPSGP	60	
			: : : : : : : : : : : : : : : :		
DB		2	SALTQPAVSVALGQSTISCTGSTSDVGNYVMFOOPHTAPAKLIISEVRNRPSGVS	61	
OY		61	DRFSGSSSGNTASTLITTTGAQAEDEADYCCSRSDSGNHWFGGGETLVLG	111	
DB		62	DRFSGSKGNATSLTISGLQAEDADYCCSITTS--NSVVFGGIKTLVLG	111	
	RESULT 13				
	LVLD_HUMAN				
	LVLD_HUMAN	STANDARD;	PRT;	111 AA.	
	P01702;				

DT	21-JUL-1986 (Rel. 01, Created)
DT	21-JUL-1986 (Rel. 01, Last sequence update)
DT	15-SEP-2003 (Rel. 42, Last annotation update)
DE	Ig lambda chain V-I region NIG-64.
OS	Homo sapiens (Human)
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC	Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
NCBI_TaxID=9606;	
RN	[1]
RP	SEQUENCE.
RX	MEDLINE=8318614; PubMed=6404900;
RA	Kamekura F., Takayasu T., Suzuki S., Shinoda T., Okuyama T.,
RA	Shimizu A.,
RT	"Comparative studies on the structure of the light chain of human
RL	immunoglobulins. IV. Assignment of a subgroup."
CC	J. Biochem. 93:421-429(1983).
DR	-1 SIMILARITY: Contains 1 immunoglobulin-like domain.
DR	PIR: A01965; L1HNB.
DR	HSSD, P01703; 7PAB.
DR	GO: 0005576; C:extracellular; NAS.
DR	GO: 0003823; F:antigen binding activity; NAS.
DR	GO: 0006955; P:immune response; NAS.
DR	InterPro: IPR007110; IG-Like.
DR	InterPro: IPR003006; IG-MHC.
DR	InterPro: IPR003596; IG_V.
DR	PIfam: PF00047; Ig, 1.
DR	SMART: SM00406; IGV, 1.
KW	PROSITE: PS50835; IG LIKE; 1.
DR	Immunoglobulin V region; Pyridoxone carboxylic acid.
FT	DOMAIN 1 105
FT	MOD_RES 1 1
FT	DISULFID 22 89
FT	NON_TER 111 111
FT	SEQUENCE 111 AA; 11454 MW; A21C6121C18A61E0 CRC64;
SO	
Query Match	56.1%; Score 327; DB 1; Length 111;
Best Local Similarity	60.0%; Pred. No. 3.3e-26;
Matches	66; Conservative 12; Mismatches 30; Indels 2; Gaps 1
QY	4 SELTQDPVAVSVALQTVRVTCQGDSS--LRSYASWYQCKPQAPVLVIYGNRRPSGIPD 61
DB	2 SVLQNPVSVSAPQGEVWISCSGSSNSINIGDFVEMVQGLPPTAPRLTLIDNNKRRSGIIP 61
QY	62 RFGSGSSGNTRASLTITGAQAEADVDYCSSPDSGNNHVPFGGTETLVLG 111
DB	62 RFGSGSGSTSAVLGITGTLQTDDEADYVCGTWDSSISVGMFGGTETLVLG 111
RESULT 14	
LV2K_HUMAN	STANDARD; PRT; 112 AA.
AC	P04209;
DT	20-MAR-1987 (Rel. 04, Created)
DT	20-MAR-1987 (Rel. 04, Last sequence update)
DT	15-SEP-2003 (Rel. 42, Last annotation update)
DE	Ig lambda chain V-II region NIG-84.
OS	Homo sapiens (Human)
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC	Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
NCBI_TaxID=9606;	
RN	[1]
RP	SEQUENCE.
RX	MEDLINE=85204383; PubMed=3922791;
RA	Tonoike H., Kamekura F., Hoshi A., Shinoda T., Isebe T.;
RT	"Amino acid sequence of an amyloidogenic Bence Jones protein in
RT	myeloma-associated systemic amyloidosis."
RL	FEBS Lett. 185:139-141(1985).
CC	-1 MISCELLANEOUS: THIS IS A BENCE-JONES PROTEIN ISOLATED FROM AN
CC	INDIVIDUAL WITH MYELOMA-ASSOCIATED SYSTEMIC AMYLOIDOSIS.
CC	-1 SIMILARITY: Contains 1 immunoglobulin-like domain.
DR	PIR: A01971; L2HNG.
DR	HSSD, P01709; 2MCG.
DR	GO: 0005576; C:extracellular; NAS.

```

4 SELTODPAVSVALGOTVRVTCQDLSL---RSYASWYQOKPGQAPVLVYGGKNNRPSGIP 60
| ||| | : ||| : : | | : | |||| | : || | ||| : : |||||

```

DT 21-JUL-1986 (Rel. 01, Created)
 DT 21-JUL-1986 (Rel. 01, Last sequence update)
 DT 15-SEP-2003 (Rel. 42, Last annotation update)
 DE IG lambda chain V-VII region MOT.
 OS Homo sapiens (Human)
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 NC NCB1_TaxID=9606;
 RN [1]

```

RP SEQUENCE.
RX MEDLINE=81122740; PubMed=6780787;
RA Kojima M., Odani S., Ikenaka T.;
RT "Amino acid sequence of the lambda type light chain of a human IgG1
RT myeloma protein (MOT) with unusual antigenicity; a possible new
RT subgroup of lambda chain having a unique N-terminal sequence.";
RL Mol. Immunol. 17:1407-1414(1980).
CC -1- MISCELLANEOUS: THIS SEQUENCE REPRESENTS A NEW LAMBDA CHAIN
CC SUBGROUP. IT HAS AN AMINO-TERMINAL EXTENSION OF THREE RESIDUES
CC COMPARED WITH OTHER HUMAN LAMBDA CHAINS.
CC -1- MISCELLANEOUS: THE C REGION OF THIS CHAIN HAS THE MCG+ AND KERN+
CC MARKERS.
CC -1- MISCELLANEOUS: THIS CHAIN WAS ISOLATED FROM A MYELOMA PROTEIN.
CC -1- SIMILARITY: Contains 1 immunoglobulin-like domain.
DR PIR: A01986; L7HJMT.
DR HSSP: P80748; ZLOI.
DR GO: GO:0005576; C:extracellular; NAS.
DR GO: GO:0003823; F:antigen binding activity; NAS.
DR GO: GO:0006955; P:immune response; NAS.
DR InterPro: IPR007110; IG-like.
DR InterPro: IPR003006; IG_MHC.
DR InterPro: IPR003596; IG_V.
DR Pfam: PF00047; Ig; 1.
DR SMART: SM00406; IGV; 1.
DR PROSITE: PS0835; IG_LIKE; 1.
KW Immunoglobulin V region.
FT DOMAIN 1 97
FT DISULFID 22 89
FT NON_TER 109 109
SQ SEQUENCE 109 AA; 11725 MW; B1785F6A8DF9BAC CRC64;

Query Match
Best Local Similarity 54.7%; Score 318; DB 1; Length 109;
Matches 64; Conservative 12; Mismatches 29; Indels 4; Gaps 2;

QY 4 SELTQDPASVALGQTVAVTCQGD--LRSYASWYQKPGQAPLVLYGKNNRPSGIPD 61
DB 2 SVLTQPPSVASAPGQKRVITSCFGSSNIGRYVWYQGLPPTPKLLYKDNQKRSGLPD 61
QY 62 RPSGSSGNTASLTITGAQAEDEADYCYSSRDSSGNHWFGGCTELTVLG 110
DB 62 RPSGSSGNTASLTITGAQAEDEADYCYSSRDSSGNHWFGGCTELTVLG 110

RESULT 19
LVL_C_HUMAN STANDARD; PRT; 111 AA.
ID LVL_C_HUMAN
AC P01701;
DT 21-JUL-1986 (Rel. 01, Created)
DR GO: GO:0005576; C:extracellular; NAS.
DR GO: GO:0003823; F:antigen binding activity; NAS.
DR GO: GO:0006955; P:immune response; NAS.
DR InterPro: IPR007110; IG-like.
DR InterPro: IPR003006; IG_MHC.
DR InterPro: IPR003596; IG_V.
DR Pfam: PF00047; Ig; 1.
DR SMART: SM00406; IGV; 1.
DR PROSITE: PS0835; IG_LIKE; 1.
KW Immunoglobulin V region; Bence-Jones protein;
KW Pyrolydione carboxylic acid.
FT DOMAIN 1 105
FT MOD_RES 1 1 PYROLYDIONE CARBOXYLIC ACID.
FT DISULFID 22 89
FT NON_TER 111 111
SQ SEQUENCE 111 AA; 11453 MW; AAECBCA3C49F2AD3 CRC64;

Query Match
Best Local Similarity 53.7%; Score 313; DB 1; Length 111;
Matches 64; Conservative 14; Mismatches 30; Indels 2; Gaps 1;

QY 4 SELTQDPASVALGQTVAVTCQGD--LRSYASWYQKPGQAPLVLYGKNNRPSGIPD 61
DB 2 SVLTQPPSVASAPGQKRVITSCFGSSNIGRYVWYQGLPPTPKLLYKDNQKRSGLPD 61
QY 62 RPSGSSGNTASLTITGAQAEDEADYCYSSRDSSGNHWFGGCTELTVLG 111
DB 62 RISASKSGTSATLTGRTGDEADYCATWDSINAVFGGCTKVTVLG 111

```

```

RP SEQUENCE.
RX MEDLINE=83221661; PubMed=6407018;
RA Takahashi Y., Takahashi N., Tetsu D., Putnam F.W.;
RT "Complete covalent structure of a human immunoglobulin D: sequence of
RT the lambda light chain.";
RL Proc. Natl. Acad. Sci. U.S.A. 80:3686-3690(1983).
DR HSSP: P01703; 7FAB.
DR GO: GO:0005576; C:extracellular; NAS.
DR GO: GO:0003823; F:antigen binding activity; NAS.
DR GO: GO:0006955; P:immune response; NAS.
DR InterPro: IPR007110; IG-like.
DR InterPro: IPR003006; IG_MHC.
DR InterPro: IPR003596; IG_V.
DR Pfam: PF00047; Ig; 1.
DR SMART: SM00406; IGV; 1.
DR PROSITE: PS0835; IG_LIKE; 1.
KW Immunoglobulin V region; Bence-Jones protein;
KW Pyrolydione carboxylic acid.
FT DOMAIN 1 105
FT MOD_RES 1 1 PYROLYDIONE CARBOXYLIC ACID.
FT DISULFID 22 89
FT NON_TER 111 111
SQ SEQUENCE 111 AA; 11453 MW; AAECBCA3C49F2AD3 CRC64;

Query Match
Best Local Similarity 57.9%; Score 319; DB 1; Length 111;
Matches 62; Conservative 14; Mismatches 31; Indels 0; Gaps 0;

QY 5 ELTQDPASVALGQTVAVTCQGDLSRSTYASWYQKPGQAPLVLYGKNNRPSGIPDRS 64
DB 5 ELTQPPSVASAPGQKRVITSCFGSSNIGRYVWYQGLPPTPKLLYKDNQKRSGLPD 64
QY 65 GSSGSSGNTASLTITGAQAEDEADYCYSSRDSSGNHWFGGCTELTVLG 111
DB 65 GYNSGNSAIIITINRVEAGDEADYCYSSRDSSGNHWFGGCTELTVLG 111

RESULT 18
LVL_F_HUMAN STANDARD; PRT; 109 AA.
ID LVL_F_HUMAN
AC P04208;
DT 20-MAR-1987 (Rel. 04, Created)
DR GO: GO:0005576; C:extracellular; NAS.
DR GO: GO:0003823; F:antigen binding activity; NAS.
DR GO: GO:0006955; P:immune response; NAS.
DR InterPro: IPR007110; IG-like.
DR InterPro: IPR003006; IG_MHC.
DR InterPro: IPR003596; IG_V.
DR Pfam: PF00047; Ig; 1.
DR SMART: SM00406; IGV; 1.
DR PROSITE: PS0835; IG_LIKE; 1.

```



```

RESULT 20
LV21 HUMAN STANDARD: PRT: 111 AA.
AC P01712:
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 15-SEP-2003 (Rel. 42, Last annotation update)
DE Ig lambda chain V-II region WIN.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Euthera; Primates; Catarrhini; Homiidae; Homo.
NCBI_TaxID=9606;
RN [1]
RP MEDLINE=79062503; PubMed=102365;
RX Chen B.L., Chiu Y.-Y.H., Humphrey R.L., Poljak R.V.;
RT "Amino acid sequence of the human myeloma lambda chain win.";
RL Biochim. Biophys. Acta 537:9-21(1978).
-1- MISCELLANEOUS: THIS IS A BENGE-JONES PROTEIN.
-1- SIMILARITY: Contains 1 immunoglobulin-like domain.
PIR: A01978; L2HJMN.
DR HSSP; P01709; 2MCG.
DR GO; GO:0005576; C:extracellular; NAS.
DR GO; GO:0003823; F:antigen binding activity; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_V.
DR Pfam; PF00047; Ig; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 1.
KW Immunoglobulin V region; Bence-Jones protein;
KM Pyroglutamate carboxylic acid.
FT DOMAIN 1 106
FT MOD_RES 1 1
FT DISULFID 22 90
FT NON_TER 111 111
SQ SEQUENCE 111 AA; 11694 MW; 8C3CE95FE721B87C CRC64;

Query Match 53.3%; Score 311; DB 1; Length 111;
Best Local Similarity 57.7%; Pred. No. 1.3e-24;
Matches 64; Conservative 17; Mismatches 26; Indels 4; Gaps 3;

OY 4 SELTODPAVSVALQGTAVTQCG--DLRSY-YASWYQKRGQAPVLYIGKNNRPSGIP 60
DB 2 SALTQPPRSVSGSPGSIYISCTGTSNVGDYKRYVWYQHPKAKLITYEVSSRPSGVP 61
61 DRFGSSSGNTASLTITGAQAEDEADYCCSRDSSGNHMFVGGCTELTVLG 111
62 DRFGSSKSNATSLTISGLQANNEADYCCSYGYTS-LIRGGTKLTVLG 111

RESULT 21
LV2E HUMAN STANDARD: PRT: 109 AA.
AC P01709:
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 15-SEP-2003 (Rel. 42, Last annotation update)
DE Ig lambda chain V-II region BUR.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Euthera; Primates; Catarrhini; Homiidae; Homo.
NCBI_TaxID=9606;
RN [1]
RP MEDLINE=80006606; PubMed=113407;
RX Infante A.J., Putnam F.W.;
RT "Primary structure of a human IgA immunoglobulin. V. Amino acid
sequence of a human IgA lambda light chain (Bur).";
RL J. Biol. Chem. 254:9006-9016(1979).
-1- MISCELLANEOUS: THE C REGION OF THIS CHAIN HAS THE KERN+ AND MCG+

```

```

CC -1- MISCELLANEOUS: THIS CHAIN WAS ISOLATED FROM A MYELOMA PROTEIN.
CC -1- SIMILARITY: Contains 1 immunoglobulin-like domain.
PIR: A01974; L2HJBR.
DR HSSP; P01709; 2MCG.
DR GO; GO:0005576; C:extracellular; NAS.
DR GO; GO:0003823; F:antigen binding activity; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_V.
DR Pfam; PF00047; Ig; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 1.
KW Immunoglobulin V region; Pyroglutamate carboxylic acid.
FT DOMAIN 1 106
FT MOD_RES 1 1
FT DISULFID 22 90
FT SITE 91 91
FT NON_TER 109 109
SQ SEQUENCE 109 AA; 11506 MW; BFD8AE1C5D267FAB CRC64;

Query Match 53.2%; Score 310; DB 1; Length 109;
Best Local Similarity 59.5%; Pred. No. 1.6e-24;
Matches 66; Conservative 15; Mismatches 24; Indels 6; Gaps 3;

OY 4 SELTODPAVSVALQGTAVTQCGDS--LRSY-YASWYQKRGQAPVLYIGKNNRPSGIP 60
DB 2 SALTQPPRSVSGSPGSIYISCTGTSNVGDYKRYVWYQHPKAKLITYEVSSRPSGVP 61
61 DRFGSSSGNTASLTITGAQAEDEADYCCSRDSSGNHMFVGGCTELTVLG 111
62 DRFGSSKSNATSLTISGLQANNEADYCCSYGYTS--YVGTGKTVLG 109

RESULT 22
LV6A HUMAN STANDARD: PRT: 112 AA.
AC P01721:
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 15-SEP-2003 (Rel. 42, Last annotation update)
DE Ig lambda chain V-VI region AR.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Euthera; Primates; Catarrhini; Homiidae; Homo.
NCBI_TaxID=9606;
RN [1]
RP MEDLINE=82091000; PubMed=6797401;
RX Sletten K., Natvig J.B., Husby G., Juul J.;
RT "The complete amino acid sequence of a prototype
immunoglobulin-lambda light-chain-type amyloid-fibril protein AR.";
RL Biochem. J. 195:561-572(1981).
-1- MISCELLANEOUS: ABOUT HALF OF THE LAMBDA CHAIN C REGION IS MISSING
FROM THIS PROTEIN.
CC -1- MISCELLANEOUS: THIS PROTEIN WAS ISOLATED FROM THE SPLEEN OF A
PATIENT WITH AMYLOIDOSIS.
CC -1- SIMILARITY: Contains 1 immunoglobulin-like domain.
PIR: A01987; L6HUAR.
DR HSSP; P01709; 2MCG.
DR GO; GO:0005576; C:extracellular; NAS.
DR GO; GO:0003823; F:antigen binding activity; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_V.
DR Pfam; PF00047; Ig; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 1.
KW Immunoglobulin V region; Amyloid.
FT DOMAIN 1 107

```

FT NON TER 112 112
SQ SEQUENCE 112 AA; 11918 MW; 570BCD9A368EF1FE CRC64;

Query Match 53.1%; Score 309.5; DB 1; Length 112;
Best Local Similarity 57.3%; Pred. No. 1,9e-24;

Matches 63; Conservative 16; Mismatches 26; Indels 5; Gaps 3;

QY 6 LTQDPASVALGQTVAVTC--OGDSLRSYASWYQOKPGQAPLVITGKNNRPSGIPDRF 63
DB 4 LTQHPHVSSESPGKTVTFSCSGSGSLADSFVQMYQORPQSAPTTVIYDNNRPSGVDRF 63
QY 64 SGS--SSGNTASLTITGAQAEDEADYCCSSRDSSGNHWFGGTELTVLG 111
DB 64 SSGIDSSANSASLTITGLKTEDEADYCCSYNSN-HHVFVGSGTKTVLIG 112

RESULT 23

LV2J HUMAN STANDARD; PRT; 131 AA.

01-JAN-1988 (Rel. 06, Created)
01-JAN-1988 (Rel. 06, Last sequence update)
15-JUL-1999 (Rel. 38, Last annotation update)
Ig lambda chain V-VI region EB4 precursor.
Homo sapiens (Human).
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
NCBI_TaxID=9606;
[1]
SEQUENCE FROM N.A.
MEDLINE=85215660; PubMed=3923440;
RA Anderson M.L.M., Brown L., McKenzie E., Kellow J.E., Young B.D.;
RT "Cloning and sequence analysis of an Ig lambda light chain mRNA
RT expressed in the Burkitt's lymphoma cell line EB4."
Nucleic Acids Res 13:2931-2941(1985).
PIR; A01990; L6HUB.
HSSP; P01709; 2MCG.
GO; GO:0005576; C:extracellular; NAS.
GO; GO:0003823; F:antigen binding activity; NAS.
GO; GO:0006955; P:immune response; NAS.
InterPro; IPR007110; IG-like.
InterPro; IPR003006; IG_MHC.
InterPro; IPR003596; IG_V.
PIfam; PF00047; IG_1.
SMART; SMO0406; IGV; 1.
DR POSITE; PS00835; IG LIKE; 1.
DR Immunoglobulin V region; Signal.
FT SIGNAL 1 19
FT CHAIN 20 131 IG LAMBDA CHAIN V-VI REGION EB4.
FT DOMAIN 20 41 FRAMEWORK-1.
FT DOMAIN 42 54 COMPLEMENTARITY-DETERMINING-1.
FT DOMAIN 55 69 FRAMEWORK-2.
FT DOMAIN 70 76 COMPLEMENTARITY-DETERMINING-2.
FT DOMAIN 77 110 FRAMEWORK-3.
FT DOMAIN 111 118 COMPLEMENTARITY-DETERMINING-3.
FT DOMAIN 119 131 FRAMEWORK-4.
FT DISULFID 41 110 BY SIMILARITY.
FT NON TER 131
SQ SEQUENCE 131 AA; 14147 MW; 02A9179C8C05C2CD CRC64;

Query Match 52.6%; Score 306.5; DB 1; Length 131;
Best Local Similarity 58.2%; Pred. No. 4,6e-24;
Matches 64; Conservative 16; Mismatches 25; Indels 5; Gaps 3;

QY 6 LTQDPASVALGQTVAVTC--SLRSYASWYQOKPGQAPLVITGKNNRPSGIPDRF 63
DB 23 LTQHPHVSSESPGKTVTFSCSGSGSLADSFVQMYQORPQSAPTTVIYDNNRPSGVDRF 82
QY 64 SGS--SSGNTASLTITGAQAEDEADYCCSSRDSSGNHWFGGTELTVLG 111
DB 83 SSGIDSSANSASLTITGLKTEDEADYCCSPNT-NGVFGSGTKTVLIG 131

RESULT 24

LV2J HUMAN STANDARD; PRT; 111 AA.

AC P01704;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 15-SEP-2003 (Rel. 42, Last annotation update)
DE Ig lambda chain V-II region TOG.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
NCBI_TaxID=9606;
[1]
SEQUENCE.
RX MEDLINE=80048495; PubMed=500108;
RA Nabeshima Y., Ikenaka T.;
RT "Primary structure of cyto Bence-Jones protein (Tog) from the urine
RT of a patient with IgD myeloma."
Mol. Immunol. 16:439-444(1979).
CC -1- MISCELLANEOUS: THIS IS A BENCE-JONES PROTEIN.
CC -1- SIMILARITY: Contains 1 Immunoglobulin-like domain.
DR PIR; A01969; L2HUTG.
DR HSSP; P01709; 2MCG.
DR GO; GO:0005576; C:extracellular; NAS.
DR GO; GO:0003823; F:antigen binding activity; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_V.
PIfam; PF00047; IG_1.
DR SMART; SMO0406; IGV; 1.
DR POSITE; PS00835; IG LIKE; 1.
KW Immunoglobulin V region; Bence-Jones protein;
KW Pyrolydione carboxylic acid.
FT DOMAIN 1 100
FT MOD RES 1 90 PYRROLIDONE CARBOXYLIC ACID.
FT DISULFID 22 90
FT NON TER 111
SQ SEQUENCE 111 AA; 11713 MW; PD20AEF4CE5364E2 CRC64;

Query Match 52.5%; Score 306; DB 1; Length 111;
Best Local Similarity 57.3%; Pred. No. 4,3e-24;
Matches 63; Conservative 19; Mismatches 24; Indels 4; Gaps 3;

QY 4 SELTQDPASVALGQTVAVTC--DSLRSY-VYSWYQOKPGQAPLVITGKNNRPSGIP 60
DB 2 SALTQDPASVASPQOSITISCTGTTNDISYSVSWYQYQKAPKVLIFVNSRPSGV 61
QY 61 DRFGSSSGNTASLTITGAQAEDEADYCCSSRDSSGNHWFGGTELTVL 110
DB 62 HRFSGSSGNTASLTITGLQAEDEAHYFCSSYRTSGT-IIFGGTGYTVL 110

RESULT 25

LV2J HUMAN STANDARD; PRT; 110 AA.

AC P01713;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 15-SEP-2003 (Rel. 42, Last annotation update)
DE Ig lambda chain V-II region NIG-58.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
NCBI_TaxID=9606;
[1]
SEQUENCE.
RX MEDLINE=81215386; PubMed=6787031;
RA Takayasu T., Takahashi N., Shinoda T., Okuyama T., Tomioka H.;
RT "Comparative studies on the structure of the light chains of human
RT immunoglobulins. III. Amino acid sequence of a lambda type Bence
RT Jones euglobulin."
J. Biochem. 89:421-436(1981).

```

CC -i SIMILARITY: Contains 1 immunoglobulin-like domain.
DR PIR: A01979; L2HUS8.
DR HSSP: P01709; 2MCG.
DR GO: GO:0005576; C:extracellular; NAS.
DR GO: GO:0003823; F:antigen binding activity; NAS.
DR GO: GO:0006955; P:immune response; NAS.
DR InterPro: IPR007110; IG-like.
DR InterPro: IPR003006; IG-MHC.
DR InterPro: IPR003596; IG_v.
DR Pfam: PF00047; Ig_1.
DR SMART: SM00406; IGV_1.
DR PROSITE: PS50835; IG-LIKE; 1.
DR Immunoglobulin V region; Pyroliidone carboxylic acid.
DR MOD_RES 1 100 PYROLIDONE CARBOXYLIC ACID (PROBABLE).
FT MOD_RES 1 100
FT DISULFID 22 90 BY SIMILARITY.
FT NON_TER 110 110
SQ SEQUENCE 110 AA; 11455 MW; 76C9F4C6B20312B6 CRC64;

Query Match
c Local Similarity 51.7%; Score 301.5; DB 1; Length 110;
Matches 66; Conservative 14; Mismatches 22; Indels 11; Gaps 4;

QY 4 SELTQDPAVSVALQGVAVTCQGS--DSLRSYASWYQKPGQAPLVLYGKNNRPSG 58
DB 2 SALTQPSASVSGSPQSLTISCSCGAPCDVDGCS--VSWYQHPKAPKLTLYGFSNRPSC 59
59 IPDEFSSSGNTASLTITGAQAEDEADYCCSS-RDSSGNHWPGGTELTLY 110
60 VPLRPSGSKGSDASLTISGLQVEADYCCSYADSS--VIFGATKLTLY 109

RESULT 26
LV11 HUMAN STANDARD; PRT; 109 AA.
AC P06888;
DT 01-JAN-1988 (Rel. 06, Created)
DT 01-JAN-1988 (Rel. 06, Last sequence update)
DT 15-SEP-2003 (Rel. 42, Last annotation update)
DE Ig lambda chain V-I region EPS.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE.
RX MEDLINE=86000126; PubMed=3929803;
F Tolt K.G., Sletten K., Husby G.;
R "The amino-acid sequence of the variable region of a carbohydrate-
containing amyloid fibril protein EPS (immunoglobulin light chain,
type lambda)";
RL Biol. Chem. Hoppe-Seyler 366:617-625(1985).
CC -i MISCELLANEOUS: RESIDUES 1-2, 56-62, AND 74-78 AND THE SEQUENCED
PEPTIDES WERE POSITIONED BY HOMOLOGY.
CC -i SIMILARITY: Contains 1 immunoglobulin-like domain.
DR PIR: A24656; LIHUEP.
DR HSSP: P01703; 7FAB.
DR GO: GO:0005576; C:extracellular; NAS.
DR GO: GO:0003823; F:antigen binding activity; NAS.
DR GO: GO:0006955; P:immune response; NAS.
DR InterPro: IPR007110; IG-like.
DR InterPro: IPR003006; IG-MHC.
DR InterPro: IPR003596; IG_v.
DR Pfam: PF00047; Ig_1.
DR SMART: SM00406; IGV_1.
DR PROSITE: PS50835; IG-LIKE; 1.
DR Immunoglobulin V region; Amyloid; Glycoprotein.
DR MOD_RES 1 105
FT CARBOHYD 104 104 N-LINKED (GLCNAC. . .).
FT DISULFID 22 89 BY SIMILARITY.
FT NON_TER 109 109
SQ SEQUENCE 109 AA; 11414 MW; 556A313E24D5AC73 CRC64;

```

```

Query Match
c Local Similarity 55.5%; Score 298; DB 1; Length 111;
Matches 61; Conservative 15; Mismatches 26; Indels 6; Gaps 4;

QY 4 SELTQDPAVSVALQGVAVTCQGS--DSLRSYASWYQKPGQAPLVLYGKNNRPSGIP 60
DB 2 SALTQPSASVSGSPQSLTISCCTTSDVGSNFWYQONPGKAPKLTLYGKNNRPSGVS 61
61 DRFGSSSGNTASLTITGAQAEDEADYCCSRDSSGNHW-VFGGTELTLY 110
62 NRFSGSKGKTASLTISGLQVEADYCCS--YAGNSTRVFGGTRVTVL 110

RESULT 27
LV2B HUMAN STANDARD; PRT; 111 AA.
AC P01705;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 15-SEP-2003 (Rel. 42, Last annotation update)
DE Ig lambda chain V-II region NEI.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE.
RX MEDLINE=72233223; PubMed=5043326;
RA Garver F.A., Hilschmann N.;
R "The primary structure of a monoclonal human lambda-type
immunoglobulin L-chain of subgroup II (Bence-Jones protein NEI).";
RL Eur. J. Biochem. 26:10-32(1972).
CC -i MISCELLANEOUS: THIS IS A BENCE-JONES PROTEIN.
CC -i SIMILARITY: Contains 1 immunoglobulin-like domain.
DR PIR: A01970; L2HUNI.
DR HSSP: P01709; 2MCG.
DR GO: GO:0005576; C:extracellular; NAS.
DR GO: GO:0003823; F:antigen binding activity; NAS.
DR GO: GO:0006955; P:immune response; NAS.
DR InterPro: IPR007110; IG-like.
DR InterPro: IPR003006; IG-MHC.
DR InterPro: IPR003596; IG_v.
DR Pfam: PF00047; Ig_1.
DR SMART: SM00406; IGV_1.
DR PROSITE: PS50835; IG-LIKE; 1.
DR Immunoglobulin V region; Bence-Jones protein; Glycoprotein;
KW Pyroliidone carboxylic acid.
FT MOD_RES 1 106
FT DISULFID 22 90 BY SIMILARITY.
FT CARBOHYD 96 96 N-LINKED (GLCNAC. . .).
FT NON_TER 111 111
SQ SEQUENCE 111 AA; 11591 MW; AD6D156584D087EB CRC64;

Query Match
c Local Similarity 57.7%; Score 298; DB 1; Length 111;
Matches 64; Conservative 15; Mismatches 26; Indels 6; Gaps 4;

QY 4 SELTQDPAVSVALQGVAVTCQGS--DSLRSYASWYQKPGQAPLVLYGKNNRPSGIP 60
DB 2 SALTQPSASVSGSPQSLTISCCTTSDVGSNFWYQONPGKAPKLTLYGKNNRPSGVS 61
61 DRFGSSSGNTASLTITGAQAEDEADYCCSRDSSGNHW-VFGGTELTLY 110
62 NRFSGSKGKTASLTISGLQVEADYCCS--YAGNSTRVFGGTRVTVL 110

RESULT 28
LV6D HUMAN STANDARD; PRT; 111 AA.
AC P06318;
DT 01-JAN-1988 (Rel. 06, Created)
DT 01-JAN-1988 (Rel. 06, Last sequence update)

```

```

DT 15-JUL-1999 (Rel. 38, Last annotation update)
DE Ig lambda chain V-VI region WLT.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE.
RX MEDLINE=8612267; PubMed=4089539;
RA Dwyer F.E., Strako K., Benson M.D.;
RT "Amino acid sequence of a lambda VI primary (AL) amyloid protein
   (WLT)".
RL Scand. J. Immunol. 22:653-660 (1985).
DR HSP; P01709; L6HUT.
DR HSP; P01709; 2MCG.
DR GO; GO:0005576; C:extracellular; NAS.
DR GO; GO:0003823; P:antigen binding activity; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003006; IG-MHC.
DR InterPro; IPR003596; IG_v.
PFam; PF00047; Ig; 1.
SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG-LIKE; 1.
KW Immunoglobulin V region.
FT DOMAIN 1 22 FRAMEWORK-1.
FT DOMAIN 2 35 COMPLEMENTARITY-DETERMINING-1.
FT DOMAIN 3 50 FRAMEWORK-2.
FT DOMAIN 4 57 COMPLEMENTARITY-DETERMINING-2.
FT DOMAIN 5 81 FRAMEWORK-3.
FT DOMAIN 6 91 FRAMEWORK-4.
FT DOMAIN 7 101 COMPLEMENTARITY-DETERMINING-3.
FT DOMAIN 8 111 FRAMEWORK-4.
FT DISULFID 22 91 BY SIMILARITY.
FT NON TER 111
SQ SEQUENCE 111 AA; 11966 MW; 0C88B2FE37BCE24F CRC64;

Query Match
Best Local Similarity 50.9%; Score 297; DB 1; Length 111;
Matches 65; Conservative 13; Mismatches 26; Indels 6; Gaps 4;

QY 6 LTQDPAVSVALGQTVAVTCQGD--SLRSYASWYQKPGQAPVLYYGNRPSGIPDF 63
DB 4 LTQPLSVSGSPKRYTISCTGSSGSGSYVQYQRPSPAPNTIYENNRPSVPPDRF 63

QY 64 SGS--SSGNASTLTITGAQAEADYCCSRDSSGNHWFGGTELTVLG 111
DB 64 SGSISSSSNSASLTISGLKTEADYCCSYDNN-NHVV-FGTRLVYLG 111

LT 29
LV2D HUMAN STANDARD; PRT; 111 AA.
AC P01707;
ID 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 15-SEP-2003 (Rel. 42, Last annotation update)
DE Ig lambda chain V-II region TRQ.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE.
RX MEDLINE=80114123; PubMed=118915;
RA Scholz R., Yang C., Hilschmann N.;
RT "Rule of antibody structure: Primary structure of a human monoclonal
   IgA1-immunoglobulin (myeloma protein TrQ). VI. Amino acid sequence of
   the L-chain, lambda-type, subgroup II."
RL Hoppe-Seyler Z. Physiol. Chem. 360:1903-1918 (1979).
CC -1- MISCELLANEOUS; THIS CHAIN WAS ISOLATED FROM A MYELOMA PROTEIN.
CC -1- SIMILARITY: Contains 1 immunoglobulin-like domain.
DR PIR; A01973; L2HTR.
DR HSP; P01709; 2MCG.

```

```

DR GO; GO:0005576; C:extracellular; NAS.
DR GO; GO:0003823; P:antigen binding activity; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003006; IG-MHC.
DR InterPro; IPR003596; IG_v.
DR Pfam; PF00047; Ig; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG-LIKE; 1.
KW Immunoglobulin V region; Pyroglutamate carboxylic acid.
FT DOMAIN 1 106 PYROGLUTAMATE CARBOXYLIC ACID.
FT MOD RES 1 1
FT DISULFID 22 90 BY SIMILARITY.
FT NON TER 111
SQ SEQUENCE 111 AA; 11561 MW; 99DC457A12E86E1 CRC64;

Query Match
Best Local Similarity 50.6%; Score 295; DB 1; Length 111;
Matches 64; Conservative 19; Mismatches 23; Indels 6; Gaps 4;

QY 4 SELTDPAVSVALGQTVAVTCQGD--LSRYA-SWYQKPGQAPVLYYGNRPSGIP 60
DB 2 SALTQPRSVSGSPGQSVTISCTGSSDVGAYSVSWYQHPKAPKIMIFVTKRPSGVP 61

QY 61 DRFGSSSGNSTALTTITGAQAEADYCCSRDSSGNHW-FGGTELTVLG 111
DB 62 DRLSSKSGDPAISLTISGLRADDEADYCCS--YAGRSVIFGGTKLVYLG 111

RESULT 30
LV6B HUMAN STANDARD; PRT; 112 AA.
AC P01722;
ID 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 15-SEP-2003 (Rel. 42, Last annotation update)
DE Ig lambda chain V-VI region NIG-48.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE.
RX MEDLINE=80094390; PubMed=118171;
RA Takahashi N., Takayasu T., Isoe T., Shinoda T., Okuyama T.,
   Shintzu A.;
RT "Comparative study on the structure of the light chains of human
   immunoglobulins. II. Assignment of a new subgroup."
RL J. Biochem. 86:1523-1535 (1979).
CC -1- MISCELLANEOUS; THIS IS A BENGE-JONES PROTEIN.
CC -1- SIMILARITY: Contains 1 immunoglobulin-like domain.
DR PIR; A01991; L6HU48.
DR HSP; P01703; 7FAB.
DR GO; GO:0005576; C:extracellular; NAS.
DR GO; GO:0003823; P:antigen binding activity; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003006; IG-MHC.
DR InterPro; IPR003596; IG_v.
DR Pfam; PF00047; Ig; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG-LIKE; 1.
KW Immunoglobulin V region; Bence-Jones protein.
FT DOMAIN 1 107 IG-LIKE.
FT NON TER 112
SQ SEQUENCE 112 AA; 12152 MW; CFBB307BC527A384 CRC64;

Query Match
Best Local Similarity 50.3%; Score 293.5; DB 1; Length 112;
Matches 61; Conservative 16; Mismatches 27; Indels 5; Gaps 3;

QY 6 LTQDPAVSVALGQTVAVTC--QGDLSRSYASWYQKPGQAPVLYYGNRPSGIPDF 63

```

```

Db      4 LIOPSPVSESGKVTVMCTRTSDSIASNYQWQRPGCAPATLLIYDNRQPVGPNR 63
QY      64 SCS---SSGNTASLTITGAQAEADYICSSSRDSSGNHNVFGGGLTLYL 110
Db      64 SGSFDSSSNSASLTISGLTNDTNAVFCQSYDSS-NLWVFGGGLTLYL 111

RESULT 31
ID      LV1B_HUMAN          STANDARD;          PRT;          112 AA.
AC      P01700;
DT      21-JUL-1986 (Rel. 01, Created)
DT      21-JUL-1986 (Rel. 01, Last sequence update)
DT      15-SEP-2003 (Rel. 42, Last annotation update)
DE      Ig lambda chain V-1 region HA.
OS      Homo sapiens (Human).
OC      Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC      Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
OX      NCB1_TaxID=9606;
OX      (1)
SEQUENCE.
RA      MEDLINE=71103824; PubMed=5532227;
RA      Shinoda T., Titani K., Putnam F.W.;
RT      "Amino acid sequence of human lambda chains. II. Chymotryptic
RL      peptides and sequence of protein Ha.";
CC      J. Biol. Chem. 245:4475-4487(1970).
CC      -1- WISCCELLANBOUS: THIS IS A BENCE-JONES PROTEIN.
CC      -1- SIMILARITY: Contains 1 immunoglobulin-like domain.
DR      HSSP; P01703; 7FAB.
DR      GO; GO:0005576; C:extracellular; NAS.
DR      GO; GO:0003823; F:antigen binding activity; NAS.
DR      GO; GO:0006955; P:immune response; NAS.
DR      InterPro; IPR007110; IG-like.
DR      InterPro; IPR003006; IG_MHC.
DR      InterPro; IPR003596; IG_V.
DR      Pfam; PF00047; Ig_1.
DR      SMART; SM00406; IGV; 1.
DR      PROSITE; PS50835; IG_LIKE; 1.
KW      Immunoglobulin V region; Bence-Jones protein;
KW      Pyroglutamine carboxylic acid.
FT      DOMAIN 1 106 IG-LIKE.
FT      MOD_RES 1 1 PYRROLIDONE CARBOXYLIC ACID.
FT      DISULFID 22 90
FT      NON_TER 112 112 BY SIMILARITY.
SQ      SEQUENCE 112 AA; 11896 MW; 8D73378F3F5CD039 CRC64;

Very Match 50.2%; Score 292.5; DB 1; Length 112;
Bit Local Similarity 54.5%; Pred. No. 9,8e-23;
Matches 60; Conservative 16; Mismatches 31; Indels 3; Gaps 1.

QY      4 SELTODPVAVSVALGGTVARVTCQGDILR---SYVASWYOOKPGQAVLYVIYGNKNSPGIP 60
Db      2 SVLTQDPVPSGSGTPGQRTVITSCSGSSNGTGNVYVYQQLPEYAKLILYRDDKPSGVP 61
QY      61 DRFGSSSSGNTASLTITGAQAEADYICSSSRDSSGNHNVFGGGLTLYL 110
Db      62 DRFGSKSGTASLTISGLRSDEAHYCAAMDYRLSAVVFEGGGLTLYL 111

RESULT 32
ID      LV1_CHICK          STANDARD;          PRT;          113 AA.
AC      P04210;
DT      20-MAR-1987 (Rel. 04, Created)
DT      20-MAR-1987 (Rel. 04, Last sequence update)
DT      15-JUL-1999 (Rel. 38, Last annotation update)
DE      Ig lambda chain V-1 region precursor.
OS      Gallus gallus (Chicken).
OC      Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC      Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;
OC      Gallus.
OX      NCB1_TaxID=9031;

```

```

RN [1] SEQUENCE FROM N.A.
RP MEDLINE=85099341; PubMed=3917859;
RX Reynaud C.A., Anguez V., Dahan A., Weill J.-C.;
RA "A single rearrangement event generates most of the chicken
RT immunoglobulin light chain diversity.";
RL Cell 40:283-291(1985).
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/or\_send\_an\_email\_to\_license@isb-sib.ch).
CC -----
CC EMBL: M12317; AAA50793.1; -.
DR PIR: A01992; LICHV.
DR HSSP; P80748; 2LOI.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_V.
DR Pfam; PF00047; IG; 1.
DR SMART; SMO0406; IGV; 1.
DR PROSITE; PSS0835; IG LIKE; 1.
KM Immunoglobulin V region; Signal.
FT SIGNAL 1 21
FT CHAIN 22 113 IG LAMBDA CHAIN V-1 REGION.
FT DOMAIN 22 41 FRAMEWORK-1.
FT DOMAIN 42 49 COMPLEMENTARITY-DETERMINING-1.
FT DOMAIN 50 65 FRAMEWORK-2.
FT DOMAIN 66 72 COMPLEMENTARITY-DETERMINING-2.
FT DOMAIN 73 104 FRAMEWORK-3.
FT DOMAIN 105 113 COMPLEMENTARITY-DETERMINING-3.
FT DISULFID 41 104 BY SIMILARITY.
FT NON TER 113
SQ SEQUENCE 113 AA; 11695 MW; 167BA8FA9449733B CRC64;

Query Match 50.1%; Score 292; DB 1; Length 113;
Best Local Similarity 65.9%; Pred. No. 1.1e-22;
Matches 60; Conservative 8; Mismatches 19; Indels 4; Gaps 3;

QY 6 LTQDPANVALGQVRYRTCCGDSLRSYIYASVYQOK-PCQAPVLYTGYANRPSGCPDRFS 64
DB 23 LTQSSVSANPGEVTKITCSGD-RSYV-GVYQOKAPGSAPEVTLIYDNTNPSNIPRFS 79
QY 65 GSSGGSNTASLITITGAQAEADADYVCSGRDSS 95
DB 80 GSKSGSTAYLTITGVQADDEAVYVCSGADSS 110

RESULT 33
LV1H HUMAN STANDARD; PRT; 112 AA.
AC P06887;
DT 01-JAN-1988 (Rel. 06, Created)
DT 01-JAN-1988 (Rel. 06, Last sequence update)
DT 15-SEP-2003 (Rel. 42, Last annotation update)
DE Ig lambda chain V-I region MEM.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrate; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
OX NCBI_Taxid=9606;
RN [1]
RP SEQUENCE.
RX MEDLINE=85257662; PubMed=2410269;
RA Mhaeseo E., Roy J.P., Congy N., Peran-Rivat L., Mhaeseo C.;
RT "The amino acid sequence of a lambda light chain presenting abnormal
RL physicochemical and antigenic features.";
RL Eur. J. Biochem. 150:349-357(1985).
CC -1- MISCELLANEOUS: RESIDUES 33-36 AND SOME OF THE SEQUENCED PEPTIDES
CC WERE POSTULATED BY HOMOLGY.
CC -1- MISCELLANEOUS: THE C REGION OF THIS CHAIN HAS THE MCG+ AND KERN+

```

CC MARKERS.
 CC -1 SIMILARITY: Contains 1 immunoglobulin-like domain.
 CC PIR: A25479; L1HMM.
 DR HSSP: P01703; 7FAB.
 DR GO: GO:0005576; C:extracellular; NAS.
 DR GO: GO:0003823; F:antigen binding activity; NAS.
 DR GO: GO:0006955; P:immune response; NAS.
 DR InterPro: IPR007110; IG-like.
 DR InterPro: IPR003006; IG_MHC.
 DR InterPro: IPR003596; IG_v.
 DR Pfam: PF00047; Ig_1.
 DR SMART; SM00406; IGV; 1.
 DR PROSITE; PS50835; IG_LIKE; 1.
 KW Immunoglobulin V region; Monoclonal antibody;
 KW Pyrolydione carboxylic acid.
 FT MOD_RES 1 106 IG-LIKE.
 FT DISULFID 22 90 PYRROLIDONE CARBOXYLIC ACID.
 FT NON_TER 112 112 BY SIMILARITY.
 SC SEQUENCE 112 AA; 11789 MW; 748124F079CFBE4 CRC64;
 Query Match 50.0%; Score 291.5; DB 1; Length 112;
 Best Local Similarity 54.5%; Pred. No. 1.2e-22;
 Matches 60; Conservative 15; Mismatches 32; Indels 3; Gaps 1;
 QY 4 SELTODPAVSVALGGTVRTVTCQDLSLR--SYASWYQOKPGQAPLVLYGKNNRPSGIP 60
 DB 2 SVLTQPPASGTPGGRVITSCGSSSNVGNZPAWYQQLPFTAKRLIYNNGRPSGV 61
 QY 61 DRFGSSSGNTASLTITTAQAEDADYCCSRDSSGNHVFSGGTETLV 110
 DB 62 DRFSASRSGTSASLAISGLQSEADYCAAMDSDLGCVFGTGTETLV 111
 RESULT 34
 LV1A_HUMAN STANDARD; PRT; 111 AA.
 AC P01699;
 DT 21-JUL-1986 (Rel. 01, Created)
 DT 21-JUL-1986 (Rel. 01, Last sequence update)
 DT 15-SEP-2003 (Rel. 42, Last annotation update)
 DE Ig lambda chain V-1 region VOR.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 NC NCBI_TaxId=9606;
 RN [1]
 RP SEQUENCE.
 RL MEDLINE=76023790; PubMed=809332;
 RL Engelhard M., Hilschmann N.;
 RL "Pattern of antibody structure. The amino acid sequence of a
 RT monoclonal immunoglobulin L-chain of lambdae-type, subgroup I
 RT (Bence-Jones-protein Vor.). A contribution to the elucidation of the
 RT origin of antibody specificity.";
 RL Hoppe-Seyler's Z. Physiol. Chem. 356:1413-1444(1975).
 CC -1- MISCELLANEOUS: THE C REGION OF THIS CHAIN HAS THE OZ+ MARKER.
 CC -1- MISCELLANEOUS: THIS IS A BENGE-JONES PROTEIN.
 CC -1- SIMILARITY: Contains 1 immunoglobulin-like domain.
 DR PIR: A01962; L1HYVO.
 DR HSSP; P01703; 7FAB.
 DR GO: GO:0005576; C:extracellular; NAS.
 DR GO: GO:0003823; F:antigen binding activity; NAS.
 DR GO: GO:0006955; P:immune response; NAS.
 DR InterPro: IPR007110; IG-like.
 DR InterPro: IPR003006; IG_MHC.
 DR InterPro: IPR003596; IG_v.
 DR Pfam; PF00047; Ig_1.
 DR SMART; SM00406; IGV; 1.
 DR PROSITE; PS50835; IG_LIKE; 1.
 KW Immunoglobulin V region; Bence-Jones protein;
 KW Pyrolydione carboxylic acid.
 FT MOD_RES 1 105 IG-LIKE.
 FT DOMAIN 1 105 PYRROLIDONE CARBOXYLIC ACID.

FT DISULFID 22 89 BY SIMILARITY.
 FT NON_TER 111 111
 SC SEQUENCE 111 AA; 11514 MW; 21D9F64250DFC8E0 CRC64;
 Query Match 48.5%; Score 283; DB 1; Length 111;
 Best Local Similarity 51.8%; Pred. No. 8.8e-22;
 Matches 57; Conservative 19; Mismatches 32; Indels 2; Gaps 1;
 QY 4 SELTODPAVSVALGGTVRTVTCQDLS--LRSYASWYQOKPGQAPLVLYGKNNRPSGIP 61
 DB 2 SVLTQPPASGTPGGRVITSCGSGNFDIGKSNVWYQVHPGTAPRLIYSSDQSSGV 61
 QY 62 RFGSSSGNTASLTITTAQAEDADYCCSRDSSGNHVFSGGTETLV 111
 DB 62 RFGSGKSTASLAISGLQSEADYFCATYDDSLDGVFGGTGTETLV 111
 RESULT 35
 LV1B_MOUSE STANDARD; PRT; 129 AA.
 AC P01724;
 DT 21-JUL-1986 (Rel. 01, Created)
 DT 21-JUL-1986 (Rel. 01, Last sequence update)
 DT 15-SEP-2003 (Rel. 42, Last annotation update)
 DE Ig lambda-1 chain V regions MOPC 104E/RPC20/J558/5104 precursor.
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 NC NCBI_TaxId=10090;
 RN [1]
 RP SEQUENCE OF 1-29 (MOPC 104E), AND REVISIONS TO 20 AND 26.
 RP MEDLINE=77148916; PubMed=403522;
 RA Birstein Y., Schechter I.;
 RT "Amino acid sequence of the NH2-terminal extra piece segments of the
 RT precursors of mouse immunoglobulin lambda1-type and kappa-type light
 RT chains.";
 RT Proc. Natl. Acad. Sci. U.S.A. 74:716-720(1977).
 RN [2]
 RP SEQUENCE OF 20-129 (MOPC 104E AND RPC 20).
 RP MEDLINE=71107854; PubMed=5276767;
 RA Appella E.;
 RT "Amino acid sequences of two mouse immunoglobulin lambda chains.";
 RT Proc. Natl. Acad. Sci. U.S.A. 68:590-594(1971).
 RN [3]
 RP REVISIONS (MOPC 104E).
 RP MEDLINE=73229669; PubMed=4516208;
 RA Appella E.;
 RL Unpublished results, cited by:
 RL Cesari I.M., Weigert M.;
 RL Proc. Natl. Acad. Sci. U.S.A. 70:2112-2116(1973).
 RN [4]
 RP SEQUENCE OF 20-129 (J558 AND S104).
 RP MEDLINE=73229669; PubMed=4516208;
 RA Cesari I.M., Weigert M.;
 RT "Mouse lambda-chain sequences.";
 RT Proc. Natl. Acad. Sci. U.S.A. 70:2112-2116(1973).
 CC -1- MISCELLANEOUS: COMPOSITIONS AND PARTIAL SEQUENCES OF RPC 20 SHOW
 CC NO DIFFERENCES FROM MOPC 104E. THE SEQUENCES OF J558 AND S104
 CC SEEMS IDENTICAL WITH THAT SHOWN.
 CC -1- MISCELLANEOUS: THESE PROTEINS WERE ISOLATED FROM SERUM OR URINE OF
 CC TUMOR-BEARING MICE.
 CC -1- MISCELLANEOUS: THE MOPC 104E PRECURSOR WAS SYNTHESIZED IN A
 CC CELL-FREE SYSTEM DIRECTED BY MRNA ISOLATED FROM MOPC 104E
 CC MYELOMA POLYSOMES. MET-1 WAS LACKING IN 90% OF THE CHAINS. IT IS
 CC PROBABLY RAPIDLY CLEAVED AFTER SYNTHESIS.
 CC -1- SIMILARITY: Contains 1 immunoglobulin-like domain.
 DR PIR; B93815; LIMS4E.
 DR PDB; 1A6U; 27-MAY-98.
 DR PDB; 1A6W; 15-JUL-98.
 DR InterPro: IPR007110; IG-like.
 DR InterPro: IPR003006; IG_MHC.
 DR InterPro: IPR003596; IG_v.
 DR Pfam; PF00047; Ig_1.

DR SMART, SM00406; IGV, 1.
DR PROSITE; PS50835; IG LIKE; 1.
KW Immunoglobulin V region; Signal; Pyrrolidone carboxylic acid;
FT SIGNAL 1 19
FT CHAIN 20 129 IG LAMBDA-1 CHAIN V REGIONS MOPC
FT DOMAIN 20 125 104E/RPC20/J558/S104.
FT MOD RES 20 20
FT NON TER 129 129 PYRROLIDONE CARBOXYLIC ACID.
SQ SEQUENCE 129 AA; 13479 MW; 03629939D5791ACO CRC64;

Query Match 48.5%; Score 282.5; DB 1; Length 129;
Best Local Similarity 55.0%; Pred. No. 1.2e-21;
Matches 60; Conservative 15; Mismatches 29; Indels 5; Gaps 2;

QY 6 LTQDPASVALGQTVRTCC--GDSLSRYASWYQKPGCAPVLVYGNKRRPSGIPDR 62
DB 23 VTQESALTTSPGEVTLTCSRSTGAVTTSNANVQKPDHLFTGLIGTNNRAPGVPAR 82
63 FSGSSGNTASLTITGAQAEADYCCSRDSSGNHWVFGGTELTIVG 111
DB 83 FSGSLIGDKALTTTGAQTEDEALYFCALWYS--NHWVFGGTVLTVLG 129

RESULT 36
KV13 RABBIT STANDARD; PRT; 110 AA.

AC P01694;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 15-JUL-1999 (Rel. 38, Last annotation update)
DE IG kappa chain V region 3547.
OS Oryctolagus cuniculus (Rabbit).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Lagomorpha; Leporidae; Oryctolagus.
OX NCBI_TaxID=9986;
RN [1]
RP SEQUENCE.
RX MEDLINE=76161170; PubMed=816371;
RA Thundberg A.L., Kindt T.J.;
RT "Amino acid sequence of rabbit light chains: variable region of a
RT light chain from a homogeneous immunoglobulin raised by streptococcal
RT immunization."
RL Biochemistry 15:1381-1386(1976).
CC -1- MISCELLANEOUS: THIS CHAIN WAS OBTAINED FROM AN IMMUNOGLOBULIN THAT
CC HAD NO DETECTABLE ANTIGEN-BINDING ACTIVITY AND THAT WAS PRODUCED
CC BY IMMUNIZATION OF A SINGLE RABBIT WITH GROUP A STREPTOCOCCAL
CC VACCINE.
DR HSP; P01607; IREI.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_V.
DR Pfam; PF00047; IGV_1.
DR SMART; SM00406; IGV, 1.
DR PROSITE; PS50835; IG LIKE; 1.
KW Immunoglobulin V region.
FT DOMAIN 1 23 FRAMEWORK-1.
FT DOMAIN 24 34 COMPLEMENTARITY-DETERMINING-1.
FT DOMAIN 35 49 FRAMEWORK-2.
FT DOMAIN 50 56 COMPLEMENTARITY-DETERMINING-2.
FT DOMAIN 57 88 FRAMEWORK-3.
FT DOMAIN 89 99 COMPLEMENTARITY-DETERMINING-3.
FT DOMAIN 100 109 FRAMEWORK-4.
FT NON TER 110 110
SQ SEQUENCE 110 AA; 11201 MW; B6268897311A352P CRC64;

Query Match 47.1%; Score 274.5; DB 1; Length 110;
Best Local Similarity 50.9%; Pred. No. 6.2e-21;
Matches 55; Conservative 14; Mismatches 38; Indels 1; Gaps 1;
QY 5 ELTQDP-ASVALGQTVRTCCGDSLSRYASWYQKPGCAPVLVYGNKRRPSGIPDR 63

DB 3 DMTQTPSSVSAAGVGTITNCQASEDISANLAWYQKPGCPKLLIYAASDLASGVPSRF 62
QY 64 SGSSGNTASLTITGAQAEADYCCSRDSSGNHWVFGGTELTIVG 111
DB 63 KGSSTGTEYTLTISGVQCADATYCCSADYSSAVTFGGTEVVGK 110

RESULT 37
LV1E MOUSE STANDARD; PRT; 129 AA.

AC P01726;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 15-SEP-2003 (Rel. 42, Last annotation update)
DE IG lambda-1 chain V region H2020 precursor.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.

RX MEDLINE=79084170; PubMed=103630;
RA Bernard O., Hozumi N., Tonegawa S.;
RT "Sequences of mouse immunoglobulin light chain genes before and after
RT somatic changes."
RL Cell 15:1133-1144(1978).
CC -1- SIMILARITY: Contains 1 immunoglobulin-like domain.
DR HSP; P80748; 2L01.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_V.
DR Pfam; PF00047; IGV_1.
DR SMART; SM00406; IGV, 1.
DR PROSITE; PS50835; IG LIKE; 1.
KW Immunoglobulin V region; Signal.

FT SIGNAL 1 19
FT CHAIN 20 129 IG LAMBDA-1 CHAIN V REGION H2020.
FT DOMAIN 20 125 IG-LIKE.
FT NON TER 129 129
SQ SEQUENCE 129 AA; 13465 MW; A57C9910157C1316 CRC64;

Query Match 46.4%; Score 270.5; DB 1; Length 129;
Best Local Similarity 52.3%; Pred. No. 1.9e-20;
Matches 57; Conservative 17; Mismatches 30; Indels 5; Gaps 2;

QY 6 LTQDPASVALGQTVRTCC--GDSLSRYASWYQKPGCAPVLVYGNKRRPSGIPDR 62
DB 23 VTQESALTTSPGEVTLTCSRSTGAVTTSNANVQKPDHLFTGLIGTNNRAPGVPAR 82
QY 63 FSGSSGNTASLTITGAQAEADYCCSRDSSGNHWVFGGTELTIVG 111
DB 83 FSGSLIGDKALTTTGAQTEDEALYFCALWYS--NHWVFGGTVLTVLG 129

RESULT 38

LV1E MOUSE STANDARD; PRT; 129 AA.

AC P01727;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 15-SEP-2003 (Rel. 42, Last annotation update)
DE IG lambda-1 chain V region 843 precursor.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.

RX MEDLINE=82220143; PubMed=6283385;
RA Boechwell A.L.M., Paekkind W., Reth M., Imanishi-Kari T., Rajewsky K.,
RA Baltimore D.;
RT "Somatic variants of murine immunoglobulin lambda light chains.";

```

RL Nature 298:380-382(1982).
CC -1 SIMILARITY: Contains 1 immunoglobulin-like domain.
DR HSSP; P80748; 2LOI.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_V.
DR Pfam; PF00047; Ig; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 1.
KW Immunoglobulin V region; Signal.
FT SIGNAL 1 19
FT CHAIN 20 129 IG LAMBDA-1 CHAIN V REGION S43.
FT DOMAIN 20 125 IG-LIKE.
FT NON_TER 129 129
SQ SEQUENCE 129 AA; 13529 MW; 84E54E7DD5791345 CRC64;

Query Match 46.4%; Score 270.5; DB 1; Length 129;
Best Local Similarity 52.3%; Pred. No. 1.9e-20;
Matches 57; Conservative 17; Mismatches 30; Indels 5; Gaps 2;

6 LTDPAVSVALGQTVRVTCQ--GSLRSYYASWYQKRGQAPVLVIYGNRRPSGIDR 62
VTQSALTSPGEVTLTLCRSNTGAVTTSNANWYQKPDHLFTGLIGINNRAFGVPAR 82

QY 63 FSGSSSGNTASLTITGAQAEDEADYCCSRDSSGNHWFGGTELTIVG 111
DB 83 FSGSLIGDKALITITGTEDEAWYFALWYS--NHWVFGGTELTIVG 129

RESULT 39
LVIC_MOUSE STANDARD; PRT; 110 AA.
ID LVIC_MOUSE
AC P01725;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 15-SEP-2003 (Rel. 42, Last annotation update)
DE IG lambda-1 chain V region S178.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
CX NCBI_TaxId=10090;
RN [1]
RP SEQUENCE.
RX MEDLINE=73229669; PubMed=4516208;
RA Cesari I.M., Weigert M.;
RT "Mouse lambda-chain sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 70:2112-2116(1973).
CC -1- MUSCULANEUS: THIS PROTEIN WAS ISOLATED FROM SERUM OR URINE OF
TUMOR-BEARING MICE.
-1- SIMILARITY: Contains 1 immunoglobulin-like domain.
DR HSSP; P80748; 2LOI.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_V.
DR Pfam; PF00047; Ig; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 1.
KW Immunoglobulin V region.
FT DOMAIN 1 106 IG-LIKE.
FT NON_TER 110 110
SQ SEQUENCE 110 AA; 11654 MW; 7D06718E1A530206 CRC64;

Query Match 46.1%; Score 268.5; DB 1; Length 110;
Best Local Similarity 53.2%; Pred. No. 2.5e-20;
Matches 58; Conservative 15; Mismatches 31; Indels 5; Gaps 2;

6 LTDPAVSVALGQTVRVTCQ--GSLRSYYASWYQKRGQAPVLVIYGNRRPSGIDR 62
VTQSALTSPGEVTLTLCRSNTGAVTTSNANWYQKPDHLFTGLIGINNRAFGVPAR 63

QY 63 FSGSSSGNTASLTITGAQAEDEADYCCSRDSSGNHWFGGTELTIVG 111
DB 64 FSGSLIGDKALITITGTEDEAWYFALWYS--NHWVFGGTELTIVG 110

```

```

RESULT 40
LV2L_HUMAN STANDARD; PRT; 111 AA.
ID LV2L_HUMAN
AC P80422;
DT 01-NOV-1995 (Rel. 32, Created)
DT 01-NOV-1995 (Rel. 32, Last sequence update)
DT 15-SEP-2003 (Rel. 42, Last annotation update)
DE IG gamma lambda chain V-II region DOT.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
CX NCBI_TaxId=9606;
RN [1]
RP SEQUENCE.
RX MEDLINE=95255298; PubMed=7737190;
RA Stoppini M., Bellotti V., Negri A., Merlini G., Garver F., Ferri G.;
RT "Characterization of the two unique human anti-flavin monoclonal
immunoglobulins.";
RL Eur. J Biochem. 228:886-893(1995).
CC -1- SIMILARITY: Contains 1 immunoglobulin-like domain.
DR HSSP; P01709; 2MCG.
DR GO; GO:0005576; C:extracellular; NAS.
DR GO; GO:0003823; F:antigen binding activity; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_V.
DR Pfam; PF00047; Ig; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 1.
KW Immunoglobulin V region.
FT DOMAIN 1 106 IG-LIKE.
FT DISULFD 22 90 BY SIMILARITY.
FT NON_TER 111 111
SQ SEQUENCE 111 AA; 11787 MW; F358B1EA2CD7109A CRC64;

Query Match 45.1%; Score 263; DB 1; Length 111;
Best Local Similarity 51.3%; Pred. No. 9e-20;
Matches 59; Conservative 19; Mismatches 27; Indels 10; Gaps 4;

3 SSELTPAVSVALGQTVRVTCQDSLSRSY-----VASWYQKRGQAPVLVIYGNRRPS 57
1 ASALTQPSLSGSGQAVTISCTG--LPSVDDNPFWSWYQOTGRAPRLTIYDLSRPS 58

QY 58 GIPRFSSSGSNTASLTITGAQAEDEADYCCSRDSSGNH-WVFGGTELTIVG 111
DB 59 GVPNRFSSGSKSDTFAALITSLQPDDEATYFCCS--YVGNVIFVFGGTELTIVG 111

RESULT 41
KV10_RABBIT STANDARD; PRT; 117 AA.
ID KV10_RABBIT
AC P01691;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 15-JUL-1999 (Rel. 38, Last annotation update)
DE IG kappa chain V region 12F2 precursor (Fragment).
OS Oryctolagus cuniculus (Rabbit).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Lagomorpha; Leporidae; Oryctolagus.
CX NCBI_TaxId=9986;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=83273646; PubMed=6410392;
RA Dieber K.L., Emorine L., Kindt T.J., Max E.E.;
RT "cDNA clone encoding a complete rabbit immunoglobulin kappa light
chain of b4 allotype.";
RL Proc. Natl. Acad. Sci. U.S.A. 80:4489-4493(1983).
CC -1- MUSCULANEUS: THIS CLONE WAS DERIVED FROM THE RABBIT-MOUSE
HYBRIDOMA 12F2; THE CHAIN PRODUCED IS A MONOCLONAL ANTIBODY
AGAINST STREPTOCOCCAL GROUP C VACCINE.

```


[2]
 RN SEQUENCE OF 30-136.
 RP MEDLINE=73053310; PubMed=4638343;
 RA Svasti J., Milstein C.;
 RT "The complete amino acid sequence of a mouse kappa light chain";
 RL Biochem. J. 128:427-444(1972).
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 CC EMBL; V00810; CAA24192.1; ALT_TERM.
 DR PIR; A93736; KWS21.
 DR PDB; 1IGC; 03-JUN-95.
 DR InterPro; IPR007110; IG-like.
 DR InterPro; IPR003006; IG_MHC.
 DR InterPro; IPR003596; IG_V.
 DR Pfam; PF00047; Ig; 1.
 DR SMART; SM00406; IGV; 1.
 DR PROSITE; PS50835; IG LIKE; 1.
 KW Immunoglobulin V region; Signal; 3D-structure.
 FT SIGNAL 1 29
 FT CHAIN 1 29 IG KAPPA CHAIN V-V REGION MOPC 21.
 FT DOMAIN 30 136 FRAMEWORK-1.
 FT DOMAIN 53 52 FRAMEWORK-2.
 FT DOMAIN 64 78 FRAMEWORK-3.
 FT DOMAIN 79 85 FRAMEWORK-4.
 FT DOMAIN 86 117 COMPLEMENTARITY-DETERMINING-1.
 FT DOMAIN 118 126 COMPLEMENTARITY-DETERMINING-2.
 FT DOMAIN 127 136 COMPLEMENTARITY-DETERMINING-3.
 FT DOMAIN 136 136 FRAMEWORK-4.
 FT NON_TER 136
 SQ SEQUENCE 136 AA; 14902 MW; 8CDD85113996D1C2 CRC64;
 Query Match 43.1%; Score 251.5; DB 1; Length 136;
 Best Local Similarity 47.6%; Pred. No. 1.6e-18;
 Matches 50; Conservative 21; Mismatches 31; Indels 3; Gaps 2;
 QY 6 LTQDP-AVSVALGQTVRVTCQSDLSRSYASWYQKPGQAPVLYVYGNKRRPSGIPDRF 64
 DB 33 MTQSKSMSSMVGKGVTLTKKASENVVYVSWYQKPEPSPLLLYGAENRTGVDRFT 92
 QY 65 GSSSGNTASLTITGAQAEDEADYICSSRDSGNHWFVGGTGLTV 109
 DB 93 GSGSATDFTLTITSSVQAEADLADYHCGQGY--YPYFGGGLTLEI 135
 RESULT 44
 KXIM HUMAN STANDARD; PRT; 108 AA.
 AC P01605;
 ID 21-JUL-1986 (Rel. 01, Created)
 DT 21-JUL-1986 (Rel. 01, Last sequence update)
 DT 15-JUL-1999 (Rel. 38, Last annotation update)
 OS Homo sapiens (Human).
 DE Ig kappa chain V-1 region Lay.
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP SEQUENCE.
 RA MEDLINE=77038198; PubMed=824717;
 RA Capra J.D., Klapper D.G.;
 RT "Complete amino acid sequence of the variable domains of two human
 RT IgM anti-gamma globulins (Lay/Pom) with shared idiotypic
 RT specificities";
 RL Scand. J. Immunol. 5:677-684(1976).
 CC -1- MISCELLANEOUS: THE SECOND AND THIRD HYPERVARIABLE REGIONS OF THIS
 CC CHAIN ARE IDENTICAL WITH THOSE OF THE HUMAN POM V-III KAPPA CHAIN,
 CC WITH WHICH IT SHARES CERTAIN IDIOTYPIC DETERMINANTS.

CC -1- MISCELLANEOUS: THIS CHAIN WAS ISOLATED FROM AN IGM WITH ANTI-GAMMA
 CC GLOBULIN ACTIVITY.
 DR PIR; A01871; KIRHLV.
 DR HSSP; P01607; IREI.
 DR GO; GO:0005576; C:extracellular; NAS.
 DR GO; GO:0003823; F:antigen binding activity; NAS.
 DR GO; GO:0006955; P:immune response; NAS.
 DR InterPro; IPR007110; IG-like.
 DR InterPro; IPR003006; IG_MHC.
 DR InterPro; IPR003596; IG_V.
 DR Pfam; PF00047; Ig; 1.
 DR SMART; SM00406; IGV; 1.
 DR PROSITE; PS50835; IG LIKE; 1.
 KW Immunoglobulin V region.
 FT DOMAIN 1 23 FRAMEWORK-1.
 FT DOMAIN 24 34 FRAMEWORK-2.
 FT DOMAIN 35 49 FRAMEWORK-3.
 FT DOMAIN 50 56 FRAMEWORK-4.
 FT DOMAIN 57 88 FRAMEWORK-5.
 FT DOMAIN 89 97 FRAMEWORK-6.
 FT DOMAIN 98 107 FRAMEWORK-7.
 FT DISULFD 108 108 BY SIMILARITY.
 FT NON_TER 108
 SQ SEQUENCE 108 AA; 11834 MW; 73993A95431434A CRC64;
 Query Match 42.5%; Score 247.5; DB 1; Length 108;
 Best Local Similarity 46.3%; Pred. No. 3.2e-18;
 Matches 50; Conservative 18; Mismatches 33; Indels 7; Gaps 3;
 QY 5 ELTQDP-AVSVALGQTVRVTCQSDLSRSYASWYQKPGQAPVLYVYGNKRRPSGIPDRF 63
 DB 3 QMTQSPSSLSVSGDVRVITTCQASQNVAVYLNWYQKRGKGLPKLLIYGASVREAGVPSRF 62
 QY 64 GSSSGNTASLTITGAQAEDEADYICSSRDSGNHWFVGGTGLTV 109
 DB 63 GSGSGTDFTLTITSSVQAEADLADYHCGQGY--NNWPPTFGGGLTLEI 106
 RESULT 45
 KX01 RABBIT STANDARD; PRT; 110 AA.
 AC P01682;
 ID 21-JUL-1986 (Rel. 01, Created)
 DT 21-JUL-1986 (Rel. 01, Last sequence update)
 DT 15-JUL-1999 (Rel. 38, Last annotation update)
 OS Oryctolagus cuniculus (Rabbit).
 DE Ig kappa chain V region 2717.
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Lagomorpha; Leporidae; Oryctolagus.
 OX NCBI_TaxID=9986;
 RN [1]
 RP SEQUENCE.
 RA MEDLINE=74022203; PubMed=4748811;
 RA Appella E., Roholt O.A., Chersi A., Radzinski G., Pressman D.;
 RT "Amino acid sequence of the light chain derived from a rabbit anti-p-
 RT azobenzene antibody of restricted heterogeneity";
 RL Biochem. Biophys. Res. Commun. 53:1122-1129(1973).
 CC -1- MISCELLANEOUS: THIS CHAIN WAS OBTAINED FROM ANTIBODY TO
 CC P-AZOBENZENE AND WAS ISOLATED FROM THE SERUM OF A SINGLE RABBIT.
 DR PIR; A01945; K4RB27.
 DR HSSP; P80362; IWTI.
 DR InterPro; IPR007110; IG-like.
 DR InterPro; IPR003006; IG_MHC.
 DR InterPro; IPR003596; IG_V.
 DR Pfam; PF00047; IGV; 1.
 DR SMART; SM00406; IGV; 1.
 DR PROSITE; PS50835; IG LIKE; 1.
 KW Immunoglobulin V region.
 FT DOMAIN 1 23 FRAMEWORK-1.
 FT DOMAIN 24 36 FRAMEWORK-2.
 FT DOMAIN 37 51 FRAMEWORK-3.
 FT DOMAIN 52 58 FRAMEWORK-4.
 FT DOMAIN 59 90 FRAMEWORK-5.

FT	DOMAIN	91	99	COMPLEMENTARITY-DETERMINING-3
FT	DOMAIN	100	109	FRAMEWORK-4.
FT	SITE	98	98	AT THE HAPTEN COMBINING SITE.
FT	NON TER	110	110	
SQ	SEQUENCE	110 AA;	11367 MW;	8A590BBD5282D107 CRC64;

Query Match	41.9%;	Score 244.5;	DB 1;	Length 110;
Best Local Similarity	45.9%;	Pred. No. 6.5e-18;		
Matches 51;	Conservative 20;	Mismatches 31;	Indels 9;	Gaps 4

```

QY      6  LTQDPA-VSYALGGTYAVTQCGDSLSRKY-----YASWYQKPGCAPVLYVIGKNNRSGIP 60
Db      4  LTQPPSPVAAGVTIVISQ--STKSYBAYBLAWYQZKRGQPKALITYTASLSAGVP 61

QY      61  DREFGSSGNTASTLTTCGADEADADYCCSRDSSGNTWVFGGTETLYVG 111
Db      62  SRFGSSSGTFTLLTSDVZCDDNATYTCGADYTG--YSGFGTEVYVVG 110

```

ULT 46	
_____HUMAN	
ID_KV3M HUMAN	STANDARD;
PRT;	129 AA

DT 01-NOV-1990 (Rel. 16, Created)
DT 01-NOV-1990 (Rel. 16, Last sequence update)
DT 15-JUL-1999 (Rel. 38, Last annotation update)
DE Ig kappa chain V-II1 region HIC precursor.
OS Homo sapiens (human) .
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
ON NCBI_TaxId=9606;
RX [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=88171307; PubMed=3127527;
RA Kripps T.J., Tomhave E., Chen P.P., Carson D.A.;
RT "antibody-associated kappa light chain variable region gene
RT expressed in chronic lymphocytic leukemia with little or no somatid
RT mutation. Implications for etiology and immunotherapy. ";
RT J. Exp. Med. 167:840-852(1988)
CC -1- DISEASE: THE PROTEIN IS ONE OF THE SURFACE IMMUNOGLOBULIN M
CC AUTOANTIBODIES EXPRESSED IN PATIENTS WITH CHRONIC LYMPHOCYTIC
CC LEUKEMIA.

Query Match	41.9%	Score 244;	DB 1;	Length 129;
Best Local Similarity	48.1%;	Pred. No. 8.8e-18;		
Matches	51;	Conservative 19;	Mismatches 32;	Indels 4;
				Gaps 3
QY	6	LTDDP-AVSVALGQVRVTCQ-GDLSLRYSVSWYQKQGGQARVLYIKGNKNNPSPGIPRF	63	

D5 24 LTQSPGLTSLSPERRALTLSCRASQSVSSSTLYAMYYQKPCQAPPLLITGASSRATGIPDNF 83

D6 64 SGSSSGNTASLITGAQAEDEADYYCSRRDSSGNHHVFGGTELTV 109

D7 84 SGSSSGTDFLTITLSRLEPXFAYYYQQQYSS--PMTFGGTKEVI 127

RESULT 47	
KV30_MOUSE	
ID_KV30_MOUSE	STANDARD;
	PRT; 111 AA

DT	21-JUL-1986	(Rel. 01, Created)
DT	21-JUL-1986	(Rel. 01, Last sequence update)
DT	15-JUL-1999	(Rel. 38, Last annotation update)
DE	IG kappa chain V-JII region	PC 6308.
OS	Mus musculus (Mouse)	
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi	
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mu	
OX	NCBI_TaxID=10090;	
RN	[1]	
RP	SEQUENCE.	
RX	MEDLINE=79073152; PubMed=103003;	
RA	Weigert M., Gacmaitan L., Loh E., Schilling J., Hood L.E.;	
RT	"Rearrangement of genetic information may produce immunoglobulin	
RT	diversity."	
RL	Nature 276:785-790(1978).	
DR	PIR; C01937; KWS08.	
DR	HSSP; P80362; IMTL.	
DR	InterPro: IPR007110; IG_1ike.	
DR	InterPro: IPR003006; IG_MHC.	
DR	InterPro: IPR003596; IG_V.	
DR	Pfam; PF00047; Ig; 1.	
DR	SMART; SM00406; IgV; 1.	
DR	PROSITE; PS50835; IG_Like; 1.	
KW	Immunoglobulin V region.	
FT	DOMAIN	1 23
FT	DOMAIN	24 38
FT	DOMAIN	39 53
FT	DOMAIN	54 60
FT	DOMAIN	61 92
FT	DOMAIN	93 101
FT	DOMAIN	102 111
FT	DISULFID	23 92
FT	NON_TER	111 111
QO	SEQUENCE	111 AA; 12071 MW; 7A4AD4DC256D29 CRC64;

Query Match	41.8%;	Score 243.5;	DB 1;	Length 111;
Best Local Similarity	46.8%;	Pred. No. 8.3e-18;		
Matches 51;	Conservative .16;	Mismatches 35;	Indels 7;	Gaps 3;

Dy 6 LTDDPA-VSYALQTVRTVCOGDSLSY-----YASNYOOKPGCAPLVLYIGKKNNRSGAP 6
:::>:::
Db 4 LTGPSPALAVSLSGRATISCKASGVSDVDGDSTVMNMYQQKPGCPFLTLITYTASNLESGAP 63

RESULT	48		
KV3P	MOUSE		
ID	KV3P_MOUSE	STANDARD;	PRT; 110 AA.
AC	P01668;		
DT	21-JUL-1986 (Rel. 01, Created)		
DT	21-JUL-1986 (Rel. 01, Last sequence update)		
DT	15-JUL-1999 (Rel. 38, Last annotation update)		
DE	IG kappa chain V-III region FC 7210.		
OS	Mus musculus (Mouse).		
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;		
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus		
CX	NCBI_TaxId=10090;		
RN	(1)		
RP	SEQUENCE.		

```

RX MEDLINE=79073152; PubMed=103003;
RA Weigert M., Gattalman L., Loh E., Schilling J., Hood L.E.;
RT "Rearrangement of genetic information may produce immunoglobulin
diversity."
RL Nature 276:785-790(1978).
DR PIR; D01937; KWS610.
DR HSSP; P01679; 2F8J.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_V.
DR Pfam; PF00047; Ig; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 1.
KW Immunoglobulin V region.
FT DOMAIN 1 23 FRAMEWORK-1.
FT DOMAIN 2 38 COMPLEMENTARITY-DETERMINING-1.
FT DOMAIN 39 53 FRAMEWORK-2.
FT DOMAIN 54 60 COMPLEMENTARITY-DETERMINING-2.
FT DOMAIN 61 92 FRAMEWORK-3.
FT DOMAIN 93 100 COMPLEMENTARITY-DETERMINING-3.
FT DOMAIN 101 110 FRAMEWORK-4.
FT DISULFID 23 92 BY SIMILARITY.
FT NON_TER 110
SQ SEQUENCE 110 AA; 11950 MW; 69F1A5CE886B1249 CRC64;

Query Match 41.7%; Score 243; DB 1; Length 110;
Best Local Similarity 46.8%; Pred.No.9.2e-18;
Matches 51; Conservative 14; Mismatches 36; Indels 8; Gaps 3;

OY 6 LTQDP-AVSVALGQTVRVTCGDSLSRSY-----YASWYQKPGQAPVLYIGKNNRPSG 60
DB 4 LTQSPSLAVSLGEGATINCKSSQSVLYSSNNKTYLAWYQKPGQPKLLIYMASTRSG 83
OY 61 DFRSSSSSGNTASLTITGAQAEDEADYICSRDSSGNHWFGGTELTIV 109
DB 64 ARFSGSGSGTDFLTINIHVEEDATYYC--HSEDPWTFSGTKLEI 109

RESULT 49
KV4B_HUMAN STANDARD; PRT; 133 AA.
AC P06313;
DT 01-JAN-1988 (Rel. 06, Created)
DT 01-JAN-1988 (Rel. 06, Last sequence update)
DT 15-JUL-1999 (Rel. 38, Last annotation update)
DE Ig kappa chain V-IV region JI precursor.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
NCBI_TaxID=9606;
[1]
RP SEQUENCE FROM N.A.
RA MEDLINE=86041853; PubMed=2997712;
RA Klobbeck H.G., Bornkamm G.W., Combliato G., Mocikat R., Pohlentz H.D.,
RA Zachau H.G.;
RT "Subgroup IV of human immunoglobulin K light chains is encoded by a
RT single germline gene."
RL Nucleic Acids Res. 13:6515-6528(1985).
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; Z00022; CAA77317.1; -
DR PIR; A01904; K4HUT1.
DR HSSP; P80362; 1WTL.
DR GO; GO:0005576; C:extracellular; NAS.
DR GO; GO:0003823; F:antigen binding activity; NAS.
DR GO; GO:0006955; P:immune response; NAS.

```

```

DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_V.
DR Pfam; PF00047; Ig; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 1.
KW Immunoglobulin V region; Signal.
FT SIGNAL 1 20
FT CHAIN 21 133 IG KAPPA CHAIN V-IV REGION JI.
FT DOMAIN 21 43 FRAMEWORK-1.
FT DOMAIN 44 60 COMPLEMENTARITY-DETERMINING-1.
FT DOMAIN 61 75 FRAMEWORK-2.
FT DOMAIN 76 82 COMPLEMENTARITY-DETERMINING-2.
FT DOMAIN 83 114 FRAMEWORK-3.
FT DOMAIN 115 122 FRAMEWORK-4.
FT DOMAIN 123 132 COMPLEMENTARITY-DETERMINING-3.
FT DISULFID 43 114 BY SIMILARITY.
FT NON_TER 133
SQ SEQUENCE 133 AA; 14632 MW; 5FB3953066744AF4 CRC64;

Query Match 41.7%; Score 243; DB 1; Length 133;
Best Local Similarity 45.0%; Pred.No.1.1e-17;
Matches 50; Conservative 18; Mismatches 33; Indels 10; Gaps 3;

OY 6 LTQDP-AVSVALGQTVRVTCGDSLSRSY-----YASWYQKPGQAPVLYIGKNNRPSG 58
DB 24 MTQSPDSLAVSLGERATINCKSSQSVLYSSNNKTYLAWYQKPGQPKLLIYMASTRSG 83
OY 59 IPRRSGSSSGNTASLTITGAQAEDEADYICSRDSSGNHWFGGTELTIV 109
DB 84 VPRRSGSGSGTDFLTITISLQAEADVAVYCCQVDITP---TFGGTKVEI 131

RESULT 50
KV14_RABBIT STANDARD; PRT; 109 AA.
AC P01655;
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 15-JUL-1999 (Rel. 38, Last annotation update)
DE Ig kappa chain V region K16-167.
OS Oryctolagus cuniculus (Rabbit).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Lagomorpha; Leporidae; Oryctolagus.
NCBI_TaxID=9986;
[1]
RP SEQUENCE.
RA MEDLINE=77162585; PubMed=404188;
RA Riesen W.F., Braun D.G.;
RT "The amino acid sequence of the eight-chain variable region of a
RT rabbit antibody against the streptococcal group A variant
RT polysaccharide (antibody K16-167).";
RL FEBS Lett. 75:254-258(1977).
[2]
RP REVISIONS TO 22 AND 105.
RA Riesen W.F., Braun D.G.;
RL FEBS Lett. 81:219-219(1977).
CC -I- MISCELLANEOUS: THIS CHAIN WAS OBTAINED FROM ANTIBODY TO THE
CC POLYSACCHARIDE OF A STREPTOCOCCAL GROUP A VARIANT AND WAS ISOLATED
CC FROM THE SERUM OF A SINGLE RABBIT.
CC -----
DR PIR; A91436; KVR16.
DR HSSP; P80362; 1WTL.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_V.
DR Pfam; PF00047; Ig; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 1.
KW Immunoglobulin V region.
FT DOMAIN 1 23 FRAMEWORK-1.
FT DOMAIN 24 35 COMPLEMENTARITY-DETERMINING-1.
FT DOMAIN 36 50 FRAMEWORK-2.
FT DOMAIN 51 57 COMPLEMENTARITY-DETERMINING-2.

```

FT DOMAIN 58 89 FRAMEWORK-3.
FT DOMAIN 90 99 COMPLEMENTARITY-DETERMINING-3.
FT DOMAIN 100 109 FRAMEWORK-4.
FT NON TER 109 109
SQ SEQUENCE 109 AA: 11268 NM; CSA2CA80587448E2 CRC64;

Query Match 41.6%; Score 242.5; DB 1; Length 109;
Best Local Similarity 48.1%; Pred. No. 1e-17;
Matches 51; Conservative 18; Mismatches 34; Indels 3; Gaps 3;

Qy 6 LTDDPA-VSVALGQTVRTCO-GDSLRSYVASYOQKPGQAPVVIYGNRRPSCIPIPRF 63
Db 4 MTQTPSPVSAVGGIVTISCOASQSVSNLWFOQKPGQPPKLLIYKASTLASGVPSRF 63
Qy 64 SSSSGNTASLTITGAQAEADADYCCSSRDSGNNHMFVGGTETLV 109
Db 64 KSGSGTQFTLPISGVECDADATYYCQG-TWNGNNIVFGTGEVYV 108

Job completed: November 26, 2003, 13:39:48
Time: 10.4872 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: November 26, 2003, 13:41:10 ; Search time 23.7179 Seconds
(without alignments)
863.195 Million cell updates/sec

Title: US-09-880-748-327_COPY_139_249

Perfect score: 583

Sequence: 1 AFSSSLTDDPAVSVAGQTV.....RDSGNHWFGGTELTVLG 111

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 673684 seqs, 184443283 residues 673684

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published Applications AA:*

1: /cgn2_6/ptodata/2/pubpaa/US07_PUBCOMB.pep:*

2: /cgn2_6/ptodata/2/pubpaa/PC7_NEW_PUB.pep:*

3: /cgn2_6/ptodata/2/pubpaa/US06_NEW_PUB.pep:*

4: /cgn2_6/ptodata/2/pubpaa/US06_PUBCOMB.pep:*

5: /cgn2_6/ptodata/2/pubpaa/US07_NEW_PUB.pep:*

6: /cgn2_6/ptodata/2/pubpaa/PC7US_PUBCOMB.pep:*

7: /cgn2_6/ptodata/2/pubpaa/US08_NEW_PUB.pep:*

8: /cgn2_6/ptodata/2/pubpaa/US08_PUBCOMB.pep:*

9: /cgn2_6/ptodata/2/pubpaa/US09_PUBCOMB.pep:*

10: /cgn2_6/ptodata/2/pubpaa/US09C_PUBCOMB.pep:*

11: /cgn2_6/ptodata/2/pubpaa/US09C_PUBCOMB.pep:*

12: /cgn2_6/ptodata/2/pubpaa/US09_NEW_PUB.pep:*

13: /cgn2_6/ptodata/2/pubpaa/US10_PUBCOMB.pep:*

14: /cgn2_6/ptodata/2/pubpaa/US10C_PUBCOMB.pep:*

15: /cgn2_6/ptodata/2/pubpaa/US10C_PUBCOMB.pep:*

16: /cgn2_6/ptodata/2/pubpaa/US10C_NEW_PUB.pep:*

17: /cgn2_6/ptodata/2/pubpaa/US60_NEW_PUB.pep:*

18: /cgn2_6/ptodata/2/pubpaa/US60_PUBCOMB.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	583	100.0	249	US-09-880-748-327	Sequence 327, App
2	583	100.0	249	US-09-880-748-327	Sequence 327, App
3	583	100.0	249	US-09-880-748-327	Sequence 327, App
4	583	100.0	249	US-09-880-748-327	Sequence 327, App
5	580	99.5	248	US-09-880-748-327	Sequence 327, App
6	580	99.5	248	US-09-880-748-327	Sequence 327, App
7	580	99.5	248	US-09-880-748-327	Sequence 327, App
8	580	99.5	248	US-09-880-748-327	Sequence 327, App
9	580	99.5	248	US-09-880-748-327	Sequence 327, App
10	580	99.5	249	US-09-880-748-327	Sequence 327, App
11	580	99.5	249	US-09-880-748-327	Sequence 327, App
12	580	99.5	249	US-09-880-748-327	Sequence 327, App
13	580	99.5	249	US-09-880-748-327	Sequence 327, App
14	580	99.5	249	US-09-880-748-327	Sequence 327, App
15	580	99.5	249	US-09-880-748-327	Sequence 327, App

16	580	99.5	249	US-09-880-748-327	Sequence 327, App
17	580	99.5	249	US-09-880-748-327	Sequence 327, App
18	580	99.5	249	US-09-880-748-327	Sequence 327, App
19	580	99.5	249	US-09-880-748-327	Sequence 327, App
20	580	99.5	249	US-09-880-748-327	Sequence 327, App
21	580	99.5	249	US-09-880-748-327	Sequence 327, App
22	580	99.5	249	US-09-880-748-327	Sequence 327, App
23	580	99.5	249	US-09-880-748-327	Sequence 327, App
24	580	99.5	249	US-09-880-748-327	Sequence 327, App
25	580	99.5	249	US-09-880-748-327	Sequence 327, App
26	580	99.5	249	US-09-880-748-327	Sequence 327, App
27	580	99.5	249	US-09-880-748-327	Sequence 327, App
28	580	99.5	249	US-09-880-748-327	Sequence 327, App
29	580	99.5	249	US-09-880-748-327	Sequence 327, App
30	580	99.5	249	US-09-880-748-327	Sequence 327, App
31	580	99.5	249	US-09-880-748-327	Sequence 327, App
32	580	99.5	249	US-09-880-748-327	Sequence 327, App
33	580	99.5	249	US-09-880-748-327	Sequence 327, App
34	580	99.5	249	US-09-880-748-327	Sequence 327, App
35	580	99.5	249	US-09-880-748-327	Sequence 327, App
36	580	99.5	249	US-09-880-748-327	Sequence 327, App
37	580	99.5	249	US-09-880-748-327	Sequence 327, App
38	580	99.5	249	US-09-880-748-327	Sequence 327, App
39	580	99.5	249	US-09-880-748-327	Sequence 327, App
40	580	99.5	249	US-09-880-748-327	Sequence 327, App
41	580	99.5	249	US-09-880-748-327	Sequence 327, App
42	580	99.5	249	US-09-880-748-327	Sequence 327, App
43	580	99.5	249	US-09-880-748-327	Sequence 327, App
44	580	99.5	249	US-09-880-748-327	Sequence 327, App
45	580	99.5	249	US-09-880-748-327	Sequence 327, App

ALIGNMENTS

US-09-880-748-327	Application US/09880748
Sequence 327, App	Publication No. US20030059937A1
GENERAL INFORMATION:	
APPLICANT: Ruben et al.	
TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys	
FILE REFERENCE: PFS23	
CURRENT APPLICATION NUMBER: US/09/880,748	
CURRENT FILING DATE: 2001-06-15	
PRIOR APPLICATION NUMBER: 60/212,210	
PRIOR FILING DATE: 2000-06-15	
PRIOR APPLICATION NUMBER: 60/240,816	
PRIOR FILING DATE: 2000-10-17	
PRIOR APPLICATION NUMBER: 60/276,248	
PRIOR FILING DATE: 2001-03-16	
PRIOR APPLICATION NUMBER: 60/277,379	
PRIOR FILING DATE: 2001-03-21	
PRIOR APPLICATION NUMBER: 60/293,499	
PRIOR FILING DATE: 2001-05-25	
NUMBER OF SEQ ID NOS: 3239	
SOFTWARE: Patent In Ver. 2.0	
SEQ ID NO: 327	
LENGTH: 249	
TYPE: PRT	
ORGANISM: Homo sapiens	
US-09-880-748-327	
Query Match	100.0%; Score 583; DB 11; Length 249;
Best Local Similarity	100.0%; Pred. No. 4; 1e-47;
Matches 111; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
QY	1 AFSSSLTDDPAVSVAGQTVVTCGDSLRYSYVSWYQKFGQAPVLYYKNNRPSGIP 60
DB	139 AFSSSLTDDPAVSVAGQTVVTCGDSLRYSYVSWYQKFGQAPVLYYKNNRPSGIP 198
QY	61 DRFGSSSSGNASTLITGAQAEADYVYSSRDSGNHWFGGTELTVLG 111


```

; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: Patentin Ver. 2.0.C
; SEQ ID NO 339
; LENGTH: 248
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-339

```

Query Match	99.5%	Score 580;	DB 11;	Length 248;
Best Local Similarity	99.1%;	Pred. No. 7.8e-47;		
Matches 110;	Conservative 1;	Mismatches 0;	Indels 0;	Gaps 0

QY 1 AFSSSETQDPAVSVALGQTVRTCCGSLRSTYASWQKPGCAPVLVIYGNRRPSCIP 60
 DB 138 AFSSSETQDPAVSVALGQTVRTCCGSLRSTYASWQKPGCAPVLVIYGNRRPSCIP 197

```
QY      61 DRFSGSSSGNTASLTITGAQAEDADYYCSSRDSGNHWVFGGGETLVLG 111  
        |||||  
Db      198 DRFSGSSSGNTASLTITGAQAEDADYYCNSRDSSGNHWVFGGGETLVLG 248
```

US-09-880-748-347
; Sequence 347, Application US/09880748
; Publication No. US20030059937A1
CURRENT INFORMATION

Indexer Match	99.5%	Score 580;	DB 11;	Length 248;
Best Local Similarity	99.1%;	Pred: 7.8e-47;		
Matches 110; Conservative	.1;	Mismatches 0;	Indels 0;	Gaps 0

QY 1 AFSESLQDPDAVVAAGQTRVTRCGQSDLSRYSYASMYQOKPQQAIVLVIYKNNRPSGIP 60
Db 138 AFSESLQDPDAVVAAGQTRVTRCGQSDLSRYSYASMYQOKPQQAIVLVIYKNNRPSGIP 197
QY 61 DRFGSSSGNTASLTITGAQEDADYCYSSPDSGCMHWFGGTELTVLG 111
Db 198 DRFGSSSGNTASLTITGAQEDADYCYNSPDSGCMHWFGGTELTVLG 248

RESULT 7
US-09-880-748-354
Sequence 354. Application US/09880748
Publication No. US20030059937A1
GENERAL INFORMATION:
APPLICANT: Puben et al.
TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blyss
FILE REFERENCE: P#523
CURRENT APPLICATION NUMBER: US/09/880,748
CURRENT FILING DATE: 2001-06-15
PRIOR APPLICATION NUMBER: 60/212,210

```

1 PRIOR FILING DATE: 2000-06-15
2 PRIOR APPLICATION NUMBER: 60/240,814
3 PRIOR FILING DATE: 2000-10-17
4 PRIOR APPLICATION NUMBER: 60/276,246
5 PRIOR FILING DATE: 2001-03-16
6 PRIOR APPLICATION NUMBER: 60/277,375
7 PRIOR FILING DATE: 2001-03-21
8 PRIOR APPLICATION NUMBER: 60/293,499
9 PRIOR FILING DATE: 2001-05-25
10 NUMBER OF SEQ ID NOS: 3239
11 SOFTWARE: PatentIn Ver. 2.0
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006

```

Query Match	99.5%	Score 580;	DB 11;	Length 248;
Best Local Similarity	-99.1%;	Pred. No. 7.8e-47;		
Matches 110;	Conservative 1;	Mismatches 0;	Indels 0;	Gaps 0

QY 1 AFSESLTOPPAVSVALGQTVRVTTCGDSLSRYSYAWYQOKGQAPVLVIYKNNRPSGIP 60

Db 138 AFSESLTOPPAVSVALGQTVRVTTCGDSLSRYSYAWYQOKGQAPVLVIYKNNRPSGIP 19

QY 61 DRFGSSSGNTASLTITGAODEDDYYICSRDSSGNNHWVGGGTETLVIG 111

Db 198 DRFGSSSGNTASLTITGAODEDDYYICNSRDSGNNHWVGGGTETLVIG 248

```

RESULT 8
US-09-880-748-597
Sequence 597, Application US/09880748
Publication No. US20030059937A1
GENERAL INFORMATION:
APPLICANT: Ruben et al.
TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blyss
FILE REFERENCE: PF523
CURRENT APPLICATION NUMBER: US/09/880,748
PRIOR FILING DATE: 2001-06-15
PRIOR APPLICATION NUMBER: 60/212,210
PRIOR FILING DATE: 2000-06-15
PRIOR APPLICATION NUMBER: 60/240,816
PRIOR FILING DATE: 2000-10-17
PRIOR APPLICATION NUMBER: 60/276,248
PRIOR FILING DATE: 2001-03-16
PRIOR APPLICATION NUMBER: 60/277,379
PRIOR FILING DATE: 2001-03-21
PRIOR APPLICATION NUMBER: 60/293,499
PRIOR FILING DATE: 2001-05-25
NUMBER OF SEQ ID NOS: 3239
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 597
LENGTH: 248
TYPE: PRT
ORGANISM: Homo sapiens
US-09-880-748-597

```

Query Match	99.5%	Score 580;	DB 11;	Length 248;
Best Local Similarity	99.1%	Pred. No. 7.8e-47;		
Matches 110; Conservative	1;	Mismatches 0;	Indels 0;	Gaps 0;

QY 1 AFSESLTDPAPVALGQTVRVTCCGDBLRSYVSWQKKGQA.PLVITGKNNRPGSIP 60
Db 138 AFSESLTDPAPVALGQTVRVTCCGDBLRSYVSWQKKGQA.PLVITGKNNRPGSIP 197
QY 61 DRSSGSSCNTASLTITGAQAEDEADYCCSRDSSGNHWFGGTELTVLG 111
Db 198 DRSGSSCNTASLTITGAQAEDEADYCCNRDSSGNHWFGGTELTVLG 248

RESULT 9
US-09-880-748-623

```
; Sequence 623, Application US/09880748
; Publication No. US20030059937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; CURRENT FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 623
; LENGTH: 248
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-623

Query Match          99.5%; Score 580; DB 11; Length 248;
Best Local Similarity 99.1%; Pred. No. 7.8e-47;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy      1 AFSSSLTQDPAAVVALGQTVRVTCGDSLSRSYASWYQKPGQAPVLVIYKNNRPSGIP 60
Db      138 AFSSSLTQDPAAVVALGQTVRVTCGDSLSRSYASWYQKPGQAPVLVIYKNNRPSGIP 197
        |||
        61 DRFSSSSGNTASLTITGAQAEDEADYCCSRDSSGNHWVFGGTELTVLG 111
        |||
        198 DRFSSSSGNTASLTITGAQAEDEADYCCSRDSSGNHWVFGGTELTVLG 248

RESULT 10
US-09-880-748-2
; Sequence 2, Application US/09880748
; Publication No. US20030059937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; CURRENT FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2
; LENGTH: 249
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-2

Query Match          99.5%; Score 580; DB 11; Length 249;
Best Local Similarity 99.1%; Pred. No. 7.8e-47;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy      1 AFSSSLTQDPAAVVALGQTVRVTCGDSLSRSYASWYQKPGQAPVLVIYKNNRPSGIP 60
Db      139 AFSSSLTQDPAAVVALGQTVRVTCGDSLSRSYASWYQKPGQAPVLVIYKNNRPSGIP 198
        |||
        61 DRFSSSSGNTASLTITGAQAEDEADYCCSRDSSGNHWVFGGTELTVLG 111
        |||
        199 DRFSSSSGNTASLTITGAQAEDEADYCCSRDSSGNHWVFGGTELTVLG 249
```

```
Db      139 AFSSSLTQDPAAVVALGQTVRVTCGDSLSRSYASWYQKPGQAPVLVIYKNNRPSGIP 198
Qy      61 DRFSSSSGNTASLTITGAQAEDEADYCCSRDSSGNHWVFGGTELTVLG 111
        |||
        199 DRFSSSSGNTASLTITGAQAEDEADYCCSRDSSGNHWVFGGTELTVLG 249

RESULT 11
US-09-880-748-323
; Sequence 323, Application US/09880748
; Publication No. US20030059937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; CURRENT FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 323
; LENGTH: 249
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-323

Query Match          99.5%; Score 580; DB 11; Length 249;
Best Local Similarity 99.1%; Pred. No. 7.8e-47;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy      1 AFSSSLTQDPAAVVALGQTVRVTCGDSLSRSYASWYQKPGQAPVLVIYKNNRPSGIP 60
Db      139 AFSSSLTQDPAAVVALGQTVRVTCGDSLSRSYASWYQKPGQAPVLVIYKNNRPSGIP 198
        |||
        61 DRFSSSSGNTASLTITGAQAEDEADYCCSRDSSGNHWVFGGTELTVLG 111
        |||
        199 DRFSSSSGNTASLTITGAQAEDEADYCCSRDSSGNHWVFGGTELTVLG 249

RESULT 12
US-09-880-748-324
; Sequence 324, Application US/09880748
; Publication No. US20030059937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; CURRENT FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 324
; LENGTH: 249
; TYPE: PRT
```

ORGANISM: Homo sapiens
US-09-880-748-324

Query Match 99.5%; Score 580; DB 11; Length 249;
Best Local Similarity 99.1%; Pred. No. 7.8e-47;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFSSSLTDDPAVVALGQTVRTCCGDSLRSYASWYQKPGQAPVLVIYGNRRPSCIP 60
DB 139 AFSSSLTDDPAVVALGQTVRTCCGDSLRSYASWYQKPGQAPVLVIYGNRRPSCIP 198

QY 61 DRFGSSSGNTASLTITGAQAEADYCCSRDSSGNHWFVGGTETLVLG 111
DB 199 DRFGSSSGNTASLTITGAQAEADYCCSRDSSGNHWFVGGTETLVLG 249

RESULT 13
US-09-880-748-326
Sequence 326, Application US/09880748
Publication No. US20030059937A1
GENERAL INFORMATION:
APPLICANT: Ruben et al.

TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
FILE REFERENCE: PF523
CURRENT APPLICATION NUMBER: US/09/880,748

PRIOR FILING DATE: 2001-06-15
PRIOR APPLICATION NUMBER: 60/212,210
PRIOR FILING DATE: 2000-06-15
PRIOR APPLICATION NUMBER: 60/240,816
PRIOR FILING DATE: 2000-10-17
PRIOR APPLICATION NUMBER: 60/276,248
PRIOR FILING DATE: 2001-03-16
PRIOR APPLICATION NUMBER: 60/277,379
PRIOR FILING DATE: 2001-03-21
PRIOR APPLICATION NUMBER: 60/293,499
PRIOR FILING DATE: 2001-05-25
NUMBER OF SEQ ID NOS: 3239
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO: 326
LENGTH: 249
TYPE: PRT

ORGANISM: Homo sapiens
US-09-880-748-326

Query Match 99.5%; Score 580; DB 11; Length 249;
Best Local Similarity 99.1%; Pred. No. 7.8e-47;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFSSSLTDDPAVVALGQTVRTCCGDSLRSYASWYQKPGQAPVLVIYGNRRPSCIP 60
DB 139 AFSSSLTDDPAVVALGQTVRTCCGDSLRSYASWYQKPGQAPVLVIYGNRRPSCIP 198

QY 61 DRFGSSSGNTASLTITGAQAEADYCCSRDSSGNHWFVGGTETLVLG 111
DB 199 DRFGSSSGNTASLTITGAQAEADYCCSRDSSGNHWFVGGTETLVLG 249

RESULT 14
US-09-880-748-332
Sequence 332, Application US/09880748
Publication No. US20030059937A1
GENERAL INFORMATION:
APPLICANT: Ruben et al.

TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
FILE REFERENCE: PF523
CURRENT APPLICATION NUMBER: US/09/880,748

PRIOR FILING DATE: 2001-06-15
PRIOR APPLICATION NUMBER: 60/212,210
PRIOR FILING DATE: 2000-06-15
PRIOR APPLICATION NUMBER: 60/240,816
PRIOR FILING DATE: 2000-10-17
PRIOR APPLICATION NUMBER: 60/276,248
PRIOR FILING DATE: 2001-03-16

PRIOR APPLICATION NUMBER: 60/277,379
PRIOR FILING DATE: 2001-03-21
PRIOR APPLICATION NUMBER: 60/293,499
PRIOR FILING DATE: 2001-05-25
NUMBER OF SEQ ID NOS: 3239
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO: 332
LENGTH: 249
TYPE: PRT

ORGANISM: Homo sapiens
US-09-880-748-332

Query Match 99.5%; Score 580; DB 11; Length 249;
Best Local Similarity 99.1%; Pred. No. 7.8e-47;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFSSSLTDDPAVVALGQTVRTCCGDSLRSYASWYQKPGQAPVLVIYGNRRPSCIP 60
DB 139 AFSSSLTDDPAVVALGQTVRTCCGDSLRSYASWYQKPGQAPVLVIYGNRRPSCIP 198

QY 61 DRFGSSSGNTASLTITGAQAEADYCCSRDSSGNHWFVGGTETLVLG 111
DB 199 DRFGSSSGNTASLTITGAQAEADYCCSRDSSGNHWFVGGTETLVLG 249

RESULT 15
US-09-880-748-333
Sequence 333, Application US/09880748
Publication No. US20030059937A1
GENERAL INFORMATION:
APPLICANT: Ruben et al.

TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
FILE REFERENCE: PF523
CURRENT APPLICATION NUMBER: US/09/880,748

PRIOR FILING DATE: 2001-06-15
PRIOR APPLICATION NUMBER: 60/212,210
PRIOR FILING DATE: 2000-06-15
PRIOR APPLICATION NUMBER: 60/240,816
PRIOR FILING DATE: 2000-10-17
PRIOR APPLICATION NUMBER: 60/276,248
PRIOR FILING DATE: 2001-03-16
PRIOR APPLICATION NUMBER: 60/277,379
PRIOR FILING DATE: 2001-03-21
PRIOR APPLICATION NUMBER: 60/293,499
PRIOR FILING DATE: 2001-05-25
NUMBER OF SEQ ID NOS: 3239
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO: 333
LENGTH: 249
TYPE: PRT

ORGANISM: Homo sapiens
US-09-880-748-333

Query Match 99.5%; Score 580; DB 11; Length 249;
Best Local Similarity 99.1%; Pred. No. 7.8e-47;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFSSSLTDDPAVVALGQTVRTCCGDSLRSYASWYQKPGQAPVLVIYGNRRPSCIP 60
DB 139 AFSSSLTDDPAVVALGQTVRTCCGDSLRSYASWYQKPGQAPVLVIYGNRRPSCIP 198

QY 61 DRFGSSSGNTASLTITGAQAEADYCCSRDSSGNHWFVGGTETLVLG 111
DB 199 DRFGSSSGNTASLTITGAQAEADYCCSRDSSGNHWFVGGTETLVLG 249

RESULT 16
US-09-880-748-334
Sequence 334, Application US/09880748
Publication No. US20030059937A1
GENERAL INFORMATION:
APPLICANT: Ruben et al.

TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys

```
/ FILE REFERENCE: PF523
/ CURRENT APPLICATION NUMBER: US/09/880,748
/ CURRENT FILING DATE: 2001-06-15
/ PRIOR APPLICATION NUMBER: 60/212,210
/ PRIOR FILING DATE: 2000-06-15
/ PRIOR APPLICATION NUMBER: 60/240,816
/ PRIOR FILING DATE: 2000-10-17
/ PRIOR APPLICATION NUMBER: 60/276,248
/ PRIOR FILING DATE: 2001-03-16
/ PRIOR APPLICATION NUMBER: 60/277,379
/ PRIOR FILING DATE: 2001-03-21
/ PRIOR APPLICATION NUMBER: 60/293,499
/ PRIOR FILING DATE: 2001-05-25
/ NUMBER OF SEQ ID NOS: 3239
/ SOFTWARE: Patent In Ver. 2.0
/ SEQ ID NO 334
/ LENGTH: 249
/ TYPE: PRT
/ ORGANISM: Homo sapiens
US-09-880-748-334
Query Match          99.5%; Score 580; DB 11; Length 249;
Best Local Similarity 99.1%; Pred. No. 7.8e-47;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFSSSETDPAVVALGQTVRTCCGDSLRSYASWYQKPGQAPLVLYGKNNRPSGIP 60
DB 139 AFSSSETDPAVVALGQTVRTCCGDSLRSYASWYQKPGQAPLVLYGKNNRPSGIP 198
DB 61 DRFSSSSGNTASLTITGAQAEDEADYCCSRDSSGNHWFVGGGTETLVLG 111
DB 199 DRFSSSSGNTASLTITGAQAEDEADYCCNSRSDSSGNHWFVGGGTETLVLG 249

RESULT 17
US-09-880-748-335
/ Sequence 335, Application US/09880748
/ Publication No. US20030059937A1
/ GENERAL INFORMATION:
/ APPLICANT: Ruben et al.
/ TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
/ FILE REFERENCE: PF523
/ CURRENT APPLICATION NUMBER: US/09/880,748
/ CURRENT FILING DATE: 2001-06-15
/ PRIOR APPLICATION NUMBER: 60/212,210
/ PRIOR FILING DATE: 2000-06-15
/ PRIOR APPLICATION NUMBER: 60/240,816
/ PRIOR FILING DATE: 2000-10-17
/ PRIOR APPLICATION NUMBER: 60/276,248
/ PRIOR FILING DATE: 2001-03-16
/ PRIOR APPLICATION NUMBER: 60/277,379
/ PRIOR FILING DATE: 2001-03-21
/ PRIOR APPLICATION NUMBER: 60/293,499
/ PRIOR FILING DATE: 2001-05-25
/ NUMBER OF SEQ ID NOS: 3239
/ SOFTWARE: Patent In Ver. 2.0
/ SEQ ID NO 335
/ LENGTH: 249
/ TYPE: PRT
/ ORGANISM: Homo sapiens
US-09-880-748-335
Query Match          99.5%; Score 580; DB 11; Length 249;
Best Local Similarity 99.1%; Pred. No. 7.8e-47;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFSSSETDPAVVALGQTVRTCCGDSLRSYASWYQKPGQAPLVLYGKNNRPSGIP 60
DB 139 AFSSSETDPAVVALGQTVRTCCGDSLRSYASWYQKPGQAPLVLYGKNNRPSGIP 198
DB 61 DRFSSSSGNTASLTITGAQAEDEADYCCSRDSSGNHWFVGGGTETLVLG 111
DB 199 DRFSSSSGNTASLTITGAQAEDEADYCCNSRSDSSGNHWFVGGGTETLVLG 249
```

```
RESULT 18
US-09-880-748-336
/ Sequence 336, Application US/09880748
/ Publication No. US20030059937A1
/ GENERAL INFORMATION:
/ APPLICANT: Ruben et al.
/ TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
/ FILE REFERENCE: PF523
/ CURRENT APPLICATION NUMBER: US/09/880,748
/ CURRENT FILING DATE: 2001-06-15
/ PRIOR APPLICATION NUMBER: 60/212,210
/ PRIOR FILING DATE: 2000-06-15
/ PRIOR APPLICATION NUMBER: 60/240,816
/ PRIOR FILING DATE: 2000-10-17
/ PRIOR APPLICATION NUMBER: 60/276,248
/ PRIOR FILING DATE: 2001-03-16
/ PRIOR APPLICATION NUMBER: 60/277,379
/ PRIOR FILING DATE: 2001-03-21
/ PRIOR APPLICATION NUMBER: 60/293,499
/ PRIOR FILING DATE: 2001-05-25
/ NUMBER OF SEQ ID NOS: 3239
/ SOFTWARE: Patent In Ver. 2.0
/ SEQ ID NO 336
/ LENGTH: 249
/ TYPE: PRT
/ ORGANISM: Homo sapiens
US-09-880-748-336
Query Match          99.5%; Score 580; DB 11; Length 249;
Best Local Similarity 99.1%; Pred. No. 7.8e-47;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFSSSETDPAVVALGQTVRTCCGDSLRSYASWYQKPGQAPLVLYGKNNRPSGIP 60
DB 139 AFSSSETDPAVVALGQTVRTCCGDSLRSYASWYQKPGQAPLVLYGKNNRPSGIP 198
DB 61 DRFSSSSGNTASLTITGAQAEDEADYCCSRDSSGNHWFVGGGTETLVLG 111
DB 199 DRFSSSSGNTASLTITGAQAEDEADYCCNSRSDSSGNHWFVGGGTETLVLG 249

RESULT 19
US-09-880-748-338
/ Sequence 338, Application US/09880748
/ Publication No. US20030059937A1
/ GENERAL INFORMATION:
/ APPLICANT: Ruben et al.
/ TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
/ FILE REFERENCE: PF523
/ CURRENT APPLICATION NUMBER: US/09/880,748
/ CURRENT FILING DATE: 2001-06-15
/ PRIOR APPLICATION NUMBER: 60/212,210
/ PRIOR FILING DATE: 2000-06-15
/ PRIOR APPLICATION NUMBER: 60/240,816
/ PRIOR FILING DATE: 2000-10-17
/ PRIOR APPLICATION NUMBER: 60/276,248
/ PRIOR FILING DATE: 2001-03-16
/ PRIOR APPLICATION NUMBER: 60/277,379
/ PRIOR FILING DATE: 2001-03-21
/ PRIOR APPLICATION NUMBER: 60/293,499
/ PRIOR FILING DATE: 2001-05-25
/ NUMBER OF SEQ ID NOS: 3239
/ SOFTWARE: Patent In Ver. 2.0
/ SEQ ID NO 338
/ LENGTH: 249
/ TYPE: PRT
/ ORGANISM: Homo sapiens
US-09-880-748-338
Query Match          99.5%; Score 580; DB 11; Length 249;
Best Local Similarity 99.1%; Pred. No. 7.8e-47;
```

Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AFSSSLTDPAAVVALGQTVRTCCGDSLSRSYASWYQOKPQAPVLVIYGNRRPSGIP 60

Db 139 AFSSSLTDPAAVVALGQTVRTCCGDSLSRSYASWYQOKPQAPVLVIYGNRRPSGIP 198

Qy 61 DRFSSSSGNTASLTITGAQAEDEADYCCSSRDSSGNHWFPGGTELTVLG 111

Db 199 DRFSSSSGNTASLTITGAQAEDEADYCCSSRDSSGNHWFPGGTELTVLG 249

RESULT 20

US-09-880-748-342

Sequence 342, Application US/09880748

Publication No. US20030059937A1

GENERAL INFORMATION:

APPLICANT: Ruben et al.

TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys

FILE REFERENCE: PF523

CURRENT APPLICATION NUMBER: US/09/880,748

PRIOR FILING DATE: 2001-06-15

PRIOR APPLICATION NUMBER: 60/212,210

PRIOR FILING DATE: 2000-06-15

PRIOR APPLICATION NUMBER: 60/240,816

PRIOR FILING DATE: 2000-10-17

PRIOR APPLICATION NUMBER: 60/276,248

PRIOR FILING DATE: 2001-03-16

PRIOR APPLICATION NUMBER: 60/277,379

PRIOR FILING DATE: 2001-03-21

PRIOR APPLICATION NUMBER: 60/293,499

PRIOR FILING DATE: 2001-05-25

NUMBER OF SEQ ID NOS: 3239

SOFTWARE: Patentin Ver. 2.0

SEQ ID NO 342

LENGTH: 249

TYPE: PRT

ORGANISM: Homo sapiens

US-09-880-748-342

Query Match 99.5%; Score 580; DB 11; Length 249;

Best Local Similarity 99.1%; Pred. No. 7.8e-47;

Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AFSSSLTDPAAVVALGQTVRTCCGDSLSRSYASWYQOKPQAPVLVIYGNRRPSGIP 60

Db 139 AFSSSLTDPAAVVALGQTVRTCCGDSLSRSYASWYQOKPQAPVLVIYGNRRPSGIP 198

Qy 61 DRFSSSSGNTASLTITGAQAEDEADYCCSSRDSSGNHWFPGGTELTVLG 111

Db 199 DRFSSSSGNTASLTITGAQAEDEADYCCSSRDSSGNHWFPGGTELTVLG 249

RESULT 21

US-09-880-748-343

Sequence 343, Application US/09880748

Publication No. US20030059937A1

GENERAL INFORMATION:

APPLICANT: Ruben et al.

TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys

FILE REFERENCE: PF523

CURRENT APPLICATION NUMBER: US/09/880,748

PRIOR FILING DATE: 2001-06-15

PRIOR APPLICATION NUMBER: 60/212,210

PRIOR FILING DATE: 2000-06-15

PRIOR APPLICATION NUMBER: 60/240,816

PRIOR FILING DATE: 2000-10-17

PRIOR APPLICATION NUMBER: 60/276,248

PRIOR FILING DATE: 2001-03-16

PRIOR APPLICATION NUMBER: 60/277,379

PRIOR FILING DATE: 2001-03-21

PRIOR APPLICATION NUMBER: 60/293,499

PRIOR FILING DATE: 2001-05-25

NUMBER OF SEQ ID NOS: 3239

SOFTWARE: Patentin Ver. 2.0

SEQ ID NO 343

LENGTH: 249

TYPE: PRT

ORGANISM: Homo sapiens

US-09-880-748-343

Query Match 99.5%; Score 580; DB 11; Length 249;

Best Local Similarity 99.1%; Pred. No. 7.8e-47;

Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AFSSSLTDPAAVVALGQTVRTCCGDSLSRSYASWYQOKPQAPVLVIYGNRRPSGIP 60

Db 139 AFSSSLTDPAAVVALGQTVRTCCGDSLSRSYASWYQOKPQAPVLVIYGNRRPSGIP 198

Qy 61 DRFSSSSGNTASLTITGAQAEDEADYCCSSRDSSGNHWFPGGTELTVLG 111

Db 199 DRFSSSSGNTASLTITGAQAEDEADYCCSSRDSSGNHWFPGGTELTVLG 249

RESULT 22

US-09-880-748-344

Sequence 344, Application US/09880748

Publication No. US20030059937A1

GENERAL INFORMATION:

APPLICANT: Ruben et al.

TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys

FILE REFERENCE: PF523

CURRENT APPLICATION NUMBER: US/09/880,748

PRIOR FILING DATE: 2001-06-15

PRIOR APPLICATION NUMBER: 60/212,210

PRIOR FILING DATE: 2000-06-15

PRIOR APPLICATION NUMBER: 60/240,816

PRIOR FILING DATE: 2000-10-17

PRIOR APPLICATION NUMBER: 60/276,248

PRIOR FILING DATE: 2001-03-16

PRIOR APPLICATION NUMBER: 60/277,379

PRIOR FILING DATE: 2001-03-21

PRIOR APPLICATION NUMBER: 60/293,499

PRIOR FILING DATE: 2001-05-25

NUMBER OF SEQ ID NOS: 3239

SOFTWARE: Patentin Ver. 2.0

SEQ ID NO 344

LENGTH: 249

TYPE: PRT

ORGANISM: Homo sapiens

US-09-880-748-344

Query Match 99.5%; Score 580; DB 11; Length 249;

Best Local Similarity 99.1%; Pred. No. 7.8e-47;

Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AFSSSLTDPAAVVALGQTVRTCCGDSLSRSYASWYQOKPQAPVLVIYGNRRPSGIP 60

Db 139 AFSSSLTDPAAVVALGQTVRTCCGDSLSRSYASWYQOKPQAPVLVIYGNRRPSGIP 198

Qy 61 DRFSSSSGNTASLTITGAQAEDEADYCCSSRDSSGNHWFPGGTELTVLG 111

Db 199 DRFSSSSGNTASLTITGAQAEDEADYCCSSRDSSGNHWFPGGTELTVLG 249

RESULT 23

US-09-880-748-345

Sequence 345, Application US/09880748

Publication No. US20030059937A1

GENERAL INFORMATION:

APPLICANT: Ruben et al.

TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys

FILE REFERENCE: PF523

CURRENT APPLICATION NUMBER: US/09/880,748

PRIOR FILING DATE: 2001-06-15

PRIOR APPLICATION NUMBER: 60/212,210

PRIOR FILING DATE: 2000-06-15

```

; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: Patent In Ver. 2.0
; SEQ ID NO 345
; LENGTH: 249
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-345

Query Match          99.5%; Score 580; DB 11; Length 249;
Best Local Similarity 99.1%; Pred. No. 7.8e-47;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Db      1 AFSSSETODPAVSVALGQTVRVTCGDSLSRSYASWYQKPGQAPVLVIYGNKNNRPSGIP 60
        |||
        139 AFSSSETODPAVSVALGQTVRVTCGDSLSRSYASWYQKPGQAPVLVIYGNKNNRPSGIP 198

QY      61 DRFSSGSSGNTASLTITGAQAEDEADYCCSRDSSGNHWFPGGTELTVLG 111
        |||
        199 DRFSSGSSGNTASLTITGAQAEDEADYCNRSRDSGNHWFPGGTELTVLG 249

RESULT 24
US-09-880-748-348
; Sequence 348, Application US/09880748
; Publication No. US20030059937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: Patent In Ver. 2.0
; SEQ ID NO 348
; LENGTH: 249
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-348

Query Match          99.5%; Score 580; DB 11; Length 249;
Best Local Similarity 99.1%; Pred. No. 7.8e-47;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Db      1 AFSSSETODPAVSVALGQTVRVTCGDSLSRSYASWYQKPGQAPVLVIYGNKNNRPSGIP 60
        |||
        139 AFSSSETODPAVSVALGQTVRVTCGDSLSRSYASWYQKPGQAPVLVIYGNKNNRPSGIP 198

QY      61 DRFSSGSSGNTASLTITGAQAEDEADYCCSRDSSGNHWFPGGTELTVLG 111
        |||
        199 DRFSSGSSGNTASLTITGAQAEDEADYCNRSRDSGNHWFPGGTELTVLG 249

RESULT 25
US-09-880-748-349
; Sequence 349, Application US/09880748
```

```

; Publication No. US20030059937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: Patent In Ver. 2.0
; SEQ ID NO 350
; LENGTH: 249
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-350

Query Match          99.5%; Score 580; DB 11; Length 249;
Best Local Similarity 99.1%; Pred. No. 7.8e-47;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Db      1 AFSSSETODPAVSVALGQTVRVTCGDSLSRSYASWYQKPGQAPVLVIYGNKNNRPSGIP 60
        |||
        139 AFSSSETODPAVSVALGQTVRVTCGDSLSRSYASWYQKPGQAPVLVIYGNKNNRPSGIP 198

QY      61 DRFSSGSSGNTASLTITGAQAEDEADYCCSRDSSGNHWFPGGTELTVLG 111
        |||
        199 DRFSSGSSGNTASLTITGAQAEDEADYCNRSRDSGNHWFPGGTELTVLG 249

RESULT 26
US-09-880-748-350
; Sequence 350, Application US/09880748
; Publication No. US20030059937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: Patent In Ver. 2.0
; SEQ ID NO 350
; LENGTH: 249
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-350

Query Match          99.5%; Score 580; DB 11; Length 249;
Best Local Similarity 99.1%; Pred. No. 7.8e-47;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Db      1 AFSSSETODPAVSVALGQTVRVTCGDSLSRSYASWYQKPGQAPVLVIYGNKNNRPSGIP 60
        |||
        139 AFSSSETODPAVSVALGQTVRVTCGDSLSRSYASWYQKPGQAPVLVIYGNKNNRPSGIP 198

QY      61 DRFSSGSSGNTASLTITGAQAEDEADYCCSRDSSGNHWFPGGTELTVLG 111
        |||
        199 DRFSSGSSGNTASLTITGAQAEDEADYCNRSRDSGNHWFPGGTELTVLG 249
```


;; PRIOR FILING DATE: 2001-03-21
;; PRIOR APPLICATION NUMBER: 60/293,499
;; PRIOR FILING DATE: 2001-05-25
;; NUMBER OF SEQ ID NOS: 3239
;; SOFTWARE: PatentIn Ver. 2.0
;; SEQ ID NO: 357
;; LENGTH: 249
;; TYPE: PRT
;; ORGANISM: Homo sapiens
US-09-880-748-357

Query Match 99.5%; Score 580; DB 11; Length 249;
Best Local Similarity 99.1%; Pred. No. 7,8e-47;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFSSSETDPAVSVALGQTVRVTCGDSLRSYASWYQKPGQAPVLVIYGNRPPSGIP 60
DB 139 AFSSSETDPAVSVALGQTVRVTCGDSLRSYASWYQKPGQAPVLVIYGNRPPSGIP 198
61 DRFGSSSSGNTASLTITGAQAEDEADYCCSRDSSGNHWFVGGGTETLVLG 111
199 DRFGSSSSGNTASLTITGAQAEDEADYCCNSRDSGNHWFVGGGTETLVLG 249

RESULT 31

US-09-880-748-358
;; Sequence 358, Application US/09880748
;; Publication No. US20030059937A1
;; GENERAL INFORMATION:
;; APPLICANT: Ruben et al.
;; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
;; FILE REFERENCE: PF523
;; CURRENT APPLICATION NUMBER: US/09/880,748
;; PRIOR FILING DATE: 2001-06-15
;; PRIOR APPLICATION NUMBER: 60/212,210
;; PRIOR FILING DATE: 2000-06-15
;; PRIOR APPLICATION NUMBER: 60/240,816
;; PRIOR FILING DATE: 2000-10-17
;; PRIOR APPLICATION NUMBER: 60/276,248
;; PRIOR FILING DATE: 2001-03-16
;; PRIOR APPLICATION NUMBER: 60/277,379
;; PRIOR FILING DATE: 2001-03-21
;; PRIOR APPLICATION NUMBER: 60/293,499
;; PRIOR FILING DATE: 2001-05-25
;; NUMBER OF SEQ ID NOS: 3239
;; SOFTWARE: PatentIn Ver. 2.0
;; SEQ ID NO: 358
;; LENGTH: 249
;; TYPE: PRT
;; ORGANISM: Homo sapiens
US-09-880-748-358

Query Match 99.5%; Score 580; DB 11; Length 249;
Best Local Similarity 99.1%; Pred. No. 7,8e-47;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFSSSETDPAVSVALGQTVRVTCGDSLRSYASWYQKPGQAPVLVIYGNRPPSGIP 60
DB 139 AFSSSETDPAVSVALGQTVRVTCGDSLRSYASWYQKPGQAPVLVIYGNRPPSGIP 198
61 DRFGSSSSGNTASLTITGAQAEDEADYCCSRDSSGNHWFVGGGTETLVLG 111
199 DRFGSSSSGNTASLTITGAQAEDEADYCCNSRDSGNHWFVGGGTETLVLG 249

RESULT 32

US-09-880-748-359
;; Sequence 359, Application US/09880748
;; Publication No. US20030059937A1
;; GENERAL INFORMATION:
;; APPLICANT: Ruben et al.
;; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
;; FILE REFERENCE: PF523

;; CURRENT APPLICATION NUMBER: US/09/880,748
;; CURRENT FILING DATE: 2001-06-15
;; PRIOR APPLICATION NUMBER: 60/212,210
;; PRIOR FILING DATE: 2000-06-15
;; PRIOR APPLICATION NUMBER: 60/240,816
;; PRIOR FILING DATE: 2000-10-17
;; PRIOR APPLICATION NUMBER: 60/276,248
;; PRIOR FILING DATE: 2001-03-16
;; PRIOR APPLICATION NUMBER: 60/277,379
;; PRIOR FILING DATE: 2001-03-21
;; PRIOR APPLICATION NUMBER: 60/293,499
;; PRIOR FILING DATE: 2001-05-25
;; NUMBER OF SEQ ID NOS: 3239
;; SOFTWARE: PatentIn Ver. 2.0
;; SEQ ID NO: 359
;; LENGTH: 249
;; TYPE: PRT
;; ORGANISM: Homo sapiens
US-09-880-748-359

Query Match 99.5%; Score 580; DB 11; Length 249;
Best Local Similarity 99.1%; Pred. No. 7,8e-47;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFSSSETDPAVSVALGQTVRVTCGDSLRSYASWYQKPGQAPVLVIYGNRPPSGIP 60
DB 139 AFSSSETDPAVSVALGQTVRVTCGDSLRSYASWYQKPGQAPVLVIYGNRPPSGIP 198
61 DRFGSSSSGNTASLTITGAQAEDEADYCCSRDSSGNHWFVGGGTETLVLG 111
199 DRFGSSSSGNTASLTITGAQAEDEADYCCNSRDSGNHWFVGGGTETLVLG 249

RESULT 33

US-09-880-748-360
;; Sequence 360, Application US/09880748
;; Publication No. US20030059937A1
;; GENERAL INFORMATION:
;; APPLICANT: Ruben et al.
;; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
;; FILE REFERENCE: PF523
;; CURRENT APPLICATION NUMBER: US/09/880,748
;; PRIOR FILING DATE: 2001-06-15
;; PRIOR APPLICATION NUMBER: 60/212,210
;; PRIOR FILING DATE: 2000-06-15
;; PRIOR APPLICATION NUMBER: 60/240,816
;; PRIOR FILING DATE: 2000-10-17
;; PRIOR APPLICATION NUMBER: 60/276,248
;; PRIOR FILING DATE: 2001-03-16
;; PRIOR APPLICATION NUMBER: 60/277,379
;; PRIOR FILING DATE: 2001-03-21
;; PRIOR APPLICATION NUMBER: 60/293,499
;; PRIOR FILING DATE: 2001-05-25
;; NUMBER OF SEQ ID NOS: 3239
;; SOFTWARE: PatentIn Ver. 2.0
;; SEQ ID NO: 360
;; LENGTH: 249
;; TYPE: PRT
;; ORGANISM: Homo sapiens
US-09-880-748-360

Query Match 99.5%; Score 580; DB 11; Length 249;
Best Local Similarity 99.1%; Pred. No. 7,8e-47;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFSSSETDPAVSVALGQTVRVTCGDSLRSYASWYQKPGQAPVLVIYGNRPPSGIP 60
DB 139 AFSSSETDPAVSVALGQTVRVTCGDSLRSYASWYQKPGQAPVLVIYGNRPPSGIP 198
61 DRFGSSSSGNTASLTITGAQAEDEADYCCSRDSSGNHWFVGGGTETLVLG 111
199 DRFGSSSSGNTASLTITGAQAEDEADYCCNSRDSGNHWFVGGGTETLVLG 249

RESULT 34
US-09-880-748-361
; Sequence 361, Application US/09880748
; Publication No. US20030059937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; CURRENT FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 361
; LENGTH: 249
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-361

Query Match 99.5%; Score 580; DB 11; Length 249;
Best Local Similarity 99.1%; Pred. No. 7,8e-47;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AFSSSLTQDPAVSVALGQTVRVTCGDSLSRSYASWYQKPGQAPVLVIYKNNRPSGIP 60
|||
Db 139 AFSSSLTQDPAVSVALGQTVRVTCGDSLSRSYASWYQKPGQAPVLVIYKNNRPSGIP 198
|||
Qy 61 DRFGSSSGNTASLTITGAQAEDEADYCCSRDSSGNNHWFGGTELTVLG 111
|||
Db 199 DRFGSSSGNTASLTITGAQAEDEADYCCSRDSSGNNHWFGGTELTVLG 249
|||

RESULT 35
US-09-880-748-363
; Sequence 363, Application US/09880748
; Publication No. US20030059937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; CURRENT FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 363
; LENGTH: 249
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-363

Query Match 99.5%; Score 580; DB 11; Length 249;
Best Local Similarity 99.1%; Pred. No. 7,8e-47;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AFSSSLTQDPAVSVALGQTVRVTCGDSLSRSYASWYQKPGQAPVLVIYKNNRPSGIP 60
|||
Db 139 AFSSSLTQDPAVSVALGQTVRVTCGDSLSRSYASWYQKPGQAPVLVIYKNNRPSGIP 198
|||
Qy 61 DRFGSSSGNTASLTITGAQAEDEADYCCSRDSSGNNHWFGGTELTVLG 111
|||
Db 199 DRFGSSSGNTASLTITGAQAEDEADYCCSRDSSGNNHWFGGTELTVLG 249
|||

RESULT 36
US-09-880-748-364
; Sequence 364, Application US/09880748
; Publication No. US20030059937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; CURRENT FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 364
; LENGTH: 249
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-364

Query Match 99.5%; Score 580; DB 11; Length 249;
Best Local Similarity 99.1%; Pred. No. 7,8e-47;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AFSSSLTQDPAVSVALGQTVRVTCGDSLSRSYASWYQKPGQAPVLVIYKNNRPSGIP 60
|||
Db 139 AFSSSLTQDPAVSVALGQTVRVTCGDSLSRSYASWYQKPGQAPVLVIYKNNRPSGIP 198
|||
Qy 61 DRFGSSSGNTASLTITGAQAEDEADYCCSRDSSGNNHWFGGTELTVLG 111
|||
Db 199 DRFGSSSGNTASLTITGAQAEDEADYCCSRDSSGNNHWFGGTELTVLG 249
|||

RESULT 37
US-09-880-748-365
; Sequence 365, Application US/09880748
; Publication No. US20030059937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; CURRENT FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0

SEQ ID NO 365
LENGTH: 249
TYPE: PRT
ORGANISM: Homo sapiens
US-09-880-748-365

Query Match 99.5%; Score 580; DB 11; Length 249;
Best Local Similarity 99.1%; Pred. No. 7.8e-47;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFSSSLTODPAVSVALGQTVRVTCGDSLSRSYASWYQKPGQAPVLYIGKNNRPSGIP 60
DB 139 AFSSSLTODPAVSVALGQTVRVTCGDSLSRSYASWYQKPGQAPVLYIGKNNRPSGIP 198
61 DRFGSSSGNTASLTITGAQAEDEADYCCSRDSSGNHWFVGGTETLVLG 111
199 DRFGSSSGNTASLTITGAQAEDEADYCCSRDSSGNHWFVGGTETLVLG 249

LT 38
US-09-880-748-367

Sequence 367, Application US/09880748
Publication No. US20030059937A1

GENERAL INFORMATION:
APPLICANT: Ruben et al.
TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
FILE REFERENCE: PF523
CURRENT APPLICATION NUMBER: US/09/880,748
CURRENT FILING DATE: 2001-06-15
PRIOR APPLICATION NUMBER: 60/212,210
PRIOR FILING DATE: 2000-06-15
PRIOR APPLICATION NUMBER: 60/240,816
PRIOR FILING DATE: 2000-10-17
PRIOR APPLICATION NUMBER: 60/276,248
PRIOR FILING DATE: 2001-03-16
PRIOR APPLICATION NUMBER: 60/277,379
PRIOR FILING DATE: 2001-03-21
PRIOR APPLICATION NUMBER: 60/293,499
PRIOR FILING DATE: 2001-05-25
NUMBER OF SEQ ID NOS: 3239
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 367
LENGTH: 249
TYPE: PRT
ORGANISM: Homo sapiens
US-09-880-748-367

Query Match 99.5%; Score 580; DB 11; Length 249;
Best Local Similarity 99.1%; Pred. No. 7.8e-47;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFSSSLTODPAVSVALGQTVRVTCGDSLSRSYASWYQKPGQAPVLYIGKNNRPSGIP 60
DB 139 AFSSSLTODPAVSVALGQTVRVTCGDSLSRSYASWYQKPGQAPVLYIGKNNRPSGIP 198
61 DRFGSSSGNTASLTITGAQAEDEADYCCSRDSSGNHWFVGGTETLVLG 111
199 DRFGSSSGNTASLTITGAQAEDEADYCCSRDSSGNHWFVGGTETLVLG 249

RESULT 39
US-09-880-748-368
Sequence 368, Application US/09880748
Publication No. US20030059937A1

GENERAL INFORMATION:
APPLICANT: Ruben et al.
TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
FILE REFERENCE: PF523
CURRENT APPLICATION NUMBER: US/09/880,748
CURRENT FILING DATE: 2001-06-15
PRIOR APPLICATION NUMBER: 60/212,210
PRIOR FILING DATE: 2000-06-15
PRIOR APPLICATION NUMBER: 60/240,816

PRIOR FILING DATE: 2000-10-17
PRIOR APPLICATION NUMBER: 60/276,248
PRIOR FILING DATE: 2001-03-16
PRIOR APPLICATION NUMBER: 60/277,379
PRIOR FILING DATE: 2001-03-21
PRIOR APPLICATION NUMBER: 60/293,499
PRIOR FILING DATE: 2001-05-25
NUMBER OF SEQ ID NOS: 3239
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 368
LENGTH: 249
TYPE: PRT
ORGANISM: Homo sapiens
US-09-880-748-368

Query Match 99.5%; Score 580; DB 11; Length 249;
Best Local Similarity 99.1%; Pred. No. 7.8e-47;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFSSSLTODPAVSVALGQTVRVTCGDSLSRSYASWYQKPGQAPVLYIGKNNRPSGIP 60
DB 139 AFSSSLTODPAVSVALGQTVRVTCGDSLSRSYASWYQKPGQAPVLYIGKNNRPSGIP 198
61 DRFGSSSGNTASLTITGAQAEDEADYCCSRDSSGNHWFVGGTETLVLG 111
199 DRFGSSSGNTASLTITGAQAEDEADYCCSRDSSGNHWFVGGTETLVLG 249

RESULT 40
US-09-880-748-369

Sequence 369, Application US/09880748
Publication No. US20030059937A1

GENERAL INFORMATION:
APPLICANT: Ruben et al.
TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
FILE REFERENCE: PF523
CURRENT APPLICATION NUMBER: US/09/880,748
CURRENT FILING DATE: 2001-06-15
PRIOR APPLICATION NUMBER: 60/212,210
PRIOR FILING DATE: 2000-06-15
PRIOR APPLICATION NUMBER: 60/240,816
PRIOR FILING DATE: 2000-10-17
PRIOR APPLICATION NUMBER: 60/276,248
PRIOR FILING DATE: 2001-03-16
PRIOR APPLICATION NUMBER: 60/277,379
PRIOR FILING DATE: 2001-03-21
PRIOR APPLICATION NUMBER: 60/293,499
PRIOR FILING DATE: 2001-05-25
NUMBER OF SEQ ID NOS: 3239
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 369
LENGTH: 249
TYPE: PRT
ORGANISM: Homo sapiens
US-09-880-748-369

Query Match 99.5%; Score 580; DB 11; Length 249;
Best Local Similarity 99.1%; Pred. No. 7.8e-47;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFSSSLTODPAVSVALGQTVRVTCGDSLSRSYASWYQKPGQAPVLYIGKNNRPSGIP 60
DB 139 AFSSSLTODPAVSVALGQTVRVTCGDSLSRSYASWYQKPGQAPVLYIGKNNRPSGIP 198
61 DRFGSSSGNTASLTITGAQAEDEADYCCSRDSSGNHWFVGGTETLVLG 111
199 DRFGSSSGNTASLTITGAQAEDEADYCCSRDSSGNHWFVGGTETLVLG 249

RESULT 41
US-09-880-748-370
Sequence 370, Application US/09880748
Publication No. US20030059937A1

```
;; GENERAL INFORMATION:
;; APPLICANT: Ruben et al.
;; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
;; FILE REFERENCE: PF523
;; CURRENT APPLICATION NUMBER: US/09/880,748
;; CURRENT FILING DATE: 2001-06-15
;; PRIOR APPLICATION NUMBER: 60/212,210
;; PRIOR FILING DATE: 2000-06-15
;; PRIOR APPLICATION NUMBER: 60/240,816
;; PRIOR FILING DATE: 2000-10-17
;; PRIOR APPLICATION NUMBER: 60/276,248
;; PRIOR FILING DATE: 2001-03-16
;; PRIOR APPLICATION NUMBER: 60/277,379
;; PRIOR FILING DATE: 2001-03-21
;; PRIOR APPLICATION NUMBER: 60/293,499
;; PRIOR FILING DATE: 2001-05-25
;; NUMBER OF SEQ ID NOS: 3239
;; SOFTWARE: PatentIn Ver. 2.0
;; SEQ ID NO 370
;; LENGTH: 249
;; TYPE: PRT
;; ORGANISM: Homo sapiens
US-09-880-748-370
```

```
Query Match          99.5%; Score 580; DB 11; Length 249;
Best Local Similarity 99.1%; Pred. No. 7.8e-47;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 1 AFSSSLTDDPAVSVAGQTVRTTCGDSLSRSYASWYQKPGQAPVLVIYGNRPPSGIP 60
Db 139 AFSSSLTDDPAVSVAGQTVRTTCGDSLSRSYASWYQKPGQAPVLVIYGNRPPSGIP 198
Qy 61 DRFSSSSSGNTASLTITGQAQAEADYYCNSRDSSGNHWFPGGTETLVLG 111
Db 199 DRFSSSSSGNTASLTITGQAQAEADYYCNSRDSSGNHWFPGGTETLVLG 249
```

```
RESULT 42
US-09-880-748-371
; Sequence 371, Application US/09880748
; Publication No. US20030059937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; CURRENT FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 371
; LENGTH: 249
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-371
```

```
Query Match          99.5%; Score 580; DB 11; Length 249;
Best Local Similarity 99.1%; Pred. No. 7.8e-47;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 1 AFSSSLTDDPAVSVAGQTVRTTCGDSLSRSYASWYQKPGQAPVLVIYGNRPPSGIP 60
Db 139 AFSSSLTDDPAVSVAGQTVRTTCGDSLSRSYASWYQKPGQAPVLVIYGNRPPSGIP 198
```

```
Qy 61 DRFSSSSSGNTASLTITGQAQAEADYYCNSRDSSGNHWFPGGTETLVLG 111
Db 199 DRFSSSSSGNTASLTITGQAQAEADYYCNSRDSSGNHWFPGGTETLVLG 249
```

```
RESULT 43
US-09-880-748-372
; Sequence 372, Application US/09880748
; Publication No. US20030059937A1
; GENERAL INFORMATION:
```

```
;; APPLICANT: Ruben et al.
;; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
;; FILE REFERENCE: PF523
;; CURRENT APPLICATION NUMBER: US/09/880,748
;; CURRENT FILING DATE: 2001-06-15
;; PRIOR APPLICATION NUMBER: 60/212,210
;; PRIOR FILING DATE: 2000-06-15
;; PRIOR APPLICATION NUMBER: 60/240,816
;; PRIOR FILING DATE: 2000-10-17
;; PRIOR APPLICATION NUMBER: 60/276,248
;; PRIOR FILING DATE: 2001-03-16
;; PRIOR APPLICATION NUMBER: 60/277,379
;; PRIOR FILING DATE: 2001-03-21
;; PRIOR APPLICATION NUMBER: 60/293,499
;; PRIOR FILING DATE: 2001-05-25
;; NUMBER OF SEQ ID NOS: 3239
;; SOFTWARE: PatentIn Ver. 2.0
;; SEQ ID NO 372
;; LENGTH: 249
;; TYPE: PRT
;; ORGANISM: Homo sapiens
US-09-880-748-372
```

```
Query Match          99.5%; Score 580; DB 11; Length 249;
Best Local Similarity 99.1%; Pred. No. 7.8e-47;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 1 AFSSSLTDDPAVSVAGQTVRTTCGDSLSRSYASWYQKPGQAPVLVIYGNRPPSGIP 60
Db 139 AFSSSLTDDPAVSVAGQTVRTTCGDSLSRSYASWYQKPGQAPVLVIYGNRPPSGIP 198
Qy 61 DRFSSSSSGNTASLTITGQAQAEADYYCNSRDSSGNHWFPGGTETLVLG 111
Db 199 DRFSSSSSGNTASLTITGQAQAEADYYCNSRDSSGNHWFPGGTETLVLG 249
```

```
RESULT 44
US-09-880-748-373
; Sequence 373, Application US/09880748
; Publication No. US20030059937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; CURRENT FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 373
; LENGTH: 249
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-373
```

```
Query Match          99.5%; Score 580; DB 11; Length 249;
Best Local Similarity 99.1%; Pred. No. 7.8e-47;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFSSSLTDDPAVSVALGQTVRTTCGDSLRSYASWYQOKPGQAPVLVIYGNRPPSGIP 60
    |||
DB 139 AFSSSLTDDPAVSVALGQTVRTTCGDSLRSYASWYQOKPGQAPVLVIYGNRPPSGIP 198
    |||

QY 61 DRFGSSSGNTASLTITGAQAEDEADYYCNSRDSSGNHWFPGGTETVLG 111
    |||
DB 199 DRFGSSSGNTASLTITGAQAEDEADYYCNSRDSSGNHWFPGGTETVLG 249
    |||

RESULT 45
US-09-880-748-375
; Sequence 375, Application US/09880748
; Publication No. US20030059937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 375
; LENGTH: 249
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-375

Query Match          99.5%; Score 580; DB 11; Length 249;
Best Local Similarity 99.1%; Pred. No. 7.8e-47;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFSSSLTDDPAVSVALGQTVRTTCGDSLRSYASWYQOKPGQAPVLVIYGNRPPSGIP 60
    |||
DB 139 AFSSSLTDDPAVSVALGQTVRTTCGDSLRSYASWYQOKPGQAPVLVIYGNRPPSGIP 198
    |||

QY 61 DRFGSSSGNTASLTITGAQAEDEADYYCNSRDSSGNHWFPGGTETVLG 111
    |||
DB 199 DRFGSSSGNTASLTITGAQAEDEADYYCNSRDSSGNHWFPGGTETVLG 249
    |||

RESULT 46
US-09-880-748-376
; Sequence 376, Application US/09880748
; Publication No. US20030059937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21

Query Match          99.5%; Score 580; DB 11; Length 249;
Best Local Similarity 99.1%; Pred. No. 7.8e-47;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFSSSLTDDPAVSVALGQTVRTTCGDSLRSYASWYQOKPGQAPVLVIYGNRPPSGIP 60
    |||
DB 139 AFSSSLTDDPAVSVALGQTVRTTCGDSLRSYASWYQOKPGQAPVLVIYGNRPPSGIP 198
    |||

QY 61 DRFGSSSGNTASLTITGAQAEDEADYYCNSRDSSGNHWFPGGTETVLG 111
    |||
DB 199 DRFGSSSGNTASLTITGAQAEDEADYYCNSRDSSGNHWFPGGTETVLG 249
    |||

RESULT 47
US-09-880-748-377
; Sequence 377, Application US/09880748
; Publication No. US20030059937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 377
; LENGTH: 249
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-377

Query Match          99.5%; Score 580; DB 11; Length 249;
Best Local Similarity 99.1%; Pred. No. 7.8e-47;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFSSSLTDDPAVSVALGQTVRTTCGDSLRSYASWYQOKPGQAPVLVIYGNRPPSGIP 60
    |||
DB 139 AFSSSLTDDPAVSVALGQTVRTTCGDSLRSYASWYQOKPGQAPVLVIYGNRPPSGIP 198
    |||

QY 61 DRFGSSSGNTASLTITGAQAEDEADYYCNSRDSSGNHWFPGGTETVLG 111
    |||
DB 199 DRFGSSSGNTASLTITGAQAEDEADYYCNSRDSSGNHWFPGGTETVLG 249
    |||

RESULT 48
US-09-880-748-379
; Sequence 379, Application US/09880748
; Publication No. US20030059937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
```

```

; CURRENT FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 379
; LENGTH: 249
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-379
```

```

Query Match          99.5%; Score 580; DB 11; Length 249;
Best Local Similarity 99.1%; Pred. No. 7,8e-47;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
```

```

QY 1 AFSSSLTDDPAVSVALGQTVRVTCGDSLSRSTYASWYQKPGQAPVLVIYGNRPPSGIP 60
    |||||
DB 139 AFSSSLTDDPAVSVALGQTVRVTCGDSLSRSTYASWYQKPGQAPVLVIYGNRPPSGIP 198
    |||||
QY 61 DRFSSSSGNTASLTITGQAEDADYYCNSRSDSGNHWFGGTELTVLG 111
    |||||
DB 199 DRFSSSSGNTASLTITGQAEDADYYCNSRSDSGNHWFGGTELTVLG 249
    |||||
```

```

RESULT 49
US-09-880-748-381
; Sequence 381, Application US/09880748
; Publication No. US20030059937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; CURRENT FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 381
; LENGTH: 249
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-381
```

```

Query Match          99.5%; Score 580; DB 11; Length 249;
Best Local Similarity 99.1%; Pred. No. 7,8e-47;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
```

```

QY 1 AFSSSLTDDPAVSVALGQTVRVTCGDSLSRSTYASWYQKPGQAPVLVIYGNRPPSGIP 60
    |||||
DB 139 AFSSSLTDDPAVSVALGQTVRVTCGDSLSRSTYASWYQKPGQAPVLVIYGNRPPSGIP 198
    |||||
QY 61 DRFSSSSGNTASLTITGQAEDADYYCNSRSDSGNHWFGGTELTVLG 111
    |||||
DB 199 DRFSSSSGNTASLTITGQAEDADYYCNSRSDSGNHWFGGTELTVLG 249
    |||||
```

```

RESULT 50
US-09-880-748-382
; Sequence 382, Application US/09880748
; Publication No. US20030059937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; CURRENT FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 382
; LENGTH: 249
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-382
```

```

Query Match          99.5%; Score 580; DB 11; Length 249;
Best Local Similarity 99.1%; Pred. No. 7,8e-47;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
```

```

QY 1 AFSSSLTDDPAVSVALGQTVRVTCGDSLSRSTYASWYQKPGQAPVLVIYGNRPPSGIP 60
    |||||
DB 139 AFSSSLTDDPAVSVALGQTVRVTCGDSLSRSTYASWYQKPGQAPVLVIYGNRPPSGIP 198
    |||||
QY 61 DRFSSSSGNTASLTITGQAEDADYYCNSRSDSGNHWFGGTELTVLG 111
    |||||
DB 199 DRFSSSSGNTASLTITGQAEDADYYCNSRSDSGNHWFGGTELTVLG 249
    |||||
```

Search completed: November 26, 2003, 13:49:52
Job time : 24.7179 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: November 26, 2003, 13:29:34 ; Search time 35.5769 Seconds
(without alignments)
495.227 Million cell updates/sec

Title: US-09-880-748-327_COPY_139_249

Perfect score: 583
Sequence: 1 AFSSRLTQDPAAVVALGQTV.....RDSGNHWVFGGTEITVLG 111

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1107863 seqs, 158726573 residues

1 number of hits satisfying chosen parameters: 1107863

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 45 summaries

Database :

A.Geneseq_13jun03.*
1: /SIDS1/gcgdata/geneeq/geneeqp-emb1/AA1980.DAT:*
2: /SIDS1/gcgdata/geneeq/geneeqp-emb1/AA1981.DAT:*
3: /SIDS1/gcgdata/geneeq/geneeqp-emb1/AA1982.DAT:*
4: /SIDS1/gcgdata/geneeq/geneeqp-emb1/AA1983.DAT:*
5: /SIDS1/gcgdata/geneeq/geneeqp-emb1/AA1984.DAT:*
6: /SIDS1/gcgdata/geneeq/geneeqp-emb1/AA1985.DAT:*
7: /SIDS1/gcgdata/geneeq/geneeqp-emb1/AA1986.DAT:*
8: /SIDS1/gcgdata/geneeq/geneeqp-emb1/AA1987.DAT:*
9: /SIDS1/gcgdata/geneeq/geneeqp-emb1/AA1988.DAT:*
10: /SIDS1/gcgdata/geneeq/geneeqp-emb1/AA1989.DAT:*
11: /SIDS1/gcgdata/geneeq/geneeqp-emb1/AA1990.DAT:*
12: /SIDS1/gcgdata/geneeq/geneeqp-emb1/AA1991.DAT:*
13: /SIDS1/gcgdata/geneeq/geneeqp-emb1/AA1992.DAT:*
14: /SIDS1/gcgdata/geneeq/geneeqp-emb1/AA1993.DAT:*
15: /SIDS1/gcgdata/geneeq/geneeqp-emb1/AA1994.DAT:*
16: /SIDS1/gcgdata/geneeq/geneeqp-emb1/AA1995.DAT:*
17: /SIDS1/gcgdata/geneeq/geneeqp-emb1/AA1996.DAT:*
18: /SIDS1/gcgdata/geneeq/geneeqp-emb1/AA1997.DAT:*
19: /SIDS1/gcgdata/geneeq/geneeqp-emb1/AA1998.DAT:*
20: /SIDS1/gcgdata/geneeq/geneeqp-emb1/AA1999.DAT:*
21: /SIDS1/gcgdata/geneeq/geneeqp-emb1/AA2000.DAT:*
22: /SIDS1/gcgdata/geneeq/geneeqp-emb1/AA2001.DAT:*
23: /SIDS1/gcgdata/geneeq/geneeqp-emb1/AA2002.DAT:*
24: /SIDS1/gcgdata/geneeq/geneeqp-emb1/AA2003.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	583	100.0	249	23	ABP44316
2	583	100.0	249	23	ABP44423
3	583	100.0	249	23	ABP44495
4	583	100.0	249	23	ABP44771
5	580	99.5	248	23	ABP44328
6	580	99.5	248	23	ABP44336
7	580	99.5	248	23	ABP44343
8	580	99.5	248	23	ABP44586
9	580	99.5	248	23	ABP44612

10	580	99.5	249	23	ABP43991	Human Blys binding
11	580	99.5	249	23	ABP44312	Human Blys binding
12	580	99.5	249	23	ABP44313	Human Blys binding
13	580	99.5	249	23	ABP44315	Human Blys binding
14	580	99.5	249	23	ABP44321	Human Blys binding
15	580	99.5	249	23	ABP44322	Human Blys binding
16	580	99.5	249	23	ABP44323	Human Blys binding
17	580	99.5	249	23	ABP44324	Human Blys binding
18	580	99.5	249	23	ABP44325	Human Blys binding
19	580	99.5	249	23	ABP44327	Human Blys binding
20	580	99.5	249	23	ABP44331	Human Blys binding
21	580	99.5	249	23	ABP44332	Human Blys binding
22	580	99.5	249	23	ABP44333	Human Blys binding
23	580	99.5	249	23	ABP44334	Human Blys binding
24	580	99.5	249	23	ABP44337	Human Blys binding
25	580	99.5	249	23	ABP44338	Human Blys binding
26	580	99.5	249	23	ABP44339	Human Blys binding
27	580	99.5	249	23	ABP44341	Human Blys binding
28	580	99.5	249	23	ABP44344	Human Blys binding
29	580	99.5	249	23	ABP44345	Human Blys binding
30	580	99.5	249	23	ABP44346	Human Blys binding
31	580	99.5	249	23	ABP44347	Human Blys binding
32	580	99.5	249	23	ABP44348	Human Blys binding
33	580	99.5	249	23	ABP44349	Human Blys binding
34	580	99.5	249	23	ABP44350	Human Blys binding
35	580	99.5	249	23	ABP44352	Human Blys binding
36	580	99.5	249	23	ABP44353	Human Blys binding
37	580	99.5	249	23	ABP44354	Human Blys binding
38	580	99.5	249	23	ABP44356	Human Blys binding
39	580	99.5	249	23	ABP44357	Human Blys binding
40	580	99.5	249	23	ABP44358	Human Blys binding
41	580	99.5	249	23	ABP44359	Human Blys binding
42	580	99.5	249	23	ABP44360	Human Blys binding
43	580	99.5	249	23	ABP44361	Human Blys binding
44	580	99.5	249	23	ABP44362	Human Blys binding
45	580	99.5	249	23	ABP44364	Human Blys binding

ALIGNMENTS

RESULT 1
ABP44316
ID ABP44316 strand: Protein; 249 AA.
XX
AC ABP44316;
XX
DT 19-AUG-2002 (first entry)
XX
DE Human Blys binding scfv SEQ ID 327.
XX
KW Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
KW tumour necrosis factor; B cell proliferation; B cell differentiation;
KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
KW common variable immunodeficiency; acquired immunodeficiency syndrome.
XX
XX Homo sapiens.
OS
PN WO200202641-A1.
XX
PD 10-JAN-2002.
XX
PF 15-JUN-2001; 2001WO-US19110.
XX
PR 16-JUN-2000; 2000US-212210P.
XX
PR 17-OCT-2000; 2000US-240816P.
XX
PR 16-MAR-2001; 2001US-276248P.
XX
PR 21-MAR-2001; 2001US-277379P.
XX
PR 25-MAY-2001; 2001US-293499P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.

PA (CAME-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
PI WPI; 2002-114799/15.
XX
PT Antibodies against B Lymphocyte Stimulating polypeptides, useful for
XX the diagnosis and treatment of cancers and immune disorders -
XX
XX Claim 1, Page 794-795, 3148pp; English.
XX
CC This invention describes novel antibodies that immunospecifically bind to
CC B Lymphocyte Stimulator (Blys) polypeptides. Blys is a member of the
CC tumour necrosis factor (TNF) super family and induces B cell
CC proliferation and differentiation. The antibodies of the invention have
CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
CC antirheumatic and antiAIDS activity and can be used in vaccines to
CC inhibit the expression and activity of Blys. The antibodies bind to Blys
CC and so may be used to detect and quantitate the presence of Blys in
CC biological samples and may be used in this way to diagnose disease
CC associated with aberrant expression of Blys. They may also be
CC administered to treat diseases associated with aberrant Blys expression
CC and activity such as cancer, immune, and autoimmune disorders and
CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
CC the antibodies and fragments of the antibodies described in the method
CC of the invention.
XX
SQ Sequence 249 AA;
XX
XX
Query Match 100.0%; Score 583; DB 23; Length 249;
Best Local Similarity 100.0%; Pred. No. 9.2e-37;
Matches 111; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1 AFSSSLTDPAVSVALGQTVRTVTCGDSLSRSYASWYQKPGQAPVLVIYGNRPSGIP 60
DB 139 AFSSSLTDPAVSVALGQTVRTVTCGDSLSRSYASWYQKPGQAPVLVIYGNRPSGIP 198
XX
QY 61 DRFGSSSGNTASLTITGAQAEDEADYCCSRDSSGNHWFGGTELTVLG 111
DB 199 DRFGSSSGNTASLTITGAQAEDEADYCCSRDSSGNHWFGGTELTVLG 249
XX
RESULT 2
ABP44423
ID ABP44423 standard; Protein; 249 AA.
XX
XX ABP44423;
XX
DT 19-AUG-2002 (first entry)
XX
XX Human Blys binding scFv SEQ ID 434.
XX
XX Blys: B lymphocyte stimulator; TNF superfamily; human; cytostatic;
XX tumour necrosis factor; B cell proliferation; B cell differentiation;
XX immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
XX antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
XX systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
XX common variable immunodeficiency; acquired immunodeficiency syndrome.
XX
OS Homo sapiens.
XX
XX WO200202641-A1.
XX
XX 10-JAN-2002.
XX
XX 15-JUN-2001; 2001WO-US19110.
XX
XX 16-JUN-2000; 2000US-212210P.
XX
XX 17-OCT-2000; 2000US-240816P.
XX
XX 16-MAR-2001; 2001US-276248P.
XX
XX 21-MAR-2001; 2001US-277379P.
XX

PR 25-MAY-2001; 2001US-293499P.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
PA (CAME-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX
XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
PI WPI; 2002-114799/15.
XX
PT Antibodies against B Lymphocyte Stimulating polypeptides, useful for
XX the diagnosis and treatment of cancers and immune disorders -
XX
XX Claim 1, Page 921-922, 3148pp; English.
XX
CC This invention describes novel antibodies that immunospecifically bind to
CC B Lymphocyte Stimulator (Blys) polypeptides. Blys is a member of the
CC tumour necrosis factor (TNF) super family and induces B cell
CC proliferation and differentiation. The antibodies of the invention have
CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
CC antirheumatic and antiAIDS activity and can be used in vaccines to
CC inhibit the expression and activity of Blys. The antibodies bind to Blys
CC and so may be used to detect and quantitate the presence of Blys in
CC biological samples and may be used in this way to diagnose disease
CC associated with aberrant expression of Blys. They may also be
CC administered to treat diseases associated with aberrant Blys expression
CC and activity such as cancer, immune, and autoimmune disorders and
CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
CC the antibodies and fragments of the antibodies described in the method
CC of the invention.
XX
SQ Sequence 249 AA;
XX
XX
Query Match 100.0%; Score 583; DB 23; Length 249;
Best Local Similarity 100.0%; Pred. No. 9.2e-37;
Matches 111; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1 AFSSSLTDPAVSVALGQTVRTVTCGDSLSRSYASWYQKPGQAPVLVIYGNRPSGIP 60
DB 139 AFSSSLTDPAVSVALGQTVRTVTCGDSLSRSYASWYQKPGQAPVLVIYGNRPSGIP 198
XX
QY 61 DRFGSSSGNTASLTITGAQAEDEADYCCSRDSSGNHWFGGTELTVLG 111
DB 199 DRFGSSSGNTASLTITGAQAEDEADYCCSRDSSGNHWFGGTELTVLG 249
XX
RESULT 3
ABP44495
ID ABP44495 standard; Protein; 249 AA.
XX
XX ABP44495;
XX
DT 19-AUG-2002 (first entry)
XX
XX Human Blys binding scFv SEQ ID 506.
XX
XX Blys: B lymphocyte stimulator; TNF superfamily; human; cytostatic;
XX tumour necrosis factor; B cell proliferation; B cell differentiation;
XX immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
XX antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
XX systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
XX common variable immunodeficiency; acquired immunodeficiency syndrome.
XX
OS Homo sapiens.
XX
XX WO200202641-A1.
XX
XX 10-JAN-2002.
XX
XX 15-JUN-2001; 2001WO-US19110.
XX
XX 16-JUN-2000; 2000US-212210P.
XX

PR 17-OCT-2000; 2000US-240816P.
 PR 16-MAR-2001; 2001US-276248P.
 PR 21-MAR-2001; 2001US-277379P.
 PR 25-MAY-2001; 2001US-293499P.
 PA (HUMA-) HUMAN GENOME SCI INC.
 PA (CAME-) CAMBRIDGE ANTIBODY TECHNOLOGY.
 PI Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
 PI WPI; 2002-114799/15.
 PT Antibodies against B Lymphocyte Stimulating polypeptides, useful for
 PT the diagnosis and treatment of cancers and immune disorders -
 PS Claim 1; Page 1006-1007; 3148pp; English.
 CC This invention describes novel antibodies that immunospecifically bind to
 CC B Lymphocyte Stimulator (BLyS) polypeptides. BLyS is a member of the
 CC tumour necrosis factor (TNF) super family and induces B cell
 CC proliferation and differentiation. The antibodies of the invention have
 CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
 CC antirheumatic and antiAIDS activity and can be used in vaccines to
 CC inhibit the expression and activity of BLyS. The antibodies bind to BLyS
 CC and so may be used to detect and quantitate the presence of BLyS in
 CC biological samples and may be used in this way to diagnose disease
 CC associated with aberrant expression of BLyS. They may also be
 CC administered to treat diseases associated with aberrant BLyS expression
 CC and activity such as cancer, immune, and autoimmune disorders and
 CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
 CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
 CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
 CC the antibodies and fragments of the antibodies described in the method
 CC of the invention.
 XX Sequence 249 AA;
 SQ

Query Match 100.0%; Score 583; DB 23; Length 249;
 Best Local Similarity 100.0%; Pred. No. 9.2e-37;
 Matches 111; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFSSSLTDDPAVSVALGQTVRVTCQGSLSRSYASWYQKPGQAPVLVIYGNRPPSGIP 60
 DB 139 AFSSSLTDDPAVSVALGQTVRVTCQGSLSRSYASWYQKPGQAPVLVIYGNRPPSGIP 198
 QY 61 DRFSGSSGNTASLTITGAQAEDEADYCCSRDSSGNHMFVCGGTETLVLG 111
 DB 199 DRFSGSSGNTASLTITGAQAEDEADYCCSRDSSGNHMFVCGGTETLVLG 249

RESULT 4
 ABP44771
 ID ABP44771 standard; Protein; 249 AA.
 AC ABP44771;
 XX
 AC
 DT 19-AUG-2002 (first entry)
 XX
 DE Human BLyS binding scFv SEQ ID 782.
 XX
 KW BLyS; B Lymphocyte stimulator; TNF superfamily; human; cytostatic;
 KW tumour necrosis factor; B cell proliferation; B cell differentiation;
 KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
 KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
 KW systemic lupus erythematosus; Rheumatoid arthritis; CVID; AIDS;
 KW common variable immunodeficiency; acquired immunodeficiency syndrome.
 XX
 OS Homo sapiens.
 XX
 PN WO200202641-A1.
 XX 10-JAN-2002.
 XX

PF 15-JUN-2001; 2001WO-US19110.
 XX
 PR 16-JUN-2000; 2000US-212210P.
 PR 17-OCT-2000; 2000US-240816P.
 PR 16-MAR-2001; 2001US-276248P.
 PR 21-MAR-2001; 2001US-277379P.
 PR 25-MAY-2001; 2001US-293499P.
 PA (HUMA-) HUMAN GENOME SCI INC.
 PA (CAME-) CAMBRIDGE ANTIBODY TECHNOLOGY.
 PI Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
 PI WPI; 2002-114799/15.
 PT Antibodies against B Lymphocyte Stimulating polypeptides, useful for
 PT the diagnosis and treatment of cancers and immune disorders -
 PS Claim 1; Page 1334-1335; 3148pp; English.
 CC This invention describes novel antibodies that immunospecifically bind to
 CC B Lymphocyte Stimulator (BLyS) polypeptides. BLyS is a member of the
 CC tumour necrosis factor (TNF) super family and induces B cell
 CC proliferation and differentiation. The antibodies of the invention have
 CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
 CC antirheumatic and antiAIDS activity and can be used in vaccines to
 CC inhibit the expression and activity of BLyS. The antibodies bind to BLyS
 CC and so may be used to detect and quantitate the presence of BLyS in
 CC biological samples and may be used in this way to diagnose disease
 CC associated with aberrant expression of BLyS. They may also be
 CC administered to treat diseases associated with aberrant BLyS expression
 CC and activity such as cancer, immune, and autoimmune disorders and
 CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
 CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
 CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
 CC the antibodies and fragments of the antibodies described in the method
 CC of the invention.
 XX Sequence 249 AA;
 SQ

Query Match 100.0%; Score 583; DB 23; Length 249;
 Best Local Similarity 100.0%; Pred. No. 9.2e-37;
 Matches 111; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFSSSLTDDPAVSVALGQTVRVTCQGSLSRSYASWYQKPGQAPVLVIYGNRPPSGIP 60
 DB 139 AFSSSLTDDPAVSVALGQTVRVTCQGSLSRSYASWYQKPGQAPVLVIYGNRPPSGIP 198
 QY 61 DRFSGSSGNTASLTITGAQAEDEADYCCSRDSSGNHMFVCGGTETLVLG 111
 DB 199 DRFSGSSGNTASLTITGAQAEDEADYCCSRDSSGNHMFVCGGTETLVLG 249

RESULT 5
 ABP44328
 ID ABP44328 standard; Protein; 248 AA.
 AC ABP44328;
 XX
 AC
 DT 19-AUG-2002 (first entry)
 XX
 DE Human BLyS binding scFv SEQ ID 339.
 XX
 KW BLyS; B Lymphocyte stimulator; TNF superfamily; human; cytostatic;
 KW tumour necrosis factor; B cell proliferation; B cell differentiation;
 KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
 KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
 KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
 KW common variable immunodeficiency; acquired immunodeficiency syndrome.
 XX
 OS Homo sapiens.
 XX
 PN WO200202641-A1.
 XX

KM	systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
XX	common variable immunodeficiency; acquired immunodeficiency syndrome
OS	Homo sapiens.
XX	
FN	WO200202641-A1.
XX	
PD	10-JAN-2002.
XX	
PF	15-JUN-2001; 2001WO-US19110.
XX	
PR	16-JUN-2000; 2000US-212210P.
PR	17-OCT-2000; 2000US-240816P.
PR	16-MAR-2001; 2001US-276248P.
PR	21-MAR-2001; 2001US-277379P.
PR	25-MAY-2001; 2001US-293499P.
XX	
PA	(HUMA-) HUMAN GENOME SCI INC.
PA	(CAME-) CAMERIDGE ANTIBODY TECHNOLOGY.

Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D,
DR WPI; 2002-114799/15.

PT Antihodies against B Lymphocyte Stimulating polypeptides, useful for the diagnosis and treatment of cancers and immune disorders -

PS Claim 1; Page 826-827; 3148pp; English.

This invention describes novel antibodies that immunospecifically bind to B Lymphocyte Stimulator (BlyS) polypeptides. BlyS is a member of the tumour necrosis factor (TNF) super family and induces B cell proliferation and differentiation. The antibodies of the invention have cytostatic, immunosuppressive, immunostimulant, immunomodulatory, antirheumatic and antiAIDS activity and can be used in vaccines to inhibit the expression and activity of BlyS. The antibodies bind to BlyS and so may be used to detect and quantitate the presence of BlyS in biological samples and may be used in this way to diagnose disease associated with aberrant expression of BlyS. They may also be administered to treat diseases associated with aberrant BlyS expression and activity such as cancer, immune, and autoimmune disorders and diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis, immunodeficiency (e.g. common variable immunodeficiency (CVID) and acquired immunodeficiency syndrome (AIDS)). ABp43390-ABp47228 represent the antibodies and fragments of the antibodies described in the method of the invention.

Sequence 248 AA;

every Match	99.5%; Score 580; DB 23; Length 248;
-------------	--------------------------------------

QY 1 AFSESLTOPPAVSVALGQIVRTVCQGDLSRYSYASWYQKQKGA.PVLYTGKNNRPGIP 60

Db 138 AFSESLTOPPAVSVALGQIVRTVCQGDLSRYSYASWYQKQKGA.PVLYTGKNNRPGIP 197

QY 61 DRFGSSSGNTASLTITGAEDEDADYYCSRDSSGNNHWFGGTELTVLG 111

Db 198 DRFGSSSGNTASLTITGAEDEDADYYCNSRDSSGNNHWFGGTELTVLG 248

RESULT 8
ABP44586
ID ABP44586 standard; Protein; 248 AA

KW tumournecrosis factor; B cell proliferation; B cell differentiation;
 KW immunosuppressive; immunostimulant; immunomodulatory; antineumatic;
 KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
 KW systemic lupus erythematosus; Rheumatoid arthritis; CVID; AIDS;
 KW common variable immunodeficiency; acquired immunodeficiency syndrome.
 XX
 XX Homo sapiens.
 OS
 XX
 PN WO200202641-A1.
 XX
 PD 10-JAN-2002.
 XX
 XX
 PF 15-JUN-2001; 2001WO-US19110.
 XX
 PR 16-JUN-2000; 2000US-2122210P.
 PR 17-OCT-2000; 2000US-240816P.
 PR 16-MAR-2001; 2001US-276248P.
 PR 21-MAR-2001; 2001US-277379P.
 PR 25-MAY-2001; 2001US-293499P.
 XX
 PA (HUMA-) HUMAN GENOME SCI INC.
 PA (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.

PI Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D,
XX
DR WPI; 2002-114799/15.

PT Antibodies against B Lymphocyte Stimulating polypeptides, useful for the diagnosis and treatment of cancers and immune disorders -

PS Claim 1; Page 1114-1115; 3148pp; English

This invention describes novel antibodies that immunospecifically bind to B Lymphocyte Stimulator (Blys) polypeptides. Blys is a member of the tumour necrosis factor (TNF) super family and induces B cell proliferation and differentiation. The antibodies of the invention have cytostatic, immunosuppressive, immunostimulant, immunomodulatory, antitumouric and antiAIDS activity and can be used in vaccines to inhibit the expression and activity of Blys. The antibodies bind to Blys and so may be used to detect and quantitate the presence of Blys in biological samples and may be used in this way to diagnose disease associated with aberrant expression of Blys. They may also be administered to treat diseases associated with aberrant Blys expression and activity such as cancer, immune, and autoimmune disorders and diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis, immunodeficiency (e.g. common variable immunodeficiency (CVID) and acquired immunodeficiency syndrome (AIDS)). ABP43390-ABP47728 represent the antibodies and fragments of the antibodies described in the method of the invention.

SQ Sequence 248 AA;

Query Match 99.5%; Score 580; DB 23; Length 248;

QY 1 AFSESLTOPPAVALGOTVRATCGGDSLRSTYASWQKRGQA.PVLVIIGKNNRPGGIP 60

Db 138 AFSESLTOPPAVALGOTVRATCGGDSLRSTYASWQKRGQA.PVLVIIGKNNRPGGIP 197

QY 61 DRSSGSSCNTASLTITGAQAEDEDVYCSSRDSGGHWWFGGTELTVLVG 111

Db 198 DRSSGSSCNTASLTITGAQAEDEDVYCSNRDSGGHWWFGGTELTVLVG 248

RESULT 9
ABP44612
ID ABP44612 standard; Protein; 248 AA
...

DE Human Blys binding scFv SEQ ID 623.
XX Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
XX tumour necrosis factor; B cell proliferation; B cell differentiation;
XX immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
XX antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
XX systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
XX common variable immunodeficiency; acquired immunodeficiency syndrome.
XX Homo sapiens.
XX WO200202641-A1.
XX
XX 10-JAN-2002.
XX
XX 15-JUN-2001; 2001WO-US19110.
XX
XX 16-JUN-2000; 2000US-212210P.
XX 17-OCT-2000; 2000US-240816P.
XX 16-MAR-2001; 2001US-276248P.
XX 21-MAR-2001; 2001US-277379P.
XX 25-MAY-2001; 2001US-293499P.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX
XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
XX WPI; 2002-114799/15.
XX
XX Antibodies against B lymphocyte stimulating polypeptides, useful for
XX the diagnosis and treatment of cancers and immune disorders -
XX
XX Claim 1; Page 1145-1146; 3148pp; English.
XX
XX This invention describes novel antibodies that immunospecifically bind to
XX B lymphocyte stimulator (Blys) polypeptides. Blys is a member of the
XX tumour necrosis factor (TNF) super family and induces B cell
XX proliferation and differentiation. The antibodies of the invention have
XX cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
XX antirheumatic and antiAIDS activity and can be used in vaccines to
XX inhibit the expression and activity of Blys. The antibodies bind to Blys
XX and so may be used to detect and quantitate the presence of Blys in
XX biological samples and may be used in this way to diagnose disease
XX associated with aberrant expression of Blys. They may also be
XX administered to treat diseases associated with aberrant Blys expression
XX and activity such as cancer, immune, and autoimmune disorders and
XX diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
XX immunodeficiency (e.g. common variable immunodeficiency (CVID) and
XX acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
XX the antibodies and fragments of the antibodies described in the method
XX of the invention.
XX
XX Sequence 248 AA;
XX
XX Query Match 99.5%; Score 580; DB 23; Length 248;
XX Best Local Similarity 99.1%; Pred. No. 1.5e-36;
XX Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1 AFSSSELTODPAVSVAGQTVRTVTCGDSLRSYASWYQOKPQAPVLVIYGNRPPSGIP 60
DB 138 AFSSSELTODPAVSVAGQTVRTVTCGDSLRSYASWYQOKPQAPVLVIYGNRPPSGIP 197
QY 61 DRFGSSSSGNTASLTITGAQAEDEADYYCNSRDSGNNHWFPGGTELTVLG 111
DB 198 DRFGSSSSGNTASLTITGAQAEDEADYYCNSRDSGNNHWFPGGTELTVLG 248
RESULT 10
ABP43991
XX ABP43991 standard; Protein; 249 AA.
AC ABP43991;

XX 19-AUG-2002 (first entry)
DT Human Blys binding scFv SEQ ID 2.
XX
XX Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
XX tumour necrosis factor; B cell proliferation; B cell differentiation;
XX immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
XX antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
XX systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
XX common variable immunodeficiency; acquired immunodeficiency syndrome.
XX Homo sapiens.
XX WO200202641-A1.
XX
XX 10-JAN-2002.
XX
XX 15-JUN-2001; 2001WO-US19110.
XX
XX 16-JUN-2000; 2000US-212210P.
XX 17-OCT-2000; 2000US-240816P.
XX 16-MAR-2001; 2001US-276248P.
XX 21-MAR-2001; 2001US-277379P.
XX 25-MAY-2001; 2001US-293499P.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX
XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
XX WPI; 2002-114799/15.
XX
XX Antibodies against B lymphocyte stimulating polypeptides, useful for
XX the diagnosis and treatment of cancers and immune disorders -
XX
XX Claim 1; Page 408-409; 3148pp; English.
XX
XX This invention describes novel antibodies that immunospecifically bind to
XX B lymphocyte stimulator (Blys) polypeptides. Blys is a member of the
XX tumour necrosis factor (TNF) super family and induces B cell
XX proliferation and differentiation. The antibodies of the invention have
XX cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
XX antirheumatic and antiAIDS activity and can be used in vaccines to
XX inhibit the expression and activity of Blys. The antibodies bind to Blys
XX and so may be used to detect and quantitate the presence of Blys in
XX biological samples and may be used in this way to diagnose disease
XX associated with aberrant expression of Blys. They may also be
XX administered to treat diseases associated with aberrant Blys expression
XX and activity such as cancer, immune, and autoimmune disorders and
XX diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
XX immunodeficiency (e.g. common variable immunodeficiency (CVID) and
XX acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
XX the antibodies and fragments of the antibodies described in the method
XX of the invention.
XX
XX Sequence 249 AA;
XX
XX Query Match 99.5%; Score 580; DB 23; Length 249;
XX Best Local Similarity 99.1%; Pred. No. 1.6e-36;
XX Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1 AFSSSELTODPAVSVAGQTVRTVTCGDSLRSYASWYQOKPQAPVLVIYGNRPPSGIP 60
DB 139 AFSSSELTODPAVSVAGQTVRTVTCGDSLRSYASWYQOKPQAPVLVIYGNRPPSGIP 198
QY 61 DRFGSSSSGNTASLTITGAQAEDEADYYCNSRDSGNNHWFPGGTELTVLG 111
DB 199 DRFGSSSSGNTASLTITGAQAEDEADYYCNSRDSGNNHWFPGGTELTVLG 249
RESULT 11
ABP44312

ID ABP44312 standard; Protein; 249 AA.
XX
AC ABP44312;
XX
DT 19-AUG-2002 (first entry)
XX
DE Human Blys binding scFv SEQ ID 323.
XX
KW Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
KW tumor necrosis factor; B cell proliferation; B cell differentiation;
KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
KW common variable immunodeficiency; acquired immunodeficiency syndrome.
OS Homo sapiens.
XX
XX WO200202641-A1.
XX
XX 10-JAN-2002.
XX
XX 15-JUN-2001; 2001WO-US19110.
XX
XX 16-JUN-2000; 2000US-212210P.
XX 17-OCT-2000; 2000US-240816P.
XX 16-MAR-2001; 2001US-276248P.
XX 21-MAR-2001; 2001US-277379P.
XX 25-MAY-2001; 2001US-293499P.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX
XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
XX WPI; 2002-114799/15.
XX
XX Antibodies against B lymphocyte stimulating polypeptides, useful for
XX the diagnosis and treatment of cancers and immune disorders -
XX
XX
XX Claim 1; Page 789-790; 3148pp; English.
XX
XX This invention describes novel antibodies that immunospecifically bind to
XX B lymphocyte stimulator (Blys) polypeptides. Blys is a member of the
XX tumor necrosis factor (TNF) super family and induces B cell
XX proliferation and differentiation. The antibodies of the invention have
XX cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
XX antirheumatic and antiAIDS activity and can be used in vaccines to
XX inhibit the expression and activity of Blys. The antibodies bind to Blys
XX and so may be used to detect and quantitate the presence of Blys in
XX biological samples and may be used in this way to diagnose disease
XX associated with aberrant expression of Blys. They may also be
XX administered to treat diseases associated with aberrant Blys expression
XX and activity such as cancer, immune, and autoimmune disorders and
XX diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
XX immunodeficiency (e.g. common variable immunodeficiency (CVID) and
XX acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
XX the antibodies and fragments of the antibodies described in the method
XX of the invention.
XX
XX Sequence 249 AA:
SQ
Query Match 99.5%; Score 580; DB 23; Length 249;
Best Local Similarity 99.1%; Pred. No. 1.6e-36;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1 AFSSSLTDDPAVVALGQTVRTTCGDSLRSYASWYQKPGQAPLVLYGKNNPSPGIP 60
DB 139 AFSSSLTDDPAVVALGQTVRTTCGDSLRSYASWYQKPGQAPLVLYGKNNPSPGIP 198
QY 61 DRFGSSSGNTASLTITGAQAEDEADYYCSSRDSGNGHWFPGGTELTVLG 111
DB 199 DRFGSSSGNTASLTITGAQAEDEADYYCSSRDSGNGHWFPGGTELTVLG 249

RESULT 12
ID ABP44313
XX ABP44313 standard; Protein; 249 AA.
XX
AC ABP44313;
XX
DT 19-AUG-2002 (first entry)
XX
DE Human Blys binding scFv SEQ ID 324.
XX
KW Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
KW tumor necrosis factor; B cell proliferation; B cell differentiation;
KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
KW common variable immunodeficiency; acquired immunodeficiency syndrome.
OS Homo sapiens.
XX
XX WO200202641-A1.
XX
XX 10-JAN-2002.
XX
XX 15-JUN-2001; 2001WO-US19110.
XX
XX 16-JUN-2000; 2000US-212210P.
XX 17-OCT-2000; 2000US-240816P.
XX 16-MAR-2001; 2001US-276248P.
XX 21-MAR-2001; 2001US-277379P.
XX 25-MAY-2001; 2001US-293499P.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX
XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
XX WPI; 2002-114799/15.
XX
XX Antibodies against B lymphocyte stimulating polypeptides, useful for
XX the diagnosis and treatment of cancers and immune disorders -
XX
XX
XX Claim 1; Page 790-791; 3148pp; English.
XX
XX This invention describes novel antibodies that immunospecifically bind to
XX B lymphocyte stimulator (Blys) polypeptides. Blys is a member of the
XX tumor necrosis factor (TNF) super family and induces B cell
XX proliferation and differentiation. The antibodies of the invention have
XX cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
XX antirheumatic and antiAIDS activity and can be used in vaccines to
XX inhibit the expression and activity of Blys. The antibodies bind to Blys
XX and so may be used to detect and quantitate the presence of Blys in
XX biological samples and may be used in this way to diagnose disease
XX associated with aberrant expression of Blys. They may also be
XX administered to treat diseases associated with aberrant Blys expression
XX and activity such as cancer, immune, and autoimmune disorders and
XX diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
XX immunodeficiency (e.g. common variable immunodeficiency (CVID) and
XX acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
XX the antibodies and fragments of the antibodies described in the method
XX of the invention.
XX
XX Sequence 249 AA:
SQ
Query Match 99.5%; Score 580; DB 23; Length 249;
Best Local Similarity 99.1%; Pred. No. 1.6e-36;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1 AFSSSLTDDPAVVALGQTVRTTCGDSLRSYASWYQKPGQAPLVLYGKNNPSPGIP 60
DB 139 AFSSSLTDDPAVVALGQTVRTTCGDSLRSYASWYQKPGQAPLVLYGKNNPSPGIP 198
QY 61 DRFGSSSGNTASLTITGAQAEDEADYYCSSRDSGNGHWFPGGTELTVLG 111

Db 199 DRFGSSSGNTASLTITGAQAEADYYCNSRDSGNHWFGGTELTVLG 249

RESULT 13
ID ABP44315 standard; Protein; 249 AA.
XX
XX ABP44315;
AC
XX
XX
DT 19-AUG-2002 (first entry)
XX
XX
DE Human Blys binding scFv SEQ ID 326.

XX Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
KW tumour necrosis factor; B cell proliferation; B cell differentiation;
KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
KM common variable immunodeficiency; acquired immunodeficiency syndrome.

OS Homo sapiens.
XX
XX WO200202641-A1.
XX
XX 10-JAN-2002.
XX
XX 15-JUN-2001; 2001WO-US19110.
XX
XX 16-JUN-2000; 2000US-212210P.
XX 17-OCT-2000; 2000US-240816P.
XX 16-MAR-2001; 2001US-276248P.
XX 21-MAR-2001; 2001US-277379P.
XX 25-MAY-2001; 2001US-293499P.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.

PI Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;

DR WPI; 2002-114799/15.

PT Antibodies against B lymphocyte stimulating polypeptides, useful for
PT the diagnosis and treatment of cancers and immune disorders -

PS Claim 1; Page 793-794; 3148bp; English.

XX This invention describes novel antibodies that immunospecifically bind to
XX B lymphocyte stimulator (Blys) polypeptides. Blys is a member of the
XX tumour necrosis factor (TNF) super family and induces B cell
XX proliferation and differentiation. The antibodies of the invention have
XX cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
XX antirheumatic and antiAIDS activity and can be used in vaccines to
XX inhibit the expression and activity of Blys. The antibodies bind to Blys
XX and so may be used to detect and quantitate the presence of Blys in
XX biological samples and may be used in this way to diagnose disease
XX associated with aberrant expression of Blys. They may also be
XX administered to treat diseases associated with aberrant Blys expression
XX and actively such as cancer, immune, and autoimmune disorders and
XX diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
XX immunodeficiency (e.g. common variable immunodeficiency (CVID) and
XX acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
XX the antibodies and fragments of the antibodies described in the method
XX of the invention.

XX Sequence 249 AA;

Query Match 99.5%; Score 580; DB 23; Length 249;
Best Local Similarity 99.1%; Pred. No. 1.6e-36;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFSSSETODPAVSVALGQTRVTCOGDSLSRSYASWYQKPEQAPLVLYGKNRPSGIP 60

Db 139 AFSSSETODPAVSVALGQTRVTCOGDSLSRSYASWYQKPEQAPLVLYGKNRPSGIP 198

QY 61 DRFGSSSGNTASLTITGAQAEADYYCNSRDSGNHWFGGTELTVLG 111
199 DRFGSSSGNTASLTITGAQAEADYYCNSRDSGNHWFGGTELTVLG 249

RESULT 14
ID ABP44321 standard; Protein; 249 AA.
XX
XX ABP44321;
AC
XX
XX
DT 19-AUG-2002 (first entry)
XX
XX
DE Human Blys binding scFv SEQ ID 332.

XX Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
KW tumour necrosis factor; B cell proliferation; B cell differentiation;
KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
KM common variable immunodeficiency; acquired immunodeficiency syndrome.

OS Homo sapiens.
XX
XX WO200202641-A1.
XX
XX 10-JAN-2002.
XX
XX 15-JUN-2001; 2001WO-US19110.
XX
XX 16-JUN-2000; 2000US-212210P.
XX 17-OCT-2000; 2000US-240816P.
XX 16-MAR-2001; 2001US-276248P.
XX 21-MAR-2001; 2001US-277379P.
XX 25-MAY-2001; 2001US-293499P.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.

PI Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;

XX WPI; 2002-114799/15.

DR WPI; 2002-114799/15.

PT Antibodies against B lymphocyte stimulating polypeptides, useful for
PT the diagnosis and treatment of cancers and immune disorders -

PS Claim 1; Page 800-801; 3148bp; English.

XX This invention describes novel antibodies that immunospecifically bind to
XX B lymphocyte stimulator (Blys) polypeptides. Blys is a member of the
XX tumour necrosis factor (TNF) super family and induces B cell
XX proliferation and differentiation. The antibodies of the invention have
XX cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
XX antirheumatic and antiAIDS activity and can be used in vaccines to
XX inhibit the expression and activity of Blys. The antibodies bind to Blys
XX and so may be used to detect and quantitate the presence of Blys in
XX biological samples and may be used in this way to diagnose disease
XX associated with aberrant expression of Blys. They may also be
XX administered to treat diseases associated with aberrant Blys expression
XX and actively such as cancer, immune, and autoimmune disorders and
XX diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
XX immunodeficiency (e.g. common variable immunodeficiency (CVID) and
XX acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
XX the antibodies and fragments of the antibodies described in the method
XX of the invention.

XX Sequence 249 AA;

Query Match 99.5%; Score 580; DB 23; Length 249;
Best Local Similarity 99.1%; Pred. No. 1.6e-36;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFSSSLTDDPAVSVALGQTVRVTCGSDLSRSYSASWYQQRKGAQPVLYVYGNRRPSCIP 60
Db 139 AFSSSLTDDPAVSVALGQTVRVTCGSDLSRSYSASWYQQRKGAQPVLYVYGNRRPSCIP 198
QY 61 DRFSGSSSGNTASLTITGAQAEADADYCCSRDSSGNNHWFGGTELTVLG 111
Db 199 DRFSGSSSGNTASLTITGAQAEADADYCCSRDSSGNNHWFGGTELTVLG 249

RESULT 15
ABP44322
ID ABP44322 standard; Protein; 249 AA.
XX
XX ABP44322;
XX
XX 19-AUG-2002 (first entry)
XX
XX Human Blys binding scFv SEQ ID 333.
XX
XX Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
XX tumour necrosis factor; B cell proliferation; B cell differentiation;
XX immunosuppressive; immunostimulant; immunomodulatory; antineumatic;
XX antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
XX systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
XX common variable immunodeficiency; acquired immunodeficiency syndrome.
XX
XX Homo sapiens.
XX
XX WO200202641-A1.
XX
XX 10-JAN-2002.
XX
XX 15-JUN-2001; 2001WO-US19110.
XX
XX 16-JUN-2000; 2000US-212210P.
XX 17-OCT-2000; 2000US-240816P.
XX 16-MAR-2001; 2001US-276248P.
XX 21-MAR-2001; 2001US-277379P.
XX 25-MAY-2001; 2001US-293499P.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX
XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
XX WPI; 2002-114799/15.
XX
XX Antibodies against B lymphocyte stimulating polypeptides, useful for
XX the diagnosis and treatment of cancers and immune disorders -
XX
XX Claim 1; Page 801-802; 3148pp; English.
XX
XX This invention describes novel antibodies that immunospecifically bind to
XX B lymphocyte stimulator (Blys) polypeptides. Blys is a member of the
XX tumour necrosis factor (TNF) super family and induces B cell
XX proliferation and differentiation. The antibodies of the invention have
XX cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
XX antineumatic and antiAIDS activity and can be used in vaccines to
XX inhibit the expression and activity of Blys. The antibodies bind to Blys
XX and so may be used to detect and quantitate the presence of Blys in
XX biological samples and may be used in this way to diagnose disease
XX associated with aberrant expression of Blys. They may also be
XX administered to treat diseases associated with aberrant Blys expression
XX and activity such as cancer, immune, and autoimmune disorders and
XX diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
XX immunodeficiency (e.g. common variable immunodeficiency (CVID) and
XX acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
XX the antibodies and fragments of the antibodies described in the method
XX of the invention.
XX
XX Sequence 249 AA;
XX

Query Match 99.5%; Score 580; DB 23; Length 249;
Best Local Similarity 99.1%; Pred. No. 1.6e-36;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1 AFSSSLTDDPAVSVALGQTVRVTCGSDLSRSYSASWYQQRKGAQPVLYVYGNRRPSCIP 60
Db 139 AFSSSLTDDPAVSVALGQTVRVTCGSDLSRSYSASWYQQRKGAQPVLYVYGNRRPSCIP 198
QY 61 DRFSGSSSGNTASLTITGAQAEADADYCCSRDSSGNNHWFGGTELTVLG 111
Db 199 DRFSGSSSGNTASLTITGAQAEADADYCCSRDSSGNNHWFGGTELTVLG 249

RESULT 16
ABP44323
ID ABP44323 standard; Protein; 249 AA.
XX
XX ABP44323;
XX
XX 19-AUG-2002 (first entry)
XX
XX Human Blys binding scFv SEQ ID 334.
XX
XX Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
XX tumour necrosis factor; B cell proliferation; B cell differentiation;
XX immunosuppressive; immunostimulant; immunomodulatory; antineumatic;
XX antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
XX systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
XX common variable immunodeficiency; acquired immunodeficiency syndrome.
XX
XX Homo sapiens.
XX
XX WO200202641-A1.
XX
XX 10-JAN-2002.
XX
XX 15-JUN-2001; 2001WO-US19110.
XX
XX 16-JUN-2000; 2000US-212210P.
XX 17-OCT-2000; 2000US-240816P.
XX 16-MAR-2001; 2001US-276248P.
XX 21-MAR-2001; 2001US-277379P.
XX 25-MAY-2001; 2001US-293499P.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX
XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
XX WPI; 2002-114799/15.
XX
XX Antibodies against B lymphocyte stimulating polypeptides, useful for
XX the diagnosis and treatment of cancers and immune disorders -
XX
XX Claim 1; Page 802-803; 3148pp; English.
XX
XX This invention describes novel antibodies that immunospecifically bind to
XX B lymphocyte stimulator (Blys) polypeptides. Blys is a member of the
XX tumour necrosis factor (TNF) super family and induces B cell
XX proliferation and differentiation. The antibodies of the invention have
XX cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
XX antineumatic and antiAIDS activity and can be used in vaccines to
XX inhibit the expression and activity of Blys. The antibodies bind to Blys
XX and so may be used to detect and quantitate the presence of Blys in
XX biological samples and may be used in this way to diagnose disease
XX associated with aberrant expression of Blys. They may also be
XX administered to treat diseases associated with aberrant Blys expression
XX and activity such as cancer, immune, and autoimmune disorders and
XX diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
XX immunodeficiency (e.g. common variable immunodeficiency (CVID) and
XX acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
XX the antibodies and fragments of the antibodies described in the method
XX of the invention.
XX

XX Sequence 249 AA;
SQ Query Match 99.5%; Score 580; DB 23; Length 249;
Best Local Similarity 99.1%; Pred. No. 1.6e-36;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
DB 1 AFSSSLTDDPAVSVALGQTVRTCCGDSLSRSYASWYQKPGQAPLVLYIGKNNRPSGIP 60
139 AFSSSLTDDPAVSVALGQTVRTCCGDSLSRSYASWYQKPGQAPLVLYIGKNNRPSGIP 198
QY 61 DRFSSSSGNTASLTITGAQAEDEADYCCSRDSSGNHWFGGTELTVLG 111
199 DRFSSSSGNTASLTITGAQAEDEADYCCSRDSSGNHWFGGTELTVLG 249
DB
RESULT 17
ABP4324
ID ABP4324 standard; Protein; 249 AA.
XX ABP4324;
XX 19-AUG-2002 (first entry)
DE Human Blys binding scFv SEQ ID 335.
XX Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
XX tumour necrosis factor; B cell proliferation; B cell differentiation;
XX immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
XX antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
XX systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
XX common variable immunodeficiency; acquired immunodeficiency syndrome.
OS Homo sapiens.
XX WO200202641-A1.
XX 10-JAN-2002.
XX 15-JUN-2001; 2001WO-US19110.
XX 16-JUN-2000; 2000US-212210P.
XX 17-OCT-2000; 2000US-240816P.
XX 16-MAR-2001; 2001US-276248P.
XX 21-MAR-2001; 2001US-277379P.
XX 25-MAY-2001; 2001US-293499P.
XX (HUMA-) HUMAN GENOME SCI INC.
XX (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
XX WPI, 2002-114799/15.
XX
XX Antibodies against B lymphocyte stimulating polypeptides, useful for
XX the diagnosis and treatment of cancers and immune disorders -
XX
XX Claim 1; Page 804-805; 3148pp; English.
XX
XX This invention describes novel antibodies that immunospecifically bind to
XX B lymphocyte stimulator (Blys) polypeptides. Blys is a member of the
XX tumour necrosis factor (TNF) super family and induces B cell
XX proliferation and differentiation. The antibodies of the invention have
XX cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
XX antirheumatic and antiAIDS activity and can be used in vaccines to
XX inhibit the expression and activity of Blys. The antibodies bind to Blys
XX and so may be used to detect and quantitate the presence of Blys in
XX biological samples and may be used in this way to diagnose disease
XX associated with aberrant expression of Blys. They may also be
XX administered to treat diseases associated with aberrant Blys expression
XX and activity such as cancer, immune, and autoimmune disorders and
XX diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
XX immunodeficiency (e.g. common variable immunodeficiency (CVID) and

CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
CC the antibodies and fragments of the antibodies described in the method
CC of the invention.
XX
XX Sequence 249 AA;
SQ Query Match 99.5%; Score 580; DB 23; Length 249;
Best Local Similarity 99.1%; Pred. No. 1.6e-36;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
DB 1 AFSSSLTDDPAVSVALGQTVRTCCGDSLSRSYASWYQKPGQAPLVLYIGKNNRPSGIP 60
139 AFSSSLTDDPAVSVALGQTVRTCCGDSLSRSYASWYQKPGQAPLVLYIGKNNRPSGIP 198
QY 61 DRFSSSSGNTASLTITGAQAEDEADYCCSRDSSGNHWFGGTELTVLG 111
199 DRFSSSSGNTASLTITGAQAEDEADYCCSRDSSGNHWFGGTELTVLG 249
DB
RESULT 18
ABP4325
ID ABP4325 standard; Protein; 249 AA.
XX ABP4325;
XX 19-AUG-2002 (first entry)
DE Human Blys binding scFv SEQ ID 336.
XX Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
XX tumour necrosis factor; B cell proliferation; B cell differentiation;
XX immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
XX antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
XX systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
XX common variable immunodeficiency; acquired immunodeficiency syndrome.
OS Homo sapiens.
XX WO200202641-A1.
XX 10-JAN-2002.
XX 15-JUN-2001; 2001WO-US19110.
XX 16-JUN-2000; 2000US-212210P.
XX 17-OCT-2000; 2000US-240816P.
XX 16-MAR-2001; 2001US-276248P.
XX 21-MAR-2001; 2001US-277379P.
XX 25-MAY-2001; 2001US-293499P.
XX (HUMA-) HUMAN GENOME SCI INC.
XX (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
XX WPI, 2002-114799/15.
XX
XX Antibodies against B lymphocyte stimulating polypeptides, useful for
XX the diagnosis and treatment of cancers and immune disorders -
XX
XX Claim 1; Page 805-806; 3148pp; English.
XX
XX This invention describes novel antibodies that immunospecifically bind to
XX B lymphocyte stimulator (Blys) polypeptides. Blys is a member of the
XX tumour necrosis factor (TNF) super family and induces B cell
XX proliferation and differentiation. The antibodies of the invention have
XX cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
XX antirheumatic and antiAIDS activity and can be used in vaccines to
XX inhibit the expression and activity of Blys. The antibodies bind to Blys
XX and so may be used to detect and quantitate the presence of Blys in
XX biological samples and may be used in this way to diagnose disease
XX associated with aberrant expression of Blys. They may also be
XX administered to treat diseases associated with aberrant Blys expression

CC and activity such as cancer, immune, and autoimmune disorders and
CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
CC acquired immunodeficiency syndrome (AIDS)). ABP4390-ABP47228 represent
CC the antibodies and fragments of the antibodies described in the method
CC of the invention.

XX Sequence 249 AA;

Query Match 99.5%; Score 580; DB 23; Length 249;
Best Local Similarity 99.1%; Pred. No. 1.6e-36;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFSSSLTDDPAVSVALGQTVRVTCGDSLRSYASWYQKPGQAPVLVIYGNRRPSGIP 60

DB 139 AFSSSLTDDPAVSVALGQTVRVTCGDSLRSYASWYQKPGQAPVLVIYGNRRPSGIP 198

QY 61 DRFSSSSGNTASLTITGAQAEADYCCSSRDSGNHWFPGGTETLVLG 111
199 DRFSSSSGNTASLTITGAQAEADYCCNSRDSGNHWFPGGTETLVLG 249

RESULT 19

ABP44327 standard; Protein; 249 AA.

XX ABP44327;

DT 19-AUG-2002 (first entry)

DE Human Blys binding scFv SEQ ID 338.

XX Blys: B lymphocyte stimulator; TNF superfamily; human; cytostatic;
XX tumour necrosis factor; B cell proliferation; B cell differentiation;
XX immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
XX antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
XX systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
XX common variable immunodeficiency; acquired immunodeficiency syndrome.

OS Homo sapiens.

PN WO200202641-A1.

PD 10-JAN-2002.

PF 15-JUN-2001; 2001WO-US19110.

PR 16-JUN-2000; 2000US-212210P.

PR 17-OCT-2000; 2000US-240816P.

PR 16-MAR-2001; 2001US-276248P.

PR 21-MAR-2001; 2001US-277379P.

PR 25-MAY-2001; 2001US-293499P.

PA (HUMA-) HUMAN GENOME SCI INC.

PA (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.

PI Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;

PI WPI; 2002-114799/15.

PT Antibodies against B lymphocyte Stimulating polypeptides, useful for

PT the diagnosis and treatment of cancers and immune disorders -

XX Claim 1; Page 807-808; 3148pp; English.

CC This invention describes novel antibodies that immunospecifically bind to
CC B lymphocyte Stimulator (Blys) polypeptides. Blys is a member of the
CC tumour necrosis factor (TNF) super family and induces B cell
CC proliferation and differentiation. The antibodies of the invention have
CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
CC antirheumatic and antiAIDS activity and can be used in vaccines to
CC inhibit the expression and activity of Blys. The antibodies bind to Blys
CC and so may be used to detect and quantitate the presence of Blys in

CC biological samples and may be used in this way to diagnose disease
CC associated with aberrant expression of Blys. They may also be
CC administered to treat diseases associated with aberrant Blys expression
CC and activity such as cancer, immune, and autoimmune disorders and
CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
CC acquired immunodeficiency syndrome (AIDS)). ABP4390-ABP47228 represent
CC the antibodies and fragments of the antibodies described in the method
CC of the invention.

XX Sequence 249 AA;

Query Match 99.5%; Score 580; DB 23; Length 249;
Best Local Similarity 99.1%; Pred. No. 1.6e-36;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFSSSLTDDPAVSVALGQTVRVTCGDSLRSYASWYQKPGQAPVLVIYGNRRPSGIP 60

DB 139 AFSSSLTDDPAVSVALGQTVRVTCGDSLRSYASWYQKPGQAPVLVIYGNRRPSGIP 198

QY 61 DRFSSSSGNTASLTITGAQAEADYCCSSRDSGNHWFPGGTETLVLG 111
199 DRFSSSSGNTASLTITGAQAEADYCCNSRDSGNHWFPGGTETLVLG 249

RESULT 20

ABP44331 standard; Protein; 249 AA.

XX ABP44331;

DT 19-AUG-2002 (first entry)

DE Human Blys binding scFv SEQ ID 342.

XX Blys: B lymphocyte stimulator; TNF superfamily; human; cytostatic;
XX tumour necrosis factor; B cell proliferation; B cell differentiation;
XX immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
XX antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
XX systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
XX common variable immunodeficiency; acquired immunodeficiency syndrome.

OS Homo sapiens.

PN WO200202641-A1.

PD 10-JAN-2002.

PF 15-JUN-2001; 2001WO-US19110.

PR 16-JUN-2000; 2000US-212210P.

PR 17-OCT-2000; 2000US-240816P.

PR 16-MAR-2001; 2001US-276248P.

PR 21-MAR-2001; 2001US-277379P.

PR 25-MAY-2001; 2001US-293499P.

PA (HUMA-) HUMAN GENOME SCI INC.

PA (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.

PI Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;

PI WPI; 2002-114799/15.

PT Antibodies against B lymphocyte Stimulating polypeptides, useful for

PT the diagnosis and treatment of cancers and immune disorders -

XX Claim 1; Page 812-813; 3148pp; English.

CC This invention describes novel antibodies that immunospecifically bind to
CC B lymphocyte Stimulator (Blys) polypeptides. Blys is a member of the
CC tumour necrosis factor (TNF) super family and induces B cell
CC proliferation and differentiation. The antibodies of the invention have
CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,

CC antirheumatic and antiAIDS activity and can be used in vaccines to
CC inhibit the expression and activity of Blys. The antibodies bind to Blys
CC and so may be used to detect and quantitate the presence of Blys in
CC biological samples and may be used in this way to diagnose disease
CC associated with aberrant expression of Blys. They may also be
CC administered to treat diseases associated with aberrant Blys expression
CC and activity such as cancer, immune, and autoimmune disorders and
CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
CC acquired immunodeficiency syndrome (AIDS)). ABP4390-ABP47228 represent
CC the antibodies and fragments of the antibodies described in the method
CC of the invention.

XX Sequence 249 AA;

Query Match 99.5%; Score 580; DB 23; Length 249;
Best Local Similarity 99.1%; Pred. No. 1.6e-36;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

DB 1 AFSSSLTDDPAVSVALGQTVRVTCGDSLSRSYASWYQKPGQAPLVLYIGKNNRPSGIP 60
139 AFSSSLTDDPAVSVALGQTVRVTCGDSLSRSYASWYQKPGQAPLVLYIGKNNRPSGIP 198

QY 61 DRFGSSSGNTASLTITGAQAEADYCYSSRDSGNNHWFGGTELTVLG 111
DB 199 DRFGSSSGNTASLTITGAQAEADYCYSSRDSGNNHWFGGTELTVLG 249

RESULT 21
ABP4332
ID ABP4332 standard; Protein; 249 AA.
XX
AC ABP4332;
XX
DT 19-AUG-2002 (first entry)
XX
DE Human Blys binding scFv SEQ ID 343.
XX

KW Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
KW tumour necrosis factor; B cell proliferation; B cell differentiation;
KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
KW common variable immunodeficiency; acquired immunodeficiency syndrome.

XX Homo sapiens.

XX WO200202641-A1.

XX 10-JAN-2002.

XX 15-JUN-2001; 2001WO-US19110.

XX 16-JUN-2000; 2000US-212210P.

XX 17-OCT-2000; 2000US-240816P.

XX 16-MAR-2001; 2001US-276248P.

XX 21-MAR-2001; 2001US-277379P.

XX 25-MAY-2001; 2001US-293499P.

XX (HUMA-) HUMAN GENOME SCI INC.

XX (CAMP-) CAMBRIDGE ANTIBODY TECHNOLOGY.

XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;

XX WPI; 2002-114799/15.

XX Antibodies against B lymphocyte stimulating polypeptides, useful for

XX the diagnosis and treatment of cancers and immune disorders -

XX Claim 1; Page 813-814; 3148pp; English.

XX This invention describes novel antibodies that immunospecifically bind to

CC tumour necrosis factor (TNF) super family and induces B cell
CC proliferation and differentiation. The antibodies of the invention have
CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
CC antirheumatic and antiAIDS activity and can be used in vaccines to
CC inhibit the expression and activity of Blys. The antibodies bind to Blys
CC and so may be used to detect and quantitate the presence of Blys in
CC biological samples and may be used in this way to diagnose disease
CC associated with aberrant expression of Blys. They may also be
CC administered to treat diseases associated with aberrant Blys expression
CC and activity such as cancer, immune, and autoimmune disorders and
CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
CC acquired immunodeficiency syndrome (AIDS)). ABP4390-ABP47228 represent
CC the antibodies and fragments of the antibodies described in the method
CC of the invention.

XX Sequence 249 AA;

Query Match 99.5%; Score 580; DB 23; Length 249;
Best Local Similarity 99.1%; Pred. No. 1.6e-36;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFSSSLTDDPAVSVALGQTVRVTCGDSLSRSYASWYQKPGQAPLVLYIGKNNRPSGIP 60
DB 139 AFSSSLTDDPAVSVALGQTVRVTCGDSLSRSYASWYQKPGQAPLVLYIGKNNRPSGIP 198

QY 61 DRFGSSSGNTASLTITGAQAEADYCYSSRDSGNNHWFGGTELTVLG 111
DB 199 DRFGSSSGNTASLTITGAQAEADYCYSSRDSGNNHWFGGTELTVLG 249

RESULT 22
ABP4333
ID ABP4333 standard; Protein; 249 AA.
XX
AC ABP4333;
XX
DT 19-AUG-2002 (first entry)
XX
DE Human Blys binding scFv SEQ ID 344.

KW Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
KW tumour necrosis factor; B cell proliferation; B cell differentiation;
KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
KW common variable immunodeficiency; acquired immunodeficiency syndrome.

XX Homo sapiens.

XX WO200202641-A1.

XX 10-JAN-2002.

XX 15-JUN-2001; 2001WO-US19110.

XX 16-JUN-2000; 2000US-212210P.

XX 17-OCT-2000; 2000US-240816P.

XX 16-MAR-2001; 2001US-276248P.

XX 21-MAR-2001; 2001US-277379P.

XX 25-MAY-2001; 2001US-293499P.

XX (HUMA-) HUMAN GENOME SCI INC.

XX (CAMP-) CAMBRIDGE ANTIBODY TECHNOLOGY.

XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;

XX WPI; 2002-114799/15.

XX Antibodies against B lymphocyte stimulating polypeptides, useful for

XX the diagnosis and treatment of cancers and immune disorders -

XX Claim 1; Page 814-815; 3148pp; English.

XX This invention describes novel antibodies that immunospecifically bind to
CC B Lymphocyte Stimulator (BLyS) polypeptides. BLyS is a member of the
CC tumor necrosis factor (TNF) super family and induces B cell
CC proliferation and differentiation. The antibodies of the invention have
CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
CC antirheumatic and antiAIDS activity and can be used in vaccines to
CC inhibit the expression and activity of BLyS. The antibodies bind to BLyS
CC and so may be used to detect and quantitate the presence of BLyS in
CC biological samples and may be used in this way to diagnose disease
CC associated with aberrant expression of BLyS. They may also be
CC administered to treat diseases associated with aberrant BLyS expression
CC and activity such as cancer, immune, and autoimmune disorders and
CC diseases, e.g., systemic lupus erythematosus, rheumatoid arthritis,
CC immunodeficiency (e.g., common variable immunodeficiency (CVID) and
CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
CC the antibodies and fragments of the antibodies described in the method
CC of the invention.

XX Sequence 249 AA:

Query Match 99.5%; Score 580; DB 23; Length 249;
Best Local Similarity 99.1%; Pred. No. 1.6e-36;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFSSSLTDDPAVSVALGQTVRTTCGDSLSRYASWYQKPCQAPVLVIYGNRPSGIP 60
DB 139 AFSSSLTDDPAVSVALGQTVRTTCGDSLSRYASWYQKPCQAPVLVIYGNRPSGIP 198
QY 61 DRFSSSSGNTASLTITGAQAEADYCCSRDSSGNTMVFSGGTETVLG 111
DB 199 DRFSSSSGNTASLTITGAQAEADYCCSRDSSGNTMVFSGGTETVLG 249

RESULT 23

ABP44334
ID ABP44334 standard; Protein; 249 AA.

XX ABP44334;

XX DT 19-AUG-2002 (first entry)

XX DE Human BLyS binding scFv SEQ ID 345.

XX KW BLyS; B lymphocyte stimulator; TNF superfamily; human; cytostatic;

XX KW tumour necrosis factor; B cell proliferation; B cell differentiation;

XX KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;

XX KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;

XX KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;

XX KW common variable immunodeficiency; acquired immunodeficiency syndrome.

XX Homo sapiens.

XX OS WO200202641-A1.

XX PD 10-JAN-2002.

XX PF 15-JUN-2001; 2001WO-US19110.

XX PR 16-JUN-2000; 2000US-212210P.

XX PR 17-OCT-2000; 2000US-240816P.

XX PR 16-MAR-2001; 2001US-276248P.

XX PR 21-MAR-2001; 2001US-277379P.

XX PR 25-MAY-2001; 2001US-293499P.

XX PA (HUMA-) HUMAN GENOME SCI INC.

XX PA (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.

XX PI Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;

XX DR WPI; 2002-114799/15.

XX FT Antibodies against B Lymphocyte Stimulating polypeptides, useful for

PT the diagnosis and treatment of cancers and immune disorders -
XX Claim 1; Page 815-816; 3148pp; English.

XX This invention describes novel antibodies that immunospecifically bind to
XX B Lymphocyte Stimulator (BLyS) polypeptides. BLyS is a member of the
XX tumor necrosis factor (TNF) super family and induces B cell
XX proliferation and differentiation. The antibodies of the invention have
XX cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
XX antirheumatic and antiAIDS activity and can be used in vaccines to
XX inhibit the expression and activity of BLyS. The antibodies bind to BLyS
XX and so may be used to detect and quantitate the presence of BLyS in
XX biological samples and may be used in this way to diagnose disease
XX associated with aberrant expression of BLyS. They may also be
XX administered to treat diseases associated with aberrant BLyS expression
XX and activity such as cancer, immune, and autoimmune disorders and
XX diseases, e.g., systemic lupus erythematosus, rheumatoid arthritis,
XX immunodeficiency (e.g., common variable immunodeficiency (CVID) and
XX acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
XX the antibodies and fragments of the antibodies described in the method
XX of the invention.

SQ Sequence 249 AA:

Query Match 99.5%; Score 580; DB 23; Length 249;
Best Local Similarity 99.1%; Pred. No. 1.6e-36;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFSSSLTDDPAVSVALGQTVRTTCGDSLSRYASWYQKPCQAPVLVIYGNRPSGIP 60
DB 139 AFSSSLTDDPAVSVALGQTVRTTCGDSLSRYASWYQKPCQAPVLVIYGNRPSGIP 198
QY 61 DRFSSSSGNTASLTITGAQAEADYCCSRDSSGNTMVFSGGTETVLG 111
DB 199 DRFSSSSGNTASLTITGAQAEADYCCSRDSSGNTMVFSGGTETVLG 249

RESULT 24

ABP44337
ID ABP44337 standard; Protein; 249 AA.

XX ABP44337;

XX DT 19-AUG-2002 (first entry)

XX DE Human BLyS binding scFv SEQ ID 348.

XX KW BLyS; B lymphocyte stimulator; TNF superfamily; human; cytostatic;

XX KW tumour necrosis factor; B cell proliferation; B cell differentiation;

XX KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;

XX KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;

XX KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;

XX KW common variable immunodeficiency; acquired immunodeficiency syndrome.

XX Homo sapiens.

XX OS WO200202641-A1.

XX PD 10-JAN-2002.

XX PF 15-JUN-2001; 2001WO-US19110.

XX PR 16-JUN-2000; 2000US-212210P.

XX PR 17-OCT-2000; 2000US-240816P.

XX PR 16-MAR-2001; 2001US-276248P.

XX PR 21-MAR-2001; 2001US-277379P.

XX PR 25-MAY-2001; 2001US-293499P.

XX PA (HUMA-) HUMAN GENOME SCI INC.

XX PA (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.

XX PI Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;

XX DR WPI; 2002-114799/15.

XX FT Antibodies against B Lymphocyte Stimulating polypeptides, useful for

DR WPI: 2002-114799/15.
XX Antibodies against B Lymphocyte Stimulating polypeptides, useful for
PT the diagnosis and treatment of cancers and immune disorders -
PS Claim 1, Page 819-820; 3148pp; English.
XX
CC This invention describes novel antibodies that immunospecifically bind to
CC B Lymphocyte Stimulator (Blys) polypeptides. Blys is a member of the
CC tumor necrosis factor (TNF) super family and induces B cell
CC proliferation and differentiation. The antibodies of the invention have
CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
CC antirheumatic and antiAIDS activity and can be used in vaccines to
CC inhibit the expression and activity of Blys. The antibodies bind to Blys
CC and so may be used to detect and quantitate the presence of Blys in
CC biological samples and may be used in this way to diagnose disease
CC associated with aberrant expression of Blys. They may also be
CC administered to treat diseases associated with aberrant Blys expression
CC and activity such as cancer, immune, and autoimmune disorders and
CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
CC the antibodies and fragments of the antibodies described in the method
CC of the invention.
XX
SQ Sequence 249 AA;
Query Match 99.5%; Score 580; DB 23; Length 249;
Best Local Similarity 99.1%; Pred. No. 1.6e-36;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1 AFSSSLTDDPAVVALGQTVRVTCQDLSRSYASWYQOKPQAPVLVLYGKNNRPSGIP 60
DB 139 AFSSSLTDDPAVVALGQTVRVTCQDLSRSYASWYQOKPQAPVLVLYGKNNRPSGIP 198
QY 61 DRFGSSSGNTASLTITGAQAEDEADYYCSDSSSGNHWFGGTELTVLG 111
DB 199 DRFGSSSGNTASLTITGAQAEDEADYYCNSRSDSSGNHWFGGTELTVLG 249
RESULT 25
ABP44338
ID ABP44338 standard; Protein; 249 AA.
AC ABP44338;
XX
DT 19-AUG-2002 (first entry)
XX
KW Human Blys binding scFv SEQ ID 349.
XX
KW Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
KW tumor necrosis factor; B cell proliferation; B cell differentiation;
KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
KW common variable immunodeficiency; acquired immunodeficiency syndrome.
XX
OS Homo sapiens.
XX
XX WO200202641-A1.
XX
PD 10-JAN-2002.
XX
PF 15-JUN-2001; 2001WO-US19110.
XX
PR 16-JUN-2000; 2000US-212210P.
PR 17-OCT-2000; 2000US-240816P.
PR 16-MAR-2001; 2001US-276248P.
PR 21-MAR-2001; 2001US-277379P.
PR 25-MAY-2001; 2001US-293499P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX (CMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.

XX
PI Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
XX WPI: 2002-114799/15.
XX
DR Antibodies against B Lymphocyte Stimulating polypeptides, useful for
PT the diagnosis and treatment of cancers and immune disorders -
PS Claim 1, Page 820-821; 3148pp; English.
XX
CC This invention describes novel antibodies that immunospecifically bind to
CC B Lymphocyte Stimulator (Blys) polypeptides. Blys is a member of the
CC tumor necrosis factor (TNF) super family and induces B cell
CC proliferation and differentiation. The antibodies of the invention have
CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
CC antirheumatic and antiAIDS activity and can be used in vaccines to
CC inhibit the expression and activity of Blys. The antibodies bind to Blys
CC and so may be used to detect and quantitate the presence of Blys in
CC biological samples and may be used in this way to diagnose disease
CC associated with aberrant expression of Blys. They may also be
CC administered to treat diseases associated with aberrant Blys expression
CC and activity such as cancer, immune, and autoimmune disorders and
CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
CC the antibodies and fragments of the antibodies described in the method
CC of the invention.
XX
SQ Sequence 249 AA;
Query Match 99.5%; Score 580; DB 23; Length 249;
Best Local Similarity 99.1%; Pred. No. 1.6e-36;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1 AFSSSLTDDPAVVALGQTVRVTCQDLSRSYASWYQOKPQAPVLVLYGKNNRPSGIP 60
DB 139 AFSSSLTDDPAVVALGQTVRVTCQDLSRSYASWYQOKPQAPVLVLYGKNNRPSGIP 198
QY 61 DRFGSSSGNTASLTITGAQAEDEADYYCSDSSSGNHWFGGTELTVLG 111
DB 199 DRFGSSSGNTASLTITGAQAEDEADYYCNSRSDSSGNHWFGGTELTVLG 249
RESULT 26
ABP44339
ID ABP44339 standard; Protein; 249 AA.
AC ABP44339;
XX
DT 19-AUG-2002 (first entry)
XX
KW Human Blys binding scFv SEQ ID 350.
XX
KW Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
KW tumor necrosis factor; B cell proliferation; B cell differentiation;
KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
KW common variable immunodeficiency; acquired immunodeficiency syndrome.
XX
OS Homo sapiens.
XX
XX WO200202641-A1.
XX
PD 10-JAN-2002.
XX
PF 15-JUN-2001; 2001WO-US19110.
XX
PR 16-JUN-2000; 2000US-212210P.
PR 17-OCT-2000; 2000US-240816P.
PR 16-MAR-2001; 2001US-276248P.
PR 21-MAR-2001; 2001US-277379P.
PR 25-MAY-2001; 2001US-293499P.

XX (HUMA-) HUMAN GENOME SCI INC.
PA (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
PI WPI; 2002-114799/15.
XX
XX Antibodies against B lymphocyte stimulating polypeptides, useful for
PT the diagnosis and treatment of cancers and immune disorders -
XX
XX Claim 1; Page 821-822; 3148pp; English.
XX
XX This invention describes novel antibodies that immunospecifically bind to
CC B lymphocyte stimulator (BLyS) polypeptides. BLyS is a member of the
CC tumour necrosis factor (TNF) super family and induces B cell
CC proliferation and differentiation. The antibodies of the invention have
CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
CC antirheumatic and antiAIDS activity and can be used in vaccines to
CC inhibit the expression and activity of BLyS. The antibodies bind to BLyS
CC and so may be used to detect and quantitate the presence of BLyS in
CC biological samples and may be used in this way to diagnose disease
CC associated with aberrant expression of BLyS. They may also be
CC administered to treat diseases associated with aberrant BLyS expression
CC and activity such as cancer, immune, and autoimmune disorders and
CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
CC the antibodies and fragments of the antibodies described in the method
CC of the invention.
XX
XX Sequence 249 AA;
SQ
Query Match 99.5%; Score 580; DB 23; Length 249;
Best Local Similarity 99.1%; Pred. No. 1.6e-36;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
OY 1 AFSSSLTODPAVSVALGQTVRTVTCGDSLRYSYASWYQKPGQAPVLVIYGNRPSPGIP 60
DB 139 AFSSSLTODPAVSVALGQTVRTVTCGDSLRYSYASWYQKPGQAPVLVIYGNRPSPGIP 198
OY 61 DRFGSSSGNTASLTITGAQAEADYCCSRDSSGNHWFVGGTGLTVLG 111
DB 199 DRFGSSSGNTASLTITGAQAEADYCCSRDSSGNHWFVGGTGLTVLG 249
RESULT 27
ABP4341
AC ABP4341 standard; Protein; 249 AA.
XX
XX 19-AUG-2002 (first entry)
XX
XX Human BLyS binding scFv SEQ ID 352.
XX
XX BLyS: B lymphocyte stimulator; TNF superfamily; human; cytostatic;
KW tumour necrosis factor; B cell proliferation; B cell differentiation;
KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
KW common variable immunodeficiency; acquired immunodeficiency syndrome.
XX
XX Homo sapiens.
XX
XX WO200202641-A1.
XX
XX 10-JAN-2002.
XX
XX 15-JUN-2001; 2001WO-US19110.
XX
XX 16-JUN-2000; 2000US-212210P.
XX
XX 17-OCT-2000; 2000US-240816P.
XX
XX

PR 16-MAR-2001; 2001US-276248P.
PR 21-MAR-2001; 2001US-277379P.
PR 25-MAY-2001; 2001US-293499P.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
PA (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
PI WPI; 2002-114799/15.
XX
XX Antibodies against B lymphocyte stimulating polypeptides, useful for
PT the diagnosis and treatment of cancers and immune disorders -
XX
XX Claim 1; Page 824-825; 3148pp; English.
XX
XX This invention describes novel antibodies that immunospecifically bind to
CC B lymphocyte stimulator (BLyS) polypeptides. BLyS is a member of the
CC tumour necrosis factor (TNF) super family and induces B cell
CC proliferation and differentiation. The antibodies of the invention have
CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
CC antirheumatic and antiAIDS activity and can be used in vaccines to
CC inhibit the expression and activity of BLyS. The antibodies bind to BLyS
CC and so may be used to detect and quantitate the presence of BLyS in
CC biological samples and may be used in this way to diagnose disease
CC associated with aberrant expression of BLyS. They may also be
CC administered to treat diseases associated with aberrant BLyS expression
CC and activity such as cancer, immune, and autoimmune disorders and
CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
CC the antibodies and fragments of the antibodies described in the method
CC of the invention.
XX
XX Sequence 249 AA;
SQ
Query Match 99.5%; Score 580; DB 23; Length 249;
Best Local Similarity 99.1%; Pred. No. 1.6e-36;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
OY 1 AFSSSLTODPAVSVALGQTVRTVTCGDSLRYSYASWYQKPGQAPVLVIYGNRPSPGIP 60
DB 139 AFSSSLTODPAVSVALGQTVRTVTCGDSLRYSYASWYQKPGQAPVLVIYGNRPSPGIP 198
OY 61 DRFGSSSGNTASLTITGAQAEADYCCSRDSSGNHWFVGGTGLTVLG 111
DB 199 DRFGSSSGNTASLTITGAQAEADYCCSRDSSGNHWFVGGTGLTVLG 249
RESULT 28
ABP4344
ID ABP4344 standard; Protein; 249 AA.
XX
XX 19-AUG-2002 (first entry)
XX
XX Human BLyS binding scFv SEQ ID 355.
XX
XX BLyS: B lymphocyte stimulator; TNF superfamily; human; cytostatic;
KW tumour necrosis factor; B cell proliferation; B cell differentiation;
KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
KW common variable immunodeficiency; acquired immunodeficiency syndrome.
XX
XX Homo sapiens.
XX
XX WO200202641-A1.
XX
XX 10-JAN-2002.
XX
XX 15-JUN-2001; 2001WO-US19110.
XX
XX

XX 16-JUN-2000; 2000US-212210P.
 PR 17-OCT-2000; 2000US-240816P.
 PR 16-MAR-2001; 2001US-276248P.
 PR 21-MAR-2001; 2001US-277379P.
 PR 25-MAY-2001; 2001US-293499P.
 XX
 PA (HUMA-) HUMAN GENOME SCI INC.
 PA (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
 PI Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
 DR WPI; 2002-114799/15.
 XX
 PT Antibodies against B Lymphocyte Stimulating polypeptides, useful for
 the diagnosis and treatment of cancers and immune disorders -
 PS Claim 1; Page 827-828; 3148pp; English.

XX This invention describes novel antibodies that immunospecifically bind to
 B Lymphocyte Stimulator (Blys) polypeptides. Blys is a member of the
 CC tumor necrosis factor (TNF) super family and induces B cell
 CC proliferation and differentiation. The antibodies of the invention have
 CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
 CC antirheumatic and antiAIDS activity and can be used in vaccines to
 CC inhibit the expression and activity of Blys. The antibodies bind to Blys
 CC and so may be used to detect and quantitate the presence of Blys in
 CC biological samples and may be used in this way to diagnose disease
 CC associated with aberrant expression of Blys. They may also be
 CC administered to treat diseases associated with aberrant Blys expression
 CC and activity such as cancer, immune, and autoimmune disorders and
 CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
 CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
 CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
 CC the antibodies and fragments of the antibodies described in the method
 CC of the invention.

XX Sequence 249 AA;

Query Match 99.5%; Score 580; DB 23; Length 249;
 Best Local Similarity 99.1%; Pred. No. 1.6e-36;
 Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFSSSLTDDPAVSVALGQTVRVTCGDSLRSYASWYQKPGQAPVLVIYGNRRPSGIP 60
 DB 139 AFSSSLTDDPAVSVALGQTVRVTCGDSLRSYASWYQKPGQAPVLVIYGNRRPSGIP 198
 61 DRFGSSSSGNTASLTITGAQAEADADYCCSRDSSGNHWHVFGGTETLVLG 111
 DB 199 DRFGSSSSGNTASLTITGAQAEADADYCCSRDSSGNHWHVFGGTETLVLG 249

RESULT 29
 ID ABP44345 standard; Protein; 249 AA.
 AC ABP44345;
 DT 19-AUG-2002 (first entry)

DE Human Blys binding scFv SEQ ID 356.
 XX
 XX

KW Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
 KW tumor necrosis factor; B cell proliferation; B cell differentiation;
 KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
 KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
 KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
 KW common variable immunodeficiency; acquired immunodeficiency syndrome.

OS Homo sapiens.
 XX
 XX WO200202641-A1.
 XX

PD 10-JAN-2002.
 XX
 XX 15-JUN-2001; 2001WO-US19110.
 PF
 XX
 PR 16-JUN-2000; 2000US-212210P.
 PR 17-OCT-2000; 2000US-240816P.
 PR 16-MAR-2001; 2001US-276248P.
 PR 21-MAR-2001; 2001US-277379P.
 PR 25-MAY-2001; 2001US-293499P.
 XX
 PA (HUMA-) HUMAN GENOME SCI INC.
 PA (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
 PI Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
 DR WPI; 2002-114799/15.
 XX
 PT Antibodies against B Lymphocyte Stimulating polypeptides, useful for
 the diagnosis and treatment of cancers and immune disorders -
 PS Claim 1; Page 828-829; 3148pp; English.

XX This invention describes novel antibodies that immunospecifically bind to
 B Lymphocyte Stimulator (Blys) polypeptides. Blys is a member of the
 CC tumor necrosis factor (TNF) super family and induces B cell
 CC proliferation and differentiation. The antibodies of the invention have
 CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
 CC antirheumatic and antiAIDS activity and can be used in vaccines to
 CC inhibit the expression and activity of Blys. The antibodies bind to Blys
 CC and so may be used to detect and quantitate the presence of Blys in
 CC biological samples and may be used in this way to diagnose disease
 CC associated with aberrant expression of Blys. They may also be
 CC administered to treat diseases associated with aberrant Blys expression
 CC and activity such as cancer, immune, and autoimmune disorders and
 CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
 CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
 CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
 CC the antibodies and fragments of the antibodies described in the method
 CC of the invention.

XX Sequence 249 AA;

Query Match 99.5%; Score 580; DB 23; Length 249;
 Best Local Similarity 99.1%; Pred. No. 1.6e-36;
 Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFSSSLTDDPAVSVALGQTVRVTCGDSLRSYASWYQKPGQAPVLVIYGNRRPSGIP 60
 DB 139 AFSSSLTDDPAVSVALGQTVRVTCGDSLRSYASWYQKPGQAPVLVIYGNRRPSGIP 198
 61 DRFGSSSSGNTASLTITGAQAEADADYCCSRDSSGNHWHVFGGTETLVLG 111
 DB 199 DRFGSSSSGNTASLTITGAQAEADADYCCSRDSSGNHWHVFGGTETLVLG 249

RESULT 30
 ID ABP44346 standard; Protein; 249 AA.
 AC ABP44346;
 DT 19-AUG-2002 (first entry)

DE Human Blys binding scFv SEQ ID 357.
 XX
 XX

KW Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
 KW tumor necrosis factor; B cell proliferation; B cell differentiation;
 KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
 KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
 KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
 KW common variable immunodeficiency; acquired immunodeficiency syndrome.

OS Homo sapiens.
 XX

XX WO200202641-A1.
XX 10-JAN-2002.
XX 15-JUN-2001; 2001WO-US19110.
XX 16-JUN-2000; 2000US-212210P.
XX 17-OCT-2000; 2000US-240816P.
XX 16-MAR-2001; 2001US-276248P.
XX 21-MAR-2001; 2001US-277379P.
XX 25-MAY-2001; 2001US-293499P.
XX (HUMA-) HUMAN GENOME SCI INC.
XX (CAME-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
XX WPI; 2002-114799/15.
XX
XX Antibodies against B Lymphocyte Stimulating polypeptides, useful for
XX the diagnosis and treatment of cancers and immune disorders -
XX
XX Claim 1; Page 830-831; 3148pp; English.
XX
XX This invention describes novel antibodies that immunospecifically bind to
XX B Lymphocyte Stimulator (BLyS) polypeptides. BLyS is a member of the
XX tumour necrosis factor (TNF) super family and induces B cell
XX proliferation and differentiation. The antibodies of the invention have
XX cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
XX antirheumatic and antiAIDS activity and can be used in vaccines to
XX inhibit the expression and activity of BLyS. The antibodies bind to BLyS
XX and so may be used to detect and quantitate the presence of BLyS in
XX biological samples and may be used in this way to diagnose disease
XX associated with aberrant expression of BLyS. They may also be
XX administered to treat diseases associated with aberrant BLyS expression
XX and actively such as cancer, immune, and autoimmune disorders and
XX diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
XX immunodeficiency (e.g. common variable immunodeficiency (CVID) and
XX acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
XX the antibodies and fragments of the antibodies described in the method
XX of the invention.
XX
XX Sequence 249 AA;
SQ
XX
XX Query Match 99.5%; Score 580; DB 23; Length 249;
XX Best Local Similarity 99.1%; Pred. No. 1.6e-36;
XX Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 AFSSSLTDDPAVSVALGQTVRTTCGDSLSRSYASWYQKPGQAPVLYIGKNNRPSGIP 60
XX 139 AFSSSLTDDPAVSVALGQTVRTTCGDSLSRSYASWYQKPGQAPVLYIGKNNRPSGIP 198
XX
XX 61 DRFGSSSGNTASLTITGAQAEADADYCCSRDSSGNNHWFGGTELTVLG 111
XX 199 DRFGSSSGNTASLTITGAQAEADADYCCSRDSSGNNHWFGGTELTVLG 249
XX
XX RESULT 31
XX ID ABP4347 standard; Protein; 249 AA.
XX AC ABP4347;
XX XX
XX 19-AUG-2002 (first entry)
XX XX
XX Human BLyS binding scFv SEQ ID 358.
XX XX
XX BLyS; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
XX tumour necrosis factor; B cell proliferation; B cell differentiation;
XX immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
XX antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
XX systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;

KW common variable immunodeficiency; acquired immunodeficiency syndrome.
XX Homo sapiens.
XX WO200202641-A1.
XX 10-JAN-2002.
XX 15-JUN-2001; 2001WO-US19110.
XX 16-JUN-2000; 2000US-212210P.
XX 17-OCT-2000; 2000US-240816P.
XX 16-MAR-2001; 2001US-276248P.
XX 21-MAR-2001; 2001US-277379P.
XX 25-MAY-2001; 2001US-293499P.
XX (HUMA-) HUMAN GENOME SCI INC.
XX (CAME-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
XX WPI; 2002-114799/15.
XX
XX Antibodies against B Lymphocyte Stimulating polypeptides, useful for
XX the diagnosis and treatment of cancers and immune disorders -
XX
XX Claim 1; Page 831-832; 3148pp; English.
XX
XX This invention describes novel antibodies that immunospecifically bind to
XX B Lymphocyte Stimulator (BLyS) polypeptides. BLyS is a member of the
XX tumour necrosis factor (TNF) super family and induces B cell
XX proliferation and differentiation. The antibodies of the invention have
XX cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
XX antirheumatic and antiAIDS activity and can be used in vaccines to
XX inhibit the expression and activity of BLyS. The antibodies bind to BLyS
XX and so may be used to detect and quantitate the presence of BLyS in
XX biological samples and may be used in this way to diagnose disease
XX associated with aberrant expression of BLyS. They may also be
XX administered to treat diseases associated with aberrant BLyS expression
XX and actively such as cancer, immune, and autoimmune disorders and
XX diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
XX immunodeficiency (e.g. common variable immunodeficiency (CVID) and
XX acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
XX the antibodies and fragments of the antibodies described in the method
XX of the invention.
XX
XX Sequence 249 AA;
SQ
XX
XX Query Match 99.5%; Score 580; DB 23; Length 249;
XX Best Local Similarity 99.1%; Pred. No. 1.6e-36;
XX Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 AFSSSLTDDPAVSVALGQTVRTTCGDSLSRSYASWYQKPGQAPVLYIGKNNRPSGIP 60
XX 139 AFSSSLTDDPAVSVALGQTVRTTCGDSLSRSYASWYQKPGQAPVLYIGKNNRPSGIP 198
XX
XX 61 DRFGSSSGNTASLTITGAQAEADADYCCSRDSSGNNHWFGGTELTVLG 111
XX 199 DRFGSSSGNTASLTITGAQAEADADYCCSRDSSGNNHWFGGTELTVLG 249
XX
XX RESULT 32
XX ID ABP4348 standard; Protein; 249 AA.
XX AC ABP4348;
XX XX
XX 19-AUG-2002 (first entry)
XX XX
XX Human BLyS binding scFv SEQ ID 359.
XX XX
XX BLyS; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
XX tumour necrosis factor; B cell proliferation; B cell differentiation;

KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
KW common variable immunodeficiency; acquired immunodeficiency syndrome.
XX Homo sapiens.
XX OS
XX PN WO200202641-A1.
XX PD 10-JAN-2002.
XX PF 15-JUN-2001; 2001WO-US19110.
XX PR 16-JUN-2000; 2000US-212210P.
XX PR 17-OCT-2000; 2000US-240816P.
XX PR 16-MAR-2001; 2001US-276248P.
XX PR 21-MAR-2001; 2001US-277379P.
XX PR 25-MAY-2001; 2001US-293499P.
XX (HUMA-) HUMAN GENOME SCI INC.
XX (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX PI Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
XX DR WPI; 2002-114799/15.
XX PT Antibodies against B lymphocyte stimulating polypeptides, useful for
XX PT the diagnosis and treatment of cancers and immune disorders -
XX PS Claim 1; Page 832-833; 3148pp; English.
XX PS This invention describes novel antibodies that immunospecifically bind to
XX CC B lymphocyte stimulator (BLyS) polypeptides. BLyS is a member of the
XX CC tumor necrosis factor (TNF) super family and induces B cell
XX CC proliferation and differentiation. The antibodies of the invention have
XX CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
XX CC antirheumatic and antiAIDS activity and can be used in vaccines to
XX CC inhibit the expression and activity of BLyS. The antibodies bind to BLyS
XX CC and so may be used to detect and quantitate the presence of BLyS in
XX CC biological samples and may be used in this way to diagnose disease
XX CC associated with aberrant expression of BLyS. They may also be
XX CC administered to treat diseases associated with aberrant BLyS expression
XX CC and activity such as cancer, immune, and autoimmune disorders and
XX CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
XX CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
XX CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
XX CC the antibodies and fragments of the antibodies described in the method
XX CC of the invention.
XX Sequence 249 AA;
XX Query Match 99.5%; Score 580; DB 23; Length 249;
XX Best Local Similarity 99.1%; Pred. No. 1.6e-36;
XX Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1 AFSSSELTQDPNAVVALGQTVRVTCQDLSRYSVSWYQOKPGQAPVLVIYKNNRPSGIP 60
DB 139 AFSSSELTQDPNAVVALGQTVRVTCQDLSRYSVSWYQOKPGQAPVLVIYKNNRPSGIP 198
QY 61 DRFGSSSGNTASLTITGAQAEADADYCCSRDSSGNHWFVGGTETLVLG 111
DB 199 DRFGSSSGNTASLTITGAQAEADADYCCSRDSSGNHWFVGGTETLVLG 249
RESULT 33
ID ABP44349 standard; Protein; 249 AA.
AC ABP44349;
XX AC
XX DT 19-AUG-2002 (first entry)
XX DE Human BLyS binding scFv SEQ ID 360.

XX BLyS; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
KW tumour necrosis factor; B cell proliferation; B cell differentiation;
KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
KW common variable immunodeficiency; acquired immunodeficiency syndrome.
XX Homo sapiens.
XX OS
XX PN WO200202641-A1.
XX PD 10-JAN-2002.
XX PF 15-JUN-2001; 2001WO-US19110.
XX PR 16-JUN-2000; 2000US-212210P.
XX PR 17-OCT-2000; 2000US-240816P.
XX PR 16-MAR-2001; 2001US-276248P.
XX PR 21-MAR-2001; 2001US-277379P.
XX PR 25-MAY-2001; 2001US-293499P.
XX (HUMA-) HUMAN GENOME SCI INC.
XX (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX PI Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
XX DR WPI; 2002-114799/15.
XX PT Antibodies against B lymphocyte stimulating polypeptides, useful for
XX PT the diagnosis and treatment of cancers and immune disorders -
XX PS Claim 1; Page 833-834; 3148pp; English.
XX PS This invention describes novel antibodies that immunospecifically bind to
XX CC B lymphocyte stimulator (BLyS) polypeptides. BLyS is a member of the
XX CC tumor necrosis factor (TNF) super family and induces B cell
XX CC proliferation and differentiation. The antibodies of the invention have
XX CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
XX CC antirheumatic and antiAIDS activity and can be used in vaccines to
XX CC inhibit the expression and activity of BLyS. The antibodies bind to BLyS
XX CC and so may be used to detect and quantitate the presence of BLyS in
XX CC biological samples and may be used in this way to diagnose disease
XX CC associated with aberrant expression of BLyS. They may also be
XX CC administered to treat diseases associated with aberrant BLyS expression
XX CC and activity such as cancer, immune, and autoimmune disorders and
XX CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
XX CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
XX CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
XX CC the antibodies and fragments of the antibodies described in the method
XX CC of the invention.
XX Sequence 249 AA;
XX Query Match 99.5%; Score 580; DB 23; Length 249;
XX Best Local Similarity 99.1%; Pred. No. 1.6e-36;
XX Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1 AFSSSELTQDPNAVVALGQTVRVTCQDLSRYSVSWYQOKPGQAPVLVIYKNNRPSGIP 60
DB 139 AFSSSELTQDPNAVVALGQTVRVTCQDLSRYSVSWYQOKPGQAPVLVIYKNNRPSGIP 198
QY 61 DRFGSSSGNTASLTITGAQAEADADYCCSRDSSGNHWFVGGTETLVLG 111
DB 199 DRFGSSSGNTASLTITGAQAEADADYCCSRDSSGNHWFVGGTETLVLG 249
RESULT 34
ID ABP44350 standard; Protein; 249 AA.
AC ABP44350;
XX AC
XX DT 19-AUG-2002 (first entry)
XX DE Human BLyS binding scFv SEQ ID 360.

DT 19-AUG-2002 (first entry)
XX Human Blys binding scFv SEQ ID 361.
XX Blys: B lymphocyte stimulator; TNF superfamily; human; cytostatic;
XX tumour necrosis factor; B cell proliferation; B cell differentiation;
XX immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
XX antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
XX systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
XX common variable immunodeficiency; acquired immunodeficiency syndrome.
OS Homo sapiens.
XX WO200202641-A1.
XX 10-JAN-2002.
XX 15-JUN-2001; 2001WO-US19110.
XX 16-JUN-2000; 2000US-212210P.
XX 17-OCT-2000; 2000US-240816P.
XX 16-MAR-2001; 2001US-276248P.
XX 21-MAR-2001; 2001US-277379P.
XX 25-MAY-2001; 2001US-293499P.
XX (HUMA-) HUMAN GENOME SCI INC.
XX (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
XX WPI; 2002-114799/15.
XX Antibodies against B lymphocyte stimulating polypeptides, useful for
XX the diagnosis and treatment of cancers and immune disorders -
XX
XX Claim 1; Page 834-835; 3148pp; English.
XX
XX This invention describes novel antibodies that immunospecifically bind to
XX B lymphocyte stimulator (Blys) polypeptides. Blys is a member of the
XX tumour necrosis factor (TNF) super family and induces B cell
XX proliferation and differentiation. The antibodies of the invention have
XX cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
XX antirheumatic and antiAIDS activity and can be used in vaccines to
XX inhibit the expression and activity of Blys. The antibodies bind to Blys
XX and so may be used to detect and quantitate the presence of Blys in
XX biological samples and may be used in this way to diagnose disease
XX associated with aberrant expression of Blys. They may also be
XX administered to treat diseases associated with aberrant Blys expression
XX and activity such as cancer, immune, and autoimmune disorders and
XX diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
XX immunodeficiency (e.g. common variable immunodeficiency (CVID) and
XX acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
XX the antibodies and fragments of the antibodies described in the method
XX of the invention.
XX
XX Sequence 249 AA;
SQ
Query Match 99.5%; Score 580; DB 23; Length 249;
Best Local Similarity 99.1%; Pred. No. 1.6e-36;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1 AFSSSELTODPAVVALGQTVRVTCQDLSRSYASWYQOKPQAPLVLYGKNNRPSGIP 60
DB 139 AFSSSELTODPAVVALGQTVRVTCQDLSRSYASWYQOKPQAPLVLYGKNNRPSGIP 198
QY 61 DRFGSSSGNTASLTITGAQAEDEADYYCSSRSDSGNHWFGGTELTVLG 111
DB 199 DRFGSSSGNTASLTITGAQAEDEADYYCNSRSDSGNHWFGGTELTVLG 249
RESULT 35
ABP44352
ID ABP44352 standard; Protein; 249 AA.

XX ABP44352;
AC
XX
XX 19-AUG-2002 (first entry)
DT Human Blys binding scFv SEQ ID 363.
XX Blys: B lymphocyte stimulator; TNF superfamily; human; cytostatic;
XX tumour necrosis factor; B cell proliferation; B cell differentiation;
XX immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
XX antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
XX systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
XX common variable immunodeficiency; acquired immunodeficiency syndrome.
OS Homo sapiens.
XX WO200202641-A1.
XX 10-JAN-2002.
XX 15-JUN-2001; 2001WO-US19110.
XX 16-JUN-2000; 2000US-212210P.
XX 17-OCT-2000; 2000US-240816P.
XX 16-MAR-2001; 2001US-276248P.
XX 21-MAR-2001; 2001US-277379P.
XX 25-MAY-2001; 2001US-293499P.
XX (HUMA-) HUMAN GENOME SCI INC.
XX (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
XX WPI; 2002-114799/15.
XX Antibodies against B lymphocyte stimulating polypeptides, useful for
XX the diagnosis and treatment of cancers and immune disorders -
XX
XX Claim 1; Page 837-838; 3148pp; English.
XX
XX This invention describes novel antibodies that immunospecifically bind to
XX B lymphocyte stimulator (Blys) polypeptides. Blys is a member of the
XX tumour necrosis factor (TNF) super family and induces B cell
XX proliferation and differentiation. The antibodies of the invention have
XX cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
XX antirheumatic and antiAIDS activity and can be used in vaccines to
XX inhibit the expression and activity of Blys. The antibodies bind to Blys
XX and so may be used to detect and quantitate the presence of Blys in
XX biological samples and may be used in this way to diagnose disease
XX associated with aberrant expression of Blys. They may also be
XX administered to treat diseases associated with aberrant Blys expression
XX and activity such as cancer, immune, and autoimmune disorders and
XX diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
XX immunodeficiency (e.g. common variable immunodeficiency (CVID) and
XX acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
XX the antibodies and fragments of the antibodies described in the method
XX of the invention.
XX
XX Sequence 249 AA;
SQ
Query Match 99.5%; Score 580; DB 23; Length 249;
Best Local Similarity 99.1%; Pred. No. 1.6e-36;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1 AFSSSELTODPAVVALGQTVRVTCQDLSRSYASWYQOKPQAPLVLYGKNNRPSGIP 60
DB 139 AFSSSELTODPAVVALGQTVRVTCQDLSRSYASWYQOKPQAPLVLYGKNNRPSGIP 198
QY 61 DRFGSSSGNTASLTITGAQAEDEADYYCSSRSDSGNHWFGGTELTVLG 111
DB 199 DRFGSSSGNTASLTITGAQAEDEADYYCNSRSDSGNHWFGGTELTVLG 249

RESULT 36
ABP44353
ID ABP44353 standard; Protein; 249 AA.
AC ABP44353;
XX
XX
DT 19-AUG-2002 (first entry)
XX
XX
DE Human Blys binding scFv SEQ ID 364.
XX
XX
KW Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
KW tumour necrosis factor; B cell proliferation; B cell differentiation;
KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
KW common variable immunodeficiency; acquired immunodeficiency syndrome.
OS Homo sapiens.
XX
XX
WO200202641-A1.
XX
XX
PD 10-JAN-2002.
XX
XX
PF 15-JUN-2001; 2001WO-US19110.
XX
XX
PR 16-JUN-2000; 2000US-212210P.
XX
PR 17-OCT-2000; 2000US-240816P.
XX
PR 16-MAR-2001; 2001US-276248P.
XX
PR 21-MAR-2001; 2001US-277379P.
XX
PR 25-MAY-2001; 2001US-293499P.
XX
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PA (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX
PI Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
XX
XX
WPI; 2002-114799/15.
XX
XX
PT Antibodies against B lymphocyte stimulating polypeptides, useful for
XX
XX
PT the diagnosis and treatment of cancers and immune disorders -
XX
XX
PS Claim 1; Page 838-839; 3148pp; English.
XX
XX
CC This invention describes novel antibodies that immunospecifically bind to
XX
XX
CC B lymphocyte stimulator (Blys) polypeptides. Blys is a member of the
XX
XX
CC tumour necrosis factor (TNF) super family and induces B cell
XX
XX
CC proliferation and differentiation. The antibodies of the invention have
XX
XX
CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
XX
XX
CC antirheumatic and antiAIDS activity and can be used in vaccines to
XX
XX
CC inhibit the expression and activity of Blys. The antibodies bind to Blys
XX
XX
CC and so may be used to detect and quantitate the presence of Blys in
XX
XX
CC biological samples and may be used in this way to diagnose disease
XX
XX
CC associated with aberrant expression of Blys. They may also be
XX
XX
CC administered to treat diseases associated with aberrant Blys expression
XX
XX
CC and activity such as cancer, immune, and autoimmune disorders and
XX
XX
CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
XX
XX
CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
XX
XX
CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
XX
XX
CC the antibodies and fragments of the antibodies described in the method
XX
XX
XX
SQ Sequence 249 AA;
XX
XX
Query Match 99.5%; Score 580; DB 23; Length 249;
Best Local Similarity 99.1%; Pred. No. 1.6e-36;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1 AFSSSLTQDPNAVVALGQTVRVTCGGDSLRSYASWYQOKPQAPVLVIYGNRRPSGIP 60
DB 139 AFSSSLTQDPNAVVALGQTVRVTCGGDSLRSYASWYQOKPQAPVLVIYGNRRPSGIP 198
QY 61 DFSSSSSGNTASLTITGAQAEADYYCNSRDSGNHWFVGGTGLTVLG 111
DB 139 AFSSSLTQDPNAVVALGQTVRVTCGGDSLRSYASWYQOKPQAPVLVIYGNRRPSGIP 198

DB 199 DFSSSSSGNTASLTITGAQAEADYYCNSRDSGNHWFVGGTGLTVLG 249
RESULT 37
ABP44354
ID ABP44354 standard; Protein; 249 AA.
AC ABP44354;
XX
XX
DT 19-AUG-2002 (first entry)
XX
XX
DE Human Blys binding scFv SEQ ID 365.
XX
XX
KW Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
KW tumour necrosis factor; B cell proliferation; B cell differentiation;
KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
KW common variable immunodeficiency; acquired immunodeficiency syndrome.
OS Homo sapiens.
XX
XX
WO200202641-A1.
XX
XX
PD 10-JAN-2002.
XX
XX
PF 15-JUN-2001; 2001WO-US19110.
XX
XX
PR 16-JUN-2000; 2000US-212210P.
XX
PR 17-OCT-2000; 2000US-240816P.
XX
PR 16-MAR-2001; 2001US-276248P.
XX
PR 21-MAR-2001; 2001US-277379P.
XX
PR 25-MAY-2001; 2001US-293499P.
XX
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PA (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX
PI Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
XX
XX
WPI; 2002-114799/15.
XX
XX
PT Antibodies against B lymphocyte stimulating polypeptides, useful for
XX
XX
PT the diagnosis and treatment of cancers and immune disorders -
XX
XX
PS Claim 1; Page 839-840; 3148pp; English.
XX
XX
CC This invention describes novel antibodies that immunospecifically bind to
XX
XX
CC B lymphocyte stimulator (Blys) polypeptides. Blys is a member of the
XX
XX
CC tumour necrosis factor (TNF) super family and induces B cell
XX
XX
CC proliferation and differentiation. The antibodies of the invention have
XX
XX
CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
XX
XX
CC antirheumatic and antiAIDS activity and can be used in vaccines to
XX
XX
CC inhibit the expression and activity of Blys. The antibodies bind to Blys
XX
XX
CC and so may be used to detect and quantitate the presence of Blys in
XX
XX
CC biological samples and may be used in this way to diagnose disease
XX
XX
CC associated with aberrant expression of Blys. They may also be
XX
XX
CC administered to treat diseases associated with aberrant Blys expression
XX
XX
CC and activity such as cancer, immune, and autoimmune disorders and
XX
XX
CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
XX
XX
CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
XX
XX
CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
XX
XX
CC the antibodies and fragments of the antibodies described in the method
XX
XX
XX
SQ Sequence 249 AA;
XX
XX
Query Match 99.5%; Score 580; DB 23; Length 249;
Best Local Similarity 99.1%; Pred. No. 1.6e-36;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1 AFSSSLTQDPNAVVALGQTVRVTCGGDSLRSYASWYQOKPQAPVLVIYGNRRPSGIP 60
DB 139 AFSSSLTQDPNAVVALGQTVRVTCGGDSLRSYASWYQOKPQAPVLVIYGNRRPSGIP 198

QY 61 DRFGSSSGNTASLTITGAQAEDEADYCCSSRDSSGNHWFGGTELTVLG 111
 DB 199 DRFGSSSGNTASLTITGAQAEDEADYCCNSRDSGNHWFGGTELTVLG 249

RESULT 38
 ID ABP44356 standard; Protein; 249 AA.
 AC ABP44356;
 DT 19-AUG-2002 (first entry)

DE Human Blys binding scFv SEQ ID 367.
 KW Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
 KM tumour necrosis factor; B cell proliferation; B cell differentiation;
 KM immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
 KM antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
 KM systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
 KM common variable immunodeficiency; acquired immunodeficiency syndrome.

OS Homo sapiens.
 XX WO200202641-A1.
 PN 10-JAN-2002.
 PD 15-JUN-2001; 2001WO-US19110.
 XX 16-JUN-2000; 2000US-212210P.
 PR 17-OCT-2000; 2000US-240816P.
 PR 16-MAR-2001; 2001US-276248P.
 PR 21-MAR-2001; 2001US-277379P.
 PR 25-MAY-2001; 2001US-293499P.

PA (HUMA-) HUMAN GENOME SCI INC.
 PA (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.

PI Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
 XX WPI; 2002-114799/15.

PT Antibodies against B lymphocyte Stimulating polypeptides, useful for
 PT the diagnosis and treatment of cancers and immune disorders -
 XX

PS Claim 1; Page 841-842; 3148pp; English.

CC This invention describes novel antibodies that immunospecifically bind to
 CC B lymphocyte Stimulator (Blys) polypeptides. Blys is a member of the
 CC tumour necrosis factor (TNF) super family and induces B cell
 CC proliferation and differentiation. The antibodies of the invention have
 CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
 CC antirheumatic and antiAIDS activity and can be used in vaccines to
 CC inhibit the expression and activity of Blys. The antibodies bind to Blys
 CC and so may be used to detect and quantitate the presence of Blys in
 CC biological samples and may be used in this way to diagnose disease
 CC associated with aberrant expression of Blys. They may also be
 CC administered to treat diseases associated with aberrant Blys expression
 CC and activity such as cancer, immune, and autoimmune disorders and
 CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis, and
 CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
 CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
 CC the antibodies and fragments of the antibodies described in the method
 CC of the invention.

XX Sequence 249 AA;
 SQ

Query Match 99.5%; Score 580; DB 23; Length 249;
 Best Local Similarity 99.1%; Pred. No. 1.6e-36;
 Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFSSSELTQDPAVSVALGQTVRVTCQSDLSRSYYASWYQOKPGQAPVLVIYKNNRPSGIP 60
 DB 139 AFSSSELTQDPAVSVALGQTVRVTCQSDLSRSYYASWYQOKPGQAPVLVIYKNNRPSGIP 198

QY 61 DRFGSSSGNTASLTITGAQAEDEADYCCSSRDSSGNHWFGGTELTVLG 111
 DB 199 DRFGSSSGNTASLTITGAQAEDEADYCCNSRDSGNHWFGGTELTVLG 249

RESULT 39
 ID ABP44357 standard; Protein; 249 AA.
 AC ABP44357;
 DT 19-AUG-2002 (first entry)

DE Human Blys binding scFv SEQ ID 368.
 KW Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
 KM tumour necrosis factor; B cell proliferation; B cell differentiation;
 KM immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
 KM antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
 KM systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
 KM common variable immunodeficiency; acquired immunodeficiency syndrome.

OS Homo sapiens.
 XX WO200202641-A1.
 PN 10-JAN-2002.
 PD 15-JUN-2001; 2001WO-US19110.
 XX 16-JUN-2000; 2000US-212210P.
 PR 17-OCT-2000; 2000US-240816P.
 PR 16-MAR-2001; 2001US-276248P.
 PR 21-MAR-2001; 2001US-277379P.
 PR 25-MAY-2001; 2001US-293499P.

PA (HUMA-) HUMAN GENOME SCI INC.
 PA (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.

PI Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
 XX WPI; 2002-114799/15.

PT Antibodies against B lymphocyte Stimulating polypeptides, useful for
 PT the diagnosis and treatment of cancers and immune disorders -
 XX

PS Claim 1; Page 843-844; 3148pp; English.

CC This invention describes novel antibodies that immunospecifically bind to
 CC B lymphocyte Stimulator (Blys) polypeptides. Blys is a member of the
 CC tumour necrosis factor (TNF) super family and induces B cell
 CC proliferation and differentiation. The antibodies of the invention have
 CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
 CC antirheumatic and antiAIDS activity and can be used in vaccines to
 CC inhibit the expression and activity of Blys. The antibodies bind to Blys
 CC and so may be used to detect and quantitate the presence of Blys in
 CC biological samples and may be used in this way to diagnose disease
 CC associated with aberrant expression of Blys. They may also be
 CC administered to treat diseases associated with aberrant Blys expression
 CC and activity such as cancer, immune, and autoimmune disorders and
 CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis, and
 CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
 CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
 CC the antibodies and fragments of the antibodies described in the method
 CC of the invention.

XX Sequence 249 AA;
 SQ

Query Match 99.5%; Score 580; DB 23; Length 249;

CC the antibodies and fragments of the antibodies described in the method
CC of the invention.

XX Sequence 249 AA;

Query Match 99.5%; Score 580; DB 23; Length 249;

Best Local Similarity 99.1%; Pred. No. 1.6e-36;

Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AFSSSLTQDPAVSVALGQTVAVTCQGDLSRSYASWYQKQGAQPVLYIGKNNRPSGIP 60
Db 139 AFSSSLTQDPAVSVALGQTVAVTCQGDLSRSYASWYQKQGAQPVLYIGKNNRPSGIP 198

Qy 61 DRFGSSSGNTASLTITGAQAEADYCCSRDSSGNNHWFGGTELTVLG 111
Db 199 DRFGSSSGNTASLTITGAQAEADYCCSRDSSGNNHWFGGTELTVLG 249

RESULT 42

ABP4360 standard; Protein; 249 AA.

AC ABP4360;

DT 19-AUG-2002 (first entry)

Human Blys binding scFv SEQ ID 371.

Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
tumour necrosis factor; B cell proliferation; B cell differentiation;
immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;

XX Homo sapiens.

XX WO200202641-A1.

PD 10-JAN-2002.

PF 15-JUN-2001; 2001WO-US19110.

PR 16-JUN-2000; 2000US-212210P.

PR 17-OCT-2000; 2000US-240816P.

PR 16-MAR-2001; 2001US-276248P.

PR 21-MAR-2001; 2001US-277379P.

PR 25-MAY-2001; 2001US-293499P.

(HUMA-) HUMAN GENOME SCI INC.
(CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.

PA Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;

PI WPI; 2002-114799/15.

Antibodies against B lymphocyte stimulating polypeptides, useful for
the diagnosis and treatment of cancers and immune disorders -

Claim 1; Page 846-847; 3148pp; English.

This invention describes novel antibodies that immunospecifically bind to
B lymphocyte stimulator (Blys) polypeptides. Blys is a member of the

tumour necrosis factor (TNF) super family and induces B cell

proliferation and differentiation. The antibodies of the invention have

cytostatic, immunosuppressive, immunostimulant, immunomodulatory,

antirheumatic and antiAIDS activity and can be used in vaccines to

inhibit the expression and activity of Blys. The antibodies bind to Blys

and so may be used to detect and quantitate the presence of Blys in

biological samples and may be used in this way to diagnose disease

associated with aberrant expression of Blys. They may also be

administered to treat diseases associated with aberrant Blys expression

and actively such as cancer, immune, and autoimmune disorders and

CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
CC the antibodies and fragments of the antibodies described in the method
CC of the invention.

XX Sequence 249 AA;

Query Match 99.5%; Score 580; DB 23; Length 249;

Best Local Similarity 99.1%; Pred. No. 1.6e-36;

Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AFSSSLTQDPAVSVALGQTVAVTCQGDLSRSYASWYQKQGAQPVLYIGKNNRPSGIP 60
Db 139 AFSSSLTQDPAVSVALGQTVAVTCQGDLSRSYASWYQKQGAQPVLYIGKNNRPSGIP 198

Qy 61 DRFGSSSGNTASLTITGAQAEADYCCSRDSSGNNHWFGGTELTVLG 111
Db 199 DRFGSSSGNTASLTITGAQAEADYCCSRDSSGNNHWFGGTELTVLG 249

RESULT 43

ABP4361 standard; Protein; 249 AA.

AC ABP4361;

DT 19-AUG-2002 (first entry)

Human Blys binding scFv SEQ ID 372.

Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
tumour necrosis factor; B cell proliferation; B cell differentiation;
immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;

XX Homo sapiens.

XX WO200202641-A1.

PD 10-JAN-2002.

PF 15-JUN-2001; 2001WO-US19110.

PR 16-JUN-2000; 2000US-212210P.

PR 17-OCT-2000; 2000US-240816P.

PR 16-MAR-2001; 2001US-276248P.

PR 21-MAR-2001; 2001US-277379P.

PR 25-MAY-2001; 2001US-293499P.

(HUMA-) HUMAN GENOME SCI INC.
(CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.

PA Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;

PI WPI; 2002-114799/15.

Antibodies against B lymphocyte stimulating polypeptides, useful for
the diagnosis and treatment of cancers and immune disorders -

Claim 1; Page 847-848; 3148pp; English.

This invention describes novel antibodies that immunospecifically bind to
B lymphocyte stimulator (Blys) polypeptides. Blys is a member of the

tumour necrosis factor (TNF) super family and induces B cell

proliferation and differentiation. The antibodies of the invention have

cytostatic, immunosuppressive, immunostimulant, immunomodulatory,

antirheumatic and antiAIDS activity and can be used in vaccines to

inhibit the expression and activity of Blys. The antibodies bind to Blys

and so may be used to detect and quantitate the presence of Blys in

biological samples and may be used in this way to diagnose disease

CC associated with aberrant expression of Blys. They may also be
CC administered to treat diseases associated with aberrant Blys expression
CC and activity such as cancer, immune, and autoimmune disorders and
CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
CC acquired immunodeficiency syndrome (AIDS)). ABP4390-ABP4728 represent
CC the antibodies and fragments of the antibodies described in the method
CC of the invention.

XX Sequence 249 AA;

Query Match 99.5%; Score 580; DB 23; Length 249;
Best Local Similarity 99.1%; Pred. No. 1.6e-36;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFSSSELTDDPAVSVALGQTVRVTCGDSLRSYASWYQKPGQAPLVITYGKNNRPSGIP 60
DB 139 AFSSSELTDDPAVSVALGQTVRVTCGDSLRSYASWYQKPGQAPLVITYGKNNRPSGIP 198

61 DRFGSSSGNTASLTITGAQAEADYCYSSRDSSGNHWVFGGTELTVLG 111
199 DRFGSSSGNTASLTITGAQAEADYCYNSRDSGNHWVFGGTELTVLG 249

RESULT 44

ID ABP4362 standard; Protein; 249 AA.

ABP4362;

19-AUG-2002 (first entry)

Human Blys binding scFv SEQ ID 373.

XX Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
XX tumour necrosis factor; B cell proliferation; B cell differentiation;
XX immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
XX antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
XX systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
XX common variable immunodeficiency; acquired immunodeficiency syndrome.

OS Homo sapiens.

PN WO200202641-A1.

10-JAN-2002.

15-JUN-2001; 2001WO-US19110.

16-JUN-2000; 2000US-212210P.

17-OCT-2000; 2000US-240816P.

16-MAR-2001; 2001US-276248P.

21-MAR-2001; 2001US-277379P.

25-MAY-2001; 2001US-293499P.

(HUMA-) HUMAN GENOME SCI INC.

(CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.

Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;

WPI; 2002-114799/15.

Antibodies against B lymphocyte stimulating polypeptides, useful for

the diagnosis and treatment of cancers and immune disorders -

Claim 1; Page 849-850; 3148pp; English.

This invention describes novel antibodies that immunospecifically bind to

B lymphocyte stimulator (Blys) polypeptides. Blys is a member of the

tumour necrosis factor (TNF) super family and induces B cell

CC inhibit the expression and activity of Blys. The antibodies bind to Blys
CC and so may be used to detect and quantitate the presence of Blys in
CC biological samples and may be used in this way to diagnose disease
CC associated with aberrant expression of Blys. They may also be
CC administered to treat diseases associated with aberrant Blys expression
CC and activity such as cancer, immune, and autoimmune disorders and
CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
CC acquired immunodeficiency syndrome (AIDS)). ABP4390-ABP4728 represent
CC the antibodies and fragments of the antibodies described in the method
CC of the invention.

XX Sequence 249 AA;

Query Match 99.5%; Score 580; DB 23; Length 249;
Best Local Similarity 99.1%; Pred. No. 1.6e-36;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFSSSELTDDPAVSVALGQTVRVTCGDSLRSYASWYQKPGQAPLVITYGKNNRPSGIP 60
DB 139 AFSSSELTDDPAVSVALGQTVRVTCGDSLRSYASWYQKPGQAPLVITYGKNNRPSGIP 198

61 DRFGSSSGNTASLTITGAQAEADYCYSSRDSSGNHWVFGGTELTVLG 111
199 DRFGSSSGNTASLTITGAQAEADYCYNSRDSGNHWVFGGTELTVLG 249

RESULT 45

ID ABP4364 standard; Protein; 249 AA.

ABP4364;

19-AUG-2002 (first entry)

Human Blys binding scFv SEQ ID 375.

XX Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
XX tumour necrosis factor; B cell proliferation; B cell differentiation;
XX immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
XX antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
XX systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
XX common variable immunodeficiency; acquired immunodeficiency syndrome.

OS Homo sapiens.

PN WO200202641-A1.

10-JAN-2002.

15-JUN-2001; 2001WO-US19110.

16-JUN-2000; 2000US-212210P.

17-OCT-2000; 2000US-240816P.

16-MAR-2001; 2001US-276248P.

21-MAR-2001; 2001US-277379P.

25-MAY-2001; 2001US-293499P.

(HUMA-) HUMAN GENOME SCI INC.

(CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.

Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;

WPI; 2002-114799/15.

Antibodies against B lymphocyte stimulating polypeptides, useful for

the diagnosis and treatment of cancers and immune disorders -

Claim 1; Page 851-852; 3148pp; English.

This invention describes novel antibodies that immunospecifically bind to

B lymphocyte stimulator (Blys) polypeptides. Blys is a member of the

tumour necrosis factor (TNF) super family and induces B cell

CC proliferation and differentiation. The antibodies of the invention have
CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
CC antirheumatic and antiAIDS activity and can be used in vaccines to
CC inhibit the expression and activity of BlyS. The antibodies bind to BlyS
CC and so may be used to detect and quantitate the presence of BlyS in
CC biological samples and may be used in this way to diagnose disease
CC associated with aberrant expression of BlyS. They may also be
CC administered to treat diseases associated with aberrant BlyS expression
CC and activity such as cancer, immune, and autoimmune disorders and
CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
CC acquired immunodeficiency syndrome (AIDS)). ABP4390-ABP4728 represent
CC the antibodies and fragments of the antibodies described in the method
CC of the invention.

CC Sequence 249 AA;

Query Match 99.5%; Score 580; DB 23; Length 249;
Best Local Similarity 99.1%; Pred. No. 1.6e-36;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

1 AFSSSLTDDPAVSVAGQTVRTVTCGDSLSRYASWYQKQKQAPVLYYGNRPSSGIP 60
139 AFSSSLTDDPAVSVAGQTVRTVTCGDSLSRYASWYQKQKQAPVLYYGNRPSSGIP 198

61 DRFGSSSGNTASLTITGAQAEADYCYCSRDSGSGNHWFGGTELYVLG 111
199 DRFGSSSGNTASLTITGAQAEADYCYCSRDSGSGNHWFGGTELYVLG 249

RESULT 46

ABP44365
ID ABP44365 standard; Protein; 249 AA.

AC ABP44365;

DT 19-AUG-2002 (first entry)

DE Human BlyS binding scFv SEQ ID 376.

XX BlyS; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
XX tumour necrosis factor; B cell proliferation; B cell differentiation;
XX immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
XX antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
XX systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
XX common variable immunodeficiency; acquired immunodeficiency syndrome.

XX Homo sapiens.

XX WO200202641-A1.

XX 10-JAN-2002.

XX 15-JUN-2001; 2001WO-US19110.

XX 16-JUN-2000; 2000US-212210P.

XX 17-OCT-2000; 2000US-240816P.

XX 16-MAR-2001; 2001US-276248P.

XX 21-MAR-2001; 2001US-277379P.

XX 25-MAY-2001; 2001US-293499P.

XX (HUMA-) HUMAN GENOME SCI INC.

XX (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.

XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;

XX WPI; 2002-114799/15.

XX Antibodies against B lymphocyte stimulating polypeptides, useful for
XX the diagnosis and treatment of cancers and immune disorders -
XX Claim 1; Page 852-853; 3148pp; English.

CC This invention describes novel antibodies that immunospecifically bind to
CC B lymphocyte stimulator (BlyS) polypeptides. BlyS is a member of the
CC tumour necrosis factor (TNF) super family and induces B cell
CC proliferation and differentiation. The antibodies of the invention have
CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
CC antirheumatic and antiAIDS activity and can be used in vaccines to
CC inhibit the expression and activity of BlyS. The antibodies bind to BlyS
CC and so may be used to detect and quantitate the presence of BlyS in
CC biological samples and may be used in this way to diagnose disease
CC associated with aberrant expression of BlyS. They may also be
CC administered to treat diseases associated with aberrant BlyS expression
CC and activity such as cancer, immune, and autoimmune disorders and
CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
CC acquired immunodeficiency syndrome (AIDS)). ABP4390-ABP4728 represent
CC the antibodies and fragments of the antibodies described in the method
CC of the invention.

CC Sequence 249 AA;

Query Match 99.5%; Score 580; DB 23; Length 249;
Best Local Similarity 99.1%; Pred. No. 1.6e-36;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

1 AFSSSLTDDPAVSVAGQTVRTVTCGDSLSRYASWYQKQKQAPVLYYGNRPSSGIP 60
139 AFSSSLTDDPAVSVAGQTVRTVTCGDSLSRYASWYQKQKQAPVLYYGNRPSSGIP 198

61 DRFGSSSGNTASLTITGAQAEADYCYCSRDSGSGNHWFGGTELYVLG 111
199 DRFGSSSGNTASLTITGAQAEADYCYCSRDSGSGNHWFGGTELYVLG 249

RESULT 47

ABP44366
ID ABP44366 standard; Protein; 249 AA.

AC ABP44366;

DT 19-AUG-2002 (first entry)

DE Human BlyS binding scFv SEQ ID 377.

XX BlyS; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
XX tumour necrosis factor; B cell proliferation; B cell differentiation;
XX immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
XX antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
XX systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
XX common variable immunodeficiency; acquired immunodeficiency syndrome.

XX Homo sapiens.

XX WO200202641-A1.

XX 10-JAN-2002.

XX 15-JUN-2001; 2001WO-US19110.

XX 16-JUN-2000; 2000US-212210P.

XX 17-OCT-2000; 2000US-240816P.

XX 16-MAR-2001; 2001US-276248P.

XX 21-MAR-2001; 2001US-277379P.

XX 25-MAY-2001; 2001US-293499P.

XX (HUMA-) HUMAN GENOME SCI INC.

XX (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.

XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;

XX WPI; 2002-114799/15.

XX Antibodies against B lymphocyte stimulating polypeptides, useful for
XX the diagnosis and treatment of cancers and immune disorders -

XX Claim 1, Page 853-854; 3148pp; English.

PS This invention describes novel antibodies that immunospecifically bind to

CC B lymphocyte Stimulator (Blys) polypeptides. Blys is a member of the

CC tumour necrosis factor (TNF) super family and induces B cell

CC proliferation and differentiation. The antibodies of the invention have

CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,

CC antirheumatic and antiAIDS activity and can be used in vaccines to

CC inhibit the expression and activity of Blys. The antibodies bind to Blys

CC and so may be used to detect and quantitate the presence of Blys in

CC biological samples and may be used in this way to diagnose disease

CC associated with aberrant expression of Blys. They may also be

CC administered to treat diseases associated with aberrant Blys expression

CC and activity such as cancer, immune, and autoimmune disorders and

CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,

CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and

CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent

CC the antibodies and fragments of the antibodies described in the method

CC of the invention.

SQ Sequence 249 AA;

Query Match 99.5%; Score 580; DB 23; Length 249;

Best Local Similarity 99.1%; Pred. No. 1.6e-36;

Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFSSSELTDDPAVSVALGQTVRVTCQSDLSRSYASWYQKPGQAPVLVIYGNRRPSGIP 60

DB 139 AFSSSELTDDPAVSVALGQTVRVTCQSDLSRSYASWYQKPGQAPVLVIYGNRRPSGIP 198

QY 61 DRFSGSSGNTASLTITGAQAEDEADYCNRSRDSGNHWFGGTELTVLG 111

DB 199 DRFSGSSGNTASLTITGAQAEDEADYCNRSRDSGNHWFGGTELTVLG 249

RESULT 48

ABP4368

ID ABP4368 standard; Protein; 249 AA.

AC ABP44368;

DT 19-AUG-2002 (first entry)

DE Human Blys binding scFv SEQ ID 379.

XX Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;

XX tumour necrosis factor; B cell proliferation; B cell differentiation;

XX immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;

XX antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;

XX systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;

XX common variable immunodeficiency; acquired immunodeficiency syndrome.

OS Homo sapiens.

PN WO200202641-A1.

XX 10-JAN-2002.

PD 15-JUN-2001; 2001WO-US19110.

PF 16-JUN-2000; 2000US-212210P.

PR 17-OCT-2000; 2000US-240816P.

PR 16-MAR-2001; 2001US-276248P.

PR 21-MAR-2001; 2001US-277379P.

PR 25-MAY-2001; 2001US-293499P.

PA (HUMA-) HUMAN GENOME SCI INC.

PA (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.

PI Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D,

XX WPI; 2002-114799/15.

XX Antibodies against B lymphocyte Stimulating polypeptides, useful for

PT the diagnosis and treatment of cancers and immune disorders -

XX Claim 1, Page 856-857; 3148pp; English.

PS This invention describes novel antibodies that immunospecifically bind to

CC B lymphocyte Stimulator (Blys) polypeptides. Blys is a member of the

CC tumour necrosis factor (TNF) super family and induces B cell

CC proliferation and differentiation. The antibodies of the invention have

CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,

CC antirheumatic and antiAIDS activity and can be used in vaccines to

CC inhibit the expression and activity of Blys. The antibodies bind to Blys

CC and so may be used to detect and quantitate the presence of Blys in

CC biological samples and may be used in this way to diagnose disease

CC associated with aberrant expression of Blys. They may also be

CC administered to treat diseases associated with aberrant Blys expression

CC and activity such as cancer, immune, and autoimmune disorders and

CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,

CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and

CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent

CC the antibodies and fragments of the antibodies described in the method

CC of the invention.

SQ Sequence 249 AA;

Query Match 99.5%; Score 580; DB 23; Length 249;

Best Local Similarity 99.1%; Pred. No. 1.6e-36;

Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 AFSSSELTDDPAVSVALGQTVRVTCQSDLSRSYASWYQKPGQAPVLVIYGNRRPSGIP 60

DB 139 AFSSSELTDDPAVSVALGQTVRVTCQSDLSRSYASWYQKPGQAPVLVIYGNRRPSGIP 198

QY 61 DRFSGSSGNTASLTITGAQAEDEADYCNRSRDSGNHWFGGTELTVLG 111

DB 199 DRFSGSSGNTASLTITGAQAEDEADYCNRSRDSGNHWFGGTELTVLG 249

RESULT 49

ABP4370

ID ABP4370 standard; Protein; 249 AA.

AC ABP44370;

DT 19-AUG-2002 (first entry)

DE Human Blys binding scFv SEQ ID 381.

XX Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;

XX tumour necrosis factor; B cell proliferation; B cell differentiation;

XX immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;

XX antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;

XX systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;

XX common variable immunodeficiency; acquired immunodeficiency syndrome.

OS Homo sapiens.

PN WO200202641-A1.

XX 10-JAN-2002.

PD 15-JUN-2001; 2001WO-US19110.

PF 16-JUN-2000; 2000US-212210P.

PR 17-OCT-2000; 2000US-240816P.

PR 16-MAR-2001; 2001US-276248P.

PR 21-MAR-2001; 2001US-277379P.

PR 25-MAY-2001; 2001US-293499P.

PA (HUMA-) HUMAN GENOME SCI INC.

PA (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.

PI Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
XX WPI; 2002-114799/15.
XX Antibodies against B Lymphocyte Stimulating polypeptides, useful for
PT the diagnosis and treatment of cancers and immune disorders -
XX
PS Claim 1; Page 858-859; 3148pp; English.
XX
CC This invention describes novel antibodies that immunospecifically bind to
CC B Lymphocyte Stimulator (Blys) polypeptides. Blys is a member of the
CC tumour necrosis factor (TNF) super family and induces B cell
CC proliferation and differentiation. The antibodies of the invention have
CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
CC antirheumatic and antiAIDS activity and can be used in vaccines to
CC inhibit the expression and activity of Blys. The antibodies bind to Blys
CC and so may be used to detect and quantitate the presence of Blys in
CC biological samples and may be used in this way to diagnose disease
CC associated with aberrant expression of Blys. They may also be
CC administered to treat diseases associated with aberrant Blys expression
CC and activity such as cancer, immune, and autoimmune disorders and
CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
CC the antibodies and fragments of the antibodies described in the method
CC of the invention.
XX
SQ Sequence 249 AA;
Query Match 99.5%; Score 580; DB 23; Length 249;
Best Local Similarity 99.1%; Pred. No. 1.6e-36;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1 AFSSSLTDDPAVSVAGQTVRVTCGDSLSRSYASWYQKPGQAPVLVIYGNRRPSGIP 60
DB 139 AFSSSLTDDPAVSVAGQTVRVTCGDSLSRSYASWYQKPGQAPVLVIYGNRRPSGIP 198
QY 61 DRFGSSSGNTASLTITGAQAEADADYCCSRDSSGNHWPFGGTELTVLG 111
DB 199 DRFGSSSGNTASLTITGAQAEADADYCCSRDSSGNHWPFGGTELTVLG 249
RESULT 50
ABP44371
ID ABP44371 standard; Protein; 249 AA.
XX
AC ABP44371;
XX
XX 19-AUG-2002 (first entry)
XX
DE Human Blys binding scFv SEQ ID 382.
XX
XX Blys; B lymphocyte stimulator; TNF superfamily; human, cytostatic;
XX tumour necrosis factor; B cell proliferation; B cell differentiation;
XX immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
XX antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
XX systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
XX common variable immunodeficiency; acquired immunodeficiency syndrome.
XX
OS Homo sapiens.
XX
XX WO200202641-A1.
XX
XX 10-JAN-2002.
XX
XX 15-JUN-2001; 2001WO-US19110.
XX
XX 16-JUN-2000; 2000US-212210P.
XX 17-OCT-2000; 2000US-240816P.
XX 16-MAR-2001; 2001US-276248P.
XX 21-MAR-2001; 2001US-277379P.
XX 25-MAY-2001; 2001US-293499P.
XX

PA (HUMA-) HUMAN GENOME SCI INC.
PA (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX
XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
PI WPI; 2002-114799/15.
XX
XX Antibodies against B Lymphocyte Stimulating polypeptides, useful for
PT the diagnosis and treatment of cancers and immune disorders -
XX
PS Claim 1; Page 859-860; 3148pp; English.
XX
XX This invention describes novel antibodies that immunospecifically bind to
XX B Lymphocyte Stimulator (Blys) polypeptides. Blys is a member of the
XX tumour necrosis factor (TNF) super family and induces B cell
XX proliferation and differentiation. The antibodies of the invention have
XX cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
XX antirheumatic and antiAIDS activity and can be used in vaccines to
XX inhibit the expression and activity of Blys. The antibodies bind to Blys
XX and so may be used to detect and quantitate the presence of Blys in
XX biological samples and may be used in this way to diagnose disease
XX associated with aberrant expression of Blys. They may also be
XX administered to treat diseases associated with aberrant Blys expression
XX and activity such as cancer, immune, and autoimmune disorders and
XX diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
XX immunodeficiency (e.g. common variable immunodeficiency (CVID) and
XX acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
XX the antibodies and fragments of the antibodies described in the method
XX of the invention.
XX
SQ Sequence 249 AA;
Query Match 99.5%; Score 580; DB 23; Length 249;
Best Local Similarity 99.1%; Pred. No. 1.6e-36;
Matches 110; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1 AFSSSLTDDPAVSVAGQTVRVTCGDSLSRSYASWYQKPGQAPVLVIYGNRRPSGIP 60
DB 139 AFSSSLTDDPAVSVAGQTVRVTCGDSLSRSYASWYQKPGQAPVLVIYGNRRPSGIP 198
QY 61 DRFGSSSGNTASLTITGAQAEADADYCCSRDSSGNHWPFGGTELTVLG 111
DB 199 DRFGSSSGNTASLTITGAQAEADADYCCSRDSSGNHWPFGGTELTVLG 249

Search completed: November 26, 2003, 13:39:15
Job time : 36.5769 secs

THIS PAGE BLANK (USPTO)